PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Birmingham, K				Birmingham, K			Meeting calls for international trials database	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1224	1224						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545975				2022-12-27	WOS:000086550600015
J	Santiago, FS; Lowe, HC; Kavurma, MM; Chesterman, CN; Baker, A; Atkins, DG; Khachigian, LM				Santiago, FS; Lowe, HC; Kavurma, MM; Chesterman, CN; Baker, A; Atkins, DG; Khachigian, LM			New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury	NATURE MEDICINE			English	Article							FACTOR-A-CHAIN; ENDOTHELIAL-CELLS; GENE-EXPRESSION; ANTISENSE OLIGONUCLEOTIDE; TRANSCRIPTION FACTORS; ARTERIAL INJURY; MESSENGER-RNA; GROWTH; RIBOZYME; ATHEROSCLEROSIS	Early growth response factor-1 (Egr-1) binds to the promoters of many genes whose products influence cell movement and replication in the artery wall. Here we targeted Egr-1 using a new class of DNA-based enzyme that specifically cleaved Egr-1 mRNA, blocked induction of Egr-1 protein, and inhibited cell proliferation and wound repair in culture. The DNA enzyme also inhibited Egr-1 induction and neointima formation after balloon injury to the rat carotid artery wall. These findings demonstrate the utility of DNA enzymes as biological tools to delineate the specific functions of a given gene, and implicate catalytic nucleic acid molecules composed entirely of DNA as potential therapeutic agents.	Univ New S Wales, Ctr Thrombosis & Vasc Res, Sydney, NSW, Australia; Prince Wales Hosp, Sydney, NSW, Australia; Johnson & Johnson Res Pty Ltd, Sydney, NSW, Australia	University of New South Wales Sydney; Johnson & Johnson	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Thrombosis & Vasc Res, Sydney, NSW, Australia.	L.Khachigian@unsw.edu.au	Khachigian, Levon/AAZ-7458-2020	Kavurma, Mary/0000-0001-7353-0932; Khachigian, Levon/0000-0003-3446-0323; Baker, Andrew/0000-0003-1441-5576				Bauer G, 1997, BLOOD, V89, P2259, DOI 10.1182/blood.V89.7.2259; BUCK RC, 1961, CIRC RES, V9, P418, DOI 10.1161/01.RES.9.2.418; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; CLOWES AW, 1983, LAB INVEST, V49, P327; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; Delbridge GJ, 1997, CIRC RES, V81, P282, DOI 10.1161/01.RES.81.2.282; Dryden S, 1998, J ENDOCRINOL, V157, P169, DOI 10.1677/joe.0.1570169; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; HALASZ P, 1984, P R MICROSCOP SOC, V19, P312; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; Horodyski J, 1996, J SURG RES, V66, P115, DOI 10.1006/jsre.1996.0381; Houston P, 1999, ARTERIOSCL THROM VAS, V19, P281, DOI 10.1161/01.ATV.19.2.281; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; James HA, 1998, BLOOD, V91, P371, DOI 10.1182/blood.V91.2.371.371_371_382; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; KOBAYASHI H, 1994, CANCER RES, V54, P1271; Kuwabara T, 1997, NUCLEIC ACIDS RES, V25, P3074, DOI 10.1093/nar/25.15.3074; LEMIRE JM, 1994, AM J PATHOL, V144, P1068; LIBBY P, 1995, CIRC RES S3, V86, P47; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MCCALL MJ, 1992, P NATL ACAD SCI USA, V89, P5710, DOI 10.1073/pnas.89.13.5710; Pitsch RJ, 1996, J VASC SURG, V23, P783, DOI 10.1016/S0741-5214(96)70240-9; Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758; Sambrock J, 1989, MOL CLONING LAB MANU, V1; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Santoro SW, 1998, BIOCHEMISTRY-US, V37, P13330, DOI 10.1021/bi9812221; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; Sumpio BE, 1998, ARTERIOSCL THROM VAS, V18, P349, DOI 10.1161/01.ATV.18.3.349; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	45	216	247	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1999	5	11					1264	1269		10.1038/15215	http://dx.doi.org/10.1038/15215			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545992				2022-12-27	WOS:000086550600036
J	Birmingham, K				Birmingham, K			Drug company settles AIDS drug suit with US university	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1224	1224						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545975				2022-12-27	WOS:000086550600017
J	Girod, A; Ried, M; Wobus, C; Lahm, H; Leike, K; Kleinschmidt, J; Deleage, G; Hallek, M				Girod, A; Ried, M; Wobus, C; Lahm, H; Leike, K; Kleinschmidt, J; Deleage, G; Hallek, M			Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2	NATURE MEDICINE			English	Article							PROTEIN SECONDARY STRUCTURE; ADENOASSOCIATED VIRUS; IDENTIFICATION; REPLICATION; SEQUENCE; VECTORS; MUTANTS; THERAPY; INVITRO	The human parvovirus adeno-associated virus type 2 (AAV2) has many features that make it attractive as a vector for gene therapy(1,2). However, the broad host range of AAV2 might represent a limitation for some applications in vivo, because recombinant AAV vector (rAAV)-mediated gene transfer would not be specific for the tissue of interest. This host range is determined by the binding of the AAV2 capsid to specific cellular receptors and/or co-receptors(3,6). The tropism of AAV2 might be changed by genetically introducing a ligand peptide into the viral capsid, thereby redirecting the binding of AAV2 to other cellular receptors. We generated six AAV2 capsid mutants by inserting a 14-amino-acid targeting peptide, L14, into six different putative loops of the AAV2 capsid protein identified by comparison with the known three-dimensional structure of canine parvovirus. All mutants were efficiently packaged. Three mutants expressed L14 on the capsid surface, and one efficiently infected wild-type AAV2-resistant cell lines that expressed the integrin receptor recognized by L14. The results demonstrate that the AAV2 capsid tolerates the insertion of a nonviral ligand sequence. This might open new perspectives for the design of targeted AAV2 vectors for human somatic gene therapy.	Univ Munich, Mol Biol Lab, Genzentrum, Klinikum Grosshadern, D-81377 Munich, Germany; Univ Munich, Med Klin 3, Klinikum Grosshadern, D-81377 Munich, Germany; Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany; Inst Biol & Chim Prot, UPR412, CNRS, Lab Conformat Prot, F-69367 Lyon 07, France	University of Munich; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Centre National de la Recherche Scientifique (CNRS)	Hallek, M (corresponding author), Univ Munich, Mol Biol Lab, Genzentrum, Klinikum Grosshadern, Feodor Lynen Str 25, D-81377 Munich, Germany.		Deléage, Gilbert/F-7163-2010; Hallek, Michael/Y-3191-2019	Deléage, Gilbert/0000-0003-1939-1614; Hallek, Michael/0000-0002-7425-4455; Wobus, Christiane/0000-0001-5286-0924				AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; Bartlett JS, 1999, NAT BIOTECHNOL, V17, P181, DOI 10.1038/6185; CARREL S, 1976, CANCER RES, V36, P3978; Chiorini JA, 1995, HUM GENE THER, V6, P1531, DOI 10.1089/hum.1995.6.12-1531; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; HALLEK M, 1998, DRUGS, V1, P561; HERMONAT PL, 1984, J VIROL, V51, P329, DOI 10.1128/JVI.51.2.329-339.1984; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOTIN RM, 1994, HUM GENE THER, V5, P793, DOI 10.1089/hum.1994.5.7-793; Mizukami H, 1996, VIROLOGY, V217, P124, DOI 10.1006/viro.1996.0099; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; RUFFING M, 1994, J GEN VIROL, V75, P3385, DOI 10.1099/0022-1317-75-12-3385; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Stewart PL, 1997, EMBO J, V16, P1189, DOI 10.1093/emboj/16.6.1189; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRATSCHIN JD, 1984, J VIROL, V51, P611, DOI 10.1128/JVI.51.3.611-619.1984; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; VAISESLAWITTMAN.S, 1994, J VIROL, V68, P4609; WHITE JM, 1993, CURR BIOL, V3, P596, DOI 10.1016/0960-9822(93)90007-B; Wistuba A, 1997, J VIROL, V71, P1341, DOI 10.1128/JVI.71.2.1341-1352.1997; Yang QC, 1998, HUM GENE THER, V9, P1929, DOI 10.1089/hum.1998.9.13-1929	24	274	341	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1052	1056		10.1038/12491	http://dx.doi.org/10.1038/12491			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470084				2022-12-27	WOS:000082337200041
J	Mack, M; Kleinschmidt, A; Bruhl, H; Klier, C; Nelson, PJ; Cihak, J; Plachy, J; Stangassinger, M; Erfle, V; Schlondorff, D				Mack, M; Kleinschmidt, A; Bruhl, H; Klier, C; Nelson, PJ; Cihak, J; Plachy, J; Stangassinger, M; Erfle, V; Schlondorff, D			Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection	NATURE MEDICINE			English	Article							HIV-1 CORECEPTOR ACTIVITY; POLYMERASE CHAIN-REACTION; CENTRAL-NERVOUS-SYSTEM; PLATELET MICROPARTICLES; ENDOTHELIAL-CELLS; IN-VITRO; ASTROCYTES; EXPRESSION; TYPE-1; INDIVIDUALS	The release of microparticles from eukaryotic cells is a well-recognized phenomenon. We demonstrate here that the chemokine receptor CCR5, the principal co-receptor for macrophage-tropic human immunodeficiency virus (HIV)-1, can be released through microparticles from the surface of CCR5(+) Chinese hamster ovary cells and peripheral blood mononuclear cells. Microparticles containing CCR5 can transfer the receptor to CCR5(-) cells and render them CCR5(+). The CCR5 transfer to CCR5-deficient peripheral blood mononuclear cells homozygous for a 32-base-pair deletion in the CCR5 gene enabled infection of these cells with macrophage-tropic: HIV-1. In monocytes, the transfer of CCR5 could be inhibited by cytochalasin D, and transferred CCR5 could be downmodulated by chemokines. A transfer of CCR5 from peripheral blood mononuclear cells to endothelial cells during transendothelial migration could be demonstrated. Thus, the transfer of CCR5 may lead to infection of tissues without endogenous CCR5 expression. Moreover, the intercellular transfer of membrane proteins by microparticles might have broader consequences for intercellular communication beyond the effects seen for HIV-1.	Univ Munich, Med Poliklin, D-80336 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Mol Virol, D-85764 Neuherberg, Germany; Univ Munich, Inst Anim Physiol, D-80539 Munich, Germany; Acad Sci Czech Republ, Inst Mol Genet, CR-16637 Prague, Czech Republic	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Mack, M (corresponding author), Univ Munich, Med Poliklin, Pettenkoferstr 8A, D-80336 Munich, Germany.		Plachy, Jiri/G-4381-2014					Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; ARMSTRONG MJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P106, DOI 10.1016/0005-2736(88)90462-2; Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Barry OP, 1998, J CLIN INVEST, V102, P136, DOI 10.1172/JCI2592; BEAUDOIN AR, 1991, BIOCHIM BIOPHYS ACTA, V1071, P203, DOI 10.1016/0304-4157(91)90014-N; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Brack-Werner R, 1999, AIDS, V13, P1, DOI 10.1097/00002030-199901140-00003; Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Fritsch L, 1998, VIROLOGY, V244, P542, DOI 10.1006/viro.1998.9120; GEORGE JN, 1982, BLOOD, V60, P834; Gluschankof P, 1997, VIROLOGY, V230, P125, DOI 10.1006/viro.1997.8453; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Husman AD, 1999, J IMMUNOL, V163, P4597; Klein RS, 1999, J IMMUNOL, V163, P1636; LEVENE RB, 1986, BLOOD, V67, P207; Lopalco L, 2000, J IMMUNOL, V164, P3426, DOI 10.4049/jimmunol.164.6.3426; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; Marechal V, 1998, J VIROL, V72, P2208; Mesri C, 1998, J IMMUNOL, V161, P4382; NUOVO GJ, 1994, AM J PATHOL, V144, P659; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Ostrowski MA, 1998, J IMMUNOL, V161, P3195; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Ray PE, 1998, KIDNEY INT, V53, P1217, DOI 10.1046/j.1523-1755.1998.00900.x; RIEBER EP, 1992, P NATL ACAD SCI USA, V89, P10792, DOI 10.1073/pnas.89.22.10792; Rottman JB, 1997, AM J PATHOL, V151, P1341; RUBSAMENWAIGMANN H, 1989, LANCET, V2, P1155; Sabri F, 1999, VIROLOGY, V264, P370, DOI 10.1006/viro.1999.9998; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SATTA N, 1994, J IMMUNOL, V153, P3245; Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67; Segerer S, 1999, KIDNEY INT, V56, P52, DOI 10.1046/j.1523-1755.1999.00544.x; Speck RF, 1999, CURR BIOL, V9, P547, DOI 10.1016/S0960-9822(99)80241-3; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILEY CA, 1994, ANN NEUROL, V36, P673, DOI 10.1002/ana.410360422; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	45	431	450	1	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					769	+		10.1038/77498	http://dx.doi.org/10.1038/77498			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888925				2022-12-27	WOS:000088040100033
J	Zion, D; Gillam, L; Loff, B				Zion, D; Gillam, L; Loff, B			The Declaration of Helsinki, CIOMS and the ethics of research on vulnerable populations	NATURE MEDICINE			English	Editorial Material									Monash Univ, Dept Epidemiol & Prevent Med, Ctr Human Bioeth, Melbourne, Vic 3004, Australia; Univ Melbourne, Ctr Study Hlth & Soc, Parkville, Vic 3052, Australia; Murdoch Inst, Eth Unit, Melbourne, Vic, Australia; Monash Univ 2, Dept Epidemiol & Prevent Med, Clayton, Vic, Australia	Monash University; University of Melbourne; Murdoch Children's Research Institute; Monash University	Zion, D (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Ctr Human Bioeth, 3-553 St Kilda Rd, Melbourne, Vic 3004, Australia.		Loff, Bebe/G-9241-2014; Zion, Deborah/M-8806-2014	Loff, Bebe/0000-0003-1963-6503; Gillam, Lynn/0000-0001-6481-5004				French Howard W, 1997, N Y Times Web, pA14; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Shue H., 1996, BASIC RIGHTS SUBSIST	3	64	70	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					615	617		10.1038/76174	http://dx.doi.org/10.1038/76174			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835665				2022-12-27	WOS:000087438300017
J	Ready, T				Ready, T			From biotech to bank robbery	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					121	121		10.1038/72198	http://dx.doi.org/10.1038/72198			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655085				2022-12-27	WOS:000085016900017
J	Hemmer, B; Gran, B; Zhao, YD; Marques, A; Pascal, J; Tzou, A; Kondo, T; Cortese, I; Bielekova, B; Straus, SE; McFarland, HF; Houghten, R; Simon, R; Pinilla, C; Martin, R				Hemmer, B; Gran, B; Zhao, YD; Marques, A; Pascal, J; Tzou, A; Kondo, T; Cortese, I; Bielekova, B; Straus, SE; McFarland, HF; Houghten, R; Simon, R; Pinilla, C; Martin, R			Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease	NATURE MEDICINE			English	Article							PEPTIDE COMBINATORIAL LIBRARIES; MYELIN BASIC-PROTEIN; BORRELIA-BURGDORFERI; TREATMENT-RESISTANT; ANTIGEN RECOGNITION; AMINOPEPTIDASE-A; CLONING; EXPRESSION; ARTHRITIS; RECEPTOR	Elucidating the cellular immune response to infectious agents is a prerequisite for understanding disease pathogenesis and designing effective vaccines. In the identification of microbial T-cell epitopes, the availability of purified or recombinant bacterial proteins has been a chief limiting factor. In chronic infectious diseases such as Lyme disease, immune-mediated damage may add to the effects of direct infection by means of molecular mimicry to tissue autoantigens. Here, we describe a new method to effectively identify both microbial epitopes and candidate autoantigens. The approach combines data acquisition by positional scanning peptide combinatorial libraries and biometric data analysis by generation of scoring matrices. In a patient with chronic neuroborreliosis, we show that this strategy leads to the identification of potentially relevant T-cell targets derived from both Borrelia burgdorferi and the host. We also found that the antigen specificity of a single T-cell clone can be degenerate and yet the clone can preferentially recognize different peptides derived from the same organism, thus demonstrating that flexibility in T-cell recognition does not preclude specificity. This approach has potential applications in the identification of ligands in infectious diseases, tumors and autoimmune diseases.	NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA; NIAID, Lab Clin Invest, NIH, Rockville, MD 20892 USA; Mixtures Sci, San Diego, CA 92121 USA; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA; Univ Marburg, Dept Neurol, D-35039 Marburg, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Torrey Pines Institute for Molecular Studies, California; Philipps University Marburg	Pinilla, C (corresponding author), NINDS, Neuroimmunol Branch, NIH, Bldg 10,Room 5B-16,10 Ctr DR MSC 1400, Bethesda, MD 20892 USA.	pinilla@tpims.org; Roland_Martin@nih.gov	Bielekova, Bibiana/V-1452-2017; Hemmer, Bernhard/AAT-8388-2021; Bielekova, Bibiana/AAA-8115-2020; Gran, Bruno/A-2288-2013; Marques, Adriana/AAU-2099-2021; Hemmer, Bernhard/GPX-8451-2022	Bielekova, Bibiana/0000-0002-0959-9430; Bielekova, Bibiana/0000-0002-0959-9430; Gran, Bruno/0000-0001-6384-2342; Marques, Adriana/0000-0002-5403-4551; Hemmer, Bernhard/0000-0001-5985-6784	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000695, ZIAAI000695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002205, ZIANS002204, Z01NS002204] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akin E, 1999, INFECT IMMUN, V67, P173, DOI 10.1128/IAI.67.1.173-181.1999; Alekshun M, 1997, GENE, V186, P227, DOI 10.1016/S0378-1119(96)00714-7; ALLEN M, 1994, HUM IMMUNOL, V39, P41, DOI 10.1016/0198-8859(94)90099-X; [Anonymous], 1995, JAMA, V274, P937; Bono JL, 1998, MICROBIOL-UK, V144, P1033, DOI 10.1099/00221287-144-4-1033; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; Fikrig E, 1997, IMMUNITY, V6, P531, DOI 10.1016/S1074-7613(00)80341-6; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GarciaMonco JC, 1997, SEMIN NEUROL, V17, P57, DOI 10.1055/s-2008-1040914; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Gran B, 1999, ANN NEUROL, V45, P559, DOI 10.1002/1531-8249(199905)45:5<559::AID-ANA3>3.0.CO;2-Q; Gross DM, 1998, J IMMUNOL, V160, P1022; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Haass A, 1998, CURR OPIN NEUROL, V11, P253, DOI 10.1097/00019052-199806000-00011; Hemmer B, 1998, J PEPT RES, V52, P338; Hemmer B, 1998, J IMMUNOL, V160, P5807; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; Hemmer B, 1998, J IMMUNOL, V160, P3631; Hemmer B, 1998, IMMUNOL TODAY, V19, P163, DOI 10.1016/S0167-5699(97)01217-6; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Illes Z, 1999, J IMMUNOL, V162, P1811; Kamradt T, 1996, INFECT IMMUN, V64, P1284, DOI 10.1128/IAI.64.4.1284-1289.1996; KOVATS S, 1994, J EXP MED, V179, P2017, DOI 10.1084/jem.179.6.2017; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAM TT, 1994, J CLIN MICROBIOL, V32, P876, DOI 10.1128/JCM.32.4.876-883.1994; LENGLJANSSEN B, 1994, J EXP MED, V180, P2069, DOI 10.1084/jem.180.6.2069; LI L, 1993, GENOMICS, V17, P657, DOI 10.1006/geno.1993.1386; MARTIN R, 1988, ANN NEUROL, V24, P509, DOI 10.1002/ana.410240406; MARTIN R, 1992, J IMMUNOL, V148, P1359; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; MORETTA A, 1983, J EXP MED, V157, P743, DOI 10.1084/jem.157.2.743; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; Oksi J, 1996, BRAIN, V119, P2143, DOI 10.1093/brain/119.6.2143; OLD IG, 1993, FEMS MICROBIOL LETT, V111, P109, DOI 10.1111/j.1574-6968.1993.tb06369.x; Oschmann P, 1997, INFECTION, V25, P292, DOI 10.1007/BF01720399; PADULA SJ, 1993, INFECT IMMUN, V61, P5097, DOI 10.1128/IAI.61.12.5097-5105.1993; PIENIAZEK NJ, 1990, NUCLEIC ACIDS RES, V18, P1901, DOI 10.1093/nar/18.7.1901; PINILLA C, 1994, BIOCHEM J, V301, P847, DOI 10.1042/bj3010847; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; REECE JC, 1993, J IMMUNOL, V151, P6175; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SCHWEICKART VL, 1994, GENOMICS, V23, P643, DOI 10.1006/geno.1994.1553; Sigal LH, 1997, SEMIN NEUROL, V17, P63, DOI 10.1055/s-2008-1040915; Sigal LH, 1997, ANNU REV IMMUNOL, V15, P63, DOI 10.1146/annurev.immunol.15.1.63; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; Sprenger H, 1997, INFECT IMMUN, V65, P4384, DOI 10.1128/IAI.65.11.4384-4388.1997; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; THOMSON BJ, 1991, NATURE, V351, P78, DOI 10.1038/351078a0; Trueba GA, 1997, RES MICROBIOL, V148, P191, DOI 10.1016/S0923-2508(97)85239-4; Vergelli M, 1997, EUR J IMMUNOL, V27, P941, DOI 10.1002/eji.1830270421; Walden P, 1996, CURR OPIN IMMUNOL, V8, P68, DOI 10.1016/S0952-7915(96)80107-5; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; Yamamoto K, 1996, HUM IMMUNOL, V48, P23, DOI 10.1016/0198-8859(96)00080-8; YAMAMOTO Y, 1994, J BIOL CHEM, V269, P31725; YSSEL H, 1991, J EXP MED, V174, P593, DOI 10.1084/jem.174.3.593	56	174	183	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1999	5	12					1375	1382						8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581079				2022-12-27	WOS:000084049700036
J	McDonald, JW; Liu, XZ; Qu, Y; Liu, S; Mickey, SK; Turetsky, D; Gottlieb, DI; Choi, DW				McDonald, JW; Liu, XZ; Qu, Y; Liu, S; Mickey, SK; Turetsky, D; Gottlieb, DI; Choi, DW			Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord	NATURE MEDICINE			English	Article							ADULT-RAT; AXONAL REGENERATION; CNS NEURONS; IN-VITRO; GROWTH; GRAFTS; BRAIN	Transplantation approaches using cellular bridges(1-2), fetal central nervous system cells(3-5), fibroblasts expressing neurotrophin-3 (ref. 6), hybridoma cells expressing inhibitory protein-blocking antibodies: or olfactory nerves ensheathing glial cells(8) transplanted into the acutely injured spinal cord have produced axonal regrowth or functional benefits. Transplants of rat or cat fetal spinal cord tissue into the chronically injured cord survive and integrate with the host cord, and may be associated with some functional improvements(9). In addition, rats transplanted with fetal spinal cord cells have shown improvements in some gait parameters(10) and the delayed transplantation of fetal raphe cells can enhance reflexes(11). We transplanted neural differentiated mouse embryonic stem cells into a rat spinal cord 9 days after traumatic injury. Histological analysis 2-5 weeks later showed that transplant-derived cells survived and differentiated into astrocytes, oligodendrocytes and neurons, and migrated as far as 8 mm away from the lesion edge. Furthermore, gait analysis demonstrated that transplanted rats showed hindlimb weight support and partial hindlimb coordination not found in 'sham-operated' controls or control rats transplanted with adult mouse neocortical cells.	Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Restorat Treatment & Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	McDonald, JW (corresponding author), Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037927, P01NS032636] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01931, NS37927, NS32636] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DK, 1991, RESTOR NEUROL NEUROS, V2, P309, DOI 10.3233/RNN-1991-245621; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BAUMRIND NL, 1992, DEV DYNAM, V194, P311, DOI 10.1002/aja.1001940407; BERNSTEIN JJ, 1987, EXP NEUROL, V98, P633, DOI 10.1016/0014-4886(87)90271-8; BREGMAN BS, 1993, EXP NEUROL, V123, P3, DOI 10.1006/exnr.1993.1136; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Grill R, 1997, J NEUROSCI, V17, P5560; HOWLAND DR, 1995, EXP NEUROL, V135, P123, DOI 10.1006/exnr.1995.1072; LAGENAUR C, 1981, J SUPRAMOL STR CELL, V15, P335, DOI 10.1002/jsscb.1981.380150404; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Liu XZ, 1997, J NEUROSCI, V17, P5395; PRIVAT A, 1989, BRAIN RES BULL, V22, P123, DOI 10.1016/0361-9230(89)90136-6; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; STOKES BT, 1992, EXP NEUROL, V116, P1, DOI 10.1016/0014-4886(92)90171-L; WAXMAN SG, 1992, J NEUROTRAUM, V9, pS105; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113	20	941	1067	1	156	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1410	1412		10.1038/70986	http://dx.doi.org/10.1038/70986			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581084				2022-12-27	WOS:000084049700041
J	Puglielli, MT; Browning, JL; Brewer, AW; Schreiber, RD; Shieh, WJ; Altman, JD; Oldstone, MBA; Zaki, SR; Ahmed, R				Puglielli, MT; Browning, JL; Brewer, AW; Schreiber, RD; Shieh, WJ; Altman, JD; Oldstone, MBA; Zaki, SR; Ahmed, R			Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway	NATURE MEDICINE			English	Article							HANTAVIRUS PULMONARY SYNDROME; TUMOR-NECROSIS-FACTOR; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-CELL RESPONSES; MONOCLONAL-ANTIBODIES; SURFACE LYMPHOTOXIN; VIRAL PERSISTENCE; KILLER-CELLS; BETA; RECEPTOR	At present, little is known about the pathogenesis of acute virus-induced shock and pulmonary failure. A chief impediment in understanding the underlying disease mechanisms and developing treatment strategies has been the lack of a suitable animal model. This study describes a mouse model of virus-induced systemic shock and respiratory distress, and shows that blockade of the lymphotoxin beta receptor pathway reverses the disease.	Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Biogen Inc, Cambridge, MA 02142 USA; Schering Plough Res Inst, Lafayette, NJ 07848 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Ctr Dis Control & Prevent, Infect Dis Pathol Act, Natl Ctr Infect Dis, Atlanta, GA 30322 USA; Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA	Emory University; Emory University; Biogen; Merck & Company; Schering-Plough Research Institute; Washington University (WUSTL); Centers for Disease Control & Prevention - USA; Scripps Research Institute	Ahmed, R (corresponding author), Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA.		Schreiber, Robert D/A-1276-2013; Schreiber, Robert/Q-7550-2019	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341; Browning, Jeffrey/0000-0001-9168-5233	NIAID NIH HHS [AI09866, AI30048] Funding Source: Medline; NINDS NIH HHS [NS21496] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030048, R37AI030048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021496] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE Y, 1992, LYMPHOKINE CYTOK RES, V11, P115; AHMED R, 1988, J EXP MED, V167, P1719, DOI 10.1084/jem.167.5.1719; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bethell DB, 1998, J INFECT DIS, V177, P778, DOI 10.1086/517807; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FORCE WR, 1995, J IMMUNOL, V155, P5280; Hallin GW, 1996, CRIT CARE MED, V24, P252, DOI 10.1097/00003246-199602000-00012; HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324; Lacy M D, 1996, Adv Pediatr Infect Dis, V12, P21; Mackay F, 1997, J IMMUNOL, V159, P3299; MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; MERTZ GJ, 1998, EMERGENCE CONTROL RO, V43, P43; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NOLTE KB, 1995, HUM PATHOL, V26, P110, DOI 10.1016/0046-8177(95)90123-X; Peters Clarence J., 1997, P779; SAYER WJ, 1955, ANN INTERN MED, V42, P839, DOI 10.7326/0003-4819-42-4-839; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; Sourdive DJD, 1998, J EXP MED, V188, P71, DOI 10.1084/jem.188.1.71; Talal N, 1974, Curr Top Microbiol Immunol, V64, P79; Toro J, 1998, EMERG INFECT DIS, V4, P687, DOI 10.3201/eid0404.980425; WARE CF, 1992, J IMMUNOL, V149, P3881; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zaki SR, 1996, ARCH PATHOL LAB MED, V120, P134; ZAKI SR, 1995, AM J PATHOL, V146, P552; 1998, MORBID MORTAL WEEKLY, V47, P449	34	55	58	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1370	1374						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581078				2022-12-27	WOS:000084049700035
J	Mateo, V; Lagneaux, L; Bron, D; Biron, G; Armant, M; Delespesse, G; Sarfati, M				Mateo, V; Lagneaux, L; Bron, D; Biron, G; Armant, M; Delespesse, G; Sarfati, M			CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia	NATURE MEDICINE			English	Article							INTEGRIN-ASSOCIATED PROTEIN; MARROW STROMAL CELLS; B-CELL; INDUCED APOPTOSIS; T-LYMPHOCYTES; IN-VITRO; MONOCLONAL-ANTIBODIES; CROSS-LINKING; TUMOR-CELLS; BCL-2	Thrombospondin forms a 'molecular bridge' between phagocytic and apoptotic cells through interaction with alpha v beta 3/CD36. We report here that engagement of CD47, a newly described thrombospondin receptor, by immobilized monoclonal antibody against CD47 or by thrombospondin induced in all B-cell chronic lymphocytic leukemia clones the cytoplasmic features of apoptosis (cell shrinkage, decrease in mitochondrial transmembrane potential and phosphatidylserine externalization) without the nuclear features (chromatin condensation, appearance of single-stranded DNA, DNA fragmentation and cleavage of poly ADP-ribose polymerase). These cytoplasmic events of apoptosis were not prevented by the addition of caspase inhibitor z-VAD-fmk, or by the presence of survival factors (such as interleukin-4 and gamma interferon) or cell activation. Morphological studies confirmed the integrity of the nucleus and showed swelling of the mitochondria. This caspase-independent death pathway may be relevant to the development of alternate therapeutic strategies in chronic lymphocytic leukemia, which remains an incurable disease.	Univ Montreal, Hop Notre Dame, Ctr Hosp, Ctr Rech,Lab Allergie, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Hop Notre Dame, Ctr Hosp, Dept Hematol, Montreal, PQ H3C 3J7, Canada; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	Universite de Montreal; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Sarfati, M (corresponding author), Univ Montreal, Hop Notre Dame, Ctr Hosp, Ctr Rech,Lab Allergie, 1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.	sarfatm@poste.umontreal.ca	Mateo, Véronique/AAD-1379-2019; Mateo, Véronique/O-9738-2017	Mateo, Véronique/0000-0002-9327-1277; Mateo, Véronique/0000-0002-9327-1277				Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Bellosillo B, 1997, BLOOD, V89, P3378, DOI 10.1182/blood.V89.9.3378; Bellosillo B, 1998, BLOOD, V92, P1406, DOI 10.1182/blood.V92.4.1406.416k17_1406_1414; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; Cantwell MJ, 1996, BLOOD, V88, P4676, DOI 10.1182/blood.V88.12.4676.bloodjournal88124676; Chandra J, 1997, BLOOD, V90, P3673, DOI 10.1182/blood.V90.9.3673; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Consoli U, 1998, BLOOD, V91, P1742, DOI 10.1182/blood.V91.5.1742.1742_1742_1748; DANCESCU M, 1992, J EXP MED, V176, P1319, DOI 10.1084/jem.176.5.1319; Deas O, 1998, J IMMUNOL, V161, P3375; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Depraetere V, 1998, SCAND J IMMUNOL, V47, P523; Dighiero G, 1998, NEW ENGL J MED, V338, P1506, DOI 10.1056/NEJM199805213382104; Douglas RS, 1997, BLOOD, V89, P941, DOI 10.1182/blood.V89.3.941; FOURNIER S, 1992, J CLIN INVEST, V89, P1312, DOI 10.1172/JCI115717; FOURNIER S, 1995, BRIT J HAEMATOL, V89, P373, DOI 10.1111/j.1365-2141.1995.tb03314.x; FUENTE M, 1999, LEUKEMIA, V13, P266; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Ghetie MA, 1997, P NATL ACAD SCI USA, V94, P7509, DOI 10.1073/pnas.94.14.7509; Guo K, 1998, BIOL REPROD, V58, P739, DOI 10.1095/biolreprod58.3.739; HANADA M, 1993, BLOOD, V82, P1820; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Keating MJ, 1998, BLOOD, V92, P1165, DOI 10.1182/blood.V92.4.1165.416k03_1165_1171; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lesage S, 1997, J IMMUNOL, V159, P4762; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; McConkey DJ, 1996, J IMMUNOL, V156, P2624; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; MOWER DA, 1994, J IMMUNOL, V152, P4832; PANAYIOTIDIS P, 1993, BRIT J HAEMATOL, V85, P439; Panayiotidis P, 1996, BRIT J HAEMATOL, V92, P97, DOI 10.1046/j.1365-2141.1996.00305.x; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; ROBERTSON LE, 1993, BLOOD, V81, P143; Romano MF, 1998, BLOOD, V92, P990; Sarfati M, 1996, BLOOD, V88, P4259; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; Savill J, 1997, BRIT MED BULL, V53, P491; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thomas A, 1996, ONCOGENE, V12, P1055; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tinhofer I, 1998, BLOOD, V91, P4273, DOI 10.1182/blood.V91.11.4273.411k25_4273_4281; Truman JP, 1997, BLOOD, V89, P1996, DOI 10.1182/blood.V89.6.1996; Wang DK, 1997, BRIT J HAEMATOL, V97, P409, DOI 10.1046/j.1365-2141.1997.422688.x; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628	55	184	217	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1999	5	11					1277	1284		10.1038/15233	http://dx.doi.org/10.1038/15233			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545994				2022-12-27	WOS:000086550600038
J	Sotomayor, EM; Borrello, I; Tubb, E; Rattis, FM; Bien, H; Lu, ZB; Fein, S; Schoenberger, S; Levitsky, HI				Sotomayor, EM; Borrello, I; Tubb, E; Rattis, FM; Bien, H; Lu, ZB; Fein, S; Schoenberger, S; Levitsky, HI			Conversion of tumor-specific CD4(+) T-cell tolerance to T-cell priming through in vivo ligation of CD40	NATURE MEDICINE			English	Article							IN-VIVO; PERIPHERAL TOLERANCE; DENDRITIC CELLS; SELF-ANTIGENS; CROSS-PRESENTATION; INDUCTION; EXPRESSION; LYMPHOCYTES; LIGAND; ACTIVATION	Tumor antigen-specific T-cell tolerance limits the efficacy of therapeutic cancer vaccines. Antigen-presenting cells mediate the induction of T-cell tolerance to self-antigens. We therefore assessed the fate of tumor-specific CD4(+) T cells in tumor-bearing recipients after in vivo activation of antigen-presenting cells with antibodies against CD40. Such treatment not only preserved the responsiveness of this population, but resulted in their endogenous activation. Established tumors regressed in vaccinated mice treated with antibody against CD40 at a time when no response was achieved with vaccination alone. These results indicate that modulation of antigen-presenting cells may be a useful strategy for enhancing responsiveness to immunization.	Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; La Jolla Inst Allergy & Immunol, Div Immune Regulat, San Diego, CA 92121 USA	Johns Hopkins University; La Jolla Institute for Immunology	Levitsky, HI (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, 720 Rutland Ave,Ross Bldg,Room 347, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA078658, K08CA078656] Funding Source: NIH RePORTER; NCI NIH HHS [CA078656, R01 CA78658] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler AJ, 1998, J EXP MED, V187, P1555, DOI 10.1084/jem.187.10.1555; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Bogen B, 1996, EUR J IMMUNOL, V26, P2671, DOI 10.1002/eji.1830261119; BOWEN F, 1995, EUR J IMMUNOL, V25, P2830, DOI 10.1002/eji.1830251018; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; CONSTANT S, 1994, EUR J IMMUNOL, V24, P1073, DOI 10.1002/eji.1830240510; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Ferlin WG, 1998, EUR J IMMUNOL, V28, P525, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;525::AID-IMMU525&gt;3.0.CO;2-M; Fuchs E J, 1996, Semin Immunol, V8, P271, DOI 10.1006/smim.1996.0035; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; Heath WR, 1998, J EXP MED, V187, P1549, DOI 10.1084/jem.187.10.1549; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Inaba K, 1997, J EXP MED, V186, P665, DOI 10.1084/jem.186.5.665; Jakobson E, 1998, INT J CANCER, V77, P849, DOI 10.1002/(SICI)1097-0215(19980911)77:6<849::AID-IJC9>3.0.CO;2-U; JANEWAY CA, 1993, SCI AM, V269, P72, DOI 10.1038/scientificamerican0993-72; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; Kluth B, 1997, CANCER RES, V57, P891; Kurts C, 1997, J EXP MED, V186, P2057, DOI 10.1084/jem.186.12.2057; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; Lane P, 1996, EUR J IMMUNOL, V26, P858, DOI 10.1002/eji.1830260420; Lanoue A, 1997, J EXP MED, V185, P405, DOI 10.1084/jem.185.3.405; Lanzavecchia A, 1998, NATURE, V393, P413, DOI 10.1038/30845; LEVITSKY HI, 1994, J EXP MED, V179, P1215, DOI 10.1084/jem.179.4.1215; LO D, 1992, EUR J IMMUNOL, V22, P1013, DOI 10.1002/eji.1830220421; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Medzhitov R, 1998, SEMIN IMMUNOL, V10, P351, DOI 10.1006/smim.1998.0136; Morgan DJ, 1998, J IMMUNOL, V160, P643; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; Pammer J, 1996, HISTOPATHOLOGY, V29, P517, DOI 10.1046/j.1365-2559.1996.d01-531.x; Pape KA, 1998, J IMMUNOL, V160, P4719; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Sotomayor EM, 1996, CRIT REV ONCOGENESIS, V7, P433, DOI 10.1615/CritRevOncog.v7.i5-6.30; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; TOPALIAN SL, 1994, CURR OPIN IMMUNOL, V6, P741, DOI 10.1016/0952-7915(94)90078-7; vandenOord JJ, 1996, AM J PATHOL, V149, P1953; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Viac J, 1997, ANTICANCER RES, V17, P569	48	351	399	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1999	5	7					780	787		10.1038/10503	http://dx.doi.org/10.1038/10503			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395323				2022-12-27	WOS:000081926600033
J	Ying, H; Zaks, TZ; Wang, RF; Irvine, KR; Kammula, US; Marincola, FM; Leitner, WW; Restifo, NP				Ying, H; Zaks, TZ; Wang, RF; Irvine, KR; Kammula, US; Marincola, FM; Leitner, WW; Restifo, NP			Cancer therapy using a self-replicating RNA vaccine	NATURE MEDICINE			English	Article							ESTABLISHED PULMONARY METASTASES; IMMUNE-RESPONSES; DNA IMMUNIZATION; VIRUS; ANTIGEN; MODEL; ENHANCEMENT; MELANOMA; CELLS	'Naked' nucleic acid Vaccines are potentially useful candidates for the treatment of patients with cancer(1-3), but their clinical efficacy has yet to be demonstrated. We sought to enhance the immunogenicity of a nucleic acid Vaccine by making it 'self-replicating'. We accomplished this by using a gene encoding an RNA replicase polyprotein derived from the Semliki forest virus, in combination with a model antigen. A single intramuscular injection of a self-replicating RNA immunogen elicited antigen-specific antibody and CD8(+) T-cell responses at doses as low as 0.1 mu g. Pre-immunization with a self-replicating RNA vector protected mice from tumor challenge, and therapeutic immunization prolonged the survival of mice with established tumors. The self-replicating RNA vectors did not mediate the production of substantially more model antigen than a conventional DNA vaccine did in vitro. However, the enhanced efficacy in vivo correlated with a caspase-dependent apoptotic death in transfected cells. This death facilitated the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity. Naked, non-infectious, self-replicating RNA may be an excellent candidate for the development of new cancer vaccines.	NCI, Surg Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Restifo, NP (corresponding author), NCI, Surg Branch, Bldg 10,Room 2B42,10 Ctr Dr, Bethesda, MD 20892 USA.		Leitner, Wolfgang W/F-5741-2011; Restifo, Nicholas Phillip/Z-1614-2019; Restifo, Nicholas P/A-5713-2008; Restifo, Nicholas Phillip/M-6549-2019	Leitner, Wolfgang W/0000-0003-3125-5922; Restifo, Nicholas P./0000-0003-4229-4580	Intramural NIH HHS [Z01 BC010763-01, Z99 CA999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Atkins GJ, 1996, MOL BIOTECHNOL, V5, P33, DOI 10.1007/BF02762410; Berglund P, 1998, NAT BIOTECHNOL, V16, P562, DOI 10.1038/nbt0698-562; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; Chappell DB, 1999, CANCER RES, V59, P59; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Dubensky TW, 1998, NAT MED, V4, P1357, DOI 10.1038/3939; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Gurunathan S, 1998, J IMMUNOL, V161, P4563; Hariharan MJ, 1998, J VIROL, V72, P950, DOI 10.1128/JVI.72.2.950-958.1998; Irvine KR, 1996, J IMMUNOL, V156, P238; Liu MA, 1998, ADV EXP MED BIOL, V452, P187; Mandl CW, 1998, NAT MED, V4, P1438, DOI 10.1038/4031; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Pardoll DM, 1998, NAT MED, V4, P525, DOI 10.1038/nm0598supp-525; Rao JB, 1996, J IMMUNOL, V156, P3357; Restifo NP, 1996, CURR OPIN IMMUNOL, V8, P658, DOI 10.1016/S0952-7915(96)80082-3; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Rosenberg SA, 1998, J NATL CANCER I, V90, P1894, DOI 10.1093/jnci/90.24.1894; Specht JM, 1997, J EXP MED, V186, P1213, DOI 10.1084/jem.186.8.1213; WANG M, 1995, J IMMUNOL, V154, P4685; Zaks TZ, 1999, J IMMUNOL, V162, P3273	23	249	318	1	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					823	827		10.1038/10548	http://dx.doi.org/10.1038/10548			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395329	Green Accepted			2022-12-27	WOS:000081926600039
J	Deng, GM; Nilsson, IM; Verdrengh, M; Collins, LV; Tarkowski, A				Deng, GM; Nilsson, IM; Verdrengh, M; Collins, LV; Tarkowski, A			Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis	NATURE MEDICINE			English	Article							STAPHYLOCOCCUS-AUREUS; SEPTIC ARTHRITIS; INTERFERON-GAMMA; IMMUNE-SYSTEM; BINDING; MICE; INTERNALIZATION; ACTIVATION; EXPRESSION; RECEPTOR	Unmethylated CpG motifs are often found in bacterial DNA, and exert immunostimulatory effects on hematopoetic cells(1-3). Bacteria produce severe joint inflammation in septic and reactive arthritides; bacterial DNA may be involved in this process. We injected bacterial DNA originating from Escherichia coli and Staphylococcus aureus and oligonucleotides containing CpG directly into the knee joints of mice of different strains. Arthritis Nas seen by histopathology within 2 hours and lasted for at east 14 days. Unmethylated CpG motifs were responsible for this induction of arthritis, as oligonucleotides containing these motifs produced the arthritis. The arthritis was characterized by an influx of monocytic, Mac-1(+) cells and by a lack of T lymphocytes. Depletion of monocytes resulted in abrogation of the synovial inflammation. Tumor necrosis factor (TNF)-alpha, a cytokine produced by cells of the monocyte/macrophage lineage, is an important mediator of this disease, as expression of mRNA for TNF-alpha was evident in the inflamed joints, and the CpG-mediated inflammation was abrogated in mice genetically unable to produce this cytokine. These findings demonstrate that bacterial DNA containing unmethylated CpG motifs induces arthritis, and indicate an important pathogenic role for bacterial DNA in septic arthritis.	Gothenburg Univ, Dept Rheumatol, S-41346 Gothenburg, Sweden	University of Gothenburg	Deng, GM (corresponding author), Gothenburg Univ, Dept Rheumatol, Guldhedsgatan 10A, S-41346 Gothenburg, Sweden.							BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CALAME W, 1994, J INFECTION, V29, P53, DOI 10.1016/S0163-4453(94)95087-3; Geselowitz D A, 1992, Antisense Res Dev, V2, P17; Goldenberg DL, 1998, LANCET, V351, P197, DOI 10.1016/S0140-6736(97)09522-6; Hultgren O, 1998, J IMMUNOL, V161, P5937; JONSSON R, 1986, J IMMUNOL METHODS, V88, P109, DOI 10.1016/0022-1759(86)90058-X; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; MAURITZ NJ, 1988, ARTHRITIS RHEUM, V31, P1297, DOI 10.1002/art.1780311012; Parks E, 1998, J IMMUNOL, V160, P4615; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Tarkowski A, 1998, MOL MED TODAY, V4, P15, DOI 10.1016/S1357-4310(97)80540-0; Verdrengh M, 1997, INFECT IMMUN, V65, P2517, DOI 10.1128/IAI.65.7.2517-2521.1997; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yi AK, 1998, J IMMUNOL, V160, P4755; Zhao YX, 1996, ARTHRITIS RHEUM-US, V39, P959, DOI 10.1002/art.1780390613; Zhao YX, 1998, IMMUNOLOGY, V93, P80	20	235	255	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					702	705		10.1038/9554	http://dx.doi.org/10.1038/9554			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371511				2022-12-27	WOS:000080823300041
J	Gupta, S; Snow, RW; Donnelly, CA; Marsh, K; Newbold, C				Gupta, S; Snow, RW; Donnelly, CA; Marsh, K; Newbold, C			Immunity to non-cerebral severe malaria is acquired after one or two infections	NATURE MEDICINE			English	Article							PLASMODIUM-FALCIPARUM; TRANSMISSION; MORBIDITY	In areas of stable transmission, clinical immunity to mild malaria is acquired slowly, so it is not usually effective until early adolescence. Life-threatening disease is, however, restricted to a much younger age group, indicating that resistance to the severe clinical consequences of infection is acquired more quickly. Understanding how rapidly immunity develops to severe malaria is essential, as severe malaria should be the primary target of intervention strategies, and predicting the result of interventions that reduce host exposure will require consideration of these dynamics(1,2). Severe disease in childhood is less frequent in areas where transmission is the greatest(3). One explanation for this is that infants experience increased exposure to infection(4-6) while they are protected from disease, possibly by maternal antibody. They therefore emerge from this period of clinical protection with considerably more immunity than those who experience lower transmission intensities. Here we use this data(3), assuming a period of clinical protection, to estimate the number of prior infections needed to reduce the risk of severe disease to negligible levels. Contrary to expectations, one or two successful infective bites seem to be all that is necessary across a broad range of transmission intensities.	Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol & Infect Dis, Oxford OX1 3PS, England; KEMRI Wellcome Trust Collaborat Programme, Nairobi, Kenya; Univ Oxford, Inst Mol Med, Oxford, England; KEMRI, Coastal Unit, Kilifi, Kenya	University of Oxford; University of Oxford	Gupta, S (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol & Infect Dis, S Parks Rd, Oxford OX1 3PS, England.		Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088; Donnelly, Christl/0000-0002-0195-2463; Newbold, Chris/0000-0002-9274-3789	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; BAIRD JK, 1995, PARASITOL TODAY, V11, P105, DOI 10.1016/0169-4758(95)80167-7; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; Gupta S, 1999, P ROY SOC B-BIOL SCI, V266, P33, DOI 10.1098/rspb.1999.0600; JEFFERY GM, 1966, B WORLD HEALTH ORGAN, V35, P873; Kitua AY, 1996, TROP MED INT HEALTH, V1, P475, DOI 10.1046/j.1365-3156.1996.d01-89.x; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MCGREGOR IA, 1987, ANN TROP MED PARASIT, V81, P647, DOI 10.1080/00034983.1987.11812166; Slutsker L, 1996, AM J TROP MED HYG, V55, P71, DOI 10.4269/ajtmh.1996.55.71; Snow RW, 1996, AM J TROP MED HYG, V55, P144, DOI 10.4269/ajtmh.1996.55.2.TM0550020144; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Snow RW, 1998, J INFECT DIS, V177, P819, DOI 10.1086/517818; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; Wagner G, 1998, AM J TROP MED HYG, V59, P115, DOI 10.4269/ajtmh.1998.59.115	14	317	322	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					340	343		10.1038/6560	http://dx.doi.org/10.1038/6560			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086393				2022-12-27	WOS:000078851600042
J	Kennedy, CRJ; Zhang, YH; Brandon, S; Guan, YF; Coffee, K; Funk, CD; Magnuson, MA; Oates, JA; Breyer, MD; Breyer, RM				Kennedy, CRJ; Zhang, YH; Brandon, S; Guan, YF; Coffee, K; Funk, CD; Magnuson, MA; Oates, JA; Breyer, MD; Breyer, RM			Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor	NATURE MEDICINE			English	Article							INDOMETHACIN; INITIATION; PREGNANCY	Prostaglandins (PGs) are ubiquitous lipid mediators derived from cyclooxygenase metabolism of arachidonic acid that exert a broad range of physiologic activities, including modulation of inflammation, ovulation(1,2) and arterial blood pressure(3,4). PGE(2), a chief cyclooxygenase product, modulates blood pressure and fertility, although the specific G protein-coupled receptors(5,6) mediating these effects remain poorly defined. To evaluate the physiologic role of the PGE(2) EP2 receptor subtype, we created mice with targeted disruption of this gene (EP2-/-). EP2-/- mice develop normally but produce small litters and have slightly elevated baseline systolic blood pressure. In EP2-/- mice, the characteristic hypotensive effect of intravenous PGE(2) infusion was absent; PGE(2) infusion instead produced hypertension. When fed a diet high in salt, the EP2-/- mice developed profound systolic hypertension, whereas wild-type mice showed no change in systolic blood pressure. Analysis of wild-type and EP2-/- mice on day 5 of pregnancy indicated that the reduced litter size of EP2-/- mice is due to a pre-implantation defect. This reduction of implanted embryos could be accounted for by impaired ovulation and dramatic reductions in fertilization observed on day 2 of pregnancy. These data demonstrate that the EP2 receptor mediates arterial dilatation, salt-sensitive hypertension, and also plays an essential part in female fertility.	Dept Med, Div Nephrol, Nashville, TN 37232 USA; Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA; Dept Pharmacol, Nashville, TN 37232 USA; Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vet Adm Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vanderbilt University	Breyer, RM (corresponding author), Dept Med, Div Nephrol, S3223 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	rich.breyer@mcmail.vanderbilt.edu	Funk, Colin D/A-9518-2010	guan, youfei/0000-0002-5231-0209; Magnuson, Mark/0000-0002-8824-6499; Breyer, Matthew/0000-0003-1880-371X; Funk, Colin/0000-0001-7029-4233	NIDDK NIH HHS [DK-46205, DK-37097] Funding Source: Medline; NIGMS NIH HHS [GM-15431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046205, R01DK037097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Challis JRG, 1997, NAT MED, V3, P1326, DOI 10.1038/nm1297-1326; Coleman R A, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P467; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; DOWNS SM, 1982, AM J ANAT, V164, P265, DOI 10.1002/aja.1001640307; GARDINER PJ, 1986, BRIT J PHARMACOL, V87, P45, DOI 10.1111/j.1476-5381.1986.tb10155.x; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781, DOI 10.1001/jama.272.10.781; HOFFMAN LH, 1978, BIOL REPROD, V18, P148, DOI 10.1095/biolreprod18.1.148; Johnson AG, 1997, DRUG SAFETY, V17, P277, DOI 10.2165/00002018-199717050-00001; KENNEDY TG, 1977, BIOL REPROD, V16, P286, DOI 10.1095/biolreprod16.3.286; LAU IF, 1973, PROSTAGLANDINS, V4, P795, DOI 10.1016/0090-6980(73)90115-9; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; LLOZUMI N, 1997, NATURE, V390, P618; PRIDDY AR, 1993, PROSTAG LEUKOTR ESS, V49, P827, DOI 10.1016/0952-3278(93)90204-A; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Simpson F. Olaf, 1995, P273; Smith G, 1996, BRIT J RHEUMATOL, V35, P458; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Weitlauf H. M., 1994, P391	20	318	331	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					217	220		10.1038/5583	http://dx.doi.org/10.1038/5583			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930871				2022-12-27	WOS:000078274400032
J	Fan, JQ; Ishii, S; Asano, N; Suzuki, Y				Fan, JQ; Ishii, S; Asano, N; Suzuki, Y			Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor	NATURE MEDICINE			English	Article							ENDOPLASMIC-RETICULUM; POINT MUTATIONS; A-GENE; DISEASE; FORM	Fabry disease is a disorder of glycosphingolipid metabolism caused by deficiency of lysosomal alpha-galactosidase A (alpha-Gal A), resulting in renal failure along with premature myocardial infarction and strokes(1,2). No effective treatment of this disorder is available at present. Studies of residual activities of mutant enzymes in many Fabry patients showed that some of them had kinetic properties similar to those for normal alpha-Gal A, but were significantly less stable, especially in conditions of neutral pH (refs. 3-5). The biosynthetic processing was delayed in cultured fibroblasts of a Fabry patient(6) and the mutant protein formed an aggregate in endoplasmic reticulum: indicating that the enzyme deficiency in some mutants was mainly caused by abortive exit from the endoplasmic reticulum(7), leading to excessive degradation of the enzyme. We report here that 1-deoxy-galactonojirimycin (DGJ), a potent competitive inhibitor of alpha-Gal A, effectively enhanced alpha-Gal A activity in Fabry lymphoblasts, when administrated at concentrations lower than that usually required for intracellular inhibition of the enzyme. DGJ seemed to accelerate transport and maturation of the mutant enzyme. Oral administration of DGJ to transgenic mice overexpressing a mutant alpha-Gal A substantially elevated the enzyme activity in some organs. We propose a new molecular therapeutic strategy for genetic metabolic diseases of administering competitive inhibitors as 'chemical chaperons' at sub-inhibitory intracellular concentrations.	Hokuriku Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9201181, Japan; Tokyo Metropolitan Inst Med Sci, Dept Membrane Biochem, Tokyo 1138613, Japan; Usuki Bio Res Ctr, Oita 8750061, Japan	Hokuriku University; Tokyo Metropolitan Institute of Medical Science	Fan, JQ (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA.							Abe A, 1996, BBA-LIPID LIPID MET, V1299, P333, DOI 10.1016/0005-2760(95)00217-0; ASANO N, 1994, J MED CHEM, V37, P3701, DOI 10.1021/jm00048a006; Asano N, 1997, J NAT PROD, V60, P98, DOI 10.1021/np960577n; BISHOP DF, 1981, AM J HUM GENET, V33, pA71; Block TM, 1998, NAT MED, V4, P610, DOI 10.1038/nm0598-610; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; DALE MP, 1985, BIOCHEMISTRY-US, V24, P3530, DOI 10.1021/bi00335a022; Desnick RJ., 1995, METABOLIC MOL BASES, P2741; Fleischer S, 1974, Methods Enzymol, V31, P6; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOSS PE, 1994, CANCER RES, V54, P1450; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ISHII S, 1992, HUM GENET, V89, P29, DOI 10.1007/BF00207037; ISHII S, 1993, BIOCHEM BIOPH RES CO, V197, P1585, DOI 10.1006/bbrc.1993.2659; Ishii S, 1996, BIOCHEM BIOPH RES CO, V220, P812, DOI 10.1006/bbrc.1996.0486; Ishii S, 1998, GLYCOCONJUGATE J, V15, P591, DOI 10.1023/A:1006915926732; LEMANSKY P, 1987, J BIOL CHEM, V262, P2062; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; NEUENHOFER S, 1985, BIOCHEMISTRY-US, V24, P525, DOI 10.1021/bi00323a042; OSHIMA A, 1994, HUM GENET, V93, P109; ROMEO G, 1975, BIOCHEM GENET, V13, P615, DOI 10.1007/BF00484919; SAKURABA H, 1990, AM J HUM GENET, V47, P784	22	516	558	3	45	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					112	115		10.1038/4801	http://dx.doi.org/10.1038/4801			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883849				2022-12-27	WOS:000077885000039
J	Klein, MA; Frigg, R; Raeber, AJ; Flechsig, E; Hegyi, I; Zinkernagel, RM; Weissmann, C; Aguzzi, A				Klein, MA; Frigg, R; Raeber, AJ; Flechsig, E; Hegyi, I; Zinkernagel, RM; Weissmann, C; Aguzzi, A			PrP expression in B lymphocytes is not required for prion neuroinvasion	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE AGENT; MICE; PROTEIN; MOUSE; CELLS; REPLICATION; ISOFORM; SPLEEN; ONSET	Prion diseases are typically initiated by infection of peripheral sites, as in the case of bovine spongiform encephalopathy, new variant Creutzfeldt-Jakob disease(1), kuru and most cases of iatrogenic Creutzfeldt-Jakob disease. In mouse scrapie, prion infectivity accumulates in lymphoid organs, and the absence of mature B lymphocytes prevents peripherally administered prions from inducing central nervous system disease(2). We have now assessed whether expression of the cellular prion protein, PrPc, is required for B lymphocytes to mediate neuroinvasion. We found that repopulation of SCID and Rag-1(-/-) mice with fetal liver cells from either PrP-expressing or PrP-deficient mice and from T-cell deficient mice, but not from B-cell deficient mice, is equally efficient in restoring neuroinvasion after intraperitoneal inoculation of scrapie prions. These results indicate that cells whose maturation depends on B cells or their products, such as follicular dendritic cells, may enhance neuroinvasion. Alternatively, B cells may transport prions to the nervous system by a PrP-independent mechanism.	Univ Zurich, Inst Neuropathol, Zurich, Switzerland; Univ Zurich, Inst Mol Biol, Zurich, Switzerland; Univ Zurich, Inst Expt Immunol, Zurich, Switzerland	University of Zurich; University of Zurich; University of Zurich	Aguzzi, A (corresponding author), Univ Zurich, Inst Neuropathol, Zurich, Switzerland.		Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; Gonzalez M, 1998, J EXP MED, V187, P997, DOI 10.1084/jem.187.7.997; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; KOSCO MH, 1992, J IMMUNOL, V148, P2331; Lasmezas CI, 1996, J VIROL, V70, P1292; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; Weissmann C, 1997, CURR OPIN NEUROBIOL, V7, P695, DOI 10.1016/S0959-4388(97)80091-8	22	227	232	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1429	1433		10.1038/4022	http://dx.doi.org/10.1038/4022			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846583				2022-12-27	WOS:000077336900041
J	Lawinger, P; Venugopal, R; Guo, ZS; Immaneni, A; Sengupta, D; Lu, WY; Rastelli, L; Carneiro, AMD; Levin, V; Fuller, GN; Echelard, Y; Majumder, S				Lawinger, P; Venugopal, R; Guo, ZS; Immaneni, A; Sengupta, D; Lu, WY; Rastelli, L; Carneiro, AMD; Levin, V; Fuller, GN; Echelard, Y; Majumder, S			The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells	NATURE MEDICINE			English	Article							RESTRICTIVE SILENCER FACTOR; GENE-EXPRESSION; P53 MUTATIONS; TARGET GENES; REST	Medulloblastoma is the most malignant pediatric brain tumor. It is believed to originate from the undifferentiated external granule layer cells in the cerebellum, but the mechanism of tumorigenesis remains unknown(1-6). Here we studied three types of human medulloblastoma cells that express markers corresponding to different levels of neuronal differentiation. They expressed the neuronal repressor element 1 (RE1) silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF; refs. 7-10) at very high levels compared with either neuronal progenitor NTera2 (NT2) cells or fully differentiated human neuron teratocarcinoma (hNT cells). To counter the effect of REST/NRSF, we used a recombinant transcription factor, REST-VP16, constructed by replacing repressor domains of REST/NRSF with the activation domain of viral protein (VP16). Transient expression of REST-VP16 in medulloblastoma cells was able to compete with the endogenous REST/NRSF for DNA binding and stimulate neuronal promoters. High-efficiency expression of REST-VP16 mediated by adenovirus vectors (Ad.REST-VP16) in medulloblastoma cells was able to counter REST/NRSF-mediated repression of neuronal promoters, stimulate expression of endogenous neuronal genes and trigger apoptosis through the activation of caspase cascades. Furthermore, intratumoral injection of Ad.REST-VP16 in established medulloblastoma tumors in nude mice inhibited their growth. Therefore, REST/NRSF may serve as a new target for therapeutic interventions for medulloblastoma through agents such as REST-VP16.	Univ Texas, MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77005 USA; NCI, Surg Branch, Bethesda, MD 20892 USA; Genzyme Transgen Corp, Framingham, MA 01710 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sanofi-Aventis	Majumder, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Brain Tumor Ctr, 1515 Holcombe Blvd,Box 316, Houston, TX 77005 USA.		Guo, Zong Sheng/H-3098-2019	Guo, Zong Sheng/0000-0002-4624-9907; Fuller, Gregory/0000-0001-9447-2647	NCI NIH HHS [CA51255] Funding Source: Medline; NIGMS NIH HHS [GM53454] Funding Source: Medline; NATIONAL CANCER INSTITUTE [S15CA051255] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADESINA AM, 1994, CANCER RES, V54, P5649; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; FULLER GN, 1996, PEDIAT NEOPLASIA MOR, P153; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Goussia AC, 2000, ANTICANCER RES, V20, P65; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HE XM, 1989, J NEUROPATH EXP NEUR, V48, P48, DOI 10.1097/00005072-198901000-00005; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; JACOBSEN PF, 1985, J NEUROPATH EXP NEUR, V44, P472, DOI 10.1097/00005072-198509000-00003; Majumder S, 1997, EMBO J, V16, P1721, DOI 10.1093/emboj/16.7.1721; McMahon AP, 2000, CELL, V100, P185, DOI 10.1016/S0092-8674(00)81555-X; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Provias JP, 1996, J NEURO-ONCOL, V29, P35, DOI 10.1007/BF00165516; RAFFEL C, 1993, NEUROSURGERY, V33, P301, DOI 10.1227/00006123-199308000-00018; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; TOHYAMA T, 1992, LAB INVEST, V66, P303; Whelan HT, 1998, PEDIATR NEUROL, V18, P103, DOI 10.1016/S0887-8994(97)00221-X; Xie JW, 1997, CANCER RES, V57, P2369	24	138	141	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					826	+		10.1038/77565	http://dx.doi.org/10.1038/77565			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888935				2022-12-27	WOS:000088040100043
J	Horwitz, MS; La Cava, A; Fine, C; Rodriguez, E; Ilic, A; Sarvetnick, N				Horwitz, MS; La Cava, A; Fine, C; Rodriguez, E; Ilic, A; Sarvetnick, N			Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis	NATURE MEDICINE			English	Article							HUMAN HEART-DISEASE; MURINE MYOCARDITIS; TRANSGENIC MICE; DILATED CARDIOMYOPATHY; B3-INDUCED MYOCARDITIS; NITRIC-OXIDE; VIRUS; PATHOGENESIS; LYMPHOCYTES; CONTRIBUTE	Cardiovascular disease is one of the leading causes of death worldwide, and has been associated with many environmental risk factors(1). Recent evidence has indicated the involvement of pathogens such as viruses as causative agents, and specifically identified the coxsackievirus B serogroup as the leading culprit(2,3). Not only has coxsackievirus B3 (CB3) been identified from patients with cardiovascular disease(4), but also infection of mice with CB3 strains can reproduce human clinical heart disease in rodents(5,6). Several mechanisms have been proposed in an attempt to distinguish between pathology mediated by direct viral destruction of cardiac muscle cells(7,8) or by the virus-induced immune response directed at infected myocytes(9-11) or at 'mimicked' epitopes shared between viral and cardiac antigens(12-14). To distinguish between these mechanisms, we infected a unique mouse that diminishes the extent of infection and spread of the virus, but allows complete immunity to the virus. Transgenic mice expressing interferon-gamma in their pancreatic beta cells failed to develop CB-3-induced myocarditis. This work challenges the idea of the function of the immune response and 'molecular mimicry' in the CB-3-induced autoimmune myocarditis model, and instead favors the idea of virus-mediated damage. These results emphasize the benefit of reducing the level of viremia early during infection, thereby reducing the incidence of virus-mediated heart damage and autoimmunity.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Sarvetnick, N (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines, La Jolla, CA 92037 USA.		/AAG-9576-2020	/0000-0002-8839-0933				Baboonian C, 1997, CURR TOP MICROBIOL, V223, P31; Baboonian C, 1997, HEART, V78, P539, DOI 10.1136/hrt.78.6.539; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; CHOW LH, 1992, LAB INVEST, V66, P24; Felker GM, 1999, MEDICINE, V78, P270, DOI 10.1097/00005792-199907000-00005; GAUNTT CJ, 1991, EUR HEART J, V12, P124, DOI 10.1093/eurheartj/12.suppl_D.124; GAUNTT CJ, 1993, CLIN IMMUNOL IMMUNOP, V68, P129, DOI 10.1006/clin.1993.1108; GODMAN GC, 1952, AM J PATHOL, V28, P223; GU DL, 1993, DEVELOPMENT, V118, P33; HASHIMOTO I, 1983, BRIT J EXP PATHOL, V64, P497; HENKE A, 1995, J VIROL, V69, P6720, DOI 10.1128/JVI.69.11.6720-6728.1995; HOHENADL C, 1994, J VIROL METHODS, V47, P279, DOI 10.1016/0166-0934(94)90025-6; Horwitz MS, 1999, J VIROL, V73, P1756, DOI 10.1128/JVI.73.3.1756-1766.1999; Horwitz MS, 1997, NAT MED, V3, P1037, DOI 10.1038/nm0997-1037; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; MARTINO TA, 1994, CIRC RES, V74, P182, DOI 10.1161/01.RES.74.2.182; MCMANUS BM, 1993, CLIN IMMUNOL IMMUNOP, V68, P159, DOI 10.1006/clin.1993.1113; Ramsingh AI, 1999, J VIROL, V73, P3080, DOI 10.1128/JVI.73.4.3080-3086.1999; ROSE NR, 1986, ANN NY ACAD SCI, V475, P146, DOI 10.1111/j.1749-6632.1986.tb20864.x; Rose NR, 1996, CLIN IMMUNOL IMMUNOP, V80, pS92, DOI 10.1006/clin.1996.0146; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; SCHNURR DP, 1984, J GEN VIROL, V65, P1197, DOI 10.1099/0022-1317-65-7-1197; WOLFGRAM LJ, 1985, J EXP MED, V161, P1112, DOI 10.1084/jem.161.5.1112	24	117	121	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					693	697		10.1038/76277	http://dx.doi.org/10.1038/76277			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835688				2022-12-27	WOS:000087438300042
J	Mauri, C; Mars, LT; Londei, M				Mauri, C; Mars, LT; Londei, M			Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; CELL-MEDIATED-IMMUNITY; CD4(+) T-CELLS; IN-VIVO; B-CELLS; TARGETING AUTOANTIGEN; CLONAL EXPANSION; INDUCTION; ACTIVATION; DISEASE	The use of agonistic monoclonal antibody against CD40 has emerged as one the most effective ways to boost immune responses against infectious agents or to fight cancer. Here, we report that the same monoclonal antibodies against CD40 (FGK45 and 3/23) previously used to elicit protective immune responses treated the autoimmune inflammatory process of chronic collagen-induced arthritis in DBA/1-TCR-beta transgenic mice, as well as collagen-induced arthritis in DBA/1 mice, both animal models of rheumatoid arthritis. This study indicates that agonistic monoclonal antibody against CD40 can potentially be used to treat chronic autoimmune inflammatory processes.	Imperial Coll, Sch Med, Kennedy Inst Rheumatol, London W6 8LH, England	Imperial College London; University of Oxford	Londei, M (corresponding author), Imperial Coll, Sch Med, Kennedy Inst Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.		Mauri, Chiara/GXN-0766-2022; Mars, Lennart T/K-7593-2014	Mars, Lennart T/0000-0001-7997-1974; Mauri, Claudia/0000-0001-9761-2625				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Balasa B, 1997, J IMMUNOL, V159, P4620; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Chu CQ, 1996, J IMMUNOL, V157, P2685; DAY MJ, 1992, J EXP MED, V175, P655, DOI 10.1084/jem.175.3.655; DEVRIES JE, 1995, ANN MED, V27, P537, DOI 10.3109/07853899509002465; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; Faassen AE, 1995, EUR J IMMUNOL, V25, P3249, DOI 10.1002/eji.1830251208; Ferlin WG, 1998, EUR J IMMUNOL, V28, P525, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;525::AID-IMMU525&gt;3.0.CO;2-M; FINKELMAN FD, 1987, J IMMUNOL, V138, P2826; FINKELMAN FD, 1986, J IMMUNOL, V137, P2878; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Griggs ND, 1996, J EXP MED, V183, P801, DOI 10.1084/jem.183.3.801; Guinan EC, 1999, NEW ENGL J MED, V340, P1704, DOI 10.1056/NEJM199906033402202; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; Hogaboam CM, 1997, J CLIN INVEST, V100, P2766, DOI 10.1172/JCI119823; Howard LM, 1999, J CLIN INVEST, V103, P281, DOI 10.1172/JCI5388; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; Macaulay AE, 1997, J IMMUNOL, V158, P4171; Maiuri L, 1998, GASTROENTEROLOGY, V115, P564, DOI 10.1016/S0016-5085(98)70135-0; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Mauri C, 1997, J IMMUNOL, V159, P5032; Mauri C, 1996, EUR J IMMUNOL, V26, P1511, DOI 10.1002/eji.1830260716; Maxwell JR, 1999, J IMMUNOL, V162, P2024; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; MOHAN C, 1995, J IMMUNOL, V154, P1470; MORI L, 1992, J EXP MED, V176, P381, DOI 10.1084/jem.176.2.381; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; POWRIE F, 1993, EUR J IMMUNOL, V23, P3043, DOI 10.1002/eji.1830231147; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SAOUDI A, 1995, J EXP MED, V182, P335, DOI 10.1084/jem.182.2.335; Skok J, 1999, J IMMUNOL, V163, P4284; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; Walmsley M, 1996, ARTHRITIS RHEUM-US, V39, P495, DOI 10.1002/art.1780390318; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784	46	100	107	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					673	679		10.1038/76251	http://dx.doi.org/10.1038/76251			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835684				2022-12-27	WOS:000087438300038
J	Moran, N; Pierce, N; Seger, J				Moran, N; Pierce, N; Seger, J			W.D. Hamilton, 1936-2000 - Obituary	NATURE MEDICINE			English	Biographical-Item									Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA; Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	University of Arizona; Harvard University; Utah System of Higher Education; University of Utah	Moran, N (corresponding author), Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA.		Moran, Nancy A/G-1591-2010						0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					367	367		10.1038/74607	http://dx.doi.org/10.1038/74607			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742130	Bronze			2022-12-27	WOS:000165474100016
J	Braun, KM; Degen, JL; Sandgren, EP				Braun, KM; Degen, JL; Sandgren, EP			Hepatocyte transplantation in a model of toxin-induced liver disease: variable therapeutic effect during replacement of damaged parenchyma by donor cells	NATURE MEDICINE			English	Article							ACUTE HEPATIC-FAILURE; HEPATOCELLULAR TRANSPLANTATION; GENE-THERAPY; TRANSGENIC MICE; PLASMINOGEN-ACTIVATOR; DEFICIENT RABBITS; MOUSE-LIVER; RAT; HYPERCHOLESTEROLEMIA; REGENERATION	To provide long-term therapy in patients with severe toxin-induced hepatic parenchymal damage, donor hepatocytes would need to replicate and replace a large portion of the damaged parenchyma. Using a mouse model developed to reproduce this type of hepatic injury, we found that hepatocyte transplantation only slightly improved survival after transplantation despite the fact that many non-survivors showed moderate liver repopulation by donor cells. Perhaps accounting for this outcome, donor parenchyma in non-survivors did not have typical lobular organization. These results indicate that the re-creation of functional parenchyma by transplanted hepatocytes requires time, during which donor cells proliferate and then establish normal parenchymal architecture.	Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA; Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA	University of Wisconsin System; University of Wisconsin Madison; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Sandgren, EP (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.				NIDDK NIH HHS [R01-DK49787] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049787] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMGARTNER D, 1983, EUR SURG RES, V15, P129, DOI 10.1159/000128344; Birraux J, 1998, EUR J PEDIATR SURG, V8, P224, DOI 10.1055/s-2008-1071159; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; Brand K, 1997, CANCER GENE THER, V4, P9; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CAMERON RG, 1996, DRUG INDUCED HEPATOT; Chowdhury JR, 1998, PEDIATRICS, V102, P647, DOI 10.1542/peds.102.3.647; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; FREEMAN SM, 1993, CANCER RES, V53, P5274; FULLER BJ, 1988, J HEPATOL, V7, P368, DOI 10.1016/S0168-8278(88)80010-2; GROSSMAN M, 1994, NAT GENET, V6, P335, DOI 10.1038/ng0494-335; GROTH CG, 1977, TRANSPLANT P, V9, P313; Gunsalus JR, 1997, NAT MED, V3, P48, DOI 10.1038/nm0197-48; Gupta S, 1999, J HEPATOL, V30, P162, DOI 10.1016/S0168-8278(99)80022-1; HABIBULLAH CM, 1994, TRANSPLANTATION, V58, P951, DOI 10.1097/00007890-199410270-00016; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; HEYMAN RA, 1989, P NATL ACAD SCI USA, V86, P2698, DOI 10.1073/pnas.86.8.2698; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Kocken JM, 1996, TRANSPLANTATION, V62, P358, DOI 10.1097/00007890-199608150-00010; Lake JR, 1998, NEW ENGL J MED, V338, P1463, DOI 10.1056/NEJM199805143382012; LEE AH, 1994, AM J MED, V96, P35, DOI 10.1016/0002-9343(94)90113-9; LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706; MAKOWKA L, 1981, CAN J SURG, V24, P39; MAKOWKA L, 1980, J SURG RES, V29, P479, DOI 10.1016/0022-4804(80)90016-5; MATAS AJ, 1976, SCIENCE, V192, P892, DOI 10.1126/science.818706; MITO M, 1993, TRANSPLANT REV, V7, P35; Moscioni AD, 1996, CELL TRANSPLANT, V5, P499, DOI 10.1016/0963-6897(95)02021-7; Oren R, 1999, HEPATOLOGY, V29, P75, DOI 10.1002/hep.510290147; Overturf K, 1997, AM J PATHOL, V151, P1273; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SMITH DD, 1988, P NATL ACAD SCI USA, V85, P160, DOI 10.1073/pnas.85.1.160; SOMMER BG, 1979, TRANSPLANT P, V11, P578; Strom SC, 1997, TRANSPLANTATION, V63, P559, DOI 10.1097/00007890-199702270-00014; SUTHERLAND DER, 1977, SURGERY, V82, P124; WALLACE H, 1994, J ENDOCRINOL, V143, P107, DOI 10.1677/joe.0.1430107; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; ZIMMERMAN HJ, 1993, DIS LIVER, V1, P707	44	74	79	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					320	326						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700235				2022-12-27	WOS:000085580500043
J	Granovsky, M; Fata, J; Pawling, J; Muller, WJ; Khokha, R; Dennis, JW				Granovsky, M; Fata, J; Pawling, J; Muller, WJ; Khokha, R; Dennis, JW			Suppression of tumor growth and metastasis in Mgat5-deficient mice	NATURE MEDICINE			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; HAMSTER-KIDNEY CELLS; BETA-1-6 BRANCHED OLIGOSACCHARIDES; ASN-LINKED OLIGOSACCHARIDES; GLCNAC-TRANSFERASE-V; PHOSPHATIDYLINOSITOL 3-KINASE; PHASEOLUS-VULGARIS; SUGAR CHAINS; HUMAN BREAST; EXPRESSION	Golgi beta 1,6N-acetylglucosaminyltransferase V (MGAT5) is required in the biosynthesis of beta 1,6GlcNAc-branched N-linked glycans attached to cell surface and secreted glycoproteins. Amounts of MGAT5 glycan products are commonly increased in malignancies, and correlate with disease progression. To study the functions of these N-glycans in development and disease, we generated mice deficient in Mgat5 by targeted gene mutation. These Mgat5(-/-) mice lacked Mgat5 products and appeared normal, but differed in their responses to certain extrinsic conditions. Mammary tumor growth and metastases induced by the polyomavirus middle T oncogene was considerably less in Mgat5(-/-) mice than in transgenic littermates expressing Mgat5. Furthermore, Mgat5 glycan products stimulated membrane ruffling and phosphatidylinositol 3 kinase-protein kinase B activation, fueling a positive feedback loop that amplified oncogene signaling and tumor growth in vivo. Our results indicate that inhibitors of MGAT5 might be useful in the treatment of malignancies by targeting their dependency on focal adhesion signaling for growth and metastasis.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada; Princess Margaret Hosp, Toronto, ON M5G 2C1, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; McMaster University	Dennis, JW (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave,R988, Toronto, ON M5G 1X5, Canada.	Dennis@mshri.on.ca	Dennis, James/E-7268-2013					ASADA M, 1991, BIOCHEMISTRY-US, V30, P1561, DOI 10.1021/bi00220a017; Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; Chen L, 1998, ONCOGENE, V17, P2087, DOI 10.1038/sj.onc.1202124; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1986, CANCER RES, V46, P5131; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DO KY, 1994, J BIOL CHEM, V269, P23456; FERNANDES B, 1991, CANCER RES, V51, P718; GOSS PE, 1994, CANCER RES, V54, P1450; Granovsky M, 1995, GLYCOBIOLOGY, V5, P797, DOI 10.1093/glycob/5.8.797; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HASTY P, 1993, GENE TARGETING PRACT, P138; HUMPHRIES MJ, 1986, P NATL ACAD SCI USA, V83, P1752, DOI 10.1073/pnas.83.6.1752; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Liu AX, 1998, CANCER RES, V58, P2973; LU Y, 1994, CLIN EXP METASTAS, V12, P47, DOI 10.1007/BF01784333; McEvoy LM, 1997, J EXP MED, V185, P1493, DOI 10.1084/jem.185.8.1493; Nakagawa H, 1996, EUR J BIOCHEM, V237, P76, DOI 10.1111/j.1432-1033.1996.0076n.x; Neznanov N, 1999, CANCER RES, V59, P4242; PIERCE M, 1986, J BIOL CHEM, V261, P772; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Seberger PJ, 1999, GLYCOBIOLOGY, V9, P235, DOI 10.1093/glycob/9.3.235; Seelentag WKF, 1998, CANCER RES, V58, P5559; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834	41	434	451	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					306	312						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700233				2022-12-27	WOS:000085580500041
J	Michele, DE; Albayya, FP; Metzger, JM				Michele, DE; Albayya, FP; Metzger, JM			Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes	NATURE MEDICINE			English	Article							THIN FILAMENT; TROPONIN-T; MUTATIONS; GENE; SENSITIVITY; EXPRESSION	Familial hypertrophic cardiomyopathy is a clinically and genetically diverse autosomal dominant disorder characterized by ventricular hypertrophy and myocyte disarray in the absence of known hypertrophic stimuli(1,2). It has been linked to many cardiac contractile proteins, including four point mutations in alpha-tropomyosin(3,4,5) (Tm). Here we use adenoviral-mediated gene transfer into adult cardiac myocytes in vitro to show that all four hypertrophic cardiomyopathy alpha-Tm proteins can be expressed and incorporated into normal sarcomeric structures in cardiac myocytes at similar levels as normal alpha-Tm proteins after 5-6 days in culture. Isometric force recordings of single cardiac myocytes demonstrated inappropriate increased force output at submaximal calcium concentration with a specific mutant allele hierarchy. These data indicate that the severity of direct calcium-sensitizing effect of mutations in alpha-Tm may predict the clinical severity of mutant alpha-Tm-associated hypertrophic cardiomyopathy.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Metzger, JM (corresponding author), Univ Michigan, Dept Physiol, 7730 Med Sci 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.							Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; Bonne G, 1998, CIRC RES, V83, P580, DOI 10.1161/01.RES.83.6.580; Bottinelli R, 1998, CIRC RES, V82, P106; Coviello DA, 1997, J AM COLL CARDIOL, V29, P635, DOI 10.1016/S0735-1097(96)00538-4; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; Golitsina N, 1999, BIOCHEMISTRY-US, V38, P3850, DOI 10.1021/bi9950701; Golitsina N, 1997, BIOCHEMISTRY-US, V36, P4637, DOI 10.1021/bi962970y; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MARTIN AF, 1981, J BIOL CHEM, V256, P964; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; METZGER JM, 1993, P NATL ACAD SCI USA, V90, P9036, DOI 10.1073/pnas.90.19.9036; Michele DE, 1999, J CELL BIOL, V145, P1483, DOI 10.1083/jcb.145.7.1483; Muthuchamy M, 1999, CIRC RES, V85, P47; NAKAJIMATANIGUCHI C, 1995, J MOL CELL CARDIOL, V27, P2053, DOI 10.1016/0022-2828(95)90026-8; Rust EM, 1998, MOL CELL BIOCHEM, V181, P143, DOI 10.1023/A:1006802719136; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; THIERFELDER L, 1993, P NATL ACAD SCI USA, V90, P6720; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; Westfall MV, 1997, METHOD CELL BIOL, V52, P307, DOI 10.1016/S0091-679X(08)60385-4; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; YamauchiTakihara K, 1996, HEART, V76, P63, DOI 10.1136/hrt.76.1.63	26	71	72	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1413	1417						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581085				2022-12-27	WOS:000084049700042
J	Young, JD; Lawrence, AJ; MacLean, AG; Leung, BP; McInnes, IB; Canas, B; Pappin, DJC; Stevenson, RD				Young, JD; Lawrence, AJ; MacLean, AG; Leung, BP; McInnes, IB; Canas, B; Pappin, DJC; Stevenson, RD			Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids	NATURE MEDICINE			English	Article							METHIONINE SULFOXIDE; HUMAN-NEUTROPHILS; OXIDATION; PROTEINS; RESIDUES; ACTIN; CELLS	The possibility that glucocorticoids upregulate the expression of anti-inflammatory mediators is an exciting prospect for therapy in inflammatory diseases, because these molecules could give the therapeutic benefits of steroids without toxic side effects(1,2). Supernatants from monocytes' and macrophages(4) cultured in the presence of glucocorticoids increase the dispersion of neutrophils from a cell pellet in the capillary tube migration assay. This supernatant factor, unlike other neutrophil agonists, promotes dispersive locomotion of neutrophils at uniform concentration, lowers their adhesion to endothelial cells, inhibits their chemotactic response to fMLP and induces distinctive morphological changes(5,6). Here we show that thymosin beta 4 sulfoxide is generated by monocytes in the presence of glucocorticoids and acts as a signal to inhibit an inflammatory response. In vitro, thymosin beta 4 sulfoxide inhibited neutrophil chemotaxis, and in vivo, the oxidized peptide, but not the native form, was a potent inhibitor of carrageenin-induced edema in the mouse paw. Thymosin beta 4 is unique, because oxidation attenuates its intracellular C-actin sequestering activity(7), but greatly enhances its extracellular signaling properties. This description of methionine oxidation conferring extracellular function on a cytosolic proteins may have far-reaching implications for future strategies of anti-inflammatory therapy.	Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Univ Glasgow, Inst Biomed & Life Sci, Dept Immunol, Glasgow G12 8QQ, Lanark, Scotland; Glasgow Royal Infirm, Dept Med, Ctr Rheumat Dis, Glasgow G31 2ES, Lanark, Scotland; Imperial Canc Res Fund, Prot Sequencing Lab, London WC2A 3PX, England; Glasgow Royal Infirm, Dept Resp Med, Glasgow G31 2ES, Lanark, Scotland	University of Glasgow; Harvard University; University of Glasgow; University of Glasgow; Cancer Research UK; University of Glasgow	Lawrence, AJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland.		CANAS, BENITO/O-9256-2019; Leung, Bernard/O-2409-2013; MacLean, Andrew/R-9906-2019	Leung, Bernard/0000-0002-1119-4934; Pappin, Darryl/0000-0002-8981-8401; McInnes, Iain/0000-0002-6462-4280; MacLean, Andrew/0000-0002-0356-0674	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBINANTENISSEN JM, 1995, AM J PHYSIOL, V268, P601; BECKSPEIER I, 1988, FEBS LETT, V227, P1, DOI 10.1016/0014-5793(88)81401-7; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; CHETTIBI S, 1994, J CELL SCI, V107, P3173; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; Feinberg J, 1996, BIOCHEM BIOPH RES CO, V222, P127, DOI 10.1006/bbrc.1996.0709; FLISS H, 1983, P NATL ACAD SCI-BIOL, V80, P7160, DOI 10.1073/pnas.80.23.7160; HANNAPPEL E, 1987, J CHROMATOGR, V397, P279, DOI 10.1016/S0021-9673(01)85010-X; HEINTZ D, 1994, EUR J BIOCHEM, V223, P345, DOI 10.1111/j.1432-1033.1994.tb19000.x; IANARO A, 1994, IMMUNOLOGY, V82, P370; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; MALINDA KM, 1997, FASEB J, V11, P472; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; SHERMAN NE, 1995, P 43 AMS C MASS SPEC; STEVENSON RD, 1977, LANCET, V1, P225; STEVENSON RD, 1976, CLIN EXP IMMUNOL, V24, P527; SWAIM MW, 1988, J LEUKOCYTE BIOL, V43, P365, DOI 10.1002/jlb.43.4.365; THURMAN GB, 1984, J BIOL RESP MODIF, V3, P160; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; VOGT W, 1992, MOL IMMUNOL, V29, P251, DOI 10.1016/0161-5890(92)90106-8; Watson AA, 1998, BIOCHEMISTRY-US, V37, P12700, DOI 10.1021/bi9810757; YOUNG JD, 1997, EXP BIOL ONLINE, V2, P7	25	167	181	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1424	1427						4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581087				2022-12-27	WOS:000084049700044
J	Lutgens, E; Gorelik, L; Daemen, MJAP; de Muinck, E; Grewal, IS; Koteliansky, VE; Flavell, RA				Lutgens, E; Gorelik, L; Daemen, MJAP; de Muinck, E; Grewal, IS; Koteliansky, VE; Flavell, RA			Requirement for CD154 in the progression of atherosclerosis	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; CD40 LIGAND; ENDOTHELIAL-CELLS; T-CELLS; MICE; MACROPHAGES; CHEMOKINES; LESIONS	Atherosclerosis is a systemic disease of the large arteries, and activation of inflammatory pathways is important in its pathogenesis(1). Increasing evidence supports the importance of CD40-CD154 interactions in atherosclerosis(2,3), interactions originally known to be essential in major immune reactions(4) and autoimmune diseases(5). CD40 is present on atheroma-derived cells in vitro and in human atheromata in situ(6). Ligation of CD40 on atheroma-associated cells in vitro activates the production of chemokines(6), cytokines(6), matrix metalloproteinases(7,8), adhesion molecules(9,10) and tissue factor: substances responsible for lesion progression and plaque destabilization(1). Administration of antibody against CD154 to low-density lipoprotein receptor-deficient mice has been shown to reduce atherosclerosis and decrease T-lymphocyte and macrophage content; however, only initial lesions were studied(3). Here, we determined the effect of genetic disruption of CD154 in ApoE(-/-) mice in both initial and advanced atherosclerotic lesions. Plaque area was reduced 550%. In contrast to previous reports, initial lesion development was not affected. Advanced plaques in CD154(-/-)ApoE(-/-) mice had a less-lipid-containing, collagen-rich, stable plaque phenotype, with a reduced T-lymphocyte/macrophage content. These data indicate that CD40-CD154 signaling is important in late atherosclerotic changes, such as lipid core formation and plaque destabilization.	Biogen, Cambridge, MA 02142 USA; Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Pathol, NL-6202 AZ Maastricht, Netherlands; Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Cardiol, NL-6202 AZ Maastricht, Netherlands; Yale Univ, Sch Med, Howard Hughes Inst, Dept Immunobiol, New Haven, CT 06520 USA	Biogen; Maastricht University; Maastricht University; Howard Hughes Medical Institute; Yale University	Daemen, MJAP (corresponding author), Biogen, 14 Cambridge Ctr, Cambridge, MA 02142 USA.		Lutgens, Esther/E-2919-2010	Lutgens, Esther/0000-0002-2609-5744; Grewal, Iqbal S/0000-0002-4775-055X				ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; Kornbluth RS, 1998, P NATL ACAD SCI USA, V95, P5205, DOI 10.1073/pnas.95.9.5205; Lutgens E, 1999, CARDIOVASC RES, V41, P473, DOI 10.1016/S0008-6363(98)00311-3; Lutgens E, 1999, CIRCULATION, V99, P276, DOI 10.1161/01.CIR.99.2.276; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Mach F, 1997, CIRCULATION, V96, P396; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Mach F, 1998, ATHEROSCLEROSIS, V137, pS89, DOI 10.1016/S0021-9150(97)00309-2; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schonbeck U, 1997, CIRC RES, V81, P448, DOI 10.1161/01.RES.81.3.448; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; Terkeltaub R, 1998, CURR OPIN LIPIDOL, V9, P397, DOI 10.1097/00041433-199810000-00003; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857	20	372	395	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1313	1316		10.1038/15271	http://dx.doi.org/10.1038/15271			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10546000				2022-12-27	WOS:000086550600044
J	Larkin, J; Clayton, M; Sun, B; Perchonock, CE; Morgan, JL; Siracusa, LD; Michaels, FH; Feitelson, MA				Larkin, J; Clayton, M; Sun, B; Perchonock, CE; Morgan, JL; Siracusa, LD; Michaels, FH; Feitelson, MA			Hepatitis B virus transgenic mouse model of chronic liver disease	NATURE MEDICINE			English	Article							HEPATOCELLULAR-CARCINOMA; AUTOANTIBODY PRODUCTION; CARRIER PATIENTS; MICE; REPLICATION; INFECTION; PATHOGENESIS; EXPRESSION; GENOME; STATE	A model for hepatitis B virus-associated chronic liver disease has been made using cloned hepatitis B virus DNA as a transgene in a severe combined immunodeficient host. These mice consistently support virus gene expression and replication. After adoptive transfer of unprimed, syngeneic splenocytes, these mice cleared virus from liver and serum, and developed chronic liver disease. This model will permit identification of the host and virus contributions to chronic liver disease in the absence of tolerance.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Feitelson, MA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 222 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.			Larkin, Jonathan/0000-0002-1202-9287	NATIONAL CANCER INSTITUTE [R01CA048656, R29CA048656, R01CA066971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER; NCI NIH HHS [CA66971, CA48656] Funding Source: Medline; NIAAA NIH HHS [AA07186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; BABINET C, 1985, SCIENCE, V230, P1160, DOI 10.1126/science.3865370; BLUM HE, 1984, VIROLOGY, V139, P87, DOI 10.1016/0042-6822(84)90332-5; Blumberg BS, 1997, RES VIROLOGY, V148, P91, DOI 10.1016/S0923-2516(97)89890-1; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; Dienstag JL, 1984, VIRAL HEPATITIS LIVE, P135; FARZA H, 1988, J VIROL, V62, P4144, DOI 10.1128/JVI.62.11.4144-4152.1988; FEITELSON M, 1994, HEPATOLOGY, V19, P558, DOI 10.1002/hep.1840190304; FEITELSON MA, 1989, MOL BIOL MED, V6, P367; FEITELSON MA, 1988, J VIROL, V62, P1408, DOI 10.1128/JVI.62.4.1408-1415.1988; FEITELSON MA, 1990, GASTROENTEROLOGY, V99, P500, DOI 10.1016/0016-5085(90)91033-3; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; HOGAN B, 1994, MANIPULATION MOUSE E; Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X; Hoofnagle J. H., 1984, VIRAL HEPATITIS LIVE, P97; Hoofnagle JH, 1997, J VIRAL HEPATITIS, V4, P41, DOI 10.1111/j.1365-2893.1997.tb00159.x; HOOFNAGLE JH, 1986, SEMIN LIVER DIS, V6, P1, DOI 10.1055/s-2008-1040787; Korba BA, 1996, HEPATOLOGY, V23, P958; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; Lohrengel B, 1998, IMMUNOGENETICS, V47, P332, DOI 10.1007/s002510050366; MASON WS, 1994, HEPATOLOGY, V19, P398; MILICH DR, 1991, P NATL ACAD SCI USA, V88, P4348, DOI 10.1073/pnas.88.10.4348; MORIYAMA T, 1990, SCIENCE, V248, P361, DOI 10.1126/science.1691527; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; OMATA M, 1990, HEPATOLOGY, V12, P364, DOI 10.1002/hep.1840120226; PUGH JC, 1990, BRIT MED BULL, V46, P329, DOI 10.1093/oxfordjournals.bmb.a072402; RAY MB, 1979, HEPATITIS B VIRUS AN; ROBINSON WS, 1982, VIRAL HEPATITIS, P57; RUIZOPAZO N, 1982, J CELL BIOCHEM, V19, P281, DOI 10.1002/jcb.240190310; Sambrook J., 2002, MOL CLONING LAB MANU; Saracco G, 1997, DRUGS, V53, P74, DOI 10.2165/00003495-199753010-00005; SCHAEFFER DO, 1994, LAB ANIM SCI, V44, P189; Shanmuganathan S, 1997, J MED VIROL, V52, P128, DOI 10.1002/(SICI)1096-9071(199706)52:2<128::AID-JMV2>3.0.CO;2-5; SUMMERS J, 1981, HEPATOLOGY, V1, P179, DOI 10.1002/hep.1840010215; THOMAS HC, 1990, J HEPATOL, V11, P583; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; Waynforth H.B, 1992, EXPT SURG TECHNIQUES; WILL H, 1982, NATURE, V299, P740, DOI 10.1038/299740a0; WIRTH S, 1995, J IMMUNOL, V154, P2504	42	54	66	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					907	912		10.1038/11347	http://dx.doi.org/10.1038/11347			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426314				2022-12-27	WOS:000081684000034
J	Marchington, DR; Barlow, D; Poulton, J				Marchington, DR; Barlow, D; Poulton, J			Transmitochondrial mice carrying resistance to chloramphenicol on mitochondrial DNA: Developing the first mouse model of mitochondrial DNA disease	NATURE MEDICINE			English	Article							RIBOSOMAL-RNA MUTATION; NON-SYNDROMIC DEAFNESS; MTDNA; SEGREGATION; PHENOTYPE; MYOPATHY; FEMALE		John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England; Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford, England	University of Oxford; University of Oxford	Poulton, J (corresponding author), John Radcliffe Hosp, Dept Paediat, Level 4, Oxford OX3 9DU, England.		Poulton, Joanna/AAB-4828-2021	Poulton, Joanna/0000-0002-2460-5587	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		FERRIS SD, 1982, NATURE, V295, P163, DOI 10.1038/295163a0; FISCHELGHODSIAN N, 1993, AM J OTOLARYNG, V14, P399, DOI 10.1016/0196-0709(93)90113-L; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963; HOWELL N, 1988, SOMAT CELL MOLEC GEN, V14, P185, DOI 10.1007/BF01534403; Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146; KEARSEY SE, 1981, NATURE, V290, P607, DOI 10.1038/290607a0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Laipis P J, 1996, Methods Enzymol, V264, P345, DOI 10.1016/S0076-6879(96)64033-6; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Meirelles FV, 1997, GENETICS, V145, P445; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Pinkert CA, 1997, TRANSGENIC RES, V6, P379, DOI 10.1023/A:1018431316831; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; WHITE S, 1999, THESIS U MELBOURNE	17	51	53	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					957	960		10.1038/11403	http://dx.doi.org/10.1038/11403			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426324				2022-12-27	WOS:000081684000044
J	Sethi, T; Rintoul, RC; Moore, SM; MacKinnon, AC; Salter, D; Choo, C; Chilvers, ER; Dransfield, I; Donnelly, SC; Strieter, R; Haslett, C				Sethi, T; Rintoul, RC; Moore, SM; MacKinnon, AC; Salter, D; Choo, C; Chilvers, ER; Dransfield, I; Donnelly, SC; Strieter, R; Haslett, C			Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo	NATURE MEDICINE			English	Article							MULTIPLE NEUROPEPTIDES; SURVIVAL FACTOR; FIBRONECTIN; INHIBITION; EXPRESSION; CARCINOMA; INTEGRIN; RECEPTOR; TENASCIN; ADHESION	Resistance to chemotherapy is a principal problem in the treatment of small cell lung cancer (SCLC). We show here that SCLC is surrounded by an extensive stroma of extracellular matrix (ECM) at both primary and metastatic sites. Adhesion of SCLC cells to ECM enhances tumorigenicity and confers resistance to chemotherapeutic agents as a result of pi integrin-stimulated tyrosine kinase activation suppressing chemotherapy-induced apoptosis. SCLC may create a specialized microenvironment, and the survival of cells bound to ECM could explain the partial responses and local recurrence of SCLC often seen clinically after chemotherapy. Strategies based on blocking pi integrin-mediated survival signals may represent a new therapeutic approach to improve the response to chemotherapy in SCLC.	Univ Edinburgh, Sch Med, Rayne Lab, Resp Med Unit, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA	University of Edinburgh; University of Edinburgh; University of Michigan System; University of Michigan	Sethi, T (corresponding author), Univ Edinburgh, Sch Med, Rayne Lab, Resp Med Unit, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.		Rintoul, Robert Campbell/Q-1727-2015; Haslett, Christopher/ABF-7689-2020	Rintoul, Robert Campbell/0000-0003-3875-3780; Donnelly, Seamas/0000-0001-7145-1843; Dransfield, Ian/0000-0001-5848-7059; Chilvers, Edwin/0000-0002-4230-9677				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BEPLER G, 1988, J CANCER RES CLIN, V114, P235, DOI 10.1007/BF00405828; Bloch W, 1997, J CELL BIOL, V139, P265, DOI 10.1083/jcb.139.1.265; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CARNEY DN, 1980, CANCER RES, V40, P1820; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DUKE RC, 1992, CURRENT PROTOCOLS IM; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FALCIONI R, 1994, EXP CELL RES, V210, P113, DOI 10.1006/excr.1994.1017; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRIDMAN R, 1990, P NATL ACAD SCI USA, V87, P6698, DOI 10.1073/pnas.87.17.6698; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIACCONE G, 1994, ANTICANCER RES, V14, P269; HEDIN U, 1991, AM J PATHOL, V139, P649; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IHDE D, 1993, CANC PRINCIPLES PRAC, P591; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kelley MJ, 1997, CHEST, V112, P256, DOI 10.1378/chest.112.1.256; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LAI SL, 1989, J NATL CANCER I, V81, P1144, DOI 10.1093/jnci/81.15.1144; LANGDON SP, 1994, CANCER TOPICS, V9, P10; MCCARTHY JB, 1985, CANCER METAST REV, V4, P125, DOI 10.1007/BF00050692; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; NICOLO G, 1990, CELL DIFFER DEV, V32, P401, DOI 10.1016/0922-3371(90)90056-3; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; SMITH PJ, 1994, BRIT J CANCER, V70, P914, DOI 10.1038/bjc.1994.420; SMYTH JF, 1986, Q J MED, V61, P969; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Suzuki J, 1998, FEBS LETT, V437, P112, DOI 10.1016/S0014-5793(98)01213-7; Tallett A, 1996, CANCER RES, V56, P4255; VOGEL BE, 1990, J BIOL CHEM, V265, P5934	40	620	644	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1999	5	6					662	668		10.1038/9511	http://dx.doi.org/10.1038/9511			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371505				2022-12-27	WOS:000080823300035
J	Lietman, T; Porco, T; Dawson, C; Blower, S				Lietman, T; Porco, T; Dawson, C; Blower, S			Global elimination of trachoma: How frequently should we administer mass chemotherapy?	NATURE MEDICINE			English	Article							SINGLE-DOSE AZITHROMYCIN; INTRINSIC TRANSMISSION DYNAMICS; CHLAMYDIA-TRACHOMATIS; ENDEMIC TRACHOMA; TUBERCULOSIS EPIDEMICS; GAMBIAN VILLAGE; WOMEN; DOXYCYCLINE; INFECTIONS; BLINDNESS	The World Health Organization has recommended repeat mass drug administration as part of their global initiative to eliminate blinding trachoma by the year 2020. The efficacy of repeat treatment will be tested empirically, but the results will not be available for many years, and recommendations for the necessary frequency of treatment are needed immediately. We have developed a mathematical model that uses available epidemiological data from a variety of countries. We recommend, based on our analysis, that in areas where trachoma is moderately prevalent (<35% in children), it should be treated annually, but hyperendemic areas (>50% in children), it should be treated biannually.	Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lietman, T (corresponding author), Dept Publ Hlth, San Francisco, CA USA.	tml@itsa.ucsf.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041935, K08AI001441] Funding Source: NIH RePORTER; NIAID NIH HHS [1R01 AI 41935, K08 AI 01441-0] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTMAN L, 1998, NY TIMES, pA7; ALTMAN LK, 1998, NY TIMES        0624, pA1; ANDERSON R, 1991, INFECT DIS HUMANS DY, V62, P172; ARNO JN, 1994, SEX TRANSM DIS, V21, P47, DOI 10.1097/00007435-199401000-00010; ASSAD FA, 1958, B WORLD HEALTH ORGAN, V34, P341; BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944; BAILEY RL, 1994, BRIT J OPHTHALMOL, V78, P813, DOI 10.1136/bjo.78.11.813; BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; BARAL K, IN PRESS B WHO; Bianchi A, 1998, SEX TRANSM DIS, V25, P366, DOI 10.1097/00007435-199808000-00008; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 1998, NAT MED, V4, P673, DOI 10.1038/nm0698-673; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; Bobo LD, 1997, J INFECT DIS, V176, P1524, DOI 10.1086/514151; COURTRIGHT P, 1989, BRIT J OPHTHALMOL, V73, P536, DOI 10.1136/bjo.73.7.536; DAWSON C, 1966, AM J EPIDEMIOL, V84, P411, DOI 10.1093/oxfordjournals.aje.a120654; DAWSON C, 1998, CHLAMYDIAL INFECT, P352; DAWSON CR, 1976, BRIT J OPHTHALMOL, V60, P245, DOI 10.1136/bjo.60.4.245; DIETZ K, 1985, LECTURE NOTES BIOMAT, V57, P115; DIETZ K, 1975, B I STUT I, V40, P531; GUPTA S, 1989, AIDS, V3, P807, DOI 10.1097/00002030-198912000-00005; HAYES LJ, 1995, J INFECT DIS, V172, P268, DOI 10.1093/infdis/172.1.268; Hethcote H., 1996, MODELS INFECT HUMAN, V215, P238, DOI 10.1017/CBO9780511662935.030; Hillis SD, 1998, SEX TRANSM DIS, V25, P5, DOI 10.1097/00007435-199801000-00002; MABEY D, 1998, CHLAMYDIAL INFECT, P351; Magid D, 1996, ANN INTERN MED, V124, P389, DOI 10.7326/0003-4819-124-4-199602150-00002; MCCORMACK WM, 1979, NEW ENGL J MED, V300, P123, DOI 10.1056/NEJM197901183000305; Munoz B, 1997, EPIDEMIOL REV, V19, P205, DOI 10.1093/oxfordjournals.epirev.a017953; MUNOZ B, 1995, ANN M SOC MATH BIOL; NGOCHADUONG T, 1995, THESIS LONDON SCH HY, P1; Porco TC, 1998, THEOR POPUL BIOL, V54, P117, DOI 10.1006/tpbi.1998.1366; Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127; SCHACHTER J, 1998, P 9 INT S HUM CHLAM, P347; SCHACHTER J, 1978, HUMAN CHLAMYDIAL INF, V35; STAMM WE, 1995, JAMA-J AM MED ASSOC, V274, P545, DOI 10.1001/jama.274.7.545; STEINGRIMSSON O, 1994, SEX TRANSM DIS, V21, P43, DOI 10.1097/00007435-199401000-00009; TAYLOR HR, 1989, INVEST OPHTH VIS SCI, V30, P1823; TAYLOR HR, 1991, J CLIN MICROBIOL, V29, P1593, DOI 10.1128/JCM.29.8.1593-1595.1991; Thorpe EM, 1996, GENITOURIN MED, V72, P93; THYGESON P, 1962, AM J OPHTHALMOL, V53, P786, DOI 10.1016/0002-9394(62)93399-8; THYLEFORS B, 1990, INT OPHTHALMOL, V14, P211, DOI 10.1007/BF00158321; TIELSCH JM, 1988, AM J TROP MED HYG, V38, P393, DOI 10.4269/ajtmh.1988.38.393; WARD M, 1990, SCAND J INFECT DIS, P137; WARD M, 1990, P 7 INT S HUM CHL IN, P591; Wehbeh HA, 1998, J REPROD MED, V43, P509; WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194; WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088; 1997, 1 M WHO ALL GLOB EL; 1998, 2 M WHO ALL GLOB EL	51	127	127	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					572	576		10.1038/8451	http://dx.doi.org/10.1038/8451			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229236				2022-12-27	WOS:000081497400040
J	Khuri, FR; Nemunaitis, J; Ganly, I; Arseneau, J; Tannock, IF; Romel, L; Gore, M; Ironside, J; MacDougall, RH; Heise, C; Randlev, B; Gillenwater, AM; Bruso, P; Kaye, SB; Hong, WK; Kirn, DH				Khuri, FR; Nemunaitis, J; Ganly, I; Arseneau, J; Tannock, IF; Romel, L; Gore, M; Ironside, J; MacDougall, RH; Heise, C; Randlev, B; Gillenwater, AM; Bruso, P; Kaye, SB; Hong, WK; Kirn, DH			A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; SQUAMOUS-CELL CARCINOMA; HIGH-DOSE CISPLATIN; 5-FU INFUSION; PHASE-III; MONOCLONAL-ANTIBODIES; ATTENUATED ADENOVIRUS; HUMAN-PAPILLOMAVIRUS; EFFICACY; THERAPY	ONYX-015 is an adenovirus with the E1B 55-kDa gene deleted, engineered to selectively replicate in and lyse p53-deficient cancer cells while sparing normal cells. Although ONYX-015 and chemotherapy have demonstrated anti-tumoral activity in patients with recurrent head and neck cancer, disease recurs rapidly with either therapy alone. We undertook a phase II trial of a combination of intratumoral ONYX-015 injection with cisplatin and 5-fluorouracil in patients with recurrent squamous cell cancer of the head and neck. There were substantial objective responses, including a high proportion of complete responses. By 6 months, none of the responding tumors had progressed, whereas all non-injected tumors treated with chemotherapy alone had progressed. The toxic effects that occurred were acceptable. Tumor biopsies obtained after treatment showed tumor-selective viral replication and necrosis induction.	Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Div Surg, Houston, TX 77030 USA; US Oncol, Dallas, TX USA; Univ Glasgow, Beatson Oncol Inst, Glasgow, Lanark, Scotland; Royal Marsden Hosp, London SW3 6JJ, England; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; ONYX Pharmaceut, Richmond, CA USA; Imperial Canc Res Fund, London WC2A 3PX, England	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; US Oncology Network; University of Glasgow; Royal Marsden NHS Foundation Trust; University of Edinburgh; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Cancer Research UK	Khuri, FR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Canc Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	Fkhuri@mdanderson.org	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Gillenwater, Ann/0000-0002-0935-0037				BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BAXTER LT, 1994, CANCER RES, V54, P1517; BAXTER LT, 1995, CANCER RES, V55, P4611; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BLICK M, 1987, CANCER RES, V47, P2986; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; CLAVEL M, 1994, ANN ONCOL, V5, P521, DOI 10.1093/oxfordjournals.annonc.a058906; Clayman GL, 1997, CANC MED, P1645; FORASTIERE AA, 1992, J CLIN ONCOL, V10, P1245, DOI 10.1200/JCO.1992.10.8.1245; FREI E, 1989, J CLIN ONCOL, V7, P291, DOI 10.1200/JCO.1989.7.3.291; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; Ganly I, 2000, CLIN CANCER RES, V6, P798; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Heise CC, 1999, CANCER GENE THER, V6, P499, DOI 10.1038/sj.cgt.7700071; JACOBS C, 1992, J CLIN ONCOL, V10, P257, DOI 10.1200/JCO.1992.10.2.257; JONES AL, 1992, CANCER CHEMOTH PHARM, V30, P73, DOI 10.1007/BF00686489; KIM D, 1998, P AN M AM SOC CLIN, V17, pA391; Kirn D, 1998, NAT MED, V4, P1341, DOI 10.1038/3902; KISH JA, 1988, AM J CLIN ONCOL-CANC, V11, P553, DOI 10.1097/00000421-198810000-00009; Krajcsi P, 1996, J VIROL, V70, P4904, DOI 10.1128/JVI.70.8.4904-4913.1996; KROSNICK JA, 1989, CANCER RES, V49, P3729; Liang Y, 2000, CANCER RES, V60, P1009; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; PAREDES J, 1988, J CLIN ONCOL, V6, P955, DOI 10.1200/JCO.1988.6.6.955; ROONEY M, 1985, CANCER, V55, P1123, DOI 10.1002/1097-0142(19850301)55:5<1123::AID-CNCR2820550530>3.0.CO;2-8; ROWLAND KM, 1986, CANCER TREAT REP, V70, P461; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; Schrijvers D, 1998, J CLIN ONCOL, V16, P1054, DOI 10.1200/JCO.1998.16.3.1054; SELBY P, 1987, BRIT J CANCER, V56, P803, DOI 10.1038/bjc.1987.294; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; STELL PM, 1990, BRIT J CANCER, V61, P311; STRONG EW, 1983, CANCER TREAT S, V2, P5; SUIT HD, 1986, INT J RADIAT ONCOL, V12, P453, DOI 10.1016/0360-3016(86)90052-0; VOKES EE, 1993, NEW ENGL J MED, V328, P84; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wildner O, 1999, HUM GENE THER, V10, P2679, DOI 10.1089/10430349950016726; Wildner O, 1999, CANCER RES, V59, P410	43	875	952	1	48	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					879	885		10.1038/78638	http://dx.doi.org/10.1038/78638			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932224				2022-12-27	WOS:000165473800030
J	Yu, YJ; Annala, AJ; Barrio, JR; Toyokuni, T; Satyamurthy, N; Namavari, M; Cherry, SR; Phelps, ME; Herschman, HR; Gambhir, SS				Yu, YJ; Annala, AJ; Barrio, JR; Toyokuni, T; Satyamurthy, N; Namavari, M; Cherry, SR; Phelps, ME; Herschman, HR; Gambhir, SS			Quantification of target gene expression by imaging reporter gene expression in living animals	NATURE MEDICINE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; TRANSLATION INITIATION; VIRUS; PET; MICROPET; SEQUENCE; THERAPY; SCANNER; INVIVO		Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Energy, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gambhir, SS (corresponding author), Crump Inst Mol Imaging, Los Angeles, CA 90095 USA.		Cherry, Simon/AAH-1000-2019	Cherry, Simon/0000-0002-0155-5644; Annala, Alexandra Jacqueline/0000-0002-5967-6596	NATIONAL CANCER INSTITUTE [R01CA082214] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82214-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alauddin MM, 1998, NUCL MED BIOL, V25, P175, DOI 10.1016/S0969-8051(97)00160-1; Barrio J. R., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P348; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; Cherry SR, 1997, IEEE T NUCL SCI, V44, P1161, DOI 10.1109/23.596981; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; DAVIES MV, 1992, J VIROL, V66, P1924, DOI 10.1128/JVI.66.4.1924-1932.1992; Gambhir SS, 2000, P NATL ACAD SCI USA, V97, P2785, DOI 10.1073/pnas.97.6.2785; Gambhir SS, 1998, J NUCL MED, V39, P2003; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; Gambhir SS, 1999, NUCL MED BIOL, V26, P481, DOI 10.1016/S0969-8051(99)00021-9; HAMACHER K, 1986, J NUCL MED, V27, P235; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; MacLaren DC, 1999, GENE THER, V6, P785, DOI 10.1038/sj.gt.3300877; PHELPS ME, 1991, NEUROCHEM RES, V16, P929, DOI 10.1007/BF00965836; PHELPS ME, 1975, J NUCL MED, V16, P210; Qi JY, 1998, PHYS MED BIOL, V43, P1001, DOI 10.1088/0031-9155/43/4/027; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SATYAMURTHY N, 1990, APPL RADIAT ISOTOPES, V41, P113; Tjuvajev JG, 1998, CANCER RES, V58, P4333; Tjuvajev Juri G., 1999, Neoplasia (New York), V1, P315, DOI 10.1038/sj.neo.7900053; Zhou Y, 1998, HUM GENE THER, V9, P287, DOI 10.1089/hum.1998.9.3-287	23	182	189	1	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					933	937		10.1038/78704	http://dx.doi.org/10.1038/78704			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932234				2022-12-27	WOS:000165473800040
J	Chapuis, AG; Rizzardi, GP; D'Agostino, C; Attinger, A; Knabenhans, C; Fleury, S; Acha-Orbea, H; Pantaleo, G				Chapuis, AG; Rizzardi, GP; D'Agostino, C; Attinger, A; Knabenhans, C; Fleury, S; Acha-Orbea, H; Pantaleo, G			Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo	NATURE MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; HIV-1 INFECTION; PROTEASE INHIBITORS; COMBINATION THERAPY; CONTROLLED TRIAL; REPLICATION; HYDROXYUREA; KINETICS; SUPPRESSION	Mycophenolic acid, a selective inhibitor of the de novo synthesis of guanosine nucleotides in T and B lymphocytes, has been proposed to inhibit human immunodeficiency virus (HIV) replication in vitro by depleting the substrate (guanosine nucleotides) for reverse transcriptase. Here we show that mycophenolic acid induced apoptosis and cell death in a large proportion of activated CD4(+) T cells, thus indicating that it may inhibit HIV infection in vitro by both virological mechanisms and Immunological mechanisms (depletion of the pool of activated CD4(+) T lymphocytes). Administration of mycophenolate mophetil, the ester derivate of mycophenolic acid, to HIV-infected subjects treated with anti-retroviral therapy and with undetectable viremia resulted in the reduction of the number of dividing CD4(+) and CD8(+) T cells and in the inhibition of virus isolation from purified CD4(+) T-cell populations. Based on these results, the potential use of mycophenolate mophetil in the treatment of HIV infection deserves further investigation in controlled clinical trials.	Univ Lausanne, CHU Vaudois, Div Infect Dis, Dept Med,Lab AIDS Immunopathogenesis, CH-1011 Lausanne, Switzerland; Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Ludwig Institute for Cancer Research; University of Lausanne; University of Lausanne	Pantaleo, G (corresponding author), Univ Lausanne, CHU Vaudois, Div Infect Dis, Dept Med,Lab AIDS Immunopathogenesis, CH-1011 Lausanne, Switzerland.	pantaleo@chuv.hospvd.ch	Pantaleo, Giuseppe/K-6163-2016	D'Agostino, Caudia/0000-0002-4399-8785				ALLISON AC, 1991, TRANSPL P, V23, P10; ALLISON AC, 1993, ANN NY ACAD SCI, V696, P63; Blaak H, 1998, J INFECT DIS, V177, P600, DOI 10.1086/514219; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; De Boer RJ, 1998, AIDS, V12, P1567, DOI 10.1097/00002030-199813000-00002; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; deJong MD, 1996, P NATL ACAD SCI USA, V93, P5501, DOI 10.1073/pnas.93.11.5501; DOMADULA G, 1999, JAMA-J AM MED ASSOC, V282, P1663; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P175, DOI 10.1111/j.1365-3083.1991.tb03747.x; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P161, DOI 10.1111/j.1365-3083.1991.tb03746.x; Eugui EM, 1998, SCAND J IMMUNOL, V48, P450; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fleury S, 2000, P NATL ACAD SCI USA, V97, P5393, DOI 10.1073/pnas.97.10.5393; Fleury S, 1998, NAT MED, V4, P794, DOI 10.1038/nm0798-794; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Fulton B, 1996, DRUGS, V51, P278, DOI 10.2165/00003495-199651020-00007; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; GAO WY, 1994, MOL PHARMACOL, V46, P767; GRINYO J, 1995, LANCET, V345, P1321; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Halloran P, 1997, TRANSPLANTATION, V63, P39, DOI 10.1097/00007890-199701150-00008; Halloran P, 1997, TRANSPLANTATION, V63, P618; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Hellerstein MK, 1999, IMMUNOL TODAY, V20, P438, DOI 10.1016/S0167-5699(99)01529-7; HIRONS GT, 1994, CYTOMETRY, V15, P129, DOI 10.1002/cyto.990150206; ICHIMURA H, 1995, VIROLOGY, V211, P554, DOI 10.1006/viro.1995.1437; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; Margolis D, 1999, J ACQ IMMUN DEF SYND, V21, P362; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Montaner JSG, 1998, LANCET, V352, P1919, DOI 10.1016/S0140-6736(98)07532-1; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pantaleo G, 1997, NAT MED, V3, P483, DOI 10.1038/nm0597-483; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Rutschmann OT, 1998, AIDS, V12, pF71, DOI 10.1097/00002030-199808000-00003; SCHEMENAUER RS, 1993, ATMOSFERA, V6, P175; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YEARLY S, 2000, AIDS, V14; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353	47	151	159	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2000	6	7					762	768		10.1038/77489	http://dx.doi.org/10.1038/77489			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888924				2022-12-27	WOS:000088040100032
J	[Anonymous]				[Anonymous]			Special focus on malaria	NATURE MEDICINE			English	Letter																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2000	6	7					720	720						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888895				2022-12-27	WOS:000088040100005
J	Niiler, E				Niiler, E			Researcher stockpiled salmonella and explosives	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					614	614		10.1038/76172	http://dx.doi.org/10.1038/76172			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835664	Bronze			2022-12-27	WOS:000087438300016
J	Rouse, R				Rouse, R			Australia to create biomedical lobby group	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					613	613		10.1038/76165	http://dx.doi.org/10.1038/76165			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835660	Bronze			2022-12-27	WOS:000087438300014
J	Rocca, B; Loeb, AL; Strauss, JF; Vezza, R; Habib, A; Li, HW; FitzGerald, GA				Rocca, B; Loeb, AL; Strauss, JF; Vezza, R; Habib, A; Li, HW; FitzGerald, GA			Directed vascular expression of the thromboxane A(2) receptor results in intrauterine growth retardation	NATURE MEDICINE			English	Article							BIRTH-WEIGHT; MICE; BIOSYNTHESIS; PREGNANCY; PLATELET; GENE	Thromboxane (Tx) A, is a platelet agonist, smooth muscle cell constrictor, and mitogen(1). Urinary Tx metabolite (Tx-M) excretion is increased in syndromes of platelet activation and early in both normal pregnancies and in pregnancy-induced hypertension(2,3). A further increment occurs in patients presenting with severe preeclampsia, in whom Tx-M correlates with other indices of disease severity(4). TxA(2) exerts its effects through a membrane receptor (TP), of which two isoforms (alpha and beta; refs. 5,6) have been cloned. Overexpression of TP in the vasculature under the control of the pre-proendothelin-1 promoter(7) results in a murine model of intrauterine growth retardation (IUGR), which is rescued by timed suppression of Tx synthesis with indomethacin. IUGR is commonly associated with maternal diabetes or cigarette smoking, both conditions associated with increased TxA(2) biosynthesis(8,9).	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	FitzGerald, GA (corresponding author), Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.		FitzGerald, Garret A/A-4222-2010; rocca, bianca/K-3922-2018	Habib, Aida/0000-0001-6027-0043	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029946] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500, R01HL057847] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57847, HL 54500] Funding Source: Medline; NICHD NIH HHS [HD 29946] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barker M, 1997, ARCH DIS CHILD, V77, P381, DOI 10.1136/adc.77.5.381; DAVI G, 1990, NEW ENGL J MED, V322, P1769, DOI 10.1056/NEJM199006213222503; FITZGERALD DJ, 1990, LANCET, V335, P751, DOI 10.1016/0140-6736(90)90869-7; FITZGERALD DJ, 1987, AM J OBSTET GYNECOL, V157, P325, DOI 10.1016/S0002-9378(87)80162-X; FITZGERALD GA, 1995, C LOEBS TXB MED, P1187; Ghidini A, 1996, Obstet Gynecol Surv, V51, P376, DOI 10.1097/00006254-199606000-00023; HARATS D, 1995, J CLIN INVEST, V95, P1335, DOI 10.1172/JCI117784; JOHNSTON BM, 1995, REPROD FERT DEVELOP, V7, P639, DOI 10.1071/RD9950639; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; LOEB AL, 1992, AM J PHYSIOL, V262, pH1494, DOI 10.1152/ajpheart.1992.262.5.H1494; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; NOWAK J, 1987, CIRCULATION, V76, P6, DOI 10.1161/01.CIR.76.1.6; NUSING RM, 1993, J BIOL CHEM, V268, P25253; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V30, P19256; Roy-Clavel E, 1999, AM J OBSTET GYNECOL, V180, P608, DOI 10.1016/S0002-9378(99)70262-0; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TALAMANTES F, 1988, INT REV CYTOL, V112, P1; VANFEIJN HP, 1980, AM J OBSTET GYNECOL, V137, P43; Vezza R, 1999, J BIOL CHEM, V274, P12774, DOI 10.1074/jbc.274.18.12774; WIGGLESWORTH JS, 1964, J PATHOL BACTERIOL, V88, P1, DOI 10.1002/path.1700880102	22	41	43	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					219	221		10.1038/72334	http://dx.doi.org/10.1038/72334			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655114				2022-12-27	WOS:000085016900046
J	Al-Mehdi, AB; Tozawa, K; Fisher, AB; Shientag, L; Lee, A; Muschel, RJ				Al-Mehdi, AB; Tozawa, K; Fisher, AB; Shientag, L; Lee, A; Muschel, RJ			Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis	NATURE MEDICINE			English	Article							MATRIX; EXPRESSION; MELANOMA; EXTRAVASATION; APOPTOSIS; SURVIVAL; ARREST; GROWTH; LUNGS; LINES	Metastasis is a frequent complication of cancer, yet the process through which circulating tumor cells form distant colonies is poorly understood. We have been able to observe the steps in early hematogenous metastasis by epifluorescence microscopy of tumor cells expressing green fluorescent protein in subpleural microvessels in intact, perfused mouse and rat lungs. Metastatic tumor cells attached to the endothelia of pulmonary pre-capillary arterioles and capillaries. Extravasation of tumor cells was rare, and it seemed that the transmigrated cells were cleared quickly by the lung, leaving only the endothelium-attached cells as the seeds of secondary tumors. Early colonies were entirely within the blood vessels. Although most models of metastasis include an extravasation step early in the process(1), here we show that in the lung, metastasis is initiated by attachment of tumor cells to the vascular endothelium and that hematogenous metastasis originates from the proliferation of attached intravascular tumor cells rather than from extravasated ones. Intravascular metastasis formation would make early colonies especially vulnerable to intravascular drugs, and this possibility has potential for the prevention of tumor cell attachment to the endothelium.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Muschel, RJ (corresponding author), Univ Penn, Dept Pathol & Lab Med, 269A John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.		Al-Mehdi, Abu-Bakr/A-8636-2009		NCI NIH HHS [R01 CA46830-09] Funding Source: Medline; NHLBI NIH HHS [P50-HL60290] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046830] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060290] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CRISSMAN JD, 1985, LAB INVEST, V53, P470; DINGEMANS KP, 1973, JNCI-J NATL CANCER I, V51, P1883, DOI 10.1093/jnci/51.6.1883; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1990, ONCOGENE, V5, P75; Hangan D, 1996, CANCER RES, V56, P3142; Hauser PJ, 1998, ONCOGENE, V17, P3083, DOI 10.1038/sj.onc.1202235; Hua J, 1996, CANCER RES, V56, P5279; LAPIS K, 1988, CLIN EXP METASTAS, V6, P73, DOI 10.1007/BF01580408; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Nikiforov MA, 1996, ONCOGENE, V13, P1709; ROOS E, 1979, BIOCHIM BIOPHYS ACTA, V560, P135, DOI 10.1016/0304-419X(79)90005-2; Scherbarth S, 1997, CANCER RES, V57, P4105; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034	20	524	542	2	49	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					100	102		10.1038/71429	http://dx.doi.org/10.1038/71429			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613833				2022-12-27	WOS:000084583300044
J	O'Donnell, RA; Saul, A; Cowman, AF; Crabb, BS				O'Donnell, RA; Saul, A; Cowman, AF; Crabb, BS			Functional conservation of the malaria vaccine antigen MSP-1(19) across distantly related Plasmodium species	NATURE MEDICINE			English	Article							MEROZOITE SURFACE PROTEIN-1; TERMINAL FRAGMENT; SERUM ANTIBODIES; FALCIPARUM; INVASION; EPITOPES; INHIBIT; REGION; CELL	The C-terminal region of Plasmodium falciparum merozoite surface protein 1 (MSP-1(19)) is at present a leading malaria vaccine candidate. Antibodies against the epidermal growth factor-like domains of MSP-1(19) are associated with immunity to P. falciparum(1-4) and active immunization with recombinant forms of the molecule protect against malaria challenge in various experimental systems(5-8), These findings, with the knowledge that epidermal growth factor-like domains in other molecules have essential binding functions, indicate the importance of this protein in merozoite invasion of red blood cells. Despite extensive molecular epidemiological investigations, only limited sequence polymorphism has been identified in P. falciparum MSP-1(19) (refs, 9-11). This indicates its sequence is functionally constrained, and is used in support of the use of MSP-1(19) as a vaccine. Here, we have successfully complemented the function of most of P. falciparum MSP-1(19) with the corresponding but highly divergent sequence from the rodent parasite P. chabaudi. The results indicate that the role of MSP-1(19) in red blood cell invasion is conserved across distantly related Plasmodium species and show that the sequence of P. falciparum MSP-1(19) is not constrained by function.	Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia; Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Univ Queensland, Brisbane, Qld 4029, Australia; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	University of Melbourne; QIMR Berghofer Medical Research Institute; University of Queensland; Walter & Eliza Hall Institute	Crabb, BS (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia.		Cowman, Alan F/C-7642-2013; Saul, Allan J/I-6968-2013; Saul, Allan/ABH-2091-2020; Crabb, Brendan/F-5287-2013	Cowman, Alan F/0000-0001-5145-9004; Saul, Allan J/0000-0003-0665-4091; Saul, Allan/0000-0003-0665-4091; 				BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389; CHANG SP, 1994, J IMMUNOL, V152, P3483; Chitarra V, 1999, MOL CELL, V3, P457, DOI 10.1016/S1097-2765(00)80473-6; COOPER JA, 1992, MOL BIOCHEM PARASIT, V51, P301, DOI 10.1016/0166-6851(92)90080-4; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; DALY TM, 1993, INFECT IMMUN, V61, P2462, DOI 10.1128/IAI.61.6.2462-2467.1993; Egan A, 1997, INFECT IMMUN, V65, P3024, DOI 10.1128/IAI.65.8.3024-3031.1997; EGAN AF, 1995, INFECT IMMUN, V63, P456, DOI 10.1128/IAI.63.2.456-466.1995; Egan AF, 1996, J INFECT DIS, V173, P765, DOI 10.1093/infdis/173.3.765; Egan AF, 1999, PARASITE IMMUNOL, V21, P133, DOI 10.1046/j.1365-3024.1999.00209.x; Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689; KANG Y, 1995, MOL BIOCHEM PARASIT, V73, P103, DOI 10.1016/0166-6851(95)00102-7; LING IT, 1994, PARASITE IMMUNOL, V16, P63, DOI 10.1111/j.1365-3024.1994.tb00324.x; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; Perera KLRL, 1998, INFECT IMMUN, V66, P1500, DOI 10.1128/IAI.66.4.1500-1506.1998; Qari SH, 1998, MOL BIOCHEM PARASIT, V92, P241, DOI 10.1016/S0166-6851(98)00010-3; Rotman HL, 1999, EXP PARASITOL, V91, P78, DOI 10.1006/expr.1999.4357	20	149	154	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					91	95		10.1038/71595	http://dx.doi.org/10.1038/71595			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613831				2022-12-27	WOS:000084583300042
J	Annas, GJ; Caplan, A; Elias, S				Annas, GJ; Caplan, A; Elias, S			Stem cell politics, ethics and medical progress	NATURE MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA; Univ Penn, Med Ctr, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Illinois, Dept Obstet & Gynecol, Chicago, IL 60612 USA	Boston University; University of Pennsylvania; Pennsylvania Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA.			Annas, George/0000-0001-5836-7831				Annas GJ, 1996, NEW ENGL J MED, V334, P1329, DOI 10.1056/NEJM199605163342012; ANNAS GJ, 1989, NEW ENGL J MED, V320, P1079, DOI 10.1056/NEJM198904203201610; CAPLAN A, 1992, NEW ENGL J MED, V322, P1592; Feiler CL, 1998, FORDHAM LAW REV, V66, P2435; *GER ETH ADV BOARD, 1998, RES HUM EMBR STEM CE, P1; Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404; *NAT BIOETH ADV CO, 1999, ETH ISS STEM CELL RE; *OFF DIR, 1999, FACT SHEET STEM CELL; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	10	29	30	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1339	1341		10.1038/70900	http://dx.doi.org/10.1038/70900			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581063	Green Published			2022-12-27	WOS:000084049700018
J	Strausbaugh, HJ; Green, PG; Lo, E; Tangemann, K; Reichling, DB; Rosen, SD; Levine, JD				Strausbaugh, HJ; Green, PG; Lo, E; Tangemann, K; Reichling, DB; Rosen, SD; Levine, JD			Painful stimulation suppresses joint inflammation by inducing shedding of L-selectin from neutrophils	NATURE MEDICINE			English	Article							CHEMOTACTIC FACTORS; ENDOTHELIAL-CELLS; SHEAR-FLOW; IN-VITRO; ADHESION; LEUKOCYTES; INVIVO; MAC-1; EXPRESSION; INJURY	Although the inflammatory response is essential for protecting tissues from injury and infection(1), unrestrained inflammation can cause chronic inflammatory diseases such as arthritis, colitis and asthma. Physiological mechanisms that downregulate inflammation are poorly understood. Potent control might be achieved by regulating early stages in the inflammatory response, such as accumulation of neutrophils at the site of injury, where these cells release chemical mediators that promote inflammatory processes including plasma extravasation(2), bacteriocide and proteolysis. To access an inflammatory site, neutrophils must first adhere to the vascular endothelium in a process mediated in part by the leukocyte adhesion molecule L-selectin(3). This adhesion is prevented when L-selectin is shed from the neutrophil membrane(4,5) Although shedding of L-selectin is recognized as a potentially important mechanism for regulating neutrophilse(4,7), its physiological function has not been demonstrated. Shedding of L-selectin may mediate endogenous downregulation of inflammation by limiting neutrophil accumulation at inflammatory sites. Here we show that activation of nociceptive neurons induces shedding of L-selectin from circulating neutrophils in vivo and that this shedding suppresses an ongoing inflammatory response by inhibiting neutrophil accumulation. These findings indicate a previously unknown mechanism for endogenous feedback control of inflammation. failure of this mechanism could contribute to the etiology of chronic inflammatory disease.	Univ Calif San Francisco, NIH, Pain Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biomed Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Immunol, San Francisco, CA 94143 USA	National Institutes of Health (NIH) - USA; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Strausbaugh, HJ (corresponding author), Univ Calif San Francisco, NIH, Pain Ctr, 521 Parnassus Ave, San Francisco, CA 94143 USA.		Green, Paul/C-5943-2011	Green, Paul/0000-0001-7648-6826; Rosen, Steven/0000-0002-6245-701X	NIADDK NIH HHS [AM32624] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; Anders R.F., 1985, Parasitology Today, V1, P152, DOI 10.1016/0169-4758(85)90171-1; Bowden JJ, 1996, AM J PHYSIOL-LUNG C, V270, pL393; BURTON JL, 1995, J LEUKOCYTE BIOL, V57, P317, DOI 10.1002/jlb.57.2.317; Carlson SL, 1996, BRAIN BEHAV IMMUN, V10, P55, DOI 10.1006/brbi.1996.0005; DIAZGONZALEZ F, 1995, J CLIN INVEST, V95, P1756, DOI 10.1172/JCI117853; DONNELLY SC, 1994, LANCET, V344, P215, DOI 10.1016/S0140-6736(94)92995-5; Gautam N, 1998, BRIT J PHARMACOL, V125, P1109, DOI 10.1038/sj.bjp.0702186; GREEN PG, 1995, J NEUROSCI, V15, P4678; Green PG, 1998, J NEUROPHYSIOL, V80, P3120, DOI 10.1152/jn.1998.80.6.3120; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; Mills PJ, 1997, BRAIN BEHAV IMMUN, V11, P333, DOI 10.1006/brbi.1997.0500; MULLIGAN MS, 1995, J IMMUNOL, V154, P1350; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SternerKock A, 1996, AM J RESP CRIT CARE, V153, P436, DOI 10.1164/ajrccm.153.1.8542155; TABORSKY GJ, 1982, AM J PHYSIOL, V242, pE317, DOI 10.1152/ajpendo.1982.242.5.E317; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0	25	36	38	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1057	1061		10.1038/12497	http://dx.doi.org/10.1038/12497			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470085				2022-12-27	WOS:000082337200042
J	Chun, TW; Engel, D; Mizell, SB; Hallahan, CW; Fischette, M; Park, S; Davey, RT; Dybul, M; Kovacs, JA; Metcalf, JA; Mican, JM; Berrey, MM; Corey, L; Lane, HC; Fauci, AS				Chun, TW; Engel, D; Mizell, SB; Hallahan, CW; Fischette, M; Park, S; Davey, RT; Dybul, M; Kovacs, JA; Metcalf, JA; Mican, JM; Berrey, MM; Corey, L; Lane, HC; Fauci, AS			Effect of interleukin-2 on the pool of latently infected, resting CD4(+) T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; CONTROLLED TRIAL; HIV ERADICATION; CANCER-PATIENTS; COMBINATION; VIREMIA; REPLICATION; INDIVIDUALS; ACTIVATION	The size of the pool of resting CD4(+) T cells containing replication-competent HIV in the blood of patients receiving intermittent interleukin (IL)-2 plus highly active anti-retroviral therapy (HAART) was significantly lower than that of patients receiving HAART alone. Virus could not be isolated from the peripheral blood CD4(+) T cells in three patients receiving IL-2 plus HAART, despite the fact that large numbers of resting CD4(+) T cells were cultured. Lymph node biopsies were done in two of these three patients and virus could not be isolated. These results indicate that the intermittent administration of IL-2 with continuous HAART may lead to a substantial reduction in the pool of resting CD4(+) T cells that contain replication-competent HIV.	NIAID, Natl Inst Hlth, Immunoregulat Lab, Bethesda, MD 20892 USA; NCI, Natl Inst Hlth, Pathol Lab, Bethesda, MD 20892 USA; Univ So Calif, Sch Med, Div Biometry, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ Washington, Dept Med & Lab Med, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern California; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Chun, TW (corresponding author), NIAID, Natl Inst Hlth, Immunoregulat Lab, Bethesda, MD 20892 USA.		Chun, Tae-Wook/AAC-3101-2020; Chun, Tae-Wook/W-9187-2019; Kovacs, Joseph/AAU-6105-2021; Corey, Lawrence/AAE-1796-2020	Chun, Tae-Wook/0000-0001-5153-7340; Kovacs, Joseph/0000-0002-5191-9880; Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000636, Z01AI000849, ZIAAI000636] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL000036] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER		BICHTHUY LT, 1987, J IMMUNOL, V139, P1550; Carr A, 1998, J INFECT DIS, V178, P992, DOI 10.1086/515653; Cavert W, 1998, SCIENCE, V280, P1865, DOI 10.1126/science.280.5371.1865; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Cohen OJ, 1998, JAMA-J AM MED ASSOC, V280, P87, DOI 10.1001/jama.280.1.87; Davey RT, 1997, J INFECT DIS, V175, P781, DOI 10.1086/513971; deJong MD, 1997, AIDS, V11, pF79, DOI 10.1097/00002030-199711000-00002; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Ho DD, 1998, SCIENCE, V280, P1866, DOI 10.1126/science.280.5371.1866; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; Kelleher AD, 1998, CLIN EXP IMMUNOL, V113, P85, DOI 10.1046/j.1365-2249.1998.00633.x; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; MCINTYRE CA, 1992, EUR J CANCER, V28A, P58, DOI 10.1016/0959-8049(92)90385-F; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PAWELEC G, 1991, BIOTHERAPY, V3, P309, DOI 10.1007/BF02221323; Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67; Simonelli C, 1998, AIDS, V12, P112; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; WEIDMANN E, 1992, J IMMUNOTHER, V12, P123, DOI 10.1097/00002371-199208000-00007; Witzke O, 1998, J INTERN MED, V244, P235; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZHANG L, IN PRESS N ENGL J ME	31	337	355	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					651	655		10.1038/9498	http://dx.doi.org/10.1038/9498			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371503				2022-12-27	WOS:000080823300033
J	Eto, T; Takahashi, H				Eto, T; Takahashi, H			Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon	NATURE MEDICINE			English	Article							BETA; EXPRESSION; CELLS; LIPOSOMES; LIVER; ALPHA; LINE; DNA	Most chronic carriers of hepatitis B virus (HBV) do not respond to interferon (IFN) treatment This limitation of IFN therapy may be due in part to scant expression of IFN receptor in the liver(1,2) Because the asialoglycoprotein (ASGP) receptor is specifically expressed in the liver at high denity(3), the ASGP receptor-binding domain was generated within an N-glycosylated human IFN-beta molecule(4,5) by the removal of sialic acid to direct this cytokine to the liver. This modified IFN (asialo-IFN-beta) demonstrated greater inhibition of HBV production in ASGP receptor-positive human liver cells transfected with a replication-competent HBV construct than did conventional IFN-alpha or IFN-beta. Furthermore, the enhanced antiviral effect of asialo-IFN-beta was supported by induction of the 2'-5' oligoadenylate synthetase, an indicator of IFN activity(6), at a level significantly higher than that produced by conventional IFN-beta Moreover, mouse asialo-IFN-beta profoundry reduced viremia in vivo in HBV-transfected athymic nude mice, in contrast to conventional IFN-beta, which had no substantial effect. These experiments demonstrate that directing IFN to ASGP receptor facilitates its signaling in the liver and augments its antiviral effect, and is therefore useful in overcoming the limited antiviral effect of conventional IFNs.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Takahashi, H (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Jackson 7,Fruit St, Boston, MA 02114 USA.				NATIONAL CANCER INSTITUTE [R29CA057584, R01CA057584] Funding Source: NIH RePORTER; NCI NIH HHS [CA57584] Funding Source: Medline; NIDDK NIH HHS [NIDDK4331] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BRANCA AA, 1982, J BIOL CHEM, V257, P13291; BURGESS JB, 1992, HEPATOLOGY, V15, P702, DOI 10.1002/hep.1840150425; CONRADT HS, 1987, J BIOL CHEM, V262, P14600; DERYNCK R, 1980, NATURE, V285, P542, DOI 10.1038/285542a0; EISENBERG C, 1991, J HEPATOL, V13, P305, DOI 10.1016/0168-8278(91)90073-K; HIGASHI Y, 1983, J BIOL CHEM, V258, P9522; HUEZ G, 1983, BIOCHEM BIOPH RES CO, V110, P155, DOI 10.1016/0006-291X(83)91273-1; HYODO I, 1993, LIVER, V13, P80; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; KAWADE Y, 1980, J INTERFERON RES, V1, P61, DOI 10.1089/jir.1980.1.61; KILLION JJ, 1989, J NATL CANCER I, V81, P1387, DOI 10.1093/jnci/81.18.1387; LEE YC, 1983, J BIOL CHEM, V258, P199; LIANG TJ, 1993, J CLIN INVEST, V91, P1241, DOI 10.1172/JCI116287; PESKA S, 1997, SEMIN ONCOL, V9; REDLICH PN, 1991, P NATL ACAD SCI USA, V88, P4040, DOI 10.1073/pnas.88.9.4040; RUBINSTEIN M, 1986, CRIT REV BIOCHEM MOL, V21, P249, DOI 10.3109/10409238609113613; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SEIF I, 1991, J VIROL, V65, P664, DOI 10.1128/JVI.65.2.664-671.1991; SHINDO M, 1988, HEPATOLOGY, V8, P366, DOI 10.1002/hep.1840080229; TAKAHASHI H, 1995, P NATL ACAD SCI USA, V92, P1470, DOI 10.1073/pnas.92.5.1470; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TRUBETSKOY VS, 1992, BIOCHIM BIOPHYS ACTA, V1131, P311, DOI 10.1016/0167-4781(92)90030-4; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	25	38	43	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					577	581		10.1038/8462	http://dx.doi.org/10.1038/8462			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229237				2022-12-27	WOS:000081497400041
J	Caughey, B				Caughey, B			Transmissible spongiform encephalopathies, amyloidoses and yeast prions: Common threads?	NATURE MEDICINE			English	Review							PROTEASE-RESISTANT FORMS; CELL-FREE CONVERSION; SACCHAROMYCES-CEREVISIAE; IN-VITRO; SUP35 PROTEIN; SCRAPIE; PROPAGATION; DISEASE; URE2P; SUSCEPTIBILITY	Mammalian transmissible spongiform encephalopathy (prion) and amyloid diseases seem to involve the self-propagation of abnormal fibrillar or sub-fibrillar protein aggregates. Similar processes explain protein-mediated inheritance by yeast prions. Indeed, yeast prions are more surely mediated solely by aberrant protein aggregates than are their mammalian namesakes. Tantalizing parallels make yeast prions attractive models of mammalian protein-folding diseases.	NIAID, Persistent Viral Dis Lab, NIH, Rocky Mt Labs, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Caughey, B (corresponding author), NIAID, Persistent Viral Dis Lab, NIH, Rocky Mt Labs, 903 S 4th St, Hamilton, MT 59840 USA.	bcaughey@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000580, ZIAAI000580] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKOWITZ A, 1990, MICROB PATHOGENESIS, V9, P33, DOI 10.1016/0882-4010(90)90038-R; Appel TR, 1999, BIOL CHEM, V380, P1295, DOI 10.1515/BC.1999.165; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chernoff YO, 2000, MOL MICROBIOL, V35, P865, DOI 10.1046/j.1365-2958.2000.01761.x; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; Coustou V, 1997, P NATL ACAD SCI USA, V94, P9773, DOI 10.1073/pnas.94.18.9773; Derkatch IL, 1996, GENETICS, V144, P1375; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Johan K, 1998, P NATL ACAD SCI USA, V95, P2558, DOI 10.1073/pnas.95.5.2558; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Kisilevsky R, 1999, AMYLOID, V6, P98, DOI 10.3109/13506129909007309; Klein TR, 1998, BIOL CHEM, V379, P655, DOI 10.1515/bchm.1998.379.6.655; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kushnirov VV, 2000, EMBO J, V19, P324, DOI 10.1093/emboj/19.3.324; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Li LM, 2000, SCIENCE, V287, P661, DOI 10.1126/science.287.5453.661; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Priola SA, 1999, BIOMED PHARMACOTHER, V53, P27, DOI 10.1016/S0753-3322(99)80057-2; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Tuite MF, 2000, CELL, V100, P289, DOI 10.1016/S0092-8674(00)80663-7; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1999, J BIOL CHEM, V274, P555, DOI 10.1074/jbc.274.2.555	47	61	61	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2000	6	7					751	754		10.1038/77476	http://dx.doi.org/10.1038/77476			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888922				2022-12-27	WOS:000088040100030
J	Zanelli, E; Toes, REM				Zanelli, E; Toes, REM			A dual function for CD40 agonists	NATURE MEDICINE			English	Editorial Material							COLLAGEN-INDUCED ARTHRITIS; ANTIBODY; LIGAND; CELL; GP39; MICE		Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Zanelli, E (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.			Toes, Rene/0000-0002-9618-6414				DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; FOY TM, 1993, J EXP MED, V178, P1567, DOI 10.1084/jem.178.5.1567; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Kyburz D, 1999, J IMMUNOL, V163, P3116; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Webster EA, 1999, ARTHRITIS RHEUM, V42, P1291, DOI 10.1002/1529-0131(199906)42:6<1291::AID-ANR29>3.0.CO;2-#; WOOLEY PH, 1981, J EXP MED, V154, P688, DOI 10.1084/jem.154.3.688	9	4	4	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					629	630		10.1038/76197	http://dx.doi.org/10.1038/76197			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835673				2022-12-27	WOS:000087438300023
J	Ronemus, M				Ronemus, M			Breaking point	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					503	503		10.1038/74974	http://dx.doi.org/10.1038/74974			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802699	Bronze			2022-12-27	WOS:000086796200023
J	Wang, H; DeVries, ME; Deng, SP; Khandaker, MH; Pickering, JG; Chow, LH; Garcia, B; Kelvin, DJ; Zhong, R				Wang, H; DeVries, ME; Deng, SP; Khandaker, MH; Pickering, JG; Chow, LH; Garcia, B; Kelvin, DJ; Zhong, R			The axis of interleukin 12 and gamma interferon regulates acute vascular xenogeneic rejection	NATURE MEDICINE			English	Article							DELAYED XENOGRAFT REJECTION; IFN-GAMMA; CARDIAC XENOTRANSPLANTATION; IL-12-DEFICIENT MICE; ALLOGRAFT-REJECTION; B-CELLS; CYTOKINE; ACTIVATION; PIG; EXPRESSION	Recent advances using transgenic animals or exogenous complement inhibitors have demonstrated prevention of hyperacute rejection of vascularized organs, but not graft loss due to acute vascular rejection. Using various wild-type and cytokine-deficient mice strains, we have examined the mechanisms of acute vascular rejection. C57BL/6 mice deficient in interleukin12 or gamma interferon showed faster acute vascular rejection than did wild-type mice. Furthermore, mice defective in B-cell development showed no acute vascular rejection. These results demonstrate that the axis of interleukin 12 and gamma interferon provides a survival advantage in vascularized xenografts by delaying or preventing acute vascular rejection caused by a B cell-dependent mechanism.	London Hlth Sci Ctr, Multi Organ Transplant Program, London, ON N6A 5A5, Canada; John P Robarts Res Inst, Expt Transplantat Surg Lab, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; John P Robarts Res Inst, Lab Mol Immunol & Inflammat, London, ON N6G 2V4, Canada	London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Kelvin, DJ (corresponding author), London Hlth Sci Ctr, Multi Organ Transplant Program, 339 Windemere Rd, London, ON N6A 5A5, Canada.		Pickering, J. Geoffrey/G-3341-2011	Pickering, J. Geoffrey/0000-0001-6474-3274				ABED NS, 1994, CELL IMMUNOL, V153, P356, DOI 10.1006/cimm.1994.1034; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Bhatti FNK, 1999, TRANSPLANT P, V31, P958, DOI 10.1016/S0041-1345(98)01855-7; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; Candinas D, 1996, TRANSPLANTATION, V62, P1920, DOI 10.1097/00007890-199612270-00042; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; Hutchinson IV, 1999, TRANSPLANT P, V31, P734, DOI 10.1016/S0041-1345(98)01746-1; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Konieczny BT, 1998, J IMMUNOL, V160, P2059; Lauwerys BR, 1998, EUR J IMMUNOL, V28, P2017, DOI 10.1002/(SICI)1521-4141(199806)28:06<2017::AID-IMMU2017>3.0.CO;2-2; LEVENTHAL JR, 1993, TRANSPLANTATION, V56, P1, DOI 10.1097/00007890-199307000-00001; Lin JS, 1998, J BIOMED SCI, V5, P101, DOI 10.1159/000025319; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Markees TG, 1998, J CLIN INVEST, V101, P2446, DOI 10.1172/JCI2703; MATSUMIYA G, 1994, TRANSPLANTATION, V57, P1653; MORRIS SC, 1994, J IMMUNOL, V152, P1047; Murphy B, 1996, TRANSPLANTATION, V61, P1133, DOI 10.1097/00007890-199604270-00001; Nickerson P, 1997, TRANSPLANTATION, V63, P489, DOI 10.1097/00007890-199702270-00001; NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987; Piccotti JR, 1996, J IMMUNOL, V157, P1951; Piccotti JR, 1998, J IMMUNOL, V160, P1132; PLATT JL, 1991, TRANSPLANTATION, V52, P1037, DOI 10.1097/00007890-199112000-00019; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TAKEUCHI T, 1992, TRANSPLANTATION, V53, P1281, DOI 10.1097/00007890-199206000-00023; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Turner D, 1997, TRANSPLANTATION, V64, P776, DOI 10.1097/00007890-199709150-00021; vandenBogaerde J, 1997, BRIT MED BULL, V53, P904; Wang H, 1999, TRANSPLANTATION, V68, P1643, DOI 10.1097/00007890-199912150-00007; Waterworth PD, 1997, TRANSPL P, V29, P899, DOI 10.1016/S0041-1345(96)00224-2; Xu H, 1998, J THORAC CARDIOV SUR, V115, P1342, DOI 10.1016/S0022-5223(98)70218-1; YOSHIDA A, 1994, BIOCHEM BIOPH RES CO, V198, P857, DOI 10.1006/bbrc.1994.1122; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948; Zaidi A, 1998, TRANSPLANTATION, V65, P1584, DOI 10.1097/00007890-199806270-00008; Zhang Z, 1996, TRANSPLANTATION, V62, P1267, DOI 10.1097/00007890-199611150-00016	37	59	64	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					549	555		10.1038/75029	http://dx.doi.org/10.1038/75029			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802711				2022-12-27	WOS:000086796200039
J	Thurston, G; Rudge, JS; Ioffe, E; Zhou, H; Ross, L; Croll, SD; Glazer, N; Holash, J; McDonald, DM; Yancopoulos, GD				Thurston, G; Rudge, JS; Ioffe, E; Zhou, H; Ross, L; Croll, SD; Glazer, N; Holash, J; McDonald, DM; Yancopoulos, GD			Angiopoietin-1 protects the adult vasculature against plasma leakage	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; PERMEABILITY FACTOR; ADENOVIRUS VECTORS; TRANSGENIC MICE; TIE2 RECEPTOR; ANGIOGENESIS; GENE; SKIN; HYPERPERMEABILITY; VASCULOGENESIS	Pathological increases in vascular leakage lead to edema and swelling, causing serious problems in brain tumors, in diabetic retinopathy, after strokes, during sepsis and also in inflammatory conditions such as rheumatoid arthritis and asthma. Although many agents and disease processes increase vascular leakage, no known agent specifically makes vessels resistant to leaking. Vascular endothelial growth factor(1) (VEGF) and the angiopoietins(2) function together during vascular development, with VEGF acting early during vessel formation(3-5), and angiopoietin-1 acting later during vessel remodeling, maturation and stabilization(6-9). Although VEGF was initially called vascular permeability factor(10,11), there has been less focus on its permeability actions and more effort devoted to its involvement in vessel growth and applications in ischemia and cancer. Recent transgenic approaches have confirmed the profound permeability effects of VEGF (refs. 12-14), and have shown that transgenic angiopoietin-1 acts reciprocally as an anti-permeability factor when provided chronically during vessel formation(14) although it also profoundly affects vascular morphology when thus delivered(14,15). To be useful clinically angiopoietin-1 would have to inhibit leakage when acutely administered to adult vessels, and this action would have to be uncoupled from its profound angiogenic capabilities. Here we show that acute administration of angiopoietin-1 does indeed protect adult vasculature from leaking, countering the potentially lethal actions of VEGF and inflammatory agents.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Regeneron; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Thurston, G (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.			Croll, Susan/0000-0002-3949-1877; Thurston, Gavin/0000-0002-4105-5919; Glazer, Nicole/0000-0002-6397-609X	NHLBI NIH HHS [HL59157, HL24136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059157, P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; COLLINS PD, 1993, BRIT J PHARMACOL, V109, P195, DOI 10.1111/j.1476-5381.1993.tb13553.x; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Davis S, 1999, CURR TOP MICROBIOL, V237, P173; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Hehir KM, 1996, J VIROL, V70, P8459, DOI 10.1128/JVI.70.12.8459-8467.1996; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; JANCSO G, 1993, AGENTS ACTIONS, V39, P31, DOI 10.1007/BF01975711; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; LIPPE IT, 1993, EUR J PHARMACOL, V232, P113, DOI 10.1016/0014-2999(93)90735-Z; MASSIE B, 1986, MOL CELL BIOL, V6, P2872, DOI 10.1128/MCB.6.8.2872; Muzzin P, 1996, P NATL ACAD SCI USA, V93, P14804, DOI 10.1073/pnas.93.25.14804; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194	25	1019	1113	2	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					460	463		10.1038/74725	http://dx.doi.org/10.1038/74725			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742156				2022-12-27	WOS:000165474100043
J	Lim, HW; Molkentin, JD				Lim, HW; Molkentin, JD			Revisiting calcineurin and human heart failure - Reply	NATURE MEDICINE			English	Letter									Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Molkentin, JD (corresponding author), Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.							Boelck B, 1999, CIRCULATION, V100, P508; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Lim HW, 1999, NAT MED, V5, P246, DOI 10.1038/6430; LIM HW, IN PRESS CIRCULATION; MCPARTLIN AE, 1991, BIOCHIM BIOPHYS ACTA, V1088, P308, DOI 10.1016/0167-4781(91)90069-X; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; TAIGEN T, IN PRESS P NATL ACAD	8	13	13	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2000	6	1					3	3		10.1038/71511	http://dx.doi.org/10.1038/71511			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613794	Bronze			2022-12-27	WOS:000084583300003
J	Ferrara, N; Alitalo, K				Ferrara, N; Alitalo, K			Clinical applications of angiogenic growth factors and their inhibitors	NATURE MEDICINE			English	Review							MEDIATED GENE-TRANSFER; TUMOR-GROWTH; IN-VIVO; VASCULAR-PERMEABILITY; ENDOTHELIAL-CELLS; VEGF GENE; RETINAL NEOVASCULARIZATION; AUGMENTS REVASCULARIZATION; VESSEL DEVELOPMENT; FACTOR RECEPTOR		Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland	Roche Holding; Genentech; University of Helsinki	Ferrara, N (corresponding author), Genentech Inc, Dept Mol Oncol, DNA Way, San Francisco, CA 94080 USA.	nf@gene.com; Kari.Alitalo@Helsinki.FI	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; BAUTERS C, 1994, AM J PHYSIOL-HEART C, V267, pH1263, DOI 10.1152/ajpheart.1994.267.4.H1263; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Bittl JA, 1996, NEW ENGL J MED, V335, P1290, DOI 10.1056/NEJM199610243351707; Borgstrom P, 1996, CANCER RES, V56, P4032; BURKE PA, 1995, BIOCHEM BIOPH RES CO, V207, P348, DOI 10.1006/bbrc.1995.1194; CAMENZIND E, 1995, CIRCULATION, V92, P2463, DOI 10.1161/01.CIR.92.9.2463; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferreira A, 1998, CONTROL ENG PRACT, V6, P1, DOI 10.1016/S0967-0661(97)10057-0; Ferrell RE, 1998, HUM MOL GENET, V7, P2073, DOI 10.1093/hmg/7.13.2073; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Garner Alec, 1994, P1625; Gasparini G, 1997, J NATL CANCER I, V89, P139, DOI 10.1093/jnci/89.2.139; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Greelish JP, 1999, NAT MED, V5, P439, DOI 10.1038/7439; HARADA K, 1994, J CLIN INVEST, V94, P623, DOI 10.1172/JCI117378; Henry TD, 1998, J AM COLL CARDIOL, V31, p65A, DOI 10.1016/S0735-1097(97)83989-7; Henry Timothy D., 1999, Journal of the American College of Cardiology, V33, p384A; HILTUNEN MO, IN PRESS CIRCULATION; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Isner JM, 1998, J VASC SURG, V28, P964, DOI 10.1016/S0741-5214(98)70022-9; Jain RK, 1998, J CONTROL RELEASE, V53, P49, DOI 10.1016/S0168-3659(97)00237-X; JEITSCH M, 1997, SCIENCE, V276, P1423; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kong HL, 1998, HUM GENE THER, V9, P823, DOI 10.1089/hum.1998.9.6-823; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Lopez JJ, 1998, CARDIOVASC RES, V40, P272, DOI 10.1016/S0008-6363(98)00136-9; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Mack CA, 1998, J THORAC CARDIOV SUR, V115, P168, DOI 10.1016/S0022-5223(98)70455-6; Mack CA, 1998, J VASC SURG, V27, P699, DOI 10.1016/S0741-5214(98)70236-8; Maeda K, 1996, CANCER, V77, P853; MCCLURE N, 1994, LANCET, V344, P235, DOI 10.1016/S0140-6736(94)93001-5; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Millauer B, 1996, CANCER RES, V56, P1615; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740; PATZ A, 1980, INVEST OPHTH VIS SCI, V19, P1133; PEARLMAN JD, 1995, NAT MED, V1, P1085, DOI 10.1038/nm1095-1085; Pham CD, 1998, CANCER INVEST, V16, P225, DOI 10.3109/07357909809039771; Presta LG, 1997, CANCER RES, V57, P4593; PU LQ, 1993, CIRCULATION, V88, P208, DOI 10.1161/01.CIR.88.1.208; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rivard A, 1998, MOL MED, V4, P429, DOI 10.1007/BF03401749; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L; Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556; Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115; Salven P, 1998, INT J CANCER, V79, P144, DOI 10.1002/(SICI)1097-0215(19980417)79:2<144::AID-IJC8>3.0.CO;2-T; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shyu KG, 1998, CIRCULATION, V98, P2081, DOI 10.1161/01.CIR.98.19.2081; SMITH LE, 1997, SCIENCE, V276, P5319; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; Strawn LM, 1996, CANCER RES, V56, P3540; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takeshita S, 1996, LAB INVEST, V75, P487; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Van Belle E, 1998, CIRCULATION, V97, P381; VANBRUGGEN N, IN PRESS J CLIN INV; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; YIAHERTTUALA S, 1997, CURR OPIN LIPIDOL, V8, P72; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	97	839	1023	2	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1999	5	12					1359	1364		10.1038/70928	http://dx.doi.org/10.1038/70928			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581076				2022-12-27	WOS:000084049700033
J	Birmingham, K				Birmingham, K			A Nobel for Blobel	NATURE MEDICINE			English	Biographical-Item																			0	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1230	1230		10.1038/15177	http://dx.doi.org/10.1038/15177			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545979	Bronze			2022-12-27	WOS:000086550600019
J	Bonetta, L				Bonetta, L			Canadian fight over thalassemia drug worsens	NATURE MEDICINE			English	News Item																		1999, NAT MED, V4, P1095	1	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1223	1223		10.1038/15165	http://dx.doi.org/10.1038/15165			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545972	Bronze			2022-12-27	WOS:000086550600014
J	Hakumaki, JM; Poptani, H; Sandmair, AM; Yla-Herttuala, S; Kauppinen, RA				Hakumaki, JM; Poptani, H; Sandmair, AM; Yla-Herttuala, S; Kauppinen, RA			H-1 MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis	NATURE MEDICINE			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; TUMOR-NECROSIS-FACTOR; IN-VIVO; THYMIDINE KINASE; LIPID DROPLETS; BRAIN-TUMORS; CELL-DEATH; ACTIVATION; PROLIFERATION; GANCICLOVIR		AI Virtanen Inst Mol Sci, NMR Res Grp, FIN-70211 Kuopio, Finland; AI Virtanen Inst Mol Sci, Mol Med Grp, FIN-70211 Kuopio, Finland		Hakumaki, JM (corresponding author), AI Virtanen Inst Mol Sci, NMR Res Grp, FIN-70211 Kuopio, Finland.	jhakumak@messi.uku.fi; kauppine@messi.uku.fi	Hakumäki, Juhana/AAH-1058-2021; Kauppinen, Risto A/F-3274-2011	Hakumaki, Juhana/0000-0001-7341-5440; Yla-Herttuala, Seppo/0000-0001-7593-2708; Poptani, Harish/0000-0002-0593-3235				AGREN JJ, 1992, J LIPID RES, V33, P1871; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Blankenberg FG, 1997, BLOOD, V89, P3778, DOI 10.1182/blood.V89.10.3778.3778_3778_3786; CALLIES R, 1993, MAGNET RESON MED, V29, P546, DOI 10.1002/mrm.1910290418; CHIOCCA EA, 1998, GENE THERAPY NEUROLO; De Valck D, 1998, J CELL BIOCHEM, V71, P392, DOI 10.1002/(SICI)1097-4644(19981201)71:3<392::AID-JCB8>3.0.CO;2-N; Finstad HS, 1998, BIOCHEM J, V336, P451, DOI 10.1042/bj3360451; FREEMAN SM, 1993, CANCER RES, V53, P5274; Hakumaki J. M., 1997, CURR TOP NEUROCHEM, V1, P59; Hakumaki JM, 1998, CANCER RES, V58, P3791; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUESEL AC, 1994, NMR BIOMED, V7, P149, DOI 10.1002/nbm.1940070308; MOUNTFORD CE, 1982, CANCER RES, V42, P2270; Negendank W, 1996, ANTICANCER RES, V16, P1533; Poptani H, 1998, CANCER GENE THER, V5, P101; Remy C, 1997, CANCER RES, V57, P407; SMITH TAD, 1991, BRIT J CANCER, V64, P821, DOI 10.1038/bjc.1991.407; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; USENIUS JPR, 1994, J COMPUT ASSIST TOMO, V18, P705, DOI 10.1097/00004728-199409000-00005; Veale MF, 1997, BIOCHEM BIOPH RES CO, V239, P868, DOI 10.1006/bbrc.1997.7566; Wei SJ, 1998, EXP CELL RES, V241, P66, DOI 10.1006/excr.1998.4005; WELLER PF, 1991, J CELL BIOL, V113, P137, DOI 10.1083/jcb.113.1.137; WHATLEY RE, 1994, J CLIN INVEST, V94, P1889, DOI 10.1172/JCI117539; Williamson MS, 1998, GRADIVA, V6, P40; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; YLAHERTTUALA S, 1985, ATHEROSCLEROSIS, V56, P1, DOI 10.1016/0021-9150(85)90079-6	28	220	224	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1999	5	11					1323	1327		10.1038/15279	http://dx.doi.org/10.1038/15279			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10546002				2022-12-27	WOS:000086550600046
J	Hille, B; Armstrong, CM; MacKinnon, R				Hille, B; Armstrong, CM; MacKinnon, R			Ion channels: From idea to reality	NATURE MEDICINE			English	Editorial Material							POTASSIUM CHANNEL; MYELINATED NERVE; SODIUM CHANNEL; SQUID AXONS; K+ CHANNEL; INACTIVATION; CONDUCTANCE; PERMEABILITY; CATIONS; PORES		Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Penn, Philadelphia, PA 19104 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	University of Washington; University of Washington Seattle; University of Pennsylvania; Marine Biological Laboratory - Woods Hole; Rockefeller University; Howard Hughes Medical Institute	Hille, B (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.							ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P645; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Heymann JB, 1998, J STRUCT BIOL, V121, P191, DOI 10.1006/jsbi.1997.3951; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1971, J GEN PHYSIOL, V58, P599, DOI 10.1085/jgp.58.6.599; Hille B., 1970, Progr. Biophys. molec. Biol., V21, P1, DOI 10.1016/0079-6107(70)90022-2; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hille B., 1992, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hodking A. L., 1955, J PHYSIOL-LONDON, V128, P61; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471	25	98	105	2	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1999	5	10					1105	1109		10.1038/13415	http://dx.doi.org/10.1038/13415			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502800				2022-12-27	WOS:000082933200021
J	Enjyoji, K; Sevigny, J; Lin, Y; Frenette, PS; Christie, PD; Esch, JSA; Imai, M; Edelberg, JM; Rayburn, H; Lech, M; Beeler, DL; Csizmadia, E; Wagner, DD; Robson, SC; Rosenberg, RD				Enjyoji, K; Sevigny, J; Lin, Y; Frenette, PS; Christie, PD; Esch, JSA; Imai, M; Edelberg, JM; Rayburn, H; Lech, M; Beeler, DL; Csizmadia, E; Wagner, DD; Robson, SC; Rosenberg, RD			Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation	NATURE MEDICINE			English	Article							ATP-DIPHOSPHOHYDROLASE; PLATELET ACTIVATION; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; EXTRACELLULAR ATP; ADP; RECEPTORS; NUCLEOTIDES; EXPRESSION; THROMBOSIS	CD39, or vascular adenosine triphosphate diphosphohydrolase, has been considered an important inhibitor of platelet activation. Unexpectedly, cd39-deficient mice had prolonged bleeding times with minimally perturbed coagulation parameters. Platelet interactions with injured mesenteric vasculature were considerably reduced in vivo and purified mutant platelets failed to aggregate to standard agonists in vitro. This platelet hypofunction was reversible and associated with purinergic type P2Y1 receptor desensitization. In keeping with deficient vascular protective mechanisms, fibrin deposition was found at multiple organ sites in cd39-deficient mice and in transplanted cardiac grafts. Our data indicate a dual role for adenosine triphosphate diphosphohydrolase in modulating hemostasis and thrombotic reactions.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Ctr Blood Res, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Rosenberg, RD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	rdrrosen@mit.edu	Esch, Jan Schulte am/AAL-9904-2021; Sevigny, Jean/E-8039-2012; Robson, Simon C./AAA-8537-2021; Frenette, Paul S/J-8272-2012; Sévigny, Jean/AGH-9323-2022	Esch, Jan Schulte am/0000-0002-2101-5012; Sevigny, Jean/0000-0003-2922-1600; Frenette, Paul S/0000-0003-0862-9922; Sévigny, Jean/0000-0003-2922-1600	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057307, R01HL041002, R37HL041002] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41002, HL57307] Funding Source: Medline; PHS HHS [P01-41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; BAKKER WW, 1989, J LAB CLIN MED, V114, P531; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Berger G, 1998, BLOOD, V92, P4446, DOI 10.1182/blood.V92.11.4446; BEURLINGHARBURY C, 1990, THROMB HAEMOSTASIS, V63, P286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Candinas D, 1996, THROMB HAEMOSTASIS, V76, P807; Chadwick A, 1998, J SMALL ANIM PRACT, V39, P357, DOI 10.1111/j.1748-5827.1998.tb03729.x; COADE SB, 1989, CIRC RES, V65, P531, DOI 10.1161/01.RES.65.3.531; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; Deguchi H, 1998, THROMB RES, V91, P57, DOI 10.1016/S0049-3848(98)00045-0; DEJANA E, 1979, THROMB RES, V15, P191, DOI 10.1016/0049-3848(79)90064-1; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Edelberg JM, 1998, J CLIN INVEST, V102, P837, DOI 10.1172/JCI3058; FIJNHEER R, 1992, THROMB HAEMOSTASIS, V68, P595; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Gayle RB, 1998, J CLIN INVEST, V101, P1851, DOI 10.1172/JCI1753; HEYNS ADP, 1977, THROMB HAEMOSTASIS, V37, P429; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Johnson EN, 1998, P NATL ACAD SCI USA, V95, P3100, DOI 10.1073/pnas.95.6.3100; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Koyamada N, 1998, TRANSPLANTATION, V65, P1210, DOI 10.1097/00007890-199805150-00012; Koyamada N, 1996, TRANSPLANTATION, V62, P1739, DOI 10.1097/00007890-199612270-00008; Liu MA, 1995, ANN NY ACAD SCI, V772, P15, DOI 10.1111/j.1749-6632.1995.tb44727.x; LUNDIN A, 1976, ANAL BIOCHEM, V75, P611, DOI 10.1016/0003-2697(76)90116-0; LUTHJE J, 1989, KLIN WOCHENSCHR, V67, P558, DOI 10.1007/BF01719786; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; MARCUS AJ, 1993, FASEB J, V7, P516, DOI 10.1096/fasebj.7.6.8472890; MOTTE S, 1995, INT J BIOCHEM CELL B, V27, P1, DOI 10.1016/1357-2725(94)00059-X; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; Saito H, 1999, AM J RESP CRIT CARE, V159, P1014, DOI 10.1164/ajrccm.159.3.9803100; Schafer AI, 1997, J CLIN INVEST, V99, P1143, DOI 10.1172/JCI119266; Sevigny J, 1997, BBA-GEN SUBJECTS, V1334, P73, DOI 10.1016/S0304-4165(96)00079-7; SHEN J, 1993, BIOPHYS J, V64, P1323, DOI 10.1016/S0006-3495(93)81498-X; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; Sun B, 1998, J BIOL CHEM, V273, P11544, DOI 10.1074/jbc.273.19.11544; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; von Albertini M, 1998, BIOCHEM BIOPH RES CO, V248, P822, DOI 10.1006/bbrc.1998.9055; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Weiler-Guettler H, 1998, J CLIN INVEST, V101, P1983, DOI 10.1172/JCI2006; Weisman GA, 1998, DRUG DEVELOP RES, V45, P222, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<222::AID-DDR20>3.0.CO;2-8; YANG ZH, 1991, LANCET, V337, P939, DOI 10.1016/0140-6736(91)91571-B; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	45	452	461	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1999	5	9					1010	1017		10.1038/12447	http://dx.doi.org/10.1038/12447			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470077				2022-12-27	WOS:000082337200034
J	Yaswen, L; Diehl, N; Brennan, MB; Hochgeschwender, U				Yaswen, L; Diehl, N; Brennan, MB; Hochgeschwender, U			Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin	NATURE MEDICINE			English	Article							MELANOCYTE-STIMULATING-HORMONE; RECEPTOR; MICE; GENE; MUTATIONS; PEPTIDES; TISSUES; PROTEIN	Pro-opiomelanocortin (POMC)-derived peptides (the melanocortins adrenocorticotropin, alpha-, beta- and gamma-melanocyte stimulating hormone; and the endogenous opioid beta-endorphin) have a diverse array of biological activities, including roles in pigmentation, adrenocortical function and regulation of energy stores, and in the immune system and the central and peripheral nervous systems'. We show here that mice lacking the POMC-derived peptides have obesity, defective adrenal development and altered pigmentation. This phenotype is similar to that of the recently identified human POMC-deficient patients(2). When treated with a stable alpha-melanocyte-stimulating hormone agonist, mutant mice lost more than 40% of their excess weight after 2 weeks. Our results identify the POMC-null mutant mouse as a model for studying the human POMC-null syndrome, and indicate the therapeutic use of peripheral melanocortin in the treatment of obesity.	Oklahoma Med Res Fdn, Dev Biol Program, Oklahoma City, OK 73104 USA; NIMH, Mol Genet Unit, Clin Neurosci Branch, Bethesda, MD 20892 USA; Eleanor Roosevelt Inst Canc Res, Denver, CO 80206 USA	Oklahoma Medical Research Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Hochgeschwender, U (corresponding author), Oklahoma Med Res Fdn, Dev Biol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.							Boston BA, 1996, ENDOCRINOLOGY, V137, P2043, DOI 10.1210/en.137.5.2043; BURCHILL SA, 1986, J ENDOCRINOL, V109, P15, DOI 10.1677/joe.0.1090015; Chen WB, 1997, CELL, V91, P789, DOI 10.1016/S0092-8674(00)80467-5; CODY WL, 1985, J MED CHEM, V28, P583, DOI 10.1021/jm50001a008; ESTIVARIZ FE, 1982, NATURE, V297, P419, DOI 10.1038/297419a0; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Hogan B, 1994, MANIPULATING MOUSE E; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Joerg H, 1996, MAMM GENOME, V7, P317, DOI 10.1007/s003359900090; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; KASTIN AJ, 1975, PHARMACOL BIOCHEM BE, V3, P121; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; NOTAKE M, 1983, FEBS LETT, V156, P67, DOI 10.1016/0014-5793(83)80250-6; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; RICHTER WO, 1987, NEUROPEPTIDES, V9, P59, DOI 10.1016/0143-4179(87)90033-3; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; SOLOMON J, 1973, ENDOCRINOLOGY, V93, P510, DOI 10.1210/endo-93-2-510; STRACK AM, 1995, AM J PHYSIOL-REG I, V268, pR1209, DOI 10.1152/ajpregu.1995.268.5.R1209; TEMPEL DL, 1994, J NEUROENDOCRINOL, V6, P479, DOI 10.1111/j.1365-2826.1994.tb00611.x; TOKUYAMA K, 1989, AM J PHYSIOL, V257, pE139, DOI 10.1152/ajpendo.1989.257.2.E139; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391	25	756	785	2	37	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1066	1070		10.1038/12506	http://dx.doi.org/10.1038/12506			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470087				2022-12-27	WOS:000082337200044
J	Carmeliet, P; Ng, YS; Nuyens, D; Theilmeier, G; Brusselmans, K; Cornelissen, I; Ehler, E; Kakkar, VV; Stalmans, I; Mattot, V; Perriard, JC; Dewerchin, M; Flameng, W; Nagy, A; Lupu, F; Moons, L; Collen, D; D'Amore, PA; Shima, DT				Carmeliet, P; Ng, YS; Nuyens, D; Theilmeier, G; Brusselmans, K; Cornelissen, I; Ehler, E; Kakkar, VV; Stalmans, I; Mattot, V; Perriard, JC; Dewerchin, M; Flameng, W; Nagy, A; Lupu, F; Moons, L; Collen, D; D'Amore, PA; Shima, DT			Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF(164) and VEGF(188)	NATURE MEDICINE			English	Article							BLOOD-VESSEL DEVELOPMENT; HIBERNATING MYOCARDIUM; DILATED CARDIOMYOPATHY; EXPRESSION PATTERN; CELL-DEATH; RECEPTOR; HYPOXIA; HEART; GENE; ANGIOPOIETIN-1		Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02115 USA; Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; Thrombosis Res Inst, Weston Expt Res Ctr, Vasc Biol Lab, London SW3 6LR, England; Katholieke Univ Leuven, Lab Expt Cardiac Surg, B-3000 Louvain, Belgium; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5 1X5, Canada; Imperial Canc Res Fund, London WC2A 3PX, England	Flanders Institute for Biotechnology (VIB); KU Leuven; Harvard University; Harvard Medical School; Schepens Eye Research Institute; Swiss Federal Institutes of Technology Domain; ETH Zurich; Thrombosis Research Institute; KU Leuven; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Cancer Research UK	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	D'Amore, Patricia A/G-5660-2017; Ng, Wing Yin/HHN-1743-2022; Carmeliet, Peter/AAQ-5140-2020; Lupu, Florea/C-3162-2009; Nagy, Andras/G-6465-2013; Lupu, Florea/AAV-3257-2021	D'Amore, Patricia A/0000-0001-9652-8974; Carmeliet, Peter/0000-0001-7961-1821; Lupu, Florea/0000-0003-1249-9278; Nagy, Andras/0000-0003-4311-0413; Lupu, Florea/0000-0003-1249-9278; Nuyens, Dieter/0000-0001-9390-3273; Ng, Yin Shan/0000-0002-4982-1999; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Ehler, Elisabeth/0000-0001-5646-5964	NCI NIH HHS [CA45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Ausma J, 1997, CIRCULATION, V96, P3157, DOI 10.1161/01.CIR.96.9.3157; Borgers Marcel, 1997, P287; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen CG, 1997, J AM COLL CARDIOL, V30, P1407, DOI 10.1016/S0735-1097(97)00309-4; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; Cheung N, 1998, HUM PATHOL, V29, P910, DOI 10.1016/S0046-8177(98)90195-2; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Elsasser A, 1997, CIRCULATION, V96, P2920, DOI 10.1161/01.CIR.96.9.2920; ELSASSER A, 1995, BASIC RES CARDIOL, V90, P47; EVANS SM, 1995, BRIT J CANCER, V72, P875, DOI 10.1038/bjc.1995.427; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FLAMENG W, 1987, J AM COLL CARDIOL, V9, P1235, DOI 10.1016/S0735-1097(87)80461-8; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Hirschi KK, 1998, J CELL BIOL, V141, P1287; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hudlicka O, 1996, J VASC RES, V33, P266, DOI 10.1159/000159155; Isner Jeffrey M., 1998, Frontiers in Bioscience, V3, pE49; Kaprielian RR, 1998, CIRCULATION, V97, P651, DOI 10.1161/01.CIR.97.7.651; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kremer C, 1997, CANCER RES, V57, P3852; LOPASCHUK GD, 1992, CARDIOVASC RES, V26, P1172, DOI 10.1093/cvr/26.12.1172; Lopaschuk GD, 1997, CIRCULATION, V95, P313; Murdah MA, 1997, PACE, V20, P2641, DOI 10.1111/j.1540-8159.1997.tb06113.x; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Risau W, 1998, KIDNEY INT, V54, pS3, DOI 10.1046/j.1523-1755.1998.06701.x; SCHAPER J, 1991, CIRCULATION, V83, P504, DOI 10.1161/01.CIR.83.2.504; Schwarz ER, 1996, J AM COLL CARDIOL, V27, P1577, DOI 10.1016/0735-1097(96)00059-9; SHAW DB, 1987, BRIT HEART J, V58, P598; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Shivalkar B, 1996, CIRCULATION, V94, P308, DOI 10.1161/01.CIR.94.3.308; SHIVALKAR B, 1999, THESIS LEUVEN U, P1; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takeshita S, 1996, LAB INVEST, V75, P487; Tokunaga T, 1998, BRIT J CANCER, V77, P998, DOI 10.1038/bjc.1998.164; Tomanek RJ, 1996, CARDIOVASC RES, V31, pE46; Vanoverschelde JLJ, 1997, CIRCULATION, V95, P1961; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; ZAREBA W, 1994, AM J CARDIOL, V74, P550, DOI 10.1016/0002-9149(94)90742-0	46	489	514	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					495	502		10.1038/8379	http://dx.doi.org/10.1038/8379			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229225				2022-12-27	WOS:000081497400029
J	Lacana', E; D'Adamio, L				Lacana', E; D'Adamio, L			Regulation of Fas ligand expression and cell death by apoptosis-linked gene 4	NATURE MEDICINE			English	Article							NF-KAPPA-B; LYMPHOPROLIFERATIVE SYNDROME; POLY(ADP-RIBOSE) POLYMERASE; LYMPHOCYTE APOPTOSIS; CLONAL ELIMINATION; SIGNALING COMPLEX; IMMUNE EVASION; T-LYMPHOCYTES; CD95 LIGAND; ACTIVATION	Programmed cell death is a process required for the normal development of an organism. One of the best understood apoptotic pathways occurs in T lymphocytes and is mediated by Fas/Fas ligand (FasL) interaction. During studies of apoptosis induced by T cell-receptor engagement, we identified ALG-4F, a truncated transcript that prevents T cell-receptor-induced FasL upregulation and cell death. Overexpression of full-length ALG-4 induced transcription of Fast and, consequently, apoptosis. These results indicate that ALG-4 is necessary and sufficient for Fast expression. Fas/FasL interaction initiates cell death in many other systems, and its dysregulation is a mechanism by which several pathologic conditions arise. Understanding the molecular mechanisms of Fast regulation could be very useful in elucidating how these diseases develop and in identifying potential therapeutic targets.	NIAID, Cellular & Mol Immunol Lab, T Cell Apoptosis Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	D'Adamio, L (corresponding author), NIAID, Cellular & Mol Immunol Lab, T Cell Apoptosis Unit, NIH, 9000 Rockville Pike,Bldg 4,Rm 111, Bethesda, MD 20892 USA.	Ld46r@nih.gov		D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Caricchio R, 1998, J IMMUNOL, V161, P241; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; D'Adamio L, 1997, Semin Immunol, V9, P17, DOI 10.1006/smim.1996.0057; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lacana E, 1997, J IMMUNOL, V158, P5129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latinis KM, 1997, J IMMUNOL, V158, P4602; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Matsui K, 1998, J IMMUNOL, V161, P3469; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; Wong B, 1997, CURR OPIN IMMUNOL, V9, P358, DOI 10.1016/S0952-7915(97)80082-9; Yang YL, 1997, BLOOD, V89, P550, DOI 10.1182/blood.V89.2.550	46	19	20	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					542	547		10.1038/8420	http://dx.doi.org/10.1038/8420			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229231				2022-12-27	WOS:000081497400035
J	Greelish, JP; Su, LT; Lankford, EB; Burkman, JM; Chen, HY; Konig, SK; Mercier, IM; Desjardins, PR; Mitchell, MA; Zheng, XG; Leferovich, J; Gao, GP; Balice-Gordon, RJ; Wilson, JM; Stedman, HH				Greelish, JP; Su, LT; Lankford, EB; Burkman, JM; Chen, HY; Konig, SK; Mercier, IM; Desjardins, PR; Mitchell, MA; Zheng, XG; Leferovich, J; Gao, GP; Balice-Gordon, RJ; Wilson, JM; Stedman, HH			Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector	NATURE MEDICINE			English	Article							GLYCOPROTEIN COMPLEX; DELTA-SARCOGLYCAN; MEDIATED TRANSFER; MDX MICE; GENE; HAMSTER; DISRUPTION; VIRUS	Limb-girdle muscular dystrophies 2C-F represent a family of autosomal recessive diseases caused by defects in sarcoglycan genes'. The cardiomyopathic hamster is a naturally occurring model for limb-girdle muscular dystrophy caused by a primary deficiency in delta-sarcoglycan(2-5). We show here that acute sarcolemmal disruption occurs in this animal model during forceful muscle contraction. A recombinant adeno-associated virus vector encoding human delta-sarcoglycan conferred efficient and stable genetic reconstitution in the adult cardiomyopathic hamster when injected directly into muscle. A quantitative assay demonstrated that vector-transduced muscle fibers are stably protected from sarcolemmal disruption; there was no associated inflammation or immunologic response to the vector-encoded protein. Efficient gene transduction with rescue of the sarcoglycan complex in muscle fibers of the distal hindlimb was also obtained after infusion of recombinant adeno-associated virus into the femoral artery in conjunction with histamine-induced endothelial permeabilization. This study provides a strong rationale for the development of gene therapy for limb-girdle muscular dystrophy.	Univ Penn Hlth Syst, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn Hlth Syst, Dept Med, Philadelphia, PA 19104 USA; Univ Penn Hlth Syst, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn Hlth Syst, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA; Univ Penn Hlth Syst, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Stedman, HH (corresponding author), Univ Penn Hlth Syst, Dept Surg, Philadelphia, PA 19104 USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131; Balice-Gordon, Rita/0000-0002-9950-7965; Koenig, Stephane/0000-0002-0801-279X	NHLBI NIH HHS [K08 HL003172-06] Funding Source: Medline; NIAMS NIH HHS [5PO1AR/NS43648] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR043648] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bonnemann Carsten G., 1996, Current Opinion in Pediatrics, V8, P569; BRUMBACK RA, 1984, COLOR ATLAS MUSCLE H, V13, P21; COX GA, 1994, NAT GENET, V8, P333, DOI 10.1038/ng1294-333; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; Deconinck N, 1996, P NATL ACAD SCI USA, V93, P3570, DOI 10.1073/pnas.93.8.3570; DeMatteo RP, 1997, J VIROL, V71, P5330, DOI 10.1128/JVI.71.7.5330-5335.1997; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; HOMBURGER F, 1966, ARCH PATHOL, V81, P302; HOMBURGER F, 1962, MED EXP, V6, P339; Nielsen HJ, 1996, ANN MED, V28, P107, DOI 10.3109/07853899609092934; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Stedman H, 1988, GENOMICS, V2, P1, DOI 10.1016/0888-7543(88)90102-4; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755	21	175	192	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					439	443		10.1038/7439	http://dx.doi.org/10.1038/7439			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202936				2022-12-27	WOS:000079574300036
J	Herzog, RW; Yang, EY; Couto, LB; Hagstrom, JN; Elwell, D; Fields, PA; Burton, M; Bellinger, DA; Read, MS; Brinkhous, KM; Podsakoff, GM; Nichols, TC; Kurtzman, GJ; High, KA				Herzog, RW; Yang, EY; Couto, LB; Hagstrom, JN; Elwell, D; Fields, PA; Burton, M; Bellinger, DA; Read, MS; Brinkhous, KM; Podsakoff, GM; Nichols, TC; Kurtzman, GJ; High, KA			Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; PREVIOUSLY UNTREATED PATIENTS; FACTOR-VIII; INTRAMUSCULAR INJECTION; IMMUNOCOMPETENT MICE; EXPRESSION; THERAPY; PROPHYLAXIS; DOGS; PERSISTENCE	Hemophilia B is a severe X-linked bleeding diathesis caused by the absence of functional blood coagulation factor TX, and is an excellent candidate for treatment of a genetic disease by gene therapy. Using an adeno-associated viral vector, we demonstrate sustained expression (>17 months) of factor IX in a large-animal model at levels that would have a therapeutic effect in humans (up to 70 ng/ml, adequate to achieve phenotypic correction, in an animal injected with 8.5 x 10(12) vector particles/kg). The five hemophilia B dogs treated showed stable, vector dose-dependent partial correction of the whole blood clotting time and, at higher doses, of the activated partial thromboplastin time. In contrast to other viral gene delivery systems, this minimally invasive procedure, consisting of a series of percutaneous intramuscular Injections at a single timepoint, was not associated with local or systemic toxicity. Efficient gene transfer to muscle was shown by immunofluorescence staining and DNA analysis of biopsied tissue, Immune responses against factor IX were either absent or transient. These data provide strong support for the feasibility of the approach for therapy of human subjects.	Univ Penn, Med Ctr, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; Avigen Inc, Alameda, CA 94502 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ Penn, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania	High, KA (corresponding author), Univ Penn, Med Ctr, Dept Pediat, Philadelphia, PA 19104 USA.	high@email.chop.edu	High, Katherine A./AAB-9322-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009397, P50HL054500, R24HL063098, R01HL053668] Funding Source: NIH RePORTER; NHLBI NIH HHS [R24 HL063098, R01 HL53668, P50 HL54500, F32 HL09397] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Afione SA, 1996, J VIROL, V70, P3235, DOI 10.1128/JVI.70.5.3235-3241.1996; Baskar JF, 1996, J VIROL, V70, P3207, DOI 10.1128/JVI.70.5.3207-3214.1996; BRAY GL, 1987, AM J DIS CHILD, V141, P1215, DOI 10.1001/archpedi.1987.04460110085030; BRAY GL, 1994, BLOOD, V83, P2428; BRINKHOUS KM, 1993, BLOOD, V82, pA592; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; EVANS JP, 1989, P NATL ACAD SCI USA, V86, P10095, DOI 10.1073/pnas.86.24.10095; EVANS JP, 1989, BLOOD, V74, P207; EYSTER ME, 1978, BLOOD, V51, P1179; Fang B, 1996, GENE THER, V3, P217; Ferrari FK, 1997, NAT MED, V3, P1295, DOI 10.1038/nm1197-1295; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Gilles JG, 1996, J CLIN INVEST, V97, P1382, DOI 10.1172/JCI118558; GILLES JGG, 1993, BLOOD, V82, P2452; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; High KA, 1995, ADV EXP MED BIOL, V386, P79; Jooss K, 1998, J VIROL, V72, P4212, DOI 10.1128/JVI.72.5.4212-4223.1998; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; KAY MA, 1994, P NATL ACAD SCI USA, V91, P2353, DOI 10.1073/pnas.91.6.2353; KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Kung SH, 1998, BLOOD, V91, P784, DOI 10.1182/blood.V91.3.784.784_784_790; Lofqvist T, 1997, J INTERN MED, V241, P395, DOI 10.1046/j.1365-2796.1997.130135000.x; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; Lusher JM, 1997, THROMB HAEMOSTASIS, V78, P726; Matsushita T, 1998, GENE THER, V5, P938, DOI 10.1038/sj.gt.3300680; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; MITRUKA BM, 1976, ANIMALS MED RES MODE, P216; Monahan PE, 1998, GENE THER, V5, P40, DOI 10.1038/sj.gt.3300548; Nakai H, 1998, BLOOD, V91, P4600, DOI 10.1182/blood.V91.12.4600.412k22_4600_4607; NIENHUIS AW, 1991, CANCER, V67, P2700, DOI 10.1002/1097-0142(19910515)67:10+<2700::AID-CNCR2820671705>3.0.CO;2-3; Ragni MV, 1997, HAEMOPHILIA, V3, P90, DOI 10.1046/j.1365-2516.1997.00100.x; Sambrook J., 1989, MOL CLONING; Svensson EC, 1997, HUM GENE THER, V8, P1797, DOI 10.1089/hum.1997.8.15-1797; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Walter J, 1996, P NATL ACAD SCI USA, V93, P3056, DOI 10.1073/pnas.93.7.3056; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Yang G, 1996, BIOL SIGNAL, V5, P1; YAO SN, 1994, GENE THER, V1, P99	42	445	497	1	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					56	63		10.1038/4743	http://dx.doi.org/10.1038/4743			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883840				2022-12-27	WOS:000077885000030
J	Stojdl, DF; Lichty, B; Knowles, S; Marius, R; Atkins, H; Sonenberg, N; Bell, JC				Stojdl, DF; Lichty, B; Knowles, S; Marius, R; Atkins, H; Sonenberg, N; Bell, JC			Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus	NATURE MEDICINE			English	Article							VESICULAR STOMATITIS-VIRUS; COMPLETE REGRESSION; CELL-LINE; ALPHA; RESISTANCE; THERAPY; MICE; REPLICATION; XENOGRAFTS; EXPRESSION	Interferons are circulating factors that bind to cell surface receptors, activating a signaling cascade, ultimately leading to both an antiviral response and an induction of growth inhibitory and/or apoptotic signals in normal and tumor cells(1). Attempts to exploit the ability of interferons to limit the growth of tumors in patients has met with limited results(2) because of cancer-specific mutations of gene products in the interferon pathway(3-7). Although interferon-non-responsive cancer cells may have acquired a growth/survival advantage over their normal counterparts, they may have simultaneously compromised their antiviral response. To test this, we used vesicular stomatitis virus (VSV), an enveloped, negative-sense RNA virus(8) exquisitely sensitive to treatment with interferon(9) VSV rapidly replicated in and selectively killed a variety of human tumor cell lines even in the presence of doses of interferon that completely protected normal human primary cell cultures. A single intratumoral injection of VSV was effective in reducing the tumor burden of nude mice bearing subcutaneous human melanoma xenografts. Our results support the use of VSV as a replication-competent oncolytic virus and demonstrate a new strategy for the treatment of interferon non-responsive tumors.	Ottawa Reg Canc Ctr, Res Labs, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; McGill University	Bell, JC (corresponding author), Ottawa Reg Canc Ctr, Res Labs, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	jbell@med.uottawa.ca	Lichty, Brian/J-2008-2012	Lichty, Brian/0000-0003-4514-1037				Abril E, 1996, TISSUE ANTIGENS, V47, P391, DOI 10.1111/j.1399-0039.1996.tb02574.x; BELKOWSKI LS, 1987, J VIROL, V61, P653, DOI 10.1128/JVI.61.3.653-660.1987; Burke F, 1999, CYTOKINES CELL MOL T, V5, P51; Cassady KA, 1998, J VIROL, V72, P7005; CAVE DR, 1985, J VIROL, V55, P366, DOI 10.1128/JVI.55.2.366-373.1985; COLAMONICI OR, 1992, BLOOD, V80, P744; Coukos G, 1999, CLIN CANCER RES, V5, P1523; HUNEYCUTT BS, 1993, J VIROL, V67, P6698, DOI 10.1128/JVI.67.11.6698-6706.1993; KLOKE O, 1990, CANCER TREAT REV, V17, P81, DOI 10.1016/0305-7372(90)90019-C; Letchworth GJ, 1999, VET J, V157, P239, DOI 10.1053/tvjl.1998.0303; LORENCE RM, 1994, JNCI-J NATL CANCER I, V86, P1228, DOI 10.1093/jnci/86.16.1228; LORENCE RM, 1994, CANCER RES, V54, P6017; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Shimada A, 1998, CANCER RES, V58, P4434; SMITH RR, 1956, CANCER, V9, P1211, DOI 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Thomsen AR, 1997, INT IMMUNOL, V9, P1757, DOI 10.1093/intimm/9.11.1757; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; XU B, 1994, BLOOD, V84, P1942	21	638	694	0	71	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2000	6	7					821	825		10.1038/77558	http://dx.doi.org/10.1038/77558			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888934				2022-12-27	WOS:000088040100042
J	Otterbein, LE; Bach, FH; Alam, J; Soares, M; Lu, HT; Wysk, M; Davis, RJ; Flavell, RA; Choi, AMK				Otterbein, LE; Bach, FH; Alam, J; Soares, M; Lu, HT; Wysk, M; Davis, RJ; Flavell, RA; Choi, AMK			Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; HEME OXYGENASE-1; SIGNAL-TRANSDUCTION; PROVIDES PROTECTION; FACTOR BIOSYNTHESIS; LETHAL ENDOTOXEMIA; OXIDATIVE STRESS; IL-12 PRODUCTION; LUNG INJURY; EXPRESSION	The stress-inducible protein heme oxygenase-1 provides protection against oxidative stress. The antiinflammatory properties of heme oxygenase-1 may serve as a basis for this cytoprotection. We demonstrate here that carbon monoxide, a by-product of heme catabolism by heme oxygenase, mediates potent anti-inflammatory effects. Both in vivo and in vitro, carbon monoxide at low concentrations differentially and selectively inhibited the expression of lipopolysaccharide-induced pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta, and macrophage inflammatory protein-lp and increased the lipopolysaccharide-induced expression of the anti-inflammatory cytokine interleukin-10. Carbon monoxide mediated these anti-inflammatory effects not through a guanylyl cyclase-cGMP or nitric oxide pathway, but instead through a pathway involving the mitogen-activated protein kinases. These data indicate the possibility that carbon monoxide may have an important protective function in inflammatory disease states and thus has potential therapeutic uses.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Connecticut Healthcare Syst, Connecticut Vet Affairs, W Haven, CT 06516 USA; Johns Hopkins Univ, Baltimore, MD 21205 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA; Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, New Orleans, LA 70121 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70121 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02215 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Johns Hopkins University; Howard Hughes Medical Institute; Yale University; Yale University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Ochsner Health System; Louisiana State University System; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Choi, AMK (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 333 Cedar St, New Haven, CT 06520 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X; Soares, Miguel/0000-0002-9314-4833	NHLBI NIH HHS [HL55330, HL60234] Funding Source: Medline; NIAID NIH HHS [AI42365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055330, R01HL060234, R01HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM J, 1994, J BIOL CHEM, V269, P25049; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BAUSS F, 1987, INFECT IMMUN, V55, P1622, DOI 10.1128/IAI.55.7.1622-1625.1987; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Foey AD, 1998, J IMMUNOL, V160, P920; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GEPPERT TD, 1994, MOL MED, V1, P93; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HAMBLETON J, 1996, P NATL ACAD SCI USA, V93, P2274; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; Hasko G, 1998, EUR J IMMUNOL, V28, P468, DOI 10.1002/(SICI)1521-4141(199802)28:02<468::AID-IMMU468>3.0.CO;2-Z; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; Jongeneel C V, 1994, Prog Clin Biol Res, V388, P367; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Nemeth ZH, 1997, SHOCK, V7, P371, DOI 10.1097/00024382-199705000-00010; Netea MG, 1998, IMMUNOLOGY, V94, P340, DOI 10.1046/j.1365-2567.1998.00532.x; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; PARILLO JE, 1992, ANN INTERN MED, V113, P991; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STUPFEL M, 1970, ANN NY ACAD SCI, V174, P342, DOI 10.1111/j.1749-6632.1970.tb49799.x; Szabo C, 1997, SHOCK, V7, P304, DOI 10.1097/00024382-199704000-00011; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tetreau C, 1999, BIOCHEMISTRY-US, V38, P7210, DOI 10.1021/bi9901026; Thomassen MJ, 1997, AM J RESP CELL MOL, V17, P279, DOI 10.1165/ajrcmb.17.3.2998m; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	45	1766	1883	8	185	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					422	428		10.1038/74680	http://dx.doi.org/10.1038/74680			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742149				2022-12-27	WOS:000165474100036
J	Dickson, D				Dickson, D			Celera: financial optimism, scientific skepticism	NATURE MEDICINE			English	Letter																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					116	116		10.1038/72174	http://dx.doi.org/10.1038/72174			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655076				2022-12-27	WOS:000085016900008
J	Liberatore, GT; Jackson-Lewis, V; Vukosavic, S; Mandir, AS; Vila, M; McAuliffe, WG; Dawson, VL; Dawson, TM; Przedborski, S				Liberatore, GT; Jackson-Lewis, V; Vukosavic, S; Mandir, AS; Vila, M; McAuliffe, WG; Dawson, VL; Dawson, TM; Przedborski, S			Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease	NATURE MEDICINE			English	Article							TYROSINE-HYDROXYLASE; NADPH-DIAPHORASE; MESSENGER-RNA; GLIAL-CELLS; BRAIN; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; NEUROTOXICITY; MICE; PEROXYNITRITE; MACROPHAGES	MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine damages dopaminergic neurons as seen in Parkinson disease. Here we show that after administration of MPTP to mice, there was a robust gliosis in the substantia nigra pars compacta associated with significant upregulation of inducible nitric oxide synthase (iNOS). These changes preceded or paralleled MPTP-induced dopaminergic neurodegeneration. We also show that mutant mice lacking the iNOS gene were significantly more resistant to MPTP than their wild-type littermates. This study demonstrates that iNOS is important in the MPTP neurotoxic process and indicates that inhibitors of iNOS may provide protective benefit in the treatment of Parkinson disease.	Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Johns Hopkins Univ, Sch Med, Dept Neurol Neurosci & Physiol, Baltimore, MD 21287 USA; Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	Columbia University; Columbia University; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Przedborski, S (corresponding author), Columbia Univ, Dept Neurol, New York, NY 10032 USA.	SP30@Columbia.edu	Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970; Vila, Miquel/0000-0002-1352-989X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037345, P50NS038370, R01NS038586] Funding Source: NIH RePORTER; NINDS NIH HHS [P50 NS38370, R29 NS37345, R01 NS38586] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams MH, 1996, ANIM BIOTECHNOL, V7, P1, DOI 10.1080/10495399609525844; Almer G, 1999, J NEUROCHEM, V72, P2415, DOI 10.1046/j.1471-4159.1999.0722415.x; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; ASMUS SE, 1994, J NEUROBIOL, V25, P156, DOI 10.1002/neu.480250207; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; DAWSON TM, 1994, J NEUROSCI, V14, P5147; Dawson TM, 1996, ANNU REV MED, V47, P219, DOI 10.1146/annurev.med.47.1.219; DAWSON TM, 1996, NITRIC OXIDE SOURCES, P349; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; Dugas N, 1998, CYTOKINE, V10, P680, DOI 10.1006/cyto.1998.0352; FAHN S, 1988, CECILS TXB MED, V18, P2143; FORNO LS, 1992, PROG BRAIN RES, V94, P429; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Garcion E, 1998, GLIA, V22, P282, DOI 10.1002/(SICI)1098-1136(199803)22:3<282::AID-GLIA7>3.0.CO;2-7; GIOVANNI A, 1991, J PHARMACOL EXP THER, V257, P691; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; HALLIWELL B, 1991, FREE RADICAL BIOL ME; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; Hara H, 1996, NEUROSCIENCE, V75, P881, DOI 10.1016/0306-4522(96)00313-2; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hornykiewicz O, 1987, Adv Neurol, V45, P19; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; JACKSONLEWIS V, 1995, NEURODEGENERATION, V4, P257, DOI 10.1016/1055-8330(95)90015-2; Keilhoff G, 1996, NEUROSCIENCE, V75, P1193, DOI 10.1016/0306-4522(96)00330-2; KOSTIC V, 1991, NEUROLOGY, V41, P202, DOI 10.1212/WNL.41.2_Part_1.202; LANGSTON JW, 1986, CLIN NEUROPHARMACOL, V9, P485, DOI 10.1097/00002826-198612000-00001; LEONARD CS, 1995, J COMP NEUROL, V362, P411, DOI 10.1002/cne.903620309; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Matthews RT, 1997, EXP NEUROL, V143, P282, DOI 10.1006/exnr.1996.6406; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1977, J EXP MED, V146, P1648, DOI 10.1084/jem.146.6.1648; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 1998, CURR OPIN NEUROL, V11, P335, DOI 10.1097/00019052-199808000-00009; Przedborski S, 1998, MOVEMENT DISORD, V13, P35; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; WALLACE MN, 1992, NEUROREPORT, V3, P953, DOI 10.1097/00001756-199211000-00001; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; YE YZ, 1996, NITRIC OXIDE PHYSL P, P201	51	888	920	4	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1999	5	12					1403	1409						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581083				2022-12-27	WOS:000084049700040
J	Slusher, BS; Vornov, JJ; Thomas, AG; Hurn, PD; Harukuni, I; Bhardwaj, A; Traystman, RJ; Robinson, MB; Britton, P; Lu, XCM; Tortella, FC; Wozniak, KM; Yudkoff, M; Potter, BM; Jackson, PF				Slusher, BS; Vornov, JJ; Thomas, AG; Hurn, PD; Harukuni, I; Bhardwaj, A; Traystman, RJ; Robinson, MB; Britton, P; Lu, XCM; Tortella, FC; Wozniak, KM; Yudkoff, M; Potter, BM; Jackson, PF			Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury	NATURE MEDICINE			English	Article							LINKED ACIDIC DIPEPTIDASE; CEREBRAL-ARTERY OCCLUSION; N-ACETYLASPARTYLGLUTAMATE; RAT-BRAIN; FOCAL ISCHEMIA; NERVOUS-SYSTEM; TISSUE-CULTURE; AMINO-ACIDS; RECEPTOR; TRANSIENT	We describe here a new strategy for the treatment of stroke, through the inhibition of NAALADase (N-acetylated-alpha-linked-acidic dipeptidase), an enzyme responsible for the hydrolysis of the neuropeptide NAAG (N-acetyl-aspartyl-glutamate) to N-acetyl-aspartate and glutamate. We demonstrate that the newly described NAALADase inhibitor 2-PMPA (2-(phosphonomethyl)pentanedioic acid) robustly protects against ischemic injury in a neuronal culture model of stroke and in rats after transient middle cerebral artery occlusion. Consistent with inhibition of NAALADase, we show that 2-PMPA increases NAAG and attenuates the ischemia-induced rise in glutamate. Both effects could contribute to neuroprotection. These data indicate that NAALADase inhibition may have use in neurological disorders in which excessive excitatory amino acid transmission is pathogenic.	Guilford Pharmaceut, Dept Res, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Walter Reed Army Med Ctr, Div Neurosci, Washington, DC 20307 USA	Johns Hopkins University; Johns Hopkins University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Slusher, BS (corresponding author), Guilford Pharmaceut, Dept Res, Baltimore, MD 21224 USA.		Vornov, James/F-6794-2013	Vornov, James/0000-0003-1965-5456				BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Britton P, 1997, LIFE SCI, V60, P1729, DOI 10.1016/S0024-3205(97)00132-X; Britton P, 1996, J NEUROCHEM, V67, P324; BRUNO V, 1995, EUR J NEUROSCI, V7, P1906, DOI 10.1111/j.1460-9568.1995.tb00712.x; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; CHEN J, 1995, BRAIN RES, V699, P121, DOI 10.1016/0006-8993(95)00868-Q; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; COYLE JT, 1991, EXCITATORY AMINO ACI, P69; FAGG GE, 1986, TRENDS PHARMACOL SCI, V7, P357, DOI 10.1016/0165-6147(86)90386-X; Fix AS, 1996, TOXICOL PATHOL, V24, P291, DOI 10.1177/019262339602400305; FUHRMAN S, 1994, J NEUROCHEM, V62, P275; Goda H, 1998, EUR J PHARMACOL, V357, P149, DOI 10.1016/S0014-2999(98)00559-7; Jackson PF, 1996, J MED CHEM, V39, P619, DOI 10.1021/jm950801q; JOHANSEN PA, 1995, MOL PHARMACOL, V48, P140; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MELDRUM B, 1990, CEREBROVAS BRAIN MET, V2, P27; MEYERHOFF JL, 1992, BRAIN RES, V593, P140, DOI 10.1016/0006-8993(92)91276-K; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; PUTTFARCKEN PS, 1993, J PHARMACOL EXP THER, V266, P796; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; ROBINSON MB, 1993, J NEUROCHEM, V61, P2099, DOI 10.1111/j.1471-4159.1993.tb07447.x; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SEKIGUCHI M, 1989, BRAIN RES, V482, P87, DOI 10.1016/0006-8993(89)90545-3; SERVAL V, 1990, J NEUROCHEM, V55, P39, DOI 10.1111/j.1471-4159.1990.tb08818.x; SLUSHER BS, 1990, J BIOL CHEM, V265, P21297; Small DL, 1997, INT REV NEUROBIOL, V40, P137; STAUCH BL, 1989, NEUROSCI LETT, V100, P295, DOI 10.1016/0304-3940(89)90702-7; Takahashi H, 1996, STROKE, V27, P2120, DOI 10.1161/01.STR.27.11.2120; THOMSEN C, 1994, EUR J PHARM-MOLEC PH, V267, P77, DOI 10.1016/0922-4106(94)90227-5; TSAI G, 1990, BRAIN RES, V518, P313, DOI 10.1016/0006-8993(90)90989-O; VALLIVULLAH HM, 1994, J NEUROCHEM, V63, P1714; VORNOV JJ, 1995, J NEUROCHEM, V65, P1681; Vornov JJ, 1996, J NEUROCHEM, V67, P2379; WAHLGREN NG, 1997, INT REV NEUROBIOL, P337; Wozniak DF, 1996, BRAIN RES, V707, P165, DOI 10.1016/0006-8993(95)01230-3; Wroblewska B, 1997, J NEUROCHEM, V69, P174; ZOLLINGER M, 1990, J CHROMATOGR, V32, P27	38	252	263	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1396	1402		10.1038/70971	http://dx.doi.org/10.1038/70971			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581082				2022-12-27	WOS:000084049700039
J	Jayaraman, KS				Jayaraman, KS			India hopes for patriotic return of neuroscientists	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1222	1222		10.1038/15160	http://dx.doi.org/10.1038/15160			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545970				2022-12-27	WOS:000086550600011
J	Triendl, R				Triendl, R			Cloning regulators accused of operating in a vacuum	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1221	1221		10.1038/15156	http://dx.doi.org/10.1038/15156			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545967	Bronze			2022-12-27	WOS:000086550600009
J	Grossman, Z; Polis, M; Feinberg, MB; Grossman, Z; Levi, I; Jankelevich, S; Yarchoan, R; Boon, J; de Wolf, F; Lange, JMA; Goudsmit, J; Dimitrov, DS; Paul, WE				Grossman, Z; Polis, M; Feinberg, MB; Grossman, Z; Levi, I; Jankelevich, S; Yarchoan, R; Boon, J; de Wolf, F; Lange, JMA; Goudsmit, J; Dimitrov, DS; Paul, WE			Ongoing HIV dissemination during HAART	NATURE MEDICINE			English	Editorial Material							T-CELL HOMEOSTASIS; ANTIRETROVIRAL THERAPY; INDUCTION THERAPY; DRUG-THERAPY; IN-VIVO; INFECTION; LYMPHOCYTES; REPLICATION; DYNAMICS; RNA		NIH, Off AIDS Res, Bethesda, MD 20892 USA; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Emory Univ, Ctr AIDS Res, Atlanta, GA 30322 USA; Chaim Sheba Med Ctr, Inst Virol, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Infect Dis, IL-52621 Tel Hashomer, Israel; NCI, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Expt & Computat Biol, Frederick Canc Res Ctr, NIH, Frederick, MD 21701 USA; Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1012 WX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1012 WX Amsterdam, Netherlands; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emory University; Chaim Sheba Medical Center; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Grossman, Z (corresponding author), NIH, Off AIDS Res, Bldg 10, Bethesda, MD 20892 USA.	grossman@helix.nih.gov	Grossman, Zvi/A-9643-2008	Polis, Michael/0000-0002-9151-2268	DIVISION OF BASIC SCIENCES - NCI [Z01BC010042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000493, ZIAAI000493, ZIAAI000390, Z01AI000390] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971; Bucy RP, 1999, AIDS RES HUM RETROV, V15, P223, DOI 10.1089/088922299311394; Cavert W, 1997, SCIENCE, V276, P1321; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; Cheynier R, 1998, NAT MED, V4, P421, DOI 10.1038/nm0498-421; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Grossman Z, 1998, IMMUNOL TODAY, V19, P528, DOI 10.1016/S0167-5699(98)01353-X; Grossman Z, 1997, NAT MED, V3, P486, DOI 10.1038/nm0597-486; Grossman Z, 1998, P NATL ACAD SCI USA, V95, P6314, DOI 10.1073/pnas.95.11.6314; Grossman Z, 1999, SCIENCE, V284, p555a, DOI [DOI 10.1126/SCIENCE.284.5414.555A, 10.1126/science.284.5414.555a]; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Igarashi T, 1999, NAT MED, V5, P211, DOI 10.1038/5576; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; Mueller BU, 1998, AIDS, V12, pF191, DOI 10.1097/00002030-199815000-00004; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Zhang LQ, 1999, J VIROL, V73, P855, DOI 10.1128/JVI.73.1.855-860.1999; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	26	129	132	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1999	5	10					1099	1104		10.1038/13410	http://dx.doi.org/10.1038/13410			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502799				2022-12-27	WOS:000082933200020
J	Sawa, A; Wiegand, GW; Cooper, J; Margolis, RL; Sharp, AH; Lawler, JF; Greenamyre, JT; Snyder, SH; Ross, CA				Sawa, A; Wiegand, GW; Cooper, J; Margolis, RL; Sharp, AH; Lawler, JF; Greenamyre, JT; Snyder, SH; Ross, CA			Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization	NATURE MEDICINE			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; PERMEABILITY TRANSITION; CELL-DEATH; LOCALIZATION; DYSFUNCTION; AGGREGATION; EXPRESSION; MEMBRANE; NECROSIS; NUCLEUS	Huntington disease (HD) is a genetically dominant condition caused by expanded CAG repeats coding for glutamine in the HD gene product huntingtin(1). Although HD symptoms reflect preferential neuronal death in specific brain regions, huntingtin is expressed in almost all tissues(2), so abnormalities outside the brain might be expected. Although involvement of nuclei(3-7) and mitochondria(8-14) in HD pathophysiology has been suggested, specific intracellular defects that might elicit cell death have been unclear. Mitochondria dysfunction is reported in HD brains(10-13); mitochondria are organelles that regulates apoptotic cell death(15,16). We now report that lymphoblasts derived from HD patients showed increased stress-induced apoptotic cell death associated with caspase-3 activation. When subjected to stress, HD lymphoblasts also manifested a considerable increase in mitochondrial depolarization correlated with increased glutamine repeats.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Program Cellular & Mol Med, Baltimore, MD 21205 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Emory University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Greenamyre, J. Timothy/B-4049-2011; Ross, Christopher A/H-8395-2013	Greenamyre, J. Timothy/0000-0003-3468-7878				ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arenas J, 1998, ANN NEUROL, V43, P397, DOI 10.1002/ana.410430321; BEAL MF, 1993, J NEUROSCI, V13, P4181; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hackam AS, 1999, HUM MOL GENET, V8, P25, DOI 10.1093/hmg/8.1.25; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Koroshetz WJ, 1997, ANN NEUROL, V41, P160, DOI 10.1002/ana.410410206; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; MacDonald ME, 1996, CURR OPIN NEUROBIOL, V6, P638, DOI 10.1016/S0959-4388(96)80097-3; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Penno M. B., 1993, Journal of Tissue Culture Methods, V15, P43, DOI 10.1007/BF02387289; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sawa A, 1997, MOL BRAIN RES, V48, P53, DOI 10.1016/S0169-328X(97)00078-8; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Schapira AHV, 1997, ANN NEUROL, V41, P141, DOI 10.1002/ana.410410203; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	33	305	309	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1194	1198		10.1038/13518	http://dx.doi.org/10.1038/13518			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502825				2022-12-27	WOS:000082933200048
J	Novak, K				Novak, K			Another tetracycline-induced transformation	NATURE MEDICINE			English	Editorial Material														Novak, Kristine/0000-0001-9314-1803					0	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					990	990		10.1038/12424	http://dx.doi.org/10.1038/12424			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470070				2022-12-27	WOS:000082337200027
J	Vlodavsky, I; Friedmann, Y; Elkin, M; Aingorn, H; Atzmon, R; Ishai-Michaeli, R; Bitan, M; Pappo, O; Peretz, T; Michal, I; Spector, L; Pecker, I				Vlodavsky, I; Friedmann, Y; Elkin, M; Aingorn, H; Atzmon, R; Ishai-Michaeli, R; Bitan, M; Pappo, O; Peretz, T; Michal, I; Spector, L; Pecker, I			Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis	NATURE MEDICINE			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; FIBROBLAST GROWTH-FACTOR; HUMAN-PLATELET HEPARITINASE; SULFATED POLYSACCHARIDES; MEDIATED DEGRADATION; LYMPHOMA-CELLS; PROTEOGLYCANS; INVASION; BINDING; MOUSE	Heparan sulfate proteoglycans interact with many extracellular matrix constituents, growth factors and enzymes. Degradation of heparan sulfate by endoglycosidic heparanase cleavage affects a variety of biological processes. We have purified a 50-kDa heparanase from human hepatoma and placenta, and now report cloning of the cDNA and gene encoding this enzyme. Expression of the cloned cDNA in insect and mammalian cells yielded 65-kDa and 50-kDa recombinant heparanase proteins. The 50-kDa enzyme represents an N-terminally processed enzyme, at least 100-fold more active than the 65-kDa form. The heparanase mRNA and protein are preferentially expressed in metastatic cell lines and specimens of human breast, colon and liver carcinomas. Low metastatic murine T-lymphoma and melanoma cells transfected with the heparanase cDNA acquired a highly metastatic phenotype in vivo, reflected by a massive liver and lung colonization. This represents the first cloned mammalian heparanase, to our knowledge, and provides direct evidence for its role in tumor metastasis. Cloning of the heparanase gene enables the development of specific molecular probes for early detection and treatment of cancer metastasis and autoimmune disorders.	Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Insight, IL-76121 Rehovot, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Vlodavsky, I (corresponding author), Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel.							Bame KJ, 1997, J BIOL CHEM, V272, P2245; BARNER M, 1985, INT J CANCER, V35, P483, DOI 10.1002/ijc.2910350411; BARNER M, 1987, BLOOD, V70, P551; BASHKIN P, 1990, BLOOD, V75, P2204; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DEVOUGE MW, 1994, INT J CANCER, V56, P286, DOI 10.1002/ijc.2910560224; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; GONZALO V, 1999, BIOCHIM BIOPHYS ACTA, V1429, P431; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; Graham LD, 1996, BIOCHEM MOL BIOL INT, V39, P563; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JIN L, 1990, INT J CANCER, V45, P1088, DOI 10.1002/ijc.2910450618; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEIN U, 1979, H-S Z PHYSIOL CHEM, V360, P1465, DOI 10.1515/bchm2.1979.360.2.1465; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LARIZZA L, 1984, J EXP MED, V160, P1579, DOI 10.1084/jem.160.5.1579; LIDER O, 1989, J CLIN INVEST, V83, P752, DOI 10.1172/JCI113953; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; Miao HQ, 1997, J CLIN INVEST, V99, P1565, DOI 10.1172/JCI119319; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NAKAGAWA H, 1988, J NEURO-ONCOL, V6, P157, DOI 10.1007/BF02327392; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; PARISH CR, 1987, INT J CANCER, V40, P511, DOI 10.1002/ijc.2910400414; PERETZ T, 1990, INT J CANCER, V45, P1054, DOI 10.1002/ijc.2910450613; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Sandback-Pikas D., 1998, J BIOL CHEM, V273, P18770; Savitsky K, 1997, NUCLEIC ACIDS RES, V25, P1678, DOI 10.1093/nar/25.9.1678; SOULE HD, 1990, CANCER RES, V50, P6075; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; Vlodavsky I, 1997, TUMOUR ANGIOGENESIS, P125; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P327; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; Vlodavsky I, 1998, ANTLANGIOGENIC AGENT, P93; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WILLENBORG DO, 1988, J IMMUNOL, V140, P3401; YAHALOM J, 1984, J CLIN INVEST, V74, P1842, DOI 10.1172/JCI111603; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	50	689	817	1	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					793	802		10.1038/10518	http://dx.doi.org/10.1038/10518			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395325				2022-12-27	WOS:000081926600035
J	Polack, FP; Auwaerter, PG; Lee, SH; Nousari, HC; Valsamakis, A; Leiferman, KM; Diwan, A; Adams, RJ; Griffin, DE				Polack, FP; Auwaerter, PG; Lee, SH; Nousari, HC; Valsamakis, A; Leiferman, KM; Diwan, A; Adams, RJ; Griffin, DE			Production of atypical measles in rhesus macaques: Evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody	NATURE MEDICINE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; TUMOR-NECROSIS-FACTOR; LUNG INJURY; T-CELLS; INFANTS; VACCINE; TITER; NUCLEOPROTEIN; MORTALITY	The severe disease atypical measles occurred when individuals immunized with a poorly protective inactivated vaccine contracted measles, and was postulated to be due to a lack of fusion-inhibiting antibodies. Here, rhesus macaques immunized with formalin-inactivated measles vaccine developed transient neutralizing and fusion-inhibiting antibodies, but no cytotoxic T-cell response. Subsequent infection with measles virus caused an atypical rash and pneumonitis, accompanied by immune complex deposition and an increase in eosinophils. Fusion-inhibiting antibody appeared earlier in these monkeys than in non-immunized monkeys. These data indicate that atypical measles results from previous priming for a nonprotective type 2 CD4 T-cell response rather than from lack of functional antibody against the fusion protein.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Comparat Med, Baltimore, MD 21287 USA; Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA; Univ Hawaii, Dept Trop Med, Honolulu, HI 96822 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Mayo Clinic; University of Hawaii System	Griffin, DE (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA.				NIAID NIH HHS [AI 35149, AI 34577] Funding Source: Medline; NINDS NIH HHS [NS07000] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035149, U01AI034577, U19AI034577] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4; ANNUNZIATO D, 1982, PEDIATRICS, V70, P203; AUWAERTER PG, IN PRESS J INFECT DI; BEAUVERGER P, 1993, J VIROL METHODS, V44, P199, DOI 10.1016/0166-0934(93)90055-V; BELLANTI J, 1969, NEW ENGL J MED, V280, P628, DOI 10.1056/NEJM196903202801202; BELLANTI JA, 1971, PEDIATRICS, V48, P715; BERRY S, 1992, PEDIATR INFECT DIS J, V11, P822, DOI 10.1097/00006454-199210000-00003; BUSER F, 1967, NEW ENGL J MED, V277, P250, DOI 10.1056/NEJM196708032770507; CARDOSO AI, 1995, VIROLOGY, V212, P255, DOI 10.1006/viro.1995.1479; CARTER CH, 1962, JAMA-J AM MED ASSOC, V179, P848, DOI 10.1001/jama.1962.03050110016003; CONNORS M, 1992, J VIROL, V66, P7444, DOI 10.1128/JVI.66.12.7444-7451.1992; *CTR DIS CONTR, 1976, MMWR-MORBID MORTAL W, V25, P245; FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956; FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075; FULGINITI VA, 1969, J PEDIATR-US, V75, P609, DOI 10.1016/S0022-3476(69)80456-7; FULGINITI VA, 1968, AMJ DIS CHILD, V115, P67; Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; GUINEE VF, 1966, PEDIATRICS, V37, P649; HALL WJ, 1979, ANN INTERN MED, V90, P882, DOI 10.7326/0003-4819-90-6-882; HANKINS RW, 1986, J CLIN MICROBIOL, V24, P324, DOI 10.1128/JCM.24.3.324-329.1986; HOLT EA, 1993, J INFECT DIS, V168, P1087, DOI 10.1093/infdis/168.5.1087; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; KRAUSE PJ, 1978, J PEDIATR-US, V93, P565, DOI 10.1016/S0022-3476(78)80889-0; LENNON RG, 1967, JAMA-J AM MED ASSOC, V200, P99; Lentsch AB, 1998, AM J PATHOL, V152, P1327; MARTIN DB, 1979, ANN INTERN MED, V90, P877, DOI 10.7326/0003-4819-90-6-877; MCLEAN DM, 1970, CAN MED ASSOC J, V103, P743; MERZ DC, 1980, J EXP MED, V151, P275, DOI 10.1084/jem.151.2.275; NADER PR, 1968, J PEDIATR-US, V72, P22, DOI 10.1016/S0022-3476(68)80396-8; NORRBY E, 1975, INFECT IMMUN, V11, P231, DOI 10.1128/IAI.11.2.231-239.1975; NORRBY E, 1975, J INFECT DIS, V132, P262, DOI 10.1093/infdis/132.3.262; NORRBY E, 1966, ACTA PAEDIATR SCAND, V55, P457, DOI 10.1111/j.1651-2227.1966.tb15236.x; RAUH LW, 1965, AM J DIS CHILD, V109, P232, DOI 10.1001/archpedi.1965.02090020234007; SCOTT TFM, 1967, NEW ENGL J MED, V277, P248, DOI 10.1056/NEJM196708032770506; WARIS M, 1990, J CLIN MICROBIOL, V28, P1159, DOI 10.1128/JCM.28.6.1159-1162.1990; WARREN J, 1962, Arch Gesamte Virusforsch, V11, P748, DOI 10.1007/BF01243313; WARREN JS, 1989, J CLIN INVEST, V84, P1873, DOI 10.1172/JCI114374; WARREN JS, 1991, AM J PATHOL, V138, P581; WILD TF, 1991, J GEN VIROL, V72, P439, DOI 10.1099/0022-1317-72-2-439; YOUNG LW, 1970, AMER J ROENTGENOL RA, V110, P439, DOI 10.2214/ajr.110.3.439	41	120	122	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					629	634		10.1038/9473	http://dx.doi.org/10.1038/9473			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371500				2022-12-27	WOS:000080823300030
J	Guevara, NV; Kim, HS; Antonova, EI; Chan, L				Guevara, NV; Kim, HS; Antonova, EI; Chan, L			The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo	NATURE MEDICINE			English	Article							APOE-DEFICIENT MICE; APOPTOSIS; RESTENOSIS; MODEL; CYTOMEGALOVIRUS; ATHEROGENESIS; PROGRESSION; LESIONS; GROWTH	The tumor suppressor protein p53 is an essential molecule in cell proliferation and programmed cell death (apoptosis), and has been postulated to play a principal part in the development of atherosclerosis. We have examined the effect of p53 inactivation on atherogenesis in apoE-knockout mice, an animal model for atherosclerosis(1,2). We found that, compared with p53(+/+)/apoE(-/-) mice, p53(-/-)apoE(-/-) mice developed considerably accelerated aortic atherosclerosis in the presence of a similar serum cholesterol in response to a high-fat diet. Furthermore, the atherosclerotic lesions in p53(-/-)apoE(-/-) mice had a significant (similar to 280%) increase in cell proliferation rate and an insignificant (similar to 180%) increase in apoptosis compared with those in p53(+/+)/apoE(-/-) mice. Our observations indicate that the role of p53 in atherosclerotic lesion development might be associated with its function in cell replication control, and that p53-independent mechanisms can mediate the apoptotic response in atherosclerosis.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Chan, L (corresponding author), Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA.			Guevara, Natalia Valentinova/0000-0002-5244-6691	NHLBI NIH HHS [HL-51586] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; BJARKERUD S, 1996, AM J PATHOL, V149, P367; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P213; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GENG YJ, 1995, AM J PATHOL, V147, P251; HAN DKM, 1995, AM J PATHOL, V147, P267; HARVEY M, 1993, ONCOGENE, V8, P2457; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kockx MM, 1998, ARTERIOSCL THROM VAS, V18, P1519, DOI 10.1161/01.ATV.18.10.1519; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Rembold C, 1996, PERSPECT BIOL MED, V39, P405; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Virchow RLK, 1863, CITED INDIRECTLY, P1; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903	23	213	222	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					335	339		10.1038/6585	http://dx.doi.org/10.1038/6585			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086392				2022-12-27	WOS:000078851600041
J	Dittmer, U; Brooks, DM; Hasenkrug, KJ				Dittmer, U; Brooks, DM; Hasenkrug, KJ			Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection	NATURE MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; MURINE LEUKEMIA VIRUSES; STREET RABIES VIRUS; FRIEND-LEUKEMIA; T-CELLS; IMMUNE-RESPONSE; NEF DELETION; SIV VACCINE; HIV; ERYTHROLEUKEMIA	Infection by live attenuated retroviruses provides excellent protection from challenge with pathogenic viruses in several animal models, but little is known about which immune effecters are necessary for protection. We examined this using adoptive transfer experiments in the Friend virus mouse model. Transfers of immune spleen cells into naive mice conferred complete protection, and transfers of purified lymphocyte subsets demonstrated that this effect required complex immune responses involving CD4(+) and CD8(+) T cells and also B cells. In addition, passive immunization experiments demonstrated that antibodies alone reduced virus loads but did not prevent infection. These findings may have implications for retroviral vaccine design in general.	NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Hasenkrug, KJ (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, 903 S 4th St, Hamilton, MT 59840 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000753, ZIAAI000753] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BRITT WJ, 1983, J IMMUNOL, V130, P2363; Burton DR, 1998, NAT MED, V4, P495, DOI 10.1038/nm0598supp-495; CEGLOWSKI WS, 1968, J IMMUNOL, V101, P594; CHESEBRO B, 1981, VIROLOGY, V112, P131, DOI 10.1016/0042-6822(81)90619-X; CHESEBRO B, 1983, VIROLOGY, V127, P134, DOI 10.1016/0042-6822(83)90378-1; Cohen I, 1997, SCIENCE, V278, P24, DOI 10.1126/science.278.5335.24; Cole KS, 1997, J VIROL, V71, P5069, DOI 10.1128/JVI.71.7.5069-5079.1997; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Desrosiers RC, 1998, NAT MED, V4, P982, DOI 10.1038/1949; Dittmer U, 1998, J VIROL, V72, P6554, DOI 10.1128/JVI.72.8.6554-6558.1998; DITTMER U, 1995, VIROLOGY, V212, P392, DOI 10.1006/viro.1995.1496; Dittmer U, 1998, J GEN VIROL, V79, P1801, DOI 10.1099/0022-1317-79-7-1801; EARL PL, 1986, SCIENCE, V234, P728, DOI 10.1126/science.3490689; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; Furci L, 1997, J EXP MED, V186, P455, DOI 10.1084/jem.186.3.455; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; Hasenkrug KJ, 1998, VIROLOGY, V248, P66, DOI 10.1006/viro.1998.9264; HASENKRUG KJ, 1995, P NATL ACAD SCI USA, V92, P10492, DOI 10.1073/pnas.92.23.10492; Hasenkrug KJ, 1998, J VIROL, V72, P6559, DOI 10.1128/JVI.72.8.6559-6564.1998; Heeney JL, 1998, P NATL ACAD SCI USA, V95, P10803, DOI 10.1073/pnas.95.18.10803; Heilman CA, 1998, NAT MED, V4, P532, DOI 10.1038/nm0598supp-532; Hoatlin Maureen E., 1995, Trends in Microbiology, V3, P51, DOI 10.1016/S0966-842X(00)88875-7; HOM RC, 1991, J VIROL, V65, P220, DOI 10.1128/JVI.65.1.220-224.1991; Johnson RP, 1997, J VIROL, V71, P7711, DOI 10.1128/JVI.71.10.7711-7718.1997; Johnson RP, 1998, CURR OPIN IMMUNOL, V10, P436, DOI 10.1016/S0952-7915(98)80118-0; Jolicoeur P, 1979, Curr Top Microbiol Immunol, V86, P67; JONES SM, 1992, VIRAL IMMUNOL, V5, P201, DOI 10.1089/vim.1992.5.201; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LILLY F, 1967, SCIENCE, V155, P461, DOI 10.1126/science.155.3761.461; LODMELL DL, 1985, J VIROL, V55, P788, DOI 10.1128/JVI.55.3.788-795.1985; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MORRISON RP, 1987, NATURE, V329, P729, DOI 10.1038/329729a0; MORRISON RP, 1986, J EXP MED, V163, P301, DOI 10.1084/jem.163.2.301; Norley S, 1996, VIROLOGY, V219, P195, DOI 10.1006/viro.1996.0237; OLDSTONE MBA, 1993, J VIROL, V67, P4372, DOI 10.1128/JVI.67.7.4372-4378.1993; PERRY LL, 1991, J VIROL, V65, P3429, DOI 10.1128/JVI.65.7.3429-3434.1991; PINCUS T, 1971, J EXP MED, V133, P1234, DOI 10.1084/jem.133.6.1234; RUPRECHT RM, 1990, P NATL ACAD SCI USA, V87, P5558, DOI 10.1073/pnas.87.14.5558; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SITBON M, 1985, VIROLOGY, V141, P110, DOI 10.1016/0042-6822(85)90187-4; StahlHennig C, 1996, IMMUNOL LETT, V51, P129, DOI 10.1016/0165-2478(96)02567-9; WALKER CM, 1989, IMMUNOLOGY, V66, P628; WEIDT G, 1995, J VIROL, V69, P2654, DOI 10.1128/JVI.69.4.2654-2658.1995; WENDLING F, 1978, INT J CANCER, V22, P479, DOI 10.1002/ijc.2910220418; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7	50	86	86	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1999	5	2					189	193		10.1038/5550	http://dx.doi.org/10.1038/5550			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930867				2022-12-27	WOS:000078274400028
J	Gupta, A; Matsui, K; Lo, JF; Silver, S				Gupta, A; Matsui, K; Lo, JF; Silver, S			Molecular basis for resistance to silver cations in Salmonella	NATURE MEDICINE			English	Article							P-TYPE ATPASES; ESCHERICHIA-COLI; ALCALIGENES-EUTROPHUS; DETERMINANT PCO; COPPER; EFFLUX; TRANSPORT; CATHETERS	Here we report the genetic and proposed molecular basis for silver resistance in pathogenic microorganisms. The silver resistance determinant from a hospital burn ward Salmonella plasmid contains nine open reading frames, arranged in three measured and divergently transcribed RNAs. The resistance determinant encodes a periplasmic silver-specific binding protein (SilE) plus apparently two parallel efflux pumps: one, a P-type ATPase (SilP); the other, a membrane potential-dependent three-polypeptide cation/proton antiporter (SilCBA). The sil determinant is governed by a two-component membrane sensor and transcriptional responder comprising silS and silR, which are co-transcribed. The availability of the sil silver-resistance determinant will be the basis for mechanistic molecular and biochemical studies as well as molecular epidemiology of silver resistance in clinical settings in which silver is used as a biocide.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gupta, A (corresponding author), Univ Illinois, Dept Microbiol & Immunol, M-C 790,Room 703,835 S Wolcott Ave, Chicago, IL 60612 USA.		Matsui, Kazuaki/S-1473-2019; Lo, Jeng-Fan/ABB-2820-2020; Lo, Jeng-Fan/AAE-9626-2020	Matsui, Kazuaki/0000-0002-1563-3308; Lo, Jeng-Fan/0000-0001-7188-9140; Lo, Jeng-Fan/0000-0001-7188-9140; Silver, Simon/0000-0002-5692-3125				ANNEAR DI, 1976, J CLIN PATHOL, V29, P441, DOI 10.1136/jcp.29.5.441; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRIDGES K, 1979, BRIT MED J, V1, P446, DOI 10.1136/bmj.1.6161.446; BROWN NL, 1995, MOL MICROBIOL, V17, P1153, DOI 10.1111/j.1365-2958.1995.mmi_17061153.x; CHU CS, 1995, J TRAUMA, V39, P273, DOI 10.1097/00005373-199508000-00014; Gabriel MM, 1996, CURR MICROBIOL, V33, P1, DOI 10.1007/s002849900064; George N, 1997, BURNS, V23, P493, DOI 10.1016/S0305-4179(97)00047-8; GREENFELD JI, 1995, CRIT CARE MED, V23, P894, DOI 10.1097/00003246-199505000-00018; Gupta A, 1998, APPL ENVIRON MICROB, V64, P5042; Gupta A, 1998, NAT BIOTECHNOL, V16, P888, DOI 10.1038/nbt1098-888; Hobman JL, 1997, MET IONS BIOL SYST, V34, P527; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Li XZ, 1997, J BACTERIOL, V179, P6127, DOI 10.1128/JB.179.19.6127-6132.1997; MCHUGH GL, 1975, LANCET, V1, P235; Modak S M, 1988, J Burn Care Rehabil, V9, P359, DOI 10.1097/00004630-198807000-00009; NIES DH, 1995, J IND MICROBIOL, V14, P186, DOI 10.1007/BF01569902; NIES DH, 1995, J BACTERIOL, V177, P2707, DOI 10.1128/jb.177.10.2707-2712.1995; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; Pruitt BA, 1998, WORLD J SURG, V22, P135; Rech S, 1996, J BIOL CHEM, V271, P2557, DOI 10.1074/jbc.271.5.2557; Rouch DA, 1997, MICROBIOL-SGM, V143, P1191, DOI 10.1099/00221287-143-4-1191; Rudd KE, 1998, MICROBIOL MOL BIOL R, V62, P985, DOI 10.1128/MMBR.62.3.985-1019.1998; SAMPATH LA, 1995, J HOSP INFECT, V30, P201, DOI 10.1016/S0195-6701(95)90315-1; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; Silver S, 1998, J IND MICROBIOL BIOT, V20, P1, DOI 10.1038/sj.jim.2900483; SILVER S, IN PRESS METAL BASED; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; TRENOR C, 1994, BIOCHEM BIOPH RES CO, V205, P1644, DOI 10.1006/bbrc.1994.2856; vanderLelie D, 1997, MOL MICROBIOL, V23, P493, DOI 10.1046/j.1365-2958.1997.d01-1866.x	32	359	379	0	60	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					183	188		10.1038/5545	http://dx.doi.org/10.1038/5545			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930866				2022-12-27	WOS:000078274400027
J	Hancock, WW; Buelow, R; Sayegh, MH; Turka, LA				Hancock, WW; Buelow, R; Sayegh, MH; Turka, LA			Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes	NATURE MEDICINE			English	Article							CHRONIC CARDIAC REJECTION; ALLOGRAFT-REJECTION; MACROPHAGE ACTIVATION; ENDOTHELIAL-CELLS; PROTECTIVE GENES; CYTOKINES; BLOCKADE; MODEL; CD40; TH2	We investigated the pathogenesis of chronic allograft rejection in mouse cardiac allografts. Long-term survival occurred after administration of monoclonal antibody to CD4 or CD40-ligand (CD40L) plus donor cells. Both treatments induced permanent graft survival, but, in contrast to transplants in mice treated with CD4 monoclonal antibody, grafts in mice treated with CD40L monoclonal antibody lacked evidence of chronic rejection, including transplant arteriosclerosis, Freedom from chronic rejection in the group treated with CD IOL monoclonal antibody correlated with vascular expression of the 'protective' genes heme oxygenase-1 (HO-1), Bcl-xL and A20. Moreover, arteriosclerosis was induced in allografts in immunoglobulin-deficient mice by antibody transfer only when the transfer was done before expression of protective genes. A direct role for protective gene expression in endothelial cells was demonstrated by in vitro experiments in which induction of HO-1 or Bcl-xL suppressed alloantibody-stimulated endothelial activation. Finally, induction of HO-1 in vivo protected allografts against chronic injury. These data show a role for protective genes in the prevention of chronic rejection, and indicate new approaches to protect grafts against development of transplant arteriosclerosis.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; LeukoSite, Cambridge, MA 02142 USA; SangStat Med Corp, Menlo Pk, CA 94205 USA; Brigham & Womens Hosp, Dept Immunogenet & Transplantat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania	Hancock, WW (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.	Wayne_Hancock@Leukosite.com			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037691, P01AI040152] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37691, AI40152] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bach FH, 1997, IMMUNOL TODAY, V18, P483, DOI 10.1016/S0167-5699(97)01129-8; Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; Bach FH, 1997, NAT MED, V3, P944, DOI 10.1038/nm0997-944; Deramaudt BMJM, 1998, J CELL BIOCHEM, V68, P121, DOI 10.1002/(SICI)1097-4644(19980101)68:1<121::AID-JCB12>3.0.CO;2-K; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HANCOCK WH, 1993, TRANSPLANTATION, V56, P643, DOI 10.1097/00007890-199309000-00028; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; HANCOCK WW, 1998, GRAFT S2, V1, P21; Larsen CP, 1996, TRANSPLANTATION, V61, P4, DOI 10.1097/00007890-199601150-00002; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; MOTTRAM PL, 1995, TRANSPLANTATION, V59, P559; Murphy B, 1997, TRANSPLANTATION, V64, P14, DOI 10.1097/00007890-199707150-00004; RUSSELL ME, 1995, TRANSPLANTATION, V59, P572; Russell ME, 1996, J CLIN INVEST, V97, P833, DOI 10.1172/JCI118483; Russell PS, 1997, TRANSPLANTATION, V64, P1531, DOI 10.1097/00007890-199712150-00005; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; WELLS AD, 1998, TRANSPLANTATION, V65, P79; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87	18	407	433	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1998	4	12					1392	1396		10.1038/3982	http://dx.doi.org/10.1038/3982			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846576				2022-12-27	WOS:000077336900034
J	Tretter, YP; Hertel, M; Munz, B; ten Bruggencate, G; Werner, S; Alzheimer, C				Tretter, YP; Hertel, M; Munz, B; ten Bruggencate, G; Werner, S; Alzheimer, C			Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor in vivo	NATURE MEDICINE			English	Article							MIDBRAIN DOPAMINERGIC-NEURONS; TRANSGENIC MICE REVEALS; BRAIN INJURY; EXPRESSION; RAT; FOLLISTATIN; BINDING; PROTECTS; LESION; REPAIR	Exogenous application of neurotrophic growth factors has emerged as a new and particularly promising approach not only to promote functional recovery after acute brain injury but also to protect neurons against the immediate effect of the injury. Among the various growth factors and cytokines studied so far, the neuroprotective and neurotrophic profile of basic fibroblast growth factor (bFGF) Is the best documented(1-5). Using an animal model of acute excitotoxic brain injury(6), we report here that the neuroprotective action of bFGF, which is now being tested in stroke patients, depends on the induction of activin A, a member of the transforming growth factor-beta superfamily. Our evidence for this previously unknown mechanism of action of bFGF is that bFGF strongly enhanced lesion-associated induction of activin A; in the presence of the activin-neutralizing protein follistatin, bFGF was no longer capable of rescuing neurons from excitotoxic death; and recombinant activin A exerted a neuroprotective effect by itself. Our data indicate that the development of substances influencing activin expression or receptor binding should offer new ways to fight neuronal loss in ischemic and traumatic brain injury.	Univ Munich, Dept Physiol, D-80336 Munich, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Swiss Fed Inst Technol, Dept Cell Biol, CH-8093 Zurich, Switzerland	University of Munich; Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich	Alzheimer, C (corresponding author), Univ Munich, Dept Physiol, Pettenkoferstr 12, D-80336 Munich, Germany.			Werner, Sabine/0000-0001-7397-8710				ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; Ay H, 1999, CEREBROVASC DIS, V9, P131, DOI 10.1159/000015941; Bethel A, 1997, STROKE, V28, P609, DOI 10.1161/01.STR.28.3.609; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Hubner G, 1996, EXP CELL RES, V228, P106, DOI 10.1006/excr.1996.0305; Hughes PE, 1999, NEUROSCIENCE, V92, P197, DOI 10.1016/S0306-4522(98)00724-6; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; KIRSCHNER PB, 1995, J CEREBR BLOOD F MET, V15, P619, DOI 10.1038/jcbfm.1995.76; Krieglstein K, 1998, EUR J NEUROSCI, V10, P2746, DOI 10.1046/j.1460-9568.1998.00324.x; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; Lai M, 1997, NEUROREPORT, V8, P2691, DOI 10.1097/00001756-199708180-00011; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; Munz B, 1999, J ENDOCRINOL, V161, P187, DOI 10.1677/joe.0.1610187; NADLER JV, 1980, J COMP NEUROL, V192, P333, DOI 10.1002/cne.901920209; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Peterson DA, 1996, J NEUROSCI, V16, P886; RIVA MA, 1994, NEUROSCIENCE, V59, P55, DOI 10.1016/0306-4522(94)90098-1; Sugino Hiromu, 1997, Journal of Medical Investigation, V44, P1; Tretter YP, 1996, NEUROREPORT, V7, P1819, DOI 10.1097/00001756-199607290-00026; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; Wu DD, 1999, BRAIN RES, V835, P369, DOI 10.1016/S0006-8993(99)01638-8; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727	25	130	137	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					812	+		10.1038/77548	http://dx.doi.org/10.1038/77548			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888932				2022-12-27	WOS:000088040100040
J	Boussiotis, VA; Freeman, GJ; Taylor, PA; Berezovskaya, A; Grass, I; Blazar, BR; Nadler, LM				Boussiotis, VA; Freeman, GJ; Taylor, PA; Berezovskaya, A; Grass, I; Blazar, BR; Nadler, LM			p27(kip1) functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes	NATURE MEDICINE			English	Article							DEPENDENT KINASE INHIBITOR; PROTEIN-TYROSINE KINASES; VERSUS-HOST DISEASE; CELL-CYCLE; SIGNALING PATHWAY; IL-2 GENE; ACTIVATION; EXPRESSION; INDUCTION; BLOCKADE	Although recent in vitro studies have begun to decipher the molecular events that characterize the anergic state, their in vivo biologic relevance and potential clinical importance remain unclear. Here, using anergic human T-cell clones and tolerant alloreactive mouse T cells that do not induce graft-versus-host disease, we show that p27(kip1) cyclin-dependent kinase inhibitor is an essential regulator responsible for the blockade of clonal expansion of anergic T cells in vitro and in vivo. Moreover, in anergic cells, p27(kip1) associates with the c-Jun co-activator JAB1, resulting in defective transactivation of AP-1 and interleukin 2 transcription. Therefore, pharmacological agents that upregulate the expression of or prevent the degradation of p27(kip1) during antigen recognition should be part of new therapeutic strategies to induce antigen-specific T-cell unresponsiveness.	Brigham & Womens Hosp, Dept Adult Oncol, Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Minnesota, Ctr Canc, Dept Pediat, Minneapolis, MN 55455 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities	Boussiotis, VA (corresponding author), Brigham & Womens Hosp, Dept Adult Oncol, Dana Farber Canc Inst, Div Med Oncol, 75 Francis St, Boston, MA 02115 USA.		Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616	NHLBI NIH HHS [HL 54785] Funding Source: Medline; NIAID NIH HHS [AI 43552, AI 41584] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI043552, R56AI043552, R01AI043552, P01AI041584] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; Blazar BR, 1998, J CLIN INVEST, V102, P473, DOI 10.1172/JCI3741; BLAZAR BR, 1994, BLOOD, V83, P3815; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHO EA, 1993, J IMMUNOL, V151, P20; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; GAJEWSKI TF, 1995, EUR J IMMUNOL, V25, P1836, DOI 10.1002/eji.1830250707; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GILBERT KM, 1993, J IMMUNOL, V151, P1245; GRANGER DK, 1994, SURGERY, V116, P236; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Guinan EC, 1999, NEW ENGL J MED, V340, P1704, DOI 10.1056/NEJM199906033402202; Kamesaki H, 1998, J IMMUNOL, V160, P770; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kwon TK, 1997, J IMMUNOL, V158, P5642; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Li YS, 1998, TRANSPLANTATION, V66, P1387, DOI 10.1097/00007890-199811270-00021; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mondino A, 1996, J IMMUNOL, V157, P2048; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Powell JD, 1999, J IMMUNOL, V162, P2775; QUILL H, 1992, J IMMUNOL, V149, P2887; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SloanLancaster J, 1996, J EXP MED, V184, P1525, DOI 10.1084/jem.184.4.1525; Tamir A, 1996, J IMMUNOL, V157, P1514; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0	45	200	205	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					290	297		10.1038/73144	http://dx.doi.org/10.1038/73144			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700231				2022-12-27	WOS:000085580500039
J	Higashitsuji, H; Itoh, K; Nagao, T; Dawson, S; Nonoguchi, K; Kido, T; Mayer, RJ; Arii, S; Fujita, J				Higashitsuji, H; Itoh, K; Nagao, T; Dawson, S; Nonoguchi, K; Kido, T; Mayer, RJ; Arii, S; Fujita, J			Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas	NATURE MEDICINE			English	Article							UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE CONTROL; P53 GENE; DEGRADATION; SUBUNIT	Hepatocellular carcinoma (HCC) is one of the most common cancers in Asia and Africa, where hepatitis virus infection and exposure to specific liver carcinogens are prevalent(1,2). Although inactivation of some tumor suppressor genes such as p53 and p16(INK4A) has been identified(3), no known oncogene is commonly activated in hepatocellular carcinomas. Here we have isolated genes overexpressed in hepatocellular carcinomas by cDNA subtractive hybridization(4), and identified an oncoprotein consisting of six ankyrin repeats (gankyrin). The expression of gankyrin was increased in all 34 hepatocellular carcinomas studied. Gankyrin induced anchorage-independent growth and tumorigenicity in NIH/3T3 cells. Gankyrin bound to the product of the retinoblastoma gene (RB1), increasing its phosphorylation and releasing the activity of the transcription factor E2F-1. Gankyrin accelerated the degradation of RB1 in vitro and in vivo, and was identical to or interacted with a subunit of the 265 proteasome(5,6). These results demonstrate the importance of ubiquitin-proteasome pathway in the regulation of cell growth and oncogenic transformation, and indicate that gankyrin overexpression contributes to hepatocarcinogenesis by destabilizing RB1.	Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto 6068507, Japan; Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci,Lab Intracellular Proteolysis, Nottingham NG7 2UH, England; Kyoto Univ, Fac Med, Dept Surg 1, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; University of Nottingham; Kyoto University	Fujita, J (corresponding author), Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.							Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Boyer SN, 1996, CANCER RES, V56, P4620; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Ciechanover A, 1995, COLD SPRING HARB SYM, V60, P491, DOI 10.1101/SQB.1995.060.01.053; Dawson S, 1997, MOL BIOL REP, V24, P39, DOI 10.1023/A:1006800522814; HIGUCHI T, 1995, ENDOCRINOLOGY, V136, P4973, DOI 10.1210/en.136.11.4973; Hori T, 1998, GENE, V216, P113, DOI 10.1016/S0378-1119(98)00309-6; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Israel A, 1997, NATURE, V388, P519, DOI 10.1038/41433; Johnson BE, 1998, MATH MECH SOLIDS, V3, P447, DOI 10.1177/108128659800300405; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; LIEW, 1999, ONCOGENE, V18, P789; Mahaffey D, 1999, FEBS LETT, V450, P123, DOI 10.1016/S0014-5793(99)00456-1; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woitach JT, 1998, NAT GENET, V19, P371, DOI 10.1038/1258	20	258	278	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					96	99		10.1038/71600	http://dx.doi.org/10.1038/71600			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613832				2022-12-27	WOS:000084583300043
J	Evans, DT; O'Connor, DH; Jing, PC; Dzuris, JL; Sidney, J; da Silva, J; Allen, TM; Horton, H; Venham, JE; Rudersdorf, RA; Vogel, T; Pauza, CD; Bontrop, RE; DeMars, R; Sette, A; Hughes, AL; Watkins, DI				Evans, DT; O'Connor, DH; Jing, PC; Dzuris, JL; Sidney, J; da Silva, J; Allen, TM; Horton, H; Venham, JE; Rudersdorf, RA; Vogel, T; Pauza, CD; Bontrop, RE; DeMars, R; Sette, A; Hughes, AL; Watkins, DI			Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef	NATURE MEDICINE			English	Article							INFECTED RHESUS-MONKEYS; HIV-1 INFECTION; IN-VIVO; ESCAPE; VARIANTS; CTL; IMMUNODOMINANT; PROGRESSION; DISEASE; PATHOGENESIS	Cytotoxic T-lymphocyte (CTL) responses to human immunodeficiency virus arise early after infection, but ultimately fail to prevent progression to AIDS. Human immunodeficiency virus may evade the CTL response by accumulating amino-acid replacements within CTL epitopes. We studied 10 CTL epitopes during the course of simian immunodeficiency virus disease progression in three related macaques. All 10 of these CTL epitopes accumulated amino-acid replacements and showed evidence of positive selection by the time the macaques died. Many of the amino-acid replacements in these epitopes reduced or eliminated major histocompatibility complex class I binding and/or CTL recognition. These findings strongly support the CTL 'escape' hypothesis.	Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA; Epimmune, San Diego, CA 92121 USA; Penn State Univ, Inst Mol Evolut Genet, University Pk, PA 16802 USA; Univ Wisconsin, Genet Lab, Madison, WI 53715 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53715 USA; TNO, Biomed Primate Res Ctr, NL-2280 HV Rijswijk, Netherlands	University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Netherlands Organization Applied Science Research	Watkins, DI (corresponding author), Univ Wisconsin, Wisconsin Reg Primate Res Ctr, 1220 Capitol Court, Madison, WI 53715 USA.		Bontrop, Ronald E./D-4844-2011; Sette, Alessandro/AFO-8916-2022; Bontrop, Ronald E/J-3628-2012; da Silva, Jack/H-1266-2014; Allen, Todd/F-5473-2011	Bontrop, Ronald E/0000-0003-0874-6467; da Silva, Jack/0000-0001-5631-5421; Allen, Todd/0000-0002-6609-1318; Dzuris, John/0000-0002-0046-8426; o'connor, david/0000-0003-2139-470X	NIAID NIH HHS [AI42641, AI32426, AI41913] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032426, R01AI041913, R21AI042641] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen TM, 1998, J IMMUNOL, V160, P6062; Balter M, 1998, SCIENCE, V280, P1860, DOI 10.1126/science.280.5371.1860; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; DAI L C, 1992, Journal of Virology, V66, P3151; DELGUERCIO MF, 1995, J IMMUNOL, V154, P685; Dykhuizen M, 1998, J GEN VIROL, V79, P2461, DOI 10.1099/0022-1317-79-10-2461; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Haas G, 1996, J IMMUNOL, V157, P4212; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, NATURE, V370, P416, DOI 10.1038/370416a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; McMichael AJ, 1997, ANNU REV IMMUNOL, V15, P271, DOI 10.1146/annurev.immunol.15.1.271; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mortara L, 1998, J VIROL, V72, P1403, DOI 10.1128/JVI.72.2.1403-1410.1998; NEI M, 1986, MOL BIOL EVOL, V3, P418; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; PAUZA CD, 1993, J MED PRIMATOL, V22, P154; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; TRIVEDI P, 1994, J VIROL, V68, P7649, DOI 10.1128/JVI.68.11.7649-7653.1994; VANBAALEN CA, 1993, AIDS, V7, P781, DOI 10.1097/00002030-199306000-00004; VOSS G, 1995, VIROLOGY, V208, P770, DOI 10.1006/viro.1995.1209; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993	37	339	351	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1270	1276		10.1038/15224	http://dx.doi.org/10.1038/15224			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545993				2022-12-27	WOS:000086550600037
J	Gallucci, S; Lolkema, M; Matzinger, P				Gallucci, S; Lolkema, M; Matzinger, P			Natural adjuvants: Endogenous activators of dendritic cells	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; MHC CLASS-II; APOPTOTIC CELLS; T-CELLS; EFFICIENT PRESENTATION; ADHESION MOLECULE-1; HOST-DEFENSE; IN-VITRO; ANTIGEN	Dendritic cells, the most potent antigen-presenting cells, need to be activated before they can function to initiate an immune response. We report here that, in the absence of any foreign substances, dendritic cells can be activated by endogenous signals received from cells that are stressed, virally infected or killed necrotically, but not by healthy cells or those dying apoptotically. Injected in vivo with an antigen, the endogenous activating substances can function as natural adjuvants to stimulate a primary immune response, and they may represent the natural initiators of transplant rejection, spontaneous tumor rejection, and some forms of autoimmunity.	NIAID, Ghost Lab, T Cell Tolerance & Memory Sect, Lab Cellular & Mol Immunol,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gallucci, S (corresponding author), NIAID, Ghost Lab, T Cell Tolerance & Memory Sect, Lab Cellular & Mol Immunol,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.		Lolkema, M.P./AAE-2906-2019	Lolkema, M.P./0000-0003-0466-2928				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARTOCCIONI E, 1994, CLIN EXP IMMUNOL, V95, P166; Bradley J A, 1996, Int Rev Immunol, V13, P245, DOI 10.3109/08830189609061751; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Chakrabarti D, 1996, J IMMUNOL, V157, P522; Cohen OJ, 1997, IMMUNOL REV, V159, P31, DOI 10.1111/j.1600-065X.1997.tb01005.x; COLE WH, 1981, J SURG ONCOL, V17, P201, DOI 10.1002/jso.2930170302; COLEY W, 1898, JAMA-J AM MED ASSOC, V20, P389; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GRESSER I, 1976, J EXP MED, V144, P1305, DOI 10.1084/jem.144.5.1305; HARDING C, 1984, EUR J CELL BIOL, V35, P256; INABA K, 1994, J EXP MED, V180, P1849, DOI 10.1084/jem.180.5.1849; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JOINER KA, 1984, ANNU REV IMMUNOL, V2, P461, DOI 10.1146/annurev.immunol.2.1.461; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; LAND W, 1994, TRANSPLANTATION, V57; LASSILA O, 1988, NATURE, V334, P253, DOI 10.1038/334253a0; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Luft T, 1998, J IMMUNOL, V161, P1947; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Pfeffer LM, 1998, CANCER RES, V58, P2489; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; Ronchetti A, 1999, J IMMUNOL, V163, P130; Rubartelli A, 1997, EUR J IMMUNOL, V27, P1893, DOI 10.1002/eji.1830270812; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SEN GC, 1992, J BIOL CHEM, V267, P5017; Slupsky JR, 1998, THROMB HAEMOSTASIS, V80, P1008; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; SWENSSON H, 1996, SCAND J IMMUNOL, V44, P164; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAHRAUS T, 1995, PLANT PHYSIOL, V109, P1259, DOI 10.1104/pp.109.4.1259; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	49	1311	1377	3	53	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1249	1255		10.1038/15200	http://dx.doi.org/10.1038/15200			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545990				2022-12-27	WOS:000086550600034
J	Waldmann, H				Waldmann, H			Transplantation tolerance - where do we stand?	NATURE MEDICINE			English	Review							T-CELL SUBSETS; BONE-MARROW TRANSPLANTATION; SKIN-GRAFT REJECTION; MONOCLONAL-ANTIBODIES; INFECTIOUS TOLERANCE; INDIRECT RECOGNITION; ISLET ALLOGRAFTS; CD95 LIGAND; INDUCTION; SURVIVAL	Our understanding of tolerance mechanisms has progressed to the point that tolerance-induction protocols are being tested in humans for organ transplantation. However, a range of scientific, ethical, logistic and commercial issues have arisen, and must be resolved before tolerance induction for human allograft patients can become a reality.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Waldmann, H (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.		waldmann, herman/F-7412-2011; waldmann, herman/W-8051-2019	Waldmann, Herman/0000-0001-7519-6720				Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Armstrong N, 1998, TRANSPLANTATION, V66, P5, DOI 10.1097/00007890-199807150-00002; AUCHINCLOSS H, 1993, P NATL ACAD SCI USA, V90, P3373, DOI 10.1073/pnas.90.8.3373; AUCHINCLOSS H, 1989, IMMUNOL RES, V8, P149, DOI 10.1007/BF02919076; BACHARLUSTIG E, 1995, NAT MED, V1, P1268, DOI 10.1038/nm1295-1268; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bemelman F, 1998, J IMMUNOL, V160, P2645; BENJAMIN RJ, 1986, NATURE, V320, P449, DOI 10.1038/320449a0; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; Calne R, 1998, LANCET, V351, P1701, DOI 10.1016/S0140-6736(05)77739-4; Chen ZHK, 1996, TRANSPLANTATION, V62, P1200, DOI 10.1097/00007890-199611150-00002; CHILLER JM, 1970, P NATL ACAD SCI USA, V65, P551, DOI 10.1073/pnas.65.3.551; COBBOLD S, 1986, TRANSPLANTATION, V41, P634, DOI 10.1097/00007890-198605000-00016; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; Davies JD, 1996, J IMMUNOL, V157, P529; FANGMANN J, 1992, J EXP MED, V175, P1521, DOI 10.1084/jem.175.6.1521; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; GOZZO J J, 1970, Surgical Forum (Chicago), V21, P281; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; GUTSTEIN NL, 1986, J IMMUNOL, V137, P1127; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; Kang SM, 1997, SCIENCE, V278, P1322, DOI 10.1126/science.278.5341.1322; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; KIRK AD, 1997, P NATL ACAD SCI USA, V94, P789; Ko S, 1999, NAT MED, V5, P1292, DOI 10.1038/15248; KONG YCM, 1989, CLIN IMMUNOL IMMUNOP, V51, P38, DOI 10.1016/0090-1229(89)90204-3; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LAFFERTY KJ, 1976, TRANSPLANTATION, V22, P138, DOI 10.1097/00007890-197608000-00009; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LEONG LYW, 1992, EUR J IMMUNOL, V22, P2825, DOI 10.1002/eji.1830221111; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Matsue H, 1999, NAT MED, V5, P930, DOI 10.1038/11375; Miller JFAP, 1998, IMMUNOL REV, V165, P267, DOI 10.1111/j.1600-065X.1998.tb01244.x; MITCHELL GF, 1968, J EXP MED, V128, P821, DOI 10.1084/jem.128.4.821; Monaco AP, 1999, TRANSPL P, V31, P67, DOI 10.1016/S0041-1345(98)02108-3; Nikolic B, 1997, CURR OPIN IMMUNOL, V9, P634, DOI 10.1016/S0952-7915(97)80042-8; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; POWRIE F, 1990, J EXP MED, V172, P1701, DOI 10.1084/jem.172.6.1701; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; REES MA, 1990, P NATL ACAD SCI USA, V87, P2765, DOI 10.1073/pnas.87.7.2765; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; ROSENBERG AS, 1986, NATURE, V322, P829, DOI 10.1038/322829a0; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; SPRENT J, 1986, IMMUNOL REV, V91, P195, DOI 10.1111/j.1600-065X.1986.tb01489.x; Starzl TE, 1996, IMMUNOL TODAY, V17, P577, DOI 10.1016/S0167-5699(96)10070-0; Sykes M, 1997, NAT MED, V3, P783, DOI 10.1038/nm0797-783; Thomas FT, 1999, TRANSPLANTATION, V67, P846, DOI 10.1097/00007890-199903270-00011; Tomita Y, 1996, TRANSPLANTATION, V61, P469, DOI 10.1097/00007890-199602150-00027; Waldmann H, 1998, ANNU REV IMMUNOL, V16, P619, DOI 10.1146/annurev.immunol.16.1.619; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wekerle T, 1998, J EXP MED, V187, P2037, DOI 10.1084/jem.187.12.2037; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260; Wise MP, 1998, J IMMUNOL, V161, P5813; Zhang H, 1999, J IMMUNOL, V162, P1423	63	67	68	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1245	1248		10.1038/15197	http://dx.doi.org/10.1038/15197			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545989				2022-12-27	WOS:000086550600033
J	Lu, W; Cao, L; Ty, L; Arlie, M; Andrieu, JM				Lu, W; Cao, L; Ty, L; Arlie, M; Andrieu, JM			Equivalent amplification of intrinsically variable nucleic acid sequences by multiple-primer-induced overlapping amplification assay: Applications for universal detection and quantitation	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; POLYMERASE CHAIN-REACTION; HIV-1 INFECTION; VIRAL LOAD; RNA; PLASMA; PCR; QUANTIFICATION; DIAGNOSIS		Univ Paris 05, Fac Med Necker, Lab Oncol & Virol Mol, Hop Laennec, F-75007 Paris, France; GeneQuant, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Lu, W (corresponding author), Univ Paris 05, Fac Med Necker, Lab Oncol & Virol Mol, Hop Laennec, F-75007 Paris, France.	weilu@intercancer.net						Alaeus A, 1997, AIDS, V11, P859, DOI 10.1097/00002030-199707000-00004; Barlow KL, 1997, J CLIN MICROBIOL, V35, P2846, DOI 10.1128/JCM.35.11.2846-2853.1997; Brown AE, 1997, TRANSFUSION, V37, P926, DOI 10.1046/j.1537-2995.1997.37997454019.x; Busch MP, 1996, TRANSFUS CLIN BIOL, V3, P7, DOI 10.1016/S1246-7820(96)80007-3; Coste J, 1996, J MED VIROL, V50, P293, DOI 10.1002/(SICI)1096-9071(199612)50:4&lt;293::AID-JMV3&gt;3.0.CO;2-3; Debyser Z, 1998, AIDS RES HUM RETROV, V14, P453, DOI 10.1089/aid.1998.14.453; Haas J, 1996, J INFECT DIS, V174, P244, DOI 10.1093/infdis/174.1.244a; LU LW, 1998, P 12 OWRLD AIDS C, P125; LU W, 1994, NATURE, V368, P269, DOI 10.1038/368269a0; LU W, 1993, J INFECT DIS, V167, P1498, DOI 10.1093/infdis/167.6.1498; LU W, 1993, J INFECT DIS, V167, P1014, DOI 10.1093/infdis/167.5.1014; Lunel F, 1999, HEPATOLOGY, V29, P528, DOI 10.1002/hep.510290237; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Nolte FS, 1998, J CLIN MICROBIOL, V36, P716, DOI 10.1128/JCM.36.3.716-720.1998; Parekh B, 1999, AIDS RES HUM RETROV, V15, P133, DOI 10.1089/088922299311556; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; TODD J, 1995, J ACQ IMMUN DEF SYND, V10, pS35; Trabaud MA, 1997, J MED VIROL, V52, P105, DOI 10.1002/(SICI)1096-9071(199705)52:1&lt;105::AID-JMV17&gt;3.0.CO;2-L; UGEN KE, 1994, J CLIN LAB ANAL, V8, P309, DOI 10.1002/jcla.1860080509; VANGEMEN B, 1994, J VIROL METHODS, V49, P157, DOI 10.1016/0166-0934(94)90040-X	21	13	14	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1999	5	9					1081	1085		10.1038/12520	http://dx.doi.org/10.1038/12520			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470090				2022-12-27	WOS:000082337200047
J	Schuetz, JD; Connelly, MC; Sun, DX; Paibir, SG; Flynn, PM; Srinivas, RV; Kumar, A; Fridland, A				Schuetz, JD; Connelly, MC; Sun, DX; Paibir, SG; Flynn, PM; Srinivas, RV; Kumar, A; Fridland, A			MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRACELLULAR METABOLISM; HIV-INFECTION; CELLS; 3'-AZIDO-3'-DEOXYTHYMIDINE; PHOSPHORYLATION; REPLICATION	Dideoxynucleosides, which are potent inhibitors of HIV reverse transcriptase and other viral DNA polymerases, are a common component of highly active anti-retroviral therapy (HAART) (ref. 1). Six reverse transcriptase inhibitors have been approved for human use: azidothymidine; 2'3'-dideoxycytidine; 2'3'-dideoxyinosine; 2',3'-didehydro-3'deoxythymidine; 2',3'-dideoxy-3'-thiacytidine; and 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol. Although drug-resistant HIV strains resulting from genetic mutation have emerged in patients treated with HAART (ref. 1), some patients show signs of drug resistance in the absence of drug-resistant viruses(2,3). In our study of alternative or additional mechanisms of resistance operating during antiviral therapy, overexpression and amplification of the MRP4 gene correlated with ATP-dependent efflux of PMEA (9-(2-phosphonylmethoxyethyl)adenine) and azidothymidine monophosphate from cells and, thus, with resistance to these drugs. Overexpression of MRP4 mRNA and MRP4 protein severely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs. Increased resistance to PMEA and amplification of the MRP4 gene correlated with enhanced drug efflux; transfer of chromosome 13 containing the amplified MRP4 gene conferred resistance to PMEA. MRP4 is the first transporter, to our knowledge, directly linked to the efflux of nucleoside monophosphate analogs from mammalian cells.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.schuetz@stjude.org	Flynn, Patricia M/N-8146-2018; Schuetz, John D/N-2692-2018		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027652, R21AI027652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005851, R29ES005851] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27652] Funding Source: Medline; NIEHS NIH HHS [ES/GM 8568, ES/GM 5851] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5; Balzarini J, 1998, NAT MED, V4, P132, DOI 10.1038/nm0298-132a; Berger EA, 1998, P NATL ACAD SCI USA, V95, P11511, DOI 10.1073/pnas.95.20.11511; BOER R, 1994, EUR J CANCER, V30A, P1117, DOI 10.1016/0959-8049(94)90469-3; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; Groschel B, 1997, INTERVIROLOGY, V40, P400, DOI 10.1159/000150572; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; KARMATA P, 1998, P AM ASSOC CANC RES, V39, P3198; Kepler TB, 1998, P NATL ACAD SCI USA, V95, P11514, DOI 10.1073/pnas.95.20.11514; Kool M, 1997, CANCER RES, V57, P3537; Lavie A, 1997, NAT MED, V3, P922, DOI 10.1038/nm0897-922; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LEVY JA, 1989, ANN NY ACAD SCI, V567, P58; MEDINA DJ, 1995, J VIROL, V69, P1606, DOI 10.1128/JVI.69.3.1606-1611.1995; Pisarev VM, 1997, MOL PHARMACOL, V52, P63, DOI 10.1124/mol.52.1.63; PLOTKIN SA, 1985, J INFECT DIS, V152, P833, DOI 10.1093/infdis/152.4.833; Robbins BL, 1996, ANTIMICROB AGENTS CH, V40, P2651, DOI 10.1128/AAC.40.11.2651; ROBBINS BL, 1995, MOL PHARMACOL, V47, P391; Schuetz EG, 1996, MOL PHARMACOL, V49, P311; SCHUETZ JD, 1989, ARCH BIOCHEM BIOPHYS, V274, P355, DOI 10.1016/0003-9861(89)90449-9; Srinivas RV, 1997, ANTIVIR RES, V35, P23, DOI 10.1016/S0166-3542(97)01035-8; WOLVERTON JS, 1989, CANCER RES, V49, P2422	22	467	485	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1999	5	9					1048	1051		10.1038/12487	http://dx.doi.org/10.1038/12487			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470083				2022-12-27	WOS:000082337200040
J	Bonadio, J; Smiley, E; Patil, P; Goldstein, S				Bonadio, J; Smiley, E; Patil, P; Goldstein, S			Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration	NATURE MEDICINE			English	Article							NATIONAL-OSTEOPOROSIS-FOUNDATION; PARATHYROID-HORMONE; BONE-FORMATION; FRACTURES; RECEPTOR; GROWTH; RATS; MICE; DNA	The inability to deliver growth factors locally in a transient but sustained manner is a substantial barrier to tissue regeneration. Systems capable of localized plasmid gene delivery for prolonged times may offer lower toxicity and should be well-suited for growth factor therapeutics. We investigated the potency of plasmid gene delivery from genes physically entrapped in a polymer matrix (gene activated matrix) using bone regeneration as the endpoint in vivo. implantation of gene activated matrices at sites of bone injury was associated with retention and expression of plasmid DNA for at least 6 weeks, and with the induction of centimeters of normal new bone in a stable, reproducible, dose- and time-dependent manner.	Univ Michigan, Sch Med, Orthopaed Res Labs, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bonadio, J (corresponding author), Select Genet, 11035 Roselle St, San Diego, CA 92121 USA.							Abraham JA, 1996, MOL CELLULAR BIOL WO, P195; Bartus RT, 1998, SCIENCE, V281, P1161, DOI 10.1126/science.281.5380.1161; Bonadio J, 1998, ADV DRUG DELIVER REV, V33, P53, DOI 10.1016/S0169-409X(98)00020-9; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; Cosman F, 1998, CALCIFIED TISSUE INT, V62, P475, DOI 10.1007/s002239900464; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753; FELDMAN AM, 1998, NAT MED, V4, P7839; Giannobile WV, 1996, BONE, V19, pS23, DOI 10.1016/S8756-3282(96)00127-5; GUNNESSHEY M, 1989, BONE, V10, P447, DOI 10.1016/8756-3282(89)90077-X; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; JETTE AM, 1987, ARCH PHYS MED REHAB, V68, P735; Kay MA, 1997, P NATL ACAD SCI USA, V94, P12744, DOI 10.1073/pnas.94.24.12744; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Langer R, 1998, NATURE, V392, P5; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEW D, 1995, HUM GENE THER, V6, P553, DOI 10.1089/hum.1995.6.5-553; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Melton LJ, 1997, J BONE MINER RES, V12, P16, DOI 10.1359/jbmr.1997.12.1.16; PARKER SE, 1995, HUM GENE THER, V6, P575, DOI 10.1089/hum.1995.6.5-575; PARSONS JA, 1974, NATURE, V250, P254, DOI 10.1038/250254a0; PARSONS JA, 1981, OSTEOPOROSIS RECENT, P457; PODBESEK R, 1983, ENDOCRINOLOGY, V112, P1000, DOI 10.1210/endo-112-3-1000; PODBESEK R, 1980, HORMONAL CONTROL CAL, P118; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHLEEF M, 1999, BIOTECHNOLOGY, P443; Segre Gino V., 1996, P377; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; SINGH RH, 1966, INDIAN J MED RES, V54, P872; TERRELL TG, 1993, INT REV EXP PATHOL, V34, P43; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; VOLPON JB, 1994, ARCH ORTHOP TRAUM SU, V113, P312, DOI 10.1007/BF00426178; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7	36	526	579	0	38	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					753	759		10.1038/10473	http://dx.doi.org/10.1038/10473			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395319				2022-12-27	WOS:000081926600029
J	Badorff, C; Lee, GH; Lamphear, BJ; Martone, ME; Campbell, KP; Rhoads, RE; Knowlton, KU				Badorff, C; Lee, GH; Lamphear, BJ; Martone, ME; Campbell, KP; Rhoads, RE; Knowlton, KU			Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy	NATURE MEDICINE			English	Article							LINKED DILATED CARDIOMYOPATHY; SEVERE COMBINED IMMUNODEFICIENCY; DUCHENNE MUSCULAR-DYSTROPHY; HEART-FAILURE; GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLE; MICE; COXSACKIEVIRUS; DEFICIENCY; MYOCARDITIS	Enteroviruses such as Coxsackievirus B3 can cause dilated cardiomyopathy, but the mechanism of this pathology is unknown. Mutations in cytoskeletal proteins such as dystrophin cause hereditary dilated cardiomyopathy, but it is unclear if similar mechanisms underlie acquired forms of heart failure. We demonstrate here that purified Coxsackievirus protease 2A cleaves dystrophin in vitro as predicted by computer analysis. Dystrophin is also cleaved during Coxsackievirus infection of cultured myocytes and in infected mouse hearts, leading to impaired dystrophin function. In vivo, dystrophin and the dystrophin-associated glycoproteins alpha-sarcoglycan and beta-dystroglycan are morphologically disrupted in infected myocytes. We suggest a molecular mechanism through which enteroviral infection contributes to the pathogenesis of acquired forms of dilated cardiomyopathy.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, Dept Neurosci, La Jolla, CA 92093 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA	University of California System; University of California San Diego; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa	Knowlton, KU (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Campbell, Kevin/0000-0003-2066-5889	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Baboonian C, 1997, CURR TOP MICROBIOL, V223, P31; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Beggs AH, 1997, CIRCULATION, V95, P2344, DOI 10.1161/01.CIR.95.10.2344; BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904; Blom N, 1996, PROTEIN SCI, V5, P2203, DOI 10.1002/pro.5560051107; CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; CHOW LH, 1992, LAB INVEST, V66, P24; Cohn JN, 1997, CIRCULATION, V95, P766; Dargie HJ, 1996, J INTERN MED, V239, P309, DOI 10.1046/j.1365-2796.1996.461800000.x; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Fadic R, 1996, NEW ENGL J MED, V334, P362, DOI 10.1056/NEJM199602083340604; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; HENKE A, 1995, J VIROL, V69, P6720, DOI 10.1128/JVI.69.11.6720-6728.1995; Knowlton KU, 1996, J VIROL, V70, P7811, DOI 10.1128/JVI.70.11.7811-7818.1996; KOENIG M, 1990, J BIOL CHEM, V265, P4560; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; Leiden JM, 1997, NEW ENGL J MED, V337, P1080, DOI 10.1056/NEJM199710093371511; Maeda M, 1997, CIRCULATION, V95, P17, DOI 10.1161/01.CIR.95.1.17; MALHOTRA SB, 1988, SCIENCE, V242, P755, DOI 10.1126/science.3055295; Morris GE, 1998, BIOCHEMISTRY-US, V37, P11117, DOI 10.1021/bi9805137; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NICHOLSON LVB, 1989, J NEUROL SCI, V94, P125, DOI 10.1016/0022-510X(89)90223-2; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Roberts RG, 1998, HUM MOL GENET, V7, P589, DOI 10.1093/hmg/7.4.589; RUECKERT RR, 1996, FUNDAMENTAL VIROLOGY, V3, P477; Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Schwarz EM, 1998, J VIROL, V72, P5654, DOI 10.1128/JVI.72.7.5654-5660.1998; SCHWIMMBECK PL, 1994, CIRC RES, V75, P156, DOI 10.1161/01.RES.75.1.156; SETOGUCHI M, 1993, BIOCHEM BIOPH RES CO, V194, P1012, DOI 10.1006/bbrc.1993.1922; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SHOEMAN RL, 1993, AM J PATHOL, V142, P221; Sole MJ, 1993, J AM COLL CARDIOL, V22, P99; Sommergruber W, 1997, VIROLOGY, V234, P203, DOI 10.1006/viro.1997.8595; Spencer MJ, 1997, J CLIN INVEST, V99, P2745, DOI 10.1172/JCI119464; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3; Wessely R, 1998, CIRCULATION, V98, P450, DOI 10.1161/01.CIR.98.5.450; Wessely R, 1998, J CLIN INVEST, V102, P1444, DOI 10.1172/JCI1972	45	398	423	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					320	326		10.1038/6543	http://dx.doi.org/10.1038/6543			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086389				2022-12-27	WOS:000078851600038
J	Igarashi, T; Brown, C; Azadegan, A; Haigwood, N; Dimitrov, D; Martin, MA; Shibata, R				Igarashi, T; Brown, C; Azadegan, A; Haigwood, N; Dimitrov, D; Martin, MA; Shibata, R			Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma	NATURE MEDICINE			English	Article							INFECTED CHIMPANZEES; HIV-1 INFECTION; IN-VIVO; MONKEYS; REPLICATION; GENERATION; RESISTANCE; STRAIN; LIVE; MAC	The concentration of human immunodeficiency virus type 1 (HIV-1) particles in blood plasma is very predictive of the subsequent disease course in an infected individual; its measurement has become one of the most important parameters for monitoring clinical status'. Steady-state virus levels in plasma reflect a balance between the rates of virions entering and leaving the peripheral blood(2). We analyzed the rate of virus clearance in the general circulation in rhesus macaques receiving a continuous infusion of cell-free particles in the presence and absence of virus-specific antibodies. Here we show, by measuring virion RNA, particle-associated p24 Gag protein and virus infectivity, that the clearance of physical and infectious particles from a primary, dual-tropic virus isolate, HIV-1(DH12), is very rapid in naive animals, with half-lives ranging from 13 to 26 minutes. In the presence of high-titer HIV-1(DH12)-specific neutralizing antibodies, the half-life of virion RNA was considerably reduced (to 3.9-7.2 minutes), and infectious virus in the blood became undetectable. Although physical virus particles were eliminated extravascularly, the loss of virus infectivity in the blood reflected the combined effects of extravascular clearance and intravascular inactivation of HIV-1 infectivity due to antibody binding.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; NIH, Vet Resources Program, Bethesda, MD 20892 USA; Seattle Biomed Res Inst, Seattle, WA 98109 USA; NCI, Lab Expt & Computat Biol, NIH, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; Center for Infectious Disease Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Igarashi, T (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA.		Haigwood, Nancy Logan/AAV-7484-2020	Haigwood, Nancy/0000-0002-1477-9575	DIVISION OF BASIC SCIENCES - NCI [Z01BC010042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000415, ZIAAI000415] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AGY MB, 1992, SCIENCE, V257, P103, DOI 10.1126/science.1621083; BRUNNER KT, 1960, J IMMUNOL, V85, P99; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; Himathongkham S, 1996, VIROLOGY, V219, P485, DOI 10.1006/viro.1996.0276; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Igarashi T, 1997, J GEN VIROL, V78, P985, DOI 10.1099/0022-1317-78-5-985; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MIMS CA, 1959, BRIT J EXP PATHOL, V40, P533; MIMS CA, 1956, BRIT J EXP PATHOL, V37, P110; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NATHANSON N, 1967, AM J EPIDEMIOL, V85, P494, DOI 10.1093/oxfordjournals.aje.a120712; *NIH, 1985, DHHS PUBL NIH, V8523; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; REED L. J., 1938, AMER JOUR HYG, V27, P493; SCHULTZ I, 1965, J IMMUNOL, V94, P833; Shibata R, 1997, AIDS RES HUM RETROV, V13, P377, DOI 10.1089/aid.1997.13.377; SHIBATA R, 1995, J GEN VIROL, V76, P2723, DOI 10.1099/0022-1317-76-11-2723; Shibata R, 1997, J INFECT DIS, V176, P362, DOI 10.1086/514053; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; Shibata R, 1996, J VIROL, V70, P4361, DOI 10.1128/JVI.70.7.4361-4369.1996; SHIBATA R, 1991, J VIROL, V65, P3514, DOI 10.1128/JVI.65.7.3514-3520.1991; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZILVERSMIT DB, 1952, J LAB CLIN MED, V40, P255	28	136	151	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					211	216		10.1038/5576	http://dx.doi.org/10.1038/5576			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930870				2022-12-27	WOS:000078274400031
J	Snyder, RO; Miao, C; Meuse, L; Tubb, J; Donahue, BA; Lin, HF; Stafford, DW; Patel, S; Thompson, AR; Nichols, T; Read, MS; Bellinger, DA; Brinkhous, KM; Kay, MA				Snyder, RO; Miao, C; Meuse, L; Tubb, J; Donahue, BA; Lin, HF; Stafford, DW; Patel, S; Thompson, AR; Nichols, T; Read, MS; Bellinger, DA; Brinkhous, KM; Kay, MA			Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors	NATURE MEDICINE			English	Article							HUMAN FACTOR-IX; DEFICIENT MOUSE MODEL; COAGULATION-FACTOR-IX; FACTOR-VIII; GENE-TRANSFER; VONWILLEBRAND-FACTOR; EXPRESSION; MICE; THERAPY; PLASMA	Hemophilia B, or factor IX deficiency, is an X-linked recessive disorder occurring in about 1 in 25,000 males. Affected individuals are at risk for spontaneous bleeding into many organs; treatment mainly consists of the transfusion of clotting factor concentrates prepared from human blood or recombinant sources after bleeding has started. Small- and large-animal models have been developed and/or characterized that closely mimic the human disease state. As a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B, respectively. There was no associated toxicity with infusion in either animal model. Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice. Mice with a steady-state concentration of 25% of the normal human level of factor IX had normal coagulation. In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.	Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Cell Genesys Inc, Foster City, CA 94404 USA; Univ Washington, Dept Med, Seattle, WA 98104 USA; Univ Washington, Puget Sound Blood Ctr, Seattle, WA 98104 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	Stanford University; Stanford University; Cell Genesys Inc; University of Washington; University of Washington Seattle; Puget Sound Blood Center; University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kay, MA (corresponding author), Stanford Univ, Dept Pediat, Sch Med, 300 Pasteur Dr,Rm G305, Stanford, CA 94305 USA.	markay@stanford.edu		Kay, Mark/0000-0002-2799-2615	NHLBI NIH HHS [HL01648, HL53682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BI L, 1995, NATURE GEN, V10; BRINKHOUS KM, 1993, THROMB HAEMOSTASIS, V69, P852; BRINKHOUS KM, 1993, BLOOD, V82, pA592; DAI Y, 1995, MED SCI, V92, P1401; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Ewenstein BM, 1997, BLOOD, V89, P1115, DOI 10.1182/blood.V89.3.1115; GILES AR, 1982, BLOOD, V60, P727; GRIGGS TR, 1974, P NATL ACAD SCI USA, V71, P2087, DOI 10.1073/pnas.71.5.2087; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P875, DOI 10.1055/s-0038-1651380; KAY MA, 1994, P NATL ACAD SCI USA, V91, P2353, DOI 10.1073/pnas.91.6.2353; KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118; KINGDON HS, 1981, BLOOD, V58, P868; Kundu RK, 1998, BLOOD, V92, P168, DOI 10.1182/blood.V92.1.168.413k06_168_174; Kung SH, 1998, BLOOD, V91, P784, DOI 10.1182/blood.V91.3.784.784_784_790; LI J, IN PRESS J VIROL; Lin HF, 1997, BLOOD, V90, P3962, DOI 10.1182/blood.V90.10.3962; Mauser AE, 1996, BLOOD, V88, P3451, DOI 10.1182/blood.V88.9.3451.bloodjournal8893451; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; Nakai H, 1998, BLOOD, V91, P4600, DOI 10.1182/blood.V91.12.4600.412k22_4600_4607; NEUENSCHWANDER S, 1994, HAEMOSTASIS, V24, P27; NICHOLS TC, 1993, BLOOD, V81, P2644; Rosenberg JB, 1998, J CLIN INVEST, V101, P613, DOI 10.1172/JCI1250; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Wang LL, 1997, P NATL ACAD SCI USA, V94, P11563, DOI 10.1073/pnas.94.21.11563; Warrier I, 1997, J PEDIAT HEMATOL ONC, V19, P23, DOI 10.1097/00043426-199701000-00003; YAO SN, 1992, P NATL ACAD SCI USA, V89, P3357, DOI 10.1073/pnas.89.8.3357; YAO SN, 1994, GENE THER, V1, P99; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	31	368	427	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1999	5	1					64	70		10.1038/4751	http://dx.doi.org/10.1038/4751			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883841				2022-12-27	WOS:000077885000031
J	Zhou, T; Song, L; Yang, P; Wang, Z; Lui, D; Jope, RS				Zhou, T; Song, L; Yang, P; Wang, Z; Lui, D; Jope, RS			Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; ANTI-FAS; IN-VIVO; EXPRESSION; LIGAND; ACTIVATION; DEATH; ENCEPHALOMYELITIS; RO-31-8220	Fas-mediated apoptosis is essential for the elimination of cells, and impaired apoptosis can have severe detrimental consequences. Bisindolyimaleimide VIII potentiated Pas-mediated apoptosis in human astrocytoma 1321N1 cells and in Molt-4 T cells, both of which were devoid of apoptosis induced by anti-fas antibody in the absence of bisindolylmaleimide VIII, and in Jurkat and CEM-B T cells, which showed slight and moderate apoptotic responses, respectively, to low levels of Fas stimulation. Potentiation of Fas-mediated apoptosis by bisindolylmaleimide VIII was elective for activated, rather than non-activated, T cells, and was Pas-dependent, as it was not observed in T cells from Fas-deficient lpr/lpr mice. Administration of bisindolylmaleimide VIII to rats during autoantigen stimulation prevented the development of symptoms of T cell-mediated autoimmune diseases in two models, the Lewis rat model of experimental allergic encephalitis and the Lewis adjuvant arthritis model. Thus, the use of agents such as bisindolylmaleimide VIII may be therapeutically useful for supporting more effective elimination of detrimental cells through enhancement of Pas-dependent apoptosis signaling.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Zhou, T (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R56MH038752, R01MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44982] Funding Source: Medline; NIA NIH HHS [AG06569] Funding Source: Medline; NIMH NIH HHS [MH38752] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Ehl S, 1996, J IMMUNOL, V156, P2357; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JACOBSON PB, 1995, J PHARMACOL EXP THER, V275, P995; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; McFarland HI, 1995, ADV EXP MED BIOL, V383, P157; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suen WE, 1997, J EXP MED, V186, P1233, DOI 10.1084/jem.186.8.1233; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; TABI Z, 1995, INT IMMUNOL, V7, P967, DOI 10.1093/intimm/7.6.967; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TOULLEC D, 1991, J BIOL CHEM, V266, P1571; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Yeo EJ, 1997, BBA-MOL CELL RES, V1356, P308, DOI 10.1016/S0167-4889(97)00006-2; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	25	108	113	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					42	48		10.1038/4723	http://dx.doi.org/10.1038/4723			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883838				2022-12-27	WOS:000077885000028
J	Vidal, V; Scragg, IG; Cutler, SJ; Rockett, KA; Fekade, D; Warrell, DA; Wright, DJM; Kwiatkowski, D				Vidal, V; Scragg, IG; Cutler, SJ; Rockett, KA; Fekade, D; Warrell, DA; Wright, DJM; Kwiatkowski, D			Variable major lipoprotein is a principal TNF-inducing factor of louse-borne relapsing fever	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; OUTER SURFACE-PROTEIN; JARISCH-HERXHEIMER REACTION; LYME-DISEASE SPIROCHETE; BORRELIA-BURGDORFERI; ANTIGENIC VARIATION; FACTOR-ALPHA; EXPRESSION; SEQUENCE; HERMSII	Massive release of tumor necrosis factor is responsible for the potentially fatal jarisch-Herxheimer reaction that follows antibiotic treatment of relapsing fever due to Borrelia recurrentis. We have undertaken the quantitative purification of the components of B. recurrentis that stimulate human monocytes to produce tumor necrosis factor. We show that the predominant factor inducing tumor necrosis factor is a variable lipoprotein homologous to the variable major protein of B. hermsii. We found antibodies to different forms of variable major protein in two patients with louse-borne relapsing fever. The three purified variable major proteins studied here differ in their ability to induce tumor necrosis factor production, which may partly explain the variable clinical severity of borrelial infection. These results may be of considerable relevance for the pathogenesis of Lyme disease and other forms of human borreliosis.	Univ Oxford, Dept Pediat, Oxford OX1 2JD, England; Univ Oxford, Ctr Trop Med, Oxford OX1 2JD, England; Univ London Imperial Coll Sci Technol & Med, Dept Med Microbiol, London, England; Black Lion Hosp, Dept Internal Med, Addis Ababa, Ethiopia	University of Oxford; University of Oxford; Imperial College London	Vidal, V (corresponding author), Univ Oxford, Dept Pediat, Oxford OX1 2JD, England.		Cutler, Sally/AAT-3350-2020	Kwiatkowski, Dominic/0000-0002-5023-0176				ALLAN RJ, 1993, INFECT IMMUN, V61, P4772, DOI 10.1128/IAI.61.11.4772-4776.1993; BARBOUR AG, 1982, J EXP MED, V156, P1312, DOI 10.1084/jem.156.5.1312; BARBOUR AG, 1990, ANNU REV MICROBIOL, V44, P155, DOI 10.1146/annurev.mi.44.100190.001103; BARBOUR AG, 1987, SCIENCE, V237, P409, DOI 10.1126/science.3603026; Bouchon B, 1997, ANAL BIOCHEM, V246, P52, DOI 10.1006/abio.1996.9982; BRAUN V, 1975, BIOCHIM BIOPHYS ACTA, V415, P335, DOI 10.1016/0304-4157(75)90013-1; BRYCESON ADM, 1976, J INFECT DIS, V133, P696, DOI 10.1093/infdis/133.6.696; CADAVID D, 1994, J EXP MED, V179, P631, DOI 10.1084/jem.179.2.631; Cutler SJ, 1997, INT J SYST BACTERIOL, V47, P958, DOI 10.1099/00207713-47-4-958; CUTLER SJ, 1994, LANCET, V343; deSilva AM, 1997, PARASITOL TODAY, V13, P267, DOI 10.1016/S0169-4758(97)01074-0; deSilva AM, 1997, J CLIN INVEST, V99, P377, DOI 10.1172/JCI119169; Fekade D, 1996, NEW ENGL J MED, V335, P311, DOI 10.1056/NEJM199608013350503; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; JOHNSON WD, 1994, PRINCIPLES PRACTICE, P2141; LUGER SW, 1995, ANTIMICROB AGENTS CH, V39, P661, DOI 10.1128/AAC.39.3.661; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; Montgomery RR, 1996, J EXP MED, V183, P261, DOI 10.1084/jem.183.1.261; NEGUSSIE Y, 1992, J EXP MED, V175, P1207, DOI 10.1084/jem.175.5.1207; PLASTERK RHA, 1985, NATURE, V318, P257, DOI 10.1038/318257a0; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; RADOLF JD, 1991, J IMMUNOL, V147, P1968; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; TAKAYAMA K, 1987, INFECT IMMUN, V55, P2311, DOI 10.1128/IAI.55.9.2311-2313.1987; WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994; WRIGHT DJM, 1980, PARASITE IMMUNOL, V2, P201, DOI 10.1111/j.1365-3024.1980.tb00054.x; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8	27	42	42	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1416	1420		10.1038/4007	http://dx.doi.org/10.1038/4007			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846580				2022-12-27	WOS:000077336900038
J	Bard, F; Cannon, C; Barbour, R; Burke, RL; Games, D; Grajeda, H; Guido, T; Hu, K; Huang, JP; Johnson-Wood, K; Khan, K; Kholodenko, D; Lee, M; Lieberburg, I; Motter, R; Nguyen, M; Soriano, F; Vasquez, N; Weiss, K; Welch, B; Seubert, P; Schenk, D; Yednock, T				Bard, F; Cannon, C; Barbour, R; Burke, RL; Games, D; Grajeda, H; Guido, T; Hu, K; Huang, JP; Johnson-Wood, K; Khan, K; Kholodenko, D; Lee, M; Lieberburg, I; Motter, R; Nguyen, M; Soriano, F; Vasquez, N; Weiss, K; Welch, B; Seubert, P; Schenk, D; Yednock, T			Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease	NATURE MEDICINE			English	Article							PRECURSOR PROTEIN; MICROGLIAL CELLS; DEGRADATION	One hallmark of Alzheimer disease is the accumulation of amyloid beta -peptide in the brain and its deposition as plaques. Mice transgenic for an amyloid beta precursor protein (APP) mini-gene driven by a platelet-derived (PD) growth factor promoter (PDAPP mice), which overexpress one of the disease-linked mutant forms of the human amyloid precursor protein, show many of the pathological features of Alzheimer disease, including extensive deposition of extracellular amyloid plaques, astrocytosis and neuritic dystrophy(1,2). Active immunization of PDAPP mice with human amyloid beta -peptide reduces plaque burden and its associated pathologies(3). Several hypotheses have been proposed regarding the mechanism of this response(4,5). Here we report that peripheral administration of antibodies against amyloid beta -peptide, was sufficient to reduce amyloid burden. Despite their relatively modest serum levels, the passively administered antibodies were able to enter the central nervous system, decorate plaques and induce clearance of preexisting amyloid. When examined in an ex vivo assay with sections of PDAPP or Alzheimer disease brain tissue, antibodies against amyloid beta -peptide triggered microglial cells to clear plaques through Fc receptor-mediated phagocytosis and subsequent peptide degradation. These results indicate that antibodies can cross the blood-brain barrier to act directly in the central nervous system and should be considered as a therapeutic approach for the treatment of Alzheimer disease and other neurological disorders.	Elan Pharmaceut, S San Francisco, CA 94080 USA		Bard, F (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, S San Francisco, CA 94080 USA.							Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Duff K, 1999, TRENDS NEUROSCI, V22, P485, DOI 10.1016/S0166-2236(99)01489-7; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; Johnson D, 1997, EDN, V42, P94; Masliah E, 1996, J NEUROSCI, V16, P5795; Paresce DM, 1997, J BIOL CHEM, V272, P29390, DOI 10.1074/jbc.272.46.29390; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; St George-Hyslop PH, 1999, NATURE, V400, P116; THOMPSON EJ, 1990, ANN CLIN BIOCHEM, V27, P425, DOI 10.1177/000456329002700503	10	1655	1877	1	175	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					916	919		10.1038/78682	http://dx.doi.org/10.1038/78682			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932230	Bronze			2022-12-27	WOS:000165473800036
J	Attaran, A; Roberts, DR; Curtis, CF; Kilama, WL				Attaran, A; Roberts, DR; Curtis, CF; Kilama, WL			Balancing risks on the backs of the poor	NATURE MEDICINE			English	Editorial Material							BREAST-CANCER RISK; MALARIA CONTROL; COST-EFFECTIVENESS; BLOOD-LEVELS; DDT; AFRICA; ORGANOCHLORINES; AMERICA; WOMEN	Malaria kills over one million people, mainly children, in the tropics each year, and DDT remains one of the few affordable, effective tools against the mosquitoes that transmit the disease. Attaran et al. explain that the scientific literature on the need to withdraw DDT is unpersuasive, and the benefits of DDT in saving lives from malaria are well worth the risks.	Harvard Univ, John F Kennedy Sch Govt, Ctr Int Dev, Cambridge, MA 02138 USA; Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; C2627 Tanzania Commiss Sci & Technol, African Malaria Vaccine Testing Network, Dar Es Salaam, Tanzania; Malaria Fdn Int, Dar Es Salaam, Tanzania	Harvard University; Uniformed Services University of the Health Sciences - USA; University of London; London School of Hygiene & Tropical Medicine	Attaran, A (corresponding author), Harvard Univ, John F Kennedy Sch Govt, Ctr Int Dev, Cambridge, MA 02138 USA.							Baris D, 1998, OCCUP ENVIRON MED, V55, P522, DOI 10.1136/oem.55.8.522; Chareonviriyaphap T, 1997, J AM MOSQUITO CONTR, V13, P171; DEZULUETA J, 1963, NATURE, V200, P860, DOI [10.1038/200860a0, 10.1038/200861a0]; GALLUP JL, 1998, EC BURDEN MALARIA; GLADEN BC, 1995, AM J PUBLIC HEALTH, V85, P504, DOI 10.2105/AJPH.85.4.504; Goodman CA, 1999, LANCET, V354, P378, DOI 10.1016/S0140-6736(99)02141-8; Goodman CA, 1999, HEALTH POLICY PLANN, V14, P301, DOI 10.1093/heapol/14.4.301; Grieco JP, 2000, J VECTOR ECOL, V25, P62; Helzlsouer KJ, 1999, CANCER EPIDEM BIOMAR, V8, P525; Hunter DJ, 1997, NEW ENGL J MED, V337, P1253, DOI 10.1056/NEJM199710303371801; Kouznetsov R L, 1977, Trop Doct, V7, P81; KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589; Longnecker MP, 1997, ANNU REV PUBL HEALTH, V18, P211, DOI 10.1146/annurev.publhealth.18.1.211; LopezCarrillo L, 1997, CANCER RES, V57, P3728; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; Metcalf CL., 1962, DESTRUCTIVE USEFUL I; Mouchet J, 1998, J AM MOSQUITO CONTR, V14, P121; Moysich KB, 1998, CANCER EPIDEM BIOMAR, V7, P181; *PHYS SOC RESP, 1999, MOD MAL CONTR HDB; Roberts DR, 1997, EMERG INFECT DIS, V3, P295, DOI 10.3201/eid0303.970305; Roberts DR, 2000, J VECTOR ECOL, V25, P48; Schecter A, 1997, ARCH ENVIRON CON TOX, V33, P453, DOI 10.1007/s002449900276; vantVeer P, 1997, BMJ-BRIT MED J, V315, P81, DOI 10.1136/bmj.315.7100.81; *WHO, 1999, SDEPHEDP04; *WHO, 1999, SDEPHEDP02 WHO; *WHO EXP COMM MAL, 1979, WHO TECH REP SER, V640; *WHO UN ENV PROGR, 1979, ENV CRIT WHO, V9; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; *WORLD WILDL FUND, 1998, RES DDT DIL; Zheng TZ, 1999, AM J EPIDEMIOL, V150, P453, DOI 10.1093/oxfordjournals.aje.a010033	30	52	55	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					729	+		10.1038/77438	http://dx.doi.org/10.1038/77438			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888909				2022-12-27	WOS:000088040100019
J	Cowan, KN; Heilbut, A; Humpl, T; Lam, C; Ito, S; Rabinovitch, M				Cowan, KN; Heilbut, A; Humpl, T; Lam, C; Ito, S; Rabinovitch, M			Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor	NATURE MEDICINE			English	Article							TENASCIN-C; INTEGRIN; ANGIOGENESIS; ALPHA(V)BETA(3); REGRESSION; SUPPRESSION; EXPRESSION; APOPTOSIS; CELLS	Progression of pulmonary hypertension is associated with increased serine elastase activity and the proteinase-dependent deposition of the extracellular matrix smooth muscle cell survival factor tenascin-C (refs. 1,2). Tenascin-C amplifies the response of smooth muscle cells to growth factors(3), which are also liberated through matrix proteolysis(4). Recent organ culture studies using hypertrophied rat pulmonary arteries have shown that elastase inhibitors suppress tenascin-C and induce smooth muscle cell apoptosis(5,6). This initiates complete regression of the hypertrophied vessel wall by a coordinated loss of cellularity and extracellular matrix. We now report that elastase inhibitors can reverse advanced pulmonary vascular disease produced in rats by injecting monocrotaline, an endothelial toxin. We began oral administration of the peptidyl trifluoromethylketone serine elastase inhibitors M249314 or ZD0892 21 days after injection of monocrotaline. A 1-week treatment resulted in 92% survival, compared with 39% survival in untreated or vehicle-treated rats. Pulmonary artery pressure and muscularization were reduced by myocyte apoptosis and loss of extracellular matrix, specifically elastin and tenascin-C. After 2 weeks, pulmonary artery pressure and structure normalized, and survival was 86%, compared with 0% in untreated or vehicle-treated rats. Although concomitant treatment with various agents can reduce pulmonary hypertension(7), we have documented complete regression after establishment of malignant monocrotaline-induced disease.	Univ Toronto, Dept Pediat, Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Rabinovitch, M (corresponding author), Univ Toronto, Dept Pediat, Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Lam, Catherine/K-6328-2014; Heilbut, Adrian M/J-9427-2012	Lam, Catherine/0000-0003-1363-5331; Heilbut, Adrian M/0000-0002-8169-7967; Cowan, Kyle/0000-0003-0109-7716				Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHOI ET, 1994, J VASC SURG, V19, P125, DOI 10.1016/S0741-5214(94)70127-X; Cowan KN, 2000, J CLIN INVEST, V105, P21, DOI 10.1172/JCI6539; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; Edwards PD, 1997, J MED CHEM, V40, P1876, DOI 10.1021/jm960819g; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FRIED R, 1984, J APPL PHYSIOL, V57, P1247, DOI 10.1152/jappl.1984.57.4.1247; Haas TL, 1999, TRENDS CARDIOVAS MED, V9, P70, DOI 10.1016/S1050-1738(99)00014-6; Jones PL, 1997, AM J PATHOL, V150, P1349; Jones PL, 1999, J CELL SCI, V112, P435; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Lee JK, 1998, NAT MED, V4, P1383, DOI 10.1038/3973; Mitani Y, 1997, CIRCULATION, V96, P689; RABINOVITCH M, 1998, COMPREHENSIVE CARDIO, P3001; SELIEM MA, 1995, PEDIATR CARDIOL, V16, P53, DOI 10.1007/BF00796817; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Thompson K, 1996, J CELL PHYSIOL, V166, P495, DOI 10.1002/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K; Wigle DA, 1998, CIRC RES, V83, P252, DOI 10.1161/01.RES.83.3.252; YE CL, 1991, AM J PHYSIOL, V261, pH1255, DOI 10.1152/ajpheart.1991.261.4.H1255	20	273	297	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					698	702		10.1038/76282	http://dx.doi.org/10.1038/76282			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835689				2022-12-27	WOS:000087438300043
J	Kugler, A; Stuhler, G; Walden, P; Zoller, G; Zobywalski, A; Brossart, P; Trefzer, U; Ullrich, S; Muller, CA; Becker, V; Gross, AJ; Hemmerlein, B; Kanz, L; Muller, GA; Ringert, RH				Kugler, A; Stuhler, G; Walden, P; Zoller, G; Zobywalski, A; Brossart, P; Trefzer, U; Ullrich, S; Muller, CA; Becker, V; Gross, AJ; Hemmerlein, B; Kanz, L; Muller, GA; Ringert, RH			RETRACTED: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids (Retracted article. See vol. 9, p. 1221, 2003)	NATURE MEDICINE			English	Article; Retracted Publication							T-LYMPHOCYTES; IMMUNITY; ANTIGEN; FUSION; CANCER		Univ Gottingen, Dept Nephrol & Rheumatol, D-3400 Gottingen, Germany; Univ Gottingen, Dept Urol, D-3400 Gottingen, Germany; Univ Tubingen, Med Clin, Dept 2, Sect Transplantat Immunol & Immunohaematol, Tubingen, Germany; Humboldt Univ, Charite, Dept Dermatol, Berlin, Germany; Univ Gottingen, Dept Pathol, D-3400 Gottingen, Germany	University of Gottingen; University of Gottingen; Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Gottingen	Muller, GA (corresponding author), Univ Gottingen, Dept Nephrol & Rheumatol, D-3400 Gottingen, Germany.	gmueller@med.uni-goettingen.de; akugler@gwdg.de						ANICHINI A, 1989, J IMMUNOL, V142, P3692; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brossart P, 1999, BLOOD, V93, P4309, DOI 10.1182/blood.V93.12.4309.412k19_4309_4317; Brossart P, 1998, CANCER RES, V58, P732; Fujita K, 1999, BRIT J CANCER, V80, P301, DOI 10.1038/sj.bjc.6690355; Gong JL, 1997, NAT MED, V3, P558, DOI 10.1038/nm0597-558; Gong JL, 1998, P NATL ACAD SCI USA, V95, P6279, DOI 10.1073/pnas.95.11.6279; GUO YJ, 1994, SCIENCE, V263, P518, DOI 10.1126/science.7507262; Jantzer P, 1998, CANCER RES, V58, P3078; Jayson GC, 1998, BRIT J CANCER, V78, P366, DOI 10.1038/bjc.1998.500; Kugler A, 1998, BRIT J UROL, V82, P487; Lokich J, 1997, AM J CLIN ONCOL-CANC, V20, P416, DOI 10.1097/00000421-199708000-00020; SALLUSTO F, 1994, J EXP MED, V179, P110; Stuhler G, 1999, P NATL ACAD SCI USA, V96, P1532, DOI 10.1073/pnas.96.4.1532; STUHLER G, 1994, CANCER IMMUNOL IMMUN, V39, P342, DOI 10.1007/s002620050136; Wang JL, 1998, J IMMUNOL, V161, P5516	16	540	686	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					332	336		10.1038/73193	http://dx.doi.org/10.1038/73193			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700237				2022-12-27	WOS:000085580500045
J	Aoki, H; Sadoshima, J; Izumo, S				Aoki, H; Sadoshima, J; Izumo, S			Myosin light chain kinase mediates sarcomere organization during cardiac hypertrophy in vitro	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-KINASE; RAT VENTRICULAR MYOCYTES; MUSCLE CELL HYPERTROPHY; ANGIOTENSIN-II; RHO-KINASE; TRANSCRIPTION FACTORS; S6 KINASE; PHOSPHORYLATION; GROWTH; STRESS	During the development of hypertrophy, cardiac myocytes increase organization of the sarcomere, a highly ordered contractile unit in striated muscle cells. Several hypertrophic agonists, such as angiotensin II, phenylephrine, and endothelin-1, have been shown to promote the sarcomere organization. However, the signaling pathway, which links extracellular stimuli to sarcomere organization, has not been clearly demonstrated. Here, we demonstrate that myosin light chain kinase specifically mediates agonist-induced sarcomere organization during early hypertrophic response. Acute administration of a hypertrophic agonist phenylephrine, or angiotensin II, causes phosphorylation of myosin light chain 2v both in cultured cardiac myocytes and in the adult heart in vivo. We also show that both sarcomere organization and myosin light chain 2v phosphorylation are dependent on the activation of Ca2+/calmodulin pathway, a known activator of myosin light chain kinase. These results define a new and specific role of myosin light chain kinase in cardiac myocytes, which may provide a rapid adaptive mechanism in response to hypertrophic stimuli.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA; Penn State Univ, Coll Med, Weis Ctr Res, Danville, PA 17822 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Izumo, S (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc, 330 Brookline Ave,SL-201, Boston, MA 02215 USA.			Sadoshima, Junichi/0000-0003-3724-4132				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; BLANCHARD EM, 1990, PFLUG ARCH EUR J PHY, V416, P219, DOI 10.1007/BF00370248; Braunwald E, 1992, HEART DIS, V1, P393; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; ECKEL J, 1991, J MOL CELL CARDIOL, V23, P617, DOI 10.1016/0022-2828(91)90053-O; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; Ferrari MB, 1998, J CELL BIOL, V141, P1349, DOI 10.1083/jcb.141.6.1349; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; HEACOCK CS, 1983, ANAL BIOCHEM, V135, P22, DOI 10.1016/0003-2697(83)90725-X; HONGO K, 1995, AM J PHYSIOL-CELL PH, V269, pC690, DOI 10.1152/ajpcell.1995.269.3.C690; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; HU ZY, 1992, BIOCHEM PHARMACOL, V44, P1543, DOI 10.1016/0006-2952(92)90470-4; KATZ AM, 1990, NEW ENGL J MED, V322, P100; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; MEBAZAA A, 1993, AM J PHYSIOL, V265, pH1841, DOI 10.1152/ajpheart.1993.265.5.H1841; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORANO I, 1985, FEBS LETT, V189, P221, DOI 10.1016/0014-5793(85)81027-9; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1995, CIRC RES, V76, P1; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; SWEENEY HL, 1986, AM J PHYSIOL, V250, pC657, DOI 10.1152/ajpcell.1986.250.4.C657; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; THORBURN A, 1993, J BIOL CHEM, V268, P2244; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Watanabe A, 1998, CARDIOVASC RES, V37, P524, DOI 10.1016/S0008-6363(97)00287-3; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951	44	117	123	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					183	188		10.1038/72287	http://dx.doi.org/10.1038/72287			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655107				2022-12-27	WOS:000085016900039
J	Baba, TW; Liska, V; Hofmann-Lehmann, R; Vlasak, J; Xu, WD; Ayehunie, S; Cavacini, LA; Posner, MR; Katinger, H; Stiegler, G; Bernacky, BJ; Rizvi, TA; Schmidt, R; Hill, LR; Keeling, ME; Lu, YC; Wright, JE; Chou, TC; Ruprecht, RM				Baba, TW; Liska, V; Hofmann-Lehmann, R; Vlasak, J; Xu, WD; Ayehunie, S; Cavacini, LA; Posner, MR; Katinger, H; Stiegler, G; Bernacky, BJ; Rizvi, TA; Schmidt, R; Hill, LR; Keeling, ME; Lu, YC; Wright, JE; Chou, TC; Ruprecht, RM			Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection	NATURE MEDICINE			English	Article							COMPLEMENT-MEDIATED LYSIS; CELL-FREE SIV; SYNERGISTIC NEUTRALIZATION; TYPE-1; MACAQUES; HIV-1; MONKEYS; EPITOPE; BINDING; GP120	Although maternal human immunodeficiency virus type 1 (HIV-1) transmission occurs during gestation, intrapartum and postpartum (by breast-feeding), 50-70% of all infected children seem to acquire HIV-1 shortly before or during delivery(1). Epidemiological evidence indicates that mucosal exposure is an important aspect of intrapartum HIV transmission(2,3). A simian immunodeficiency virus (SIV) macaque model has been developed(4) that mimics the mucosal exposure that can occur during intrapartum HIV-1 transmission. To develop immunoprophylaxis against intrapartum HIV-1 transmission, we used SHIV-vpu(+) (refs. 5,6), a chimeric simian-human virus that encodes the env gene of HIV-IIIB. Several combinations of human monoclonal antibodies against HIV-1. have been identified that neutralize SHIV-vpu(+) completely in vitro through synergistic interaction(7). Here, we treated four pregnant macaques with a triple combination of the human IgG1 monoclonal antibodies F105, 2G12 and 2F5. All four macaques were protected against intravenous SHIV-vpu(+) challenge after delivery. The infants received monoclonal antibodies after birth and were challenged orally with SHIV-vpu(+) shortly thereafter. We found no evidence of infection in any infant during 6 months of follow-up. This demonstrates that IgG1 monoclonal antibodies protect against mucosal lentivirus challenge in neonates. We conclude that epitopes recognized by the three monoclonal antibodies are important determinants for achieving substantial protection, thus providing a rational basis for AIDS vaccine development.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pediat, Div Newborn Med, Boston, MA 02111 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Inst Appl Microbiol, A-1190 Vienna, Austria; Univ Texas, MD Anderson Canc Ctr, Dept Vet Sci, Bastrop, TX 78602 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Biochem Pharmacol Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Preclin Pharmacol Core Facil, New York, NY 10021 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Tufts University; Harvard University; Beth Israel Deaconess Medical Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard T.H. Chan School of Public Health; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Ruprecht, RM (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.		Ayehunie, Seyoum/K-3514-2019; Hofmann-Lehmann, Regina/C-6528-2009; Chou, Ting-Chao/B-4111-2009; Chou, Ting-Chao/AAA-7881-2020	Hofmann-Lehmann, Regina/0000-0001-9750-4296; Chou, Ting-Chao/0000-0002-3340-1594; Chou, Ting-Chao/0000-0002-3340-1594; Rizvi, Tahir A/0000-0002-2572-1678	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026926, R01AI032330, R01AI034266] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI32330, R01 AI34266, R01 AI26926] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; Baba TW, 1996, SCIENCE, V272, P1486, DOI 10.1126/science.272.5267.1486; CAVACINI LA, 1994, J IMMUNOTHER, V15, P251, DOI 10.1097/00002371-199405000-00003; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Conley AJ, 1996, J VIROL, V70, P6751, DOI 10.1128/JVI.70.10.6751-6758.1996; Joag SV, 1999, AIDS RES HUM RETROV, V15, P391, DOI 10.1089/088922299311367; Li A, 1998, J VIROL, V72, P3235, DOI 10.1128/JVI.72.4.3235-3240.1998; LI JT, 1995, J VIROL, V69, P7061, DOI 10.1128/JVI.69.11.7061-7067.1995; Liska V, 1999, AIDS RES HUM RETROV, V15, P445, DOI 10.1089/088922299311196; Lu YC, 1996, J ACQ IMMUN DEF SYND, V12, P99, DOI 10.1097/00042560-199606010-00001; Mascola JR, 1997, J VIROL, V71, P7198, DOI 10.1128/JVI.71.10.7198-7206.1997; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; MOFENSON L, 1998, PEDIAT AIDS CHALLENG, P487; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; POSNER MR, 1993, J ACQ IMMUN DEF SYND, V6, P7; POSNER MR, 1992, AIDS RES HUM RETROV, V8, P553, DOI 10.1089/aid.1992.8.553; POSNER MR, 1991, J IMMUNOL, V146, P4325; Rogers MF, 1999, NEW ENGL J MED, V341, P441, DOI 10.1056/NEJM199908053410609; Ruprecht RM, 1999, J INFECT DIS, V179, pS408, DOI 10.1086/314794; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; SPOUGE JL, 1992, P NATL ACAD SCI USA, V89, P7581, DOI 10.1073/pnas.89.16.7581; Sullivan BL, 1996, J IMMUNOL, V157, P1791; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Van Rompay KKA, 1998, J INFECT DIS, V177, P1247, DOI 10.1086/515270; WILLIAMSHERMAN D, 1993, INT C AIDS 6 11 JUN	25	745	793	0	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					200	206		10.1038/72309	http://dx.doi.org/10.1038/72309			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655110	Bronze			2022-12-27	WOS:000085016900042
J	Balomenos, D; Martin-Caballero, J; Garcia, MI; Prieto, I; Flores, JM; Serrano, M; Martinez, C				Balomenos, D; Martin-Caballero, J; Garcia, MI; Prieto, I; Flores, JM; Serrano, M; Martinez, C			The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development	NATURE MEDICINE			English	Article							MICE; ERYTHEMATOSUS; KINASE; DEFICIENCY; RADIATION; MEMORY	Here we show that the cell-cycle regulator p21 is involved in immune system function. T lymphocytes from p21(-/-) mice exhibit significant proliferative advantage over wild-type cells following prolonged stimulation, but not after primary activation. Consistent with this, p27-deficient mice accumulate abnormal amounts of CD4(+) memory cells, and develop loss of tolerance towards nuclear antigens. Similar to human lupus, female p21-deficient mice develop antibodies against dsDNA, lymphadenopathy, and glomerulonephritis, leading to decreased viability. These data demonstrate a specialized role for p21 in the control of T-cell proliferation, tolerance to nuclear antigens, and female-prone lupus. These findings could be the basis for new therapeutic approaches to lupus.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Complutense Madrid, Fac Vet, Dept Patol Anim 2, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Complutense University of Madrid	Balomenos, D (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Plaza Murillo 2, E-28049 Madrid, Spain.		Serrano, Manuel/H-2634-2015; Balomenos, Dimitrios/I-3850-2015	Serrano, Manuel/0000-0001-7177-9312; Balomenos, Dimitrios/0000-0002-1252-0850				Balomenos D, 1998, J CLIN INVEST, V101, P364, DOI 10.1172/JCI750; BERDEN JHM, 1983, J IMMUNOL, V130, P1699; Bickerstaff MCM, 1999, NAT MED, V5, P694, DOI 10.1038/9544; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gaffney PM, 1998, P NATL ACAD SCI USA, V95, P14875, DOI 10.1073/pnas.95.25.14875; Kim YG, 1999, KIDNEY INT, V55, P2349, DOI 10.1046/j.1523-1755.1999.00504.x; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; London CA, 1999, J IMMUNOL, V162, P766; Megyesi J, 1998, J CLIN INVEST, V101, P777, DOI 10.1172/JCI1497; Moser KL, 1998, P NATL ACAD SCI USA, V95, P14869, DOI 10.1073/pnas.95.25.14869; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHASHI PS, 1997, CURR OPIN IMMUNOL, V8, P815; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Pape KA, 1997, IMMUNOL REV, V156, P67, DOI 10.1111/j.1600-065X.1997.tb00959.x; Paul E, 1999, NAT MED, V5, P607, DOI 10.1038/9450; Sabzevari H, 1997, EUR J IMMUNOL, V27, P1901, DOI 10.1002/eji.1830270813; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Takahashi S, 1996, J CLIN INVEST, V97, P1597, DOI 10.1172/JCI118584; Theofilopoulos AN, 1998, ANN NY ACAD SCI, V841, P225, DOI 10.1111/j.1749-6632.1998.tb10932.x; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590	27	167	170	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					171	176		10.1038/72272	http://dx.doi.org/10.1038/72272			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655105				2022-12-27	WOS:000085016900037
J	Li, J; Post, M; Volk, R; Gao, Y; Li, M; Metais, C; Sato, K; Tsai, J; Aird, W; Rosenberg, RD; Hampton, TG; Li, JY; Sellke, F; Carmeliet, P; Simons, M				Li, J; Post, M; Volk, R; Gao, Y; Li, M; Metais, C; Sato, K; Tsai, J; Aird, W; Rosenberg, RD; Hampton, TG; Li, JY; Sellke, F; Carmeliet, P; Simons, M			PR39, a peptide regulator of angiogenesis	NATURE MEDICINE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; INDUCIBLE FACTOR 1-ALPHA; ANTIMICROBIAL PEPTIDE; ISCHEMIC-HEART; IN-VITRO; EXPRESSION; HYPOXIA; PR-39; GENE; THERMOTOLERANCE	Although tissue injury and inflammation are considered essential for the induction of angiogenesis, the molecular controls of this cascade are mostly unknown. Here we show that a macrophage-derived peptide, PR39, inhibited the ubiquitin-proteasome-dependent degradation of hypoxia-inducible factor-1 alpha protein, resulting in accelerated formation of vascular structures in vitro and increased myocardial vasculature in mice. For the latter, coronary flow studies demonstrated that PR39-induced angiogenesis resulted in the production of functional blood vessels. These findings show that PR39 and related compounds can be used as potent inductors of angiogenesis, and that selective inhibition of hypoxia-inducible factor-la degradation may underlie the mechanism of inflammation-induced angiogenesis.	Beth Israel Deaconess Med Ctr, Dept Surg, Angiogenesis Res Ctr, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Div Hematol & Mol Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Catholic Univ Louvain, B-3000 Louvain, Belgium	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Universite Catholique Louvain	Simons, M (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, Angiogenesis Res Ctr, Boston, MA 02215 USA.	msimons@caregroup.harvard.edu	Carmeliet, Peter/AAQ-5140-2020; Simons, Michael/G-8553-2014	Carmeliet, Peter/0000-0001-7961-1821; Simons, Michael/0000-0003-0348-7734	NHLBI NIH HHS [HL 46716, R01 HL53793, P50 HL 56993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056993, R01HL053793, R01HL046716, R29HL046716] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Arras M, 1998, BASIC RES CARDIOL, V93, P97, DOI 10.1007/s003950050069; Bein K, 1997, J CELL PHYSIOL, V173, P319, DOI 10.1002/(SICI)1097-4652(199712)173:3<319::AID-JCP3>3.0.CO;2-Q; Bouloumie A, 1999, CARDIOVASC RES, V41, P773, DOI 10.1016/S0008-6363(98)00228-4; Bush KT, 1997, J BIOL CHEM, V272, P9086; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1998, NATURE, V395, P525, DOI 10.1038/26791; Chan YR, 1998, J BIOL CHEM, V273, P28978, DOI 10.1074/jbc.273.44.28978; Dhanabal M, 1999, CANCER RES, V59, P189; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5; GUDMUNDSSON GH, 1995, P NATL ACAD SCI USA, V92, P7085, DOI 10.1073/pnas.92.15.7085; Guillot PV, 1999, J CLIN INVEST, V103, P799, DOI 10.1172/JCI6017; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Li J, 1997, J CLIN INVEST, V100, P18, DOI 10.1172/JCI119510; Li JA, 1997, CIRC RES, V81, P785; Martin C, 1998, AM J OBSTET GYNECOL, V178, P527, DOI 10.1016/S0002-9378(98)70433-8; MAULIK N, 1995, CARDIOVASC RES, V30, P593, DOI 10.1016/0008-6363(95)00093-3; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; PASSANITI A, 1992, LAB INVEST, V67, P519; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sellke FW, 1996, SURGERY, V120, P182, DOI 10.1016/S0039-6060(96)80286-8; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shi JS, 1996, P NATL ACAD SCI USA, V93, P6014, DOI 10.1073/pnas.93.12.6014; SUNDERKOTTER C, 1991, PHARMACOL THERAPEUT, V51, P195, DOI 10.1016/0163-7258(91)90077-Y; Ware JA, 1997, NAT MED, V3, P158, DOI 10.1038/nm0297-158	35	315	368	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2000	6	1					49	55		10.1038/71527	http://dx.doi.org/10.1038/71527			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613823				2022-12-27	WOS:000084583300034
J	Gerber, HP; Vu, TH; Ryan, AM; Kowalski, J; Werb, Z; Ferrara, N				Gerber, HP; Vu, TH; Ryan, AM; Kowalski, J; Werb, Z; Ferrara, N			VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; VASCULAR ENDOTHELIUM; PLATE CARTILAGE; RECEPTOR FLT-1; EXON STRUCTURE; EXPRESSION; CELLS; GENE; CHONDROCYTES	Hypertrophic chondrocytes in the epiphyseal growth plate express the angiogenic protein vascular endothelial growth factor (VEGF). To determine the role of VECF in endochondral bone formation, we inactivated this factor through the systemic administration of a soluble receptor chimeric protein (Flt-(1-3)-IgG) to 24-day-old mice. Blood vessel invasion was almost completely suppressed, concomitant with impaired trabecular bone formation and expansion of hypertrophic chondrocyte zone. Recruitment and/or differentiation of chondroclasts, which express gelatinase B/matrix metalloproteinase-9, and resorption of terminal chondrocytes decreased. Although proliferation, differentiation and maturation of chondrocytes were apparently normal, resorption was inhibited. Cessation of the anti-VEGF treatment was followed by capillary invasion, restoration of bone growth, resorption of the hypertrophic cartilage and normalization of the growth plate architecture. These findings indicate that VEGF-mediated capillary invasion is an essential signal that regulates growth plate morphogenesis and triggers cartilage remodeling. Thus, VECF is an essential coordinator of chandrocyte death, chondroclast function, extracellular matrix remodeling, angiogenesis and bone formation in the growth plate.	Genentech Inc, Dept Cardiovasc Res, S San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Med Ctr, Dept Anat, San Francisco, CA 94143 USA	Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California San Francisco	Ferrara, N (corresponding author), Genentech Inc, Dept Cardiovasc Res, 1 DNA Way, S San Francisco, CA 94080 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03880] Funding Source: Medline; NIDCR NIH HHS [DE10306] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALAKOKKO L, 1990, GENOMICS, V8, P454, DOI 10.1016/0888-7543(90)90031-O; Albrecht U, 1997, MOL CELLULAR METHODS, P23; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Barleon B, 1997, CANCER RES, V57, P5421; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BARNESS LA, 1997, POTTERS PATHOLOGY FE, P561; BARON J, 1994, ENDOCRINOLOGY, V135, P2790, DOI 10.1210/en.135.6.2790; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; ELIMA K, 1993, BIOCHEM J, V289, P247, DOI 10.1042/bj2890247; Enholm B, 1998, TRENDS CARDIOVAS MED, V8, P292, DOI 10.1016/S1050-1738(98)00026-7; FARNUM CE, 1989, AM J ANAT, V186, P346, DOI 10.1002/aja.1001860404; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FINNERTY H, 1993, ONCOGENE, V8, P2293; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Jee W., 1988, CELL TISSUE BIOL TXB, P213; JINGUSHI S, 1995, J ORTHOPAED RES, V13, P761, DOI 10.1002/jor.1100130516; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; LEWINSON D, 1992, ANAT REC, V233, P504, DOI 10.1002/ar.1092330403; MAROTEAUX P, 1984, AM J MED GENET, V19, P171, DOI 10.1002/ajmg.1320190117; METSARANTA M, 1991, BIOCHIM BIOPHYS ACTA, V1089, P241, DOI 10.1016/0167-4781(91)90014-D; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; POOLE AR, 1991, CARTILAGE MOL ASPECT, P179; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115; Schlaeppi JM, 1997, ENDOCR RES, V23, P213, DOI 10.3109/07435809709031855; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEHAN DC, 1980, THEORY PRACTICE HIST; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158; SIMIONESCU N, 1992, ENDOTHELIAL CELL DYS; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WALTNEBERGER J, 1994, J BIOL CHEM, V268, P26988; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	44	1540	1663	4	125	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					623	628		10.1038/9467	http://dx.doi.org/10.1038/9467			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371499				2022-12-27	WOS:000080823300029
J	Reddy, TR; Xu, WD; Mau, JKL; Goodwin, CD; Suhasini, M; Tang, HL; Frimpong, K; Rose, DW; Wong-Staal, F				Reddy, TR; Xu, WD; Mau, JKL; Goodwin, CD; Suhasini, M; Tang, HL; Frimpong, K; Rose, DW; Wong-Staal, F			Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev	NATURE MEDICINE			English	Article							VIRUS TYPE-1 REV; RNA-BINDING PROTEIN; HUMAN T-CELLS; NUCLEAR EXPORT; REGULATORY PROTEINS; ACTIVATION DOMAIN; PROTECTIVE GENE; EXPRESSION; RECEPTOR; MITOSIS	The HIV-1 Rev protein facilitates the nuclear export of mRNA containing the Rev response element (RRE) through binding to the export receptor CRM-1. Here we show that a cellular nuclear protein, Sam68 (Src-associated protein in mitosis), specifically interacts with RRE and can partially substitute for as well as synergize with Rev in RRE-mediated gene expression and virus replication. Differential sensitivity to leptomycin B, an inhibitor of CRM-1, indicates that the export pathways mediated by Rev and Sam68 are distinct. C-terminally deleted mutants of Sam68 inhibited the transactivation of RRE-mediated expression by both wild-type Sam68 and Rev. They were retained in the cytoplasm and impeded the nuclear localization of Rev in coexpressed cells. These mutants also inhibited wild-type HIV-1 replication to the same extent as the RevM 10 mutant, and may be useful as anti-viral agents in the treatment of AIDS.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Whittier Diabetes Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Vet Med Res Fdn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Veterans Medical Research Foundation	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.		Tang, Hengli/F-2085-2014; Williamson, James R/B-2891-2009	Williamson, James R/0000-0002-8772-468X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056089] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [P30AI 36214-06] Funding Source: Medline; NIGMS NIH HHS [GM056089] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Chen TR, 1997, IEEE PHOTONIC TECH L, V9, P17, DOI 10.1109/68.554156; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Diaz JJ, 1996, NATURE, V379, P273, DOI 10.1038/379273a0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES DR, 1995, PHYSIOL ZOOL, V68, P9, DOI 10.1086/physzool.68.4.30166356; Junker U, 1998, HUM GENE THER, V9, P333, DOI 10.1089/hum.1998.9.3-333; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MYER BE, 1994, GENE DEV, V8, P1538; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Powell DM, 1997, P NATL ACAD SCI USA, V94, P973, DOI 10.1073/pnas.94.3.973; Ranga U, 1998, P NATL ACAD SCI USA, V95, P1201, DOI 10.1073/pnas.95.3.1201; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WOFFENDIN C, 1994, P NATL ACAD SCI USA, V91, P11581, DOI 10.1073/pnas.91.24.11581; Woffendin C, 1996, P NATL ACAD SCI USA, V93, P2889, DOI 10.1073/pnas.93.7.2889; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xu Yuan, 1996, Journal of Biomedical Science, V3, P82, DOI 10.1007/BF02255535; YU M, 1994, GENE THER, V1, P13	39	131	139	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					635	642		10.1038/9479	http://dx.doi.org/10.1038/9479			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371501				2022-12-27	WOS:000080823300031
J	Sawa, T; Yahr, TL; Ohara, M; Kurahashi, K; Gropper, MA; Wiener-Kronish, JP; Frank, DW				Sawa, T; Yahr, TL; Ohara, M; Kurahashi, K; Gropper, MA; Wiener-Kronish, JP; Frank, DW			Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury	NATURE MEDICINE			English	Article							AERUGINOSA EXOENZYME-S; YERSINIA YOP VIRULON; FUSION PEPTIDE; SECRETION SYSTEMS; EUKARYOTIC CELLS; ADP-RIBOSYLATES; STRUCTURAL GENE; PESTIS; CYTOTOXICITY; VIRULENCE	Pseudomonas aeruginosa is an opportunistic bacterial pathogen that can cause fatal acute lung infections in critically ill individuals. Damage to the lung epithelium is associated with the expression of toxins that are directly injected into eukaryotic cells through a type Ill-mediated secretion and translocation mechanism. Here we show that the P. aeruginosa homolog of the Yersinia V antigen, PcrV, is involved in the translocation of type III toxins. Vaccination against PcrV ensured the survival of challenged mice and decreased lung inflammation and injury. Antibodies to PcrV inhibited the translocation of type III toxins.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Medical College of Wisconsin; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Dartmouth College	Frank, DW (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Planck Rd, Milwaukee, WI 53226 USA.	frankd@mcw.edu	Kurahashi, Kiyoyasu/AAE-9806-2021	Yahr, Timothy/0000-0001-9054-8704				AIDI Y, 1990, J IMMUNOL METHODS, V132, P191; Anderson GW, 1996, INFECT IMMUN, V64, P4580, DOI 10.1128/IAI.64.11.4580-4585.1996; APODACA G, 1995, INFECT IMMUN, V63, P1541, DOI 10.1128/IAI.63.4.1541-1551.1995; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; Cornelis GR, 1998, J BACTERIOL, V180, P5495, DOI 10.1128/JB.180.21.5495-5504.1998; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; FALLMAN M, 1995, INFECT IMMUN, V63, P3117; FinckBarbancon V, 1997, MOL MICROBIOL, V25, P547, DOI 10.1046/j.1365-2958.1997.4891851.x; Fleiszig SMJ, 1997, INFECT IMMUN, V65, P579, DOI 10.1128/IAI.65.2.579-586.1997; FRANK DW, 1994, INFECT IMMUN, V62, P554, DOI 10.1128/IAI.62.2.554-563.1994; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; Frithz-Lindsten E, 1998, MOL MICROBIOL, V29, P1155, DOI 10.1046/j.1365-2958.1998.00994.x; FrithzLindsten E, 1997, MOL MICROBIOL, V25, P1125, DOI 10.1046/j.1365-2958.1997.5411905.x; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; Hauser AR, 1998, MOL MICROBIOL, V27, P807, DOI 10.1046/j.1365-2958.1998.00727.x; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Knight DA, 1997, INFECT IMMUN, V65, P3304, DOI 10.1128/IAI.65.8.3304-3309.1997; KUDOH I, 1994, AM J PHYSIOL-LUNG C, V267, P551; KULICH SM, 1994, J BIOL CHEM, V269, P10431; LEARY SEC, 1995, INFECT IMMUN, V63, P2854, DOI 10.1128/IAI.63.8.2854-2858.1995; Lee CA, 1997, TRENDS MICROBIOL, V5, P148, DOI 10.1016/S0966-842X(97)01029-9; MOTIN VL, 1994, INFECT IMMUN, V62, P4192, DOI 10.1128/IAI.62.10.4192-4201.1994; NAKAJIMA R, 1995, INFECT IMMUN, V63, P3021, DOI 10.1128/IAI.63.8.3021-3029.1995; Nedialkov YA, 1997, INFECT IMMUN, V65, P1196, DOI 10.1128/IAI.65.4.1196-1203.1997; Nilles ML, 1998, J BACTERIOL, V180, P3410, DOI 10.1128/JB.180.13.3410-3420.1998; Sarker MR, 1998, J BACTERIOL, V180, P1207, DOI 10.1128/JB.180.5.1207-1214.1998; Sawa T, 1998, INFECT IMMUN, V66, P3242, DOI 10.1128/IAI.66.7.3242-3249.1998; Sawa T, 1997, J IMMUNOL, V159, P2858; SCHWEIZER HP, 1992, MOL MICROBIOL, V6, P1195, DOI 10.1111/j.1365-2958.1992.tb01558.x; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; SKRZYPEK E, 1995, J BACTERIOL, V177, P2530, DOI 10.1128/jb.177.9.2530-2542.1995; Vallis AJ, 1999, INFECT IMMUN, V67, P914, DOI 10.1128/IAI.67.2.914-920.1999; VALLIS AJ, IN PRESS INFECT IMMU; Welkos S, 1998, MICROB PATHOGENESIS, V24, P185, DOI 10.1006/mpat.1997.0188; YAHR TL, 1995, J BACTERIOL, V177, P1169, DOI 10.1128/jb.177.5.1169-1178.1995; Yahr TL, 1996, MOL MICROBIOL, V22, P991, DOI 10.1046/j.1365-2958.1996.01554.x; Yahr TL, 1996, J BACTERIOL, V178, P1412, DOI 10.1128/jb.178.5.1412-1419.1996; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yahr TL, 1997, J BACTERIOL, V179, P7165, DOI 10.1128/jb.179.22.7165-7168.1997	40	283	301	2	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					392	398		10.1038/7391	http://dx.doi.org/10.1038/7391			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202927				2022-12-27	WOS:000079574300027
J	Horwitz, EM; Prockop, DJ; Fitzpatrick, LA; Koo, WWK; Gordon, PL; Neel, M; Sussman, M; Orchard, P; Marx, JC; Pyeritz, RE; Brenner, MK				Horwitz, EM; Prockop, DJ; Fitzpatrick, LA; Koo, WWK; Gordon, PL; Neel, M; Sussman, M; Orchard, P; Marx, JC; Pyeritz, RE; Brenner, MK			Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta	NATURE MEDICINE			English	Article							MALIGNANT OSTEOPETROSIS; GENE-THERAPY; EXPRESSION; GROWTH; REPAIR; MICE	In principle, transplantation of mesenchymal progenitor cells would attenuate or possibly correct genetic disorders of bone, cartilage and muscle, but clinical support for this concept is lacking. Here we describe the initial results of allogeneic bone marrow transplantation in three children with osteogenesis imperfecta, a genetic disorder in which osteoblasts produce defective type I collagen, leading to osteopenia, multiple fractures, severe bony deformities and considerably shortened stature. Three months after osteoblast engraftment (1.5-2.0% donor cells), representative specimens of trabecular bone showed histologic changes indicative of new dense bone formation. All patients had increases in total body bone mineral content ranging from 21 to 29 grams (median, 28), compared with predicted values of 0 to 4 grams (median, 0) for healthy children with similar changes in weight. These improvements were associated with increases in growth velocity and reduced frequencies of bone fracture. Thus, allogeneic bone marrow transplantation can lead to engraftment of functional mesenchymal progenitor cells, indicating the feasibility of this strategy in the treatment of osteogenesis imperfecta and perhaps other mesenchymal stem cell disorders as well.	St Jude Childrens Res Hosp, Cell & Gene Therapy Program, Memphis, TN 38105 USA; Allegheny Univ Hlth Sci, Philadelphia, PA 19102 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Wayne State Univ, Detroit, MI 48201 USA; Shriners Hosp Children, Portland, OR 97201 USA; Univ Minnesota, Minneapolis, MN 55455 USA	St Jude Children's Research Hospital; Drexel University; Mayo Clinic; Wayne State University; University of Minnesota System; University of Minnesota Twin Cities	Horwitz, EM (corresponding author), St Jude Childrens Res Hosp, Cell & Gene Therapy Program, 332 N Lauderdale St, Memphis, TN 38105 USA.		Lima, Thaísa/AAG-6483-2021; Koo, Winston/Q-5251-2017; Pyeritz, Reed/A-1364-2010; Brenner, Malcolm/Y-2509-2019	Koo, Winston/0000-0002-0428-6603; 	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003266] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [K08 HL 03266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aubin Jane E., 1996, P51; BLAZAR BR, 1985, TRANSPLANTATION, V39, P597, DOI 10.1097/00007890-198506000-00004; BYERS PH, 1995, METABOLIC MOL BASES, P4029; COCCIA PF, 1980, NEW ENGL J MED, V302, P701, DOI 10.1056/NEJM198003273021301; CONSTANTINOU CD, 1990, AM J HUM GENET, V47, P670; Fedde K. N., 1996, American Journal of Human Genetics, V59, pA15; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FROST HM, 1973, ORTHOPEDIC LECT, V3, P59; Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402; GOSHIMA J, 1991, CLIN ORTHOP RELAT R, P298; GROWCHOW LB, 1993, SEMIN ONCOL S4, V20, P18; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HARTMANN O, 1986, J CLIN ONCOL, V4, P1804, DOI 10.1200/JCO.1986.4.12.1804; HOU Z, 1997, J BONE MINER RES, pS428; JETT S, 1966, ARCH PATHOL, V81, P112; KOO WWK, 1995, J BONE MINER RES, V10, P1111; Koo WWK, 1998, J AM COLL NUTR, V17, P65, DOI 10.1080/07315724.1998.10720457; Koo WWK, 1996, J BONE MINER RES, V11, P997; Lajeunesse D, 1996, J CLIN INVEST, V98, P1835, DOI 10.1172/JCI118984; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; MARINI JC, 1993, AM J MED GENET, V45, P261, DOI 10.1002/ajmg.1320450223; Marini JC, 1997, JAMA-J AM MED ASSOC, V277, P746, DOI 10.1001/jama.277.9.746; NAKAHARA H, 1991, J ORTHOP RES, V9, P465, DOI 10.1002/jor.1100090402; OHGUSHI H, 1989, ACTA ORTHOP SCAND, V60, P334, DOI 10.3109/17453678909149289; Onyia JE, 1998, J BONE MINER RES, V13, P20, DOI 10.1359/jbmr.1998.13.1.20; PARSONS V, 1980, COLOR ATLAS BONE DIS, P85; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; SANDVOSS G, 1986, NEUROCHIRURGIA, V29, P1; SILLENCE DO, 1997, PRINCIPLES PRACTICE, P2779; SOKOLOV BP, 1993, BIOCHEMISTRY-US, V32, P9242, DOI 10.1021/bi00086a033; Teitelbaum SL, 1997, J LEUKOCYTE BIOL, V61, P381, DOI 10.1002/jlb.61.4.381; Triffitt James T., 1996, P39	36	1399	1530	6	127	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					309	313		10.1038/6529	http://dx.doi.org/10.1038/6529			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086387				2022-12-27	WOS:000078851600036
J	Plymale, DR; Haskins, JR; de la Iglesia, FA				Plymale, DR; Haskins, JR; de la Iglesia, FA			Monitoring simultaneous subcellular events in vitro by means of coherent multiprobe fluorescence	NATURE MEDICINE			English	Article							LIGHT-MICROSCOPY; CELL-DEATH; MITOCHONDRIAL; PHALLOIDIN; APOPTOSIS; DYNAMICS; ACTIN		Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Pathol & Expt Toxicol Dept, Ann Arbor, MI 48105 USA	Pfizer	de la Iglesia, FA (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Pathol & Expt Toxicol Dept, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	Felix.DeLaIglesia@wl.com						BERRIDGE MJ, 1997, J PHYSL, V499, P297; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CORNUT I, 1993, AMPHIPATHIC HELIX, P174; FARKAS DL, 1993, ANNU REV PHYSIOL, V55, P785, DOI 10.1146/annurev.physiol.55.1.785; FEUER G, 1996, DRUG INDUCED HEPATOT, V121, P46; GARINI Y, 1996, CHEM ANAL SERIES MON, V137, P87; Garner DL, 1997, BIOL REPROD, V57, P1401, DOI 10.1095/biolreprod57.6.1401; Giuliano KA, 1998, TECH MOD B, P53; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JOHNSON LV, 1981, J CELL BIOL, V88, P526, DOI 10.1083/jcb.88.3.526; MIKI M, 1987, EUR J BIOCHEM, V165, P125, DOI 10.1111/j.1432-1033.1987.tb11202.x; Monteith DK, 1998, ARCH TOXICOL, V72, P147, DOI 10.1007/s002040050481; PLYMALE DR, IN PRESS J APPL TOXI; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; SchulteHermann R, 1997, CELL BIOL TOXICOL, V13, P339, DOI 10.1023/A:1007495626864; SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0; TAYLOR DL, 1994, TOXICOL PATHOL, V22, P145, DOI 10.1177/019262339402200208; Taylor DL, 1997, ANN NY ACAD SCI, V820, P208, DOI 10.1111/j.1749-6632.1997.tb46197.x; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; Wachman ES, 1997, BIOPHYS J, V73, P1215, DOI 10.1016/S0006-3495(97)78154-2; Waggoner A, 1996, HUM PATHOL, V27, P494, DOI 10.1016/S0046-8177(96)90092-1; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572	22	17	20	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					351	355		10.1038/6574	http://dx.doi.org/10.1038/6574			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086396				2022-12-27	WOS:000078851600045
J	Bossi, G; Griffiths, GM				Bossi, G; Griffiths, GM			Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells	NATURE MEDICINE			English	Article							SECRETORY LYSOSOMES; LYMPHOCYTES-T; GRANULES; RECEPTOR; ANTIGEN; CYTOTOXICITY; ACTIVATION; MECHANISM; PERFORIN; RELEASE	Fas ligand (FasL) triggers apoptosis during cytotoxicity mediated by cytotoxic T lymphocytes and during immune downregulation(1). The ability of T cells and natural killer cells to trigger apoptosis through this mechanism is controlled by the cell surface expression of Fast (ref. 2). Because Fast expression is upregulated on activation(2,3), Fast was thought to be delivered directly to the cell surface. Here we show that newly synthesized Fast is stored in specialized secretory lysosomes in both CD4(+) and CD8(+) T cells and natural killer cells, and that polarized degranulation controls the delivery of Fast to the cell surface. In this way, Fast-mediated apoptosis is finely controlled by receptor-mediated target-cell recognition. The cytoplasmic tail of Fast contains signals that sort Fast to secretory lysosomes in hemopoietic cells. This pathway may provide a general mechanism for controlling the cell surface appearance of proteins involved in immune regulation.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Griffiths, GM (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.			Griffiths, Gillian/0000-0003-0434-5842	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffiths G M, 1997, Semin Immunol, V9, P109, DOI 10.1006/smim.1997.0059; Griffiths GM, 1996, TRENDS CELL BIOL, V6, P329, DOI 10.1016/0962-8924(96)20031-5; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; ISAAZ S, 1995, EUR J IMMUNOL, V25, P1071, DOI 10.1002/eji.1830250432; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kiener PA, 1997, J IMMUNOL, V159, P1594; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MONTEL AH, 1995, CELL IMMUNOL, V166, P236, DOI 10.1006/cimm.1995.9974; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; SHIVER JW, 1991, CELL, V64, P1175, DOI 10.1016/0092-8674(91)90272-Z; STOKES TA, 1998, SCIENCE, V279, P2015; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAYAMA H, 1987, J EXP MED, V166, P725, DOI 10.1084/jem.166.3.725; Uellner R, 1997, EMBO J, V16, P7287, DOI 10.1093/emboj/16.24.7287; Valitutti S, 1996, J EXP MED, V183, P1917, DOI 10.1084/jem.183.4.1917; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; YODOI J, 1985, J IMMUNOL, V134, P1623; ZIEGLER SF, 1993, EUR J IMMUNOL, V23, P1643, DOI 10.1002/eji.1830230737	26	311	317	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					90	96		10.1038/4779	http://dx.doi.org/10.1038/4779			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883845				2022-12-27	WOS:000077885000035
J	Gurunathan, S; Prussin, C; Sacks, DL; Seder, RA				Gurunathan, S; Prussin, C; Sacks, DL; Seder, RA			Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection	NATURE MEDICINE			English	Article							LEISHMANIA-MAJOR INFECTION; INTERFERON-GAMMA PRODUCTION; CD4(+) T-CELLS; BALB/C MICE; INTERLEUKIN-12; IL-12; DNA; RESPONSES; ANTIGEN; RESISTANCE	The humoral immunity induced by many viral and bacterial vaccines mediates protection that is maintained over a long period of time. In contrast, for other intracellular infections (such as with Leishmania major or Mycobacterium tuberculosis) for which cell-mediated immunity is required for protection, the mechanisms for developing durable responses after vaccination have not been well defined. Here we demonstrate that vaccination with plasmid DNA encoding a specific leishmanial antigen is more effective than leishmanial protein plus recombinant IL-12 in eliciting long-term immunity capable of controlling L. major infection. We also show that leishmanial protein plus IL-12 DNA produces an immunity that lasts much longer than does immunity elicited by leishmanial protein plus IL-12 protein, indicating that the persistence of IL-12 may be the essential determinant in maintaining durable cell-mediated immune responses for an intracellular parasitic infection.	NIH, Bethesda, MD 20892 USA; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Seder, RA (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.	rseder@nih.gov		Prussin, Calman/0000-0002-3917-3326				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; Behr MA, 1997, NATURE, V389, P133, DOI 10.1038/38151; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; CLERICI M, 1994, P NATL ACAD SCI USA, V91, P11811, DOI 10.1073/pnas.91.25.11811; Conceicao-Silva F, 1998, EUR J IMMUNOL, V28, P237, DOI 10.1002/(SICI)1521-4141(199801)28:01&lt;237::AID-IMMU237&gt;3.0.CO;2-O; DACONCEICAOSILVA F, 1994, EUR J IMMUNOL, V24, P2813, DOI 10.1002/eji.1830241135; Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HuLi J, 1997, P NATL ACAD SCI USA, V94, P3189, DOI 10.1073/pnas.94.7.3189; Jankovic D, 1997, J IMMUNOL, V159, P2409; Julia V, 1996, SCIENCE, V274, P421, DOI 10.1126/science.274.5286.421; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Launois P, 1997, J IMMUNOL, V158, P3317; Launois P, 1997, IMMUNITY, V6, P541, DOI 10.1016/S1074-7613(00)80342-8; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MA X, 1996, J EXP MED, V183; Marth T, 1996, J IMMUNOL, V157, P2348; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; MULLER I, 1991, INT IMMUNOL, V3, P587, DOI 10.1093/intimm/3.6.587; MULLER I, 1993, INFECT IMMUN, V61, P3730; MURPHY EE, 1994, J EXP MED, V180, P223, DOI 10.1084/jem.180.1.223; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; SCHARTONKERSTEN T, 1995, J IMMUNOL, V154, P5320; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Seder RA, 1996, J IMMUNOL, V157, P2745; STEFANI MMA, 1994, EUR J IMMUNOL, V24, P746, DOI 10.1002/eji.1830240338; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; Zimmermann S, 1998, J IMMUNOL, V160, P3627	32	190	201	1	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1409	1415		10.1038/4000	http://dx.doi.org/10.1038/4000			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846579				2022-12-27	WOS:000077336900037
J	Zhang, D; Gaussin, V; Taffet, GE; Belaguli, NS; Yamada, M; Schwartz, RJ; Michael, LH; Overbeek, PA; Schneider, MD				Zhang, D; Gaussin, V; Taffet, GE; Belaguli, NS; Yamada, M; Schwartz, RJ; Michael, LH; Overbeek, PA; Schneider, MD			TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice	NATURE MEDICINE			English	Article							SERUM RESPONSE FACTOR; ALPHA-ACTIN GENE; RAT CARDIAC MYOCYTES; KINASE CASCADE; VENTRICULAR MYOCYTES; SIGNAL-TRANSDUCTION; MECHANICAL-STRESS; IN-VIVO; PROTEIN; EXPRESSION	The transforming-growth-factor-beta-activated kinase TAK1 is a member of the mitogen-activated protein kinase kinase kinase family, which couples extracellular stimuli to gene transcription. The in vivo function of TAK1 is not understood. Here, we investigated the potential involvement of TAK1 in cardiac hypertrophy. In adult mouse myocardium, TAK1 kinase activity was upregulated 7 days after aortic banding, a mechanical load that induces hypertrophy and expression of transforming growth factor beta. An activating mutation of TAK1 expressed in myocardium of transgenic mice was sufficient to produce p38 mitogen-activated protein kinase phosphorylation in vivo, cardiac hypertrophy, interstitial fibrosis, severe myocardial dysfunction, 'fetal' gene induction, apoptosis and early lethality. Thus, TAK1 activity is induced as a delayed response to mechanical stress, and can suffice to elicit myocardial hypertrophy and fulminant heart failure.	Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, DeBakey Heart Ctr Grad Program Cardiovasc Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Schneider, MD (corresponding author), Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA.			Schneider, Michael/0000-0001-9645-1938; Overbeek, Paul/0000-0001-9784-2084				ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Charng MJ, 1998, DEV BIOL, V199, P72, DOI 10.1006/dbio.1998.8905; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Georgakopoulos D, 1999, NAT MED, V5, P327, DOI 10.1038/6549; HARTLEY CJ, 1995, AM J PHYSIOL-HEART C, V268, pH499, DOI 10.1152/ajpheart.1995.268.1.H499; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; Kapadia SR, 1997, CIRC RES, V81, P187, DOI 10.1161/01.RES.81.2.187; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; MACLELLAN WR, 1998, CARDIAC DEV, P405; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RINDT H, 1993, J BIOL CHEM, V268, P5332; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shioi T, 1997, CIRC RES, V81, P664; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	45	273	288	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					556	563		10.1038/75037	http://dx.doi.org/10.1038/75037			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802712				2022-12-27	WOS:000086796200040
J	Krause, PR; Klinman, DM				Krause, PR; Klinman, DM			Varicella vaccination: Evidence for frequent reactivation of the vaccine strain in healthy children	NATURE MEDICINE			English	Article							ZOSTER VIRUS-INFECTIONS; FOLLOW-UP; EFFICACY; IMMUNIZATION; EPIDEMIOLOGY; CHICKENPOX; IMMUNITY	Wild-type varicella tester virus (VZV) causes chickenpox, a common childhood illness characterized by fever and a vesicular rash(1) and rare serious complications'. Wild-type VZV persists in a latent form in the sensory ganglia, and can re-activate to cause herpes zoster(3). More than 10 million American children have received the live attenuated Oka strain VZV vaccine (OkaVZV) since its licensure in 1995. Pre-licensure clinical studies showed that mean serum anti-VZV levels among vaccinees continued to increase with time after vaccination. This was attributed to immunologic boosting caused by exposure to wild-type VZV in the community(4,5). Here, we examine the alternative, that large-scale asymptomatic reactivation of OkaVZV might occur in vaccinees. We analyzed serum antibody levels and infection rates for 4 years of follow-up in 4,631 children immunized with OkaVZV. Anti-VZV titers decreased over time in high-responder subjects, but rose in vaccinees with low titers. Among subjects with low anti-VZV titers, the frequency of clinical infection and immunological boosting substantially exceeded the 13%-per-year rate of exposure to wild-type varicella. These findings indicate that OkaVZV persisted in vivo and reactivated as serum antibody titers decreased after vaccination. This has salient consequences for individuals immunized with OkaVZV.	US FDA, Lab DNA Viruses, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; US FDA, Sect Retroviral Res, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Krause, PR (corresponding author), US FDA, Lab DNA Viruses, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.	krause@cber.fda.gov		Krause, Philip/0000-0002-1045-7536				ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200; ASANO Y, 1994, PEDIATRICS, V94, P524; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; BRUNNER U, 1986, APPL GEOGR, V6, P77, DOI 10.1016/0143-6228(86)90030-5; CHOO PW, 1995, J INFECT DIS, V172, P706, DOI 10.1093/infdis/172.3.706; Cohen JI, 1999, ANN INTERN MED, V130, P922, DOI 10.7326/0003-4819-130-11-199906010-00017; COLTON T, 1974, STAT MED, P153; FINGER R, 1994, PUBLIC HEALTH REP, V109, P750; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; KELLER PM, 1986, J VIROL METHODS, V14, P177, DOI 10.1016/0166-0934(86)90048-0; KRAUSE PR, 1995, J PEDIATR-US, V127, P518, DOI 10.1016/S0022-3476(95)70106-0; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LJUNGMAN P, 1986, J INFECT DIS, V153, P840, DOI 10.1093/infdis/153.5.840; LUBY JP, 1977, J INFECT DIS, V135, P659, DOI 10.1093/infdis/135.4.659; *MERCK CO, 1998, PHYS DESK REF, P1762; Schenk LM, 1999, OBSTET GYN CLIN N AM, V26, P1, DOI 10.1016/S0889-8545(05)70054-1; STRAUS SE, 1984, NEW ENGL J MED, V311, P1362, DOI 10.1056/NEJM198411223112107; TOMITA H, 1988, ACTA OTO-LARYNGOL, P10; Varis T, 1996, J INFECT DIS, V174, pS330, DOI 10.1093/infdis/174.Supplement_3.S330; WASMUTH EH, 1990, J MED VIROL, V32, P189, DOI 10.1002/jmv.1890320310; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; Wharton M, 1996, INFECT DIS CLIN N AM, V10, P571, DOI 10.1016/S0891-5520(05)70313-5; WILSON A, 1992, J INFECT DIS, V165, P119, DOI 10.1093/infdis/165.1.119	24	69	76	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2000	6	4					451	454		10.1038/74715	http://dx.doi.org/10.1038/74715			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742154				2022-12-27	WOS:000165474100041
J	Roy, NS; Wang, S; Jiang, L; Kang, J; Benraiss, A; Harrison-Restelli, C; Fraser, RAR; Couldwell, WT; Kawaguchi, A; Okano, H; Nedergaard, M; Goldman, SA				Roy, NS; Wang, S; Jiang, L; Kang, J; Benraiss, A; Harrison-Restelli, C; Fraser, RAR; Couldwell, WT; Kawaguchi, A; Okano, H; Nedergaard, M; Goldman, SA			In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus	NATURE MEDICINE			English	Article							GREEN FLUORESCENT PROTEIN; RAT DENTATE GYRUS; NEURAL STEM-CELLS; GENE-EXPRESSION; TUBULIN PROMOTER; ALPHA-TUBULIN; NEURONS; DIFFERENTIATION; PRECURSORS; ASTROCYTES	Neurogenesis persists in the adult mammalian hippocampus. To identify and isolate neuronal progenitor cells of the adult human hippocampus, we transfected ventricular zone-free dissociates of surgically-excised dentate gyrus with DNA encoding humanized green fluorescent protein (hGFP), placed under the control of either the nestin enhancer (E/nestin) or the T alpha 1 tubulin promoter (P/T alpha 1), two regulatory regions that direct transcription in neural progenitor cells. The resultant P/T alpha 1:hGFP(+) and E/nestin:enhanced (E)GFP(+) cells expressed beta III-tubulin or microtubule-associated protein-2; many incorporated bromodeoxyuridine, indicating their genesis in vitro. Using fluorescence-activated cell sorting, the E/nestin:EGFP(+) and P/T alpha 1:hGFP(+) cells were isolated to near purity, and matured antigenically and physiologically as neurons. Thus, the adult human hippocampus contains mitotically competent neuronal progenitors that can be selectively extracted. The isolation of these cells may provide a cellular substrate for re-populating the damaged or degenerated adult hippocampus.	Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Neurosurg, New York, NY 10021 USA; New York Med Coll, Dept Neurosurg, Valhalla, NY 10585 USA; New York Med Coll, Dept Cell Biol, Valhalla, NY 10585 USA; Osaka Univ, Grad Sch Med, Div Neuroanat, Osaka 5650867, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5650867, Japan	Cornell University; Cornell University; New York Medical College; New York Medical College; Osaka University; Japan Science & Technology Agency (JST)	Goldman, SA (corresponding author), Cornell Univ, Coll Med, Dept Neurol & Neurosci, 1300 York Ave,Room E607, New York, NY 10021 USA.		Okano, Hideyuki/I-7584-2019; Benraiss, Abdellatif/AAI-8584-2021; Kawaguchi, Ayano/I-7286-2014	Benraiss, Abdellatif/0000-0002-0325-6234; Goldman, Steven/0000-0002-5498-4303; Kawaguchi, Ayano/0000-0002-0339-3992	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029813, R01NS033106] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS29813, R01NS33106] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; BARNEA A, 1994, P NATL ACAD SCI USA, V91, P11217, DOI 10.1073/pnas.91.23.11217; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; GOULD E, 1992, J NEUROSCI, V12, P3642; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; KAPLAN SL, 1992, INFECT DIS CLIN N AM, V6, P197; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; LEE WL, 1990, EPILEPSY RES, V6, P87, DOI 10.1016/0920-1211(90)90082-7; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Levy JP, 1996, NAT BIOTECHNOL, V14, P610, DOI 10.1038/nbt0596-610; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; MILLER FD, 1987, J CELL BIOL, V105, P3065, DOI 10.1083/jcb.105.6.3065; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; SONTHEIMER H, 1991, J NEUROSCI RES, V30, P275, DOI 10.1002/jnr.490300202; SONTHEIMER H, 1992, J NEUROPHYSIOL, V68, P985, DOI 10.1152/jn.1992.68.4.985; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; TSE FW, 1992, J NEUROSCI, V12, P1781; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Wang S, 2000, DEV NEUROSCI-BASEL, V22, P167, DOI 10.1159/000017437; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	40	436	485	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					271	277						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700228				2022-12-27	WOS:000085580500036
J	Rouse, R				Rouse, R			Australian universities told to commercialize	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					120	120		10.1038/72189	http://dx.doi.org/10.1038/72189			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655083				2022-12-27	WOS:000085016900013
J	Birmingham, K				Birmingham, K			Rock around the clock	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					981	981		10.1038/12937	http://dx.doi.org/10.1038/12937			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10471269	Bronze			2022-12-27	WOS:000082337200021
J	Lamlum, H; Ilyas, M; Rowan, A; Clark, S; Johnson, V; Bell, J; Frayling, I; Efstathiou, J; Pack, K; Payne, S; Roylance, R; Gorman, P; Sheer, D; Neale, K; Phillips, R; Talbot, I; Bodmer, W; Tomlinson, I				Lamlum, H; Ilyas, M; Rowan, A; Clark, S; Johnson, V; Bell, J; Frayling, I; Efstathiou, J; Pack, K; Payne, S; Roylance, R; Gorman, P; Sheer, D; Neale, K; Phillips, R; Talbot, I; Bodmer, W; Tomlinson, I			The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis	NATURE MEDICINE			English	Article							COLORECTAL TUMORS; DESMOID TUMORS; GENE; COMPLEX; PROTEIN; ALLELES; FAP	APC is often cited as a prime example of a tumor suppressor gene. Truncating germline and somatic mutations (or, infrequently, allelic loss) occur in tumors in FAP (familial adenomatous polyposis). Most sporadic colorectal cancers also have two APC mutations'. Clues from attenuated polyposis(2-4), missense germline variants with mild disease(5,6) and the somatic mutation cluster region (codons 1,250-1,450)(1,7,8) indicate, however, that APC mutations might not result in simple loss of protein function. We have found that FAP patients with germline APC mutations within a small region (codons 1,194-1,392 at most) mainly show allelic loss in their colorectal adenomas, in contrast to other FAP patients, whose 'second hits' tend to occur by truncating mutations in the mutation cluster region. Our results indicate that different APC mutations provide cells with different selective advantages, with mutations close to codon 1,300 providing the greatest advantage. Allelic loss is selected strongly in cells with one mutation near codon 1,300. A different germline-somatic APC mutation association exists in FAP desmoids. APC is not, therefore, a classical tumor suppressor. Our findings also indicate a new mechanism for disease severity: if a broader spectrum of mutations is selected in tumors, the somatic mutation rate is effectively higher and more tumors grow.	Imperial Canc Res Fund, Mol & Populat Genet Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Human Cytogenet Lab, London WC2A 3PX, England; John Radcliffe Hosp, Canc Immunol & Genet Lab, Imperial Canc Res Fund, Inst Mol Med, Oxford OX3 9DZ, England; St Marks & Northwick Pk Hosp NHS Trust, Imperial Canc Res Fund, Colorectal Unit, Harrow HA1 3UJ, Middx, England; St Marks & Northwick Pk Hosp NHS Trust, Kennedy Galton Ctr, Dept Clin Genet, Harrow HA1 3UJ, Middx, England; St Marks & Northwick Pk Hosp NHS Trust, Polyposis Registry, Harrow HA1 3UJ, Middx, England; St Marks & Northwick Pk Hosp NHS Trust, Acad Dept Histopathol, Harrow HA1 3UJ, Middx, England	Cancer Research UK; Cancer Research UK; University of Oxford	Tomlinson, I (corresponding author), Imperial Canc Res Fund, Mol & Populat Genet Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Sheer, Denise/C-6705-2011; Clark, Susan/J-8103-2012	Sheer, Denise/0000-0001-9067-1796; Clark, Susan/0000-0002-6929-8082; Frayling, Ian/0000-0002-3420-0794; Bodmer, Walter/0000-0001-6244-9792	Cancer Research UK [A3585] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Berx G, 1998, CELL ADHES COMMUN, V6, P171, DOI 10.3109/15419069809004474; Biggs PJ, 1996, ONCOGENE, V12, P1375; CASPARI R, 1995, HUM MOL GENET, V4, P337, DOI 10.1093/hmg/4.3.337; Frayling Ian M., 1996, P63; Frayling IM, 1998, P NATL ACAD SCI USA, V95, P10722, DOI 10.1073/pnas.95.18.10722; Friedl W, 1996, HUM GENET, V97, P579; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; HODGSON GS, 1993, ST COMP COM, V5, P369; ICHII S, 1993, ONCOGENE, V8, P2399; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; LUONGO C, 1994, CANCER RES, V54, P5947; MIYAKI M, 1994, CANCER RES, V54, P3011; MIYAKI M, 1993, CANCER RES, V53, P5079; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Novelli MR, 1996, SCIENCE, V272, P1187, DOI 10.1126/science.272.5265.1187; NUGENT KP, 1994, GUT, V35, P1622, DOI 10.1136/gut.35.11.1622; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; Spirio LN, 1998, NAT GENET, V20, P385, DOI 10.1038/3865; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; Wells D, 1999, NUCLEIC ACIDS RES, V27, P1214, DOI 10.1093/nar/27.4.1214; Won YJ, 1999, J HUM GENET, V44, P103, DOI 10.1007/s100380050118	25	276	295	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1071	1075		10.1038/12511	http://dx.doi.org/10.1038/12511			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470088				2022-12-27	WOS:000082337200045
J	Czermak, BJ; Sarma, V; Pierson, CL; Warner, RL; Huber-Lang, M; Bless, NM; Schmal, H; Friedl, HP; Ward, PA				Czermak, BJ; Sarma, V; Pierson, CL; Warner, RL; Huber-Lang, M; Bless, NM; Schmal, H; Friedl, HP; Ward, PA			Protective effects of C5a blockade in sepsis	NATURE MEDICINE			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; INFLAMMATORY RESPONSE SYNDROME; RECEPTOR; COMPLEMENT; ENDOTOXIN; INFECTION; SHOCK; INTERNALIZATION; PHOSPHORYLATION; ANTIBODIES	Sepsis in humans is a difficult condition to treat and is often associated with a high mortality rate. In this study, we induced sepsis in rats using cecal ligation and puncture (CLP). In rats depleted of the complement factor C3, CLP led to very short survival times (about 4 days). Of the rats that underwent CLP ('CLP rats') that were C3-intact and treated with preimmune Igc, most (92%) were dead by 7 days. Blood neutrophils from these rats contained on their surfaces the powerful complement activation product C5a. This group had high levels of bacteremia, and their blood neutrophils when stimulated in vitro had greatly reduced production of H2O2 which is known to be essential for the bactericidal function of neutrophils. In contrast, when companion CLP rats were treated with IgG antibody against C5a, survival rates were significantly improved, levels of bacteremia were considerably reduced, and the H2O2 response of blood neutrophils was preserved. Bacterial colony-forming units in spleen and liver were very high in CLP rats treated with preimmune IgG and very low in CLP rats treated with IgG antibody against C5a, similar to values obtained in rats that underwent 'sham' operations (without CLP). These data indicate that sepsis causes an excessive production of C5a, which compromises the bactericidal function of neutrophils. Thus, C5a may be a useful target for the treatment of sepsis.	Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA; Univ Freiburg, Sch Med, Dept Trauma Surg, D-79106 Freiburg, Germany	University of Michigan System; University of Michigan; University of Freiburg	Ward, PA (corresponding author), Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA.		Huber-Lang, Markus/AAJ-2209-2020; Schmal, Hagen/B-2684-2016	Schmal, Hagen/0000-0002-8801-2385				ALEXANDER JW, 1979, SURGER, V86, P84; Bock D, 1997, EUR J IMMUNOL, V27, P1522, DOI 10.1002/eji.1830270631; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BORDER JR, 1987, ANN SURG, V206, P427, DOI 10.1097/00000658-198710000-00004; Czermak BJ, 1999, AM J PATHOL, V154, P1057, DOI 10.1016/S0002-9440(10)65358-8; Deitch EA, 1997, SHOCK, V9, P1; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; ELSBACH P, 1985, IMMUNOL LETT, V11, P159, DOI 10.1016/0165-2478(85)90163-4; Fischer MB, 1997, J IMMUNOL, V159, P976; GIANNINI E, 1995, J IMMUNOL, V154, P4055; HILL JH, 1971, J EXP MED, V133, P885, DOI 10.1084/jem.133.4.885; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; JOHNSON KJ, 1971, J IMMUNOL, V106, P1125; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; KOEHL J, 1993, ANAPHYLOTOXINS COMPL, P299; KUBENS BS, 1988, COMPLEMENT SYSTEM, P469; MAY JE, 1972, J IMMUNOL, V109, P893; Mohr M, 1998, EUR J CLIN INVEST, V28, P227; Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818; Naik N, 1997, J CELL SCI, V110, P2381; Nakae H, 1996, SURG TODAY, V26, P225, DOI 10.1007/BF00311579; NICHOLS RL, 1984, NEW ENGL J MED, V311, P1065, DOI 10.1056/NEJM198410253111701; OLSON LM, 1985, ANN SURG, V202, P771, DOI 10.1097/00000658-198512000-00018; QUEZADO ZMN, 1994, J EXP MED, V179, P569, DOI 10.1084/jem.179.2.569; Rothermel E, 1997, BBA-GENE STRUCT EXPR, V1351, P9, DOI 10.1016/S0167-4781(97)00006-7; SCHUMACHER WA, 1991, AGENTS ACTIONS, V34, P345, DOI 10.1007/BF01988727; SOLOMKIN JS, 1981, SURGERY, V90, P319; STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506; VANEPPS DE, 1993, J IMMUNOL, V150, P246; VANEPPS DE, 1990, J IMMUNOL, V144, P1062; WARD PA, 1968, J EXP MED, V127, P693, DOI 10.1084/jem.127.4.693; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2	33	303	333	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					788	792		10.1038/10512	http://dx.doi.org/10.1038/10512			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395324				2022-12-27	WOS:000081926600034
J	May, A; Ashburner, J; Buchel, C; McGonigle, DJ; Friston, KJ; Frackowiak, RSJ; Goadsby, PJ				May, A; Ashburner, J; Buchel, C; McGonigle, DJ; Friston, KJ; Frackowiak, RSJ; Goadsby, PJ			Correlation between structural and functional changes in brain in an idiopathic headache syndrome	NATURE MEDICINE			English	Article							CLUSTER HEADACHE	Fundamental to the concept of idiopathic or primary headache, including migraine, tension-type headache and cluster headache, is the currently accepted view that these conditions are due to abnormal brain function with completely normal brain structure(1). Cluster headache is one such idiopathic headache with many similarities to migraine, including normal brain structure on magnetic resonance imaging and abnormal function in the hypothalamic grey matter by positron emission tomography(2). Given the consistency of the positron emission tomography findings with the clinical presentation, we sought to assess whether the brains of such patients were structurally normal. We used voxel-based morphometry, an objective and automated method of analyzing changes in brain structure, to study the structure of the brains of patients with cluster headache. We found a co-localization of structural changes and changes in local brain activity with positron emission tomography in the same area of the brain in the same patients. The results indicate that the current view of the neurobiology of cluster headache requires complete revision and that this periodic headache is associated with a hitherto unrecognized brain abnormality in the hypothalamic region. We believe that voxel-based morphometry has the potential to change in the most fundamental way our concept of primary headache disorders, requiring a radical reappraisal of the tenet of structural normality.	UCL Natl Hosp Neurol & Neurosurg, Univ Dept Clin Neurol, Neurol Inst, London, England; UCL Natl Hosp Neurol & Neurosurg, Wellcome Dept Cognit Neurol, Neurol Inst, London, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Goadsby, PJ (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Univ Dept Clin Neurol, Neurol Inst, Queen Sq, London, England.	peterg@ion.ucl.ac.uk	McGonigle, David/Q-2166-2019; Frackowiak, Richard/H-4383-2011; Frackowiak, Richard S/I-1809-2013; Friston, Karl/D-9230-2011; Goadsby, Peter J/B-2267-2009; Ashburner, John/I-3757-2013; Goadsby, Peter J/Z-1970-2019; McGonigle, David/A-2760-2009	McGonigle, David/0000-0001-9595-6352; Frackowiak, Richard/0000-0002-3151-822X; Friston, Karl/0000-0001-7984-8909; Ashburner, John/0000-0001-7605-2518; Goadsby, Peter J/0000-0003-3260-5904; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Ashburner J, 1997, NEUROIMAGE, V6, P344, DOI 10.1006/nimg.1997.0299; ASHBURNER J, IN PRESS NEUROIMAGE; EVANS AC, 1994, NATO ADV SCI INST SE, V264, P263; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; ISLER H, 1993, CEPHALALGIA, V13, P172, DOI 10.1046/j.1468-2982.1993.1303172.x; Lance JW, 1998, MECH MANAGEMENT HEAD; LEONE M, 1990, CEPHALALGIA, V10, P235, DOI 10.1046/j.1468-2982.1990.1005235.x; May A, 1998, LANCET, V352, P275, DOI 10.1016/S0140-6736(98)02470-2; May A, 1998, CURR OPIN NEUROL, V11, P199, DOI 10.1097/00019052-199806000-00002; Sjaastad O., 1992, CLUSTER HEADACHE SYN; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TFELTHANSEN P, 1982, CEPHALALGIA, V2, P25, DOI 10.1046/j.1468-2982.1982.0201025.x; Wright IC, 1995, NEUROIMAGE, V2, P244, DOI 10.1006/nimg.1995.1032	14	395	399	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1999	5	7					836	838		10.1038/10561	http://dx.doi.org/10.1038/10561			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395332				2022-12-27	WOS:000081926600042
J	Roy, K; Mao, HQ; Huang, SK; Leong, KW				Roy, K; Mao, HQ; Huang, SK; Leong, KW			Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy	NATURE MEDICINE			English	Article							CHOLERA-TOXIN; IN-VIVO; DRUG-DELIVERY; IGE ANTIBODY; IMMUNIZATION; INDUCTION; ANAPHYLAXIS; ABSORPTION; INHIBITION; IMMUNITY	Food allergy is a common and often fatal disease with no effective treatment. We describe here a new immunoprophylactic strategy using oral allergen-gene immunization to modulate peanut antigen-induced murine anaphylactic responses. Oral administration of DNA nanoparticles synthesized by complexing plasmid DNA with chitosan, a natural biocompatible polysaccharide, resulted in transduced gene expression in the intestinal epithelium. Mice receiving nanoparticles containing a dominant peanut allergen gene (pCMVArah2) produced secretory IgA and serum lgG2a. Compared with non-immunized mice or mice treated with 'naked' DNA, mice immunized with nanoparticles showed a substantial reduction in allergen-induced anaphylaxis associated with reduced levels of IgE, plasma histamine and vascular leakage. These results demonstrate that oral allergen-gene immunization with chitosan-DNA nanoparticles is effective in modulating murine anaphylactic responses, and indicate its prophylactic utility in treating food allergy.	Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Dept Med, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Leong, KW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.		Leong, Kam W/A-7270-2009; Huang, Shau-Ku/F-5509-2010	Leong, Kam W/0000-0002-8133-4955; Mao, Hai-Quan/0000-0002-4262-9988	NATIONAL CANCER INSTITUTE [R01CA068011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040274, R29AI034002] Funding Source: NIH RePORTER; NCI NIH HHS [CA68011] Funding Source: Medline; NIAID NIH HHS [AI40274, AI34002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai K., 1968, B TOKAI REG FISH LAB, V56, P889; ARTURSSON P, 1994, PHARMACEUT RES, V11, P1358, DOI 10.1023/A:1018967116988; Aspden TJ, 1997, J PHARM SCI, V86, P509, DOI 10.1021/js960182o; Bernkop-Schnurch A, 1998, J CONTROL RELEASE, V50, P215, DOI 10.1016/S0168-3659(97)00136-3; BODMEIER R, 1989, PHARMACEUT RES, V6, P413, DOI 10.1023/A:1015987516796; Chen SC, 1998, J VIROL, V72, P5757, DOI 10.1128/JVI.72.7.5757-5761.1998; During MJ, 1998, NAT MED, V4, P1131, DOI 10.1038/2625; Etchart N, 1997, J GEN VIROL, V78, P1577, DOI 10.1099/0022-1317-78-7-1577; Ferrari F, 1997, FARMACO, V52, P493; Hsu CH, 1996, INT IMMUNOL, V8, P1405, DOI 10.1093/intimm/8.9.1405; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; ILLUM L, 1994, PHARMACEUT RES, V11, P1186, DOI 10.1023/A:1018901302450; KANAUCHI O, 1994, BIOSCI BIOTECH BIOCH, V58, P1617, DOI 10.1271/bbb.58.1617; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Lee WY, 1998, ARZNEIMITTELFORSCH, V48, P300; Leong KW, 1998, J CONTROL RELEASE, V53, P183, DOI 10.1016/S0168-3659(97)00252-6; LYCKE N, 1990, J IMMUNOL, V145, P3316; MAEZAKI Y, 1993, BIOSCI BIOTECH BIOCH, V57, P1439, DOI 10.1271/bbb.57.1439; MIYAZAKI S, 1994, BIOL PHARM BULL, V17, P745; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; ROY K, 1997, 24 INT S CONTR REL B, V24, P673; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SNIDER DP, 1994, J IMMUNOL, V153, P647; STROBER W, 1994, IMMUNOLOGY, P541; TAKEUCHI H, 1994, CHEM PHARM BULL, V42, P1954; Tozaki H, 1997, J PHARM SCI, V86, P1016, DOI 10.1021/js970018g; Ulmer J B, 1997, Behring Inst Mitt, P79; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG QF, 1997, J ALLERGY CLIN IMMUN, V99, P480; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	35	929	1012	5	206	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					387	391		10.1038/7385	http://dx.doi.org/10.1038/7385			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202926				2022-12-27	WOS:000079574300026
J	Gerdts, V; Babiuk, LA; Littel-van den Hurk, SV; Griebel, PJ				Gerdts, V; Babiuk, LA; Littel-van den Hurk, SV; Griebel, PJ			Fetal immunization by a DNA vaccine delivered into the oral cavity	NATURE MEDICINE			English	Article							NEONATAL TOLERANCE; INDUCTION; INFANTS; VIRUS	Infectious diseases are the main cause of neonatal morbidity and mortality in humans. The World Health Organization estimated that in 1995 approximately 8 million infants died within the first year of life from infectious diseases, including 5 million during the first week of life. Some of the salient pathogens involved include herpes simplex virus, human immunodeficiency virus, hepatitis B virus, human cytomegalovirus, group B streptococcus, hemophilus and chlamydia(1,2). Infection with these pathogens usually occurs at the end of pregnancy, during birth or by breastfeeding. To reduce the risk of disease transmission, caesarian sections, prophylactic treatment with antibiotics or maternal antiviral therapy during the last trimester are used where available, together with improved neonatal care. None of these approaches, however, completely eliminates the risk of neonatal infection. Therefore, active or passive immunization of the fetus might represent an effective approach to reduce the high risk of neonatal diseases. Here, we demonstrate that a single immunization with a DNA vaccine delivered into the amniotic fluid in the oral cavity induces high serum antibody titers and a cell-mediated immune response, combined with induction of local immunity in the oral cavities of fetal lambs.	Univ Saskatchewan, Vet Infect Dis Org, Saskatoon, SK S7N 5E3, Canada	University of Saskatchewan	Griebel, PJ (corresponding author), Univ Saskatchewan, Vet Infect Dis Org, Saskatoon, SK S7N 5E3, Canada.	griebelp@sask.usask.ca		Gerdts, Volker/0000-0001-8229-1611				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; BRAUN R, 1997, VACCINE RES, V6, P151; Butts C, 1998, VACCINE, V16, P1444, DOI 10.1016/S0264-410X(98)00106-6; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; Gaensler KML, 1999, NAT BIOTECHNOL, V17, P1188, DOI 10.1038/70729; HEIN WR, 1995, IMMUNOLOGIST, V3, P12; Ichino M, 1999, J IMMUNOL, V162, P3814; Ishii KJ, 1999, VACCINE, V18, P703, DOI 10.1016/S0264-410X(99)00267-4; Iwamoto HS, 1999, GENE THER, V6, P98, DOI 10.1038/sj.gt.3300804; Littel-van den Hurk SV, 1999, VIRAL IMMUNOL, V12, P67, DOI 10.1089/vim.1999.12.67; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; McCluskie MJ, 1999, CRIT REV IMMUNOL, V19, P303; Mor G, 1996, J CLIN INVEST, V98, P2700, DOI 10.1172/JCI119094; Mulholland K, 1998, VACCINE, V16, P1360, DOI 10.1016/S0264-410X(98)00092-9; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; Watts AM, 1999, NAT MED, V5, P427, DOI 10.1038/7426; Wright PF, 1998, VACCINE, V16, P1355, DOI 10.1016/S0264-410X(98)00091-7	20	59	62	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					929	932		10.1038/78699	http://dx.doi.org/10.1038/78699			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932233				2022-12-27	WOS:000165473800039
J	Zhang, ZX; Yang, L; Young, KJ; DuTemple, B; Zhang, L				Zhang, ZX; Yang, L; Young, KJ; DuTemple, B; Zhang, L			Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression	NATURE MEDICINE			English	Article							IN-VIVO; TRANSPLANTATION TOLERANCE; RENAL-ALLOGRAFTS; TRANSGENIC MICE; RECEPTOR; CD8; ENCEPHALOMYELITIS; AUTOIMMUNITY; ASSOCIATION; LYMPHOCYTES	Despite increasing evidence for the existence of antigen-specific regulatory T cells, the mechanisms underlying suppression remain unclear. In this study we have identified and cloned a novel subset of antigen-specific regulatory T cells and demonstrated that these T cells possess a unique combination of cell surface markers and array of cytokines. The regulatory T cells are able to inhibit the function of T cells carrying the same T-cell receptor specificity and prevent skin allograft rejection in an antigen-specific, dose-dependent manner. The regulatory T cells are able to acquire alloantigen from antigen-presenting cells, present the alloantigen to activated syngeneic CD8(+) T cells and then send death signals to CD8(+) T cells. These findings provide a novel mechanism of regulatory T-cell-mediated, antigen-specific suppression.	Univ Toronto, Toronto Gen Hosp, Res Inst,Dept Lab Med & Pathol, UHN,Multi Organ Transplantat Program, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Zhang, L (corresponding author), Univ Toronto, Toronto Gen Hosp, Res Inst,Dept Lab Med & Pathol, UHN,Multi Organ Transplantat Program, 100 Coll St, Toronto, ON M5G 2C4, Canada.		Zhang, Zhu-Xu/G-3361-2011	Zhang, Zhu-Xu/0000-0002-8335-3738				ABRAHAM VS, 1992, J IMMUNOL, V148, P3746; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; Bushell A, 1999, J IMMUNOL, V162, P1359; CAI ZL, 1994, J EXP MED, V179, P2005, DOI 10.1084/jem.179.6.2005; Chai JG, 1999, EUR J IMMUNOL, V29, P686, DOI 10.1002/(SICI)1521-4141(199902)29:02<686::AID-IMMU686>3.0.CO;2-N; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Cobbold S, 1998, CURR OPIN IMMUNOL, V10, P518, DOI 10.1016/S0952-7915(98)80217-3; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Han HS, 1996, J AUTOIMMUN, V9, P331, DOI 10.1006/jaut.1996.0045; Huang JF, 1999, SCIENCE, V286, P952, DOI 10.1126/science.286.5441.952; Ierino FL, 1999, J IMMUNOL, V162, P550; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Khan Q, 1999, J IMMUNOL, V162, P5860; King C, 1998, IMMUNITY, V8, P601, DOI 10.1016/S1074-7613(00)80565-8; Kuwano K, 1996, CELL IMMUNOL, V169, P288, DOI 10.1006/cimm.1996.0120; LANCASTER F, 1985, NATURE, V315, P336, DOI 10.1038/315336a0; LOMBARDI G, 1994, SCIENCE, V264, P1587, DOI 10.1126/science.8202711; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; Ohteki T, 1999, EUR J IMMUNOL, V29, P2886, DOI 10.1002/(SICI)1521-4141(199909)29:09<2886::AID-IMMU2886>3.0.CO;2-A; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; Patel DM, 1999, J IMMUNOL, V163, P5201; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; SAMBHARA SR, 1991, SCIENCE, V252, P1424; Seddon B, 1999, J EXP MED, V189, P877, DOI 10.1084/jem.189.5.877; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Smyth MJ, 1998, EUR J IMMUNOL, V28, P4162, DOI 10.1002/(SICI)1521-4141(199812)28:12<4162::AID-IMMU4162>3.3.CO;2-5; Sprent J, 1999, J IMMUNOL, V163, P4629; STROBER S, 1987, J IMMUNOL, V138, P699; Strohmaier W, 1996, PTERIDINES, V7, P1; SYKES M, 1990, CELL IMMUNOL, V129, P478, DOI 10.1016/0008-8749(90)90222-D; Tanchot C, 1998, IMMUNITY, V8, P581, DOI 10.1016/S1074-7613(00)80563-4; Thilenius ARB, 1999, J IMMUNOL, V162, P643; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; Waldmann H, 1999, NAT MED, V5, P1245, DOI 10.1038/15197; Yang LM, 1999, TRANSPLANTATION, V67, P1404, DOI 10.1097/00007890-199906150-00003; Yang PY, 1998, J NUTR BIOCHEM, V9, P324, DOI 10.1016/S0955-2863(98)00010-2; Zhai Y, 1999, CURR OPIN IMMUNOL, V11, P497, DOI 10.1016/S0952-7915(99)00007-2; Zhang L, 1996, J EXP MED, V183, P2065, DOI 10.1084/jem.183.5.2065; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	40	348	377	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					782	789		10.1038/77513	http://dx.doi.org/10.1038/77513			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888927				2022-12-27	WOS:000088040100035
J	Ready, T				Ready, T			Survey shows secrecy among scientists	NATURE MEDICINE			English	News Item																			0	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					365	365		10.1038/74605	http://dx.doi.org/10.1038/74605			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742129	Bronze			2022-12-27	WOS:000165474100015
J	Mascola, JR; Stiegler, G; VanCott, TC; Katinger, H; Carpenter, CB; Hanson, CE; Beary, H; Hayes, D; Frankel, SS; Birx, DL; Lewis, MG				Mascola, JR; Stiegler, G; VanCott, TC; Katinger, H; Carpenter, CB; Hanson, CE; Beary, H; Hayes, D; Frankel, SS; Birx, DL; Lewis, MG			Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 INFECTION; RHESUS MACAQUES; AIDS; HIV; INOCULATION; DISEASE; EPITOPE; MONKEYS; WOMEN	The development of the human immunodeficiency virus-1 (HIV-1)/simian immunodeficiency virus (SIV) chimeric virus macaque model (SHIV) permits the in vivo evaluation of anti-HIV-1. envelope glycoprotein immune responses(1-3), Using this model, others, and we have shown that passively infused antibody can protect against an intravenous challenge(4,5). However, HIV-1 is most often transmitted across mucosal surfaces(6-9) and the intravenous challenge model may not accurately predict the role of antibody in protection against mucosal exposure. After controlling the macaque estrous cycle with progesterone(10), anti-HIV-1 neutralizing monoclonal antibodies 2F5 and 2G12, and HIV immune globulin were tested(11-13). Whereas all five control monkeys displayed high plasma viremia and rapid CD4 cell decline, 14 antibody-treated macaques were either completely protected against infection or against pathogenic manifestations of SHIV-infection. Infusion of all three antibodies together provided the greatest amount of protection, but a single monoclonal antibody, with modest virus neutralizing activity, was also protective. Compared with our previous intravenous challenge study with the same virus and antibodies: the data indicated that greater protection was achieved after vaginal challenge. This study demonstrates that antibodies can affect transmission and subsequent disease course after vaginal SHIV-challenge; the data begin to define the type of antibody response that could play a role in protection against mucosal transmission of HIV-1.	Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA; Henry M Jackson Fdn, Rockville, MD 20850 USA; Univ Agr Vienna, Inst Appl Microbiol, Vienna, Austria; USN, Med Res Ctr, Dept Infect Dis, Forrest Glenn, MD 20910 USA; Walter Reed Army Inst Res, Div Vet Med, Forrest Glenn, MD 20910 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; University of Natural Resources & Life Sciences, Vienna; United States Department of Defense; United States Navy; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Mascola, JR (corresponding author), Walter Reed Army Inst Res, Div Retrovirol, 1 Taft Court,Suite 250, Rockville, MD 20850 USA.	jmascola@hiv.hif.org	Mascola, John/AAI-7193-2021					Artenstein AW, 1997, J INFECT DIS, V175, P265, DOI 10.1093/infdis/175.2.265; BURTON DR, 1997, AIDS SA, V11, P587; Frankel SS, 1998, J VIROL, V72, P9788, DOI 10.1128/JVI.72.12.9788-9794.1998; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; Kutteh WH, 1998, AIDS RES HUM RETROV, V14, pS51; Lambert G, 1997, J PEDIATR-US, V130, P890, DOI 10.1016/S0022-3476(97)70274-9; Lambert JS, 1997, J INFECT DIS, V175, P283, DOI 10.1093/infdis/175.2.283; Lewis MG, 1999, J VIROL, V73, P1262, DOI 10.1128/JVI.73.2.1262-1270.1999; Lu YC, 1998, J ACQ IMMUN DEF SYND, V19, P6, DOI 10.1097/00042560-199809010-00002; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Mascola JR, 1997, J VIROL, V71, P7198, DOI 10.1128/JVI.71.10.7198-7206.1997; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Miller CJ, 1996, NAT MED, V2, P751, DOI 10.1038/nm0796-751; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Piot P, 1998, SCIENCE, V280, P1844, DOI 10.1126/science.280.5371.1844; Reimann KA, 1996, J VIROL, V70, P3198, DOI 10.1128/JVI.70.5.3198-3206.1996; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; Shibata R, 1997, J INFECT DIS, V176, P362, DOI 10.1086/514053; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Vahey Maryanne T., 1995, P313	22	1081	1145	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					207	210		10.1038/72318	http://dx.doi.org/10.1038/72318			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655111				2022-12-27	WOS:000085016900043
J	Scheffold, A; Assenmacher, M; Reiners-Schramm, L; Lauster, R; Radbruch, A				Scheffold, A; Assenmacher, M; Reiners-Schramm, L; Lauster, R; Radbruch, A			High-sensitivity immunofluorescence for detection of the pro- and anti-inflammatory cytokines gamma interferon and interleukin-10 on the surface of cytokine-secreting cells	NATURE MEDICINE			English	Article							COLLAGEN PRODUCTION; DERMAL FIBROBLASTS; TUMOR-GROWTH; T-CELLS; EXPRESSION; INHIBITION; RECEPTOR; CONTACT; MOUSE		Deutsch Rheuma Forschungszentrum Berlin, D-10115 Berlin, Germany; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany	Deutsches Rheuma-Forschungszentrum (DRFZ); Miltenyi Biotec	Scheffold, A (corresponding author), Deutsch Rheuma Forschungszentrum Berlin, Hannoversche Str 27, D-10115 Berlin, Germany.		Scheffold, Alexander/S-2090-2016	Scheffold, Alexander/0000-0002-0626-343X; Radbruch, Andreas/0000-0001-5753-0000				Assenmacher M, 1996, EUR J IMMUNOL, V26, P263, DOI 10.1002/eji.1830260141; BROTHERICK I, 1994, CYTOMETRY, V16, P262, DOI 10.1002/cyto.990160311; Bruno L, 1999, CURR BIOL, V9, P559, DOI 10.1016/S0960-9822(99)80259-0; Chizzolini C, 1998, ARTHRITIS RHEUM-US, V41, P2039; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LOLLINI PL, 1993, INT J CANCER, V55, P320, DOI 10.1002/ijc.2910550224; Rezzonico R, 1998, J BIOL CHEM, V273, P18720, DOI 10.1074/jbc.273.30.18720; RICHTER G, 1993, CANCER RES, V53, P4134; SCHEFFOLD A, 1995, IMMUNOTECHNOLOGY, V1, P127, DOI 10.1016/1380-2933(95)00014-3; Shapiro H. M., 1988, PRACTICAL FLOW CYTOM; Zola H, 1994, IMMUNOLOGIST, V2, P47	14	65	70	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					107	110		10.1038/71441	http://dx.doi.org/10.1038/71441			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613835				2022-12-27	WOS:000084583300046
J	Jones, CR; Campbell, SS; Zone, SE; Cooper, F; DeSano, A; Murphy, PJ; Jones, B; Czajkowski, L; Ptacek, LJ				Jones, CR; Campbell, SS; Zone, SE; Cooper, F; DeSano, A; Murphy, PJ; Jones, B; Czajkowski, L; Ptacek, LJ			Familial advanced sleep-phase syndrome: A short-period circadian rhythm variant in humans	NATURE MEDICINE			English	Article							CLOCK	Biological circadian clocks oscillate with an approximately 24-hour period, are ubiquitous, and presumably confer a selective advantage by anticipating the transitions between day and night. The circadian rhythms of sleep, melatonin secretion and body core temperature are thought to be generated by the suprachiasmatic nucleus of the hypothalamus, the anatomic locus of the mammalian circadian clock(1,2). Autosomal semi-dominant mutations in rodents with fast or slow biological clocks (that is, short or long endogenous period lengths; tau) are associated with phase-advanced or delayed sleep-wake rhythms, respectively. These models predict the existence of familial human circadian rhythm variants(3,4) but none of the human circadian rhythm disorders are known to have a familial tendency(5). Although a slight 'morning lark' tendency is common, individuals with a large and disabling sleep phase-advance are rare. This disorder, advanced sleep-phase syndrome, is characterized by very early sleep onset and offset; only two cases are reported in young adults(6,7). Here we describe three kindreds with a profound phase advance of the sleep-wake, melatonin and temperature rhythms associated with a very short tau. The trait segregates as an autosomal dominant with high penetrance. These kindreds represent a well-characterized familial circadian rhythm variant in humans and provide a unique opportunity for genetic analysis of human circadian physiology.	Univ Utah, Dept Neurol, Salt Lake City, UT 84112 USA; Univ Hosp, Sleep Disorders Ctr, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Management, Salt Lake City, UT 84112 USA; Univ Utah, David Eccles Sch Business, Salt Lake City, UT 84112 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Program Neurosci, Salt Lake City, UT 84112 USA; Cornell Univ, Weill Med Coll, Dept Psychiat, White Plains, NY 10605 USA	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Cornell University	Ptacek, LJ (corresponding author), Univ Utah, Dept Neurol, Salt Lake City, UT 84112 USA.			Jones, Bryan/0000-0001-5527-6643	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059596] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NHLBI NIH HHS [HL/HD 59596] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM SLEEP DIS ASS, 1997, INT CLASS SLEEP DIS, P133; Beck A.T, 1978, BECK DEPRESSION INVE; Billiard M, 1993, SLEEP RES, V22, P109; CAMPBELL SS, 1989, SLEEP, V12, P529; CAMPBELL SS, 1993, SLEEP, V16, P638; CARSKADON MA, 1975, ELECTROEN CLIN NEURO, V39, P145, DOI 10.1016/0013-4694(75)90004-8; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; CZEISLER CA, 1980, SCIENCE, V210, P1264, DOI 10.1126/science.7434029; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Drennan M. D., 1992, Society for Neuroscience Abstracts, V18, P196; Duffy J. F, 1999, SLEEP, V22, pS92; GREENWOOD KM, 1994, ERGONOMICS, V37, P377, DOI 10.1080/00140139408963653; Haimov I, 1997, SLEEP, V20, P294, DOI 10.1093/sleep/20.4.294; HORNE J A, 1976, International Journal of Chronobiology, V4, P97; Katzenberg D, 1998, SLEEP, V21, P569, DOI 10.1093/sleep/21.6.569; KEENAN SA, 1994, SLEEP DISORDERS MED, P79; Klerman EB, 1996, AM J PHYSIOL-REG I, V270, pR271, DOI 10.1152/ajpregu.1996.270.1.R271; LAVIE P, 1986, ELECTROEN CLIN NEURO, V63, P414, DOI 10.1016/0013-4694(86)90123-9; LEWY AJ, 1989, CHRONOBIOL INT, V6, P93, DOI 10.3109/07420528909059144; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RECHTSCHAFFEN A, 1968, MANUAL STANDARDIZED, P1; SHANAHAN TL, 1991, J CLIN ENDOCR METAB, V73, P27; Singer CM, 1989, SLEEP RES, V18, P445; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325	24	359	372	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1062	1065		10.1038/12502	http://dx.doi.org/10.1038/12502			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470086				2022-12-27	WOS:000082337200043
J	Pawliuk, R; Bachelot, T; Wise, RJ; Mathews-Roth, MM; Leboulch, P				Pawliuk, R; Bachelot, T; Wise, RJ; Mathews-Roth, MM; Leboulch, P			Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy	NATURE MEDICINE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; BETA-GLOBIN GENE; RETROVIRAL VECTORS; HOST-DEFENSE; HOUSE MOUSE; STEM-CELLS; IN-VIVO; FERROCHELATASE; SELECTION; EXPRESSION	Definitive cure of an animal model of a human disease by gene transfer into hematopoietic stem cells has not yet been accomplished in the absence of spontaneous in vivo selection for transduced cells. Erythropoietic protoporphyria is a genetic disease in which ferrochelatase is defective. Protoporphyrin accumulates in erythrocytes, leaks into the plasma and results in severe skin photosensitivity. Using a mouse model of erythropoietic protoporphyria, we demonstrate here that ex vivo preselection of hematopoietic stem cells transduced with a polycistronic retrovirus expressing both human ferrochelatase and green fluorescent protein results in complete and long-term correction of skin photosensitivity in all transplanted mice.	Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA; Genetix Pharmaceut, Cambridge, MA 02139 USA; MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT)	Mathews-Roth, MM (corresponding author), Harvard Univ, Sch Med, 181 Longwood Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL55435] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bjorgvinsdottir H, 1997, BLOOD, V89, P41, DOI 10.1182/blood.V89.1.41.41_41_48; BOULECHFAR S, 1993, GENOMICS, V16, P645, DOI 10.1006/geno.1993.1242; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; Cheng LZ, 1998, BLOOD, V92, P83, DOI 10.1182/blood.V92.1.83.413k09_83_92; Conneally E, 1998, BLOOD, V91, P3487, DOI 10.1182/blood.V91.9.3487.3487_3487_3493; DESNICK R, 1994, HARRISONS PRINCIPLES, V1, P2073; deTorres I, 1996, TRANSPLANTATION, V61, P1412, DOI 10.1097/00007890-199605150-00024; HAWLEY RG, 1994, GENE THER, V1, P136; HUANG ZM, 1995, MOL CELL BIOL, V15, P3864; LEBOULCH P, 1994, EMBO J, V13, P3065, DOI 10.1002/j.1460-2075.1994.tb06605.x; Mardiney M, 1997, BLOOD, V89, P2268, DOI 10.1182/blood.V89.7.2268; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MATHEWSROTH MM, 1977, ARCH DERMATOL, V113, P1229, DOI 10.1001/archderm.113.9.1229; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; PAWLIUK R, 1994, BLOOD, V84, P2868, DOI 10.1182/blood.V84.9.2868.bloodjournal8492868; Pawliuk R, 1997, HUM GENE THER, V8, P1595, DOI 10.1089/hum.1997.8.13-1595; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perez-Tamayo R, 1979, Pathol Annu, V14 Pt 2, P183; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; PIOMELLI S, 1977, CLIN CHEM, V23, P264; Raftopoulos H, 1997, BLOOD, V90, P3414, DOI 10.1182/blood.V90.9.3414; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; TUTOIS S, 1991, J CLIN INVEST, V88, P1730, DOI 10.1172/JCI115491; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Youssoufian H, 1996, NAT GENET, V13, P255, DOI 10.1038/ng0796-255; Zimmermann A, 1997, SCHWEIZ MED WSCHR, V127, P812	27	70	71	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1999	5	7					768	773		10.1038/10488	http://dx.doi.org/10.1038/10488			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395321				2022-12-27	WOS:000081926600031
J	Atkinson, MA; Leiter, EH				Atkinson, MA; Leiter, EH			The NOD mouse model of type 1 diabetes: As good as it gets?	NATURE MEDICINE			English	Editorial Material									Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Jackson Lab, Bar Harbor, ME 04609 USA	State University System of Florida; University of Florida; Jackson Laboratory	Atkinson, MA (corresponding author), Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA.							Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; Ellerman KE, 1996, DIABETES, V45, P557, DOI 10.2337/diabetes.45.5.557; Komeda K, 1998, ENDOCR J, V45, P737, DOI 10.1507/endocrj.45.737; LEITER EH, 1998, MED INTELLIGENCE UNI; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.3.CO;2-M; Takahashi K, 1998, J IMMUNOL, V161, P2629	6	469	508	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1999	5	6					601	604		10.1038/9442	http://dx.doi.org/10.1038/9442			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371488				2022-12-27	WOS:000080823300018
J	Wang, ZQ; Boudjelal, M; Kang, S; Voorhees, JJ; Fisher, GJ				Wang, ZQ; Boudjelal, M; Kang, S; Voorhees, JJ; Fisher, GJ			Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment	NATURE MEDICINE			English	Article							IN-VIVO; NUCLEAR RECEPTORS; RXR HETERODIMERS; UV-RADIATION; MOUSE SKIN; EXPRESSION; ACTIVATION; BINDING; PROTEIN; PROGRESSION	We report here that ultraviolet irradiation substantially reduced the mRNA and protein of the two major nuclear retinoid receptors, RAR-gamma and RXR-alpha, in human skin in vivo. Pre-treatment with retinoic acid mitigated this loss of nuclear retinoid receptors. Ultraviolet irradiation caused a near-total loss of retinoic acid induction of two RAR/RXR target genes, cellular retinoic acid binding protein-II and RA 4-hydroxylase, but did not affect 1,25-dihydroxyvitamin D-3 induction of the vitamin D receptor/RXR-regulated gene vitamin D 24-hydroxylase. In effect, ultraviolet irradiation causes a functional vitamin A deficiency that may have deleterious effects on skin function, contributing to skin photo-aging and carcinogenesis.	Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), Univ Michigan, Dept Dermatol, 1150 W Med Ctr Dr,Med Sci 1 R6447, Ann Arbor, MI 48109 USA.	dianemch@umich.edu						ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARBOUR NC, 1993, MOL ENDOCRINOL, V7, P1307, DOI 10.1210/me.7.10.1307; ASTROM A, 1991, J BIOL CHEM, V266, P17662; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL C, 1993, CANCER RES, V53, P2697; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; Darwiche N, 1996, CANCER RES, V56, P4942; DARWICHE N, 1995, CANCER RES, V55, P2774; DE LUCA LM, 1991, FASEB J, V5, P2924; DE LUCA LM, 1994, NUTR REV, V52, P45; Duell EA, 1996, J INVEST DERMATOL, V106, P316, DOI 10.1111/1523-1747.ep12342972; Feng X, 1997, GENE DEV, V11, P59, DOI 10.1101/gad.11.1.59; Fisher G J, 1998, J Investig Dermatol Symp Proc, V3, P61; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; FISHER GJ, 1995, J INVEST DERMATOL, V105, P80, DOI 10.1111/1523-1747.ep12313352; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; Fitzgerald P, 1997, CANCER RES, V57, P2642; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FUTORYAN T, 1994, NUTR REV, V52, P299, DOI 10.1111/j.1753-4887.1994.tb01461.x; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HOLICK MF, 1995, AM J CLIN NUTR, V61, p638S, DOI 10.1093/ajcn/61.3.638S; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; Kang SW, 1997, J INVEST DERMATOL, V108, P513, DOI 10.1111/1523-1747.ep12289736; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KUMAR R, 1994, CARCINOGENESIS, V15, P701, DOI 10.1093/carcin/15.4.701; Li XY, 1997, J INVEST DERMATOL, V108, P506, DOI 10.1111/1523-1747.ep12289733; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, V1, P910; vanderLeun JC, 1996, J PHOTOCH PHOTOBIO B, V35, P237, DOI 10.1016/S1011-1344(95)07188-1; White SD, 1997, J COMPUT INFORM SYST, V38, P1; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001	44	92	94	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					418	422		10.1038/7417	http://dx.doi.org/10.1038/7417			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202931				2022-12-27	WOS:000079574300031
J	Grivel, JC; Margolis, LB				Grivel, JC; Margolis, LB			CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue	NATURE MEDICINE			English	Article							CORECEPTOR USAGE; INFECTION; HISTOCULTURES; PHENOTYPE; TYPE-1	A rapid decline in T-cell counts and the progression to AIDS is often associated with a switch from CCR5-tropic (R5) HIV-1 to CXCR4-tropic (X4) HIV-1 or R5/X4 HIV-1 variants(1,2) Experimental infection with R5 HIV-1 causes less T-cell depletion than infection with X4 or R5/X4 variants in T-cell cultures(3), in ex vivo infected human lymphoid tissue(4,5) and in SCID/hu mice(6), despite similar replication levels. Experimental genetic changes in those sequences in gp120 that transform R5 HIV-1 variants into otherwise isogenic X4 viruses make them highly cytopathic(6,7). Thus, it is now believed that R5 variants are less cytopathic for T cells than are X4 variants. However, it is not known why CCR5-mediated HIV-1 infection does not lead to a massive CD4(+) T-cell depletion, as occurs in CXCR4-mediated HIV-1 infection. Here we demonstrate that R5 HIV-1 isolates are indeed highly cytopathic, but only for CCR5(+)/CD4(+) T cells. Because these cells constitute only a small fraction of CD4(+) T cells, their depletion does not substantially change the total CD4(+) T-cell count. These results may explain why the clinical stage of HIV disease correlates with viral tropism.	NICHHD, Lab Mol & Cellular Biophys, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Margolis, LB (corresponding author), NICHHD, Lab Mol & Cellular Biophys, NIH, Bethesda, MD 20892 USA.			Grivel, Jean-Charles/0000-0003-0365-3181				Berger EA, 1997, AIDS, V11, pS3; Bjorndal A, 1997, J VIROL, V71, P7478; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Casella C R, 1997, Curr Opin Hematol, V4, P24; Glushakova S, 1997, AIDS RES HUM RETROV, V13, P461, DOI 10.1089/aid.1997.13.461; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; Glushakova S, 1998, NAT MED, V4, P346, DOI 10.1038/nm0398-346; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Penn ML, 1999, P NATL ACAD SCI USA, V96, P663, DOI 10.1073/pnas.96.2.663; Picchio GR, 1998, J VIROL, V72, P2002, DOI 10.1128/JVI.72.3.2002-2009.1998; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; TERSMETTE M, 1989, LANCET, V1, P983; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369	15	143	145	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					344	346		10.1038/6565	http://dx.doi.org/10.1038/6565			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086394				2022-12-27	WOS:000078851600043
J	Lapham, CK; Zaitseva, MB; Lee, S; Romanstseva, T; Golding, H				Lapham, CK; Zaitseva, MB; Lee, S; Romanstseva, T; Golding, H			Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR; CELL-LINES; T-CELL; INFECTION; TROPISM; ENTRY; 7-TRANSMEMBRANE; GLYCOPROTEINS; CORECEPTOR	Human macrophages can be infected more efficiently by M-tropic than by T-tropic HIV-1 strains, despite surface expression of both CXCR4 and CCR5 co-receptors. Western blot analyses of total cell extracts and surface proteins from multiple sets of monocytes and macrophages demonstrated substantial differences between CXCR4 molecules. CXCR4 was mainly a monomer in monocytes, but was mainly a species of higher molecular weight (90 kDa) on the surface of macrophages. CCR5 was monomeric in both cell types. A constitutive association between CD4 and the co-receptors was seen in monocytes and macrophages. However, CD4 co-precipitated with CCR5 and CXCR4 monomers, but not with the high-molecular-weight forms of CXCR4, indicating that the high-molecular-weight CXCR4 species in macrophages are not available for association with CD4, which may contribute to the inefficient entry of T-tropic strains into mature macrophages.	US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Lapham, CK (corresponding author), US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, HFM-454,8800 Rockville Pike, Bethesda, MD 20892 USA.	Lapham@CBER.FDA.GOV						Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHAYT KJ, 1997, JAMA-J AM MED ASSOC, V256, P2356; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; ChengMayer C, 1997, J VIROL, V71, P1657, DOI 10.1128/JVI.71.2.1657-1661.1997; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Di Marzio P, 1998, AIDS RES HUM RETROV, V14, P129, DOI 10.1089/aid.1998.14.129; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ghorpade A, 1998, J VIROL, V72, P3340, DOI 10.1128/JVI.72.4.3340-3350.1998; Hill CM, 1997, J VIROL, V71, P6296, DOI 10.1128/JVI.71.9.6296-6304.1997; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; NUOVO GJ, 1993, AM J PATHOL, V143, P40; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OVARECZ T, 1997, J EXP MED, V184, P1865; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; Schmidtmayerova H, 1998, J VIROL, V72, P4633, DOI 10.1128/JVI.72.6.4633-4642.1998; Simmons G, 1998, J VIROL, V72, P8453, DOI 10.1128/JVI.72.10.8453-8457.1998; SPENCER LT, 1994, J INFECT DIS, V169, P491, DOI 10.1093/infdis/169.3.491; Strizki JM, 1997, J VIROL, V71, P5678, DOI 10.1128/JVI.71.7.5678-5683.1997; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Verani A, 1998, J IMMUNOL, V161, P2084; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Yi YJ, 1998, J VIROL, V72, P772, DOI 10.1128/JVI.72.1.772-777.1998; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369; Zaitseva MB, 1998, J IMMUNOL, V161, P3103; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	33	102	104	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					303	308		10.1038/6523	http://dx.doi.org/10.1038/6523			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086386				2022-12-27	WOS:000078851600035
J	Artandi, SE; DePinho, RA				Artandi, SE; DePinho, RA			Mice without telomerase: what can they teach us about human cancer?	NATURE MEDICINE			English	Editorial Material							COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-DIPLOID FIBROBLASTS; MOUSE CELLS LACKING; LARGE T-ANTIGEN; LIFE-SPAN; CELLULAR SENESCENCE; TUMOR SUPPRESSION; EPITHELIAL-CELLS; INK4A LOCUS; IMMORTALIZATION	Unicellular organisms, human cells and mice have provided insights into how the processes of senescence, crisis, genomic instability and cancer in humans. Here, Artandi and DePinho discuss how studies in mice have uncovered a complex interplay between the ARF-p53 pathway, genomic Instability due to telomere dysfunction, and the suppression or promotion of cancer.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Artandi, SE (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.			DePinho, Ronald/0000-0002-5625-577X				Al-Mulla F, 1999, GENE CHROMOSOME CANC, V24, P306, DOI 10.1002/(SICI)1098-2264(199904)24:4<306::AID-GCC3>3.0.CO;2-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L; CHADENEAU C, 1995, CANCER RES, V55, P2533; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 1999, SCIENCE, V283, P947, DOI 10.1126/science.283.5404.947; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McClintock B, 1941, GENETICS, V26, P234; Muller H., 1938, COLLECT NET, V13, P182; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	40	107	112	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					852	855		10.1038/78595	http://dx.doi.org/10.1038/78595			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932211				2022-12-27	WOS:000165473800015
J	Schuchert, MJ; Wright, RD; Colson, YL				Schuchert, MJ; Wright, RD; Colson, YL			Characterization of a newly discovered T-cell receptor beta-chain heterodimer expressed on a CD8(+) bone marrow subpopulation that promotes allogeneic stem cell engraftment	NATURE MEDICINE			English	Article							VERSUS-HOST DISEASE; NATURAL-KILLER-CELLS; ANTIGEN RECEPTOR; GRAFT-REJECTION; IMMATURE THYMOCYTES; MONOCLONAL-ANTIBODY; SUBUNIT COMPOSITION; LYMPHOCYTE-SURFACE; FACILITATING CELLS; CD3 COMPLEXES	The facilitating cell is a rare CD8(+) bone marrow subpopulation that can enhance allogeneic hematopoietic stem cell engraftment across complete major histocompatibility complex barriers without inducing acute graft-versus-host disease. Here we describe a CD3 epsilon -associated complex on the facilitating cell surface that consists of the T-cell receptor beta -chain disulfide-linked to a previously unknown 33-kilodalton glycoprotein. Provisionally called FCp33, this glycoprotein does not represent any of the known protein chains or surrogates associated with CD3-T-cell receptor beta. Expression of this CD3-T-cell receptor beta -FCp33 complex directly correlates with the facilitating cell's functional ability to enhance allogeneic stem cell engraftment in vivo.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA; Univ Pittsburgh, Med Ctr Hlth Syst, Dept Surg, Pittsburgh, PA 15261 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute	Colson, YL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA.				NIAID NIH HHS [R29-AI4093] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; Barber DF, 1998, J IMMUNOL, V161, P11; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; Berger MA, 1997, J EXP MED, V186, P1461, DOI 10.1084/jem.186.9.1461; Chen B G, 1996, Transpl Immunol, V4, P158, DOI 10.1016/S0966-3274(96)80010-4; Drobyski W R, 1999, Biol Blood Marrow Transplant, V5, P222, DOI 10.1053/bbmt.1999.v5.pm10465102; El-Badri NS, 1998, EXP HEMATOL, V26, P110; Fowler DH, 1998, BLOOD, V91, P4045, DOI 10.1182/blood.V91.11.4045.411k17_4045_4050; Gaines BA, 1996, EXP HEMATOL, V24, P902; GALE RP, 1986, LANCET, V1, P1468; Gallardo D, 1997, BONE MARROW TRANSPL, V20, P945, DOI 10.1038/sj.bmt.1701008; GROETTRUP M, 1993, EUR J IMMUNOL, V23, P1393, DOI 10.1002/eji.1830230633; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; HOCHSTENBACH F, 1989, NATURE, V340, P562, DOI 10.1038/340562a0; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; IOANNIDES CG, 1987, P NATL ACAD SCI USA, V84, P4244, DOI 10.1073/pnas.84.12.4244; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KAUFMAN CL, 1994, BLOOD, V84, P2436; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; Kosugi A, 1997, IMMUNOLOGY, V91, P618, DOI 10.1046/j.1365-2567.1997.00294.x; KUBO RT, 1989, J IMMUNOL, V142, P2336; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPIDOT T, 1992, BLOOD, V80, P2406; LEY SC, 1989, EUR J IMMUNOL, V19, P2309, DOI 10.1002/eji.1830191220; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MARTIN PJ, 1993, J EXP MED, V178, P703, DOI 10.1084/jem.178.2.703; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; Modigliani Y, 1997, SCAND J IMMUNOL, V46, P117, DOI 10.1046/j.1365-3083.1997.d01-114.x; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY WJ, 1992, J IMMUNOL, V148, P2953; MURPHY WJ, 1990, J IMMUNOL, V144, P3305; Neipp M, 1998, BLOOD, V92, P3177, DOI 10.1182/blood.V92.9.3177.421k51_3177_3188; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SYKES M, 1989, J IMMUNOL, V143, P3503; Tanaka Y, 1999, JPN J PSYCHOL, V70, P1, DOI 10.4992/jjpsy.70.1; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x	43	46	50	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					904	909		10.1038/78667	http://dx.doi.org/10.1038/78667			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932228				2022-12-27	WOS:000165473800034
J	Zhao, XY; Malloy, PJ; Krishnan, AV; Swami, S; Navone, NM; Peehl, DM; Feldman, D				Zhao, XY; Malloy, PJ; Krishnan, AV; Swami, S; Navone, NM; Peehl, DM; Feldman, D			Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor	NATURE MEDICINE			English	Article							GENE-MUTATIONS; LNCAP CELLS; EXPRESSION; CORTISOL; ANTIGEN; MODEL	The androgen receptor (AR) is involved in the development, growth and progression of prostate cancer(1) (CaP). CaP often progresses from an androgen-dependent to an androgen-independent tumor, making androgen ablation therapy ineffective. However, the mechanisms for the development of androgen-independent CaP are unclear. More than 80% of clinically androgen-independent prostate tumors show high levels of AR expression(1). In some CaPs, AR levels are increased because of gene amplification(2) and/or overexpression, whereas in others, the AR is mutated(3-5). Nonetheless, the involvement of the AR in the transition of CaP to androgen-independent growth and the subsequent failure of endocrine therapy are not fully understood. Here we show that in CaP cells from a patient who failed androgen ablation therapy, a doubly mutated AR functioned as a high-affinity cortisol/cortisone receptor (AR(ccr)). Cortisol, the main circulating glucocorticoid, and its metabolite, cortisone, both equally stimulate the growth of these CaP cells and increase the secretion of prostate-specific antigen in the absence of androgens. The physiological concentrations of free cortisol and total cortisone in men(6,7) greatly exceed the binding affinity of the androgen and cortisol/cortisone receptor (AR(ccr)) and would activate the receptor, promoting CaP cell proliferation. Our data demonstrate a previously unknown mechanism for the androgen-independent growth of advanced CaP. Understanding this mechanism and recognizing the presence of glucocorticoid-responsive AR mutants are important for the development of new forms of therapy for the treatment of this subset of CaP.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	Stanford University; Stanford University; University of Texas System; UTMD Anderson Cancer Center	Feldman, D (corresponding author), Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.							Cleutjens CBJM, 1997, ENDOCRINOLOGY, V138, P5293, DOI 10.1210/en.138.12.5293; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Oakley RH, 1997, ENDOCRINOLOGY, V138, P5028, DOI 10.1210/en.138.11.5028; Roux S, 1996, MOL ENDOCRINOL, V10, P1214, DOI 10.1210/me.10.10.1214; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Trapman J, 1996, PATHOL RES PRACT, V192, P752, DOI 10.1016/S0344-0338(96)80097-5; VanCauter E, 1996, J CLIN ENDOCR METAB, V81, P2468, DOI 10.1210/jc.81.7.2468; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Walker BR, 1997, J CLIN ENDOCR METAB, V82, P4015, DOI 10.1210/jc.82.12.4015; WARRIAR N, 1994, BIOCHEMISTRY-US, V33, P12837, DOI 10.1021/bi00209a015; Watanabe M, 1997, JPN J CLIN ONCOL, V27, P389, DOI 10.1093/jjco/27.6.389; Zhao XY, 1999, J UROLOGY, V162, P2192, DOI 10.1016/S0022-5347(05)68158-X	20	409	429	2	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					703	706		10.1038/76287	http://dx.doi.org/10.1038/76287			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835690				2022-12-27	WOS:000087438300044
J	Ault, A				Ault, A			GMO controversy has adverse effects on UK research	NATURE MEDICINE			English	News Item																		Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607	1	0	0	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					364	364		10.1038/74599	http://dx.doi.org/10.1038/74599			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742126				2022-12-27	WOS:000165474100013
J	Anderson, DE; Bieganowska, KD; Bar-Or, A; Oliveira, EML; Carreno, B; Collins, M; Hafler, DA				Anderson, DE; Bieganowska, KD; Bar-Or, A; Oliveira, EML; Carreno, B; Collins, M; Hafler, DA			Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population	NATURE MEDICINE			English	Article							MULTIPLE-SCLEROSIS; COSTIMULATION; COEXPRESSION; ACTIVATION; INFECTION; PEPTIDE; CLONES; B7-1; CD28; VIVO	T-cell co-stimulation delivered by the molecules B7-1 or B7-2 through CD28 has a positive effect on T-cell activation(1), whereas engagement of cytotoxic T-lymphocyte antigen 4 (CTLA-4) by these molecules inhibits activation(2). In vivo administration to mice of blocking monoclonal antibodies or Fab fragments against CTLA-4 can augment antigen-specific T-cell responses(3,4) and, thus, therapy with monoclonal antibody against CTLA-4 has potential applications for tumor therapy and enhancement of vaccine immunization(5-7). The effects of B7-1 and B7-2 co-stimulation through CD28 depend on the strength of the signal delivered through the T-cell receptor (TCR)(8,9) and the activation state of T cells during activation(10,11). Thus, we sought to determine whether these factors similarly influence the effect of B7-mediated signals delivered through CTLA-4 during T-cell activation. Using freshly isolated human T cells and Fab fragments of a monoclonal antibody against CTLA-4 we demonstrate here that CTLA-4 blockade can enhance or inhibit the clonal expansion of different T cells that respond to the same antigen, depending on both the T-cell activation state and the strength of the T-cell receptor signal delivered during T-cell stimulation. Thus, for whole T-cell populations, blocking a negative signal may paradoxically inhibit immune responses. These results provide a theoretical framework for clinical trials in which co-stimulatory signals are manipulated in an attempt to modulate the immune response in human disease.	Harvard Univ, Sch Med, Div Med Sci, Comm Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Genet Inst, Cambridge, MA 02140 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Hafler, DA (corresponding author), Harvard Univ, Sch Med, Div Med Sci, Comm Immunol, Boston, MA 02115 USA.		Oliveira, Enedina M.L/B-2720-2016; Bar-Or, Amit/C-4213-2011	Oliveira, Enedina M.L/0000-0002-4939-7200; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024247] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK52127] Funding Source: Medline; NINDS NIH HHS [R01NS2424710A2] Funding Source: Medline; PHS HHS [IPO1A139671-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson DE, 1997, J IMMUNOL, V159, P1669; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; Bieganowska KD, 1997, J EXP MED, V185, P1585, DOI 10.1084/jem.185.9.1585; Fields PE, 1998, J IMMUNOL, V161, P5268; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; Jeannin P, 1999, J IMMUNOL, V162, P2044; KEARNEY ER, 1995, J IMMUNOL, V155, P1032; Kwon ED, 1997, P NATL ACAD SCI USA, V94, P8099, DOI 10.1073/pnas.94.15.8099; LASALLE JM, 1991, CELL IMMUNOL, V138, P197, DOI 10.1016/0008-8749(91)90144-Z; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; Lovett-Racke AE, 1998, J CLIN INVEST, V101, P725, DOI 10.1172/JCI1528; McCoy K, 1997, J EXP MED, V186, P183, DOI 10.1084/jem.186.2.183; Metz DP, 1998, J IMMUNOL, V161, P5855; Murphy ML, 1998, J IMMUNOL, V161, P4153; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Saha B, 1998, EUR J IMMUNOL, V28, P4213, DOI 10.1002/(SICI)1521-4141(199812)28:12&lt;4213::AID-IMMU4213&gt;3.0.CO;2-C; Scholz C, 1998, J IMMUNOL, V160, P1532; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; Walunas TL, 1998, J IMMUNOL, V160, P3855; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	21	58	92	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					211	214		10.1038/72323	http://dx.doi.org/10.1038/72323			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655112				2022-12-27	WOS:000085016900044
J	Pitt, D; Werner, P; Raine, CS				Pitt, D; Werner, P; Raine, CS			Glutamate excitotoxicity in a model of multiple sclerosis	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NMDA RECEPTOR; INVITRO; BRAIN; MICE	Glutamate excitotoxicity mediated by the AMPA/kainate type of glutamate receptors damages not only neurons but also the myelin-producing cell of the central nervous system, the oligodendrocyte(1). In multiple sclerosis, myelin, oligodendrocytes and some axons are lost as a result of an inflammatory attack on the central nervous system(2). Because glutamate is released in large quantities by activated immune cells(3), we expected that during inflammation in MS, glutamate excitotoxicity might contribute to the lesion. We addressed this by using the AMPA/kainate antagonist NBQX to treat mice sensitized for experimental autoimmune encephalomyelitis, a demyelinating model that mimics many of the clinical and pathologic features of multiple sclerosis. Treatment resulted in substantial amelioration of disease, increased oligodendrocyte survival and reduced dephosphorylation of neurofilament H, an indicator of axonal damage(4). Despite the clinical differences, treatment with NBQX had no effect on lesion size and did not reduce the degree of central nervous system inflammation. In addition, NBQX did not alter the proliferative activity of antigen-primed T cells in vitro, further indicating a lack of effect on the immune system. Thus, glutamate excitotoxicity seems to be an important mechanism in autoimmune demyelination, and its prevention with AMPA/kainate antagonists may prove to be an effective therapy for multiple sclerosis.	Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Beth Israel Med Ctr, Dept Neurol, New York, NY 10003 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Beth Israel Deaconess Medical Center	Werner, P (corresponding author), Albert Einstein Coll Med, Dept Neurol, F-121N,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011920, P01NS011920] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 07098, NS 08952, NS 11920] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RD, 1952, AM J MED, V12, P510, DOI 10.1016/0002-9343(52)90234-9; BURYAKOVA AV, 1975, ARCH NEUROL-CHICAGO, V32, P28, DOI 10.1001/archneur.1975.00490430050007; Cannella B, 1998, P NATL ACAD SCI USA, V95, P10100, DOI 10.1073/pnas.95.17.10100; COLLINS RC, 1989, ANN INTERN MED, V110, P992, DOI 10.7326/0003-4819-110-12-992; Ding MZ, 1998, J IMMUNOL, V160, P2560; Espey MG, 1998, J NEUROCHEM, V71, P2079; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; GIJBELS K, 1994, J CLIN INVEST, V94, P2177, DOI 10.1172/JCI117578; HardinPouzet H, 1997, GLIA, V20, P79, DOI 10.1002/(SICI)1098-1136(199705)20:1<79::AID-GLIA8>3.0.CO;2-0; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; O'Neill MJ, 1998, NEUROPHARMACOLOGY, V37, P1211, DOI 10.1016/S0028-3908(98)00134-8; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Prineas J. W., 1997, GREENFIELDS NEUROPAT, P813; Raine C.S., 1997, MULTIPLE SCLEROSIS C, P243; RodriguezMoreno A, 1997, NEURON, V19, P893, DOI 10.1016/S0896-6273(00)80970-8; Rosenberg LJ, 1999, J NEUROSCI, V19, P464, DOI 10.1523/JNEUROSCI.19-01-00464.1999; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; Stover JF, 1997, EUR J CLIN INVEST, V27, P1038, DOI 10.1046/j.1365-2362.1997.2250774.x; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Yoshioka A, 1996, J NEUROSCI RES, V46, P427	22	662	696	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					67	70		10.1038/71555	http://dx.doi.org/10.1038/71555			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613826				2022-12-27	WOS:000084583300037
J	Bendandi, M; Gocke, CD; Kobrin, CB; Benko, FA; Sternas, LA; Pennington, R; Watson, TM; Reynolds, CW; Gause, BL; Duffey, PL; Jaffe, ES; Creekmore, SP; Longo, DL; Kwak, LW				Bendandi, M; Gocke, CD; Kobrin, CB; Benko, FA; Sternas, LA; Pennington, R; Watson, TM; Reynolds, CW; Gause, BL; Duffey, PL; Jaffe, ES; Creekmore, SP; Longo, DL; Kwak, LW			Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma	NATURE MEDICINE			English	Article							B-CELL LYMPHOMA; CYTOTOXIC T-LYMPHOCYTES; POLYMERASE CHAIN-REACTION; IN-VITRO; DENDRITIC CELLS; FOLLICULAR LYMPHOMAS; IMMUNE-RESPONSES; RESIDUAL CELLS; ANTI-IDIOTYPE; TUMOR-CELLS	Lymphomas express a tumor-specific antigen which can be targeted by cancer vaccination. We evaluated the ability of a new idiotype protein Vaccine formulation to eradicate residual t(14;18)+ lymphoma cells in 20 patients in a homogeneous, chemotherapy-induced first clinical complete remission. All 11 patients with detectable translocations in their primary tumors had cells from the malignant clone detectable in their blood by PCR both at diagnosis and after chemotherapy, despite being in complete remission. However, 8 of 11 patients converted to lacking cells in their blood from the malignant clone detectable by PCR after vaccination and sustained their molecular remissions. Tumor-specific cytotoxic CD8(+) and CD4(+) T cells were uniformly found (19 of 20 patients), whereas antibodies were detected, but apparently were not required for molecular remission. Vaccination was thus associated with clearance of residual tumor cells from blood and long-term disease-free survival. The demonstration of molecular remissions, analysis of cytotoxic T lymphocytes against autologous tumor targets, and addition of granulocyte-monocyte colony-stimulating factor to the vaccine formulation provide principles relevant to the design of future clinical trials of other cancer vaccines administered in a minimal residual disease setting.	NCI, Dept Expt Transplantat & Immunol, Med Branch, Div Clin Sci, Bethesda, MD 20892 USA; NCI, Biol Resources Branch, Div Canc Treatment & Diag, Bethesda, MD 20892 USA; NCI, Pathol Lab, Bethesda, MD 20892 USA; Penn State Univ, Dept Pathol, Hershey, PA 17033 USA; Sci Applicat Int Corp, Frederick, MD USA; NIA, NIH, Gerontol Res Ctr, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Kwak, LW (corresponding author), NCI, Dept Expt Transplantat & Immunol, Med Branch, Div Clin Sci, Bethesda, MD 20892 USA.	kwak@mail.ncifcrf.gov	Longo, Dan L./F-6022-2011; Jaffe, Elaine/G-8981-2014	Kwak, Larry/0000-0002-1884-5349				Brossart P, 1998, CANCER RES, V58, P732; Correale P, 1997, JNCI-J NATL CANCER I, V89, P293, DOI 10.1093/jnci/89.4.293; CORTOPASSI GA, 1992, MUTAT RES, V277, P239, DOI 10.1016/0165-1110(92)90046-C; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; GRABBE S, 1995, IMMUNOL TODAY, V16, P117, DOI 10.1016/0167-5699(95)80125-1; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; GRIBBEN JG, 1991, BLOOD, V78, P3275; Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Kato K, 1998, J CLIN INVEST, V101, P1133, DOI 10.1172/JCI1472; KIM HT, 1995, J IMMUNOL, V154, P1614; Kobrin CB, 1997, CANCER INVEST, V15, P577, DOI 10.3109/07357909709047600; Kwak LW, 1996, P NATL ACAD SCI USA, V93, P10972, DOI 10.1073/pnas.93.20.10972; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; KWAK LW, 1995, LANCET, V345, P1016, DOI 10.1016/S0140-6736(95)90757-2; LEE MS, 1987, SCIENCE, V237, P175, DOI 10.1126/science.3110950; Lopez-Guillermo A, 1998, BLOOD, V91, P2955, DOI 10.1182/blood.V91.8.2955.2955_2955_2960; LYNCH RG, 1972, P NATL ACAD SCI USA, V69, P1540, DOI 10.1073/pnas.69.6.1540; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; Nelson EL, 1996, BLOOD, V88, P580, DOI 10.1182/blood.V88.2.580.bloodjournal882580; Osterborg A, 1998, BLOOD, V91, P2459, DOI 10.1182/blood.V91.7.2459.2459_2459_2466; RAFFELD M, 1985, NEW ENGL J MED, V312, P1653, DOI 10.1056/NEJM198506273122601; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; SCHULTZE JL, 1995, P NATL ACAD SCI USA, V92, P8200, DOI 10.1073/pnas.92.18.8200; Schultze JL, 1997, BLOOD, V89, P3806, DOI 10.1182/blood.V89.10.3806.3806_3806_3816; SHU S, 1987, J IMMUNOL, V139, P295; STEVENSON GT, 1975, NATURE, V254, P714, DOI 10.1038/254714a0; WILTROUT RH, 1981, J IMMUNOL METHODS, V43, P319, DOI 10.1016/0022-1759(81)90180-0	31	470	497	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1999	5	10					1171	1177		10.1038/13928	http://dx.doi.org/10.1038/13928			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502821				2022-12-27	WOS:000082933200044
J	Hahn, WC; Stewart, SA; Brooks, MW; York, SG; Eaton, E; Kurachi, A; Beijersbergen, RL; Knoll, JHM; Meyerson, M; Weinberg, RA				Hahn, WC; Stewart, SA; Brooks, MW; York, SG; Eaton, E; Kurachi, A; Beijersbergen, RL; Knoll, JHM; Meyerson, M; Weinberg, RA			Inhibition of telomerase limits the growth of human cancer cells	NATURE MEDICINE			English	Article							CATALYTIC SUBUNIT GENE; HUMAN FIBROBLASTS; IMMORTAL CELLS; RNA COMPONENT; FISSION YEAST; LIFE-SPAN; IN-VITRO; P53; SENESCENCE; APOPTOSIS	Telomerase is a ribonucleoprotein enzyme that maintains the protective structures at the ends of eukaryotic chromosomes, called telomeres. In most human somatic cells, telomerase expression is repressed, and telomeres shorten progressively with each cell division. In contrast, most human tumors express telomerase, resulting in stabilized telomere length. These observations indicate that telomere maintenance is essential to the proliferation of tumor cells. We show here that expression of a mutant catalytic subunit of human telomerase results in complete inhibition of telomerase activity, reduction in telomere length and death of tumor cells. Moreover, expression of this mutant telomerase eliminated tumorigenicity in vivo. These observations demonstrate that disruption of telomere maintenance limits cellular lifespan in human cancer cells, thus validating human telomerase reverse transcriptase as an important target for the development of anti-neoplastic therapies.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol,Cytogenet Serv, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Weinberg, RA (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Meyerson, Matthew L/E-7123-2012; Stewart, Sheila A/C-5213-2012	Knoll, Joan/0000-0001-6691-1710; Beijersbergen, Roderick/0000-0003-0116-4130				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Bisoffi M, 1998, EUR J CANCER, V34, P1242, DOI 10.1016/S0959-8049(98)00049-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Goi K, 1997, CANCER RES, V57, P1895; GREIDER CW, 1995, TELOMERES, P35; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; LANDSDORP PM, 1996, HUM MOL GENET, V5, P685; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Ramakrishnan S, 1998, CANCER RES, V58, P622; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; SCHMID I, 1991, CYTOMETRY, V12, P279, DOI 10.1002/cyto.990120312; SEABRIGH.M, 1971, LANCET, V2, P971; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Strahl C, 1996, MOL CELL BIOL, V16, P53; Strobel T, 1998, ONCOGENE, V17, P2419, DOI 10.1038/sj.onc.1202180; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	57	885	943	4	107	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1164	1170		10.1038/13495	http://dx.doi.org/10.1038/13495			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502820				2022-12-27	WOS:000082933200043
J	Lahn, M; Kanehio, A; Takeda, K; Joetham, A; Schwarze, J; Kohler, G; O'Brien, R; Gelfand, EW; Born, W				Lahn, M; Kanehio, A; Takeda, K; Joetham, A; Schwarze, J; Kohler, G; O'Brien, R; Gelfand, EW; Born, W			Negative regulation of airway responsiveness that is dependent on gamma delta T cells and independent of alpha beta T cells	NATURE MEDICINE			English	Article							MURINE MODEL; MICE; HYPERRESPONSIVENESS; LYMPHOCYTES; HYPERREACTIVITY; RECEPTOR; ANTIGEN; SENSITIZATION; INFLAMMATION; REQUIREMENT	The mechanisms regulating airway function are complex and still poorly understood. In diseases such as asthma, involvement of immune-dependent mechanisms has been suggested in causing changes in airway responsiveness to bronchoconstrictors. We now demonstrate that gamma delta T cells can regulate airway function in an alpha beta T cell-independent manner, identifying them as important cells in pulmonary homeostasis. This function of gamma delta T cells differs from previously described immune-dependent mechanisms and may reflect their interaction with innate systems of host defense.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Div Basic Immunol, Denver, CO 80206 USA; Univ Freiburg, Inst Pathol, D-79104 Freiburg, Germany	National Jewish Health; National Jewish Health; University of Freiburg	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.		Schwarze, Jürgen/F-7396-2011	Schwarze, Jurgen/0000-0002-6899-748X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI001291, R01AI040611] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAID NIH HHS [AI-01291, AI-40611] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; BALA V, 1995, IEEE T PARALL DISTR, V6, P154, DOI 10.1109/71.342126; Bix M, 1998, J EXP MED, V188, P2289, DOI 10.1084/jem.188.12.2289; Boismenu R, 1996, J IMMUNOL, V157, P985; Born W, 1999, Adv Immunol, V71, P77; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; DeSanctis GT, 1997, NAT MED, V3, P460, DOI 10.1038/nm0497-460; DiTirro J, 1998, INFECT IMMUN, V66, P2284, DOI 10.1128/IAI.66.5.2284-2289.1998; GARSSEN J, 1991, AM REV RESPIR DIS, V144, P931, DOI 10.1164/ajrccm/144.4.931; Geba GP, 1997, J CLIN INVEST, V100, P629, DOI 10.1172/JCI119574; Gelfand EW, 1997, NAT MED, V3, P382, DOI 10.1038/nm0497-382; Guery JC, 1996, J EXP MED, V183, P485, DOI 10.1084/jem.183.2.485; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; King DP, 1999, J IMMUNOL, V162, P5033; Lahn M, 1998, J IMMUNOL, V160, P5221; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Penido C, 1997, J IMMUNOL, V159, P853; Schramm CM, 1999, AM J RESP CRIT CARE, V159, pA255; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Strickland D, 1996, IMMUNOLOGY, V87, P250, DOI 10.1046/j.1365-2567.1996.459542.x; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; TAKEDA K, 1998, AM J RESP CRIT CARE, V157, pA599; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679; WOOLCOCK AJ, 1994, TXB RESP MED, V2, P1288; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	32	152	158	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1150	1156		10.1038/13476	http://dx.doi.org/10.1038/13476			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502818				2022-12-27	WOS:000082933200041
J	Ellerby, HM; Arap, W; Ellerby, LM; Kain, R; Andrusiak, R; Del Rio, G; Krajewski, S; Lombardo, CR; Rao, R; Ruoslahti, E; Bredesen, DE; Pasqualini, R				Ellerby, HM; Arap, W; Ellerby, LM; Kain, R; Andrusiak, R; Del Rio, G; Krajewski, S; Lombardo, CR; Rao, R; Ruoslahti, E; Bredesen, DE; Pasqualini, R			Anti-cancer activity of targeted pro-apoptotic peptides	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; ANTIMICROBIAL PEPTIDES; OUTER-MEMBRANE; RAT-LIVER; MITOCHONDRIAL; ANGIOGENESIS; CARDIOLIPIN; RECEPTOR; RESIDUES; MODEL	We have designed short peptides composed of two functional domains, one a tumor blood vessel 'homing' motif and the other a programmed cell death-inducing sequence, and synthesized them by simple peptide chemistry. The 'homing' domain was designed to guide the peptide to targeted cells and allow its internalization. The pro-apoptotic domain was designed to be nontoxic outside cells, but toxic when internalized into targeted cells by the disruption of mitochondrial membranes. Although our prototypes contain only 21 and 26 residues, they were selectively toxic to angiogenic endothelial cells and showed anti-cancer activity in mice. This approach may yield new therapeutic agents.	Burnham Inst, Program Aging & Canc, La Jolla, CA 92037 USA; Burnham Inst, Program Cell Adhes, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, Program Aging & Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kain, Renate/ACR-4709-2022	Kain, Renate/0000-0002-2428-543X	NATIONAL CANCER INSTITUTE [P01CA028896, R01CA074238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033376] Funding Source: NIH RePORTER; NCI NIH HHS [CA28896, CA74238] Funding Source: Medline; NINDS NIH HHS [NS33376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALVAREZBRAVO J, 1994, BIOCHEM J, V302, P535, DOI 10.1042/bj3020535; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014; BAITCHEFFSKY H, 1981, MITOCHONDRIA MICROSO; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; Bicknell R, 1997, TUMOUR ANGIOGENESIS, P19; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V882, P1; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Epand RM, 1993, AMPHIPATHIC HELIX; Folkman Judah, 1997, P3075; GOTO F, 1993, LAB INVEST, V69, P508; HART SL, 1994, J BIOL CHEM, V269, P12468; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; HOVIUS R, 1993, FEBS LETT, V330, P71, DOI 10.1016/0014-5793(93)80922-H; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; Mancheno JM, 1998, J PEPT RES, V51, P142; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PASQUALINI R, IN PRESS PHAGE DISPL; PASQUALINI R, 1996, NATURE, V380, P36; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Samaniego F, 1998, AM J PATHOL, V152, P1433; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	31	785	888	5	152	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1032	1038		10.1038/12469	http://dx.doi.org/10.1038/12469			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470080				2022-12-27	WOS:000082337200037
J	Novak, K				Novak, K			Feeling sleepy? Its in your genes!	NATURE MEDICINE			English	News Item														Novak, Kristine/0000-0001-9314-1803					0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					981	981		10.1038/12412	http://dx.doi.org/10.1038/12412			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470064	Bronze			2022-12-27	WOS:000082337200020
J	Klivenyi, P; Ferrante, RJ; Matthews, RT; Bogdanov, MB; Klein, AM; Andreassen, OA; Mueller, G; Wermer, M; Kaddurah-Daouk, R; Beal, MF				Klivenyi, P; Ferrante, RJ; Matthews, RT; Bogdanov, MB; Klein, AM; Andreassen, OA; Mueller, G; Wermer, M; Kaddurah-Daouk, R; Beal, MF			Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis	NATURE MEDICINE			English	Article							SUPEROXIDE-DISMUTASE MUTATION; NMR MAGNETIZATION-TRANSFER; MOTOR-NEURON DISEASE; MOUSE MODEL; KINASE; DEGENERATION; BRAIN; EXPRESSION; MICE	Mitochondria are particularly vulnerable to oxidative stress, and mitochondrial swelling and vacuolization are among the earliest pathologic features found in two strains of transgenic amyotrophic lateral sclerosis (ALS) mice with SOD1 mutations(1,2). Mice with the G93A human SOD1 mutation have altered electron transport enzymes, and expression of the mutant enzyme in vitro results in a loss of mitochondrial membrane potential and elevated cytosolic calcium concentration(3). Mitochondrial dysfunction may lead to ATP depletion, which may contribute to cell death. If this is true, then buffering intracellular energy levels could exert neuroprotective effects. Creatine kinase and its substrates creatine and phosphocreatine constitute an intricate cellular energy buffering and transport system connecting sites of energy production (mitochondria) with sites of energy consumption(4) and creatine administration stabilizes the mitochondrial creatine kinase and inhibits opening of the mitochondrial transition pore(5). We found that oral administration of creatine produced a dose-dependent improvement in motor performance and extended survival in G93A transgenic mice, and it protected mice from loss of both motor neurons and substantia nigra neurons at 120 days of age. Creatine administration protected G93A transgenic mice from increases in biochemical indices of oxidative damage. Therefore, creatine administration may be a new therapeutic strategy for ALS.	Massachusetts Gen Hosp, Neurol Serv, Neurochem Lab, Boston, MA 02118 USA; Harvard Univ, Sch Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Dept Vet Affairs, Bedford, MA 01730 USA; Avicena Grp Inc, Cambridge, MA 02142 USA; Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University; Boston University; Boston University; Cornell University	Beal, MF (corresponding author), Massachusetts Gen Hosp, Neurol Serv, Neurochem Lab, 32 Fruit St, Boston, MA 02118 USA.		Andreassen, Ole A./AAY-7531-2020	Klivenyi, Peter/0000-0002-5389-3266; Kaddurah-Daouk, Rima/0000-0003-1858-5732; Andreassen, Ole A./0000-0002-4461-3568	NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH011692] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG12292] Funding Source: Medline; NIMH NIH HHS [MH11692] Funding Source: Medline; NINDS NIH HHS [NS37102] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLANCHARD V, 1994, MOL BRAIN RES, V22, P29, DOI 10.1016/0169-328X(94)90029-9; Bogdanov MB, 1998, J NEUROCHEM, V71, P1321; Carri MT, 1997, FEBS LETT, V414, P365, DOI 10.1016/S0014-5793(97)01051-X; CORBETT RJT, 1994, J CEREBR BLOOD F MET, V14, P1070, DOI 10.1038/jcbfm.1994.140; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; HEMMER W, 1993, DEV NEUROSCI-BASEL, V15, P249, DOI 10.1159/000111342; Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x; Kostic V, 1997, ANN NEUROL, V41, P497, DOI 10.1002/ana.410410413; Matthews RT, 1998, J NEUROSCI, V18, P156; OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SASAKI S, 1990, J NEUROL SCI, V97, P233, DOI 10.1016/0022-510X(90)90221-8; SAUTER A, 1993, J BIOL CHEM, V268, P13166; Siklos L, 1996, ANN NEUROL, V39, P203, DOI 10.1002/ana.410390210; SIPILA I, 1981, NEW ENGL J MED, V304, P867, DOI 10.1056/NEJM198104093041503; White RJ, 1996, J NEUROSCI, V16, P5688; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Xu CJ, 1996, J BIOL CHEM, V271, P13435, DOI 10.1074/jbc.271.23.13435	22	551	583	1	39	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					347	350		10.1038/6568	http://dx.doi.org/10.1038/6568			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086395				2022-12-27	WOS:000078851600044
J	Shibata, R; Igarashi, T; Haigwood, N; Buckler-White, A; Ogert, R; Ross, W; Willey, R; Cho, MW; Martin, MA				Shibata, R; Igarashi, T; Haigwood, N; Buckler-White, A; Ogert, R; Ross, W; Willey, R; Cho, MW; Martin, MA			Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE GLOBULIN; MONOCLONAL-ANTIBODY; VACCINE DEVELOPMENT; CHIMPANZEES; TYPE-1; CHALLENGE; PROTECTION; GP120; PREVENTION	Virus-specific antibodies protect individuals against a wide variety of viral infections(1-7). To assess whether human immunodeficiency virus type 1 (HIV-1) envelope-specific antibodies confer resistance against primate lentivirus infections, we purified immunoglobulin (IgG) from chimpanzees infected with several different HIV-1 isolates, and used this for passive immunization of pig-tailed macaques. These monkeys were subsequently challenged intravenously with a chimeric simian-human immunodeficiency virus (SHIV) bearing an envelope glycoprotein derived form HIV-1(DH12), a dual-tropic primary virus isolate. Here we show that anti-SHIV neutralizing activity, determined in vitro using an assay measuring loss of infectivity, is the absolute requirement for antibody-mediated protection in vivo. Using an assay that measures 100% neutralization, the titer in plasma for complete protection of the SHIV-challenged macaques was in the range of 1:5-1:8. The HIV-1-specific neutralizing antibodies studied are able to bind to native gp120 present on infectious virus particles. Administration of non-neutralizing anti-HIV IgG neither inhibited nor enhanced a subsequent SHIV infection.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Seattle Biomed Res Inst, Seattle, WA 98109 USA; Georgetown Med Ctr, Div Mol Virol & Immunol, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Center for Infectious Disease Research; Georgetown University	Shibata, R (corresponding author), VaxGen, 1000 Marina Blvd, Brisbane, CA 94005 USA.		Haigwood, Nancy Logan/AAV-7484-2020	Haigwood, Nancy/0000-0002-1477-9575; Cho, Michael/0000-0003-0522-345X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000415, ZIAAI000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR LO, 1989, J VIROL, V63, P5046, DOI 10.1128/JVI.63.12.5046-5053.1989; BEASLEY RP, 1983, HEPATOLOGY, V3, P135; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BOGERS WMJM, 1995, AIDS, V9, pF13; BRUCK C, 1994, VACCINE, V12, P1141, DOI 10.1016/0264-410X(94)90185-6; Cho MW, 1998, J VIROL, V72, P2509, DOI 10.1128/JVI.72.3.2509-2515.1998; Conley AJ, 1996, J VIROL, V70, P6751, DOI 10.1128/JVI.70.10.6751-6758.1996; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; HAMMON WM, 1953, JAMA-J AM MED ASSOC, V151, P1272; JANEWAY CA, 1945, B NEW YORK ACAD MED, V21, P202; Johnson RP, 1996, CURR OPIN IMMUNOL, V8, P554, DOI 10.1016/S0952-7915(96)80046-X; KRUGMAN S, 1960, JAMA-J AM MED ASSOC, V174, P83; Moore J, 1997, AIDS RES HUM RETROV, V13, P733, DOI 10.1089/aid.1997.13.733; *NIH, 1985, DHHS PUBL NIH, V8523; PRINCE PN, 1991, OMEGA-J DEATH DYING, V23, P1; REED L. J., 1938, AMER JOUR HYG, V27, P493; Shibata R, 1997, AIDS RES HUM RETROV, V13, P377, DOI 10.1089/aid.1997.13.377; Shibata R, 1997, J INFECT DIS, V176, P362, DOI 10.1086/514053; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; Shibata R, 1996, J VIROL, V70, P4361, DOI 10.1128/JVI.70.7.4361-4369.1996; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; Stott E J, 1994, Curr Top Microbiol Immunol, V188, P221; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; WILLEY RL, 1994, J VIROL, V68, P1029, DOI 10.1128/JVI.68.2.1029-1039.1994; WILLEY RL, 1991, VIROLOGY, V184, P319, DOI 10.1016/0042-6822(91)90848-6; Willey RL, 1996, J VIROL, V70, P6431, DOI 10.1128/JVI.70.9.6431-6436.1996	31	480	516	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					204	210		10.1038/5568	http://dx.doi.org/10.1038/5568			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930869	Bronze			2022-12-27	WOS:000078274400030
J	Walczak, H; Miller, RE; Ariail, K; Gliniak, B; Griffith, TS; Kubin, M; Chin, W; Jones, J; Woodward, A; Le, T; Smith, C; Smolak, P; Goodwin, RG; Rauch, CT; Schuh, JCL; Lynch, DH				Walczak, H; Miller, RE; Ariail, K; Gliniak, B; Griffith, TS; Kubin, M; Chin, W; Jones, J; Woodward, A; Le, T; Smith, C; Smolak, P; Goodwin, RG; Rauch, CT; Schuh, JCL; Lynch, DH			Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo	NATURE MEDICINE			English	Article							TNF RECEPTOR SUPERFAMILY; TRAIL-INDUCED APOPTOSIS; FAS-LIGAND; RECOMBINANT HUMAN; RHEUMATOID-ARTHRITIS; DEATH DOMAIN; CELL-DEATH; T-CELLS; FAMILY; ACTIVATION	To evaluate the utility of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic, we created leucine zipper (LZ) forms of human (hu) and murine (mu) TRAIL to promote and stabilize the formation of trimers. Both were biologically active, inducing apoptosis of both human and murine target cells in vitro with similar specific activities. In contrast to the fulminant hepatotoxicity of LZ-huCD95L in vivo, administration of either LZ-huTRAIL or LZ-muTRAIL did not seem toxic to normal tissues of mice. Finally, repeated treatments with LZ-huTRAIL actively suppressed growth of the TRAIL-sensitive human mammary adenocarcinoma cell line MDA-231 in CB. 17 (SCID) mice, and histologic examination of tumors from SCID mice treated with LZ-huTRAIL demonstrated clear areas of apoptotic necrosis within 9-12 hours of injection.	Immunex Res & Dev Corp, Seattle, WA 98101 USA		Lynch, DH (corresponding author), Immunex Res & Dev Corp, 51 Univ St, Seattle, WA 98101 USA.	Lynch@Immunex.com	Griffith, Thomas/ABF-8225-2020	Walczak, Henning/0000-0002-6312-4591; Schuh, JoAnn C. L./0000-0002-2399-8518				ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BROUCKAERT PGG, 1986, INT J CANCER, V38, P763, DOI 10.1002/ijc.2910380521; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CERAMI A, 1988, IMMUNOL TODAY, V9, P28, DOI 10.1016/0167-5699(88)91353-9; COHEN J, 1988, BONE MARROW TRANSPL, V3, P193; COSMAN D, 1994, STEM CELLS, V12, P440, DOI 10.1002/stem.5530120501; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Fanslow W C, 1994, Semin Immunol, V6, P267, DOI 10.1006/smim.1994.1035; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Griffith TS, 1998, J IMMUNOL, V161, P2833; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter ME, 1997, BRIT MED BULL, V53, P604; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; REVEL M, 1987, CIBA F SYMP, V129, P223; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Tanaka M, 1997, J IMMUNOL, V158, P2303; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	46	2163	2318	1	86	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					157	163		10.1038/5517	http://dx.doi.org/10.1038/5517			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930862				2022-12-27	WOS:000078274400023
J	Machelska, H; Cabot, PJ; Mousa, SA; Zhang, Q; Stein, C				Machelska, H; Cabot, PJ; Mousa, SA; Zhang, Q; Stein, C			Pain control in inflammation governed by selectins	NATURE MEDICINE			English	Article							CORTICOTROPIN-RELEASING FACTOR; PERIPHERAL OPIOID ANALGESIA; INFLAMED TISSUE; POLYSACCHARIDE FUCOIDIN; GENE-EXPRESSION; BETA-ENDORPHIN; IMMUNE CELLS; P-SELECTIN; RECEPTORS; RATS	Opioid-containing immune cells migrate preferentially to inflamed sites, where they release beta-endorphin which activates peripheral opioid receptors to inhibit pain(1,2). Immunocyte recruitment is a multistep, sequential engagement of various adhesion molecules located on immune cells and vascular endothelium. Selectins mediate the initial phase of immunoctye extravasation into inflamed sites(3,4). Here we show that anti-selectin treatment abolishes peripheral opioid analgesia elicited either endogenously (by stress) or by corticotropin-releasing factor. This results from a blockade of the infiltration of immunocytes containing beta-endorphin and the consequent decrease of the beta-endorphin content in the inflamed tissue. These findings indicate that the immune system uses mechanisms of cell migration not only to fight pathogens but also to control pain in injured tissue. Thus, pain is exacerbated by measures inhibiting the immigration of opioid-producing cells or, conversely, analgesia might be conveyed by adhesive interactions that recruit those cells to injured tissue.	Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; NIDA, Preclin Pharmacol Lab, IRP, NIH, Baltimore, MD 21224 USA; Free Univ Berlin, Klinikum Benjamin Franklin, Klin Anaesthesiol & Operat Intens Med, D-12200 Berlin, Germany	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Machelska, H (corresponding author), Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St, Baltimore, MD 21287 USA.		Mousa, Shaker A/A-7151-2017; Cabot, Peter John/B-2424-2013	Mousa, Shaker A/0000-0002-9294-015X; Cabot, Peter John/0000-0003-1778-3753; Machelska, Halina/0000-0001-6315-2958; Stein, Christoph/0000-0001-5240-6836				ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; Bochner BS, 1995, INFLAMMATION MEDIATO, P29; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Davenpeck KL, 1997, J IMMUNOL, V159, P1977; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; Ji RR, 1995, J NEUROSCI, V15, P8156; Kanwar S, 1997, J EXP MED, V185, P1077, DOI 10.1084/jem.185.6.1077; KUBES P, 1995, J CLIN INVEST, V95, P2510, DOI 10.1172/JCI117952; LEY K, 1993, BLOOD, V81, P177; LIM HC, 1988, EXP NEUROL, V99, P133, DOI 10.1016/0014-4886(88)90133-1; Lyons PD, 1997, J NEUROIMMUNOL, V78, P47, DOI 10.1016/S0165-5728(97)00081-7; MEBIUS RE, 1993, J IMMUNOL, V151, P3252; Mousa SA, 1996, EUR J PHARMACOL, V311, P221, DOI 10.1016/0014-2999(96)00440-2; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; Schafer M, 1996, P NATL ACAD SCI USA, V93, P6096, DOI 10.1073/pnas.93.12.6096; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Sharp B, 1997, NAT MED, V3, P831, DOI 10.1038/nm0897-831; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; Stein C, 1996, J CLIN INVEST, V98, P793, DOI 10.1172/JCI118852; STEIN C, 1990, J NEUROSCI, V10, P1292; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Teixeira MM, 1997, BRIT J PHARMACOL, V120, P1059, DOI 10.1038/sj.bjp.0701024	27	140	144	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1425	1428		10.1038/4017	http://dx.doi.org/10.1038/4017			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846582				2022-12-27	WOS:000077336900040
J	Ikemoto, M; Takita, M; Imamura, T; Inoue, K				Ikemoto, M; Takita, M; Imamura, T; Inoue, K			Increased sensitivity to the stimulant effects of morphine conferred by anti-adhesive glycoprotein SPARC in amygdala	NATURE MEDICINE			English	Article							VENTRAL TEGMENTAL AREA; MU-OPIOID-RECEPTOR; EXTRACELLULAR-MATRIX GLYCOPROTEIN; NUCLEUS-ACCUMBENS; BEHAVIORAL SENSITIZATION; IMMUNOHISTOCHEMICAL LOCALIZATION; MOLECULAR-CLONING; REVERSE TOLERANCE; PREFRONTAL CORTEX; PROTEIN-SYNTHESIS	Repeated administration of morphine substantially increases its locomotor-enhancing activity, a phenomenon termed locomotor sensitization. Here we show that secreted protein acidic and rich in cysteine (SPARC), an anti-adhesive glycoprotein present in the basolateral amygdala, contributes to the establishment of locomotor sensitization. The morphine-induced increase in SPARC levels in the basolateral amygdala persisted after morphine withdrawal and coincided with the duration of locomotor sensitization. Moreover, a single injection of morphine after SPARC infusion into the basolateral amygdala of previously uninjected mice substantially enhanced locomotor activity. Thus, SPARC may be an important element for establishing locomotor sensitization to morphine.	Minist Int Trade & Ind, Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Dept Biomol Engn, Tsukuba, Ibaraki 3058566, Japan; Minist Int Trade & Ind, Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Dept Biosignaling, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Ikemoto, M (corresponding author), Minist Int Trade & Ind, Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Dept Biomol Engn, 1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.		IKEMOTO, Mitsushi J/L-8861-2018; Takita, Masatoshi/N-3378-2016	IKEMOTO, Mitsushi J/0000-0001-5799-0672; Takita, Masatoshi/0000-0003-1140-5268				Akirav I, 1999, NEUROSCI LETT, V270, P83, DOI 10.1016/S0304-3940(99)00488-7; Bassuk JA, 1996, ARCH BIOCHEM BIOPHYS, V325, P8, DOI 10.1006/abbi.1996.0002; BRADY LS, 1981, PHARMACOL BIOCHEM BE, V14, P361, DOI 10.1016/0091-3057(81)90403-2; BUNNEY WC, 1984, PSYCHOPHARMACOLOGY, V82, P318, DOI 10.1007/BF00427677; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; Collins DR, 1999, J NEUROSCI, V19, P836; CRISWELL HE, 1990, BRAIN RES, V512, P284, DOI 10.1016/0006-8993(90)90638-R; Ding YQ, 1996, J COMP NEUROL, V367, P375; DOU CL, 1994, J NEUROSCI, V14, P7616; ELLINWOO.EH, 1971, SCIENCE, V171, P420, DOI 10.1126/science.171.3969.420; GUITART X, 1992, J NEUROCHEM, V58, P1168, DOI 10.1111/j.1471-4159.1992.tb09377.x; Hatfield T, 1996, J NEUROSCI, V16, P5256; IKEMOTO M, 1995, NEUROREPORT, V6, P262, DOI 10.1097/00001756-199501000-00009; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; KANETO H, 1973, JPN J PHARMACOL, V23, P701, DOI 10.1254/jjp.23.701; KARLER R, 1993, BRAIN RES, V603, P19, DOI 10.1016/0006-8993(93)91294-3; KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3; KELLEY AE, 1982, NEUROSCIENCE, V7, P615, DOI 10.1016/0306-4522(82)90067-7; Killcross S, 1997, NATURE, V388, P377, DOI 10.1038/41097; KURIBARA H, 1989, JPN J PHARMACOL, V49, P197, DOI 10.1254/jjp.49.197; MANN K, 1987, FEBS LETT, V218, P167, DOI 10.1016/0014-5793(87)81040-2; MANSOUR A, 1995, J CHEM NEUROANAT, V8, P283, DOI 10.1016/0891-0618(95)00055-C; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MATSUI M, 1996, NEUROSCIENCE PROTOCO, V20, P1; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mendis DB, 1996, BRAIN RES, V713, P53, DOI 10.1016/0006-8993(95)01472-1; MENDIS DB, 1995, BRAIN RES, V676, P69, DOI 10.1016/0006-8993(95)00101-U; MURAMOTO K, 1993, NEUROSCIENCE, V52, P621, DOI 10.1016/0306-4522(93)90411-8; NAKAMURA H, 1978, PSYCHOPHARMACOLOGY, V56, P269, DOI 10.1007/BF00432849; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; PHILLIPSON OT, 1979, J COMP NEUROL, V187, P117, DOI 10.1002/cne.901870108; POST RM, 1976, NATURE, V260, P731, DOI 10.1038/260731a0; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHINONAGA Y, 1994, NEUROSCIENCE, V58, P389, DOI 10.1016/0306-4522(94)90045-0; Soderling JA, 1997, J HISTOCHEM CYTOCHEM, V45, P823, DOI 10.1177/002215549704500607; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; SORG BA, 1995, SYNAPSE, V20, P217, DOI 10.1002/syn.890200305; SPANAGEL R, 1995, BEHAV BRAIN RES, V70, P37, DOI 10.1016/0166-4328(94)00176-G; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; VEZINA P, 1987, BRAIN RES, V417, P51, DOI 10.1016/0006-8993(87)90178-8; WALLACE DM, 1992, BRAIN RES BULL, V28, P447, DOI 10.1016/0361-9230(92)90046-Z; Wang SJ, 1999, J NEUROSCI, V19, P10656, DOI 10.1523/JNEUROSCI.19-24-10656.1999; Wang XB, 1997, J NEUROSCI, V17, P5993; WOLF ME, 1995, NEUROSCIENCE, V69, P417, DOI 10.1016/0306-4522(95)00248-H; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	49	25	29	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					910	915		10.1038/78675	http://dx.doi.org/10.1038/78675			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932229				2022-12-27	WOS:000165473800035
J	Lakkis, FG; Arakelov, A; Konieczny, BT; Inoue, Y				Lakkis, FG; Arakelov, A; Konieczny, BT; Inoue, Y			Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue	NATURE MEDICINE			English	Article							T-CELLS; ENDOTHELIAL-CELLS; IMMUNE-RESPONSES; IFN-GAMMA; MOUSE; MICE; REJECTION; MUTATION; ROLES; CD40	Secondary lymphoid organs (the spleen, lymph nodes and mucosal lymphoid tissues) provide the proper environment for antigen-presenting cells to interact with and activate naive T and B lymphocytes(1). Although it is generally accepted that secondary lymphoid organs are essential for initiating immune responses to microbial antigens and to skin allografts(2-6), the prevailing view has been that the immune response to primarily vascularized organ transplants such as hearts and kidneys does not require the presence of secondary lymphoid tissue. The assumption has been that the immune response to such organs is initiated in the graft itself when recipient lymphocytes encounter foreign histocompatibility antigens presented by the graft's endothelial cells(7-13). In contrast to this view, we show here that cardiac allografts are accepted indefinitely in recipient mice that lack secondary lymphoid tissue, indicating that the alloimmune response to a vascularized organ transplant cannot be initiated in the graft itself. Moreover, we demonstrate that the permanent acceptance of these grafts is not due to tolerance but is because of immunologic 'ignorance'.	Vet Affairs Med Ctr, Atlanta, GA 30033 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Lakkis, FG (corresponding author), Emory Univ, Sch Med, Dept Med, Div Renal, 1670 Clairmont Rd, Atlanta, GA 30033 USA.				NIAID NIH HHS [AI41643, AI44644] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041643] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER CF, 1968, J EXP MED, V128, P197, DOI 10.1084/jem.128.1.197; BRENT L, 1967, BRIT MED BULL, V23, P55, DOI 10.1093/oxfordjournals.bmb.a070517; Briscoe DM, 1998, CURR OPIN IMMUNOL, V10, P525, DOI 10.1016/S0952-7915(98)80218-5; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; GOES N, 1995, J IMMUNOL, V155, P4559; Goodnow CC, 1997, IMMUNOL REV, V156, P5, DOI 10.1111/j.1600-065X.1997.tb00954.x; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; Konieczny BT, 1998, J IMMUNOL, V160, P2059; Ma WL, 1998, J IMMUNOL, V161, P2158; MEDAWAR PB, 1957, P ROY SOC LOND B BIO, V149, P145; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; PEDERSEN NC, 1970, J EXP MED, V131, P936, DOI 10.1084/jem.131.5.936; Perez VL, 1998, CELL IMMUNOL, V189, P31, DOI 10.1006/cimm.1998.1362; Picker L.J., 1999, FUNDAMENTAL IMMUNOLO, P479; Pober JS, 1996, TRANSPLANTATION, V61, P343, DOI 10.1097/00007890-199602150-00001; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; STROBER S, 1965, J EXP MED, V122, P347, DOI 10.1084/jem.122.2.347; VETTO RM, 1967, TRANSPLANTATION, V5, P1537; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	23	332	334	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					686	688		10.1038/76267	http://dx.doi.org/10.1038/76267			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835686				2022-12-27	WOS:000087438300040
J	Werkele, T; Kurtz, J; Ito, H; Ronquillo, JV; Dong, V; Zhao, GL; Shaffer, J; Sayegh, MH; Sykes, M				Werkele, T; Kurtz, J; Ito, H; Ronquillo, JV; Dong, V; Zhao, GL; Shaffer, J; Sayegh, MH; Sykes, M			Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment	NATURE MEDICINE			English	Article							NONLETHAL PREPARATIVE REGIMEN; RENAL-ALLOGRAFT REJECTION; T-CELLS; CLONAL DELETION; CHIMERISM; MICE; ENGRAFTMENT; INDUCTION; ACCEPTANCE; RECONSTITUTION	Allogeneic bone marrow transplantation tin immunocompetent adults) has always required cytoreductive treatment of recipients with irradiation or cytotoxic drugs to achieve lasting engraftment at levels detectable by non-PCR-based techniques ('macrochimerism' or 'mixed chimerism')(1-11). Only syngeneic marrow engraftment at such levels has been achieved in unconditioned hosts(12,13). This requirement for potentially toxic myelosuppressive host pre-conditioning has precluded the clinical use of allogeneic bone marrow transplantation for many indications other than malignancies, including tolerance induction. We demonstrate here that treatment of naive mice with a high dose of fully major histocompatibility complex-mismatched allogeneic bone marrow, followed by one injection each of monoclonal antibody against CD154 and cytotoxic T-lymphocyte antigen 4 immunoglobulin, resulted in multi-lineage hematopoietic macrochimerism (of about 15%) that persisted for up to 34 weeks. Long-term chimeras developed donor-specific tolerance (donor skin graft survival of more than 145 days) and demonstrated ongoing intrathymic deletion of donor-reactive T cells. A protocol of high-dose bone marrow transplantation and co-stimulatory blockade can thus achieve allogeneic bone marrow engraftment without cytoreduction or T-cell depletion of the host, and eliminates a principal barrier to the more widespread use of allogeneic bone marrow transplantation(14-18). Although efforts have been made to minimize host pre-treatment for allogeneic bone marrow transplantation for tolerance induction, so far none have succeeded in eliminating pre-treatment completely. Our demonstration that this can be achieved provides the rationale for a safe approach for inducing robust transplantation tolerance in large animals and humans.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr,BMT Sect, Boston, MA 02129 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Lab Immunogenet & Transplantat, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sykes, M (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr,BMT Sect, MGH E,Bldg 149-5102,13th St, Boston, MA 02129 USA.			Wekerle, Thomas/0000-0001-5159-2796	NHLBI NIH HHS [R01HL49915] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049915] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; BACHARLUSTIG E, 1995, NAT MED, V1, P1268, DOI 10.1038/nm1295-1268; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; Brocker T, 1997, J EXP MED, V185, P541, DOI 10.1084/jem.185.3.541; Colson YL, 1996, J IMMUNOL, V157, P2820; COLSON YL, 1997, BLOOD, V88, P4601; deVriesvanderZwan A, 1997, BLOOD, V89, P2596, DOI 10.1182/blood.V89.7.2596; DOWN JD, 1993, EXP HEMATOL, V21, P913; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; Elwood ET, 1998, TRANSPLANTATION, V65, P1422, DOI 10.1097/00007890-199806150-00002; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; Krivit W, 1999, Curr Opin Neurol, V12, P167, DOI 10.1097/00019052-199904000-00007; KRIVIT W, 1994, BONE MARROW TRANSPL, P883; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li H, 1996, J IMMUNOL, V156, P380; MAYUMI H, 1989, J EXP MED, V169, P213, DOI 10.1084/jem.169.1.213; Messner RP, 1997, J RHEUMATOL, V24, P819; NOMOTO K, 1995, TRANSPLANTATION, V59, P395, DOI 10.1097/00007890-199502150-00015; Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SHARABI Y, 1990, J EXP MED, V172, P195, DOI 10.1084/jem.172.1.195; STEWART FM, 1993, BLOOD, V81, P2566; Storb R, 1997, BLOOD, V89, P3048, DOI 10.1182/blood.V89.8.3048; Sykes M, 1997, NAT MED, V3, P783, DOI 10.1038/nm0797-783; Sykes M, 1998, EXP HEMATOL, V26, P457; Sykes M, 1996, CURR OPIN IMMUNOL, V8, P694, DOI 10.1016/S0952-7915(96)80088-4; TOMITA Y, 1994, J IMMUNOL, V153, P1087; TOMONARI K, 1991, IMMUNOGENETICS, V33, P157, DOI 10.1007/BF01719234; Trambley J, 1999, J CLIN INVEST, V104, P1715, DOI 10.1172/JCI8082; Wang BY, 1997, P NATL ACAD SCI USA, V94, P12065, DOI 10.1073/pnas.94.22.12065; Wekerle T, 1998, J EXP MED, V187, P2037, DOI 10.1084/jem.187.12.2037	35	400	417	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					464	469		10.1038/74731	http://dx.doi.org/10.1038/74731			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742157				2022-12-27	WOS:000165474100044
J	Herrera, VLM; Makrides, SC; Xie, HX; Adari, H; Krauss, RM; Ryan, US; Ruiz-Opazo, N				Herrera, VLM; Makrides, SC; Xie, HX; Adari, H; Krauss, RM; Ryan, US; Ruiz-Opazo, N			Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein	NATURE MEDICINE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; APOLIPOPROTEIN-A-I; MESSENGER-RNA; AORTIC ATHEROSCLEROSIS; MICE; GENE; SUSCEPTIBILITY; LIPOPROTEINS; TISSUES; PLASMA	The acceleration of atherosclerosis by polygenic (essential) hypertension is well-characterized in humans; however, the lack of an animal model that simulates human disease hinders the elucidation of pathogenic mechanisms. We report here a transgenic atherosclerosis-polygenic hypertension model in Dahl salt-sensitive hypertensive rats that overexpress the human cholesteryl ester transfer protein (Tg[hCETP](DS)). Male Tg[hCETP](DS) rats fed regular rat chow showed age-dependent severe combined hyperlipidemia, atherosclerotic lesions, myocardial infarctions and decreased survival. These findings differ from various mouse atherosclerosis models, demonstrating the necessity of complex disease modeling in different species. The data demonstrate that cholesteryl ester transfer protein can be proatherogenic. The interaction of polygenic hypertension and hyperlipidemia in the pathogenesis of atherosclerosis in Tg[hCETP](DS) rats substantiates epidemiological observations in humans.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Avant Immunotherapies, Needham, MA 02494 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol Med, Berkeley, CA 94720 USA	Boston University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Herrera, VLM (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 700 Albany St, Boston, MA 02118 USA.			Ruiz-Opazo, Nelson/0000-0001-8234-1332; Herrera, Victoria/0000-0001-8991-2134				ADARI H, 1998, NATO ASI SER, P235; ATKINSON JB, 1997, INT J CARDIOL, V6, pS125; BORHANI NO, 1992, ATHEROSCLEROSIS CHOL; Boyle JJ, 1997, J PATHOL, V181, P93, DOI 10.1002/(SICI)1096-9896(199701)181:1<93::AID-PATH696>3.0.CO;2-H; Brasen JH, 1998, VIRCHOWS ARCH, V432, P557, DOI 10.1007/s004280050205; BUJA LM, 1994, CIRCULATION, V89, P503, DOI 10.1161/01.CIR.89.1.503; Capers Q, 1997, HYPERTENSION, V30, P1397, DOI 10.1161/01.HYP.30.6.1397; Chobanian AV, 1996, ARCH INTERN MED, V156, P1952, DOI 10.1001/archinte.156.17.1952; CHOBANIAN AV, 1990, HYPERTENSION, V15, P666, DOI 10.1161/01.HYP.15.6.666; CHOBANIAN AV, 1989, HYPERTENSION, V14, P203, DOI 10.1161/01.HYP.14.2.203; DAVIES H, 1989, INT J CARDIOL, V25, P99, DOI 10.1016/0167-5273(89)90169-1; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; Ebara T, 1997, J CLIN INVEST, V99, P2672, DOI 10.1172/JCI119456; Foger B, 1996, ARTERIOSCL THROM VAS, V16, P1430, DOI 10.1161/01.ATV.16.12.1430; GRASS DS, 1995, J LIPID RES, V36, P1082; Guyard-Dangremont V, 1998, COMP BIOCHEM PHYS B, V120, P517, DOI 10.1016/S0305-0491(98)10038-X; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; Herrera VLM, 1998, J CLIN INVEST, V102, P1102, DOI 10.1172/JCI3868; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; JIANG XC, 1993, J BIOL CHEM, V268, P27406; Kitagawa S, 1996, EUR J PHARMACOL, V297, P71, DOI 10.1016/0014-2999(95)00729-6; KJELSBERG MO, 1986, PREV MED, V15, P254; KRAUSS RM, 1990, ENDOCRINOLOGY, V127, P1016, DOI 10.1210/endo-127-3-1016; Krauss Ronald M., 1998, American Journal of Medicine, V105, p58S, DOI 10.1016/S0002-9343(98)00213-7; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; Lefer DJ, 1999, CIRC RES, V84, P1353, DOI 10.1161/01.RES.84.11.1353; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; Moulin P, 1996, HORM RES, V45, P238, DOI 10.1159/000184795; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; NEIKEN NA, 1991, J CLIN INVEST, V88, P1121; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; ONG GL, 1989, J IMMUNOL METHODS, V125, P147, DOI 10.1016/0022-1759(89)90088-4; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; Plump AS, 1999, ARTERIOSCL THROM VAS, V19, P1105, DOI 10.1161/01.ATV.19.4.1105; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; RUSSELL PS, 1994, AM J PATHOL, V144, P260; Schecter AD, 1997, J BIOL CHEM, V272, P28568, DOI 10.1074/jbc.272.45.28568; Sechi LA, 1997, AM J HYPERTENS, V10, P1223, DOI 10.1016/S0895-7061(97)00220-3; SHIH DM, 1995, MOL MED TODAY, V1, P364, DOI 10.1016/S1357-4310(95)93834-6; Shioi T, 1997, CIRC RES, V81, P664; SHIOMI M, 1992, ATHEROSCLEROSIS, V96, P43, DOI 10.1016/0021-9150(92)90036-G; Torzewski J, 1997, ATHEROSCLEROSIS, V132, P131, DOI 10.1016/S0021-9150(97)00100-7; Tropea BI, 1996, J VASC SURG, V23, P596, DOI 10.1016/S0741-5214(96)80038-3; YAMASHITA S, 1991, METABOLISM, V40, P756, DOI 10.1016/0026-0495(91)90097-G; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751	48	108	115	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1383	1389		10.1038/70956	http://dx.doi.org/10.1038/70956			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581080				2022-12-27	WOS:000084049700037
J	Cella, M; Jarrossay, D; Facchetti, F; Alebardi, O; Nakajima, H; Lanzavecchia, A; Colonna, M				Cella, M; Jarrossay, D; Facchetti, F; Alebardi, O; Nakajima, H; Lanzavecchia, A; Colonna, M			Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon	NATURE MEDICINE			English	Article							ALPHA-PRODUCING CELLS; T-CELLS; DENDRITIC CELLS; RECEPTOR; CHEMOKINES; INDUCTION; DISTINCT; MATURE; PROLIFERATION; LYMPHADENITIS	We have identified two cell subsets in human blood based on the lack of lineage markers (lin(-)) and the differential expression of immunoglobulin-like transcript receptor 1 (ILT1) and ILT3. One subset (lin(-)/ILT3(+)/ILT1(+)) is related to myeloid dendritic cells. The other subset (lin(-)/ILi3(+)/ILT1(-)) corresponds to 'plasmacytoid monocytes'. These cells are found in inflamed lymph nodes in and around the high endothelial venules. They express CD62L and CXCR3, and produce extremely large amounts of type I interferon after stimulation with influenza virus or CD40L. These results, with the distinct cell phenotype, indicate that plasmacytoid monocytes represent a specialized cell lineage that enters inflamed lymph nodes at high endothelial venules, where it produces type I interferon. Plasmacytoid monocytes may protect other cells from viral infections and promote survival of antigen-activated T cells.	Beckman Coulter Co, Basel Inst Immunol, Marseille, France; Beckman Coulter Co, Immunotech, Marseille, France; Univ Brescia, Spedali Civili Brescia, Ist Anat Patol, Brescia, Italy	Beckman Coulter Inc.; Beckman Coulter Inc.; Hospital Spedali Civili Brescia; University of Brescia	Colonna, M (corresponding author), Beckman Coulter Co, Basel Inst Immunol, Marseille, France.		Cella, Marina/G-8850-2011; Facchetti, Fabio/E-7190-2010; Cella, Marina/ABA-8564-2020	Facchetti, Fabio/0000-0003-4975-2388; Cella, Marina/0000-0003-1230-1313; Colonna, Marco/0000-0001-5222-4987				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Belardelli F, 1998, CANCER RES, V58, P5795; Bjorck P, 1997, EUR J IMMUNOL, V27, P1266, DOI 10.1002/eji.1830270531; Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; CHEHIMI J, 1989, IMMUNOLOGY, V68, P488; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; FACCHETTI F, 1989, J PATHOL, V158, P57, DOI 10.1002/path.1711580112; FACCHETTI F, 1989, HUM PATHOL, V20, P588, DOI 10.1016/0046-8177(89)90248-7; FACCHETTI F, 1989, AM J CLIN PATHOL, V92, P42, DOI 10.1093/ajcp/92.1.42; FACCHETTI F, 1988, AM J PATHOL, V133, P15; FACCHETTI F, 1990, AM J SURG PATHOL, V14, P101, DOI 10.1097/00000478-199002000-00001; Facchetti F, 1991, Sarcoidosis, V8, P170; FACCHETTI F, 1991, AM J SURG PATHOL, V15, P1012, DOI 10.1097/00000478-199110000-00014; FACCHETTI F, 1990, AM J DERMATOPATH, V12, P363, DOI 10.1097/00000372-199008000-00006; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; FELDMAN M, 1990, J INTERFERON RES, V10, P435, DOI 10.1089/jir.1990.10.435; FITZGERALDBOCARSLY P, 1993, PHARMACOL THERAPEUT, V60, P39, DOI 10.1016/0163-7258(93)90021-5; FITZGERALDBOCARSLY P, 1988, J LEUKOCYTE BIOL, V43, P323, DOI 10.1002/jlb.43.4.323; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Grouard G, 1996, NATURE, V384, P364, DOI 10.1038/384364a0; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; HORNY HP, 1987, HUM PATHOL, V18, P28, DOI 10.1016/S0046-8177(87)80189-2; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; MULLERHERMELINK HK, 1983, AM J SURG PATHOL, V7, P849, DOI 10.1097/00000478-198307080-00013; Nakajima H, 1999, J IMMUNOL, V162, P5; NEDERMAN T, 1990, BIOLOGICALS, V18, P29, DOI 10.1016/1045-1056(90)90066-9; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; PERUSSIA B, 1985, Natural Immunity and Cell Growth Regulation, V4, P120; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; PRASTHOFER EF, 1985, AM J SURG PATHOL, V9, P380; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947	39	1299	1355	2	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					919	923		10.1038/11360	http://dx.doi.org/10.1038/11360			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426316				2022-12-27	WOS:000081684000036
J	Newberry, RD; Stenton, WF; Lorenz, RG				Newberry, RD; Stenton, WF; Lorenz, RG			Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen	NATURE MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; CD4(+) T-CELLS; PROSTAGLANDIN E-2; TRANSGENIC MICE; GENE DISRUPTION; LAMINA PROPRIA; B-CELLS; EXPRESSION; LIPOPOLYSACCHARIDE; LYMPHOCYTES	Intestinal inflammatory diseases are mediated by dysregulated immune responses to undefined luminal antigens. Feeding hen egg-white lysozyme to mice expressing a transgenic T-cell receptor that recognizes hen egg-white lysozyme peptide 46-61 resulted in no intestinal pathology; however, simultaneous administration of cyclooxygenase-2 inhibitors and dietary hen egg-white lysozyme resulted in increased proliferation of lamina propria mononuclear cells and crypt epithelial cells, crypt expansion and villus blunting. Lamina propria mononuclear cells produce high levels of cyclooxygenase-2-dependent arachidonic acid metabolites, which act as immunomodulators in the immune response to dietary antigen. These findings establish that cyclooxygenzse-2-dependent arachidonic acid metabolites are essential in the development and maintenance of intestinal immune homeostasis.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Gastroenterol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Lorenz, RG (corresponding author), Washington Univ, Sch Med, Dept Internal Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	lorenz@pathbox.wustl.edu	Lorenz, Robin G/AAJ-1499-2021	Lorenz, Robin G/0000-0002-2514-9819; Newberry, Rodney/0000-0002-4152-5191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055753, R01DK033165] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33165, DK-55753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AABAKKEN L, 1989, SCAND J GASTROENTERO, V24, P48, DOI 10.3109/00365528909091175; Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; BETZ M, 1991, J IMMUNOL, V146, P108; BJARNASON I, 1993, GASTROENTEROLOGY, V104, P1832, DOI 10.1016/0016-5085(93)90667-2; Braunstein J, 1997, GUT, V41, P215, DOI 10.1136/gut.41.2.215; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Davidson NJ, 1996, J EXP MED, V184, P241, DOI 10.1084/jem.184.1.241; Demeure CE, 1997, EUR J IMMUNOL, V27, P3526, DOI 10.1002/eji.1830271254; ELLNER JJ, 1979, J IMMUNOL, V123, P2689; FERREIRA RD, 1990, GASTROENTEROLOGY, V98, P1255, DOI 10.1016/0016-5085(90)90342-X; FREUDENBERG MA, 1988, INFECT IMMUN, V56, P1352, DOI 10.1128/IAI.56.5.1352-1357.1988; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Gonnella PA, 1998, J IMMUNOL, V160, P4708; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; HO WY, 1994, J EXP MED, V179, P1539, DOI 10.1084/jem.179.5.1539; Hurst SD, 1997, P NATL ACAD SCI USA, V94, P3920, DOI 10.1073/pnas.94.8.3920; Kalinski P, 1997, J IMMUNOL, V159, P28; KAUFMANN HJ, 1987, ANN INTERN MED, V107, P513, DOI 10.7326/0003-4819-107-4-513; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; KRUISBEEK AM, 1997, CURRENT PROTOCOLS IM; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LIONETTI P, 1993, GASTROENTEROLOGY, V105, P373, DOI 10.1016/0016-5085(93)90710-T; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; MOOLENBEEK C, 1981, LAB ANIM, V15, P57, DOI 10.1258/002367781780958577; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Morham SG, 1997, ADV EXP MED BIOL, V407, P131; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Nilsen EM, 1998, GASTROENTEROLOGY, V115, P551, DOI 10.1016/S0016-5085(98)70134-9; Parronchi P, 1997, AM J PATHOL, V150, P823; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; POWRIE F, 1995, IMMUNITY, V3, P171, DOI 10.1016/1074-7613(95)90086-1; SCHIEFERDECKER HL, 1992, J IMMUNOL, V149, P2816; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; SNYDER DS, 1982, NATURE, V299, P163, DOI 10.1038/299163a0; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; Wu CY, 1998, J IMMUNOL, V161, P2723; YAMADA T, 1993, INFLAMMATION, V17, P641, DOI 10.1007/BF00920471; ZIEGLERHEITBROCK HWL, 1995, IMMUNOBIOLOGY, V193, P217	45	227	234	1	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1999	5	8					900	906		10.1038/11341	http://dx.doi.org/10.1038/11341			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426313				2022-12-27	WOS:000081684000033
J	Taniguchi, K; Kohsaka, H; Inoue, N; Terada, Y; Ito, H; Hirokawa, K; Miyasaka, N				Taniguchi, K; Kohsaka, H; Inoue, N; Terada, Y; Ito, H; Hirokawa, K; Miyasaka, N			Induction of the p16(INK4a) senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; ADENOVIRUS-MEDIATED TRANSFER; DEPENDENT KINASE INHIBITORS; CELL-CYCLE ARREST; REPLICATIVE SENESCENCE; FUSION PROTEIN; GLIOMA-CELLS; TGF-BETA; EXPRESSION; SUPPRESSION	Synovial tissue affected by rheumatoid arthritis is characterized by proliferation, which leads to irreversible cartilage and bone destruction. Current and experimental treatments have been aimed mainly at correcting the underlying immune abnormalities, but these treatments often prove ineffective in preventing the invasive destruction. We studied the expression of cyclin-dependent kinase inhibitors in rheumatoid synovial cells as a means of suppressing synovial cell proliferation. Synovial cells derived from hypertrophic synovial tissue readily expressed p16(1NK4a) when they were growth-inhibited. This was not seen in other fibroblasts, including those derived from normal and osteoarthritis-affected synovial tissues. In vivo adenoviral gene therapy with the p16(1NK4a) gene efficiently inhibited the pathology in an animal model of rheumatoid arthritis. Thus, the induction of p16(1NK4a) may provide a new approach to the effective treatment of rheumatoid arthritis.	Tokyo Med & Dent Univ, Dept Internal Med 1, Sch Med, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Dept Internal Med 1, Sch Med, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Dept Pathol & Immunol, Sch Med, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Kohsaka, H (corresponding author), Tokyo Med & Dent Univ, Dept Internal Med 1, Sch Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Apparailly F, 1998, J IMMUNOL, V160, P5213; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bakker AC, 1997, ARTHRITIS RHEUM, V40, P893, DOI 10.1002/art.1780400517; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Feldmann M, 1997, ADV IMMUNOL, V64, P283, DOI 10.1016/S0065-2776(08)60891-3; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; Fox DA, 1997, ARTHRITIS RHEUM, V40, P598, DOI 10.1002/art.1780400403; Fueyo J, 1996, ONCOGENE, V12, P103; Ghivizzani SC, 1998, P NATL ACAD SCI USA, V95, P4613, DOI 10.1073/pnas.95.8.4613; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUANG SA, 1995, J VIROL, V69, P2257, DOI 10.1128/JVI.69.4.2257-2263.1995; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; Le CH, 1997, ARTHRITIS RHEUM, V40, P1662, DOI 10.1002/art.1780400916; LOIS AF, 1995, CANCER RES, V55, P4010; MAINI RN, 1995, IMMUNOL REV, V144, P195, DOI 10.1111/j.1600-065X.1995.tb00070.x; MATHIAS P, 1994, J VIROL, V68, P6811, DOI 10.1128/JVI.68.10.6811-6814.1994; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Otani K, 1996, J IMMUNOL, V156, P3558; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; ROESSLER BJ, 1993, J CLIN INVEST, V92, P1085, DOI 10.1172/JCI116614; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Song XY, 1998, J CLIN INVEST, V101, P2615, DOI 10.1172/JCI2480; Terada Y, 1997, J AM SOC NEPHROL, V8, P51; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Wang XQ, 1996, CANCER RES, V56, P2510; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; WICKHAM TJ, 1994, J CELL BIOL, V127, P257, DOI 10.1083/jcb.127.1.257; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang HD, 1997, J CLIN INVEST, V100, P1951, DOI 10.1172/JCI119726; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; ZVAIFLER NJ, 1987, ARTHRITIS RHEUM, V30, P109, DOI 10.1002/art.1780300117	45	131	151	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					760	767		10.1038/10480	http://dx.doi.org/10.1038/10480			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395320				2022-12-27	WOS:000081926600030
J	Sewell, AK; Gerth, UC; Price, DA; Purbhoo, MA; Boulter, JM; Gag, GF; Bell, JI; Phillips, RE; Jakobsen, BK				Sewell, AK; Gerth, UC; Price, DA; Purbhoo, MA; Boulter, JM; Gag, GF; Bell, JI; Phillips, RE; Jakobsen, BK			Antagonism of cytotoxic T-lymphocyte activation by soluble CD8	NATURE MEDICINE			English	Article							CELL RECEPTOR ANTAGONISTS; CLASS-I MOLECULE; INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION; ANTIGEN RECOGNITION; TYROSINE KINASE; ALPHA-3 DOMAIN; LIGANDS; COMPLEX; SELECTION	The CD8 co-receptor is important in the differentiation and selection of class 1 MHC-restricted 7 cells during thymic development, and in the activation of mature T lymphocytes in response to antigen. Here we show that soluble CD8 alpha alpha receptor, despite an extremely low affinity for MHC, inhibits activation of cytotoxic lymphocytes by obstructing CD3 zeta-chain phosphorylation. We propose a model for this effect that involves interference of productive receptor multimerization at the T-cell surface. These results provide new insights into the mechanism of T-cell activation and evidence that CD8 function is exquisitely sensitive to disruption, an effect that might be exploited by molecular therapeutics.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Clin Med,Mol Immunol Grp, Oxford OX3 9DS, England	University of Oxford	Jakobsen, BK (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Clin Med,Mol Immunol Grp, Oxford OX3 9DS, England.		Price, David A/C-7876-2013; Sewell, Andrew/GPT-4220-2022	Price, David A/0000-0001-9416-2737; Sewell, Andrew/0000-0003-3194-3135	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGOSTINI C, 1989, CLIN IMMUNOL IMMUNOP, V50, P146, DOI 10.1016/0090-1229(89)90229-8; ALLEN PM, 1994, NATURE, V369, P355, DOI 10.1038/369355a0; Anel A, 1996, EUR J IMMUNOL, V26, P2310, DOI 10.1002/eji.1830261007; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; CERUNDOLO V, 1991, P ROY SOC B-BIOL SCI, V244, P169, DOI 10.1098/rspb.1991.0066; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; Choksi S, 1998, NAT MED, V4, P309, DOI 10.1038/nm0398-309; COBBOLD SP, 1992, IMMUNOL REV, V129, P165, DOI 10.1111/j.1600-065X.1992.tb01423.x; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DOHERTY PC, 1985, BRIT MED BULL, V41, P7, DOI 10.1093/oxfordjournals.bmb.a072028; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; GIBLIN P, 1989, P NATL ACAD SCI USA, V86, P998, DOI 10.1073/pnas.86.3.998; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; Hampl J, 1997, IMMUNITY, V7, P379, DOI 10.1016/S1074-7613(00)80359-3; HO AD, 1989, LEUKEMIA, V3, P718; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Kessler BM, 1997, J EXP MED, V185, P629, DOI 10.1084/jem.185.4.629; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KWANLIM GE, 1993, INT IMMUNOL, V5, P1219, DOI 10.1093/intimm/5.10.1219; LEUNG WPF, 1991, CELL, V65, P443; LEUNG WPF, 1993, EUR J IMMUNOL, V23, P212; LINKERISRAELI M, 1994, J IMMUNOL, V152, P3158; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MAIMONE D, 1991, NEUROLOGY, V41, P851, DOI 10.1212/WNL.41.6.851; MASON DW, 1986, ANNU REV IMMUNOL, V4, P119, DOI 10.1146/annurev.immunol.4.1.119; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OROURKE AM, 1992, NATURE, V358, P253, DOI 10.1038/358253a0; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; Preckel T, 1997, J EXP MED, V185, P1803, DOI 10.1084/jem.185.10.1803; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Price DA, 1998, J MOL MED-JMM, V76, P699, DOI 10.1007/s001090050270; Purbhoo MA, 1998, P NATL ACAD SCI USA, V95, P4527, DOI 10.1073/pnas.95.8.4527; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; Sewell AK, 1997, EUR J IMMUNOL, V27, P2323, DOI 10.1002/eji.1830270929; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WILLIAMS O, 1991, INT IMMUNOL, V3, P785, DOI 10.1093/intimm/3.8.785; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; YOON ST, 1994, IMMUNITY, V1, P563; ZAMOYSKA R, 1994, IMMUNITY, V1, P243, DOI 10.1016/1074-7613(94)90075-2; ZIELINSKI CC, 1990, CLIN IMMUNOL IMMUNOP, V57, P74, DOI 10.1016/0090-1229(90)90023-J	54	32	36	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					399	404		10.1038/7398	http://dx.doi.org/10.1038/7398			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202928				2022-12-27	WOS:000079574300028
J	Takahashi, T; Kalka, C; Masuda, H; Chen, D; Silver, M; Kearney, M; Magner, M; Isner, JM; Asahara, T				Takahashi, T; Kalka, C; Masuda, H; Chen, D; Silver, M; Kearney, M; Magner, M; Isner, JM; Asahara, T			Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; GRANULOCYTE-COLONY; ANGIOGENESIS; ACTIVATION; MODEL; MICE	Endothelial progenitor cells (EPCs) have been isolated from circulating mononuclear cells in human peripheral blood and shown to be incorporated into foci of neovascularization, consistent with postnatal vasculogenesis'. We determined whether endogenous stimuli (tissue ischemia) and exogenous cytokine therapy (granulocyte macrophage-colony stimulating factor, GM-CSF) mobilize EPCs and thereby contribute to neovascularization of ischemic tissues. The development of regional ischemia in both mice and rabbits increased the frequency of circulating EPCs. In mice, the effect of ischemia-induced EPC mobilization was demonstrated by enhanced ocular neovascularization after cornea micropocket surgery in mice with hindlimb ischemia compared with that in non-ischemic control mice. In rabbits with hindlimb ischemia, circulating EPCs were further augmented after pretreatment with CM-CSF, with a corresponding improvement in hindlimb neovascularization. There was direct evidence that EPCs that contributed to enhanced corneal neovascularization were specifically mobilized from the bone marrow in response to ischemia and GM-CSF in mice transplanted with bone marrow from transgenic donors expressing P-galactosidase transcriptionally regulated by the endothelial cell-specific Tie-2 promoter. These findings indicate that circulating EPCs are mobilized endogenously in response to tissue ischemia or exogenously by cytokine therapy and thereby augment neovascularization of ischemic tissues.	Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Med Cardiol, Boston, MA 02135 USA; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Biomed Res, Boston, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University	Isner, JM (corresponding author), Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Med Cardiol, 736 Cambridge St, Boston, MA 02135 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL002824, R01HL040518, R01HL057516] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57516, HL02824, HL 40518] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGLIETTA M, 1989, J CLIN INVEST, V83, P551, DOI 10.1172/JCI113917; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; ASAHARA T, 1997, SCIENCE, V275, P965; BUSSOLINO F, 1991, J CLIN INVEST, V87, P986, DOI 10.1172/JCI115107; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; BUSSOLINO F, 1989, J BIOL CHEM, V264, P18284; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; Couffinhal T, 1998, AM J PATHOL, V152, P1667; DEDHAR S, 1988, P NATL ACAD SCI USA, V85, P9253, DOI 10.1073/pnas.85.23.9253; FLEISCHMAN RA, 1995, EXP HEMATOL, V23, P1407; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1652; LEDNEY GD, 1985, J SURG RES, V38, P55, DOI 10.1016/0022-4804(85)90010-1; PERKINS S, 1990, BLOOD, V75, P620; PROKOP DJ, 1997, SCIENCE, V276, P71; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; SOCINSKI MA, 1988, LANCET, V1, P1194; Soldi R, 1997, BLOOD, V89, P863, DOI 10.1182/blood.V89.3.863; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018	18	2000	2190	0	90	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					434	438		10.1038/7434	http://dx.doi.org/10.1038/7434			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202935				2022-12-27	WOS:000079574300035
J	Genain, CP; Cannella, B; Hauser, SL; Raine, CS				Genain, CP; Cannella, B; Hauser, SL; Raine, CS			Identification of autoantibodies associated with myelin damage in multiple sclerosis	NATURE MEDICINE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; OLIGODENDROCYTE GLYCOPROTEIN; BASIC-PROTEIN; NONHUMAN PRIMATE; CELL; DEMYELINATION; RATS; LOCALIZATION; SPECIFICITY; ANTIBODIES	The molecular mechanisms underlying myelin sheath destruction in multiple sclerosis lesions remain unresolved. With immunogold-labeled peptides of myelin antigens and high-resolution microscopy, techniques that can detect antigen-specific antibodies in situ, we have identified autoantibodies specific for the central nervous system myelin antigen myelin/oligodendrocyte glycoprotein. These autoantibodies were specifically bound to disintegrating myelin around axons in lesions of acute multiple sclerosis and the marmoset model of allergic encephalomyelitis. These findings represent direct evidence that autoantibodies against a specific myelin protein mediate target membrane damage in central nervous system demyelinating disease.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol Neuropathol, Bronx, NY 10461 USA	University of California System; University of California San Francisco; Yeshiva University; Albert Einstein College of Medicine	Genain, CP (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.		Hauser, Stephen L/J-2978-2016		NIAID NIH HHS [AI 43073] Funding Source: Medline; NINDS NIH HHS [NS 11920, NS 08952] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011920, R01NS008952, P50NS011920] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEU FP, 1963, J NEUROPATH EXP NEUR, V22, P403, DOI 10.1097/00005072-196307000-00003; AMOR S, 1994, J IMMUNOL, V153, P4349; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Brosnan C F, 1983, Acta Neuropathol Suppl, V9, P59; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; BRUNNER C, 1989, J NEUROCHEM, V52, P296, DOI 10.1111/j.1471-4159.1989.tb10930.x; COMPSTON A, 1991, TRENDS NEUROSCI, V14, P175, DOI 10.1016/0166-2236(91)90099-G; DALCANTO MC, 1975, J NEUROL SCI, V24, P313, DOI 10.1016/0022-510X(75)90251-8; EPSTEIN LG, 1983, J NEUROL SCI, V61, P341, DOI 10.1016/0022-510X(83)90167-3; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Genain CP, 1995, J CLIN INVEST, V96, P2966, DOI 10.1172/JCI118368; GERRITSE K, 1994, J NEUROIMMUNOL, V49, P153, DOI 10.1016/0165-5728(94)90191-0; Hohlfeld R, 1997, BRAIN, V120, P865, DOI 10.1093/brain/120.5.865; Ichikawa M, 1996, J IMMUNOL, V157, P919; Kirschner Daniel A., 1992, P3; LASSMANN H, 1988, ACTA NEUROPATHOL, V75, P566, DOI 10.1007/BF00686201; Lassmann H, 1998, J NEUROIMMUNOL, V86, P213, DOI 10.1016/S0165-5728(98)00031-9; LININGTON C, 1987, J NEUROIMMUNOL, V17, P61, DOI 10.1016/0165-5728(87)90031-2; MOORE GRW, 1988, LAB INVEST, V59, P641; MORRIS G, 1996, EPITOPE MAPPING PROT, P1; PHAMDINH D, 1994, J NEUROCHEM, V63, P2353; PIDDLESDEN SJ, 1993, AM J PATHOL, V143, P555; PRINEAS JW, 1978, NEUROLOGY, V28, P68, DOI 10.1212/WNL.28.9_Part_2.68; RAINE CS, 1981, J NEUROL SCI, V52, P117, DOI 10.1016/0022-510X(81)90140-4; RAINE CS, 1974, LAB INVEST, V31, P369; RAINE CS, 1973, J NEUROL SCI, V20, P127, DOI 10.1016/0022-510X(73)90026-9; RAINE CS, 1970, J NEUROPATH EXP NEUR, V29, P177, DOI 10.1097/00005072-197004000-00002; SEIL FJ, 1968, EXP NEUROL, V22, P545, DOI 10.1016/0014-4886(68)90148-9; SUN JB, 1991, J IMMUNOL, V146, P1490; Tabira Takeshi, 1992, P783; TAKIZAWA T, 1994, J HISTOCHEM CYTOCHEM, V43, P1615; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WILLENBORG DO, 1983, J NEUROIMMUNOL, V5, P99, DOI 10.1016/0165-5728(83)90001-2; Wolf SD, 1996, J EXP MED, V184, P2271, DOI 10.1084/jem.184.6.2271	35	677	706	0	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					170	175		10.1038/5532	http://dx.doi.org/10.1038/5532			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930864				2022-12-27	WOS:000078274400025
J	Brodie, SJ; Lewinsohn, DA; Patterson, BK; Jiyamapa, D; Krieger, J; Corey, L; Greenberg, PD; Riddell, SR				Brodie, SJ; Lewinsohn, DA; Patterson, BK; Jiyamapa, D; Krieger, J; Corey, L; Greenberg, PD; Riddell, SR			In vivo migration and function of transferred HIV-1-specific cytotoxic T cells	NATURE MEDICINE			English	Article							ALLOGENEIC BONE-MARROW; VIRUS TYPE-1 INFECTION; EPSTEIN-BARR-VIRUS; HIV-1 INFECTION; IN-VIVO; LYMPHOCYTE RESPONSES; ADOPTIVE TRANSFER; IMMUNE-RESPONSES; FLOW-CYTOMETRY; VIRAL LOAD	The persistence of HIV replication in infected individuals may reflect an inadequate host HIV-specific CD8(+) cytotoxic T lymphocyte (CTL) response. The functional activity of HIV-specific CTLs and the ability of these effector cells to migrate in vivo to sites of infection was directly assessed by expanding autologous HIV-1 Gag-specific CD8(+) CTL clones in vitro and adoptively transferring these CTLs to HIV-infected individuals, The transferred CTLs retained lytic function in vivo, accumulated adjacent to HIV-infected cells in lymph nodes and transiently reduced the levels of circulating productively infected CD4(+) T cells. These results provide direct evidence that HIV-specific CTLs target sites of HIV replication and mediate antiviral activity, and indicate that the development of immunotherapeutic approaches to sustain a strong CTL response to HIV may be a useful adjunct to treatment of HIV infection.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Lab Med, Seattle, WA 98101 USA; Univ Washington, Dept Pediat, Seattle, WA 98101 USA; Univ Washington, Dept Urol, Seattle, WA 98101 USA; Univ Washington, Dept Med, Seattle, WA 98101 USA; Univ Washington, Dept Immunol, Seattle, WA 98101 USA; Northwestern Univ, Sch Med, Dept Obstet & Gynecol, Foster City, CA 94404 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Northwestern University	Riddell, SR (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D3-100, Seattle, WA 98109 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI036613, U01AI041535] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41535, AI36613] Funding Source: Medline; NICHD NIH HHS [HD28834] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADA GL, 1986, CURR TOP MICROBIOL, V128, P1; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Brodie SJ, 1998, J VIROL, V72, P5599, DOI 10.1128/JVI.72.7.5599-5609.1998; BRODIE SJ, 1995, AM J PATHOL, V146, P250; BRODIE SJ, 1994, J IMMUNOL, V153, P5790; Brodie SJ, 1998, J VIROL, V72, P3863, DOI 10.1128/JVI.72.5.3863-3871.1998; BYRNE JA, 1986, J IMMUNOL, V136, P698; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Diamond C, 1998, J VIROL, V72, P6223, DOI 10.1128/JVI.72.7.6223-6227.1998; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOX WS, 1994, REV HIGH EDUC, V18, P1; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Harrer T, 1996, J IMMUNOL, V156, P2616; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; JASSOY C, 1992, J IMMUNOL, V149, P3113; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LI CR, 1994, BLOOD, V83, P1971, DOI 10.1182/blood.V83.7.1971.1971; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Pantaleo G, 1997, EUR J IMMUNOL, V27, P3166, DOI 10.1002/eji.1830271213; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PATTERSON BK, 1995, J VIROL, V69, P4316, DOI 10.1128/JVI.69.7.4316-4322.1995; Patterson BK, 1998, CYTOMETRY, V31, P265, DOI 10.1002/(SICI)1097-0320(19980401)31:4&lt;265::AID-CYTO6&gt;3.0.CO;2-I; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; Posavad CM, 1997, P NATL ACAD SCI USA, V94, P10289, DOI 10.1073/pnas.94.19.10289; REDDEHASE MJ, 1987, J EXP MED, V165, P650, DOI 10.1084/jem.165.3.650; REUSSER P, 1991, BLOOD, V78, P1373; RIDDELL SR, 1993, CURR OPIN IMMUNOL, V5, P484, DOI 10.1016/0952-7915(93)90027-P; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; RIDDELL SR, 1992, SCIENCE, V257, P238; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SAFRIT JT, 1995, CURR OPIN IMMUNOL, V7, P456, DOI 10.1016/0952-7915(95)80088-3; Walker RE, 1998, NAT MED, V4, P852, DOI 10.1038/nm0798-852; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Woffendin C, 1996, P NATL ACAD SCI USA, V93, P2889, DOI 10.1073/pnas.93.7.2889; Yang LP, 1998, J EXP MED, V187, P1139, DOI 10.1084/jem.187.7.1139; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1	49	275	295	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1999	5	1					34	41		10.1038/4716	http://dx.doi.org/10.1038/4716			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883837				2022-12-27	WOS:000077885000027
J	Hollon, T				Hollon, T			NIH expands graduate student training programs	NATURE MEDICINE			English	News Item																		1999, NATURE MED, V5, P1098	1	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					847	847		10.1038/78588	http://dx.doi.org/10.1038/78588			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932208	Bronze			2022-12-27	WOS:000165473800012
J	Conne, B; Stutz, A; Vassalli, JD				Conne, B; Stutz, A; Vassalli, JD			The 3 ' untranslated region of messenger RNA: A molecular 'hotspot' for pathology?	NATURE MEDICINE			English	Review							AU-RICH ELEMENTS; MYOTONIC-DYSTROPHY; BINDING-PROTEIN; TRINUCLEOTIDE REPEAT; 3'-UNTRANSLATED REGION; HUMAN NEUROBLASTOMA; TRANSLATIONAL CONTROL; REDUCES EXPRESSION; MOUSE OOCYTES; MICE LACKING		Univ Geneva CMU, Fac Med, Dept Morphol, CH-1211 Geneva 4, Switzerland	University of Geneva	Conne, B (corresponding author), CMU, Dept Pathol, CH-1211 Geneva 4, Switzerland.	conne@medecine.unige.ch						BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chagnovich D, 1997, EUR J CANCER, V33, P2064, DOI 10.1016/S0959-8049(97)00208-6; Chagnovich D, 1996, J BIOL CHEM, V271, P33587, DOI 10.1074/jbc.271.52.33587; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; Eriksson N, 1999, HUM MOL GENET, V8, P1053, DOI 10.1093/hmg/8.6.1053; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gao FB, 1998, BIOESSAYS, V20, P70, DOI 10.1002/(SICI)1521-1878(199801)20:1<70::AID-BIES10>3.0.CO;2-5; Groenen PJTA, 2000, HUM MOL GENET, V9, P605, DOI 10.1093/hmg/9.4.605; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Korade-Mirnics Z, 1998, NUCLEIC ACIDS RES, V26, P1363, DOI 10.1093/nar/26.6.1363; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; Morales J, 1997, J BIOL CHEM, V272, P6607, DOI 10.1074/jbc.272.10.6607; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; RIMOKH R, 1994, BLOOD, V83, P3689; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; Russell JE, 1996, BLOOD, V87, P5314, DOI 10.1182/blood.V87.12.5314.bloodjournal87125314; Sasagawa N, 1999, BIOCHEM BIOPH RES CO, V264, P76, DOI 10.1006/bbrc.1999.1435; StebbinsBoaz B, 1997, CRIT REV EUKAR GENE, V7, P73, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.50; Storbeck CJ, 1998, J BIOL CHEM, V273, P9139, DOI 10.1074/jbc.273.15.9139; Strong PN, 1997, J INHERIT METAB DIS, V20, P159, DOI 10.1023/A:1005396420442; Stutz A, 1997, MOL CELL BIOL, V17, P1759, DOI 10.1128/MCB.17.4.1759; Stutz A, 1998, GENE DEV, V12, P2535, DOI 10.1101/gad.12.16.2535; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; Timchenko LT, 1999, AM J HUM GENET, V64, P360, DOI 10.1086/302268; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; WANG XM, 1995, MOL CELL BIOL, V15, P2331; WEISS IM, 1995, MOL CELL BIOL, V15, P2457	38	448	456	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2000	6	6					637	641		10.1038/76211	http://dx.doi.org/10.1038/76211			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835679				2022-12-27	WOS:000087438300033
J	van Egmond, M; van Garderen, E; van Spriel, AB; Damen, CA; van Amersfoort, ES; van Zandbergen, G; van Hattum, J; Kuiper, J; van de Winkel, JGJ				van Egmond, M; van Garderen, E; van Spriel, AB; Damen, CA; van Amersfoort, ES; van Zandbergen, G; van Hattum, J; Kuiper, J; van de Winkel, JGJ			Fc alpha RI-positive liver Kupffer cells: Reappraisal of the function of immunoglobulin A in immunity	NATURE MEDICINE			English	Article							HUMAN-IGA; POLYMORPHONUCLEAR LEUKOCYTES; RECEPTOR EXPRESSION; PHAGOCYTOSIS; CD89; ANTIBODIES; CHEMILUMINESCENCE; NEUTROPHILS; ENHANCEMENT; MECHANISM	Despite the well-recognized involvement of immunoglobulin (Ig) A in mucosal immunity, the function of its receptor, Fc alpha RI (CD89), is poorly understood. The ability of Fc alpha RI to activate leukocytes seems to conflict with the proposed anti-inflammatory activity of secretory IgA. We show here that in a transgenic mouse model, inflammatory mediators induced expression of Fc alpha RI on Kupffer cells, which enabled efficient phagocytosis in vivo of bacteria coated with serum IgA. Secretory IgA did not initiate phagocytosis. Therefore, interactions between serum IgA and Fc alpha RI on Kupffer cells may provide a 'second line of defense' in mucosal immunity, by eliminating invasive bacteria entering through the portal circulation and thus preventing disease.	Univ Utrecht, Med Ctr, Dept Immunol & Medarex Europe, NL-3584 EA Utrecht, Netherlands; Univ Utrecht, Fac Vet Med, Dept Pathol, NL-3508 TD Utrecht, Netherlands; LACDR, Sylvius Labs, Div Biopharmaceut, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Nephrol, NL-2300 RC Leiden, Netherlands; Univ Utrecht, Med Ctr, Dept Gastroenterol, NL-3584 EA Utrecht, Netherlands	Utrecht University; Utrecht University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University	van de Winkel, JGJ (corresponding author), Univ Utrecht, Med Ctr, Dept Immunol & Medarex Europe, Lundlaan 6, NL-3584 EA Utrecht, Netherlands.		van Spriel, Annemiek/Q-6044-2019; van Spriel, Annemiek/O-1639-2013; van Zandbergen, Ger/M-1571-2013; van Amersfoort, Edwin S/J-9944-2018	van Spriel, Annemiek/0000-0002-3590-2368; 				AVERY VM, 1991, EUR J CLIN MICROBIOL, V10, P1034, DOI 10.1007/BF01984925; Brandtzaeg P, 1999, IMMUNOL TODAY, V20, P141, DOI 10.1016/S0167-5699(98)01413-3; DECHATELET LR, 1982, J IMMUNOL, V129, P1589; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; Deo YM, 1998, J IMMUNOL, V160, P1677; GORTER A, 1987, IMMUNOLOGY, V61, P303; HOSTOFFER RW, 1994, J INFECT DIS, V170, P82, DOI 10.1093/infdis/170.1.82; KAN ZX, 1995, HEPATOLOGY, V21, P487, DOI 10.1002/hep.1840210233; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; Kerr MA, 1998, MUCOSAL IMMUNOLOGY, P213; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MAZANEC MB, 1992, P NATL ACAD SCI USA, V89, P6901, DOI 10.1073/pnas.89.15.6901; MAZANEC MB, 1993, IMMUNOL TODAY, V14, P430, DOI 10.1016/0167-5699(93)90245-G; MESTECKY J, 1986, CLIN IMMUNOL IMMUNOP, V40, P105, DOI 10.1016/0090-1229(86)90073-5; MONTEIRO RC, 1992, J IMMUNOL, V148, P1764; MONTEIRO RC, 1990, J EXP MED, V171, P597, DOI 10.1084/jem.171.3.597; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; NIKOLOVA EB, 1995, J LEUKOCYTE BIOL, V57, P875, DOI 10.1002/jlb.57.6.875; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Russell MW, 1997, BIOCHEM SOC T, V25, P466, DOI 10.1042/bst0250466; RUSSELL MW, 1998, MUCOSAL IMMUNOLOGY, P225; SHEN L, 1994, J IMMUNOL, V152, P4080; SHEN L, 1989, IMMUNOLOGY, V68, P491; SHEN L, 1989, J IMMUNOL, V143, P4117; STEWART WW, 1990, IMMUNOLOGY, V71, P328; Valerius T, 1997, BLOOD, V90, P4485, DOI 10.1182/blood.V90.11.4485.4485_4485_4492; Van Berkel TJC, 1998, BIOCHEM J, V331, P29, DOI 10.1042/bj3310029; van Egmond M, 1999, IMMUNOL LETT, V68, P83, DOI 10.1016/S0165-2478(99)00034-6; van Egmond M, 1999, BLOOD, V93, P4387, DOI 10.1182/blood.V93.12.4387.412k08_4387_4394; VANDEWINKEL JGJ, 1998, IMMUNOGLOBULIN RECEP; WEISBART RH, 1988, NATURE, V332, P647, DOI 10.1038/332647a0; Westerhuis R, 1999, J AM SOC NEPHROL, V10, P770; Wisse E, 1996, TOXICOL PATHOL, V24, P100, DOI 10.1177/019262339602400114	35	177	184	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					680	685		10.1038/76261	http://dx.doi.org/10.1038/76261			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835685				2022-12-27	WOS:000087438300039
J	Birmingham, K				Birmingham, K			Ministers pledge to stop TB	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					491	491		10.1038/74953	http://dx.doi.org/10.1038/74953			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802691	Bronze			2022-12-27	WOS:000086796200017
J	Lavon, I; Goldberg, I; Amit, S; Landsman, L; Jung, S; Tsuberi, BZ; Barshack, I; Kopolovic, J; Galun, E; Bujard, H; Ben-Neriah, Y				Lavon, I; Goldberg, I; Amit, S; Landsman, L; Jung, S; Tsuberi, BZ; Barshack, I; Kopolovic, J; Galun, E; Bujard, H; Ben-Neriah, Y			High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappa B activation	NATURE MEDICINE			English	Article							EMBRYONIC LETHALITY; GENE-EXPRESSION; TRANSGENIC MICE; APOPTOSIS; DEGENERATION; INHIBITION; PROTECTION; DEFICIENT; INJURY	Based on the essential involvement of NF-kappa B in immune and inflammatory responses and its apoptosis-rescue function in normal and malignant cells, inhibitors of this transcription factor are potential therapeutics for the treatment of a wide range of diseases, from bronchial asthma to cancer(1,2). Yet, given the essential function of NF-kappa B in the embryonic liver(3-6), it is important to determine its necessity in the liver beyond embryogenesis. NF-kappa B is normally retained in the cytoplasm by its inhibitor I kappa B, which is eliminated upon cell stimulation through phosphorylation-dependent ubiquitin degradation(7). Here, we directed a degradation-resistant I kappa B alpha transgene to mouse hepatocytes in an inducible manner and showed substantial tissue specificity using various means, including a new method for live-animal imaging. Transgene expression resulted in obstruction of NF-kappa B activation, yet produced no signs of liver dysfunction, even when implemented over 15 months. However, the transgene-expressing mice were very vulnerable both to a severe immune challenge and to a systemic bacterial infection. Despite having intact immunocytes and inflammatory cells, these mice were unable to clear Listeria monocytogenes from the liver and succumbed to sepsis. These findings indicate the essential function of the hepatocyte through NF-kappa B activation in certain systemic infections, possibly by coordinating innate immunity in the liver.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Pathol, Tel Hashomer, Israel; Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; Hadassah Univ Hosp, Goldyne Savad Gene Therapy Inst, IL-91120 Jerusalem, Israel; Heidelberg Univ, Zentrum Mol Biol, D-69052 Heidelberg, Germany	Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Ruprecht Karls University Heidelberg	Ben-Neriah, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel.	yinon@cc.huji.ac.il	Ben-Neriah, Yinon/L-6285-2019; Lavon, Iris/ABE-6651-2021; Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716; Landsman, Limor/0000-0002-8974-1344				Armstrong D, 1995, PRINCIPLES PRACTICE, P1880; Attar RM, 1997, SEMIN CANCER BIOL, V8, P93, DOI 10.1006/scbi.1997.0060; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bellas RE, 1997, AM J PATHOL, V151, P891; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CONLAN JW, 1994, J EXP MED, V179, P259, DOI 10.1084/jem.179.1.259; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Endres R, 1997, IMMUNITY, V7, P419, DOI 10.1016/S1074-7613(00)80363-5; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Rogers HW, 1996, J IMMUNOL, V156, P679; TALBOT D, 1994, NUCLEIC ACIDS RES, V22, P756, DOI 10.1093/nar/22.5.756; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Taub R, 1998, HEPATOLOGY, V27, P1445, DOI 10.1002/hep.510270538; TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410	25	136	147	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2000	6	5					573	577		10.1038/75057	http://dx.doi.org/10.1038/75057			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802715				2022-12-27	WOS:000086796200043
J	McDonald, JW; Gottlieb, DI; Choi, DW				McDonald, JW; Gottlieb, DI; Choi, DW			What is a functional recovery after spinal cord injury?	NATURE MEDICINE			English	Letter									Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	McDonald, JW (corresponding author), Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, Box 8111, St Louis, MO 63110 USA.								0	12	14	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					358	358		10.1038/74759	http://dx.doi.org/10.1038/74759			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742118				2022-12-27	WOS:000165474100004
J	Tamada, K; Shimozaki, K; Chapoval, AI; Zhu, GF; Sica, G; Flies, D; Boone, T; Hsu, HL; Fu, YX; Nagata, S; Ni, J; Chen, LP				Tamada, K; Shimozaki, K; Chapoval, AI; Zhu, GF; Sica, G; Flies, D; Boone, T; Hsu, HL; Fu, YX; Nagata, S; Ni, J; Chen, LP			Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway	NATURE MEDICINE			English	Article							HERPESVIRUS ENTRY MEDIATOR; LYMPHOTOXIN-BETA-RECEPTOR; CRYSTAL-STRUCTURE; ACTIVATION; MEMBER; COSTIMULATION; SUPERFAMILY; LIGAND; PROLIFERATION; LYMPHOCYTES	LIGHT was recently described as a member of the tumor necrosis factor (TNF) 'superfamily'. We have isolated a mouse homolog of human LIGHT and investigated its immunoregulatory functions in vitro and in vivo. LIGHT has potent, CD28-independent co-stimulatory activity leading to T-cell growth and secretion of gamma interferon and granulocyte-macrophage colony-stimulating factor. Gene transfer of LIGHT induced an antigen-specific cytolytic T-cell response and therapeutic immunity against established mouse P815 tumor. In contrast, blockade of LIGHT by administration of soluble receptor or antibody led to decreased cell-mediated immunity and ameliorated graft-versus-host disease. Our studies identify a previously unknown T-cell co-stimulatory pathway as a potential therapeutic target.	Mayo Clin & Mayo Fdn, Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA; Osaka Univ, Sch Med, Dept Genet, Osaka, Japan; Amgen Inc, Thousand Oaks, CA 91320 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	Mayo Clinic; Osaka University; Amgen; University of Chicago; GlaxoSmithKline; Human Genome Sciences Inc	Ni, J (corresponding author), Mayo Clin & Mayo Fdn, Mayo Clin & Mayo Grad Sch Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.	jian_ni@hgsi.com; chen.lieping@mayo.edu	Nagata, Shigekazu/AAG-3203-2019; Chapoval, Andrei/N-9568-2013	Nagata, Shigekazu/0000-0001-9758-8426; Chapoval, Andrei/0000-0002-3426-1036; fu, yang-xin/0000-0001-8441-6617	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD073104] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA015083, R01CA079915] Funding Source: NIH RePORTER; NCI NIH HHS [CA15083, CA79915] Funding Source: Medline; NICHD NIH HHS [HD73104] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BLAZAR BR, 1994, BLOOD, V83, P3815; Browning JL, 1997, J IMMUNOL, V159, P3288; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN YM, 1993, MOL CRYST LIQ CRYS B, V4, P71; CROSS AH, 1995, J CLIN INVEST, V95, P2783, DOI 10.1172/JCI117982; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; FORCE WR, 1995, J IMMUNOL, V155, P5280; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Harrop JA, 1998, J IMMUNOL, V161, P1786; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Johnson AJ, 1999, J VIROL, V73, P3702, DOI 10.1128/JVI.73.5.3702-3708.1999; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Speiser DE, 1997, J IMMUNOL, V158, P5185; VIA CS, 1988, IMMUNOL TODAY, V9, P207, DOI 10.1016/0167-5699(88)91215-7; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492	33	259	298	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					283	289						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700230				2022-12-27	WOS:000085580500038
J	de Kruif, J; Tijmensen, M; Goldsein, J; Logtenberg, T				de Kruif, J; Tijmensen, M; Goldsein, J; Logtenberg, T			Recombinant lipid-tagged antibody fragments as functional cell-surface receptors	NATURE MEDICINE			English	Article							SINGLE-CHAIN ANTIBODY; ESCHERICHIA-COLI; DENDRITIC CELLS; DISPLAY; PHAGE; IMMUNOLIPOSOMES; EXPRESSION; LIBRARIES; SELECTION; ANTIGEN		Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Utrecht Biotechnol Syst, Utrecht, Netherlands; Medarex Inc, Annandale, NJ USA	Utrecht University; Utrecht University Medical Center	de Kruif, J (corresponding author), Univ Utrecht Hosp, Dept Immunol, HP-F03-821,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.							Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Berd D, 1998, SEMIN ONCOL, V25, P646; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; deKruif J, 1996, FEBS LETT, V399, P232, DOI 10.1016/S0014-5793(96)01335-X; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Eshhar Z, 1997, CANCER IMMUNOL IMMUN, V45, P131, DOI 10.1007/s002620050415; FRANCISCO JA, 1992, P NATL ACAD SCI USA, V89, P2713, DOI 10.1073/pnas.89.7.2713; Gong JL, 1997, NAT MED, V3, P558, DOI 10.1038/nm0597-558; GOSSELIN EJ, 1992, J IMMUNOL, V149, P3477; GRAYEB J, 1984, J BIOL CHEM, V259, P463; GRAZIANO RF, 1995, J IMMUNOL, V155, P4996; GROUARD G, 1995, J IMMUNOL, V155, P3345; Haas C, 1999, CANCER GENE THER, V6, P254, DOI 10.1038/sj.cgt.7700048; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; LAUKKANEN ML, 1993, PROTEIN ENG, V6, P449, DOI 10.1093/protein/6.4.449; LAUKKANEN ML, 1994, BIOCHEMISTRY-US, V33, P11664, DOI 10.1021/bi00204a031; Liu CL, 1996, J CLIN INVEST, V98, P2001, DOI 10.1172/JCI119004; Nawrocki S, 1999, CANCER TREAT REV, V25, P29, DOI 10.1053/ctrv.1998.0104; PACK P, 1993, BIO-TECHNOL, V11, P1271; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schirrmacher V, 1999, GENE THER, V6, P63, DOI 10.1038/sj.gt.3300787; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Vermorken JB, 1999, LANCET, V353, P345, DOI 10.1016/S0140-6736(98)07186-4	27	24	25	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					223	227		10.1038/72339	http://dx.doi.org/10.1038/72339			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655115				2022-12-27	WOS:000085016900047
J	Heymans, S; Luttun, A; Nuyens, D; Theilmeier, G; Creemers, E; Moons, L; Dyspersin, GD; Cleutjens, JPM; Shipley, M; Angellilo, A; Levi, M; Nube, O; Baker, A; Keshet, E; Lupu, F; Herbert, JM; Smits, JFM; Shapiro, SD; Baes, M; Borgers, M; Collen, D; Daemen, MJAP; Carmeliet, P				Heymans, S; Luttun, A; Nuyens, D; Theilmeier, G; Creemers, E; Moons, L; Dyspersin, GD; Cleutjens, JPM; Shipley, M; Angellilo, A; Levi, M; Nube, O; Baker, A; Keshet, E; Lupu, F; Herbert, JM; Smits, JFM; Shapiro, SD; Baes, M; Borgers, M; Collen, D; Daemen, MJAP; Carmeliet, P			Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure	NATURE MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR FREE-WALL; DEFICIENT MICE; GENE-TRANSFER; EXPRESSION; COLLAGEN; PROLIFERATION; MIGRATION; OCCLUSION; RECEPTOR	Cardiac rupture is a fatal complication of acute myocardial infarction lacking treatment. Here, acute myocardial infarction resulted in rupture in wild-type mice and in mice lacking tissue-type plasminogen activator, urokinase receptor, matrix metalloproteinase stromelysin-1 or metallo-elastase. Instead, deficiency of urokinase-type plasminogen activator (u-PA(-/-)) completely protected against rupture, whereas lack of gelatinase-B partially protected against rupture. However, u-PA(-/-) mice showed impaired scar formation and infarct revascularization, even after treatment with vascular endothelial growth factor, and died of cardiac failure due to depressed contractility, arrhythmias and ischemia. Temporary administration of PA inhibitor-1 or the matrix metalloproteinase-inhibitor TIMP-1 completely protected wild-type mice against rupture but did not abort infarct healing, thus constituting a new approach to prevent cardiac rupture after acute myocardial infarction.	Flanders Interuniv, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Univ Maastricht, Cardiovasc Res Inst, NL-6200 MD Maastricht, Netherlands; Janssen Res Fdn, B-2340 Beerse, Belgium; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 14, Switzerland; Univ Glasgow, Western Infirm, Dept Med, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Therapeut, Glasgow G11 6NT, Lanark, Scotland; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Thrombosis Res Inst, Weston Expt Res Ctr, Vasc Biol Lab, London SW3 6LR, England; Sanofi Rech, Haeobiol Res Dept, F-31036 Toulouse, France	Maastricht University; Johnson & Johnson; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Geneva; University of Glasgow; University of Glasgow; Hebrew University of Jerusalem; Thrombosis Research Institute; Sanofi-Aventis; Sanofi France	Carmeliet, P (corresponding author), Flanders Interuniv, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Keshet, Eli/GQR-0445-2022; Carmeliet, Peter/AAQ-5140-2020; Nüsse, Oliver/J-8645-2013; Luttun, Aernout/AAZ-6540-2020; Lupu, Florea/C-3162-2009; Baker, Andy/AAO-5250-2021; Lupu, Florea/AAV-3257-2021; Cleutjens, Jack P.M./F-6242-2012	Carmeliet, Peter/0000-0001-7961-1821; Nüsse, Oliver/0000-0003-0068-8346; Luttun, Aernout/0000-0001-7902-9524; Lupu, Florea/0000-0003-1249-9278; Baker, Andy/0000-0003-1441-5576; Lupu, Florea/0000-0003-1249-9278; Cleutjens, Jack P.M./0000-0002-4346-1785; Angelillo-Scherrer, Anne/0000-0003-2872-4863; Creemers, Esther/0000-0002-9001-3854; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Levi, Moshe/0000-0002-6225-946X; Nuyens, Dieter/0000-0001-9390-3273; Heymans, Stephane/0000-0001-9477-7803; Baes, Myriam/0000-0002-2525-2269				ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1998, THROMB RES, V91, P255, DOI 10.1016/S0049-3848(98)00122-4; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Dalrymple-Hay M J, 1998, Semin Thorac Cardiovasc Surg, V10, P111; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; Feldhaus LM, 1998, J MOL CELL CARDIOL, V30, P2475, DOI 10.1006/jmcc.1998.0810; Frangogiannis NG, 1998, J MOL CELL CARDIOL, V30, P2567, DOI 10.1006/jmcc.1998.0829; George SJ, 1998, HUM GENE THER, V9, P867, DOI 10.1089/hum.1998.9.6-867; HAMSTEN A, 1987, LANCET, V2, P3; Henry M, 1998, ARTERIOSCL THROM VAS, V18, P84, DOI 10.1161/01.ATV.18.1.84; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KNOEPFLER PS, 1995, J MOL CELL CARDIOL, V27, P1317, DOI 10.1016/S0022-2828(05)82394-6; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Lee JK, 1998, NAT MED, V4, P1383, DOI 10.1038/3973; LIJNEN HR, 1989, FIBRINOLYSIS, V3, P67, DOI 10.1016/0268-9499(89)90034-9; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lutgens E, 1999, CARDIOVASC RES, V41, P586, DOI 10.1016/S0008-6363(98)00216-8; Nunes I, 1996, INT J OBESITY, V20, pS4; Peuhkurinen K, 1996, AM HEART J, V131, P7, DOI 10.1016/S0002-8703(96)90044-7; Plesner T, 1997, STEM CELLS, V15, P398, DOI 10.1002/stem.150398; PRZYKLENK K, 1987, AM HEART J, V114, P1349, DOI 10.1016/0002-8703(87)90536-9; REDDY SG, 1989, AM J CARDIOL, V63, P906, DOI 10.1016/0002-9149(89)90137-9; Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699-0463.1999.tb01529.x; Robert V, 1997, LAB INVEST, V76, P729; Rohde LE, 1999, CIRCULATION, V99, P3063, DOI 10.1161/01.CIR.99.23.3063; Schaffer CJ, 1996, INT REV CYTOL, V169, P151, DOI 10.1016/S0074-7696(08)61986-5; SEVERS NJ, 1994, J CARDIOVASC ELECTR, V5, P462, DOI 10.1111/j.1540-8167.1994.tb01185.x; Tyagi SC, 1996, CAN J PHYSIOL PHARM, V74, P983, DOI 10.1139/cjpp-74-8-983; VANDEPLASSCHE G, 1991, CARDIOSCIENCE, V2, P47; Varbella F, 1999, G Ital Cardiol, V29, P163; Zahger D, 1996, AM J CARDIOL, V78, P681, DOI 10.1016/S0002-9149(96)00396-7; Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788	39	656	695	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1999	5	10					1135	1142		10.1038/13459	http://dx.doi.org/10.1038/13459			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502816				2022-12-27	WOS:000082933200039
J	Benzing, T; Brandes, R; Sellin, L; Schermer, B; Lecker, S; Walz, G; Kim, E				Benzing, T; Brandes, R; Sellin, L; Schermer, B; Lecker, S; Walz, G; Kim, E			Upregulation of RGS7 may contribute to tumor necrosis factor-induced changes in central nervous function	NATURE MEDICINE			English	Article							HETEROTRIMERIC G-PROTEINS; C-JUN; BETA-CATENIN; MAP KINASES; PHOSPHORYLATION; ALPHA; REGULATORS; EXPRESSION; RECEPTOR; ELEGANS	The central nervous dysfunctions of lethargy, fever and anorexia are manifestations of sepsis that seem to be mediated by increased cytokine production. Here we demonstrate that tumor necrosis factor (TNF)-alpha, an essential mediator of endotoxin-induced sepsis, prevents the proteasome-dependent degradation of RGS7, a regulator of C-protein signaling. The stabilization of RGS7 by TNF-alpha requires activation of the stress-activated protein kinase p38 and the presence of candidate mitogen-activated protein kinase phosphorylation sites. In vivo, RGS7 is rapidly upregulated in mouse brain after exposure to either endotoxin or TNF-alpha, a response that is nearly abrogated in mice lacking TNF receptor 1. Our findings indicate that TNF-mediated upregulation of RGS7 may contribute to sepsis-induced changes in central nervous function.	Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Univ Hosp Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany; Harvard Med Sch, Dept Cell Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Harvard University; Harvard Medical School	Kim, E (corresponding author), Beth Israel Deaconess Med Ctr, Dept Psychiat, 330 Brookline Ave, Boston, MA 02215 USA.	ekim@caregroup.harvard.edu	Benzing, Thomas/X-5476-2019; Schermer, Bernhard/E-9972-2014; Brandes, Ralf/L-3058-2017	Schermer, Bernhard/0000-0002-5194-9000; Brandes, Ralf/0000-0002-8035-0048	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH001147] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK52897] Funding Source: Medline; NIMH NIH HHS [MH01147] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Boone E, 1998, FEBS LETT, V441, P275, DOI 10.1016/S0014-5793(98)01567-1; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Dunn AJ, 1998, ANN NY ACAD SCI, V840, P577, DOI 10.1111/j.1749-6632.1998.tb09596.x; Fang JD, 1997, J NEUROSCI, V17, P5949; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Gold SJ, 1997, J NEUROSCI, V17, P8024; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ingi T, 1998, J NEUROSCI, V18, P7178; KAPAS L, 1992, AM J PHYSIOL, V263, pR708, DOI 10.1152/ajpregu.1992.263.3.R708; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Khawaja XZ, 1999, J NEUROCHEM, V72, P174, DOI 10.1046/j.1471-4159.1999.0720174.x; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REMICK DG, 1993, INT REV EXP PATHOL, V34, P7; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Saugstad JA, 1998, J NEUROSCI, V18, P905; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SELBY P, 1987, BRIT J CANCER, V56, P803, DOI 10.1038/bjc.1987.294; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Thomas EA, 1998, J NEUROSCI RES, V52, P118, DOI 10.1002/(SICI)1097-4547(19980401)52:1<118::AID-JNR11>3.0.CO;2-6; Waage A, 1991, Infect Dis Clin North Am, V5, P781; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014	33	64	66	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1999	5	8					913	918		10.1038/11354	http://dx.doi.org/10.1038/11354			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426315				2022-12-27	WOS:000081684000035
J	Gilroy, DW; Colville-Nash, PR; Willis, D; Chivers, J; Paul-Clark, MJ; Willoughby, DA				Gilroy, DW; Colville-Nash, PR; Willis, D; Chivers, J; Paul-Clark, MJ; Willoughby, DA			Inducible cyclooxygenase may have anti-inflammatory properties	NATURE MEDICINE			English	Article							INHIBITION; SYNTHASE; RATS; EXPRESSION; MODELS	Cyclooxygenase (COX) has two isoforms. Generally, COX 1 is constitutively expressed in most tissues, where it maintains physiological processes(1); inducible COX 2 is considered a pro-inflammatory enzyme and a chief target for the treatment of inflammatory diseases(2). Here we present evidence that COX 2 may have anti-inflammatory properties. In carrageenin-induced pleurisy in rats, the predominant cells at 2 hours are polymorphonuclear leucocytes, whereas mononuclear cells dominate from 24 hours until resolution at 48 hours(3). In this model, COX 2 protein expression peaked initially at 2 hours, associated with maximal prostaglandin E-2 synthesis. However, at 48 hours there was a second increase in COX 2 expression, 350% greater than that at 2 hours. Paradoxically, this coincided with inflammatory resolution and was associated with minimal prostaglandin E-2 synthesis. In contrast, levels of prostaglandin D-2, and 15deoxy Delta(12-14)prostaglandin J(2) were high at 2 hours, decreased as inflammation increased, but were increased again at 48 hours. The selective COX 2 inhibitor NS-398 and the dual COX 1/COX 2 inhibitor indomethacin inhibited inflammation at 2 hours but significantly exacerbated inflammation at 48 hours. This exacerbation was associated with reduced exudate prostaglandin D-2 and 15deoxy Delta(12-14)prostaglandin J(2) concentrations, and was reversed by replacement of these prostaglandins. Thus, COX 2 may be pro-inflammatory during the early phase of a carrageenin-induced pleurisy, dominated by polymorphonuclear leucocytes, but may aid resolution at the later, mononuclear cell-dominated phase by generating an alternative set of anti-inflammatory prostaglandins.	St Bartholomews & Royal London Sch Med & Dent, Dept Expt Pathol, London EC1M 6BQ, England	University of London; Queen Mary University London	Colville-Nash, PR (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Expt Pathol, London EC1M 6BQ, England.	p.r.colville-nash@mds.qmw.ac.uk	Gilroy, Derek W/C-2588-2009; Gilroy, Derek/AAP-7227-2020	Gilroy, Derek/0000-0003-3476-0844				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Gilroy DW, 1998, INFLAMMATION, V22, P509, DOI 10.1023/A:1022350111213; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MASSO JM, 1994, AGENTS ACTIONS, V42, P118, DOI 10.1007/BF01983476; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672; Shigeta JI, 1998, J PHARMACOL EXP THER, V286, P1383; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, 1959, ANN RHEUM DIS, V18, P173; TOMLINSON A, 1994, BRIT J PHARMACOL, V113, P693, DOI 10.1111/j.1476-5381.1994.tb17048.x; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V260, P521, DOI 10.1016/0003-9861(88)90477-8; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WILLIAMS KI, 1988, J PATHOL, V156, P101, DOI 10.1002/path.1711560204; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87	19	1043	1091	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1999	5	6					698	701		10.1038/9550	http://dx.doi.org/10.1038/9550			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371510				2022-12-27	WOS:000080823300040
J	Tomlinson, I; Bodmer, W				Tomlinson, I; Bodmer, W			Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog	NATURE MEDICINE			English	Editorial Material							CARCINOGENESIS; PHENOTYPE; TUMORS		Imperial Canc Res Fund, Mol & Populat Genet Lab, London WC2A 3PX, England; John Radcliffe Hosp, Imperial Canc Res Fund, Inst Mol Med, Canc & Immunogenet Lab, Oxford OX3 9DZ, England	Cancer Research UK; University of Oxford	Tomlinson, I (corresponding author), Imperial Canc Res Fund, Mol & Populat Genet Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Bodmer, Walter/0000-0001-6244-9792				BRANCH P, 1995, NAT GENET, V9, P231, DOI 10.1038/ng0395-231; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Cairns J, 1998, GENETICS, V148, P1433; Davis TW, 1998, CANCER RES, V58, P767; Homfray TFR, 1998, HUM MUTAT, V11, P114, DOI 10.1002/(SICI)1098-1004(1998)11:2<114::AID-HUMU3>3.0.CO;2-J; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; LOEB LA, 1974, CANCER RES, V34, P2311; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; Richards B, 1997, SCIENCE, V277, P1523, DOI 10.1126/science.277.5331.1523; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; TOMLINSON IPM, 1995, P NATL ACAD SCI USA, V92, P11130, DOI 10.1073/pnas.92.24.11130; Tomlinson IPM, 1996, P NATL ACAD SCI USA, V93, P14800, DOI 10.1073/pnas.93.25.14800; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	19	231	236	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					11	12		10.1038/4687	http://dx.doi.org/10.1038/4687			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883827				2022-12-27	WOS:000077885000016
J	Moley, KH; Chi, MMY; Knudson, CM; Korsmeyer, SJ; Mueckler, MM				Moley, KH; Chi, MMY; Knudson, CM; Korsmeyer, SJ; Mueckler, MM			Hyperglycemia induces apoptosis in pre-implantation embryos through cell death effector pathways	NATURE MEDICINE			English	Article							PREIMPLANTATION EMBRYO; PROTEASES; MALFORMATIONS; MECHANISM; ANOMALIES; MICE	Although perinatal mortality rates have improved for pregnant diabetic women because of insulin therapy and tight metabolic control, infants of diabetics still experience significantly higher rates of congenital malformations and spontaneous miscarriages compared with those of non-diabetic women(1). Our results here indicate that hyperglycemic conditions, either in vivo or in vitro, modulate the expression of an apoptosis regulatory gene as early as the pre-implantation blastocyst stage in the mouse. Apoptosis in the mammalian pre-implantation blastocyst is a normal process, thought to protect the early embryo by eliminating abnormal cells'. Here we demonstrate that expression of Bar, a Bcl-2-like protein, is increased at the blastocyst stage in the presence of high concentrations of glucose, and that these changes correlate morphologically with increased DNA fragmentation. Expression of Bar and caspase are necessary for this in vitro glucose-induced apoptotic event, and ceramide is involved in mediating this embryotoxic effect of glucose. We also show that these apoptotic cellular changes can be prevented in vivo by treating hyperglycemic mice with insulin before and immediately after conception. These findings emphasize the importance of tight glycemic control in diabetic women at the earliest stages after conception.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol & Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Mueckler, MM (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012	Knudson, Charles Michael/0000-0003-3964-5466				BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRINSON DR, 1996, MOL REPROD DEV, V44, P171; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; FREINKEL N, 1988, HORM METAB RES, V20, P463, DOI 10.1055/s-2007-1010861; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jurisicova A, 1996, MOL HUM REPROD, V2, P93, DOI 10.1093/molehr/2.2.93; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lea RG, 1996, DIABETES, V45, P1463, DOI 10.2337/diabetes.45.11.1463; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; Moley KH, 1998, AM J PHYSIOL-ENDOC M, V275, pE38, DOI 10.1152/ajpendo.1998.275.1.E38; MOLEY KH, 1991, J REPROD FERTIL, V93, P325; Ortiz A, 1997, J INVEST MED, V45, P50; Pampfer S, 1997, DEVELOPMENT, V124, P4827; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; PIERCE GB, 1989, P NATL ACAD SCI USA, V86, P3654, DOI 10.1073/pnas.86.10.3654; Polifka JE, 1996, TERATOLOGY, V53, P1, DOI 10.1002/(SICI)1096-9926(199601)53:1<1::AID-TERA1>3.0.CO;2-A; Reece EA, 1996, OBSTET GYN CLIN N AM, V23, P29, DOI 10.1016/S0889-8545(05)70243-6; Siman CM, 1997, DIABETES, V46, P1054, DOI 10.2337/diabetes.46.6.1054; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; TAM PPL, 1988, TERATOLOGY, V37, P205, DOI 10.1002/tera.1420370305; WANG E, 1991, J BIOL CHEM, V266, P14486; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	23	268	283	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1421	1424		10.1038/4013	http://dx.doi.org/10.1038/4013			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846581				2022-12-27	WOS:000077336900039
J	Simon, JHM; Gaddis, NC; Fouchier, RAM; Malim, MH				Simon, JHM; Gaddis, NC; Fouchier, RAM; Malim, MH			Evidence for a newly discovered cellular anti-HIV-1 phenotype	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 INFECTION; DNA-SYNTHESIS; VIF MUTANTS; SOR GENE; PROTEINS; CELLS; TRANSMISSION; REPLICATION; REQUIREMENT	Animal cells have developed many ways to suppress viral replication, and viruses have evolved diverse strategies to resist these. Here we provide evidence that the virion infectivity factor protein of human immunodeficiency virus type 1 (HIV-1) functions to counteract a newly discovered activity in human cells that otherwise inhibits virus replication. This anti-viral phenotype is shown by human T cells, the principal in vivo targets for HIV-1, and, based on our present understanding of virion infectivity factor action, is presumed to act by interfering with a late step(s) in the virus life cycle. These observations indicate that the inhibition of virion infectivity factor function in vivo may prevent HIV-1 replication by 'unmasking' an innate anti-viral phenotype.	Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Malim, MH (corresponding author), Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.		Gaddis, Nathan/GXG-6447-2022; Fouchier, Ron A/A-1911-2014; Gaddis, Nathan/GXG-6395-2022	Fouchier, Ron A/0000-0001-8095-2869; Gaddis, Nathan/0000-0001-5205-7138; Malim, Michael/0000-0002-7699-2064	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038715] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38715] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEGGS AH, 1988, P NATL ACAD SCI USA, V85, P7632, DOI 10.1073/pnas.85.20.7632; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0; Bouyac M, 1997, J VIROL, V71, P2473, DOI 10.1128/JVI.71.3.2473-2477.1997; DESGROSEILLERS L, 1983, J VIROL, V48, P685, DOI 10.1128/JVI.48.3.685-696.1983; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; DUBAY JW, 1992, J VIROL, V66, P6616, DOI 10.1128/JVI.66.11.6616-6625.1992; FAN LJ, 1992, VIROLOGY, V190, P19, DOI 10.1016/0042-6822(92)91188-Z; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Harmache A, 1996, VIROLOGY, V224, P246, DOI 10.1006/viro.1996.0526; Hu SM, 1997, J BIOL CHEM, V272, P9621; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MARRACK P, 1994, CELL, V76, P323, DOI 10.1016/0092-8674(94)90339-5; Mathews M B, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P173; MEVELNINIO M, 1981, J CELL BIOL, V90, P339, DOI 10.1083/jcb.90.2.339; Moss B., 1996, FIELDS VIROLOGY, P2637; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; REDDY TR, 1995, J VIROL, V69, P3549, DOI 10.1128/JVI.69.6.3549-3553.1995; SAKAI H, 1993, J VIROL, V67, P1663, DOI 10.1128/JVI.67.3.1663-1666.1993; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Simon JHM, 1997, J VIROL, V71, P5259, DOI 10.1128/JVI.71.7.5259-5267.1997; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; Smith GL, 1996, CURR OPIN IMMUNOL, V8, P467, DOI 10.1016/S0952-7915(96)80032-X; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; STEEVES R, 1977, ANNU REV GENET, V11, P277, DOI 10.1146/annurev.ge.11.120177.001425; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TOMONAGA K, 1992, J VIROL, V66, P6181, DOI 10.1128/JVI.66.10.6181-6185.1992; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389	38	228	231	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1397	1400		10.1038/3987	http://dx.doi.org/10.1038/3987			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846577				2022-12-27	WOS:000077336900035
J	Tinsley, J; Deconinck, N; Fisher, R; Kahn, D; Phelps, S; Gillis, JM; Davies, K				Tinsley, J; Deconinck, N; Fisher, R; Kahn, D; Phelps, S; Gillis, JM; Davies, K			Expression of full-length utrophin prevents muscular dystrophy in mdx mice	NATURE MEDICINE			English	Article							MOUSE; CONTRACTIONS; MUSCLES; GENE	Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fiber leading to the gradual depletion of skeletal muscle(1). The molecular structure of dystrophin is very similar to that of the related protein utrophin(2). Utrophin is found in all tissues(3) and is confined to the neuromuscular and myotendinous junctions in mature muscle(4). Sarcolemmal localization of a truncated utrophin transgene in the dystrophin-deficient mdx mouse significantly improves the dystrophic muscle phenotype(5,6). Therefore, upregulation of utrophin by drug therapy is a plausible therapeutic approach in the treatment of DMD. Here we demonstrate that expression of full-length utrophin in mdx mice prevents the development of muscular dystrophy. We assessed muscle morphology, fiber regeneration and mechanical properties (force development and resistance to stretch) of mdx and transgenic mdx skeletal and diaphragm muscle. The utrophin levels required in muscle are significantly less than the normal endogenous utrophin levels seen in lung and kidney, and we provide evidence that the pathology depends on the amount of utrophin expression. These results also have important implications for DMD therapies in which utrophin replacement is achieved by delivery using exogenous vectors.	Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England; Univ Catholique Louvain, Dept Physiol, UCL 5540, B-1200 Brussels, Belgium	University of Oxford; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Tinsley, J (corresponding author), Univ Oxford, Dept Human Anat & Genet, S Parks Rd, Oxford OX1 3QX, England.							Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; BLAKE DJ, 1995, P NATL ACAD SCI USA, V92, P3697, DOI 10.1073/pnas.92.9.3697; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CARLSON CG, 1990, MUSCLE NERVE, V13, P480, DOI 10.1002/mus.880130603; DECONINCK AE, 1997, J CELL BIOL, V136, P88; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; Nguyen T M, 1991, J Cell Biol, V115, P1695, DOI 10.1083/jcb.115.6.1695; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8	20	455	488	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1441	1444		10.1038/4033	http://dx.doi.org/10.1038/4033			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846586				2022-12-27	WOS:000077336900044
J	Bosch, X				Bosch, X			Spanish oncology center under threat	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					847	847		10.1038/78590	http://dx.doi.org/10.1038/78590			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932209	Bronze			2022-12-27	WOS:000165473800013
J	Wright, WE; Shay, JW				Wright, WE; Shay, JW			Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology	NATURE MEDICINE			English	Editorial Material							LARGE-T-ANTIGEN; HUMAN-DIPLOID FIBROBLASTS; NORMAL HUMAN-CELLS; LIFE-SPAN; EPITHELIAL-CELLS; IN-VITRO; CELLULAR SENESCENCE; IMMORTALIZATION; INHIBITION; ATM	Cells from the telomerase knockout mouse immortalize with an approximately ten million-fold greater frequency than human cells. In this commentary, Wright and Shay discuss the implications of this difference between mice and men and its relationship to cancer.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wright, WE (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Shay, Jerry W/F-7878-2011					Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Kamijo T, 1999, CANCER RES, V59, P2464; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rubin H, 1997, MECH AGEING DEV, V98, P1, DOI 10.1016/S0047-6374(97)00067-5; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Westphal CH, 1997, CANCER RES, V57, P1664; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	35	298	306	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					849	851		10.1038/78592	http://dx.doi.org/10.1038/78592			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932210				2022-12-27	WOS:000165473800014
J	Goldman, S; Roy, N				Goldman, S; Roy, N			Human neural progenitor cells: better blue than green? Reply	NATURE MEDICINE			English	Letter							FLUORESCENT PROTEIN; MAMMALIAN-CELLS; EXPRESSION; PROMOTER; MICE		Cornell Univ, Dept Neurol & Neurosci, Coll Med, New York, NY 10021 USA	Cornell University	Goldman, S (corresponding author), Cornell Univ, Dept Neurol & Neurosci, Coll Med, New York, NY 10021 USA.			Goldman, Steven/0000-0002-5498-4303				Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Fuss B, 2000, DEV BIOL, V218, P259, DOI 10.1006/dbio.1999.9574; Gubin AN, 1997, BIOCHEM BIOPH RES CO, V236, P347, DOI 10.1006/bbrc.1997.6963; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954; Plautz JD, 1996, GENE, V173, P83, DOI 10.1016/0378-1119(95)00700-8; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Roy NS, 2000, NAT MED, V6, P271; Villa A, 2000, EXP NEUROL, V161, P67, DOI 10.1006/exnr.1999.7237; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601	13	9	9	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					483	484		10.1038/74920	http://dx.doi.org/10.1038/74920			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802678				2022-12-27	WOS:000086796200004
J	Sun, LW; Li, J; Xiao, X				Sun, LW; Li, J; Xiao, X			Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; TRANSMEMBRANE CONDUCTANCE REGULATOR; IN-VIVO EXPRESSION; GENE-TRANSFER; MUSCULAR-DYSTROPHY; DETROIT-6 CELLS; MUSCLE-TISSUE; AAV VECTOR; PROTEIN; MICE		Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Gene Therapy Ctr, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Duchenne Muscular Dystrophy Res Ctr, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Xiao, X (corresponding author), Univ Pittsburgh, Dept Mol Genet & Biochem, Room W1213,BST, Pittsburgh, PA 15261 USA.				NIAMS NIH HHS [AR45967, AR 45925] Funding Source: Medline; NIDDK NIH HHS [R21 DK55966] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045925, R01AR045967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK055966] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEUNG AKM, 1980, J VIROL, V33, P739, DOI 10.1128/JVI.33.2.739-748.1980; Dong JY, 1996, HUM GENE THER, V7, P2101, DOI 10.1089/hum.1996.7.17-2101; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Duan DS, 1999, VIROLOGY, V261, P8, DOI 10.1006/viro.1999.9821; Duan DS, 1999, J VIROL, V73, P861, DOI 10.1128/JVI.73.1.861-861.1999; During MJ, 1998, GENE THER, V5, P820, DOI 10.1038/sj.gt.3300650; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; KOTIN RM, 1989, VIROLOGY, V170, P460, DOI 10.1016/0042-6822(89)90437-6; Lewin AS, 1998, NAT MED, V4, P1081, DOI 10.1038/2077; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; Xiao WD, 1998, J VIROL, V72, P10222, DOI 10.1128/JVI.72.12.10222-10226.1998; Xiao X, 2000, J VIROL, V74, P1436, DOI 10.1128/JVI.74.3.1436-1442.2000; Xiao X, 1997, BRAIN RES, V756, P76, DOI 10.1016/S0006-8993(97)00120-0; Xiao X, 1997, J VIROL, V71, P941, DOI 10.1128/JVI.71.2.941-948.1997; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996	25	171	179	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					599	602		10.1038/75087	http://dx.doi.org/10.1038/75087			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802720				2022-12-27	WOS:000086796200048
J	Galve-Roperh, I; Sanchez, C; Cortes, ML; del Pulgar, TG; Izquierdo, M; Guzman, M				Galve-Roperh, I; Sanchez, C; Cortes, ML; del Pulgar, TG; Izquierdo, M; Guzman, M			Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation	NATURE MEDICINE			English	Article							MALIGNANT BRAIN-TUMORS; NERVE GROWTH-FACTOR; PROTEIN-KINASE; SPHINGOMYELIN HYDROLYSIS; HIPPOCAMPAL-NEURONS; GLIOMA-CELLS; RECEPTOR; ANANDAMIDE; APOPTOSIS; DEATH	Delta(9)-Tetrahydrocannabinol, the main active component of marijuana, induces apoptosis of transformed neural cells in culture. Here, we show that intratumoral administration of Delta(9)-tetrahydrocannabinol and the synthetic cannabinoid agonist WIN-55,212-2 induced a considerable regression of malignant gliomas in Wistar rats and in mice deficient in recombination activating gene 2. Cannabinoid treatment did not produce any substantial neurotoxic effect in the conditions used. Experiments with two subclones of C6 glioma cells in culture showed that cannabinoids signal apoptosis by a pathway involving cannabinoid receptors, sustained ceramide accumulation and Raf1/extracellular signal-regulated kinase activation. These results may provide the basis for a new therapeutic approach for the treatment of malignant gliomas.	Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; Univ Autonoma Madrid, Sch Sci, Severo Ochoa Mol Biol Ctr, Dept Mol Biol, E-28049 Madrid, Spain	Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Guzman, M (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain.		Gomez del Pulgar, Teresa/GXV-5256-2022; Sanchez, Cristina/AFQ-4745-2022; Galve-Roperh, Ismael/AAG-2369-2020; Sanchez, Cristina/H-4980-2017	Sanchez, Cristina/0000-0002-1428-3078; Guzman, Manuel/0000-0001-7475-118X				Ariga T, 1998, J LIPID RES, V39, P1; Avgeropoulos N G, 1999, Oncologist, V4, P209; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; Baudet C, 1996, J NEUROSCI RES, V46, P540, DOI 10.1002/(SICI)1097-4547(19961201)46:5<540::AID-JNR3>3.0.CO;2-J; Blazquez C, 1999, J NEUROCHEM, V72, P1759, DOI 10.1046/j.1471-4159.1999.721759.x; Brotchie JM, 1997, CURR OPIN NEUROL, V10, P340, DOI 10.1097/00019052-199708000-00010; Childers SR, 1998, DRUG ALCOHOL DEPEN, V51, P173, DOI 10.1016/S0376-8716(98)00075-1; Cortes ML, 1998, GENE THER, V5, P1499, DOI 10.1038/sj.gt.3300751; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Derkinderen P, 1999, NEUROREPORT, V10, pR24; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Felder CC, 1998, ANNU REV PHARMACOL, V38, P179, DOI 10.1146/annurev.pharmtox.38.1.179; Galve-Roperh I, 1998, J NEUROCHEM, V71, P498; GRINSPOON L, 1995, JAMA-J AM MED ASSOC, V273, P1875, DOI 10.1001/jama.273.23.1875; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; IZQUIERDO M, 1995, GENE THER, V2, P66; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Marshall CJ, 1998, NATURE, V392, P553, DOI 10.1038/33293; Martuza RL, 1997, NAT MED, V3, P1323, DOI 10.1038/nm1297-1323; Mason W, 1997, J CLIN ONCOL, V15, P3423, DOI 10.1200/JCO.1997.15.12.3423; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Michaud NR, 1998, P NATL ACAD SCI USA, V95, P2714; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Price DL, 1999, NATURE, V399, pA3, DOI 10.1038/399a003; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; ROSER K, 1991, EXP CELL RES, V197, P200, DOI 10.1016/0014-4827(91)90423-R; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sanchez C, 1998, MOL PHARMACOL, V54, P834, DOI 10.1124/mol.54.5.834; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Voth EA, 1997, ANN INTERN MED, V126, P791, DOI 10.7326/0003-4819-126-10-199705150-00008; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	49	503	530	0	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					313	319		10.1038/73171	http://dx.doi.org/10.1038/73171			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700234				2022-12-27	WOS:000085580500042
J	Manley, GT; Fujimura, M; Ma, TH; Noshita, N; Filiz, F; Bollen, AW; Chan, P; Verkman, AS				Manley, GT; Fujimura, M; Ma, TH; Noshita, N; Filiz, F; Bollen, AW; Chan, P; Verkman, AS			Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke	NATURE MEDICINE			English	Article							FOCAL CEREBRAL-ISCHEMIA; ORTHOGONAL ARRAYS; CHANNEL AQUAPORIN-4; PLASMA-MEMBRANES; RAT-BRAIN; TISSUES; LACKING; VOLUME; KIDNEY; INJURY	Cerebral edema contributes significantly to morbidity and death associated with many common neurological disorders. However, current treatment options are limited to hyperosmolar agents and surgical decompression, therapies introduced more than 70 years ago. Here we show that mice deficient in aquaporin-4 (AQP4), a glial membrane water channel, have much better survival than wild-type mice in a model of brain edema caused by acute water intoxication. Brain tissue water content and swelling of pericapillary astrocytic foot processes in AQP4-deficient mice were significantly reduced. In another model of brain edema, focal ischemic stroke produced by middle cerebral artery occlusion, AQP4-deficient mice had improved neurological outcome. Cerebral edema, as measured by percentage of hemispheric enlargement at 24 h, was decreased by 35% in AQP4-deficient mice. These results implicate a key role for AQP4 in modulating brain water transport, and suggest that AQP4 inhibition may provide a new therapeutic option for reducing brain edema in a wide variety of cerebral disorders.	Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.	manley@itsa.ucsf.edu		Ma, Tonghui/0000-0001-9338-1030				BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Carrillo P, 1998, J TRAUMA, V45, P239, DOI 10.1097/00005373-199808000-00007; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; Fujimura M, 1999, J NEUROSCI, V19, P3414; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; HATTON JD, 1984, EPILEPSIA, V25, P145, DOI 10.1111/j.1528-1157.1984.tb04170.x; Hossmann KA, 1998, CARDIOVASC RES, V39, P106, DOI 10.1016/S0008-6363(98)00075-3; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; KLATZO I, 1994, ACTA NEUROCHIR, P3; Kondo T, 1997, J NEUROSCI, V17, P4180; LANDIS DMD, 1974, J CELL BIOL, V60, P316, DOI 10.1083/jcb.60.1.316; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; SUZUKI M, 1984, BRAIN RES, V300, P141, DOI 10.1016/0006-8993(84)91348-9; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TRACHTMAN H, 1992, PEDIATR NEPHROL, V6, P104, DOI 10.1007/BF00856852; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; WASTERLAIN CG, 1968, ARCH NEUROL-CHICAGO, V19, P71, DOI 10.1001/archneur.1968.00480010089007; WASTERLAIN CG, 1968, ARCH NEUROL-CHICAGO, V19, P79, DOI 10.1001/archneur.1968.00480010097008; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531; Yang BX, 1996, J BIOL CHEM, V271, P4577; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165	34	1188	1336	5	151	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					159	163		10.1038/72256	http://dx.doi.org/10.1038/72256			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655103				2022-12-27	WOS:000085016900035
J	Carballido, JM; Namikawa, R; Carballido-Perrig, N; Antonenko, S; Roncarolo, MG; de Vries, JE				Carballido, JM; Namikawa, R; Carballido-Perrig, N; Antonenko, S; Roncarolo, MG; de Vries, JE			Generation of primary antigen-specific human T- and B-cell responses in immunocompetent SCID-hu mice	NATURE MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; PERIPHERAL-BLOOD LYMPHOCYTES; VERSUS-HOST DISEASE; IMMUNOGLOBULIN PRODUCTION; MONONUCLEAR-CELLS; MOUSE; ENGRAFTMENT; GRAFT; IMMUNIZATION; CHIMERAS		Novartis Res Inst, Dept Immunol, A-1235 Vienna, Austria; DNAX Res Inst Mol & Cellular Biol Inc, Dept Human Immunol, Palo Alto, CA 94304 USA; Hosp San Raffaele, Telethon Inst Gene Therapy, I-20132 Milan, Italy	Novartis; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Fondazione Telethon; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Carballido, JM (corresponding author), Novartis Res Inst, Dept Immunol, Brunner Str 59, A-1235 Vienna, Austria.			RONCAROLO, Maria Grazia/0000-0002-2193-9186	Telethon [TGT00A01, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ABEDI MR, 1992, EUR J IMMUNOL, V22, P823, DOI 10.1002/eji.1830220329; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CARBALLIDO JM, 1995, J IMMUNOL, V155, P4162; Delhem N, 1998, J IMMUNOL, V161, P2060; DUCHOSAL MA, 1992, NATURE, V355, P258, DOI 10.1038/355258a0; FRASER CC, 1995, BLOOD, V86, P183, DOI 10.1182/blood.V86.1.183.bloodjournal861183; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; HOFFMANNFEZER G, 1993, BLOOD, V81, P3440; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KROWKA JF, 1991, J IMMUNOL, V146, P3751; KYOIZUMI S, 1992, BLOOD, V79, P1704; MARTENSSON C, 1994, IMMUNOLOGY, V83, P171; MAZINGUE C, 1991, EUR J IMMUNOL, V21, P1763, DOI 10.1002/eji.1830210728; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MURPHY WJ, 1992, EUR J IMMUNOL, V22, P1421, DOI 10.1002/eji.1830220614; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; PFLUMIO F, 1993, INT IMMUNOL, V5, P1509, DOI 10.1093/intimm/5.12.1509; Roncarolo M G, 1996, Semin Immunol, V8, P207, DOI 10.1006/smim.1996.0026; RONCAROLO MG, 1998, CURRENT PROTOCOLS IM; SANDHU J, 1994, J IMMUNOL, V152, P3806; STEIN H, 1982, CLIN HAEMATOL, V11, P531; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; TARYLEHMANN M, 1994, J EXP MED, V180, P1817, DOI 10.1084/jem.180.5.1817	24	38	40	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					103	106		10.1038/71434	http://dx.doi.org/10.1038/71434			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613834				2022-12-27	WOS:000084583300045
J	Sanchez-Prieto, R; de Alava, E; Palomino, T; Guinea, J; Fernandez, V; Cebrian, S; Lleonart, M; Cabello, P; Martin, P; San Roman, C; Bornstein, R; Pardo, J; Martinez, A; Diaz-Espada, F; Barrios, Y; Cajal, SRY				Sanchez-Prieto, R; de Alava, E; Palomino, T; Guinea, J; Fernandez, V; Cebrian, S; Lleonart, M; Cabello, P; Martin, P; San Roman, C; Bornstein, R; Pardo, J; Martinez, A; Diaz-Espada, F; Barrios, Y; Cajal, SRY			An association between viral genes and human oncogenic alterations: The adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1	NATURE MEDICINE			English	Article							CHROMOSOME-TRANSLOCATION; CELL-LINES; EXPRESSION; RECOMBINATION; PROTEIN; P53	Malignant transformation of human cells requires the accumulation of multiple genetic alterations, such as the activation of oncogenes and loss of function of tumor suppressor genes or those related to genomic instability. Among the genetic alterations most frequently found in human tumors are chromosomal translocations' that may result in the expression of chimeric products with transforming capability or are able to change the expression of oncogenes. We show here that the adenovirus early region 1A (E1A) gene can induce a specific human fusion transcript (EWS-FLI1) that is characteristic of Ewing tumors(2). This fusion transcript was detected by RT-PCR in normal human fibroblasts and keratinocytes after expression of the adenovirus E1A gene, as well as in human cell lines immortalized by adenoviruses. Cloning and sequencing of the RT-PCR product showed fusion points between EWS and FLI1 cDNA identical to those detected in Ewing tumors. In addition, we detected a chimeric protein by western blot analysis and immunoprecipitation and a t(11,22) by fluorescent in situ hybridization. This association between a single viral gene and a specific human fusion transcript indicates a direct link between viral genes and chromosome translocations, one of the hallmarks of many human tumors.	Clin Puerta de Hierro, Dept Pathol, Madrid 28035, Spain; Clin Puerta de Hierro, Dept Immunol, Madrid 28035, Spain; Univ Navarra Clin, Dept Pathol, Pamplona 31008, Spain; Hosp Ramon y Cajal, Dept Genet, E-28034 Madrid, Spain; Hosp 12 Octubre, Dept Hematol, E-28041 Madrid, Spain	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; University of Navarra; Hospital Universitario Ramon y Cajal; Hospital Universitario 12 de Octubre	Cajal, SRY (corresponding author), Clin Puerta de Hierro, Dept Pathol, San Martin de Porres 4, Madrid 28035, Spain.		IBIS, SARCOMAS/O-1893-2015; LLeonart, Matilde E./Q-2662-2019; de Alava, Enrique/GOH-0368-2022; Sanchez-Prieto, Ricardo/AAY-4271-2021; Espinosas, Maribel/H-8083-2012; Sanchez-Prieto, Ricardo/B-6877-2008; Barrios, Yvelise/AGR-9501-2022; Prieto, Ricardo/AAZ-7221-2021; Ramon y Cajal, Santiago/H-4955-2016	LLeonart, Matilde E./0000-0002-6196-7405; de Alava, Enrique/0000-0001-8400-046X; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Barrios, Yvelise/0000-0002-6994-2034; Bornstein, Rafael/0000-0002-3229-7852; Ramon y Cajal, Santiago/0000-0002-3867-1390; Fernandez-Soria, Victor Manuel/0000-0002-4225-8697				Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; CAJAL SRY, 1995, HISTOL HISTOPATHOL, V10, P811; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FUKAMIZU A, 1994, J BIOL CHEM, V269, P31252; HIORN K, 1998, CELL, V94, P463; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; Mymryk JS, 1997, BIOCHEM CELL BIOL, V75, P95, DOI 10.1139/bcb-75-2-95; Mymryk JS, 1996, ONCOGENE, V13, P1581; Sanchez-Prieto R, 1998, CANCER GENE THER, V5, P215; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SCHRAMAYR S, 1990, J VIROL, V64, P2090, DOI 10.1128/JVI.64.5.2090-2095.1990; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	20	27	27	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1076	1079		10.1038/12516	http://dx.doi.org/10.1038/12516			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470089				2022-12-27	WOS:000082337200046
J	Hoe, NP; Nakashima, K; Lukomski, S; Grigsby, D; Liu, MY; Kordari, P; Dou, SJ; Pan, X; Vuopio-Varkila, J; Salmelinna, S; McGeer, A; Low, DE; Schwartz, B; Schuchat, A; Naidich, S; De Lorenzo, D; Fu, YX; Musser, JM				Hoe, NP; Nakashima, K; Lukomski, S; Grigsby, D; Liu, MY; Kordari, P; Dou, SJ; Pan, X; Vuopio-Varkila, J; Salmelinna, S; McGeer, A; Low, DE; Schwartz, B; Schuchat, A; Naidich, S; De Lorenzo, D; Fu, YX; Musser, JM			Rapid selection of complement-inhibiting protein variants in group A Streptococcus epidemic waves	NATURE MEDICINE			English	Article							GROUP-A STREPTOCOCCUS; MOLECULAR EPIDEMIOLOGY; SIZE MUTANTS; INFECTIONS; SEROTYPE; DISEASE; GLYCOPROTEIN; ATLANTA; STRAINS; SPREAD	Serotype M1 group A Streptococcus strains cause epidemic waves of human infections long thought to be mono- or pauciclonal. The gene encoding an extracellular group A Streptococcus protein (streptococcal inhibitor of complement) that inhibits human complement was sequenced in 1,132 M1 strains recovered from population-based surveillance of infections in Canada, Finland and the United States. Epidemic waves are composed of strains expressing a remarkably heterogeneous array of variants of streptococcal inhibitor of complement that arise very rapidly by natural selection on mucosal surfaces. Thus, our results enhance the understanding of pathogen population dynamics in epidemic waves and infectious disease reemergence.	Natl Publ Hlth Inst, Dept Bacteriol, FIN-00300 Helsinki, Finland; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON M5G 1X5, Canada; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Genomics, New York, NY 10013 USA; Univ Texas, Hlth Sci Ctr, Ctr Human Genet, Houston, TX 77030 USA	Finland National Institute for Health & Welfare; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Centers for Disease Control & Prevention - USA; University of Texas System; University of Texas Health Science Center Houston	Musser, JM (corresponding author), NIAID, Rocky Mt Lab, NIH, 903 S 4th St, Hamilton, MT 59840 USA.	jmusser@bcm.tmc.edu	mcgeer, allison/H-7747-2014; Low, Donald/B-1726-2012; McGeer, Allison/AAB-6885-2020; de Lorenzo, David/C-2677-2009	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137; de Lorenzo, David/0000-0003-2042-0961	NIAID NIH HHS [AI-33119] Funding Source: Medline; NIGMS NIH HHS [GM-50428] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050428, R29GM050428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; Beall B, 1997, J CLIN MICROBIOL, V35, P1231, DOI 10.1128/JCM.35.5.1231-1235.1997; CLEARY PP, 1992, LANCET, V339, P518, DOI 10.1016/0140-6736(92)90339-5; Davies HD, 1996, NEW ENGL J MED, V335, P547, DOI 10.1056/NEJM199608223350803; DEMALMANCHE SA, 1994, MED MICROBIOL IMMUN, V183, P299, DOI 10.1007/BF00196680; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; FISCHETTI VA, 1986, J EXP MED, V164, P971, DOI 10.1084/jem.164.4.971; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FITCH WM, 1977, AM NAT, V111, P223, DOI 10.1086/283157; FU YX, 1995, THEOR POPUL BIOL, V48, P172, DOI 10.1006/tpbi.1995.1025; GARCIA O, 1994, J VIROL, V68, P5448; HARBAUGH MP, 1993, MOL MICROBIOL, V8, P981, DOI 10.1111/j.1365-2958.1993.tb01642.x; Hennessy TW, 1996, NEW ENGL J MED, V334, P1281, DOI 10.1056/NEJM199605163342001; Hoe N, 1999, EMERG INFECT DIS, V5, P254, DOI 10.3201/eid0502.990210; HOLLINGSHEAD SK, 1987, MOL GEN GENET, V207, P196, DOI 10.1007/BF00331578; JONES KF, 1988, P NATL ACAD SCI USA, V85, P8271, DOI 10.1073/pnas.85.21.8271; Krause RM, 1998, EMERGING INFECT; Lubinski JM, 1998, J VIROL, V72, P8257, DOI 10.1128/JVI.72.10.8257-8263.1998; MARTIN DR, 1993, J INFECT DIS, V167, P1112, DOI 10.1093/infdis/167.5.1112; Morelli G, 1997, MOL MICROBIOL, V25, P1047, DOI 10.1046/j.1365-2958.1997.5211882.x; Muotiala A, 1997, J INFECT DIS, V175, P392, DOI 10.1093/infdis/175.2.392; MUSSER JM, 1995, INFECT IMMUN, V63, P994, DOI 10.1128/IAI.63.3.994-1003.1995; Musser JM, 1998, BIOMED RES REP, P185; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PIFFARETTI JC, 1989, P NATL ACAD SCI USA, V86, P3818, DOI 10.1073/pnas.86.10.3818; Stockbauer KE, 1998, P NATL ACAD SCI USA, V95, P3128, DOI 10.1073/pnas.95.6.3128; Swofford D., 1998, PAUP PHYLOGENETIC AN; TAJIMA F, 1989, GENETICS, V123, P585; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; VILLASENOR A, 1998, AM SOC MICR 98 GEN M; Wachsmuth I.K., 1994, VIBRIO CHOLERAE CHOL; Webster RG, 1998, BIOMED RES REP, P275; Zurawski CA, 1998, CLIN INFECT DIS, V27, P150, DOI 10.1086/514632	34	72	73	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1999	5	8					924	929		10.1038/11369	http://dx.doi.org/10.1038/11369			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426317				2022-12-27	WOS:000081684000037
J	Watts, AM; Stanley, JR; Shearer, MH; Hefty, PS; Kennedy, RC				Watts, AM; Stanley, JR; Shearer, MH; Hefty, PS; Kennedy, RC			Fetal immunization of baboons induces a fetal-specific antibody response	NATURE MEDICINE			English	Article							INFECTION	Neonates face a high risk of infection because of the immaturity of their immune systems. Although the transplacental transfer of maternal antibodies to the fetus may convey improved postnatal immunity, this transfer occurs late in gestation and may fail to prevent in utero infection. Both fetal immunization and in utero exposure to antigen can result in a state of immunologic tolerance in the neonate. Tolerance induction of fetal and premature infant lymphocytes has become a paradigm for neonatal responsiveness(1,2). However, fetal IgM responses have been demonstrated to maternal immunization with tetanus toroid and to congenital infections such as rubella, toxoplasma, cytomegalovirus and human immunodeficiency virus(3-6). Moreover, 1-week-old infants can respond to standard pediatric vaccination, and neonates immunized with polysaccharide antigens do not develop immunologic tolerance(7). Here, direct immunization of the baboon fetus with recombinant hepatitis B surface antigen produced a specific fetal IgG antibody response. No specific maternal antibody response was detected, eliminating the possibility of vertical antibody transmission to the fetus. Some infants also responded to later vaccinations with hepatitis B surface antigen, indicating that no immunological tolerance was induced by prior fetal immunization. These results characterize the ability of the fetal immune system to respond to in utero vaccination. We demonstrate that active fetal immunization can serve as a safe and efficient vaccination strategy for the fetus and neonate.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Kennedy, RC (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA.				NCRR NIH HHS [P40 RR-12317] Funding Source: Medline; PHS HHS [T32 A1-07634] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012317] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ATTANASIO R, 1991, J IMMUNOL, V146, P507; BONA C, 1997, IMMUNOLOGIST, V5, P5; DELPORTILLO HA, 1987, VET IMMUNOL IMMUNOP, V16, P201, DOI 10.1016/0165-2427(87)90018-3; ENDERS G, 1985, REV INFECT DIS, V7, pS113; GILL TJ, 1983, J CLIN INVEST, V72, P987, DOI 10.1172/JCI111071; GRIFFITHS PD, 1982, PEDIATRICS, V69, P544; HOWARD JG, 1976, EUR J IMMUNOL, V6, P486, DOI 10.1002/eji.1830060708; KENNEDY RC, 1983, J IMMUNOL, V130, P385; KENNEDY RC, 1997, IMMUNOLOGIST, V5, P150; NAOT Y, 1981, J PEDIATR-US, V98, P32, DOI 10.1016/S0022-3476(81)80528-8; OWEN RD, 1957, PROC R SOC SER B-BIO, V146, P8; Shearer MH, 1997, INFECT IMMUN, V65, P3267, DOI 10.1128/IAI.65.8.3267-3270.1997; SHEARER MH, 1995, DEV COMP IMMUNOL, V6, P547	13	47	48	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					427	430		10.1038/7426	http://dx.doi.org/10.1038/7426			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202933				2022-12-27	WOS:000079574300033
J	Itoh, K; Yoshioka, K; Akedo, H; Uehata, M; Ishizaki, T; Narumiya, S				Itoh, K; Yoshioka, K; Akedo, H; Uehata, M; Ishizaki, T; Narumiya, S			An essential part for Rho-associated kinase in the transcellular invasion of tumor cells	NATURE MEDICINE			English	Article							BINDING PROTEIN-RHO; CANCER METASTASIS; FOCAL ADHESIONS; GTPASE	Adhesion of tumor cells to host cell layers and subsequent transcellular migration are pivotal steps in cancer invasion and metastasis(1-3). The small GTPase Rho controls cell adhesion and motility through reorganization of the actin cytoskeleton and regulation of actomyosin contractility(4). Cultured rat MM1 hepatoma cells migrate through a mesothelial cell monolayer in vitro in a serum-dependent, Rho-mediated manner(5). Among several proteins isolated as putative target molecules of Rho, the ROCK (ROK) family of Rho-associated serine-threonine protein kinases(6-8) are thought to participate in the induction of focal adhesions and stress fibers in cultured cells(9), and to mediate calcium sensitization of smooth muscle contraction by enhancing phosphorylation of the regulatory light chain of myosin(10) Transfection of MM1 cells with cDNA encoding a dominant active mutant of ROCK conferred invasive activity independently of serum and Rho. In contrast, expression of a dominant negative, kinase-defective ROCK mutant substantially attenuated the invasive phenotype. A specific ROCK inhibitor (Y-27632; ref. 11) blocked both Rho-mediated activation of actomyosin and invasive activity of these cells. Furthermore, continuous delivery of this inhibitor using osmotic pumps considerably reduced the dissemination of MM1 cells implanted into the peritoneal cavity of syngeneic rats. These results indicate that ROCK plays an essential part in tumor cell invasion, and demonstrate its potential as a therapeutic target for the prevention of cancer invasion and metastasis.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Tumor Biol, Higashinari Ku, Osaka 5378511, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Kyoto University	Itoh, K (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Tumor Biol, Higashinari Ku, 1-3-3 Nakamichi, Osaka 5378511, Japan.			Itoh, Kazuyuki/0000-0002-0761-0499				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; FIDLER IJ, 1991, BRIT MED BULL, V47, P157, DOI 10.1093/oxfordjournals.bmb.a072453; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NICOLSON GL, 1989, INVAS METAST, V9, P102; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Talbot DC, 1996, EUR J CANCER, V32A, P2528; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VIEMINCKX K, 1991, CELL, V66, P107; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	20	551	596	0	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					221	225		10.1038/5587	http://dx.doi.org/10.1038/5587			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930872				2022-12-27	WOS:000078274400033
J	Chun, TW; Davey, RT; Ostrowski, M; Justement, JS; Engel, D; Mullins, JI; Fauci, AS				Chun, TW; Davey, RT; Ostrowski, M; Justement, JS; Engel, D; Mullins, JI; Fauci, AS			Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; POTENT ANTIRETROVIRAL THERAPY; HETERODUPLEX MOBILITY ASSAY; COMBINATION THERAPY; HIV-1 INFECTION; REPLICATION; ERADICATION; EVOLUTION; AIDS	We examined the pathogenic significance of the latent viral reservoir in the resting CD4(+) T cell compartment of HIV-1-infected individuals as well as its involvement in the rebound of plasma viremia after discontinuation of highly active anti-retroviral therapy (HAART). Using heteroduplex mobility and tracking assays, we show that the detectable pool of latently infected, resting CD4(+) T cells does not account entirely for the early rebounding plasma HIV in infected individuals in whom HAART has been discontinued. In the majority of patients examined, the rebounding plasma virus was genetically distinct from both the cell-associated HIV RNA and the replication-competent virus within the detectable pool of latently infected, resting CD4(+) T cells. These results indicate the existence of other persistent HIV reservoirs that could prompt rapid emergence of plasma viremia after cessation of HAART and underscore the necessity to develop therapies directed toward such populations of infected cells.	NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Univ Washington, Dept Microbiol, Seattle, WA 98104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle	Chun, TW (corresponding author), NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.		Chun, Tae-Wook/AAC-3101-2020; Chun, Tae-Wook/W-9187-2019	Chun, Tae-Wook/0000-0001-5153-7340	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000865, Z01AI000865] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cavert W, 1998, SCIENCE, V280, P1865, DOI 10.1126/science.280.5371.1865; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Cohen OJ, 1998, JAMA-J AM MED ASSOC, V280, P87, DOI 10.1001/jama.280.1.87; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Delwart EL, 1997, METHODS, V12, P348, DOI 10.1006/meth.1997.0489; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DELWART EL, 1995, PCR METH APPL, V4, pS202; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Dore G J, 1998, AIDS, V12 Suppl B, pS1; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 1999, J VIROL, V73, P9404; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Ho DD, 1998, SCIENCE, V280, P1866, DOI 10.1126/science.280.5371.1866; Hoyert D L, 1999, Natl Vital Stat Rep, V47, P1; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Lukashov V V, 1998, AIDS, V12 Suppl A, pS43; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Ostrowski MA, 1998, J VIROL, V72, P7772, DOI 10.1128/JVI.72.10.7772-7784.1998; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	42	354	359	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					757	761		10.1038/77481	http://dx.doi.org/10.1038/77481			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888923				2022-12-27	WOS:000088040100031
J	Fox, JG; Beck, P; Dangler, CA; Whary, MT; Wang, TC; Shi, HN; Nagler-Anderson, C				Fox, JG; Beck, P; Dangler, CA; Whary, MT; Wang, TC; Shi, HN; Nagler-Anderson, C			Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy	NATURE MEDICINE			English	Article							DELAYED-TYPE HYPERSENSITIVITY; PYLORI INFECTION; C57BL/6 MICE; HELIGMOSOMOIDES-POLYGYRUS; T-LYMPHOCYTES; SOUTH-AFRICA; EXPRESSION; FELIS; CELLS; CANCER	Helicobacter pylori is causally associated with gastritis and gastric cancer. Some developing countries with a high prevalence of infection have high gastric cancer rates, whereas in others, these rates are low. The progression of helicobacter-induced gastritis and gastric atrophy mediated by type 1 T-helper cells may be modulated by concurrent parasitic infection. Here, in mice with concurrent helminth infection, helicobacter-associated gastric atrophy was reduced considerably despite chronic inflammation and high helicobacter colonization. This correlated with a substantial reduction in mRNA for cytokines and chemokines associated with a gastric inflammatory response of type 1 T-helper cells. Thus, concurrent enteric helminth infection can attenuate gastric atrophy, a premalignant lesion.	MIT, Div Comparat Med, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Dept Med, Mucosal Immunol Lab, Pediat Gastroenterol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Mucosal Immunol Lab, Gastroenterol Unit, Boston, MA 02114 USA	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Fox, JG (corresponding author), MIT, Div Comparat Med, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NCI NIH HHS [CA7529, CA74463] Funding Source: Medline; NIAID NIH HHS [AI37740] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Ally R, 1999, GUT, V45, pA97; Appleton CC, 1996, ANN TROP MED PARASIT, V90, P181, DOI 10.1080/00034983.1996.11813042; Bamford KB, 1998, GASTROENTEROLOGY, V114, P482, DOI 10.1016/S0016-5085(98)70531-1; BARNISH G, 1990, PARASSITOLOGIA, V322, P245; BEHNKE JM, 1992, J PARASITOL, V22, P351; Berg DJ, 1998, AM J PATHOL, V152, P1377; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Chan MS, 1997, PARASITOL TODAY, V13, P438, DOI 10.1016/S0169-4758(97)01144-7; CORREA P, 1990, CANCER-AM CANCER SOC, V66, P2569, DOI 10.1002/1097-0142(19901215)66:12<2569::AID-CNCR2820661220>3.0.CO;2-I; Eaton KA, 1999, INFECT IMMUN, V67, P4594, DOI 10.1128/IAI.67.9.4594-4602.1999; Finkelman FD, 1997, ANNU REV IMMUNOL, V15, P505, DOI 10.1146/annurev.immunol.15.1.505; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; Fox JG, 1999, CANCER RES, V59, P4823; GENTA RM, 1995, ANN MED, V27, P595, DOI 10.3109/07853899509002475; Goto T, 1999, INFECT IMMUN, V67, P2531, DOI 10.1128/IAI.67.5.2531-2539.1999; Graham DY, 1997, GASTROENTEROLOGY, V113, P1983, DOI 10.1016/S0016-5085(97)70019-2; HOLCOMBE C, 1992, GUT, V33, P429, DOI 10.1136/gut.33.4.429; Huang JQ, 1998, GASTROENTEROLOGY, V114, P1169, DOI 10.1016/S0016-5085(98)70422-6; Jemaneh L, 1998, ETHIOPIAN MED J, V36, P1; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Marshall AJ, 1999, J IMMUNOL, V163, P2089; Mohammadi M, 1996, J IMMUNOL, V156, P4729; MONROY FG, 1992, PARASITOL TODAY, V8, P49, DOI 10.1016/0169-4758(92)90084-F; PRONOVOST AD, 1994, J CLIN MICROBIOL, V32, P46, DOI 10.1128/JCM.32.1.46-50.1994; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Roth KA, 1999, J IMMUNOL, V163, P1490; Sakagami T, 1996, GUT, V39, P639, DOI 10.1136/gut.39.5.639; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sawai N, 1999, INFECT IMMUN, V67, P279, DOI 10.1128/IAI.67.1.279-285.1999; SCHAAP HB, 1992, TROP GEOGR MED, V44, P19; Shi HN, 1998, J IMMUNOL, V160, P2449; SHI HN, 1995, PARASITOLOGY, V110, P599, DOI 10.1017/S003118200006532X; STELLATO C, 1995, J IMMUNOL, V155, P410; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Whary MT, 1998, INFECT IMMUN, V66, P3142, DOI 10.1128/IAI.66.7.3142-3148.1998; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	39	380	392	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					536	542		10.1038/75015	http://dx.doi.org/10.1038/75015			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802709				2022-12-27	WOS:000086796200037
J	Iwata, N; Tsubuki, S; Takaki, Y; Watanabe, K; Sekiguchi, M; Hosoki, E; Kawashima-Morishima, M; Lee, HJ; Hama, E; Sekine-Aizawa, Y; Saido, TC				Iwata, N; Tsubuki, S; Takaki, Y; Watanabe, K; Sekiguchi, M; Hosoki, E; Kawashima-Morishima, M; Lee, HJ; Hama, E; Sekine-Aizawa, Y; Saido, TC			Identification of the major A beta(1-42)-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition	NATURE MEDICINE			English	Article							AMYLOID BETA-PROTEIN; HUMAN NEUROBLASTOMA-CELLS; INSULIN-DEGRADING ENZYME; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; TRANSGENIC MICE; SENILE PLAQUES; A-BETA; DEGRADATION; INHIBITOR	Alzheimer amyloid beta-peptide (A beta) is a physiological peptide constantly anabolized and catabolized under normal conditions. We investigated the mechanism of catabolism by tracing multiple-radiolabeled synthetic peptide injected into rat hippocampus. The A beta(1-42) peptide underwent full degradation through limited proteolysis conducted by neutral endopeptidase (NEP) similar or identical to neprilysin as biochemically analyzed. Consistently, NEP inhibitor infusion resulted in both biochemical and pathological deposition of endogenous A beta(42) in brain. This NEP-catalyzed proteolysis therefore limits the rate of A beta(42) catabolism, up-regulation of which could reduce the risk of developing Alzheimer's disease by preventing A beta accumulation.	RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Tokyo	Saido, TC (corresponding author), RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903				BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Funato H, 1998, AM J PATHOL, V152, P1633; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HERSH LB, 1986, J BIOL CHEM, V261, P6433; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Ida N, 1996, FEBS LETT, V394, P174, DOI 10.1016/0014-5793(96)00948-9; MacPherson LJ, 1997, J MED CHEM, V40, P2525, DOI 10.1021/jm960871c; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Naslund J, 1996, J NEUROCHEM, V67, P294; NISHIMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P713, DOI 10.1006/bbrc.1993.1880; OCUINN G, 1995, METABOLISM BRAIN PEP, P99; ORLOWSKI M, 1981, BIOCHEMISTRY-US, V20, P4942, DOI 10.1021/bi00520a021; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; POZSGAY M, 1986, BIOCHEMISTRY-US, V25, P1292, DOI 10.1021/bi00354a015; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROQUES BP, 1995, METHOD ENZYMOL, V248, P263; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; Turner AJ, 1996, ADV EXP MED BIOL, V389, P141; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	34	696	738	0	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					143	150		10.1038/72237	http://dx.doi.org/10.1038/72237			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655101				2022-12-27	WOS:000085016900033
J	Ogawa, T; Dobrinski, I; Avarbock, MR; Brinster, RL				Ogawa, T; Dobrinski, I; Avarbock, MR; Brinster, RL			Transplantation of male germ line stem cells restores fertility in infertile mice	NATURE MEDICINE			English	Article							TYROSINE KINASE RECEPTOR; C-KIT PROTOONCOGENE; GROWTH-FACTOR; SI-LOCUS; W-LOCUS; SPERMATOGONIAL TRANSPLANTATION; HEREDITARY ANEMIAS; PROTO-ONCOGENE; MUTANT MICE; MOUSE	Azoospermia or oligozoospermia due to disruption of spermatogenesis are common causes of human male infertility. We used the technique of spermatogonial transplantation in two infertile mouse strains, Steel (SI) and dominant white spotting (W), to determine if stem cells from an infertile male were capable of generating spermatogenesis. Transplantation of germ cells from infertile SI/SId mutant male mice to infertile W/W-v or W-v/W-54 mutant male mice restored fertility to the recipient mice. Thus, transplantation of spermatogonial stem cells from an infertile donor to a permissive testicular environment can restore fertility and result in progeny with the genetic makeup of the infertile donor male.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Yokohama City Univ, Sch Med, Dept Urol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Univ Penn, New Bolton Ctr, Sch Vet Med, Dept Clin Studies, Kennett Square, PA 19348 USA	University of Pennsylvania; Yokohama City University; University of Pennsylvania	Brinster, RL (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3850 Baltimore Ave, Philadelphia, PA 19104 USA.		Dobrinski, Ina/A-1095-2007	Brinster, Ralph/0000-0003-1408-7656	NICHD NIH HHS [R01 HD036504, HD 36504] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036504] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Avarbock MR, 1996, NAT MED, V2, P693, DOI 10.1038/nm0696-693; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BERNSTEIN SE, 1970, AM J SURG, V119, P448, DOI 10.1016/0002-9610(70)90148-0; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Clouthier DE, 1996, NATURE, V381, P418, DOI 10.1038/381418a0; Dirami G, 1999, BIOL REPROD, V61, P225, DOI 10.1095/biolreprod61.1.225; Dobrinski I, 1999, BIOL REPROD, V61, P1331, DOI 10.1095/biolreprod61.5.1331; Dobrinski I, 1999, MOL REPROD DEV, V53, P142, DOI 10.1002/(SICI)1098-2795(199906)53:2&lt;142::AID-MRD3&gt;3.0.CO;2-O; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GREENBERG SH, 1978, J UROLOGY, V119, P507, DOI 10.1016/S0022-5347(17)57531-X; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUSZAR D, 1991, DEVELOPMENT, V112, P131; Jiang FX, 1995, INT J ANDROL, V18, P326, DOI 10.1111/j.1365-2605.1995.tb00570.x; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MARTINDUPAN RC, 1993, FERTIL STERIL, V60, P937; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCOSHEN JA, 1975, EXPERIENTIA, V31, P589, DOI 10.1007/BF01932475; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; Nagano M, 1998, TISSUE CELL, V30, P389, DOI 10.1016/S0040-8166(98)80053-0; NAKAYAMA H, 1988, DEVELOPMENT, V102, P117; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Ogawa T, 1999, TISSUE CELL, V31, P461, DOI 10.1054/tice.1999.0060; Ogawa T, 1998, TISSUE CELL, V30, P583, DOI 10.1016/S0040-8166(98)80039-6; Ogawa T, 1997, INT J DEV BIOL, V41, P111; Ogawa T, 1999, BIOL REPROD, V60, P515, DOI 10.1095/biolreprod60.2.515; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1959, JNCI-J NATL CANCER I, V23, P557; Russell LD, 1996, J ANDROL, V17, P603; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; Schlatt S, 1999, HUM REPROD, V14, P144, DOI 10.1093/humrep/14.1.144; Shinohara T, 1999, P NATL ACAD SCI USA, V96, P5504, DOI 10.1073/pnas.96.10.5504; Sigman M, 1997, INFERTILITY MALE, P173; SILBER SJ, 1995, HUM REPROD, V10, P503, DOI 10.1093/oxfordjournals.humrep.a135977; Silvers W.K., 1979, COAT COLORS MICE, P206; SORRENTINO V, 1991, ONCOGENE, V6, P149; TESARIK JN, 1995, NEW ENGL J MED, V333, P525, DOI 10.1056/NEJM199508243330819; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	45	251	278	2	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					29	34		10.1038/71496	http://dx.doi.org/10.1038/71496			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613820	Green Accepted			2022-12-27	WOS:000084583300031
J	Ko, S; Deiwick, A; Jager, MD; Dinkel, A; Rohde, F; Fischer, R; Tsui, TY; Rittmann, KL; Wonigeit, K; Schlitt, HJ				Ko, S; Deiwick, A; Jager, MD; Dinkel, A; Rohde, F; Fischer, R; Tsui, TY; Rittmann, KL; Wonigeit, K; Schlitt, HJ			The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat	NATURE MEDICINE			English	Article							DONOR-TYPE MICROCHIMERISM; BONE-MARROW; TRANSPLANTATION TOLERANCE; ORGAN-TRANSPLANTATION; ALLOGENEIC MICROCHIMERISM; LIVER-TRANSPLANTATION; CARDIAC ALLOGRAFTS; CHRONIC REJECTION; QUANTITATIVE PCR; GRAFT ACCEPTANCE	With an organ transplant, hematopoietic donor cells are transferred to the recipient. To study the relevance of the resulting microchimerism for allograft acceptance, we analyzed a rat model of cyclosporine-induced tolerance for strongly incompatible heart allografts. Using a monoclonal antibody that detects a donor-specific CD45 allotype (RT7(a)), we selectively depleted donor leukocytes at different times after transplantation (days 0 or 18). Depletion was similarly effective at both times. However, only depletion on day 0 prevented tolerance induction and was associated with severe acute or chronic graft rejection. This indicates that passenger leukocytes have an essential immunomodulatory effect on the induction phase of allograft acceptance.	Med Hsch Hannover, Viszeral & Transplantat Chirurg Klin, D-30623 Hannover, Germany	Hannover Medical School	Schlitt, HJ (corresponding author), Med Hsch Hannover, Viszeral & Transplantat Chirurg Klin, Carl-Neuberg Str 1, D-30623 Hannover, Germany.		Schlitt, Hans J./ABG-4368-2020					Demetris AJ, 1997, AM J PATHOL, V150, P563; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; Ehl S, 1998, NAT MED, V4, P1015, DOI 10.1038/2001; Heidecke CD, 1996, TRANSPLANTATION, V61, P948, DOI 10.1097/00007890-199603270-00018; Hisanaga M, 1996, TRANSPLANTATION, V61, P40, DOI 10.1097/00007890-199601150-00010; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; KAMPINGA J, 1990, SCAND J IMMUNOL, V31, P699, DOI 10.1111/j.1365-3083.1990.tb02821.x; Khan A, 1996, TRANSPLANTATION, V62, P380, DOI 10.1097/00007890-199608150-00014; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; Lombardi G, 1996, J IMMUNOL, V156, P2769; McSherry C, 1996, TRANSPLANTATION, V62, P1811, DOI 10.1097/00007890-199612270-00023; Murase N, 1997, TRANSPLANTATION, V63, P1840, DOI 10.1097/00007890-199706270-00024; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Raddatz G, 1998, IMMUNOLOGY, V94, P101; Santin AD, 1998, INT J RADIAT BIOL, V73, P699, DOI 10.1080/095530098141951; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SCHLITT HJ, 1994, NEW ENGL J MED, V330, P646, DOI 10.1056/NEJM199403033300919; SCHLITT HJ, 1993, TRANSPLANTATION, V56, P1001, DOI 10.1097/00007890-199310000-00042; Schlitt HJ, 1997, TRANSPL P, V29, P82, DOI 10.1016/S0041-1345(96)00016-4; Schmid C, 1996, TRANSPLANTATION, V61, P1695, DOI 10.1097/00007890-199606270-00005; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SCHWINZER R, 1989, EUR J IMMUNOL, V19, P1841, DOI 10.1002/eji.1830191013; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SIEGLING A, 1994, J IMMUNOL METHODS, V177, P23, DOI 10.1016/0022-1759(94)90139-2; SRIWATANAWONGSA V, 1995, NAT MED, V1, P428, DOI 10.1038/nm0595-428; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; Starzl TE, 1998, NEW ENGL J MED, V339, P1905, DOI 10.1056/NEJM199812243392607; Strehlau J, 1996, CLIN NEPHROL, V46, P30; SUN JH, 1995, TRANSPLANTATION, V60, P233, DOI 10.1097/00007890-199508000-00004; THOMAS JM, 1994, TRANSPLANTATION, V57, P101, DOI 10.1097/00007890-199401000-00018; THOMAS JM, 1994, CLIN TRANSPLANT, V8, P195; TOMITA Y, 1994, J IMMUNOL, V153, P1087; TSUI TY, IN PRESS TRANSPLANTA; Ueda M, 1997, CLIN TRANSPLANT, V11, P193; WONIGEIT K, 1979, TRANSPLANT P, V11, P1631; Wood K, 1996, IMMUNOL TODAY, V17, P584, DOI 10.1016/S0167-5699(96)10069-4; Wood PJ, 1996, TRANSPLANTATION, V61, P1440, DOI 10.1097/00007890-199605270-00003	40	112	113	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1292	1297		10.1038/15248	http://dx.doi.org/10.1038/15248			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545996				2022-12-27	WOS:000086550600040
J	Frasson, M; Sahel, JA; Fabre, M; Simonutti, M; Dreyfus, H; Picaud, S				Frasson, M; Sahel, JA; Fabre, M; Simonutti, M; Dreyfus, H; Picaud, S			Retinitis pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse	NATURE MEDICINE			English	Article							RETINAL-DEGENERATION; CYCLIC-GMP; OUTER-SEGMENT; CONE SURVIVAL; BETA-SUBUNIT; CELLS; DILTIAZEM; PHOSPHODIESTERASE; CONDUCTANCE; TRANSPLANTS	Retinitis pigmentosa is an inherited degenerative disease of photoreceptors leading to blindness. A well-characterized model for this disease is provided by the retinal degeneration mouse, in which the gene for the rod cGMP phosphodiesterase is mutated, as in some affected human families. We report that D-cis-diltiazem, a calcium-channel blocker that also acts at light-sensitive cGMP-gated channels, rescued photoreceptors and preserved visual function in the retinal degeneration mouse. The long record of diltiazem prescription in cardiology should facilitate the design of clinical trials for some forms of retinitis pigmentosa.	Univ Strasbourg 1, Lab Physiopathol Retinienne, F-67091 Strasbourg, France; Univ Strasbourg 1, Lab Physiopathol Cellulaire & Mol Retine, F-67091 Strasbourg, France; Univ Strasbourg 1, Inst Histol, F-67091 Strasbourg, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Picaud, S (corresponding author), Univ Strasbourg 1, Lab Physiopathol Retinienne, BP 426,1 Pl Hop, F-67091 Strasbourg, France.		Picaud, Serge/H-4012-2014; Sahel, Jose-Alain/F-3172-2017	Picaud, Serge/0000-0002-0548-5145; Sahel, Jose-Alain/0000-0002-4831-1153				Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BUCKLEY MMT, 1990, DRUGS, V39, P757, DOI 10.2165/00003495-199039050-00009; BUDAVARI S, 1996, MERCK INDEX, P451; COBBS WH, 1985, NATURE, V313, P585, DOI 10.1038/313585a0; FARBER DB, 1974, SCIENCE, V186, P449, DOI 10.1126/science.186.4162.449; FARBER DB, 1994, PROG RETIN EYE RES, V13, P31, DOI 10.1016/1350-9462(94)90004-3; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GOURAS P, 1994, INVEST OPHTH VIS SCI, V35, P3145; HARMAN JG, 1996, GOODMAN GILMANS PHAR; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; KOCH KW, 1985, J BIOL CHEM, V260, P6788; LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; LOLLEY RN, 1977, SCIENCE, V196, P664, DOI 10.1126/science.193183; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357; MohandSaid S, 1997, OPHTHALMIC RES, V29, P290, DOI 10.1159/000268027; NOELL WK, 1958, ARCH OPHTHALMOL-CHIC, V60, P702; PEACHEY NS, 1993, NEUROSCI LETT, V162, P9, DOI 10.1016/0304-3940(93)90547-X; SAHLY I, 1992, P NATL ACAD SCI USA, V89, P435, DOI 10.1073/pnas.89.1.435; Schmitz Y, 1997, NEUROSCIENCE, V78, P1209, DOI 10.1016/S0306-4522(96)00678-1; SILVERMAN MS, 1989, INVEST OPHTH VIS SCI, V30, P1684; STERN JH, 1986, P NATL ACAD SCI USA, V83, P1163, DOI 10.1073/pnas.83.4.1163; ULSHAFER RJ, 1980, INVEST OPHTH VIS SCI, V19, P1326; Yu WP, 1996, FEBS LETT, V393, P211, DOI 10.1016/0014-5793(96)00889-7	28	191	200	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1183	1187		10.1038/13508	http://dx.doi.org/10.1038/13508			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502823				2022-12-27	WOS:000082933200046
J	Moore, RJ; Owens, DM; Stamp, G; Arnott, C; Burke, F; East, N; Holdsworth, H; Turner, L; Rollins, B; Pasparakis, M; Kollias, G; Balkwill, F				Moore, RJ; Owens, DM; Stamp, G; Arnott, C; Burke, F; East, N; Holdsworth, H; Turner, L; Rollins, B; Pasparakis, M; Kollias, G; Balkwill, F			Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis	NATURE MEDICINE			English	Article							MULTISTAGE CARCINOGENESIS; CANCER; EXPRESSION; PROMOTION; PREVENTION; METASTASIS; INHIBITION; FOLLICLES; DISEASE	Given the associations between chronic inflammation and epithelial cancer(1,2) , we studied susceptibility to skin carcinogenesis(3,4) in mice deficient for the pro-inflammatory cytokine TNF-alpha (refs. 5,6). TNF-alpha(-/-) mice were resistant to development of benign and malignant skin tumors, whether induced by initiation with DMBA and promotion with TPA or by repeated dosing with DMBA. TNF-alpha(-/-) mice developed 5-10% the number of tumors developed by wild-type mice during initiation/promotion and 25% of those in wild-type mice after repeated carcinogen treatment. TNF-alpha could influence tumor and stromal cells during tumor development. The early stages of TPA promotion are characterized by keratinocyte hyperproliferation and inflammation. These were diminished in TNF-alpha(-/-) mice. TNF-alpha was extensively induced in the epidermis, but not the dermis, in TPA-treated wild-type skin, indicating that dermal inflammation is controlled by keratinocyte TNF-a production. Deletion of a TNF-alpha inducible chemokine also conferred some resistance to skin tumor development. TNF-alpha has little influence on later stages of carcinogenesis, as tumors in wild-type and TNF-alpha(-/-) mice had similar rates of malignant progression. These data provide evidence that a pro-inflammatory cytokine is required for de novo carcinogenesis and that TNF-alpha is important to the early stages of tumor promotion. Strategies that neutralize TNF-alpha production may be useful in cancer treatment and prevention.	Imperial Canc Res Fund, Biol Therapy Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Keratinocyte Lab, London WC2A 3PX, England; Univ London Imperial Coll Sci Technol & Med, Div Invest Sci, Dept Histopathol, London W12 0NN, England; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Hellen Pasteur Inst, Dept Mol Genet, GR-11521 Athens, Greece; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Cancer Research UK; Cancer Research UK; Imperial College London; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Balkwill, F (corresponding author), Imperial Canc Res Fund, Biol Therapy Lab, POB 123, London WC2A 3PX, England.		Kollias, George/A-7079-2012; Pasparakis, Manolis/H-9292-2017	Kollias, George/0000-0003-1867-3150; Pasparakis, Manolis/0000-0002-9870-0966; Balkwill, Frances/0000-0002-5587-9759				Arbeit JM, 1996, CANCER SURV, V26, P7; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BROWN DE, 1995, OPERAT RES COMP SCI, V3, P1; CORREA P, 1992, CANCER RES, V52, P6735; Eggermont AMM, 1996, J CLIN ONCOL, V14, P2653, DOI 10.1200/JCO.1996.14.10.2653; Feldmann M, 1997, ADV IMMUNOL, V64, P283, DOI 10.1016/S0065-2776(08)60891-3; FISCHER SM, 1989, CANCER RES, V49, P6693; KOMORI A, 1993, CANCER RES, V53, P1982; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; MALIK STA, 1990, EUR J CANCER, V26, P1031, DOI 10.1016/0277-5379(90)90044-T; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; Negus RPM, 1998, J LEUKOCYTE BIOL, V63, P758, DOI 10.1002/jlb.63.6.758; OROSZ P, 1995, INT J CANCER, V60, P867, DOI 10.1002/ijc.2910600624; Palli D, 1998, GUT, V42, P175, DOI 10.1136/gut.42.2.175; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; REINERS JJ, 1984, CARCINOGENESIS, V5, P301, DOI 10.1093/carcin/5.3.301; Robertson FM, 1996, CARCINOGENESIS, V17, P1719, DOI 10.1093/carcin/17.8.1719; Suganuma M, 1996, CANCER RES, V56, P3711; Warzocha K, 1998, BLOOD, V91, P3574; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195	21	702	721	3	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					828	831		10.1038/10552	http://dx.doi.org/10.1038/10552			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395330				2022-12-27	WOS:000081926600040
J	Polack, FP; Lee, SH; Permar, S; Manyara, E; Nousari, HG; Jeng, Y; Mustafa, F; Valsamakis, A; Adams, RJ; Robinson, HL; Griffin, DE				Polack, FP; Lee, SH; Permar, S; Manyara, E; Nousari, HG; Jeng, Y; Mustafa, F; Valsamakis, A; Adams, RJ; Robinson, HL; Griffin, DE			Successful DNA immunization against measles: Neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; VIRUS HEMAGGLUTININ; IMMUNE-RESPONSE; VACCINE; INFANTS; TITER; MICE; INFECTION; INDUCTION; MORTALITY	Measles remains a principal cause of worldwide mortality, in part because young infants cannot be immunized effectively. Development of new vaccines has been hindered by previous experience with a formalin-inactivated vaccine that predisposed to a severe form of disease (atypical measles). Here we have developed and tested potential DNA vaccines for immunogenicity, efficacy and safety in a rhesus macaque model of measles. DNA protected from challenge with wildtype measles virus. Protection correlated with levels of neutralizing antibody and not with cytotoxic T lymphocyte activity. There was no evidence in any group, including those receiving hemagglutinin-encoding DNA alone, of 'priming' for atypical measles.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Div Comparat Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; Emory Univ, Dept Mol Microbiol & Immunol, Atlanta, GA 30329 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Emory University	Griffin, DE (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.		Mustafa, Farah/AAI-9415-2021	Mustafa, Farah/0000-0002-1081-3756	NIAID NIH HHS [AI-07541, AI-07417, AI-35149] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035149] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4; ANNUNZIATO D, 1982, PEDIATRICS, V70, P203; Auwaerter PG, 1999, J INFECT DIS, V180, P950, DOI 10.1086/314993; BERRY S, 1992, PEDIATR INFECT DIS J, V11, P822, DOI 10.1097/00006454-199210000-00003; Cardoso AI, 1996, VIROLOGY, V225, P293, DOI 10.1006/viro.1996.0603; Cardoso AI, 1998, J VIROL, V72, P2516, DOI 10.1128/JVI.72.3.2516-2518.1998; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; Damien B, 1998, J MED VIROL, V56, P85, DOI 10.1002/(SICI)1096-9071(199809)56:1&lt;85::AID-JMV14&gt;3.0.CO;2-V; Davis HL, 1996, P NATL ACAD SCI USA, V93, P7213, DOI 10.1073/pnas.93.14.7213; DONNELLY JJ, 1995, NAT MED, V1, P583, DOI 10.1038/nm0695-583; DRILLIEN R, 1988, P NATL ACAD SCI USA, V85, P1252, DOI 10.1073/pnas.85.4.1252; Etchart N, 1997, J GEN VIROL, V78, P1577, DOI 10.1099/0022-1317-78-7-1577; Fooks AR, 1996, VIRAL IMMUNOL, V9, P65, DOI 10.1089/vim.1996.9.65; FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075; Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; GIRAUDON P, 1985, VIROLOGY, V144, P46, DOI 10.1016/0042-6822(85)90303-4; HOLT EA, 1993, J INFECT DIS, V168, P1087, DOI 10.1093/infdis/168.5.1087; Lodmell DL, 1998, NAT MED, V4, P949, DOI 10.1038/nm0898-949; MALVOISIN E, 1990, J VIROL, V64, P5160, DOI 10.1128/JVI.64.10.5160-5162.1990; MERZ DC, 1980, J EXP MED, V151, P275, DOI 10.1084/jem.151.2.275; NADER PR, 1968, J PEDIATR-US, V72, P22, DOI 10.1016/S0022-3476(68)80396-8; NORRBY E, 1975, INFECT IMMUN, V11, P231, DOI 10.1128/IAI.11.2.231-239.1975; NORRBY E, 1975, J INFECT DIS, V132, P262, DOI 10.1093/infdis/132.3.262; Polack FP, 1999, NAT MED, V5, P629, DOI 10.1038/9473; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Robinson HL, 1999, NAT MED, V5, P526, DOI 10.1038/8406; Yang K, 1997, VACCINE, V15, P888, DOI 10.1016/S0264-410X(96)00261-7	29	98	106	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					776	+		10.1038/77506	http://dx.doi.org/10.1038/77506			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888926				2022-12-27	WOS:000088040100034
J	Wu, SJL; Grouard-Vogel, G; Sun, W; Mascola, JR; Brachtel, E; Putvatana, R; Louder, MK; Filgueira, L; Marovich, MA; Wong, HK; Blauvelt, A; Murphy, GS; Robb, ML; Innes, BL; Birx, DL; Hayes, CG; Frankel, SS				Wu, SJL; Grouard-Vogel, G; Sun, W; Mascola, JR; Brachtel, E; Putvatana, R; Louder, MK; Filgueira, L; Marovich, MA; Wong, HK; Blauvelt, A; Murphy, GS; Robb, ML; Innes, BL; Birx, DL; Hayes, CG; Frankel, SS			Human skin Langerhans cells are targets of dengue virus infection	NATURE MEDICINE			English	Article							ANTIBODY-DEPENDENT ENHANCEMENT; MONOCLONAL-ANTIBODIES; DENDRITIC CELLS; TRANSMISSION; DETERMINANTS; MATURATION; SURFACE; RNA	Dengue virus (DV), an arthropod-borne flavivirus, causes a febrile illness for which there is no antiviral treatment and no vaccine(1,2). Macrophages are important in dengue pathogenesis; however, the initial target cell for DV infection remains unknown. As DV is introduced into human skin by mosquitoes of the genus Aedes, we undertook experiments to determine whether human dendritic cells (DCs) were permissive for the growth of DV. Initial experiments demonstrated that blood-derived DCs were 10-fold more permissive for DV infection than were monocytes or macrophages. We confirmed this with human skin DCs (Langerhans cells and dermal/interstitial DCs). Using cadaveric human skin explants, we exposed skin DCs to DV ex vivo. Of the human leukoctye antigen DR-positive DCs that migrated from the skin, emigrants from both dermis and epidermis, 60-80% expressed DV antigens. These observations were supported by histologic findings from the skin rash of a human subject who received an attenuated tetravalent dengue vaccine. Immunohistochemistry of the skin showed CD1a-positive DCs double-labeled with an antibody against DV envelope glycoprotein. These data demonstrate that human skin DCs are permissive for DV infection, and provide a potential mechanism for the transmission of DV into human skin.	Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA; Naval Med Res Ctr, Viral & Rickettsial Dis Dept, Bethesda, MD 20889 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20889 USA; Dept Prevent Med, Bethesda, MD 20889 USA; Dept Biometr, Bethesda, MD 20889 USA; Dept Med, Bethesda, MD 20889 USA; Henry M Jackson Fdn, Rockville, MD 20850 USA; Walter Reed Army Inst Res, Div Viral Dis, Bethesda, MD 20889 USA; Armed Forces Inst Pathol, Dept Infect & Parasit Dis Pathol, Washington, DC 20306 USA; Univ Zurich Irchel, Inst Anat, CH-8057 Zurich, Switzerland; NCI, Dermatol Branch, Bethesda, MD 20892 USA; Walter Reed Army Med Ctr, Dept Dermatol, Bethesda, MD 20889 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Naval Medical Research Center (NMRC); Uniformed Services University of the Health Sciences - USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; University of Zurich; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Army	Frankel, SS (corresponding author), Walter Reed Army Inst Res, Div Retrovirol, 13 Taft Court,Suite 200, Rockville, MD 20850 USA.		Filgueira, Luis/B-6492-2008; Mascola, John/AAI-7193-2021; Wong, Henry K/AAU-8810-2021	Filgueira, Luis/0000-0002-2266-6650				Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9; Frankel SS, 1998, J VIROL, V72, P9788, DOI 10.1128/JVI.72.12.9788-9794.1998; Frankel SS, 1997, AM J PATHOL, V151, P89; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HALSTEAD SB, 1977, J EXP MED, V146, P218, DOI 10.1084/jem.146.1.218; HENCHAL EA, 1985, AM J TROP MED HYG, V34, P162, DOI 10.4269/ajtmh.1985.34.162; Labuda M, 1996, VIROLOGY, V219, P357, DOI 10.1006/viro.1996.0261; MORENS DM, 1985, J CLIN MICROBIOL, V22, P250, DOI 10.1128/JCM.22.2.250-254.1985; MORENS DM, 1987, J MED VIROL, V22, P163, DOI 10.1002/jmv.1890220207; MORENS DM, 1987, MICROB PATHOGENESIS, V3, P231, DOI 10.1016/0882-4010(87)90056-8; OSULLIVAN MA, 1994, J GEN VIROL, V75, P2387, DOI 10.1099/0022-1317-75-9-2387; POPE M, 1995, J INVEST DERMATOL, V104, P11, DOI 10.1111/1523-1747.ep12613452; Pope M, 1997, J VIROL, V71, P8001, DOI 10.1128/JVI.71.10.8001-8007.1997; Raviprakash K, 1998, AM J TROP MED HYG, V58, P90, DOI 10.4269/ajtmh.1998.58.90; RICE CM, 1996, FIELDS VIROLOGY, P931; Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7; Taweechaisupapong S, 1996, J MED MICROBIOL, V45, P138, DOI 10.1099/00222615-45-2-138; Taweechaisupapong Suwimol, 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P664; WU SJL, 1995, AM J TROP MED HYG, V52, P468, DOI 10.4269/ajtmh.1995.52.468	21	479	509	2	40	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					816	820		10.1038/77553	http://dx.doi.org/10.1038/77553			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888933				2022-12-27	WOS:000088040100041
J	Abonour, R; Williams, DA; Einhorn, L; Hall, KM; Chen, J; Coffman, J; Traycoff, CM; Bank, A; Kato, I; Ward, M; Williams, SD; Hromas, R; Robertson, MJ; Smith, FO; Woo, D; Mills, B; Srour, EF; Cornetta, K				Abonour, R; Williams, DA; Einhorn, L; Hall, KM; Chen, J; Coffman, J; Traycoff, CM; Bank, A; Kato, I; Ward, M; Williams, SD; Hromas, R; Robertson, MJ; Smith, FO; Woo, D; Mills, B; Srour, EF; Cornetta, K			Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells	NATURE MEDICINE			English	Article							BONE-MARROW CELLS; FIBRONECTIN FRAGMENT CH-296; COLONY-STIMULATING FACTOR; RHESUS PERIPHERAL-BLOOD; HUMAN MDR1 GENE; PROGENITOR CELLS; CD34(+) CELLS; VECTOR TRANSDUCTION; TRANSPLANTED MICE; CANCER-PATIENTS	Pre-clinical studies indicate that efficient retrovirus-mediated gene transfer into hematopoietic stem cells and progenitor cells can be achieved by co-localizing retroviral particles and target cells on specific adhesion domains of fibronectin, In this pilot study, we used this technique to transfer the human multidrug resistance 1 gene into stem and progenitor cells of patients with germ cell tumors undergoing autologous transplantation. There was efficient gene transfer into stem and progenitor cells in the presence of recombinant fibronectin fragment CH-296. The infusion of these cells was associated with no harmful effects and led to prompt hematopoietic recovery. There was in vivo vector expression, but it may have been limited by the high rate of aberrant splicing of the multidrug resistance 1 gene in the vector. Gene marking has persisted more than a year at levels higher than previously reported in humans.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Howard Hughes Med Inst, Indianapolis, IN 46202 USA; Columbia Univ, New York, NY 10032 USA; Takara Shuzo, Biomed Grp, Otsu, Shiga 5202193, Japan; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Amgen Corp, Thousand Oaks, CA 91320 USA; Nexell Therapeut, Irvine, CA 92618 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Howard Hughes Medical Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Columbia University; Takara Holdings Inc.; Indiana University System; Indiana University-Purdue University Indianapolis; Amgen	Abonour, R (corresponding author), Indiana Univ, Sch Med, Dept Med, 1044 W Walnut,Rm 402, Indianapolis, IN 46202 USA.			Cornetta, Kenneth/0000-0003-1415-3668	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NCI NIH HHS [CA11148] Funding Source: Medline; NCRR NIH HHS [U42 RR/1148, M01 RR00750] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAUM C, 1995, J VIROL, V69, P7541, DOI 10.1128/JVI.69.12.7541-7547.1995; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; Cavazzana-Calvo M, 1999, BLOOD, V94, p367A; Chou PM, 1997, CANCER-AM CANCER SOC, V79, P2430, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2430::AID-CNCR20>3.0.CO;2-R; COOPER MA, 1995, J CLIN ONCOL, V13, P1167, DOI 10.1200/JCO.1995.13.5.1167; CORNETTA K, 1992, BRIT J HAEMATOL, V80, P421, DOI 10.1111/j.1365-2141.1992.tb04552.x; CORNETTA K, 1993, HUM GENE THER, V4, P579, DOI 10.1089/hum.1993.4.5-579; Cowan KH, 1999, CLIN CANCER RES, V5, P1619; Dao MA, 1998, BLOOD, V92, P4612, DOI 10.1182/blood.V92.12.4612.424k04_4612_4621; Dunbar C, 1996, HUM GENE THER, V7, P231, DOI 10.1089/hum.1996.7.2-231; Dunbar CE, 1996, P NATL ACAD SCI USA, V93, P11871, DOI 10.1073/pnas.93.21.11871; DUNBAR CE, 1995, BLOOD, V85, P3048, DOI 10.1182/blood.V85.11.3048.bloodjournal85113048; Emmons RVB, 1997, BLOOD, V89, P4040, DOI 10.1182/blood.V89.11.4040; Fan Y, 1998, CLIN CANCER RES, V4, P93; Galipeau J, 1997, HUM GENE THER, V8, P1773, DOI 10.1089/hum.1997.8.15-1773; Goerner M, 1999, BLOOD, V94, P2287, DOI 10.1182/blood.V94.7.2287.419k29_2287_2292; Hanania EG, 1996, P NATL ACAD SCI USA, V93, P15346, DOI 10.1073/pnas.93.26.15346; Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876; Hanenberg H, 1997, HUM GENE THER, V8, P2193, DOI 10.1089/hum.1997.8.18-2193; Hennemann B, 1999, EXP HEMATOL, V27, P817, DOI 10.1016/S0301-472X(99)00021-1; Hesdorffer C, 1998, J CLIN ONCOL, V16, P165, DOI 10.1200/JCO.1998.16.1.165; Kiem HP, 1998, BLOOD, V92, P1878, DOI 10.1182/blood.V92.6.1878.418k39_1878_1886; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Kohn DB, 1999, BLOOD, V94, P368, DOI 10.1182/blood.V94.1.368.413a47_368_371; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; MacNeill EC, 1999, J VIROL, V73, P3960, DOI 10.1128/JVI.73.5.3960-3967.1999; MOORE KA, 1992, BLOOD, V79, P1393; MORGAN RA, 1990, HUM GENE THER, V1, P136; MORITZ T, 1994, J CLIN INVEST, V93, P1451, DOI 10.1172/JCI117122; Moscow JA, 1999, BLOOD, V94, P52, DOI 10.1182/blood.V94.1.52.413k35_52_61; Orlic D, 1998, BLOOD, V91, P3247, DOI 10.1182/blood.V91.9.3247.3247_3247_3254; RICHARDSON C, 1995, BLOOD, V86, P2579, DOI 10.1182/blood.V86.7.2579.bloodjournal8672579; SORRENTINO BP, 1995, BLOOD, V86, P491, DOI 10.1182/blood.V86.2.491.bloodjournal862491; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; Stewart AK, 1999, HUM GENE THER, V10, P1953, DOI 10.1089/10430349950017310; Thomsen S, 1998, ACTA HAEMATOL-BASEL, V99, P148, DOI 10.1159/000040829; Tisdale JF, 1998, BLOOD, V92, P1131, DOI 10.1182/blood.V92.4.1131.416k41_1131_1141; Traycoff CM, 1997, LEUKEMIA, V11, P159, DOI 10.1038/sj.leu.2400529; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; WARD M, 1994, BLOOD, V84, P1408; Ward M, 1996, CLIN CANCER RES, V2, P873	43	225	234	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					652	658		10.1038/76225	http://dx.doi.org/10.1038/76225			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835681				2022-12-27	WOS:000087438300035
J	Ballmaier, M				Ballmaier, M			Can Veronesi transform Italian research?	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					610	610		10.1038/76151	http://dx.doi.org/10.1038/76151			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835654				2022-12-27	WOS:000087438300008
J	Shih, IM; Torrance, C; Sokoll, LJ; Chan, DW; Kinzler, KW; Vogelstein, B				Shih, IM; Torrance, C; Sokoll, LJ; Chan, DW; Kinzler, KW; Vogelstein, B			Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin	NATURE MEDICINE			English	Article							ORGAN ENVIRONMENT; CARCINOMA CELLS; GROWTH; GENE; KINETICS; MODEL; MICE		Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine	Vogelstein, B (corresponding author), Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.	vogelbe@welchlink.welch.jhu.edu	sdsd, shihieih/ABE-6190-2020		NCI NIH HHS [CA 62924, CA 57345, CA 43460] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345, R37CA043460, P50CA062924, R01CA043460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; Cole LA, 1998, J REPROD MED, V43, P3; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DIPERSIO L, 1979, J NATL CANCER I, V62, P375; FIDLER IJ, 1994, CANCER METAST REV, V13, P209, DOI 10.1007/BF00689637; Galons Jean-Philippe, 1999, Neoplasia (New York), V1, P113, DOI 10.1038/sj.neo.7900009; Jacobs Andreas, 1999, Neoplasia (New York), V1, P154, DOI 10.1038/sj.neo.7900007; KANAZAWA K, 1989, ACTA OBSTET GYN SCAN, V68, P429, DOI 10.3109/00016348909021015; KELLEN JA, 1982, CANCER-AM CANCER SOC, V49, P2300, DOI 10.1002/1097-0142(19820601)49:11<2300::AID-CNCR2820491117>3.0.CO;2-Y; Kerbel RS, 1998, CANCER METAST REV, V17, P301, DOI 10.1023/A:1006152915959; Killion JJ, 1998, CANCER METAST REV, V17, P279, DOI 10.1023/A:1006140513233; MacLaren DC, 1999, GENE THER, V6, P785, DOI 10.1038/sj.gt.3300877; MARINI FC, 1995, GENE THER, V2, P655; Newman D.J., 1999, TIETZ TXB CLIN CHEM, P1204; PESCE AJ, 1977, CANCER RES, V37, P1998; RAIKOW RB, 1986, AM J REPROD IMMUNOL, V12, P99; Shih I-M, 1999, DIAGNOSTIC SURG PATH, P2067; STAROSELSKY AN, 1992, INT J CANCER, V51, P130, DOI 10.1002/ijc.2910510123; Stegman LD, 1999, P NATL ACAD SCI USA, V96, P9821, DOI 10.1073/pnas.96.17.9821; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; TAKAHASHI Y, 1991, J SURG ONCOL, V48, P96, DOI 10.1002/jso.2930480205; WILLIAMS NN, 1992, INT J CANCER, V50, P274, DOI 10.1002/ijc.2910500218; WILMANNS C, 1992, INT J CANCER, V52, P98, DOI 10.1002/ijc.2910520118; WU AHB, 1987, CLIN CHEM, V33, P1424; Yang M, 1999, CANCER RES, V59, P781	25	29	30	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2000	6	6					711	714		10.1038/76299	http://dx.doi.org/10.1038/76299			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835692				2022-12-27	WOS:000087438300046
J	Honore, P; Luger, NM; Sabino, MAC; Schwei, MJ; Rogers, SD; Mach, DB; O'Keefe, PF; Ramnaraine, ML; Clohisy, DR; Mantyh, PW				Honore, P; Luger, NM; Sabino, MAC; Schwei, MJ; Rogers, SD; Mach, DB; O'Keefe, PF; Ramnaraine, ML; Clohisy, DR; Mantyh, PW			Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; SUBSTANCE-P RECEPTOR; C-FOS EXPRESSION; IMMUNOREACTIVE NERVES; BREAKTHROUGH PAIN; BREAST-CANCER; GROWTH-FACTOR; DORSAL HORN; LAMINA-I; RAT	Bone cancer pain is common among cancer patients and can have a devastating effect on their quality of life. A chief problem in designing new therapies for bone cancer pain is that it is unclear what mechanisms drive this distinct pain condition. Here we show that osteoprotegerin, a secreted 'decoy' receptor that inhibits osteoclast activity, also blocks behaviors indicative of pain in mice with bone cancer. A substantial part of the actions of osteoprotegerin seems to result from inhibition of tumor-induced bone destruction that in turn inhibits the neurochemical changes in the spinal cord that are thought to be involved in the generation and maintenance of cancer pain. These results demonstrate that excessive tumor-induced bone destruction is involved in the generation of bone cancer pain and that osteoprotegerin may provide an effective treatment for this common human condition.	Univ Minnesota, Neurosyst Ctr, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Prevent Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Vet Adm Med Ctr, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Orthoped Surg, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Clohisy, DR (corresponding author), Univ Minnesota, Neurosyst Ctr, Minneapolis, MN 55455 USA.				NIDA NIH HHS [DA11986] Funding Source: Medline; NIDCR NIH HHS [DEO7288] Funding Source: Medline; NINDS NIH HHS [NS23970] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023970, R37NS023970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011986] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ABBADIE C, 1993, BRAIN RES, V607, P195, DOI 10.1016/0006-8993(93)91507-O; Abbadie C, 1997, J NEUROSCI, V17, P8049; BANNING A, 1991, PAIN, V45, P45, DOI 10.1016/0304-3959(91)90163-R; Bekker PJ, 1999, J BONE MINER RES, V14, pS180; BJURHOLM A, 1988, PEPTIDES, V9, P165, DOI 10.1016/0196-9781(88)90023-X; Catheline G, 1999, PAIN, V80, P347, DOI 10.1016/S0304-3959(98)00234-6; Clohisy DR, 1998, J ORTHOPAED RES, V16, P660, DOI 10.1002/jor.1100160606; Colburn RW, 1999, EXP NEUROL, V157, P289, DOI 10.1006/exnr.1999.7065; Colburn RW, 1997, J NEUROIMMUNOL, V79, P163, DOI 10.1016/S0165-5728(97)00119-7; COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13; Coleman RE, 1998, EUR J CANCER, V34, P820, DOI 10.1016/S0959-8049(97)10155-1; Coleman Robert E., 1998, Current Opinion in Oncology, V10, pS7; Delaisse Jean-Marie, 1992, P289; Doyle CA, 1999, NEUROSCIENCE, V89, P17, DOI 10.1016/S0306-4522(98)00276-0; DRAISCI G, 1991, BRAIN RES, V560, P186, DOI 10.1016/0006-8993(91)91231-O; Fulfaro F, 1998, PAIN, V78, P157, DOI 10.1016/S0304-3959(98)00135-3; GONI MH, 1993, ANTICANCER RES, V13, P1155; HILL EL, 1991, CELL TISSUE RES, V264, P469, DOI 10.1007/BF00319037; Honore P, 1996, J PHARMACOL EXP THER, V278, P393; Honore P, 1999, J NEUROSCI, V19, P7670, DOI 10.1523/JNEUROSCI.19-17-07670.1999; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; Josien R, 1999, J IMMUNOL, V162, P2562; KONG, 1999, NATURE, V402, P304; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kostenuik PJ, 1999, J BONE MINER RES, V14, pS166; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lipton A, 1997, CANCER, V80, P1668, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1668::AID-CNCR17>3.3.CO;2-5; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304-3959(96)03267-8; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112; O'Connell JX, 1998, MODERN PATHOL, V11, P175; Olson TH, 1998, NEUROREPORT, V9, P1109, DOI 10.1097/00001756-199804200-00028; Payne R, 1998, Oncology (Williston Park), V12, P169; Payne R, 1997, CANCER, V80, P1608, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1608::AID-CNCR11>3.0.CO;2-3; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Rosier R, 1992, Am J Hosp Palliat Care, V9, P37, DOI 10.1177/104990919200900610; RUDA MA, 1988, P NATL ACAD SCI USA, V85, P622, DOI 10.1073/pnas.85.2.622; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19-24-10886.1999; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Sorkin LS, 1997, NEUROSCIENCE, V81, P255, DOI 10.1016/S0306-4522(97)00147-4; SUZUKI K, 1994, BONE MINER, V27, P219, DOI 10.1016/S0169-6009(08)80195-X; Tabarowski Z, 1996, ACTA HISTOCHEM, V98, P453, DOI 10.1016/S0065-1281(96)80013-4; Tonussi CR, 1999, PAIN, V82, P81, DOI 10.1016/S0304-3959(99)00035-4; WATKINS LR, 1994, BRAIN RES, V654, P15, DOI 10.1016/0006-8993(94)91566-0; Woolf CJ, 1998, PAIN, V77, P227, DOI 10.1016/S0304-3959(98)00099-2; Woolf CJ, 1997, BRIT J PHARMACOL, V121, P417, DOI 10.1038/sj.bjp.0701148	50	388	430	3	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					521	528		10.1038/74999	http://dx.doi.org/10.1038/74999			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802707				2022-12-27	WOS:000086796200035
J	Anderson, RP; Degano, P; Godkin, AJ; Jewell, DP; Hill, AVS				Anderson, RP; Degano, P; Godkin, AJ; Jewell, DP; Hill, AVS			In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope	NATURE MEDICINE			English	Article							SEQUENCE-SPECIFIC PRIMERS; PCR-SSP; DEAMIDATION; TOXICITY; HLA-DQB1	Celiac disease (CD) is an increasingly diagnosed enteropathy (prevalence, 1:200-1:300)(1) that is induced by dietary exposure to wheat gliadins(2) (as well as related proteins in rye and barley) and is strongly associated with HLA-DQ2 (alpha 1*0501, beta 1*0201), which is present in over 90% of CD patients(3). Because a variety of gliadin peptides have been identified as epitopes for gliadin-specific T-cell clones(4-6) and as bioactive sequences in feeding studies and in ex vivo CD intestinal biopsy challenge(7-9), it has been unclear whether a 'dominant' T-cell epitope is associated with CD. Here, we used fresh peripheral blood lymphocytes from individual subjects undergoing shortterm antigen challenge and tissue transglutaminase-treated, overlapping synthetic peptides spanning A-gliadin to demonstrate a transient, disease-specific, DQ2-restricted, CD4 T-cell response to a single dominant epitope. Optimal gamma interferon release in an ELISPOT assay was elicited by a 17-amino-acid peptide corresponding to the partially deamidated peptide of A-gliadin amino acids 57-73 (Q65E). Consistent with earlier reports indicating that host tissue transglutaminase modification of gliadin enhances gliadin-specific CD T-cell responses(10), tissue transglutaminase specifically deamidated Q65 in the peptide of A-gliadin amino acids 56-75. Discovery of this dominant epitope may allow development of antigen-specific immunotherapy for CD.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Gastroenterol Unit, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Anderson, RP (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DU, England.		HILL, Adrian V>S>/C-1306-2008	Anderson, Robert/0000-0002-0764-7267; Godkin, Andrew/0000-0002-1910-7567				Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; DERITIS G, 1988, GASTROENTEROLOGY, V94, P41, DOI 10.1016/0016-5085(88)90607-5; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; Hin H, 1999, BMJ-BRIT MED J, V318, P164, DOI 10.1136/bmj.318.7177.164; KASARDA DD, 1984, P NATL ACAD SCI-BIOL, V81, P4712, DOI 10.1073/pnas.81.15.4712; KENDALL MJ, 1972, LANCET, V2, P1065; Lahat N, 1999, SCAND J IMMUNOL, V49, P441; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MANTZARIS G, 1991, SCAND J GASTROENTERO, V26, P392, DOI 10.3109/00365529108996500; MAURI L, 1996, SCAND J GASTROENTERO, V31, P247; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Molberg O, 1997, SCAND J IMMUNOL, V46, P103, DOI 10.1046/j.1365-3083.1997.d01-93.x; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Mullighan CG, 1997, TISSUE ANTIGENS, V50, P688, DOI 10.1111/j.1399-0039.1997.tb02936.x; OLERUP O, 1993, TISSUE ANTIGENS, V41, P119, DOI 10.1111/j.1399-0039.1993.tb01991.x; Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12&lt;4345::AID-IMMU4345&gt;3.0.CO;2-P; Sjostrom H, 1998, SCAND J IMMUNOL, V48, P111; SOLLID LM, 1993, GASTROENTEROLOGY, V105, P910, DOI 10.1016/0016-5085(93)90912-V; van de Wal Y, 1998, J IMMUNOL, V161, P1585; Vartdal F, 1996, EUR J IMMUNOL, V26, P2764, DOI 10.1002/eji.1830261132; WARD R, 1999, CODEX ALIMENTARIUS P	22	445	464	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					337	342		10.1038/73200	http://dx.doi.org/10.1038/73200			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700238				2022-12-27	WOS:000085580500046
J	Tajima, K; Sonoda, S				Tajima, K; Sonoda, S			Origins of HTLV-1 in South America	NATURE MEDICINE			English	Letter									Aichi Canc Ctr, Res Inst, Div Epidemiol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Kagoshima Univ, Fac Med, Dept Virol, Kagoshima 8908520, Japan	Aichi Cancer Center	Tajima, K (corresponding author), Aichi Canc Ctr, Res Inst, Div Epidemiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ktajima@aichi-cc.pref.aichi.jp							0	2	2	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					233	233		10.1038/73025	http://dx.doi.org/10.1038/73025			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700197				2022-12-27	WOS:000085580500004
J	Picaud, S; Sahel, J				Picaud, S; Sahel, J			Rod photoreceptor rescue or degeneration - Reply	NATURE MEDICINE			English	Letter									Univ Strasbourg 1, Lab Physiopathol Cellulaire & Mol Retine, INSERM, EMI 99 18, F-67091 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Picaud, S (corresponding author), Univ Strasbourg 1, Lab Physiopathol Cellulaire & Mol Retine, INSERM, EMI 99 18, BP426,1 Pl Hop, F-67091 Strasbourg, France.		Picaud, Serge/H-4012-2014; Sahel, Jose-Alain/F-3172-2017	Picaud, Serge/0000-0002-0548-5145; Sahel, Jose-Alain/0000-0002-4831-1153				EDWARD DP, 1993, GRAEF ARCH CLIN EXP, V231, P289, DOI 10.1007/BF00919107; Frasson M, 1999, NAT MED, V5, P1183, DOI 10.1038/13508; HICKS D, 1987, EUR J CELL BIOL, V44, P341; HICKS D, 1994, BRAIN RES, V643, P302, DOI 10.1016/0006-8993(94)90037-X	4	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					116	116		10.1038/72172	http://dx.doi.org/10.1038/72172			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655078	Bronze			2022-12-27	WOS:000085016900007
J	Jones, MK; Wang, HT; Peskar, BM; Levin, E; Itani, RM; Sarfeh, IJ; Tarnawski, AS				Jones, MK; Wang, HT; Peskar, BM; Levin, E; Itani, RM; Sarfeh, IJ; Tarnawski, AS			Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing	NATURE MEDICINE			English	Article							IN-VITRO; PROSTAGLANDIN; INDUCTION; SYNTHASE; DISEASE; CELLS; RATS	Angiogenesis, the formation of new capillary blood vessels, is essential not only for the growth and metastasis of solid tumors, but also for wound and ulcer healing, because without the restoration of blood flow, oxygen and nutrients cannot be delivered to the healing site(1,2). Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, indomethacin and ibuprofen are the most widely used drugs for pain, arthritis, cardiovascular diseases and, more recently, the prevention of colon cancer and Alzheimer disease(3-7). However, NSAIDs produce gastroduodenal ulcers in about 25% of users (often with bleeding and/or perforations) and delay ulcer healing(8,9), presumably by blocking prostaglandin synthesis from cyclooxygenase (COX)-1 and COX-2 (ref. 10). The hypothesis that the gastrointestinal side effects of NSAIDs result from inhibition of COX-1, but not COX-2 (ref. 11), prompted the development of NSAIDs that selectively inhibit only COX-2 (such as celecoxib and rofecoxib). Our study demonstrates that both selective and nonselective NSAIDs inhibit angiogenesis through direct effects on endothelial cells. We also show that this action involves inhibition of mitogen-activated protein (MAP) kinase (ERK2) activity, interference with ERK nuclear translocation, is independent of protein kinase C and has prostaglandin-dependent and prostaglandin-independent components. Finally, we show that both COX-1 and COX-2 are important for the regulation of angiogenesis. These findings challenge the premise that selective COX-2 inhibitors will not affect the gastrointestinal tract and ulcer/wound healing.	Vet Affairs Med Ctr, Dept Med, Long Beach, CA 90822 USA; Vet Affairs Med Ctr, Dept Surg, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Surg, Irvine, CA 92697 USA; Ruhr Univ Bochum, Dept Expt Clin Med, D-44780 Bochum, Germany	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; Ruhr University Bochum	Tarnawski, AS (corresponding author), Vet Affairs Med Ctr, Dept Med, 5901 E 7th St, Long Beach, CA 90822 USA.							DeWitt D L, 1993, Am J Med, V95, p40S, DOI 10.1016/0002-9343(93)90396-7; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRIES JF, 1991, J RHEUMATOL, V18, P6; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Goodnight S H, 1996, Curr Opin Hematol, V3, P355; Jones MK, 1998, BIOCHEM BIOPH RES CO, V249, P118, DOI 10.1006/bbrc.1998.9095; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MCCARTHY DM, 1995, SCNA J GASTROENTEROL, V208, P9; Nicosia RF, 1997, AM J PATHOL, V151, P1379; Pai R, 1998, GASTROENTEROLOGY, V114, P706, DOI 10.1016/S0016-5085(98)70584-0; PESKAR BA, 1979, RADIOIMMUNOASSAY DRU, P239; SCHARSCHMIDT LA, 1983, J CLIN INVEST, V71, P1756, DOI 10.1172/JCI110931; Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672; Schuna A A, 1998, J Am Pharm Assoc (Wash), V38, P728; SHEADONOHUE T, 1990, GASTROENTEROLOGY, V98, P284, DOI 10.1016/0016-5085(90)90816-J; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Skopinska-Rozewska E, 1998, INT J TISSUE REACT, V20, P85; Sloane PD, 1998, AM FAM PHYSICIAN, V58, P1577; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TAMAWSKI A, 1991, MECH INJURY PROTECTI, P521; TAMAWSKI A, 1989, GASTROENTEROLOGY, V96, pA505; TARNAWSKI A, 1991, FALK SYMP, V59, P165; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6	25	750	779	0	85	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1418	1423						6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581086				2022-12-27	WOS:000084049700043
J	Sinderby, C; Navalesi, P; Beck, J; Skrobik, Y; Comtois, N; Friberg, S; Gottfried, SB; Lindstrom, L				Sinderby, C; Navalesi, P; Beck, J; Skrobik, Y; Comtois, N; Friberg, S; Gottfried, SB; Lindstrom, L			Neural control of mechanical ventilation in respiratory failure	NATURE MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; END-EXPIRATORY PRESSURE; CONTRACTILE PROPERTIES; AIRWAY PRESSURE; HUMAN DIAPHRAGM; INTRINSIC PEEP; SUPPORT; HYPERINFLATION; DYSPNEA; WORK		Univ Montreal, Maisonneuve Rosemont Hosp, Dept Med, Guy Bernier Res Ctr,Intens Care Div, Montreal, PQ, Canada; Univ Gothenburg, Sahlgrenska Hosp, Inst Clin Neurosci, Gothenburg, Sweden; Osped Valduce, Pulm Unit, Rehabil Ctr Villa Beretta, Costamasnaga, LC, Italy; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Univ Gothenburg, Sahlgrens Hosp, Dept Clin Physiol, Gothenburg, Sweden; McGill Univ, Ctr Hlth, Div Resp Med, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Div Crit Care Med, Montreal, PQ, Canada	Universite de Montreal; Sahlgrenska University Hospital; University of Gothenburg; McGill University; McGill University; Sahlgrenska University Hospital; University of Gothenburg; McGill University; McGill University	Sinderby, C (corresponding author), Univ Montreal, Maisonneuve Rosemont Hosp, Dept Med, Guy Bernier Res Ctr,Intens Care Div, Montreal, PQ, Canada.		Navalesi, Paolo/I-9584-2019; Navalesi, Paolo/F-9559-2010; Skrobik, Yoanna/K-8165-2014; Skrobik, Yoanna/J-6393-2013	Navalesi, Paolo/0000-0002-3733-3453; Navalesi, Paolo/0000-0002-3733-3453; Skrobik, Yoanna/0000-0002-5315-6020; 				APPENDINI L, 1994, AM J RESP CRIT CARE, V149, P1069, DOI 10.1164/ajrccm.149.5.8173743; ARGOV Z, 1979, NEW ENGL J MED, V301, P409, DOI 10.1056/NEJM197908233010805; AYRES SM, 1969, AM J MED, V46, P495, DOI 10.1016/0002-9343(69)90069-2; Beck J, 1996, J APPL PHYSIOL, V81, P1434, DOI 10.1152/jappl.1996.81.3.1434; Beck J, 1998, J APPL PHYSIOL, V85, P1123, DOI 10.1152/jappl.1998.85.3.1123; BERNSTEIN G, 1993, AM REV RESPIR DIS, V148, P358, DOI 10.1164/ajrccm/148.2.358; BROCHARD L, 1991, ANESTHESIOLOGY, V75, P739, DOI 10.1097/00000542-199111000-00004; Drinker P, 1929, J AMER MED ASSOC, V92, P1658, DOI 10.1001/jama.1929.02700460014005; GOTTFRIED SB, 1995, THORAX, P2471; JARDIN F, 1981, NEW ENGL J MED, V304, P387, DOI 10.1056/NEJM198102123040703; KLIBURN KH, 1966, ANN INTERN MED, V65, P977; Konyukov YA, 1996, INTENS CARE MED, V22, P363, DOI 10.1007/BF01700461; LEBOURDELLES G, 1994, AM J RESP CRIT CARE, V149, P1539, DOI 10.1164/ajrccm.149.6.8004310; LESSARD MR, 1995, AM J RESP CRIT CARE, V151, P562, DOI 10.1164/ajrccm.151.2.7842221; Leung P, 1997, AM J RESP CRIT CARE, V155, P1940, DOI 10.1164/ajrccm.155.6.9196100; LOURENCO RV, 1966, J APPL PHYSIOL, V21, P527, DOI 10.1152/jappl.1966.21.2.527; MACKLEM PT, 1984, AM REV RESPIR DIS, V129, P1; MALTAIS F, 1994, AM J RESP CRIT CARE, V150, P1318, DOI 10.1164/ajrccm.150.5.7952559; MARINI JJ, 1992, CRIT CARE MED, V20, P1604, DOI 10.1097/00003246-199211000-00020; MARINI JJ, 1998, AM REV RESPIR DIS, V140, P1; Martin RJ, 1994, PRINCIPLES PRACTICE, P511; NAVA S, 1995, INTENS CARE MED, V21, P871, DOI 10.1007/BF01712327; NINANE V, 1993, AM REV RESPIR DIS, V148, P1037, DOI 10.1164/ajrccm/148.4_Pt_1.1037; Parthasarathy S, 1998, AM J RESP CRIT CARE, V158, P1471, DOI 10.1164/ajrccm.158.5.9802014; PETROF BJ, 1990, AM REV RESPIR DIS, V141, P281, DOI 10.1164/ajrccm/141.2.281; QVIST J, 1975, ANESTHESIOLOGY, V42, P45, DOI 10.1097/00000542-197501000-00009; RANIERI VM, 1993, AM REV RESPIR DIS, V147, P5, DOI 10.1164/ajrccm/147.1.5; REMMERS JE, 1976, J APPL PHYSIOL, V41, P252, DOI 10.1152/jappl.1976.41.2.252; SIMILOWSKI T, 1991, NEW ENGL J MED, V325, P917, DOI 10.1056/NEJM199109263251304; Sinderby C, 1998, J APPL PHYSIOL, V85, P2146, DOI 10.1152/jappl.1998.85.6.2146; Sinderby CA, 1997, J APPL PHYSIOL, V82, P1370, DOI 10.1152/jappl.1997.82.4.1370; TOBIN MJ, 1994, PRINCIPLES PRACTICE, P1149; YOUNES M, 1992, AM REV RESPIR DIS, V145, P114, DOI 10.1164/ajrccm/145.1.114	33	405	450	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1433	1436		10.1038/71012	http://dx.doi.org/10.1038/71012			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581089	Bronze			2022-12-27	WOS:000084049700046
J	Desrosiers, RC				Desrosiers, RC			Strategies used by human immunodeficiency virus that allow persistent viral replication	NATURE MEDICINE			English	Editorial Material							CYTOTOXIC T-LYMPHOCYTES; GP120 ENVELOPE GLYCOPROTEIN; HIV-1 NEF PROTEIN; MONOCLONAL-ANTIBODIES; CELLULAR-LOCALIZATION; LYMPHOID-TISSUES; RHESUS-MONKEYS; IMMUNE EVASION; TYPE-1; NEUTRALIZATION		Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA	Harvard University	Desrosiers, RC (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, 1 Pine Hill Dr,Box 9102, Southborough, MA 01772 USA.	ronald_desrosiers@hms.harvard.edu						ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; Binley JM, 1997, J VIROL, V71, P2799, DOI 10.1128/JVI.71.4.2799-2809.1997; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; BURNS DPW, 1993, J VIROL, V67, P4104, DOI 10.1128/JVI.67.7.4104-4113.1993; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Chang YS, 1997, SOLID STATE ELECTRON, V41, P1189, DOI 10.1016/S0038-1101(97)00020-8; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; COFFIN JM, 1986, CELL, V46, P1, DOI 10.1016/0092-8674(86)90851-2; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Dyer WB, 1999, J VIROL, V73, P436, DOI 10.1128/JVI.73.1.436-443.1999; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Fouts TR, 1997, J VIROL, V71, P2779, DOI 10.1128/JVI.71.4.2779-2785.1997; GAUDUIN MC, IN PRESS J MED PRIMA; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; Greenough TC, 1999, NEW ENGL J MED, V340, P236, DOI 10.1056/NEJM199901213400314; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; Myers GK, 1995, HUMAN RETROVIRUSES A; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Parren PWHI, 1998, J VIROL, V72, P3512, DOI 10.1128/JVI.72.5.3512-3519.1998; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; RINGLER DJ, 1989, AM J PATHOL, V134, P373; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rosenberg ES, 1998, AIDS RES HUM RETROV, V14, pS143; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Takefman DM, 1998, VIROLOGY, V246, P370, DOI 10.1006/viro.1998.9205; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WYAND MS, 1989, AM J PATHOL, V134, P385; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	43	49	52	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1999	5	7					723	725		10.1038/10439	http://dx.doi.org/10.1038/10439			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395309	Bronze			2022-12-27	WOS:000081926600018
J	Hirsch, VM; Sharkey, ME; Brown, CR; Brichacek, B; Goldstein, S; Wakefield, J; Byrum, R; Elkins, WR; Hahn, BH; Lifson, JD; Stevenson, M				Hirsch, VM; Sharkey, ME; Brown, CR; Brichacek, B; Goldstein, S; Wakefield, J; Byrum, R; Elkins, WR; Hahn, BH; Lifson, JD; Stevenson, M			Vpx is required for dissemination and pathogenesis of SIVSM PBj: Evidence of macrophage-dependent viral amplification	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-CYCLE ARREST; INFECTION; HIV-1; MACAQUES; REPLICATION; GENE; TRANSMISSION; PROTEIN; AIDS	The viral accessory protein Vpx is required for productive in vitro infection of macrophages by simian immunodeficiency virus from sooty mangabey monkeys (SIVSM). To evaluate the roles of Vpx and macrophage infection in vivo, we inoculated pigtailed macaques intravenously or intrarectally with the molecularly cloned, macrophage tropic, acutely pathogenic virus SIVSM PBj 6.6, or accessory gene deletion mutants (Delta Vpr or Delta Vpx) of this virus. Both wild-type and SIVSM PBj Delta Vpx viruses were readily transmitted across the rectal mucosa. A subsequent 'stepwise' process of local amplification of infection and dissemination was observed for wild-type virus, but not for SIVSM PBj Delta Vpx, which also showed considerable impairment of the overall kinetics and extent of its replication. In animals co-inoculated with equivalent amounts of wild-type and SIVSM Pbj Delta Vpx intravenously ol intrarectally, the Delta Vpx mutant was at a strong competitive disadvantage. Vpx-dependent viral amplification at local sites of initial infection, perhaps through a macrophage-dependent mechanism, may be a prerequisite for efficient dissemination of infection and pathogenic consequences after exposure through either mucosal or intravenous routes.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; NIAID, Mol Microbiol Lab, Twin Facil, Rockville, MD 20852 USA; Univ Alabama, Birmingham, AL 35294 USA; Bioqual Inc, Rockville, MD 20850 USA; NIAID, Infect Dis Lab, Rockville, MD 20852 USA; NCI, Lab Retroviral Pathogenesis, AIDS Vaccine Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Alabama System; University of Alabama Birmingham; BIOQUAL Inc.; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Stevenson, M (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.			Hahn, Beatrice/0000-0002-9400-9887	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR011589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037475, R37AI037475] Funding Source: NIH RePORTER; NCRR NIH HHS [RR11589] Funding Source: Medline; NHLBI NIH HHS [HL57880] Funding Source: Medline; NIAID NIH HHS [R37 AI037475, R21 AI127091, AI37475, R01 AI037475, R01 AI032890] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILLIET JW, 1994, VIROLOGY, V200, P623; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Campbell BJ, 1997, J VIROL, V71, P5593, DOI 10.1128/JVI.71.7.5593-5602.1997; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DESROSIERS RC, 1991, AM J PATHOL, V139, P29; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; DU Z, 1995, CELL, V82, P655; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; FULTZ PN, 1994, VIRUS RES, V32, P205, DOI 10.1016/0168-1702(94)90042-6; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Hirsch VM, 1996, J VIROL, V70, P3741, DOI 10.1128/JVI.70.6.3741-3752.1996; ISRAEL ZR, 1993, AIDS RES HUM RETROV, V9, P277, DOI 10.1089/aid.1993.9.277; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; Lifson JD, 1997, J VIROL, V71, P9508, DOI 10.1128/JVI.71.12.9508-9514.1997; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LU L, 1996, J VIROL, V70, P3045; MANN DL, 1990, J IMMUNOL, V144, P2152; Marx PA, 1998, SEMIN IMMUNOL, V10, P215, DOI 10.1006/smim.1998.0135; Miller C J, 1994, Curr Top Microbiol Immunol, V188, P107; NIELSEN C, 1993, AIDS, V7, P1035, DOI 10.1097/00002030-199308000-00002; NOVEMBRE FJ, 1993, J VIROL, V67, P2466, DOI 10.1128/JVI.67.5.2466-2474.1993; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; Reece JC, 1998, J EXP MED, V187, P1623, DOI 10.1084/jem.187.10.1623; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; SCHRIER RD, 1993, J VIROL, V67, P5713, DOI 10.1128/JVI.67.10.5713-5720.1993; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Sharp PM, 1996, NATURE, V383, P586, DOI 10.1038/383586a0; SLEIGH R, 1998, VIROLOGY, V245; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Stivahtis GL, 1997, J VIROL, V71, P4331, DOI 10.1128/JVI.71.6.4331-4338.1997; Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Watson A, 1997, J VIROL, V71, P284, DOI 10.1128/JVI.71.1.284-290.1997; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369; ZHANG L, 1998, 5 C RETR OPP INF CHI; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	45	146	150	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1401	1408		10.1038/3992	http://dx.doi.org/10.1038/3992			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846578	Green Accepted			2022-12-27	WOS:000077336900036
J	Mandl, CW; Aberle, JH; Aberle, SW; Holzmann, H; Allison, SL; Heinz, FX				Mandl, CW; Aberle, JH; Aberle, SW; Holzmann, H; Allison, SL; Heinz, FX			In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model	NATURE MEDICINE			English	Article							BORNE ENCEPHALITIS-VIRUS; GENETIC IMMUNIZATION; DNA VACCINES	Live virus vaccines have in many cases proven to be an extremely effective tool for the prevention of viral diseases(1,2). However, the production of conventional live vaccines in eu; karyotic cell cultures has many disadvantages, including the potential for contamination with adventitious agents(3) and genetic alterations during propagation, making it necessary to do extensive testing before distribution(4,5). Based on results obtained with a flavivirus(6) (tick-borne encephalitis virus) in an experimental animal system, we propose a novel live attenuated virus vaccination strategy consisting of the application of in vitro-synthesized infectious RNA instead of the live virus itself. When administered using the GeneGun, less than 1 ng of RNA was required to initiate replication of virus that was attenuated by a specifically engineered deletion(7) and this induced a protective immunity in laboratory mice. Because this approach uses RNA, it does not have the potential drawbacks of DNA vaccines(8-10) and thus combines the advantages of conventional live virus vaccines(1,2) (for example, mimicking natural infection and inducing long-lasting immunity) with those of nucleic acid-based vaccines(2,8,11,12) (for example, ease of production without a requirement for eukaryotic cell culture, stability and purity).	Univ Vienna, Inst Virol, A-1095 Vienna, Austria	University of Vienna	Mandl, CW (corresponding author), Univ Vienna, Inst Virol, Kinderspitalgasse 15, A-1095 Vienna, Austria.							Ada G, 1997, MOL BIOTECHNOL, V8, P123, DOI 10.1007/BF02752256; Chattergoon M, 1997, FASEB J, V11, P753, DOI 10.1096/fasebj.11.10.9271360; Conry RM, 1996, SEMIN ONCOL, V23, P135; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Gregoriadis G, 1998, PHARM RES-DORDR, V15, P661, DOI 10.1023/A:1011950415325; HEINZ FX, 1986, J BIOL STAND, V14, P133, DOI 10.1016/0092-1157(86)90032-6; Liu MA, 1998, NAT MED, V4, P515, DOI 10.1038/nm0598supp-515; Mandl CW, 1998, J VIROL, V72, P2132, DOI 10.1128/JVI.72.3.2132-2140.1998; Manickan E, 1997, CRIT REV IMMUNOL, V17, P139, DOI 10.1615/CritRevImmunol.v17.i2.20; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; PARKMAN PD, 1994, VACCINES, P889; PETRICCIANI JC, 1991, DEV BIOLOGICALS, V75, P9; Qiu P, 1996, GENE THER, V3, P262; REED L. J., 1938, AMER JOUR HYG, V27, P493; RICE CM, 1996, FIELDS VIROLOGY, P931; VOGEL FR, 1995, CLIN MICROBIOL REV, V8, P406, DOI 10.1128/CMR.8.3.406; WENGLER G, 1995, VIRUS TAXONOMY, P415; Wood DJ, 1997, BIOLOGICALS, V25, P3, DOI 10.1006/biol.1997.0055; ZHOU X, 1994, VACCINE, V12, P1510, DOI 10.1016/0264-410X(94)90074-4	20	84	93	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1438	1440		10.1038/4031	http://dx.doi.org/10.1038/4031			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846585				2022-12-27	WOS:000077336900043
J	Bonday, ZQ; Dhanasekaran, S; Rangarajan, PN; Padmanaban, G				Bonday, ZQ; Dhanasekaran, S; Rangarajan, PN; Padmanaban, G			Import of host delta-aminolevulinate dehydratase into the malarial parasite: Identification of a new drug target	NATURE MEDICINE			English	Article							PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; PURIFICATION; BIOSYNTHESIS; PROTEINS; VACUOLE; CELL; DUCT	The parasite Plasmodium berghei imports the enzyme delta -aminolevulinate dehydratase (ALAD), and perhaps the subsequent enzymes of the pathway from the host red blood cell to sustain heme synthesis. Here we have studied the mechanism of this import. A 65-kDa protein on the P. berghei membrane specifically bound to mouse red blood cell ALAD, and a 93-amino-acid fragment (ALAD-Delta NC) of the host erythrocyte ALAD was able to compete with the full-length enzyme for binding to the P. berghei membrane. ALAD-Delta NC was taken up by the infected red blood cell when added to a culture of P. falciparum and this led to a substantial decrease in ALAD protein and enzyme activity and, subsequently, heme synthesis in the parasite, resulting in its death.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Padmanaban, G (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	geepee@biochem.iisc.ernet.in	Rangarajan, Pundi/A-7365-2009	Rangarajan, Pundi/0000-0002-6536-9891				ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; Bonday ZQ, 1997, J BIOL CHEM, V272, P21839, DOI 10.1074/jbc.272.35.21839; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; HALDAR K, 1994, PARASITOL TODAY, V10, P393, DOI 10.1016/0169-4758(94)90230-5; Hibbs AR, 1997, EUR J CELL BIOL, V72, P182; HIBBS AR, 1994, EXP PARASITOL, V79, P260, DOI 10.1006/expr.1994.1089; JENSEN JB, 1977, J PARASITOL, V63, P883, DOI 10.2307/3279900; Le Bonniec S, 1999, J BIOL CHEM, V274, P14218, DOI 10.1074/jbc.274.20.14218; Lingelbach K, 1998, J CELL SCI, V111, P1467; MAUZERALL D, 1956, J BIOL CHEM, V219, P435; POUVELLE B, 1994, MOL BIOCHEM PARASIT, V66, P83, DOI 10.1016/0166-6851(94)90038-8; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; SANTIYANONT R, 1985, PARASITE IDENTIFICAT, P413; SCHMITT J, 1993, MOL BIOL REP, V18, P223, DOI 10.1007/BF01674434; SLATER AFG, 1992, EXP PARASITOL, V74, P362, DOI 10.1016/0014-4894(92)90162-4; SOKHANEKOVA TL, 1984, MED PARASITOL MOSC, V1, P46; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; SUROLIA N, 1992, BIOCHEM BIOPH RES CO, V187, P744, DOI 10.1016/0006-291X(92)91258-R; SUROLIA N, 1991, P NATL ACAD SCI USA, V88, P4786, DOI 10.1073/pnas.88.11.4786; TRAGER W, 1995, PARASITOL TODAY, V11, P69, DOI 10.1016/0169-4758(95)80121-9; Wilson CM, 1996, MOL BIOCHEM PARASIT, V79, P135, DOI 10.1016/0166-6851(96)02690-4	21	70	70	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					898	903		10.1038/78659	http://dx.doi.org/10.1038/78659			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932227				2022-12-27	WOS:000165473800033
J	Zisman, A; Peroni, OD; Abel, ED; Michael, MD; Mauvais-Jarvis, F; Lowell, BB; Wojtaszewski, JFP; Hirshman, MF; Virkamaki, A; Goodyear, LJ; Kahn, CR; Kahn, BB				Zisman, A; Peroni, OD; Abel, ED; Michael, MD; Mauvais-Jarvis, F; Lowell, BB; Wojtaszewski, JFP; Hirshman, MF; Virkamaki, A; Goodyear, LJ; Kahn, CR; Kahn, BB			Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance	NATURE MEDICINE			English	Article							KNOCKOUT MICE; GLUT4; GLYCOGEN; EXPRESSION; METABOLISM; EXERCISE; TISSUES; BRAIN	The prevalence of type 2 diabetes mellitus is growing worldwide. By the year 2020, 250 million people will be afflicted(1). Most forms of type 2 diabetes are polygenic with complex inheritance patterns, and penetrance is strongly influenced by environmental factors(2). The specific genes involved are not yet known, but impaired glucose uptake in skeletal muscle is an early, genetically determined defect that is present in nondiabetic relatives of diabetic subjects(3). The rate-limiting step in muscle glucose use is the transmembrane transport of glucose mediated by glucose transporter (GLUT) 4 (ref. 4), which is expressed mainly in skeletal muscle, heart and adipose tissues. GLUT4 mediates glucose transport stimulated by insulin and contraction/exercise. The importance of GLUT4 and glucose uptake in muscle, however, was challenged by two recent observations. Whereas heterozygous GLUT4 knockout mice show moderate glucose intolerance(6), homozygous whole-body GLUT4 knockout (GLUT4-null) mice have only mild perturbations in glucose homeostasis and have growth retardation, depletion of fat stores, cardiac hypertrophy and failure, and a shortened life span(7). Moreover, muscle-specific inactivation of the insulin receptor results in minimal, if any, change in glucose tolerances. To determine the importance of glucose uptake into muscle for glucose homeostasis, we disrupted GLUT4 selectively in mouse muscles. A profound reduction in basal glucose transport and near-absence of stimulation by insulin or contraction resulted. These mice showed severe insulin resistance and glucose intolerance from an early age. Thus, GLUT4-mediated glucose transport in muscle is essential to the maintenance of normal glucose homeostasis.	Beth Israel Deaconess Med Ctr, Div Endocrine, Boston, MA 02215 USA; Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrine, Boston, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021; Wojtaszewski, Jørgen FP/P-6583-2014	Kahn, Ronald/0000-0002-7583-9228; Wojtaszewski, Jørgen FP/0000-0001-9785-6830; wojtaszewski, jorgen/0000-0001-8185-3408; Abel, E. Dale/0000-0001-5290-0738; Michael, Mervyn/0000-0002-0224-1065	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK046200, R01DK043051, R37DK043051] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43051, DK33201, R01 DK043051, DK46200] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BROSIUS FC, 1992, KIDNEY INT, V42, P1086, DOI 10.1038/ki.1992.391; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; DeFronzo RA, 1997, DIABETES REV, V5, P1; Etgen GJ, 1997, DIABETES, V46, P1915, DOI 10.2337/diabetes.46.11.1915; Frevert EU, 1996, BIOCHEM J, V316, P865, DOI 10.1042/bj3160865; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOM FG, 1984, DIABETES, V33, P141, DOI 10.2337/diabetes.33.2.141; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Leloup C, 1996, MOL BRAIN RES, V38, P45, DOI 10.1016/0169-328X(95)00306-D; ORahilly S, 1997, NAT MED, V3, P1080, DOI 10.1038/nm1097-1080; PARNIAK M, 1985, CAN J BIOCHEM CELL B, V63, P333, DOI 10.1139/o85-049; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; Virkamaki A, 1997, DIABETES, V46, P1106, DOI 10.2337/diabetes.46.7.1106; WARRAM JH, 1995, JOSLINS DIABETES MEL; Wojtaszewski JFP, 1999, J CLIN INVEST, V104, P1257, DOI 10.1172/JCI7961; Young ME, 1997, BIOCHEM J, V322, P223, DOI 10.1042/bj3220223	25	524	556	1	55	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					924	928		10.1038/78693	http://dx.doi.org/10.1038/78693			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932232				2022-12-27	WOS:000165473800038
J	Brinkmann, AO; Trapman, J				Brinkmann, AO; Trapman, J			Prostate cancer schemes for androgen escape	NATURE MEDICINE			English	Editorial Material							RECEPTOR GENE; MUTATIONS; CELLS		Erasmus Univ, Med Ctr Rotterdam, Dept Endocrinol & Reprod, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Med Ctr Rotterdam, Dept Pathol, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Brinkmann, AO (corresponding author), Erasmus Univ, Med Ctr Rotterdam, Dept Endocrinol & Reprod, POB 1738, NL-3000 DR Rotterdam, Netherlands.							Navone NM, 1997, CLIN CANCER RES, V3, P2493; SCHUURMANS ALG, 1988, INT J CANCER, V42, P917, DOI 10.1002/ijc.2910420622; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Watanabe M, 1997, JPN J CLIN ONCOL, V27, P389, DOI 10.1093/jjco/27.6.389; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Zhao XY, 1999, J UROLOGY, V162, P2192, DOI 10.1016/S0022-5347(05)68158-X; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	10	61	63	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					628	629		10.1038/76194	http://dx.doi.org/10.1038/76194			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835672				2022-12-27	WOS:000087438300022
J	Lu, DC; Rabizadeh, S; Chandra, S; Shayya, RF; Ellerby, LM; Ye, X; Salvesen, GS; Koo, EH; Bredesen, DE				Lu, DC; Rabizadeh, S; Chandra, S; Shayya, RF; Ellerby, LM; Ye, X; Salvesen, GS; Koo, EH; Bredesen, DE			A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor	NATURE MEDICINE			English	Article							APOPTOTIC CELL-DEATH; ALZHEIMERS-DISEASE; NEURONAL APOPTOSIS; RECEPTOR; DEGENERATION; ACTIVATION; CLEAVAGE; CASPASES; MICE; IDENTIFICATION	The amyloid beta -protein precursor gives rise to the amyloid beta -protein, the principal constituent of senile plaques and a cytotoxic fragment involved in the pathogenesis of Alzheimer disease. Here we show that amyloid beta -protein precursor was proteolytically cleaved by caspases in the C terminus to generate a second unrelated peptide, called C31. The resultant C31 peptide was a potent inducer of apoptosis. Both caspase-cleaved amyloid beta -protein precursor and activated caspase-9 were present in brains of Alzheimer disease patients but not in control brains. These findings indicate the possibility that caspase cleavage of amyloid beta -protein precursor with the generation of C31 may be involved in the neuronal death associated with Alzheimer disease.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Burnham Inst, Program Aging, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Interdepartmental Program Neurosci, Los Angeles, CA 90024 USA; Buck Ctr Res Aging, Novato, CA 94948 USA	University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Los Angeles; Buck Institute for Research on Aging	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	edkoo@ucsd.edu; dbredesen@buckcenter.org			NIA NIH HHS [AG05131, AG12282] Funding Source: Medline; NINDS NIH HHS [NS37776] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barnes NY, 1998, J NEUROSCI, V18, P5869; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; Chan SL, 1999, J NEUROSCI RES, V57, P315, DOI 10.1002/(SICI)1097-4547(19990801)57:3<315::AID-JNR3>3.3.CO;2-R; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; FUKUCHI K, 1993, NEUROSCI LETT, V154, P145, DOI 10.1016/0304-3940(93)90192-N; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Hui KS, 1998, J BIOL CHEM, V273, P31053, DOI 10.1074/jbc.273.47.31053; KOO EH, 1994, J BIOL CHEM, V269, P17386; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; Masliah E, 1998, J NEURAL TRANSM-SUPP, P147; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; McPhie DL, 1997, J BIOL CHEM, V272, P24743, DOI 10.1074/jbc.272.40.24743; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selznick LA, 1999, J NEUROPATH EXP NEUR, V58, P1020, DOI 10.1097/00005072-199909000-00012; Shindler KS, 1997, J NEUROSCI, V17, P3112; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SOPHER BL, 1994, MOL BRAIN RES, V26, P207, DOI 10.1016/0169-328X(94)90092-2; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yang FS, 1998, AM J PATHOL, V152, P379; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	35	335	355	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2000	6	4					397	404		10.1038/74656	http://dx.doi.org/10.1038/74656			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742146				2022-12-27	WOS:000165474100033
J	Kretz-Rommel, A; Rubin, RL				Kretz-Rommel, A; Rubin, RL			Disruption of positive selection of thymocytes causes autoimmunity	NATURE MEDICINE			English	Article							T-CELL-RECEPTOR; INTERCELLULAR-ADHESION MOLECULE-1; PIGEON CYTOCHROME-C; DRUG-INDUCED LUPUS; NEGATIVE SELECTION; CLASS-II; SELF-PEPTIDES; ANTIGEN RECEPTOR; TRANSGENIC MICE; CLONAL DELETION	To differentiate into T cells, immature thymocytes must engage, through their antigen-specific T-cell receptor, peptides derived from self proteins presented by cortical epithelial cells in the thymus, a process called positive selection. Despite this requirement for self-recognition during development, mature T cells do not normally show autoreactivity. Mice injected in the thymus with procainamide-hydroxylamine, a metabolite of procainamide, develop autoimmune features resembling drug-induced lupus. Here, we show that when thymocytes undergo positive selection in the presence of procainamide-hydroxylamine, they fail to establish unresponsiveness to low affinity selecting self antigens, resulting in systemic autoimmunity.	Scripps Res Inst, Dept Mol & Expt Med, Wm Keck Autoimmune Dis Ctr, La Jolla, CA 92037 USA	Scripps Research Institute	Rubin, RL (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Wm Keck Autoimmune Dis Ctr, MEM 131,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rrubin@scripps.edu			NIAID NIH HHS [AI45978] Funding Source: Medline; NIEHS NIH HHS [ES06334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALLEN PM, 1994, CELL, V76, P593, DOI 10.1016/0092-8674(94)90497-9; Barton GM, 1999, SCIENCE, V283, P67, DOI 10.1126/science.283.5398.67; BURLINGAME RW, 1990, J IMMUNOL METHODS, V134, P187, DOI 10.1016/0022-1759(90)90380-E; Cavenagh JD, 1997, BRIT J HAEMATOL, V97, P673, DOI 10.1046/j.1365-2141.1997.982913.x; Chmielowski B, 1999, J IMMUNOL, V162, P95; Davey GM, 1998, J EXP MED, V188, P1867, DOI 10.1084/jem.188.10.1867; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; Gapin L, 1998, J EXP MED, V187, P1871, DOI 10.1084/jem.187.11.1871; GONZALEZQUINTIAL R, 1992, J IMMUNOL, V149, P230; Grossman Z, 1996, P NATL ACAD SCI USA, V93, P14747, DOI 10.1073/pnas.93.25.14747; Grubin CE, 1997, IMMUNITY, V7, P197, DOI 10.1016/S1074-7613(00)80523-3; HESS EV, 1991, B RHEUM DIS, V40, P1; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; JANEWAY CA, 1991, ADV IMMUNOL, V50, P1; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kishimoto H, 1996, J EXP MED, V184, P531, DOI 10.1084/jem.184.2.531; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kretz-Rommel A, 1999, J IMMUNOL, V162, P813; KretzRommel A, 1997, J IMMUNOL, V158, P4465; KretzRommel A, 1997, J CLIN INVEST, V99, P1888, DOI 10.1172/JCI119356; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; Liu CP, 1997, J EXP MED, V186, P1441, DOI 10.1084/jem.186.9.1441; Liu CP, 1998, P NATL ACAD SCI USA, V95, P4522, DOI 10.1073/pnas.95.8.4522; LUCAS B, 1999, CELL, V10, P367; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Mackall CL, 1998, EUR J IMMUNOL, V28, P1886, DOI 10.1002/(SICI)1521-4141(199806)28:06<1886::AID-IMMU1886>3.0.CO;2-M; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; Matechak EO, 1996, IMMUNITY, V4, P337, DOI 10.1016/S1074-7613(00)80247-2; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nakano N, 1997, SCIENCE, V275, P678, DOI 10.1126/science.275.5300.678; Oehen S, 1996, J EXP MED, V183, P2617, DOI 10.1084/jem.183.6.2617; OGASAWARA K, 1989, J IMMUNOL, V142, P1448; Ohashi PS, 1996, CURR OPIN IMMUNOL, V8, P808, DOI 10.1016/S0952-7915(96)80009-4; PAGE DM, 1994, P NATL ACAD SCI USA, V91, P4057, DOI 10.1073/pnas.91.9.4057; Pawlowski TJ, 1996, EUR J IMMUNOL, V26, P851, DOI 10.1002/eji.1830260419; RUBIN RL, 1987, J PHARMACOL EXP THER, V242, P833; Rubin RL, 1999, CRIT REV IMMUNOL, V19, P199; RUBIN RL, 1997, DUBOIS LUPUS ERYTHEM, P871; SantAngelo DB, 1997, IMMUNITY, V7, P517, DOI 10.1016/S1074-7613(00)80373-8; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; Surh CD, 1997, IMMUNITY, V7, P209, DOI 10.1016/S1074-7613(00)80524-5; SUZUKI G, 1986, J IMMUNOL, V136, P230; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; VASQUEZ NJ, 1994, IMMUNITY, V1, P45, DOI 10.1016/1074-7613(94)90008-6; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; Weinberg K, 1995, Biol Blood Marrow Transplant, V1, P18; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61	56	58	62	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					298	305						8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700232				2022-12-27	WOS:000085580500040
J	Tomazin, R; Boname, J; Hegde, NR; Lewinsohn, DM; Altschuler, Y; Jones, TR; Cresswell, P; Nelson, JA; Riddell, SR; Johnson, DC				Tomazin, R; Boname, J; Hegde, NR; Lewinsohn, DM; Altschuler, Y; Jones, TR; Cresswell, P; Nelson, JA; Riddell, SR; Johnson, DC			Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4(+) T cells	NATURE MEDICINE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; HEAVY-CHAINS; HLA-DM; EXPRESSION; GENE; DEGRADATION; PROTEASOME; LYMPHOCYTES	Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that causes life-threatening disease in patients who are immunosuppressed for bone marrow or tissue transplantation or who have AIDS (ref. 1). HCMV establishes lifelong latent infections and, after periodic: reactivation from latency, uses a panel of immune evasion proteins to survive and replicate in the face of robust, fully primed host immunity(2,3). Monocyte/macrophages are important host cells for HCMV, serving as a latent reservoir and as a means of dissemination throughout the body(4). Macrophages and other HCMV-permissive cells, such as endothelial and glial cells, can express MHC class II proteins and present antigens to CD4+ T lymphocytes. Here, we show that the HCMV protein US2 causes degradation of two essential proteins in the MHC class II antigen presentation pathway: HLA-DR-c( and DM-a. This was unexpected, as US2 has been shown to cause degradation of MHC class I (refs. 5,6), which has only limited homology with class II proteins. Expression of US2 in cells reduced or abolished their ability to present antigen to CD4+ T lymphocytes. Thus, US2 may allow HCMV-infected macrophages to remain relatively 'invisible' to CD4+ T cells, a property that would be important after virus reactivation.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Portland VA Med Ctr, Div Pulm & Crit Care Med, Portland, OR 97207 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Wyeth Ayerst Res, Dept Biol Mol, Pearl River, NY 10965 USA; Yale Univ, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; University of California System; University of California San Francisco; Pfizer; Howard Hughes Medical Institute; Yale University; Fred Hutchinson Cancer Center	Johnson, DC (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.		Hegde, Nagendra R/H-3132-2019; Lewinsohn, David/I-4936-2013	Hegde, Nagendra R/0000-0001-5260-2159; Boname, Jessica/0000-0002-5149-5934; Lewinsohn, David/0000-0001-9906-9494	NATIONAL EYE INSTITUTE [R01EY011245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024178, R01AI041754] Funding Source: NIH RePORTER; NEI NIH HHS [EY11245] Funding Source: Medline; NIAID NIH HHS [AI24178, AI41754] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASTA PV, 1987, J IMMUNOL, V138, P1275; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Cresswell P, 1999, CURR OPIN IMMUNOL, V11, P61, DOI 10.1016/S0952-7915(99)80011-9; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Dusseljee S, 1998, J CELL SCI, V111, P2217; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fish KN, 1998, J VIROL, V72, P6657, DOI 10.1128/JVI.72.8.6657-6664.1998; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Johnson DC, 1998, CURR TOP MICROBIOL, V232, P149; Jones TR, 1997, J VIROL, V71, P2970, DOI 10.1128/JVI.71.4.2970-2979.1997; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; LIGAS MW, 1988, J VIROL, V62, P1486, DOI 10.1128/JVI.62.5.1486-1494.1988; Miller DM, 1998, J EXP MED, V187, P675, DOI 10.1084/jem.187.5.675; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Nordeng TW, 1998, CURR TOP MICROBIOL, V232, P179; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schust DJ, 1998, J EXP MED, V188, P497, DOI 10.1084/jem.188.3.497; SODERBERGNAUCLE.C, 1998, PERSISTENT VIRAL INF, P209; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	28	203	210	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1039	1043		10.1038/12478	http://dx.doi.org/10.1038/12478			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470081				2022-12-27	WOS:000082337200038
J	Wang, YF; Tao, L; Mitchell, E; Bravery, C; Berlingieri, P; Armstrong, P; Vaughan, R; Underwood, J; Lehner, T				Wang, YF; Tao, L; Mitchell, E; Bravery, C; Berlingieri, P; Armstrong, P; Vaughan, R; Underwood, J; Lehner, T			Allo-immunization elicits CD8(+) T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GP120 ENVELOPE GLYCOPROTEIN; RECEPTOR CXCR4; MACAQUES; VACCINE; LYMPHOCYTES; ENTRY; REPLICATION; INDIVIDUALS; PROTECTION	We assessed the potential for an allogeneic-based vaccine against HIV infection in women who were allo-immunized with their partners' mononuclear leucocytes to prevent spontaneous recurrent abortion. Within 1 month of allo-immunization, there was significant upregulation in the concentrations of CD8 cell-derived suppressor factor activity, RANTES, and macrophage inflammatory proteins 1 alpha and 1 beta. Allo-immunization also downregulated the proportion of cells with CCR5 and CXCR4 receptors. We also found a dose-dependent decrease in HIV infectivity of CD4+ cells in vitro after allo-immunization with both primary and T-cell line adapted HIV-1. This study provides a rational basis for an alternative or complementary strategy of allo-immunization against HIV infection.	Guys Hosp, Guys Kings & St Thomas Med & Dent Sch, Dept Immunobiol, London SE1 9RT, England; Guys Hosp, Guys Kings & St Thomas Med & Dent Sch, Dept Tissue Typing, London SE1 9RT, England; Royal London Hosp, Dept Gynaecol, London E1 2AD, England; St Marys Hosp, Imperial Coll, Dept Obstet & Gynaecol, Fac Med, London W2 1PG, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Barts Health NHS Trust; Royal London Hospital; Imperial College London	Lehner, T (corresponding author), Guys Hosp, Guys Kings & St Thomas Med & Dent Sch, Dept Immunobiol, 3rd Floor,Med Sch Bldg, London SE1 9RT, England.	thomas.lehner@kcl.ac.uk						Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; Bruhl P, 1996, AIDS RES HUM RETROV, V12, P31, DOI 10.1089/aid.1996.12.31; Bunce M., 1997, Tissue Antigens, V50, P100, DOI 10.1111/j.1399-0039.1997.tb02847.x; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CELUM CL, 1994, ARCH INTERN MED, V154, P1129, DOI 10.1001/archinte.154.10.1129; CLERICI M, 1993, EUR J IMMUNOL, V23, P2022, DOI 10.1002/eji.1830230845; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Heeney JL, 1998, P NATL ACAD SCI USA, V95, P10803, DOI 10.1073/pnas.95.18.10803; KIND C, 1995, EUR J PEDIATR, V154, P542, DOI 10.1007/s004310050339; Kishore R, 1996, J Obstet Gynaecol Res, V22, P177; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MORLUCHI H, 1999, J IMMUNOL, V162, P7543; MOWBRAY JF, 1987, LANCET, V2, P679; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Pinto LA, 1998, BLOOD, V92, P3346, DOI 10.1182/blood.V92.9.3346.421k40_3346_3354; PLUMMER FA, 1993, 9 INT C AIDS HIV STD; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SHEARER GM, 1993, SCIENCE, V262, P161, DOI 10.1126/science.8211133; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; STOTT J, 1994, NEUVIERNE COLL CENT, P219; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Wang YF, 1998, P NATL ACAD SCI USA, V95, P5223, DOI 10.1073/pnas.95.9.5223; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	37	97	100	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1999	5	9					1004	1009		10.1038/12440	http://dx.doi.org/10.1038/12440			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470076				2022-12-27	WOS:000082337200033
J	Zheng, F; Kundu, GC; Zhang, ZJ; Ward, J; DeMayo, F; Mukherjee, AB				Zheng, F; Kundu, GC; Zhang, ZJ; Ward, J; DeMayo, F; Mukherjee, AB			Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice	NATURE MEDICINE			English	Article							HUMAN MESANGIAL CELLS; A NEPHROPATHY; IGA NEPHROPATHY; GROWTH-FACTOR; BINDING PROTEINS; GENE-EXPRESSION; MESSENGER-RNA; FIBRONECTIN; REGION; PROMOTER	The molecular mechanism(s) of immunoglobulin A (IgA) nephropathy, the most common primary renal glomerular disease worldwide, is unknown. Its pathologic features include hematuria, high levels of circulating IgA-fibronectin (Fn) complexes, and glomerular deposition of IgA, complement C3, Fn and collagen. We report here that two independent mouse models (gene knockout and antisense transgenic), both manifesting deficiency of an anti-inflammatory protein, uteroglobin (UG), develop almost all of the pathologic features of human IgA nephropathy. We further demonstrate that Fn-UG heteromerization, reported to prevent abnormal glomerular deposition of Fn and collagen, also abrogates both the formation of IgA-Fn complexes and their binding to glomerular cells. Moreover, UG prevents glomerular accumulation of exogenous IgA in UG-null mice. These results define an essential role for UG in preventing mouse IgA nephropathy and warrant further studies to determine if a similar mechanism(s) underlies the human disease.	NICHHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; NCI, Vet & Tumor Pathol Sect, Frederick, MD 21702 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine	Mukherjee, AB (corresponding author), NICHHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA.	mukherja@exchange.nih.gov	Kundu, Gopal C./ABA-9897-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000910] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000910] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aoki A, 1996, MOL HUM REPROD, V2, P489, DOI 10.1093/molehr/2.7.489; BALDREE LA, 1993, AM J KIDNEY DIS, V22, P1; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BERGER J, 1968, J UROL NEPHROL, V74, P694; Bergijk EC, 1996, J PATHOL, V178, P462; BERNARD AM, 1989, CLIN CHEM, V35, P2141; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; CEDERHOLM B, 1986, P NATL ACAD SCI USA, V83, P6151, DOI 10.1073/pnas.83.16.6151; D'Amico G, 1998, CURR OPIN NEPHROL HY, V7, P247, DOI 10.1097/00041552-199805000-00001; EMANCIPATOR SN, 1992, J AM SOC NEPHROL, V2, pS149; ENDO Y, 1994, PATHOL INT, V44, P1, DOI 10.1111/j.1440-1827.1994.tb02579.x; GomezGuerrero C, 1996, J IMMUNOL, V156, P4369; Hewetson A, 1997, MOL CELL ENDOCRINOL, V136, P1, DOI 10.1016/S0303-7207(97)00203-7; HOWIE AJ, 1990, J CLIN PATHOL, V43, P257, DOI 10.1136/jcp.43.3.257; HYNES RO, 1986, SCI AM, V254, P42, DOI 10.1038/scientificamerican0686-42; Johnston CJ, 1999, EXP LUNG RES, V25, P7, DOI 10.1080/019021499270394; KIKUKAWA T, 1989, MOL CELL ENDOCRINOL, V62, P177, DOI 10.1016/0303-7207(89)90004-X; KLEINSCHNEEGANS AS, 1989, J IMMUNOL METHODS, V119, P117, DOI 10.1016/0022-1759(89)90388-8; KLEISSANFRANCISCO S, 1993, MOL ENDOCRINOL, V7, P214, DOI 10.1210/me.7.2.214; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; Kundu GC, 1998, J BIOL CHEM, V273, P22819, DOI 10.1074/jbc.273.35.22819; Lai KN, 1996, KIDNEY INT, V49, P839, DOI 10.1038/ki.1996.116; Launay P, 1999, J BIOL CHEM, V274, P7216, DOI 10.1074/jbc.274.11.7216; Magdaleno SM, 1997, AM J PHYSIOL-LUNG C, V272, pL1142, DOI 10.1152/ajplung.1997.272.6.L1142; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; Naito T, 1997, J LAB CLIN MED, V130, P63, DOI 10.1016/S0022-2143(97)90059-7; OH E, 1981, P NATL ACAD SCI-BIOL, V78, P3218, DOI 10.1073/pnas.78.5.3218; Ohmacht C, 1997, TRANSPLANTATION, V64, P1493, DOI 10.1097/00007890-199711270-00024; PERI A, 1993, J CLIN INVEST, V92, P2099, DOI 10.1172/JCI116810; PETEN EP, 1992, AM J PHYSIOL, V263, pF951, DOI 10.1152/ajprenal.1992.263.5.F951; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; Shaddy RE, 1996, BIOCHEM MOL MED, V57, P10, DOI 10.1006/bmme.1996.0002; Shijubo N, 1999, LUNG, V177, P45, DOI 10.1007/PL00007626; VOLVOVITZ B, 1988, INT ARCH ALLER A IMM, V86, P420; Waga S, 1999, J AM SOC NEPHROL, V10, P256; YANG CW, 1995, J AM SOC NEPHROL, V5, P1610; Yao XL, 1998, AM J PHYSIOL-LUNG C, V274, pL864, DOI 10.1152/ajplung.1998.274.5.L864; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284; Zhang ZJ, 1997, DNA CELL BIOL, V16, P73, DOI 10.1089/dna.1997.16.73; Zhang ZJ, 1997, SCIENCE, V276, P1408, DOI 10.1126/science.276.5317.1408; Zheng F, 1998, KIDNEY INT, V54, P1999, DOI 10.1046/j.1523-1755.1998.00219.x	42	80	91	2	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1999	5	9					1018	1025		10.1038/12458	http://dx.doi.org/10.1038/12458			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470078				2022-12-27	WOS:000082337200035
J	Ikeda, K; Ichikawa, T; Wakimoto, H; Silver, JS; Deisboeck, TS; Finkelstein, D; Harsh, GR; Louis, DN; Bartus, RT; Hochberg, FH; Chiocca, EA				Ikeda, K; Ichikawa, T; Wakimoto, H; Silver, JS; Deisboeck, TS; Finkelstein, D; Harsh, GR; Louis, DN; Bartus, RT; Hochberg, FH; Chiocca, EA			Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses	NATURE MEDICINE			English	Article							HERPES-SIMPLEX VIRUS-1; THYMIDINE KINASE GENE; IN-VIVO; RIBONUCLEOTIDE REDUCTASE; BRADYKININ ANALOG; DNA-SYNTHESIS; HUMAN GLIOMA; HUMAN SERUM; MUTANT; VECTOR	The occurrence of multiple tumors in an organ heralds a rapidly fatal course. Although intravascular administration may deliver oncolytic viruses/vectors to each of these tumors, its efficiency is impeded by an antiviral activity present in complement-depleted plasma of rodents and humans. Here, this activity was shown to interact with complement in a calcium-dependent fashion, and antibody neutralization studies indicated preimmune IgM has a contributing role. Short-term exposure to cyclophosphamide (CPA) partially suppressed this activity in rodents and humans. At longer time points, cyclophosphamide also abrogated neutralizing antibody responses. Cyclophosphamide treatment of rats with large single or multiple intracerebral tumors substantially increased viral survival and propagation, leading to neoplastic regression.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurooncol Labs, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurosurg Serv, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Alkermes, Cambridge, MA 02111 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Alkermes	Chiocca, EA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurooncol Labs, Charlestown, MA 02129 USA.		Wakimoto, Hiroaki/H-4533-2019	Wakimoto, Hiroaki/0000-0001-8225-241X	NATIONAL CANCER INSTITUTE [P01CA069246] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 69246] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreansky S, 1997, CANCER RES, V57, P1502; Barnett FH, 1999, CANCER GENE THER, V6, P14, DOI 10.1038/sj.cgt.7700003; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Black KL, 1997, J NEUROSURG, V86, P603, DOI 10.3171/jns.1997.86.4.0603; BOVIATSIS EJ, 1994, CANCER RES, V54, P5745; BOVIATSIS EJ, 1994, GENE THER, V1, P323; Bui LA, 1997, HUM GENE THER, V8, P2173, DOI 10.1089/hum.1997.8.18-2173; Chase M, 1998, NAT BIOTECHNOL, V16, P444, DOI 10.1038/nbt0598-444; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; COCHRANE CG, 1970, J IMMUNOL, V105, P55; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Elliott PJ, 1996, EXP NEUROL, V141, P214, DOI 10.1006/exnr.1996.0156; Fehr T, 1998, NAT MED, V4, P945, DOI 10.1038/nm0898-945; Fike JR, 1998, J NEURO-ONCOL, V37, P199, DOI 10.1023/A:1005874206814; GOLDSTEIN DJ, 1988, J VIROL, V62, P2970, DOI 10.1128/JVI.62.8.2970-2977.1988; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; Herrlinger U, 1998, GENE THER, V5, P809, DOI 10.1038/sj.gt.3300643; HUEMER HP, 1988, INTERVIROLOGY, V29, P68; JAMES K, 1982, AM J MED TECHNOL, V48, P735; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; Kucharczuk JC, 1997, CANCER RES, V57, P466; LeMay DR, 1998, HUM GENE THER, V9, P989, DOI 10.1089/hum.1998.9.7-989; Lubinski JM, 1998, J VIROL, V72, P8257, DOI 10.1128/JVI.72.10.8257-8263.1998; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Nagashunmugam T, 1998, J VIROL, V72, P5351, DOI 10.1128/JVI.72.7.5351-5359.1998; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Pyles RB, 1997, HUM GENE THER, V8, P533, DOI 10.1089/hum.1997.8.5-533; Rainov NG, 1995, HUM GENE THER, V6, P1543, DOI 10.1089/hum.1995.6.12-1543; Rampling R, 1998, NAT MED, V4, P133, DOI 10.1038/nm0298-133c; ROIZMAN B, 1968, J VIROL, V2, P83, DOI 10.1128/JVI.2.1.83-84.1968; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; Schuler M, 1998, HUM GENE THER, V9, P2075, DOI 10.1089/hum.1998.9.14-2075; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; Welsh RM, 1998, J VIROL, V72, P4650, DOI 10.1128/JVI.72.6.4650-4656.1998; WOOD MJA, 1994, GENE THER, V1, P283	38	257	290	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					881	887		10.1038/11320	http://dx.doi.org/10.1038/11320			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426310				2022-12-27	WOS:000081684000030
J	Kozyraki, R; Fyfe, J; Kristiansen, M; Gerdes, C; Jacobsen, C; Cui, SY; Christensen, EI; Aminoff, M; de la Chapelle, A; Krahe, R; Verroust, PJ; Moestrup, SK				Kozyraki, R; Fyfe, J; Kristiansen, M; Gerdes, C; Jacobsen, C; Cui, SY; Christensen, EI; Aminoff, M; de la Chapelle, A; Krahe, R; Verroust, PJ; Moestrup, SK			The intrinsic factor-vitamin B-12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein	NATURE MEDICINE			English	Article							FACTOR-COBALAMIN RECEPTOR; YOLK-SAC; SR-BI; TERATOGENIC ANTIBODIES; BRUSH-BORDER; PROTEIN; IDENTIFICATION; INHIBITION; TARGET; CELLS	Cubilin is the intestinal receptor for the endocytosis of intrinsic factor-vitamin B-12. However, several lines of evidence, including a high expression in kidney and yolk sac, indicate it may have additional functions. We isolated apolipoprotein A-I (apoA-I), the main protein of high-density lipoprotein (HDL), using cubilin affinity chromatography. Surface plasmon resonance analysis demonstrated a high-affinity binding of apoA-I and HDL to cubilin, and cubilin-expressing yolk sac cells showed efficient I-125-HDL endocytosis that could be inhibited by IgG antibodies against apoA-I and cubilin. The physiological relevance of the cubilin-apoA-I interaction was further emphasized by urinary apoA-I loss in some known cases of functional cubilin deficiency. Therefore, cubilin is a receptor in epithelial apoA-I/HDL metabolism.	Aarhus Univ, Dept Med Biochem, Aarhus, Denmark; Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; Aarhus Univ Hosp, Dept Med & Cardiol A, Aarhus, Denmark; Aarhus Univ, Inst Anat, Dept Cell Biol, DK-8000 Aarhus C, Denmark; Ohio State Univ, Div Human Canc Genet, Dept Immunol & Microbiol, Ctr Comprehens Canc, Columbus, OH USA; Univ Helsinki, Folkhalsan Inst Genet, FIN-00014 Helsinki, Finland; Hop Tenon, Inst Natl Sante & Rech Med, U489, Paris, France	Aarhus University; Michigan State University; Aarhus University; Aarhus University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Helsinki; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Moestrup, SK (corresponding author), Aarhus Univ, Dept Med Biochem, Aarhus, Denmark.		Kozyraki, Renata/G-5321-2017; Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Madsen, Mette/0000-0001-7241-6505; Kozyraki, Renata/0000-0001-9779-5898	NCI NIH HHS [P30 CA16058] Funding Source: Medline; NIDDK NIH HHS [DK45341] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045341] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Aminoff M, 1999, NAT GENET, V21, P309, DOI 10.1038/6831; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Farese RV, 1996, J LIPID RES, V37, P347; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; FYFE JC, 1991, J BIOL CHEM, V266, P4489; GLASS C, 1985, J BIOL CHEM, V260, P744; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; Hatch F T, 1968, Adv Lipid Res, V6, P1; Hatzopoulos AK, 1998, J LIPID RES, V39, P495; HOMANICS GE, 1995, TERATOLOGY, V51, P1, DOI 10.1002/tera.1420510102; IMERSLUND O, 1960, Acta Paediatr Suppl, V49(Suppl 119), P1; KolfClauw M, 1996, TERATOLOGY, V54, P115, DOI 10.1002/(SICI)1096-9926(199609)54:3<115::AID-TERA1>3.0.CO;2-2; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Kozyraki R, 1998, BLOOD, V91, P3593; LEPANSE S, 1995, EUR J CELL BIOL, V67, P120; Moestrup SK, 1998, J CLIN INVEST, V102, P902, DOI 10.1172/JCI3772; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; MOESTRUP SK, J BIOL CHEM, V5235, P98; PLUMP AS, 1997, J LIPID RES, V36, P1933; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; SAHALI D, 1988, J EXP MED, V167, P213, DOI 10.1084/jem.167.1.213; SAHALI D, 1993, AM J PATHOL, V142, P1654; SAKU K, 1984, METABOLISM, V33, P432, DOI 10.1016/0026-0495(84)90143-4; Seetharam B, 1997, J CLIN INVEST, V99, P2317, DOI 10.1172/JCI119411; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Wyne KL, 1998, J LIPID RES, V39, P518	33	212	218	2	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					656	661		10.1038/9504	http://dx.doi.org/10.1038/9504			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371504				2022-12-27	WOS:000080823300034
J	Hewitson, L; Dominko, T; Takahashi, D; Martinovich, C; Ramalho-Santos, J; Sutovsky, P; Fanton, J; Jacob, D; Monteith, D; Neuringer, M; Battaglia, D; Simerly, C; Schatten, G				Hewitson, L; Dominko, T; Takahashi, D; Martinovich, C; Ramalho-Santos, J; Sutovsky, P; Fanton, J; Jacob, D; Monteith, D; Neuringer, M; Battaglia, D; Simerly, C; Schatten, G			Unique checkpoints during the first cell cycle of fertilization after intracytoplasmic sperm injection in rhesus monkeys	NATURE MEDICINE			English	Article							HUMAN OOCYTES; CHILDREN; MOUSE; MITOSIS; EMBRYOS; ICSI	Intracytoplasmic sperm injection has begun an era of considerable improvements in treating male infertility. Despite its success, questions remain about the dangers of transmitting traits responsible for male infertility, sex and autosomal chromosome aberrations' and possible mental, physical and reproductive abnormalities(2,3). We report here the first births of rhesus monkeys produced by intracytoplasmic sperm injection at rates greater or equal to those reported by clinics. Essential assumptions about this process are flawed, as shown by results with the preclinical, nonhuman primate model and with clinically discarded specimens. Dynamic imaging demonstrated the variable position of the second meiotic spindle in relation to the first polar body; consequently, microinjection targeting is imprecise and potentially lethal. Intracytoplasmic sperm injection resulted in abnormal sperm decondensation, with the unusual retention of vesicle-associated membrane protein and the perinuclear theca, and the exclusion of the nuclear mitotic apparatus from the decondensing sperm nuclear apex. Male pronuclear remodeling in the injected oocytes was required before replication of either parental genome, indicating a unique G(1)-to-S transition checkpoint during zygotic interphase (the first cell cycle). These irregularities indicate that the intracytoplasmic sperm injection itself might lead to the observed increased chromosome anomalies(4-5).	Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Dev & Cell Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Oregon Reg Primate Res Ctr, Portland, OR 97201 USA; Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA; Univ Coimbra, Dept Zool, Ctr Neurosci Coimbra, P-3000 Coimbra, Portugal	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon National Primate Research Center; University of Washington; University of Washington Seattle; Universidade de Coimbra	Schatten, G (corresponding author), Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	schatten@ohsu.edu	Schatten, Gerald/B-3253-2009; Santos, João/HHZ-5595-2022; simerly, Calvin/AAC-9564-2021; Ramalho-Santos, João/F-8641-2012	Schatten, Gerald/0000-0001-5206-7782; Ramalho-Santos, João/0000-0002-1172-4018; Sutovsky, Peter/0000-0002-9231-2823				Antczak M, 1997, MOL HUM REPROD, V3, P1067, DOI 10.1093/molehr/3.12.1067; Bonduelle M, 1998, LANCET, V351, P1553, DOI 10.1016/S0140-6736(98)24021-9; Bonduelle M, 1998, HUM REPROD, V13, P781, DOI 10.1093/humrep/13.4.781; Bowen JR, 1998, LANCET, V351, P1529, DOI 10.1016/S0140-6736(98)10168-X; Cohen J, 1998, MOL HUM REPROD, V4, P269, DOI 10.1093/molehr/4.3.269; COMPTON DA, 1994, CURR OPIN CELL BIOL, V6, P343, DOI 10.1016/0955-0674(94)90024-8; Conner S, 1997, MOL REPROD DEV, V48, P106; DALE B, 1995, ZYGOTE, V3, P31, DOI 10.1017/S0967199400002355; Edwards RG, 1997, MOL HUM REPROD, V3, P863, DOI 10.1093/molehr/3.10.863; FISHEL S, 1995, LANCET, V345, P1641, DOI 10.1016/S0140-6736(95)90149-3; GORBSKY GJ, 1990, P NATL ACAD SCI USA, V87, P6049, DOI 10.1073/pnas.87.16.6049; Hewitson L, 1998, HUM REPROD, V13, P3449, DOI 10.1093/humrep/13.12.3449; INTVELD P, 1995, LANCET, V773, P346; Kent-First MG, 1996, MOL HUM REPROD, V2, P943, DOI 10.1093/molehr/2.12.943; LUETJENS M, 1998, J REPROD FERT, V22; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Schatten G, 1998, J LAW MED ETHICS, V26, P29, DOI 10.1111/j.1748-720X.1998.tb01903.x; SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256; Silber SJ, 1998, HUM REPROD, V13, P509, DOI 10.1093/humrep/13.3.509; SILVA CP, 1998, 54 ANN M AM SOC REPR, pP742; Simerly C, 1998, MOL BIOL CELL, V9, P2509, DOI 10.1091/mbc.9.9.2509; Sofikitis N, 1998, LANCET, V351, P1177, DOI 10.1016/S0140-6736(05)79121-2; Sutovsky P, 1997, DEV BIOL, V188, P75, DOI 10.1006/dbio.1997.8618; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192	24	178	189	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					431	433		10.1038/7430	http://dx.doi.org/10.1038/7430			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202934				2022-12-27	WOS:000079574300034
J	Hartley, CJ; Lacy, JL; Dai, DY; Nayak, N; Taffet, GE; Entman, ML; Michael, LH				Hartley, CJ; Lacy, JL; Dai, DY; Nayak, N; Taffet, GE; Entman, ML; Michael, LH			Functional cardiac imaging in mice using Ta-178	NATURE MEDICINE			English	Article							MULTIWIRE GAMMA-CAMERA; TANTALUM-178; DISEASE; MODEL; MOUSE		Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, Houston, TX 77030 USA; Proport Technol, Houston, TX 77054 USA	Baylor College of Medicine	Hartley, CJ (corresponding author), Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022512, P01HL042550, R44HL057086] Funding Source: NIH RePORTER; NHLBI NIH HHS [R44-HL57086, P01-HL42550, R37-HL22512] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHIEN KR, 1995, AM J PHYSIOL-HEART C, V269, pH755, DOI 10.1152/ajpheart.1995.269.3.H755; Franco F, 1998, AM J PHYSIOL-HEART C, V274, pH679, DOI 10.1152/ajpheart.1998.274.2.H679; HARTLEY CJ, 1995, AM J PHYSIOL-HEART C, V268, pH499, DOI 10.1152/ajpheart.1995.268.1.H499; ISKANDRIAN AS, 1996, NUCL CARDIAC IMAGING; Iwase M, 1996, CIRC RES, V78, P517, DOI 10.1161/01.RES.78.4.517; James JF, 1998, CIRC RES, V82, P407, DOI 10.1161/01.RES.82.4.407; KISHIMOTO C, 1991, J AM COLL CARDIOL, V17, P821, DOI 10.1016/S0735-1097(10)80203-7; LACY JL, 1988, J NUCL MED, V29, P1526; LACY JL, 1988, J NUCL MED, V29, P293; Li BS, 1997, AM J PHYSIOL-HEART C, V273, pH2508, DOI 10.1152/ajpheart.1997.273.5.H2508; MANNING WJ, 1993, LAB ANIM SCI, V43, P583; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Patten RD, 1998, AM J PHYSIOL-HEART C, V274, pH1812, DOI 10.1152/ajpheart.1998.274.5.H1812; ROCKMAN HA, 1993, CIRCULATION, V87, P14; ROCKMAN HA, 1994, P NATL ACAD SCI USA, V91, P2694, DOI 10.1073/pnas.91.7.2694; SLUTSKY RA, 1983, AM HEART J, V105, P802, DOI 10.1016/0002-8703(83)90244-2; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; VERANI MS, 1992, J AM COLL CARDIOL, V19, P297, DOI 10.1016/0735-1097(92)90482-3; Williams RV, 1998, AM J PHYSIOL-HEART C, V274, pH1828, DOI 10.1152/ajpheart.1998.274.5.H1828	20	12	12	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					237	239		10.1038/5602	http://dx.doi.org/10.1038/5602			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930875				2022-12-27	WOS:000078274400036
J	Mason, CAE; Bigras, JL; O'Blenes, SB; Zhou, B; McIntyre, B; Nakamura, N; Kaneda, Y; Rabinovitch, M				Mason, CAE; Bigras, JL; O'Blenes, SB; Zhou, B; McIntyre, B; Nakamura, N; Kaneda, Y; Rabinovitch, M			Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectin-dependent neointimal formation	NATURE MEDICINE			English	Article							INTIMAL PROLIFERATION; EXTRACELLULAR-MATRIX; CARDIAC MALFORMATION; C-MYC; BINDING; PROSTAGLANDIN-E1; EXPRESSION; THERAPY	Closure of the ductus arteriosus requires prenatal formation of intimal cushions, which occlude the vessel lumen at birth. Survival of newborns with severe congenital heart defects, however, depends on ductal patency. We used a gene transfer approach to create a patent ductus arteriosus by targeting the fibronectin-dependent smooth muscle cell migration required for intimal cushion formation. Fetal lamb ductus arteriosus was transfected in utero with hemagglutinating virus of Japan liposomes containing plasmid encoding 'decoy' RNA to sequester the fibronectin mRNA binding protein. Fibronectin translation was inhibited and intimal cushion formation was prevented. We thus established the essential role of fibronectin-dependent smooth muscle cell migration in intimal cushion formation in the intact animal and the feasibility of incorporating biological engineering in the management of congenital heart disease.	Univ Toronto, Hosp Sick Children, Dept Pediat, Inst Res,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Lab Med & Pathobiol, Inst Res,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Med, Inst Res,Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 565, Japan	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Osaka University	Rabinovitch, M (corresponding author), Univ Toronto, Hosp Sick Children, Dept Pediat, Inst Res,Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							BOTNEY MD, 1992, AM J PATHOL, V140, P357; BOUDREAU N, 1991, DEV BIOL, V143, P235, DOI 10.1016/0012-1606(91)90074-D; BOUDREAU N, 1992, LAB INVEST, V67, P350; BOUDREAU N, 1991, LAB INVEST, V64, P187; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CLAUSELL N, 1995, BRIT HEART J, V73, P534; Forsyth EA, 1997, J VASC SURG, V26, P1002, DOI 10.1016/S0741-5214(97)70013-2; GITTENBERGERDEGROOT AC, 1980, J PEDIATR-US, V96, P88, DOI 10.1016/S0022-3476(80)80337-4; GITTENBERGERDEGROOT AC, 1985, J AM COLL CARDIOL, V6, P394, DOI 10.1016/S0735-1097(85)80178-9; GITTENBERGERDEGROOT AC, 1980, CIRCULATION, V62, P183, DOI 10.1161/01.CIR.62.1.183; HALLIDIESMITH KA, 1984, ARCH DIS CHILD, V59, P1020, DOI 10.1136/adc.59.11.1020; HORNBLAD PY, 1967, CARDIOLOGIA, V51, P262, DOI 10.1159/000165823; HOST A, 1988, DAN MED BULL, V35, P81; Jones PL, 1997, AM J PATHOL, V150, P1349; Kaneda Y, 1997, ANN NY ACAD SCI, V811, P299, DOI 10.1111/j.1749-6632.1997.tb52010.x; KANEDA Y, 1989, J BIOL CHEM, V264, P12126; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; Liebermann DA, 1998, INT J ONCOL, V12, P685; Mann MJ, 1997, MOL CELL BIOCHEM, V172, P3, DOI 10.1023/A:1006801807206; MOLOSSI S, 1995, J CLIN INVEST, V95, P2601, DOI 10.1172/JCI117962; MOLOSSI S, 1993, CIRCULATION, V88, P248; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; OILEY PM, 1976, CIRCULATION, V53, P728; ROME JJ, 1994, HUM GENE THER, V5, P1249, DOI 10.1089/hum.1994.5.10-1249; SANDERS M, 1994, PHARMACOL THERAPEUT, V61, P109, DOI 10.1016/0163-7258(94)90060-4; SILVER MM, 1981, HUM PATHOL, V12, P1123, DOI 10.1016/S0046-8177(81)80333-4; Veyrune J L, 1997, Prog Mol Subcell Biol, V18, P35; YODER MJ, 1978, ANAT REC, V192, P19, DOI 10.1002/ar.1091920103; Zhou B, 1997, J CLIN INVEST, V100, P3070, DOI 10.1172/JCI119862; Zhou B, 1998, CIRC RES, V83, P481, DOI 10.1161/01.RES.83.5.481	31	69	71	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					176	182		10.1038/5538	http://dx.doi.org/10.1038/5538			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930865				2022-12-27	WOS:000078274400026
J	Luo, L; Salunga, RC; Guo, HQ; Bittner, A; Joy, KC; Galindo, JE; Xiao, HN; Rogers, KE; Wan, JS; Jackson, MR; Erlander, MG				Luo, L; Salunga, RC; Guo, HQ; Bittner, A; Joy, KC; Galindo, JE; Xiao, HN; Rogers, KE; Wan, JS; Jackson, MR; Erlander, MG			Gene expression profiles of laser-captured adjacent neuronal subtypes	NATURE MEDICINE			English	Article							DIFFERENTIAL EXPRESSION; MESSENGER-RNA; RAT; MICROARRAY; GANGLIA; CDNA		RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA	Johnson & Johnson; Johnson & Johnson USA; Johnson & Johnson; Johnson & Johnson USA	Erlander, MG (corresponding author), RW Johnson Pharmaceut Res Inst, 3535 Gen Atom Court,Suite 100, San Diego, CA 92121 USA.							Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; COGGESHALL RE, 1991, SENSORY MECH SPINAL; Costigan M, 1998, J NEUROSCI, V18, P5891; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Goldstein ME, 1996, NEUROSCIENCE, V71, P243, DOI 10.1016/0306-4522(95)00404-1; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; LOCKHART DJ, 1998, NUCL ACIDS S SER, V38, P11; Naciff JM, 1996, J COMP NEUROL, V368, P356; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; OH YS, 1995, MOL BRAIN RES, V30, P357, DOI 10.1016/0169-328X(95)00052-T; PARYSEK LM, 1988, NEURON, V1, P395, DOI 10.1016/0896-6273(88)90189-4; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Shalon D, 1998, PATHOL BIOL, V46, P107; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059	23	593	631	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					117	122		10.1038/4806	http://dx.doi.org/10.1038/4806			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883850				2022-12-27	WOS:000077885000040
J	Brinkmeier, H; Aulkemeyer, P; Wollinsky, KH; Rudel, R				Brinkmeier, H; Aulkemeyer, P; Wollinsky, KH; Rudel, R			An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system	NATURE MEDICINE			English	Article							GUILLAIN-BARRE-SYNDROME; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; NEUROLOGICAL DISEASE; ANTIBODIES; SERUM	Reversible blockade of sodium channels by endogenous substances has been claimed to account for the fast exacerbations and relapses commonly seen in demyelinating autoimmune diseases(1-4). Evidence has been provided that in the cerebrospinal fluid of patients with multiple sclerosis(5) or Guillain-Barre syndrome(6), a sodium-channel-blocking factor exists that has properties of local anesthetic agents(7,8). This factor could contribute to the nerve conduction block and paresis seen in these disorders(9-11). We describe here a previously unknown endogenous substance in human cerebrospinal fluid with distinct channel-blocking properties even at very tow (0.00001 M) concentrations. The pentapeptide with the sequence Gln-Tyr-Asn-Ala-Asp exerted its blocking action by shifting the steady-state inactivation curve of the sodium channels to more-negative potentials, as most local anesthetics do. In the cerebrospinal fluid of healthy individuals, its concentration was about 3 mu M, whereas in patients with multiple sclerosis and Guillain-Barre syndrome, it increased 300-1,400%. At these concentrations, the peptide's blocking efficacy was higher than that of 50 mu M lidocaine. At a concentration of 10 mu M, lidocaine is able to 'unmask' subclinical lesions in multiple sclerosis(12); thus, the endogenous pentapeptide may well contribute to the fast changes of symptoms. Furthermore, it may become valuable as a marker of disease activity.	Univ Ulm, Dept Gen Physiol, D-89069 Ulm, Germany; Rehabil Hosp Ulm, Dept Anaesthesiol & Intens Care, D-89081 Ulm, Germany	Ulm University	Rudel, R (corresponding author), Univ Ulm, Dept Gen Physiol, D-89069 Ulm, Germany.							Aulkemeyer P, 2000, J NEUROL SCI, V172, P49, DOI 10.1016/S0022-510X(99)00285-3; Aulkemeyer P, 1996, NEUROSCI LETT, V216, P37; BRINKMEIER H, 1992, PFLUG ARCH EUR J PHY, V421, P552, DOI 10.1007/BF00375050; Brinkmeier H, 1996, MUSCLE NERVE, V19, P54, DOI 10.1002/(SICI)1097-4598(199601)19:1<54::AID-MUS7>3.0.CO;2-7; BRINKMEIER H, 1993, NEUROSCI LETT, V156, P172, DOI 10.1016/0304-3940(93)90465-W; CATTERALL WA, 1992, PHYSIOL REV, V72, P515; Griffin JW, 1996, ANN NEUROL, V39, P17, DOI 10.1002/ana.410390105; Gutmann L, 1996, NEUROLOGY, V47, P18, DOI 10.1212/WNL.47.1.18; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P316; Koller H, 1996, BRAIN, V119, P457, DOI 10.1093/brain/119.2.457; Koller H, 1997, PROG NEUROBIOL, V52, P1, DOI 10.1016/S0301-0082(96)00065-2; PARRY GJ, 1993, GUILLAINBARRE SYNDRO, P1; RAGSDALE DS, 1991, MOL PHARMACOL, V40, P756; SAKURAI M, 1992, NEUROLOGY, V42, P2088, DOI 10.1212/WNL.42.11.2088; TAKIGAWA T, 1995, ANN NEUROL, V37, P436, DOI 10.1002/ana.410370405; WAXMAN SG, 1995, ANN NEUROL, V37, P421, DOI 10.1002/ana.410370403; Weber F, 1999, J NEUROL, V246, P955, DOI 10.1007/s004150050490; WURZ A, 1995, MUSCLE NERVE, V18, P772, DOI 10.1002/mus.880180715	18	64	67	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					808	811		10.1038/77543	http://dx.doi.org/10.1038/77543			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888931				2022-12-27	WOS:000088040100039
J	Duan, DS; Yue, YP; Yan, ZY; Engelhardt, JF				Duan, DS; Yue, YP; Yan, ZY; Engelhardt, JF			A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation	NATURE MEDICINE			English	Article							ADENOASSOCIATED VIRUS		Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Ctr Gene Therapy, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Engelhardt, JF (corresponding author), Univ Iowa, Coll Med, Dept Anat & Cell Biol, 51 Newton Rd,Room 1-101 BSB, Iowa City, IA 52242 USA.			Engelhardt, John/0000-0003-2389-9277; Yan, Ziying/0000-0001-8210-5567; Duan, Dongsheng/0000-0003-4109-1132	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58430, R01 HL058340] Funding Source: Medline; NIDDK NIH HHS [P30 DK054759, P30 DK54759] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Duan DS, 1999, VIROLOGY, V261, P8, DOI 10.1006/viro.1999.9821; Duan DS, 1997, VIRUS RES, V48, P41, DOI 10.1016/S0168-1702(96)01425-6; Duan DS, 1999, J VIROL, V73, P161, DOI 10.1128/JVI.73.1.161-169.1999; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; LEWIN B, 1997, GENES, V6, P1260; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; Wagner JA, 1998, LANCET, V351, P1702, DOI 10.1016/S0140-6736(05)77740-0; Yang JS, 1999, J VIROL, V73, P9468, DOI 10.1128/JVI.73.11.9468-9477.1999	9	135	142	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					595	598		10.1038/75080	http://dx.doi.org/10.1038/75080			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802719				2022-12-27	WOS:000086796200047
J	Guleria, I; Pollard, JW				Guleria, I; Pollard, JW			The trophoblast is a component of the innate immune system during pregnancy	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; PLACENTAL DEVELOPMENT; FACTOR-I; MACROPHAGES; MOUSE; DIFFERENTIATION; LISTERIOSIS; EXPRESSION; CSF-1; CELLS	Systemic infection with Listeria monocytogenes, a Gram-positive intracellular bacterium, has been used extensively to analyze the innate immune response(1,2). Macrophages are central to this response, acting as both the host for and principal defense against this bacterium. During pregnancy L. monocytogenes has a predilection for replication at the maternal-placental interface and consequently is an important cause of fetal morbidity and mortality(3,4). However, macrophages are mostly excluded from the murine placenta with neutrophils acting as the main immune effector cell against this bacterium(3,5,6). Colony stimulating factor (CSF)-1, a macrophage growth factor, is synthesized in high concentrations by the uterine epithelium during pregnancy, where it is targeted to trophoblast bearing CSF-1-receptors(7,8). To define the involvement of CSF-1 in placental immunity, we infected pregnant mice either homozygous or heterozygous for an inactivating recessive mutation in the gene for CSF-1 (osteopetrotic; Csfm(op)) with L. monocytogenes(9). CSF-1 was required to recruit neutrophils to the site of listerial infection in the decidua basalis, and infection by Listeria remained unrestrained in its absence. CSF-1 acted by inducing the trophoblast to synthesize the neutrophil chemoattractants (KC) and macrophage inflammatory protein (MIP)-2. Thus, during pregnancy, trophoblast responsive to CSF-1 acts to organize the maternal immune response to bacterial infection at the utero-placental interface. This previously unknown function indicates that the trophoblast acts as a pregnancy-specific component of the innate immune system.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Obstet & Gynecol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Womens Hlth, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Pollard, JW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	pollard@aecom.yu.edu		GULERIA, INDIRA/0000-0002-0622-3585	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030280] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA13330] Funding Source: Medline; NICHD NIH HHS [HD30280] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; Ashkar AA, 1999, BIOL REPROD, V61, P493, DOI 10.1095/biolreprod61.2.493; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; GUILBERT L, 1993, IMMUNOL CELL BIOL, V71, P49, DOI 10.1038/icb.1993.5; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; KISO Y, 1992, EXPERIENTIA, V48, P973, DOI 10.1007/BF01919144; Lorber B, 1997, CLIN INFECT DIS, V24, P1, DOI 10.1093/clinids/24.1.1; LU CY, 1991, MOLECULAR AND CELLULAR IMMUNOBIOLOGY OF THE MATERNAL FETAL INTERFACE, P141; NILSSON SK, 1995, BLOOD, V86, P66, DOI 10.1182/blood.V86.1.66.bloodjournal86166; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; Pollard JW, 1998, CONT ENDOCRINOL, V9, P59; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; Pollard JW., 1996, ADV D BIOCH, V4, P153; REDLINE RW, 1988, J IMMUNOL, V140, P3947; REINER SL, 1994, J IMMUNOL METHODS, V175, P275, DOI 10.1016/0022-1759(94)90370-0; REINER SL, 1994, J IMMUNOL METHODS, V173, P133, DOI 10.1016/0022-1759(94)90291-7; REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F; SCHAIBLE U, 1999, ADV IMMUNOL, P267; TAKAHASHI K, 1991, J LEUKOCYTE BIOL, V50, P57, DOI 10.1002/jlb.50.1.57; Unanue ER, 1997, IMMUNOL REV, V158, P11, DOI 10.1111/j.1600-065X.1997.tb00988.x; Unanue ER, 1996, RES IMMUNOL, V147, P499, DOI 10.1016/S0923-2494(97)85214-5; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	23	147	154	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2000	6	5					589	593		10.1038/75074	http://dx.doi.org/10.1038/75074			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802718				2022-12-27	WOS:000086796200046
J	Kroemer, G; Reed, JC				Kroemer, G; Reed, JC			Mitochondrial control of cell death	NATURE MEDICINE			English	Review							PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; AMYOTROPHIC-LATERAL-SCLEROSIS; CYCLOSPORINE-A; URSODEOXYCHOLIC ACID; PARKINSONS-DISEASE; BAX TRANSLOCATION; APOPTOSIS; BCL-2; MECHANISM	In many instances, permeabilization of mitochondrial membranes is a rate-limiting step of apoptotic or necrotic cell demise. This has important consequences for the pathophysiology of cell death, as well as for its pharmacological control.	Inst Gustave Roussy, CNRS, ULR 1599, F-94805 Villejuif, France; Burnham Inst, La Jolla, CA 92037 USA	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Sanford Burnham Prebys Medical Discovery Institute	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, ULR 1599, 24 Rue Calmette Desmoulins, F-94805 Villejuif, France.	kroemer@infobiogen.fr; jreed@burnhan.org	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; türkel, ibrahim/H-3143-2015	KROEMER, Guido/0000-0002-9334-4405; 				Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Barath P, 1999, J BIOL CHEM, V274, P3378, DOI 10.1074/jbc.274.6.3378; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Carri MT, 1997, FEBS LETT, V414, P365, DOI 10.1016/S0014-5793(97)01051-X; Carthy CM, 1999, LAB INVEST, V79, P953; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Cassarino DS, 1998, BIOCHEM BIOPH RES CO, V248, P168, DOI 10.1006/bbrc.1998.8866; Cooper JM, 1997, J BIOENERG BIOMEMBR, V29, P175, DOI 10.1023/A:1022642114734; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DRAKE MF, 1999, NEUROSCIENCE, V90, P1325; Elleaume P, 1998, J SYNCHROTRON RADIAT, V5, P1, DOI 10.1107/S0909049597012818; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo Q, 1999, J NEUROSCI RES, V56, P457, DOI 10.1002/(SICI)1097-4547(19990601)56:5<457::AID-JNR2>3.0.CO;2-P; Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Joshi B, 1999, CANCER RES, V59, P4343; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Katabi MM, 1999, HUM GENE THER, V10, P155, DOI 10.1089/10430349950018959; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kwong J, 1999, CELL TISSUE RES, V298, P123, DOI 10.1007/s004419900057; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Marchetti P, 1999, CANCER RES, V59, P6257; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; Miccoli L, 1998, CANCER RES, V58, P5777; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nomura M, 1999, CANCER RES, V59, P5542; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; PUTHALALATH G, 1999, MOL CELL, V3, P287; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Rodrigues CMP, 1999, CELL DEATH DIFFER, V6, P842, DOI 10.1038/sj.cdd.4400560; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Sheehan JP, 1997, J NEUROCHEM, V68, P1221; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Tabouy L, 1998, LIFE SCI, V63, P2259, DOI 10.1016/S0024-3205(98)00511-6; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vander Heiden MG, 1999, MOL CELL, V3, P159; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3	81	2653	2778	6	238	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2000	6	5					513	519		10.1038/74994	http://dx.doi.org/10.1038/74994			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802706				2022-12-27	WOS:000086796200034
J	Smith, T; Groom, A; Zhu, B; Turski, L				Smith, T; Groom, A; Zhu, B; Turski, L			Autoimmune encephalomyelitis ameliorated by AMPA antagonists	NATURE MEDICINE			English	Article							MULTIPLE-SCLEROSIS; BASIC-PROTEIN; MYELIN	Multiple sclerosis is an immune-mediated disorder of the central nervous system leading to progressive decline of motor and sensory functions and permanent disability(1,2). The therapy of multiple sclerosis is only partially effective, despite anti-inflammatory, immunosuppresive and immunomodulatory measures(3). White matter inflammation and loss of myelin, the pathological hallmarks of multiple sclerosis, are thought to determine disease severity(4,5). Experimental autoimmune encephalomyelitis reproduces the features of multiple sclerosis in rodents and in nonhuman primates(6,7). The dominant early clinical symptom of acute autoimmune encephalomyelitis is progressive ascending muscle weakness(6). However, demyelination may not be profound and its extent may not correlate with severity of neurological decline(8), indicating that targets unrelated to myelin or oligodendrocytes may contribute to the pathogenesis of acute autoimmune encephalomyelitis. Here we report that within the spinal cord in the course of autoimmune encephalomyelitis not only myelin but also neurons are subject to lymphocyte attack and may degenerate. Blockade of glutamate AMPA receptors ameliorated the neurological sequelae of autoimmune encephalomyelitis, indicating the potential for AMPA antagonists in the therapy of multiple sclerosis.	UCL, Eisai London Res Labs, London WC1E 6BT, England	Eisai Co Ltd; University of London; University College London	Turski, L (corresponding author), UCL, Eisai London Res Labs, Bernard Katz Bldg,Gower St, London WC1E 6BT, England.	terence_smith@eisai.net; lechoslaw.turski@solvay.com						Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; CARNEGIE PR, 1974, NATURE, V249, P147, DOI 10.1038/249147a0; DUNKLEY PR, 1974, BIOCHEM J, V141, P243, DOI 10.1042/bj1410243; Feldmeyer D, 1999, NAT NEUROSCI, V2, P57, DOI 10.1038/4561; FFRENCHCONSTANT C, 1994, LANCET, V343, P271, DOI 10.1016/S0140-6736(94)91118-5; HardinPouzet H, 1997, GLIA, V20, P79, DOI 10.1002/(SICI)1098-1136(199705)20:1<79::AID-GLIA8>3.0.CO;2-0; HUMBLE JG, 1956, BRIT J HAEMATOL, V2, P283, DOI 10.1111/j.1365-2141.1956.tb06700.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 1996, J NEUROPATH EXP NEUR, V55, P211, DOI 10.1097/00005072-199602000-00010; Jm C., 1868, GAZ HOPITAUX, P554; MARTIN R, 1997, MULTIPLE SCLEROSIS C, P221; Matute C, 1998, P NATL ACAD SCI USA, V95, P10229, DOI 10.1073/pnas.95.17.10229; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; MIKHAILOVSKAYA EV, 1997, CYTOL GENET, V31, P81; Nakamura R, 1994, Rinsho Shinkeigaku, V34, P679; Paxinos G., 1998, RAT BRAIN STEROTAXIC; PRINEAS JW, 1997, GREENFIELDS NEUROPAT, V1, P813; Rudick RA, 1997, NEW ENGL J MED, V337, P1604, DOI 10.1056/NEJM199711273372207; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; Stover JF, 1997, EUR J CLIN INVEST, V27, P1038, DOI 10.1046/j.1365-2362.1997.2250774.x; Tarnawa I, 1998, RESTOR NEUROL NEUROS, V13, P41; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; WEKERLE H, 1994, ANN NEUROL, V36, P547; [No title captured]	25	391	411	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					62	66		10.1038/71548	http://dx.doi.org/10.1038/71548			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613825				2022-12-27	WOS:000084583300036
J	Li, HC; Fujiyoshi, T; Lou, H; Yashiki, S; Sonoda, S; Cartier, L; Nunez, L; Munoz, I; Horai, S; Tajima, K				Li, HC; Fujiyoshi, T; Lou, H; Yashiki, S; Sonoda, S; Cartier, L; Nunez, L; Munoz, I; Horai, S; Tajima, K			The presence of ancient human T-cell lymphotropic virus type I provirus DNA in an Andean mummy	NATURE MEDICINE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; LEUKEMIA-VIRUS; ENZYMATIC AMPLIFICATION; GENE; CARRIERS; HTLV-1	The worldwide geographic and ethnic clustering of patients with diseases related to human T-cell lymphotropic virus type I (HTLV-I) may be explained by the natural history of HTLV-I infection(1,2) 2. The genetic characteristics of indigenous people in the Andes are similar to those of the Japanese(3,4), and HTLV-I is generally detected in both groups(5). To clarify the common origin of HTLV-I in Asia and the Andes, we analyzed HTLV-I provirus DNA from Andean mummies about 1,500 years old. Two of 104 mummy bone marrow specimens yielded a band of human beta-globin gene DNA 110 base pairs in length, and one of these two produced bands of HTLV-I-pX (open reading frame encoding p40(x), p27(x)) and HTLV-I-LTR (long terminal repeat) gene DNA 159 base pairs and 157 base pairs in length, respectively. The nucleotide sequences of ancient HTLV-I-pX and HTLV-I-LTR clones isolated from mummy bone marrow were similar to those in contemporary Andeans and Japanese, although there was microheterogeneity in the sequences of some mummy DNA clones. This result provides evidence that HTLV-I was carried with ancient Mongoloids to the Andes before the Colonial era. Analysis of ancient HTLV-I sequences could be a useful tool for studying the history of human retroviral infection as well as human prehistoric migration.	Aichi Canc Ctr, Res Inst, Div Epidemiol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Kagoshima Univ, Fac Med, Dept Virol, Kagoshima 8908520, Japan; Univ Chile, Dept Clin Neurol, Santiago, Chile; N Catholic Univ, Dept Archaeol, San Pedro De Atacama, Region II, Chile; Univ Tarapaca, Dept Archaeol, Arica, Region I, Chile; Grad Univ Adv Studies, Dept Biosyst Sci, Hayamacho 2400193, Japan	Aichi Cancer Center; Universidad de Chile; Universidad Catolica del Norte; Universidad de Tarapaca; Graduate University for Advanced Studies - Japan	Tajima, K (corresponding author), Aichi Canc Ctr, Res Inst, Div Epidemiol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.	ktajima@aichi-cc.pref.aichi.jp						ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; CANO RJ, 1993, BIOTECHNIQUES, V15, P432; Fujiyoshi T, 1999, AIDS RES HUM RETROV, V15, P1235, DOI 10.1089/088922299310124; FULLERTON SM, 1994, P NATL ACAD SCI USA, V91, P1805, DOI 10.1073/pnas.91.5.1805; Handt O, 1996, AM J HUM GENET, V59, P368; HORAI S, 1996, PREHISTORIC MONGOLOI, P270; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; KWOK S, 1988, BLOOD, V72, P1117; Miura T, 1997, J MOL EVOL, V44, pS76, DOI 10.1007/PL00000053; MIURA T, 1994, P NATL ACAD SCI USA, V91, P1124, DOI 10.1073/pnas.91.3.1124; NIEWIESK S, 1994, J VIROL, V68, P6778, DOI 10.1128/JVI.68.10.6778-6781.1994; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Saito M, 1996, J NEUROVIROL, V2, P330, DOI 10.3109/13550289609146897; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOTOHNO K, 1985, P NATL ACAD SCI USA, V82, P3101, DOI 10.1073/pnas.82.10.3101; SONODA S, 1996, CAN MONOGR CAN RES, V44, P207; TAJIMA K, 1996, GANN MONOGR CANC RES, V44, P123; Tajima K, 1992, GANN MONOGR CANC RES, P129; THOMAS WK, 1993, METHOD ENZYMOL, V224, P406; WATANABE T, 1984, VIROLOGY, V133, P238, DOI 10.1016/0042-6822(84)90446-X; Yamashita M, 1998, J MED VIROL, V55, P152, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;152::AID-JMV12&gt;3.0.CO;2-K; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121	22	73	79	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1428	1432						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581088				2022-12-27	WOS:000084049700045
J	Ready, T				Ready, T			Genome patenting concerns intensify	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1223	1223		10.1038/15164	http://dx.doi.org/10.1038/15164			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545971	Bronze			2022-12-27	WOS:000086550600013
J	Woolhouse, MEJ; Hagan, P				Woolhouse, MEJ; Hagan, P			Seeking the ghost of worms past	NATURE MEDICINE			English	Editorial Material							SCHISTOSOMA-HAEMATOBIUM; INFECTION; RESPONSES; IMMUNITY; CHEMOTHERAPY; EPIDEMIOLOGY; PATTERNS; MANSONI; IGG4; IGE		Univ Edinburgh, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland; Univ Glasgow, IBLS, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland	University of Edinburgh; University of Glasgow	Woolhouse, MEJ (corresponding author), Univ Edinburgh, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland.			Hagan, Paul/0000-0002-3516-2283				ANDERSON RM, 1985, NATURE, V315, P493, DOI 10.1038/315493a0; BUTTERWORTH AE, 1992, IMMUNOL INVEST, V21, P391, DOI 10.3109/08820139209069381; FISHER A. C., 1934, TRANS ROY SAC TROP MED AND HYG, V28, P277, DOI 10.1016/S0035-9203(34)90066-3; Grogan JL, 1996, J INFECT DIS, V173, P1242, DOI 10.1093/infdis/173.5.1242; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; Mutapi F, 1997, PARASITE IMMUNOL, V19, P255, DOI 10.1046/j.1365-3024.1997.d01-206.x; Mutapi F, 1998, PARASITE IMMUNOL, V20, P595, DOI 10.1046/j.1365-3024.1998.00192.x; Mutapi F, 1998, J INFECT DIS, V178, P289, DOI 10.1086/517456; vanDam GJ, 1996, J INFECT DIS, V173, P1232, DOI 10.1093/infdis/173.5.1232; WOOLHOUSE MEJ, 1991, NATURE, V351, P757, DOI 10.1038/351757a0; Woolhouse MEJ, 1998, PARASITOL TODAY, V14, P428, DOI 10.1016/S0169-4758(98)01318-0	12	95	95	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1225	1227		10.1038/15169	http://dx.doi.org/10.1038/15169			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545976				2022-12-27	WOS:000086550600018
J	Fabre, JE; Nguyen, MT; Latour, A; Keifer, JA; Audoly, LP; Coffman, TM; Koller, BH				Fabre, JE; Nguyen, MT; Latour, A; Keifer, JA; Audoly, LP; Coffman, TM; Koller, BH			Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y(1)-deficient mice	NATURE MEDICINE			English	Article							P2Y(1) RECEPTOR; MOLECULAR-BASIS; ACTIVATION; PURINOCEPTORS; DISTINCT; CLONING	Platelet activation is characterized by shape change, induction of fibrinogen receptor expression and release of granular contents, leading to aggregation and plug formation(1). While this response is essential for hemostasis(2), it is also important in the pathogenesis of a broad spectrum of diseases, including myocardial infarction, stroke and unstable angina. Adenosine 5'-diphosphate (ADP) induces platelet aggregation, but the mechanism for this has not been established, and the relative contribution of ADP in hemostasis and the development of arterial thrombosis' is poorly understood. We show here that the purinoceptor P2Y(1) is required for platelet shape change in response to ADP and is also a principal receptor mediating ADP-induced platelet aggregation. Activation of P2Y(1) resulted in increased intracellular calcium but no alteration in cyclic adenosine monophosphate (cAMP) levels. P2Y(1)-deficient platelets partially aggregated at higher ADP concentrations, and the lack of P2Y(1) did not alter the ability of ADP to inhibit cAMP, indicating that platelets express at least one additional ADP receptor. In vivo, the lack of P2Y(1) expression increased bleeding time and protected from collagen- and ADP-induced thromboembolism. These findings support the hypothesis that the ATP receptor P2Y(1) is a principal receptor mediating both physiologic: and pathological ADP-induced processes in platelets.	Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University	Koller, BH (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA.				NHLBI NIH HHS [HL 58554, HL 51791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058554] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*ANT TRIAL COLL, 1994, BMJ-BRIT MED J, V308, P159; BEARER EL, 1995, CELL MOTIL CYTOSKEL, V30, P50, DOI 10.1002/cm.970300107; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; DIMINNO G, 1983, J PHARMACOL EXP THER, V225, P57; Fagura MS, 1998, BRIT J PHARMACOL, V124, P157, DOI 10.1038/sj.bjp.0701827; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Geiger J, 1998, EUR J PHARMACOL, V351, P235, DOI 10.1016/S0014-2999(98)00305-7; Hechler B, 1998, BRIT J HAEMATOL, V103, P858, DOI 10.1046/j.1365-2141.1998.01056.x; Hechler B, 1998, BLOOD, V92, P152, DOI 10.1182/blood.V92.1.152.413k27_152_159; HEERMSKERK JWM, 1994, PLATELETS, V5, P295; Janssens R, 1996, BIOCHEM BIOPH RES CO, V221, P588, DOI 10.1006/bbrc.1996.0640; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Leon C, 1996, GENE, V171, P295, DOI 10.1016/0378-1119(96)00027-3; Leon C, 1997, FEBS LETT, V403, P26, DOI 10.1016/S0014-5793(97)00022-7; MACFARLANE DE, 1987, RESPONSES METABOLISM, P19; MacKenzie AB, 1996, J BIOL CHEM, V271, P2879, DOI 10.1074/jbc.271.6.2879; MAFFRAND JP, 1988, THROMB HAEMOSTASIS, V59, P225; MUNRO JM, 1988, LAB INVEST, V58, P249; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; PACKHAM MA, 1994, CAN J PHYSIOL PHARM, V72, P278, DOI 10.1139/y94-043; Savi P, 1998, FEBS LETT, V422, P291, DOI 10.1016/S0014-5793(98)00025-8; Schachter JB, 1997, BRIT J PHARMACOL, V122, P1021, DOI 10.1038/sj.bjp.0701479; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; Vial C, 1997, THROMB HAEMOSTASIS, V78, P1500	25	352	370	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1199	1202		10.1038/13522	http://dx.doi.org/10.1038/13522			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502826				2022-12-27	WOS:000082933200049
J	Nyberg-Hoffman, C; Aguilar-Cordova, E				Nyberg-Hoffman, C; Aguilar-Cordova, E			Instability of adenoviral vectors during transport and its implication for clinical studies	NATURE MEDICINE			English	Article									Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine	Aguilar-Cordova, E (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, MC 3-2374,1102 Bates,Suite 1170, Houston, TX 77030 USA.				NCRR NIH HHS [MO1RR00188] Funding Source: Medline; PHS HHS [P50-58204] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Budavari S., 1989, MERCK INDEX; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; MCQUARRIE DA, 1987, GEN CHEM, P360; NybergHoffman C, 1997, NAT MED, V3, P808, DOI 10.1038/nm0797-808; WADE LG, 1991, ORGANIC CHEM, P1139	5	60	65	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					955	957		10.1038/11400	http://dx.doi.org/10.1038/11400			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426323				2022-12-27	WOS:000081684000043
J	Springer, JE; Azbill, RD; Knapp, PE				Springer, JE; Azbill, RD; Knapp, PE			Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury	NATURE MEDICINE			English	Article							CYTOCHROME-C; DNA FRAGMENTATION; BRAIN INJURY; CONTUSION; PROTEOLYSIS; INHIBITOR; CLEAVAGE; PROTEIN; RATS	Traumatic spinal cord injury often results in complete loss of voluntary motor and sensory function below the site of injury. The long-term neurological deficits after spinal cord trauma may be due in part to widespread apoptosis of neurons and oligodendroglia in regions distant from and relatively unaffected by the initial injury(1-4). The caspase family of cysteine proteases regulates the execution of the mammalian apoptotic cell death program(5-7). Caspase-3 cleaves several essential downstream substrates involved in the expression of the apoptotic phenotype in vitro, including gelsolin, PAK2, fodrin, nuclear lamins and the inhibitory subunit of DNA fragmentation facto(8-12). Caspase-3 activation in vitro can be triggered by upstream events, leading to the release of cytochrome c from the mitochondria and the subsequent transactivation of procaspase-9 by Apaf-1 (refs. 13-15). We report here that these upstream and downstream components of the caspase-3 apoptotic pathway are activated after traumatic spinal cord injury in rats, and occur early in (sic) the injury site and hours to days later in oligodendroglia adjacent to and distant from the injury site. Given these findings, targeting the upstream events of the caspase-3 cascade has therapeutic potential in the treatment of acute traumatic injury to the spinal cord.	Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky	Springer, JE (corresponding author), Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, 800 Rose St, Lexington, KY 40536 USA.			Azbill, David/0000-0001-7989-1771	NINDS NIH HHS [NS-30248] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030248] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu N, 1996, J MOL NEUROSCI, V7, P1, DOI 10.1007/BF02736844; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu XZ, 1997, J NEUROSCI, V17, P5395; NAKAMURA S, 1998, J NEUROSCI, V18, P3659; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	25	357	384	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					943	946		10.1038/11387	http://dx.doi.org/10.1038/11387			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426320				2022-12-27	WOS:000081684000040
J	Aridor, M; Balch, WE				Aridor, M; Balch, WE			Integration of endoplasmic reticulum signaling in health and disease	NATURE MEDICINE			English	Review							GOLGI INTERMEDIATE COMPARTMENT; PELIZAEUS-MERZBACHER DISEASE; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; SECRETORY PATHWAY; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; RETROGRADE TRANSPORT; MOLECULAR-BIOLOGY; MEMBRANE-PROTEIN; CHOP GADD153		Dept Cell Biol, La Jolla, CA 92037 USA; Dept Mol Biol, La Jolla, CA 92037 USA		Aridor, M (corresponding author), Dept Cell Biol, 10550 N Torrey Pines Rd,IMMI, La Jolla, CA 92037 USA.	webalch@scripps.edu						Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Brooks DA, 1997, FEBS LETT, V409, P115, DOI 10.1016/S0014-5793(97)00423-7; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Culvenor JG, 1997, J NEUROSCI RES, V49, P719, DOI 10.1002/(SICI)1097-4547(19970915)49:6<719::AID-JNR6>3.0.CO;2-A; D'Urso D, 1998, J NEUROSCI, V18, P731; De Jonghe P, 1997, J Peripher Nerv Syst, V2, P370; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doedens JR, 1997, J VIROL, V71, P9054, DOI 10.1128/JVI.71.12.9054-9064.1997; Fiedler K, 1997, J BIOL CHEM, V272, P24739, DOI 10.1074/jbc.272.40.24739; Gardner R, 1998, MOL BIOL CELL, V9, P2611, DOI 10.1091/mbc.9.9.2611; Gow A, 1996, NAT GENET, V13, P422, DOI 10.1038/ng0896-422; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Haass Christian, 1999, Trends in Cell Biology, V9, P241, DOI 10.1016/S0962-8924(99)01576-7; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; HODES ME, 1993, DEV NEUROSCI-BASEL, V15, P383, DOI 10.1159/000111361; Hodes ME, 1996, AM J HUM GENET, V59, P12; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Kuhn LC, 1999, TRENDS BIOCHEM SCI, V24, P164, DOI 10.1016/S0968-0004(99)01386-9; Kukuruzinska MA, 1998, CRIT REV ORAL BIOL M, V9, P415, DOI 10.1177/10454411980090040301; Kuwana T, 1998, P NATL ACAD SCI USA, V95, P1056, DOI 10.1073/pnas.95.3.1056; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Lord JM, 1998, J CELL BIOL, V140, P733; MACINTYRE S, 1994, J BIOL CHEM, V269, P24496; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Mattson MP, 1998, J NEUROCHEM, V70, P1; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Qu DF, 1997, J GASTROEN HEPATOL, V12, P404, DOI 10.1111/j.1440-1746.1997.tb00451.x; Saito Y, 1999, J BIOCHEM-TOKYO, V125, P130, DOI 10.1093/oxfordjournals.jbchem.a022249; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SHEINESS GS, 1999, J NUTR, V129, pS456; SIFERS RN, 1992, SEMIN LIVER DIS, V12, P301, DOI 10.1055/s-2008-1040399; SIMPSON JC, 1995, J BIOL CHEM, V270, P20078, DOI 10.1074/jbc.270.34.20078; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; White AL, 1997, J BIOL CHEM, V272, P5048, DOI 10.1074/jbc.272.8.5048; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; ZHEN LD, 1993, ARCH BIOCHEM BIOPHYS, V304, P402, DOI 10.1006/abbi.1993.1368; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	79	233	252	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1999	5	7					745	751		10.1038/10466	http://dx.doi.org/10.1038/10466			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395318				2022-12-27	WOS:000081926600028
J	Diehl, L; den Boer, AT; Schoenberger, SP; van der Voort, EIH; Schumacher, TNM; Melief, CJM; Offringa, R; Toes, REM				Diehl, L; den Boer, AT; Schoenberger, SP; van der Voort, EIH; Schumacher, TNM; Melief, CJM; Offringa, R; Toes, REM			CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy	NATURE MEDICINE			English	Article							IMMUNE-RESPONSES; DENDRITIC CELLS; IN-VIVO; HELP; INDUCTION; MOUSE; IMMUNOPATHOLOGY; INFLAMMATION; ENHANCEMENT; OUTGROWTH	The outcome of antigen recognition by naive CD8(+) cytotoxic T lymphocytes (CTLs) in the periphery is orchestrated by CD4(+) T-helper cells, and can either lead to priming or tolerization. The presence of T-helper cells favors the induction of CTL immunity, whereas the absence of T-helper cells can result in CTL tolerance. The action of T helper cells in CTL priming is mediated by CD40-CD40 ligand interactions. We demonstrate here that triggering of CD40 in vivo can considerably enhance the efficacy of peptide-based anti-tumor vaccines. The combination of a tolerogenic peptide vaccine containing a minimal essential CTL epitope with an activating antibody against CD40 converts tolerization into strong CTL priming. Moreover, CD40 ligation can provide an already protective tumor-specific peptide vaccine with the capacity to induce therapeutic CTL immunity in tumor-bearing mice. These findings indicate that the CD40-CD40 ligand pair can act as a 'switch', determining whether naive peripheral CTLs are primed or tolerized, and support the clinical use of CD40-stimulating agents as components of anti-cancer vaccines.	Leiden Univ, Ctr Med, Dept Immunohaematol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Bloodbank, NL-2300 RA Leiden, Netherlands; La Jolla Inst Allergy & Immunol, Div Immune Regulat, San Diego, CA 92121 USA; Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; Univ Tubingen, Dept Immunol, D-72076 Tubingen, Germany	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; La Jolla Institute for Immunology; Netherlands Cancer Institute; Eberhard Karls University of Tubingen	Toes, REM (corresponding author), Leiden Univ, Ctr Med, Dept Immunohaematol, Albinusdreef 2,POB 9600, NL-2300 RA Leiden, Netherlands.		Schumacher, Ton/Y-2432-2019	Schumacher, Ton/0000-0003-0517-8804; Toes, Rene/0000-0002-9618-6414				AICHELE P, 1994, P NATL ACAD SCI USA, V91, P444, DOI 10.1073/pnas.91.2.444; Aichele P, 1997, IMMUNITY, V6, P519, DOI 10.1016/S1074-7613(00)80340-4; AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ANDERTON SM, 1993, EUR J IMMUNOL, V23, P33, DOI 10.1002/eji.1830230107; Bennett SRM, 1998, J EXP MED, V188, P1977, DOI 10.1084/jem.188.11.1977; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Ding L, 1996, J IMMUNOL, V157, P1389; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Ehl S, 1998, J EXP MED, V187, P763, DOI 10.1084/jem.187.5.763; Fayolle C, 1996, IMMUNOLOGY, V89, P41, DOI 10.1046/j.1365-2567.1996.d01-704.x; FELTKAMP MCW, 1995, EUR J IMMUNOL, V25, P2638, DOI 10.1002/eji.1830250935; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; Haanen JBAG, 1999, EUR J IMMUNOL, V29, P1168, DOI 10.1002/(SICI)1521-4141(199904)29:04<1168::AID-IMMU1168>3.0.CO;2-J; HOWELL CD, 1994, CLIN IMMUNOL IMMUNOP, V72, P76, DOI 10.1006/clin.1994.1109; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Kurts C, 1997, J EXP MED, V186, P2057, DOI 10.1084/jem.186.12.2057; Lin KY, 1996, CANCER RES, V56, P21; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; REES MA, 1990, P NATL ACAD SCI USA, V87, P2765, DOI 10.1073/pnas.87.7.2765; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Schoenberger SP, 1998, CANCER RES, V58, P3094; SHCOENBERGER SP, 1998, NATURE, V393, P480; Toes REM, 1998, J IMMUNOL, V160, P4449; Toes REM, 1996, J IMMUNOL, V156, P3911; Toes REM, 1996, P NATL ACAD SCI USA, V93, P7855, DOI 10.1073/pnas.93.15.7855; Yang YP, 1996, J VIROL, V70, P6370, DOI 10.1128/JVI.70.9.6370-6377.1996	32	386	428	2	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					774	779		10.1038/10495	http://dx.doi.org/10.1038/10495			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395322				2022-12-27	WOS:000081926600032
J	Cafaro, A; Caputo, A; Fracasso, C; Maggiorella, MT; Goletti, D; Baroncelli, S; Pace, M; Sernicola, L; Koanga-Mogtomo, ML; Betti, M; Borsetti, A; Belli, R; Akerblom, L; Corrias, F; Butto, S; Heeney, J; Verani, P; Titti, F; Ensoli, B				Cafaro, A; Caputo, A; Fracasso, C; Maggiorella, MT; Goletti, D; Baroncelli, S; Pace, M; Sernicola, L; Koanga-Mogtomo, ML; Betti, M; Borsetti, A; Belli, R; Akerblom, L; Corrias, F; Butto, S; Heeney, J; Verani, P; Titti, F; Ensoli, B			Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; TRANS-ACTIVATOR GENE; KAPOSIS-SARCOMA; ATTENUATED SIV; GROWTH-FACTOR; CELL-GROWTH; TNF-ALPHA; HTLV-III; NEF GENE	Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show that vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein is safe, elicits a broad (humoral and cellular) specific immune response and reduces infection with the highly pathogenic simian-human immunodeficiency virus (SHIV)-89.6P to undetectable levels, preventing the CD4(+) T-cell decrease. These results may provide new opportunities for the development of a vaccine against AIDS.	Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Univ Ferrara, Dept Exp & Diagnost Med, I-44100 Ferrara, Italy; Natl Vet Inst, Dept Virol, Biomed Ctr, S-75183 Uppsala, Sweden; Biomed Primate Res Ctr, Dept Virol, NL-2288 GJ Rijswijk ZH, Netherlands	Istituto Superiore di Sanita (ISS); University of Ferrara; National Veterinary Institute SVA	Ensoli, B (corresponding author), Ist Super Sanita, Virol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Buttò, Stefano/J-9324-2018; Cafaro, Aurelio/K-5314-2016; borsetti, alessandra/K-4103-2016; goletti, delia/AAM-6577-2020; maggiorella, maria teresa/K-4072-2016; Caputo, Antonella/ABE-7851-2020; Ensoli, Barbara/J-9169-2016	borsetti, alessandra/0000-0002-5401-135X; maggiorella, maria teresa/0000-0001-5058-476X; Caputo, Antonella/0000-0002-1241-0299; Ensoli, Barbara/0000-0002-0545-8737; Goletti, Delia/0000-0001-8360-4376; Heeney, Jonathan/0000-0003-2702-1621; Cafaro, Aurelio/0000-0001-9675-6344; Butto, Stefano/0000-0002-3289-2686				ALMOND NM, 1998, AIDS, V12, P133; Ando K, 1997, J IMMUNOL, V158, P5283; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BUONAGURO L, 1995, J VIROL, V69, P7971, DOI 10.1128/JVI.69.12.7971-7981.1995; Burton DR, 1998, NAT MED, V4, P495, DOI 10.1038/nm0598supp-495; Calarota S, 1998, LANCET, V351, P1320, DOI 10.1016/S0140-6736(97)09440-3; CASELLI E, IN PRESS J IMMUNOL; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; CHEN ZW, 1992, J IMMUNOL, V149, P4060; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Davis D, 1997, VACCINE, V15, P1661, DOI 10.1016/S0264-410X(97)00084-4; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; EZZELL C, 1997, J NIH RES, V9, P21; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FIORE JR, 1991, AIDS, V5, P1034, DOI 10.1097/00002030-199108000-00021; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FROEBEL KS, 1994, AIDS RES HUM RETROV, V2, P83; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; Gringeri A, 1998, J Hum Virol, V1, P293; Huang L, 1998, J VIROL, V72, P8952, DOI 10.1128/JVI.72.11.8952-8960.1998; *HUM RETR AIDS, 1995, COMP AN NUCL AIDS AM; JASSOY C, 1993, J VIROL, V67, P2844, DOI 10.1128/JVI.67.5.2844-2852.1993; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kim DT, 1997, J IMMUNOL, V159, P1666; LAMHAMEDICHERRADI S, 1992, AIDS, V6, P1249, DOI 10.1097/00002030-199211000-00002; Li CJ, 1997, P NATL ACAD SCI USA, V94, P8116, DOI 10.1073/pnas.94.15.8116; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LOVGREN J, 1994, J IMMUNOL METHODS, V173, P119, DOI 10.1016/0022-1759(94)90289-5; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RATNER A, 1993, J IMMUNOL, V150, P4303; RE C, 1995, J ACQ IMMUN DEF SYND, V10, P408; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; REISS P, 1990, J MED VIROL, V30, P163, DOI 10.1002/jmv.1890300303; RINALDO CR, 1995, AIDS RES HUM RETROV, V11, P481, DOI 10.1089/aid.1995.11.481; RODMAN TC, 1993, P NATL ACAD SCI USA, V90, P7719, DOI 10.1073/pnas.90.16.7719; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sodora DL, 1998, AIDS RES HUM RETROV, V14, P171, DOI 10.1089/aid.1998.14.171; Stott EJ, 1998, J GEN VIROL, V79, P423; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; Titti F, 1997, J GEN VIROL, V78, P2529, DOI 10.1099/0022-1317-78-10-2529; vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913; VENET A, 1992, J IMMUNOL, V148, P2899; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WHATMORE AM, 1995, J VIROL, V69, P5117, DOI 10.1128/JVI.69.8.5117-5123.1995; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3851, DOI 10.1073/pnas.95.7.3851; Zagury J F, 1998, J Hum Virol, V1, P282; ZAGURY JF, 1996, CELL PHARM, V3, P123; Zauli G, 1996, J IMMUNOL, V157, P2216	58	265	284	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					643	650		10.1038/9488	http://dx.doi.org/10.1038/9488			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371502	Bronze			2022-12-27	WOS:000080823300032
J	Ochiya, T; Takahama, Y; Nagahara, S; Sumita, Y; Hisada, A; Itoh, H; Nagai, Y; Terada, M				Ochiya, T; Takahama, Y; Nagahara, S; Sumita, Y; Hisada, A; Itoh, H; Nagai, Y; Terada, M			New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet	NATURE MEDICINE			English	Article							DIRECT GENE-TRANSFER; SKELETAL-MUSCLE INVIVO; INTRAMUSCULAR INJECTION; MOUSE MUSCLE; EXPRESSION; MICE; VACCINATION; ADENOVIRUS; COLLAGEN; VECTOR		Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; Sumitomo Pharmaceut Co Ltd, Res Ctr, Mfg Technol Res Labs, Ibaraki, Osaka 567, Japan; Sumitomo Pharmaceut Co Ltd, Res Ctr, Discovery Res Labs 3, Ibaraki, Osaka 567, Japan; Koken Biosci Inst, Shinjuku Ku, Tokyo 169, Japan	National Cancer Center - Japan	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 104, Japan.		Ochiya, Takahiro/AAH-7585-2019					Anwer K, 1998, HUM GENE THER, V9, P659, DOI 10.1089/hum.1998.9.5-659; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; FUJIOKA K, 1995, J CONTROL RELEASE, V33, P307, DOI 10.1016/0168-3659(94)00107-6; Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; Jong YS, 1997, J CONTROL RELEASE, V47, P123, DOI 10.1016/S0168-3659(97)01637-4; Jorgensen L G, 1991, Eur J Vasc Surg, V5, P87, DOI 10.1016/S0950-821X(05)80933-8; KAMER FM, 1984, ARCH OTOLARYNGOL, V110, P93; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; Kumar V, 1996, NAT MED, V2, P857, DOI 10.1038/nm0896-857; Levy MY, 1996, GENE THER, V3, P201; MA JX, 1995, J BIOL CHEM, V270, P451, DOI 10.1074/jbc.270.1.451; MANTHORPE M, 1993, HUM GENE THER, V4, P419, DOI 10.1089/hum.1993.4.4-419; Monahan PE, 1998, GENE THER, V5, P40, DOI 10.1038/sj.gt.3300548; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; RUBIN AL, 1973, J CLIN PHARMACOL, V13, P309, DOI 10.1002/j.1552-4604.1973.tb00217.x; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Sambrook J., 2002, MOL CLONING LAB MANU; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; THOMASON DB, 1990, AM J PHYSIOL, V258, pC578, DOI 10.1152/ajpcell.1990.258.3.C578; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Truong-Le VL, 1998, HUM GENE THER, V9, P1709, DOI 10.1089/hum.1998.9.12-1709; Vitiello L, 1996, GENE THER, V3, P396; Waisman A, 1996, NAT MED, V2, P899, DOI 10.1038/nm0896-899; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363	30	198	216	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					707	710		10.1038/9560	http://dx.doi.org/10.1038/9560			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371512				2022-12-27	WOS:000080823300042
J	Schneider, A; Martin-Villalba, A; Weih, F; Vogel, J; Wirth, T; Schwaninger, M				Schneider, A; Martin-Villalba, A; Weih, F; Vogel, J; Wirth, T; Schwaninger, M			NF-kappa B is activated and promotes cell death in focal cerebral ischemia	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR; ARTERY OCCLUSION; SODIUM-SALICYLATE; INDUCED APOPTOSIS; OXIDATIVE STRESS; GLOBAL-ISCHEMIA; PRIMARY NEURONS; RAT; NEUROPROTECTION; PROTEIN	The transcription factor NF-kappa B is a regulator of cell death or survival. To investigate the role of NF-kappa B in neuronal cell death, we studied its activation in a rodent model of stroke. In the ischemic hemisphere, NF-kappa B was activated, as determined by increased expression of an NF-kappa B-driven reporter transgene, nuclear translocation of NF-kappa B in neurons and enhanced DNA binding of NF-kappa B subunits RelA and p50. In p50 knockout mice, ischemic damage was significantly reduced. This indicates a cell death-promoting role of NF-kappa B in focal ischemia. NF-kappa B may provide a new pharmacological target in neurologic disease.	Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; BASF LYNX Biosci AG, Dept Neurosci, D-69120 Heidelberg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Dept Physiol, D-69120 Heidelberg, Germany; Inst Radiobiol & Cell Res, D-97078 Wurzburg, Germany	Ruprecht Karls University Heidelberg; BASF; Helmholtz Association; Karlsruhe Institute of Technology	Schwaninger, M (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.		Wirth, Thomas/X-7172-2019	Martin-Villalba, Ana/0000-0002-9405-8910				Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARONE FC, 1993, J CEREBR BLOOD F MET, V13, P683, DOI 10.1038/jcbfm.1993.87; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Clark WM, 1997, NEUROL RES, V19, P641; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KALTSCHMIDT C, 1995, BIOL CHEM H-S, V376, P9; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; LI Y, 1995, AM J PATHOL, V146, P1045; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; MARTINVILLALBA A, IN PRESS J NEUROSCI; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Namura S, 1998, J NEUROSCI, V18, P3659; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Perovic S, 1996, EUR J PHARMACOL, V317, P157, DOI 10.1016/S0014-2999(96)00712-1; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; Rong YQ, 1996, J NEUROCHEM, V67, P662; Sandercock P, 1997, LANCET, V349, P1569; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; SCHNEIDER A, 1995, P NATL ACAD SCI USA, V92, P4447, DOI 10.1073/pnas.92.10.4447; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; VOGEL J, IN PRESS STROKE; WEIH F, 1994, ONCOGENE, V9, P3289; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	46	569	619	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					554	559		10.1038/8432	http://dx.doi.org/10.1038/8432			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229233				2022-12-27	WOS:000081497400037
J	Summerford, C; Samulski, RJ				Summerford, C; Samulski, RJ			Viral receptors and vector purification: New approaches for generating clinical-grade reagents	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS		Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Samulski, RJ (corresponding author), Univ N Carolina, Gene Therapy Ctr, 7119 Thurston Bowles,CB 7352, Chapel Hill, NC 27599 USA.							CLARK KR, 1995, HUM GENE THER, V6, P1329, DOI 10.1089/hum.1995.6.10-1329; CLARK KR, IN PRESS HUM GENE TH; Friedmann T., 1999, DEV HUMAN GENE THERA, P1; Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Wistuba A, 1997, J VIROL, V71, P1341, DOI 10.1128/JVI.71.2.1341-1352.1997; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; ZOLOTUKHIN S, IN PRESS GENE THER; 1998, WILL BIOPR FDN M VIR	11	47	55	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					587	588		10.1038/8470	http://dx.doi.org/10.1038/8470			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229239				2022-12-27	WOS:000081497400043
J	Levi, M; Friederich, PW; Middleton, S; de Groot, PG; Wu, YP; Harris, R; Biemond, BJ; Heijnen, HFG; Levin, J; ten Cate, JW				Levi, M; Friederich, PW; Middleton, S; de Groot, PG; Wu, YP; Harris, R; Biemond, BJ; Heijnen, HFG; Levin, J; ten Cate, JW			Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits	NATURE MEDICINE			English	Article							VESSEL WALL; INHIBITION; PLASMA; CELLS; TIME	Severe thrombocytopenia frequently occurs in patients receiving chemotherapy and in patients with autoimmune disorders. Thrombocytopenia is associated with bleeding, which may be serious and life threatening(1-3). Current treatment strategies for thrombocytopenia may require transfusion of allogeneic platelets, which is associated with serious drawbacks'. These include the occurrence of anti-platelet antibodies, which may result in refractoriness to further platelet transfusions, and the potential risk of transfer of blood-borne diseases(5,6). Therefore, we have recently developed a platelet substitute product (Synthocytes), which is composed of human albumin microcapsules with fibrinogen immobilized on their surface. Here we show that the intravenous administration of these microcapsules not only corrects the prolonged bleeding time in rabbits rendered thrombocytopenic either by anti-platelet antibodies or by chemotherapy, but also reduces bleeding from surgical wounds inflicted in the abdominal skin and musculature. No potential systemic prothrombotic effect of the microcapsules was observed in a model of rabbit venous thrombosis. As for the mechanism of action, experiments with normal and thrombocytopenic human blood in an endothelial cell matrix-coated perfusion chamber demonstrated an interaction between the fibrinogen-coated albumin microcapsules and native platelets. It was shown that the fibrinogen-coated albumin microcapsules could facilitate platelet adhesion to endothelial cell matrix and correct the impaired formation of platelet aggregates in relatively platelet-poor blood. This study indicates that fibrinogen-coated albumin microcapsules can act to improve primary hemostasis under thrombocytopenic conditions and may eventually be a promising agent for prophylaxis and treatment of bleeding in patients with severe thrombocytopenia.	Univ Amsterdam, Acad Med Ctr, Ctr Hemostasis Thrombosis Atherosclerosis & Infla, NL-1105 AZ Amsterdam, Netherlands; Andaris, Nottingham NG11 6JS, England; Univ Utrecht, Dept Hematol, NL-3508 GA Utrecht, Netherlands; Univ Calif San Francisco, Sch Med, Dept Lab Med, San Francisco, CA 94121 USA; VA Med Ctr, San Francisco, CA 94121 USA	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; University of California System; University of California San Francisco	Levi, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Hemostasis Thrombosis Atherosclerosis & Infla, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.m.levi@amc.uva.nl	Levi, Marcel/AAZ-8559-2020					BENEDICT CR, 1995, CIRCULATION, V92, P3032, DOI 10.1161/01.CIR.92.10.3032; BLAJCHMAN MA, 1979, J CLIN INVEST, V63, P1026, DOI 10.1172/JCI109371; BLAJCHMAN MA, 1997, TRANSFUS MED REV, V11, P99; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; EVATT BL, 1979, BLOOD, V54, P377; KUTER DJ, 1995, BLOOD, V85, P2710; LEVI M, 1992, CIRCULATION, V85, P305, DOI 10.1161/01.CIR.85.1.305; McFarland J, 1997, NEW ENGL J MED, V337, P1861; *NIH CONS C, 1987, TRANSFUS MED REV, V1, P195; Rebulla P, 1997, NEW ENGL J MED, V337, P1870, DOI 10.1056/NEJM199712253372602; RODGERS RPC, 1990, SEMIN THROMB HEMOST, V16, P1, DOI 10.1055/s-2007-1002658; ROY AJ, 1973, TRANSFUSION, V13, P283, DOI 10.1111/j.1537-2995.1973.tb05490.x; SAELMAN EUM, 1993, ARTERIOSCLER THROMB, V13, P1164, DOI 10.1161/01.ATV.13.8.1164; SAKARIASSEN KS, 1983, J LAB CLIN MED, V102, P522; SLICHTER SJ, 1995, HEMATOLOGY BASIC PRI, P419; VANBREUGEL HHFI, 1992, BLOOD, V80, P953; YEN RCK, 1995, TRANSFUSION, V35, P415; ZWAGINGA JJ, 1990, ARTERIOSCLEROSIS, V10, P437, DOI 10.1161/01.ATV.10.3.437	18	100	107	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					107	111		10.1038/4795	http://dx.doi.org/10.1038/4795			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883848				2022-12-27	WOS:000077885000038
J	Summerford, C; Bartlett, JS; Samulski, RJ				Summerford, C; Bartlett, JS; Samulski, RJ			alpha V beta 5 integrin: a co-receptor for adeno-associated virus type 2 infection	NATURE MEDICINE			English	Article							GENE-THERAPY; ENTRY; CELLS; ADENOVIRUS-2	Understanding the primary steps of viral entry can have important implications for strategies to prevent infection of known viral pathogens as well as determining parameters for efficient gene delivery using viral vectors. Recently, a two-step process for viral infection involving attachment of virus to a primary receptor (coxsackievirus adenovirus receptor and heparan sulfate proteoglycan) and subsequent mediation of virus entry by a coreceptor (alpha V integrins and HVEM) has been determined for both adenovirus and HSV, respectively(1-4). Heparan sulfate proteoglycan serves as a primary attachment receptor for adenoassociated virus type 2 (AAV-2)(ref. 5). Here we determined that alpha V beta 5 integrin plays a part in efficient AAV infection. Experiments using the chelating agent EDTA to disrupt integrin function resulted in a corresponding decrease in AAV infection, consistent with the possibility that integrin mediates infection. Viral overlay experiments on purified plasma membrane proteins as well as immunoprecipitated integrin beta 5 subunit demonstrated that AAV directly associates with the beta 5 subunit of alpha V beta 5 integrin. Genetically defined cells expressing alpha V beta 5 integrin showed increased susceptibility to AAV infection, demonstrating a biological role of this integrin in AAV infection. Finally, viral binding and internalization studies indicate that alpha V beta 5 integrin is: not a primary attachment receptor for AAV-2, bur is instead involved in facilitating virus internalization. This study supports the idea that alpha V beta 5 integrin serves as a co;receptor for AAV-2 virions, and should have a substantial effect on the use of AAV vectors in human gene therapy.	Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis & Pulm Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Samulski, RJ (corresponding author), Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [NHLBI 539490] Funding Source: Medline; PHS HHS [533016] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARTH A, 1981, DIPEPTIDYL PEPTIDASE, V2, P2; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Croyle MA, 1998, HUM GENE THER, V9, P561, DOI 10.1089/hum.1998.9.4-561; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; FERRARI FK, 1996, J VIROL, V7, P3277; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Gavrilovskaya IN, 1998, P NATL ACAD SCI USA, V95, P7074, DOI 10.1073/pnas.95.12.7074; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Goldman M, 1996, GENE THER, V3, P811; GOLDMAN MJ, 1995, J VIROL, V69, P5951, DOI 10.1128/JVI.69.10.5951-5958.1995; Hashimoto Y, 1997, BIOCHEM BIOPH RES CO, V240, P88, DOI 10.1006/bbrc.1997.7534; HENNACHE B, 1977, BIOCHEM J, V166, P237, DOI 10.1042/bj1660237; HUANG SA, 1995, J VIROL, V69, P2257, DOI 10.1128/JVI.69.4.2257-2263.1995; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; PASQUALINI R, 1993, J CELL SCI, V105, P101; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; SHEIH M, 1992, J CELL BIOL, V116, P1273; Snyder R, 1996, CURRENT PROTOCOLS HU; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; SVENSSON U, 1984, J VIROL, V51, P687, DOI 10.1128/JVI.51.3.687-694.1984; Takayama K, 1998, GENE THER, V5, P361, DOI 10.1038/sj.gt.3300608; Teramoto S, 1998, J VIROL, V72, P8904, DOI 10.1128/JVI.72.11.8904-8912.1998; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WICHAM TJ, 1993, CELL, V73, P309; WICHAM TJ, 1994, J CELL BIOL, V127, P257; WIDNELL CC, 1968, P NATL ACAD SCI USA, V61, P1050, DOI 10.1073/pnas.61.3.1050; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998	29	521	564	2	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					78	82		10.1038/4768	http://dx.doi.org/10.1038/4768			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883843				2022-12-27	WOS:000077885000033
J	Gupta, P; Collins, K; Patterson, B; Naus, G; Landers, D				Gupta, P; Collins, K; Patterson, B; Naus, G; Landers, D			In vitro models of mucosal HIV transmission - Reply	NATURE MEDICINE			English	Letter									Univ Pittsburgh, Magee Womens Hosp, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15261 USA; Northwestern Univ, Childrens Mem Hosp, Sch Med, Dept Pediat,Div Special Infect Dis, Chicago, IL 60614 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	Gupta, P (corresponding author), Univ Pittsburgh, Magee Womens Hosp, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.							Collins KB, 2000, NAT MED, V6, P475, DOI 10.1038/74743; FRIEDRICH E R, 1973, P79; GORODESKI GI, 1994, DIFFERENTIATION, V56, P107, DOI 10.1046/j.1432-0436.1994.56120107.x; Greenhead P, 2000, J VIROL, V74, P5577, DOI 10.1128/JVI.74.12.5577-5586.2000; KING BF, 1983, J ULTRA MOL STRUCT R, V83, P99, DOI 10.1016/S0022-5320(83)90068-0; Warner RR, 1999, J INVEST DERMATOL, V113, P960, DOI 10.1046/j.1523-1747.1999.00774.x	6	4	6	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					607	608		10.1038/76141	http://dx.doi.org/10.1038/76141			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835651				2022-12-27	WOS:000087438300004
J	Stevenson, M				Stevenson, M			HIV nuclear import: What's the flap	NATURE MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; NONDIVIDING CELLS; MATRIX PROTEIN; VPR PROTEIN; MACROPHAGE INFECTION; LOCALIZATION; COMPLEX; PATHWAY; MITOSIS		Univ Massachusetts, Med Ctr, Dept Mol Genet, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Microbiol, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Stevenson, M (corresponding author), Univ Massachusetts, Med Ctr, Dept Mol Genet, 373 Plantat St, Worcester, MA 01605 USA.							BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Dupont S, 1999, NATURE, V402, P681, DOI 10.1038/45272; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	16	29	31	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					626	628		10.1038/76191	http://dx.doi.org/10.1038/76191			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835671				2022-12-27	WOS:000087438300021
J	Triendl, R				Triendl, R			Japanese research center changers career structure	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					488	488		10.1038/74937	http://dx.doi.org/10.1038/74937			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802684				2022-12-27	WOS:000086796200011
J	Schratzberger, P; Schratzberger, G; Silver, M; Curry, C; Kearney, M; Magner, M; Alroy, J; Adelman, LS; Weinberg, DH; Ropper, AH; Isner, JM				Schratzberger, P; Schratzberger, G; Silver, M; Curry, C; Kearney, M; Magner, M; Alroy, J; Adelman, LS; Weinberg, DH; Ropper, AH; Isner, JM			Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CORONARY COLLATERAL DEVELOPMENT; THERAPEUTIC ANGIOGENESIS; HINDLIMB ISCHEMIA; VESSEL DEVELOPMENT; ARTERY OCCLUSION; CELL MIGRATION; RABBIT MODEL; TUMOR-CELLS; RAT MODEL	Ischemic peripheral neuropathy is a frequent, irreversible complication of lower extremity vascular insufficiency. We investigated whether ischemic peripheral neuropathy could be prevented and/or reversed by gene transfer of an endothelial cell mitogen designed to promote therapeutic angiogenesis. Intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor (VEGF) simultaneously with induction of hindlimb ischemia in rabbits abrogated the substantial decrease in motor and sensory nerve parameters, and nerve function recovered promptly. When gene transfer was administered 10 days after induction of ischemia, nerve function was restored earlier and/or recovered faster than in untreated rabbits. These findings are due in part to enhanced hindlimb perfusion. In addition, however, the demonstration of functional VEGF receptor expression by Schwann cells indicates a direct effect of VEGF on neural integrity as well. These findings thus constitute a new paradigm for the treatment of ischemic peripheral neuropathy.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Vasc Med, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Neurol, Boston, MA 02135 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Neuropathol, Boston, MA 02111 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; Tufts University; Tufts University	Isner, JM (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, 736 Cambridge St, Boston, MA 02135 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057516, R01HL060911, R01HL053354, R37HL053354] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57516, HL60911, HL53354] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BAUTERS C, 1995, CIRCULATION, V91, P2802, DOI 10.1161/01.CIR.91.11.2802; BAUTERS C, 1995, J VASC SURG, V21, P314, DOI 10.1016/S0741-5214(95)70272-5; BAUTERS C, 1994, AM J PHYSIOL-HEART C, V267, pH1263, DOI 10.1152/ajpheart.1994.267.4.H1263; Bentley FH, 1943, J PHYSIOL-LONDON, V102, P62, DOI 10.1113/jphysiol.1943.sp004015; BLUNT MJ, 1960, ARCH NEUROL-CHICAGO, V2, P528, DOI 10.1001/archneur.1960.03840110042005; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CARROLL SM, 1993, CIRCULATION, V88, P198, DOI 10.1161/01.CIR.88.1.198; CHERVU A, 1989, J SURG RES, V47, P12, DOI 10.1016/0022-4804(89)90041-3; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Couffinhal T, 1999, CIRCULATION, V99, P3188, DOI 10.1161/01.CIR.99.24.3188; EAMES RA, 1967, J NEUROL NEUROSUR PS, V30, P215, DOI 10.1136/jnnp.30.3.215; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Hobson MI, 1997, BRIT J PLAST SURG, V50, P125, DOI 10.1016/S0007-1226(97)91325-4; HUNTER GC, 1988, J SURG RES, V45, P96, DOI 10.1016/0022-4804(88)90027-3; Isner JM, 1996, HUM GENE THER, V7, P959, DOI 10.1089/hum.1996.7.8-959; Kearney M, 1997, CIRCULATION, V95, P1998, DOI 10.1161/01.CIR.95.8.1998; MCCARTHY JB, 1983, J CELL BIOL, V97, P772, DOI 10.1083/jcb.97.3.772; MELLICK RS, 1968, BRAIN, V91, P141, DOI 10.1093/brain/91.1.141; Miglietta O, 1967, Arch Phys Med Rehabil, V48, P89; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Osborne W A, 1900, J Physiol, V25, P283; Patel MK, 1997, ARTERIOSCL THROM VAS, V17, P2107, DOI 10.1161/01.ATV.17.10.2107; Pu L Q, 1994, J Invest Surg, V7, P49, DOI 10.3109/08941939409018282; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; Takeshita S, 1997, CIRCULATION, V95, P805; TAKESHITA S, 1994, CIRCULATION, V90, P228; Takeshita S, 1996, BIOCHEM BIOPH RES CO, V227, P628, DOI 10.1006/bbrc.1996.1556; Takeshita S, 1998, CIRCULATION, V98, P1261, DOI 10.1161/01.CIR.98.13.1261; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; VanBelle E, 1997, CIRCULATION, V96, P2667, DOI 10.1161/01.CIR.96.8.2667; WHITE FC, 1992, CIRC RES, V71, P1490, DOI 10.1161/01.RES.71.6.1490; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	44	198	215	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					405	413		10.1038/74664	http://dx.doi.org/10.1038/74664			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742147				2022-12-27	WOS:000165474100034
J	Teicher, MH; Anderson, CM; Polcari, A; Glod, CA; Maas, LC; Renshaw, PF				Teicher, MH; Anderson, CM; Polcari, A; Glod, CA; Maas, LC; Renshaw, PF			Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry	NATURE MEDICINE			English	Article							HYPERACTIVITY DISORDER; METHYLPHENIDATE; PREVALENCE; METABOLISM	Attention-deficit/hyperactivity disorder is a highly heritable and prevalent neuropsychiatric disorder estimated to affect 6% of school-age children(1-3). Its clinical hallmarks are inattention, hyperactivity and impulsivity(4,5), which often respond substantially to treatment with methylphenidate or dextroamphetamine. Etiological theories suggest a deficit in corticostriatal circuits, particularly those components modulated by dopamine. We developed a new functional magnetic resonance imaging procedure (T2 relaxometry) to indirectly assess blood volume in the striatum (caudate and putamen) of boys 6-12 years of age in steady-state conditions. Boys with attention-deficit/hyperactivity disorder had higher T2 relaxation time measures in the putamen bilaterally than healthy control subjects. Relaxation times strongly correlated with the child's capacity to sit still and his accuracy in accomplishing a computerized attention task. Daily treatment with methylphenidate significantly changed the T2 relaxation times in the putamen of children with attention-deficit/hyperactivity disorder, although the magnitude and direction of the effect was strongly dependent on the child's unmedicated activity state. There was a similar but nonsignificant trend in the right caudate. T2 relaxation time measures in thalamus did not differ significantly between groups, and were not affected by methylphenidate. Attention-deficit/hyperactivity disorder symptoms may be closely tied to functional abnormalities in the putamen, which is mainly involved in the regulation of motor behavior.	Harvard Univ, Sch Med, Consolidated Dept Psychiat, Boston, MA 02114 USA; McLean Hosp, Dev Biopsychiat Res Program, Belmont, MA 02178 USA; McLean Hosp, Brain Imaging Ctr, Belmont, MA 02178 USA; Northeastern Univ, Sch Nursing, Boston, MA 02115 USA; MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Harvard University; McLean Hospital; Harvard University; McLean Hospital; Northeastern University; Harvard University; Massachusetts Institute of Technology (MIT)	Teicher, MH (corresponding author), Harvard Univ, Sch Med, Consolidated Dept Psychiat, Boston, MA 02114 USA.		Renshaw, Perry/O-1384-2018; Teicher, Martin H/P-3906-2017	Teicher, Martin H/0000-0002-6036-0177	NIDA NIH HHS [DA09448] Funding Source: Medline; NIMH NIH HHS [MH48343, MH53636] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009448] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDERSON PF, 1987, LIBR SOFTWARE REV, V6, P44; BARKLEY RA, 1990, J DEV BEHAV PEDIATR, V11, P343; BIRD HR, 1988, ARCH GEN PSYCHIAT, V45, P1120; ERNST M, 1994, J AM ACAD CHILD PSY, V33, P858, DOI 10.1097/00004583-199407000-00012; Ernst M, 1998, J NEUROSCI, V18, P5901; GOLDBERG MA, 1993, AM J ROENTGENOL, V160, P1011, DOI 10.2214/ajr.160.5.8470568; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; GREENBERG LM, 1987, PSYCHOPHARMACOL BULL, V23, P279; Kety S. S., 1960, METHOD MED RES, V8, P228; LOU HC, 1984, ARCH NEUROL-CHICAGO, V41, P825, DOI 10.1001/archneur.1984.04050190031010; LOU HC, 1989, ARCH NEUROL-CHICAGO, V46, P48, DOI 10.1001/archneur.1989.00520370050018; Maas LC, 1997, MAGNET RESON MED, V37, P131, DOI 10.1002/mrm.1910370119; Ogawa S, 1998, ANNU REV BIOPH BIOM, V27, P447, DOI 10.1146/annurev.biophys.27.1.447; Orvaschel H, 1987, SCHEDULE AFFECTIVE D; Pauling L, 1936, P NATL ACAD SCI USA, V22, P210, DOI 10.1073/pnas.22.4.210; PAULUS MP, 1992, NEUROPSYCHOPHARMACOL, V7, P15; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P219, DOI 10.1111/j.1469-7610.1989.tb00236.x; Teicher MH, 1996, J AM ACAD CHILD PSY, V35, P334, DOI 10.1097/00004583-199603000-00015; TRYON WW, 1993, BEHAV MODIF, V17, P371, DOI 10.1177/01454455930174001; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; van Zijl PCM, 1998, NAT MED, V4, P159, DOI 10.1038/nm0298-159; Volkow ND, 1997, AM J PSYCHIAT, V154, P50	22	239	250	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					470	473		10.1038/74737	http://dx.doi.org/10.1038/74737			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742158				2022-12-27	WOS:000165474100045
J	Paton, AW; Morona, R; Paton, JC				Paton, AW; Morona, R; Paton, JC			A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans	NATURE MEDICINE			English	Article							HEMOLYTIC-UREMIC SYNDROME; TOXIN TYPE-II; BACTERIAL LIPOPOLYSACCHARIDES; NEISSERIA-MENINGITIDIS; MOLECULAR MIMICRY; COLI STRAINS; MOUSE MODEL; LIPOOLIGOSACCHARIDE; DISEASE; CLONING	Gastrointestinal disease caused by Shiga toxin-producing bacteria (such as Escherichia coli O157:H7 and Shigella dysenteriae) is often complicated by life-threatening toxin-induced systemic sequelae, including hemolytic-uremic syndrome. Such infections can now be diagnosed very early in the course of the disease, but at present no effective therapeutic intervention is possible. Here, we constructed a recombinant bacterium that displayed a Shiga toxin receptor mimic on its surface, and it adsorbed and neutralized Shiga toxins with very high efficiency. Moreover, oral administration of the recombinant bacterium completely protected mice from challenge with an otherwise 100%-fatal dose of Shiga toxigenic E. coli. Thus, the bacterium shows great promise as a 'probiotic' treatment for Shiga toxigenic E. coli infections and dysentery.	Womens & Childrens Hosp, Mol Microbiol Unit, Adelaide, SA 5006, Australia; Univ Adelaide, Dept Microbiol & Immunol, Adelaide, SA 5005, Australia	Womens & Childrens Hospital Australia; University of Adelaide	Paton, JC (corresponding author), Womens & Childrens Hosp, Mol Microbiol Unit, Adelaide, SA 5006, Australia.	patonj@wch.sn.gov.au	Morona, Renato/B-7746-2013; Paton, James C/A-9920-2008	Morona, Renato/0000-0001-7009-7440; 				ARMSTRONG GD, 1991, J INFECT DIS, V164, P1160, DOI 10.1093/infdis/164.6.1160; ARMSTRONG GD, 1995, J INFECT DIS, V171, P1042, DOI 10.1093/infdis/171.4.1042; CLEMENTS JD, 1988, VACCINE, V6, P269, DOI 10.1016/0264-410X(88)90223-X; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; ITO H, 1990, MICROB PATHOGENESIS, V8, P47, DOI 10.1016/0882-4010(90)90007-D; Jennings MP, 1995, MOL MICROBIOL, V18, P729, DOI 10.1111/j.1365-2958.1995.mmi_18040729.x; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; KLAUSER T, 1990, EMBO J, V9, P1991, DOI 10.1002/j.1460-2075.1990.tb08327.x; Liljeqvist S, 1999, J BIOTECHNOL, V73, P1, DOI 10.1016/S0168-1656(99)00107-8; LINDGREN SW, 1993, INFECT IMMUN, V61, P3832, DOI 10.1128/IAI.61.9.3832-3842.1993; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; MANDRELL RE, 1993, IMMUNOBIOLOGY, V187, P382, DOI 10.1016/S0171-2985(11)80352-9; Maniatis T, 1982, MOL CLONING LABORATO, P68; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; MORONA R, 1991, FEMS MICROBIOL LETT, V82, P279, DOI 10.1016/0378-1097(91)90274-E; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; OBRIEN AD, 1984, SCIENCE, V226, P694, DOI 10.1126/science.6387911; OBRIEN AD, 1987, MICROBIOL REV, V51, P206, DOI 10.1128/MMBR.51.2.206-220.1987; Paton AW, 1999, J CLIN MICROBIOL, V37, P3357, DOI 10.1128/JCM.37.10.3357-3361.1999; Paton AW, 1996, J CLIN MICROBIOL, V34, P1622, DOI 10.1128/JCM.34.7.1622-1627.1996; PATON AW, 1993, MICROB PATHOGENESIS, V15, P77, DOI 10.1006/mpat.1993.1058; PATON AW, 1995, GENE, V153, P71, DOI 10.1016/0378-1119(94)00777-P; Paton JC, 1998, CLIN MICROBIOL REV, V11, P450, DOI 10.1128/CMR.11.3.450; Risberg A, 1999, EUR J BIOCHEM, V261, P171, DOI 10.1046/j.1432-1327.1999.00248.x; ROGERS JE, 1997, 3 INT S WORKSH SHIG; Takeda T, 1999, MICROBIOL IMMUNOL, V43, P331, DOI 10.1111/j.1348-0421.1999.tb02413.x; Vinogradov EV, 1999, EUR J BIOCHEM, V261, P629, DOI 10.1046/j.1432-1327.1999.00280.x; WADOLKOWSKI EA, 1990, INFECT IMMUN, V58, P3959, DOI 10.1128/IAI.58.12.3959-3965.1990; WADOLKOWSKI EA, 1990, INFECT IMMUN, V58, P2438, DOI 10.1128/IAI.58.8.2438-2445.1990; Wakarchuk WW, 1998, EUR J BIOCHEM, V254, P626, DOI 10.1046/j.1432-1327.1998.2540626.x; Yang QL, 1996, J EXP MED, V183, P323, DOI 10.1084/jem.183.1.323; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	161	170	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					265	270		10.1038/73111	http://dx.doi.org/10.1038/73111			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700227				2022-12-27	WOS:000085580500035
J	Klein, L; Klugmann, M; Nave, KA; Tuohy, VK; Kyewski, B				Klein, L; Klugmann, M; Nave, KA; Tuohy, VK; Kyewski, B			Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN PROTEOLIPID PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; ENCEPHALITOGENIC DETERMINANT; DEMYELINATING DISEASES; BASIC-PROTEIN; SJL MICE; TOLERANCE	Intrathymic expression of tissue-specific self antigens may be involved in immunological tolerance and protection from autoimmune disease. We have analyzed the role of T-cell tolerance to proteolipid protein (PLP), the main protein of the myelin sheath, in susceptibility to experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. Intrathymic expression of PLP was largely restricted to the shorter splice variant, DM20. Expression of DM20 by thymic epithelium was sufficient to confer T-cell tolerance to all epitopes of PLP in EAE-resistant C57BL/6 mice. In contrast, the major T-cell epitope in SJL/J mice was only encoded by the central nervous system-specific exon of PLP, but not by thymic DM20. Thus, lack of tolerance to this epitope offers an explanation for the exquisite susceptibility of SJL/J mice to EAE. As PLP expression in the human thymus is also restricted to the DM20 isoform, these findings have implications for selection of the autoimmune T-cell repertoire in multiple sclerosis.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; Heidelberg Univ, Ctr Mol Biol, D-69120 Heidelberg, Germany; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Cleveland Clinic Foundation	Kyewski, B (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, INF 280, D-69120 Heidelberg, Germany.	b.kyewski@dkfz-heidelberg.de	Klein, Ludger/G-8785-2011; Nave, Klaus-Armin/C-8883-2011	Klein, Ludger/0000-0003-2054-071X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037476, R01NS036054] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 36054, NS 37476] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alferink J, 1999, IMMUNOL REV, V169, P255, DOI 10.1111/j.1600-065X.1999.tb01320.x; Anderton S, 1999, IMMUNOL REV, V169, P123, DOI 10.1111/j.1600-065X.1999.tb01311.x; Butterfield RJ, 1998, J IMMUNOL, V161, P1860; Chang JT, 1999, J EXP MED, V189, P969, DOI 10.1084/jem.189.6.969; Egwuagu CE, 1997, J IMMUNOL, V159, P3109; Encinas JA, 1996, J IMMUNOL, V157, P2186; Encinas JA, 1999, NAT GENET, V21, P158, DOI 10.1038/5941; Fritz RB, 1996, J NEUROSCI RES, V45, P471, DOI 10.1002/(SICI)1097-4547(19960815)45:4<471::AID-JNR17>3.0.CO;2-3; GREER JM, 1992, J IMMUNOL, V149, P783; Greer JM, 1996, J IMMUNOL, V156, P371; Hanahan D, 1998, CURR OPIN IMMUNOL, V10, P656, DOI 10.1016/S0952-7915(98)80085-X; Harrington CJ, 1998, IMMUNITY, V8, P571, DOI 10.1016/S1074-7613(00)80562-2; Heath VL, 1998, J AUTOIMMUN, V11, P309, DOI 10.1006/jaut.1998.0210; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; Klein L, 1998, J EXP MED, V188, P5, DOI 10.1084/jem.188.1.5; Klugmann M, 1997, NEURON, V18, P59, DOI 10.1016/S0896-6273(01)80046-5; Kojima K, 1997, INT IMMUNOL, V9, P897, DOI 10.1093/intimm/9.6.897; KYEWSKI BA, 1986, J EXP MED, V163, P231, DOI 10.1084/jem.163.2.231; MARKOVICPLESE S, 1995, J IMMUNOL, V155, P982; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MCRAE BL, 1995, J EXP MED, V182, P75, DOI 10.1084/jem.182.1.75; MILLER SD, 1995, IMMUNOL REV, V144, P225, DOI 10.1111/j.1600-065X.1995.tb00071.x; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; Oukka M, 1996, IMMUNITY, V4, P545, DOI 10.1016/S1074-7613(00)80481-1; Pribyl TM, 1996, J NEUROSCI RES, V45, P812; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Segal BM, 1996, J EXP MED, V184, P771, DOI 10.1084/jem.184.2.771; Smith KM, 1997, INT IMMUNOL, V9, P1355, DOI 10.1093/intimm/9.9.1355; Sospedra M, 1998, J IMMUNOL, V161, P5918; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Stockinger B, 1999, Adv Immunol, V71, P229; Targoni OS, 1998, J EXP MED, V187, P2055, DOI 10.1084/jem.187.12.2055; Trotter JL, 1998, J NEUROIMMUNOL, V84, P172, DOI 10.1016/S0165-5728(97)00260-9; TUOHY VK, 1995, J NEUROIMMUNOL, V56, P161, DOI 10.1016/0165-5728(94)00143-C; Tuohy VK, 1998, IMMUNOL REV, V164, P93, DOI 10.1111/j.1600-065X.1998.tb01211.x; TUOHY VK, 1988, J IMMUNOL, V140, P1868; Tuohy VK, 1997, J CLIN INVEST, V99, P1682, DOI 10.1172/JCI119331; TUOHY VK, 1989, J IMMUNOL, V142, P1523; Tuohy VK, 1999, J EXP MED, V189, P1033, DOI 10.1084/jem.189.7.1033; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Vanderlugt CL, 1998, IMMUNOL REV, V164, P63, DOI 10.1111/j.1600-065X.1998.tb01208.x; Voskuhl RR, 1998, IMMUNOL REV, V164, P81, DOI 10.1111/j.1600-065X.1998.tb01210.x; Wekerle H, 1996, IMMUNOL REV, V149, P231, DOI 10.1111/j.1600-065X.1996.tb00907.x; Wekerle H, 1993, Curr Opin Neurobiol, V3, P779, DOI 10.1016/0959-4388(93)90153-P; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777	46	305	307	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2000	6	1					56	61		10.1038/71540	http://dx.doi.org/10.1038/71540			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613824				2022-12-27	WOS:000084583300035
J	Sharkey, ME; Teo, I; Greenough, T; Sharova, N; Luzuriaga, K; Sullivan, JL; Bucy, RP; Kostrikis, LG; Haase, A; Veryard, C; Davaro, RE; Cheeseman, SH; Daly, JS; Bova, C; Ellison, RT; Mady, B; Lai, KK; Moyle, G; Nelson, M; Gazzard, B; Shaunak, S; Stevenson, M				Sharkey, ME; Teo, I; Greenough, T; Sharova, N; Luzuriaga, K; Sullivan, JL; Bucy, RP; Kostrikis, LG; Haase, A; Veryard, C; Davaro, RE; Cheeseman, SH; Daly, JS; Bova, C; Ellison, RT; Mady, B; Lai, KK; Moyle, G; Nelson, M; Gazzard, B; Shaunak, S; Stevenson, M			Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy	NATURE MEDICINE			English	Article							ANTIRETROVIRAL THERAPY; T-CELLS; INTEGRATION; LYMPHOCYTES; REPLICATION; EXPRESSION; RESERVOIR	Treatment of HIV-1-infected individuals with a combination of anti-retroviral agents results in sustained suppression of HIV-1 replication, as evidenced by a reduction in plasma viral RNA to levels below the limit of detection of available assays(1,2). However, even in patients whose plasma viral RNA levels have been suppressed to below detectable levels for up to 30 months, replication-competent virus can routinely be recovered from patient peripheral blood mononuclear cells(3,4) and from semen(5). A reservoir of latently infected cells established early in infection(6) may be involved in the maintenance of viral persistence despite highly active anti-retroviral therapy(.)(3-5) However, whether virus replication persists in such patients is unknown. HIV-1 cDNA episomes are labile products of virus infection and indicative of recent infection events. Using episome-specific PCR, we demonstrate here ongoing virus replication in a large percentage of infected individuals on highly active anti-retroviral therapy, despite sustained undetectable levels of plasma viral RNA. The presence of a reservoir of 'covert' virus replication in patients on highly active antiretroviral therapy has important implications for the clinical management of HIV-1-infected individuals and for the development of virus eradication strategies.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Hammersmith Hosp, Imperial Coll, Sch Med, Dept Infect Dis, London W12 0NN, England; Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35233 USA; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Massachusetts Mem Hlth Care, Div Infect Dis, Worcester, MA 01655 USA; Chelsea & Westminster Hosp, London SW10 9NH, England	University of Massachusetts System; University of Massachusetts Worcester; Imperial College London; University of Massachusetts System; University of Massachusetts Worcester; University of Alabama System; University of Alabama Birmingham; Rockefeller University; University of Minnesota System; University of Minnesota Twin Cities; University of Massachusetts System; University of Massachusetts Worcester; University Massachusetts Worcester Hospital; Imperial College London	Stevenson, M (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Suite 319, Worcester, MA 01605 USA.		KOSTRIKIS, LEONDIOS G/A-5330-2016	KOSTRIKIS, LEONDIOS G/0000-0002-5340-7109; Bova, Carol/0000-0002-4400-9678; Veryard, Claire/0000-0002-6637-1686	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR011589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032391] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR011589, RR11589] Funding Source: Medline; NHLBI NIH HHS [HLS7880, R01 HL057880] Funding Source: Medline; NIAID NIH HHS [T32 AI007272, R01 AI032890, U01 AI032907, AI 32391, R01 AI032391, R01 AI049152] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Livingstone WJ, 1996, LANCET, V348, P649, DOI 10.1016/S0140-6736(96)02091-0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Riley JL, 1998, J VIROL, V72, P8273, DOI 10.1128/JVI.72.10.8273-8280.1998; Sonza S, 1996, J VIROL, V70, P3863, DOI 10.1128/JVI.70.6.3863-3869.1996; Spina CA, 1997, J CLIN INVEST, V99, P1774, DOI 10.1172/JCI119342; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; Zhang LQ, 1999, J VIROL, V73, P855, DOI 10.1128/JVI.73.1.855-860.1999; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	21	337	342	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					76	81		10.1038/71569	http://dx.doi.org/10.1038/71569			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613828	Green Accepted			2022-12-27	WOS:000084583300039
J	Dewey, RA; Morrissey, G; Cowsill, CM; Stone, D; Bolognani, F; Dodd, NJF; Southgate, TD; Klatzmann, D; Lassmann, H; Castro, MG; Lowenstein, PR				Dewey, RA; Morrissey, G; Cowsill, CM; Stone, D; Bolognani, F; Dodd, NJF; Southgate, TD; Klatzmann, D; Lassmann, H; Castro, MG; Lowenstein, PR			Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials	NATURE MEDICINE			English	Article							MAGNETIZATION-TRANSFER; FAS LIGAND; TUMOR-REGRESSION; MALIGNANT GLIOMA; IN-VIVO; VECTOR; RAT; CELLS; BETA; GANCICLOVIR	The long-term consequences of adenovirus-mediated conditional cytotoxic gene therapy for gliomas remain uncharacterized. We report here detection of active brain inflammation 3 months after successful inhibition of syngeneic glioma growth. The inflammatory infiltrate consisted of activated macrophages/microglia and astrocytes, and T lymphocytes positive for leucosyalin, CD3 and CD8, and included secondary demyelination. We detected strong widespread herpes simplex virus 1 thymidine kinase immunoreactivity and vector genomes throughout large areas of the brain. Thus, patient evaluation and the design of clinical trials in ongoing and future gene therapy for brain glioblastoma must address not only tumor-killing efficiency, but also long-term active brain inflammation, loss of myelin fibers and persistent transgene expression.	Univ Manchester, Sch Med, Mol Med & Gene Therapy Unit, Manchester M13 9PT, Lancs, England; Univ Manchester, Dept Med Biophys, Manchester M13 9PT, Lancs, England; Univ Paris 06, CNRS, Hop La Pitie Salpetriere, Lab Biol & Therapeut Pathol Immunitaires, F-75651 Paris, France; Univ Vienna, Inst Neurol, A-1090 Vienna, Austria	University of Manchester; University of Manchester; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University of Vienna	Lowenstein, PR (corresponding author), Univ Manchester, Sch Med, Mol Med & Gene Therapy Unit, Room 1-302 Stopford Bldg, Manchester M13 9PT, Lancs, England.		Castro, Maria/ABC-5182-2021; Lassmann, Hans/Z-2269-2019	Castro, Maria/0000-0003-2237-2756; Lassmann, Hans/0000-0001-8617-5052; Klatzmann, David/0000-0002-0054-3422; Dewey, Ricardo/0000-0003-1677-2745; Stone, Daniel/0000-0003-1619-7541				Ambar BB, 1999, HUM GENE THER, V10, P1641, DOI 10.1089/10430349950017644; BARBA D, 1994, P NATL ACAD SCI USA, V91, P4348, DOI 10.1073/pnas.91.10.4348; BECKWITH J, 1995, HUM GENOME NEWS, V6, P6; Blomer U, 1997, J VIROL, V71, P6641; Byrnes AP, 1996, J NEUROSCI, V16, P3045; BYRNES AP, 1995, NEUROSCIENCE, V66, P1015, DOI 10.1016/0306-4522(95)00068-T; Cartmell T, 1999, J NEUROSCI, V19, P1517; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; COTTEN M, 1994, GENE THER, V1, P239; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DEWEY RA, 1998, ABSTR SOC NEUR 2, V2165; Dion LD, 1996, J VIROL METHODS, V56, P99, DOI 10.1016/0166-0934(95)01973-1; Easton RM, 1998, MOL CELL NEUROSCI, V11, P334, DOI 10.1006/mcne.1998.0690; Eck SL, 1996, HUM GENE THER, V7, P1465, DOI 10.1089/hum.1996.7.12-1465; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FREEMAN SM, 1993, CANCER RES, V53, P5274; Freeman SM, 1997, LANCET, V349, P2, DOI 10.1016/S0140-6736(97)22001-5; Gagandeep S, 1996, CANCER GENE THER, V3, P83; Geddes BJ, 1997, NAT MED, V3, P1402, DOI 10.1038/nm1297-1402; Ghodsi A, 1998, HUM GENE THER, V9, P2331, DOI 10.1089/hum.1998.9.16-2331; Goodman JC, 1996, HUM GENE THER, V7, P1241, DOI 10.1089/hum.1996.7.10-1241; Gratas C, 1997, BRAIN PATHOL, V7, P863, DOI 10.1111/j.1750-3639.1997.tb00889.x; Hauss-Wegrzyniak B, 1998, BRAIN RES, V794, P211, DOI 10.1016/S0006-8993(98)00227-3; Hermens WTJMC, 1998, BRAIN RES BULL, V47, P133, DOI 10.1016/S0361-9230(98)00042-2; Izquierdo M, 1996, GENE THER, V3, P491; IZQUIERDO M, 1995, GENE THER, V2, P66; Klatzmann D, 1998, HUM GENE THER, V9, P2595, DOI 10.1089/hum.1998.9.17-2595; Klinkert WEF, 1997, J NEUROIMMUNOL, V72, P163, DOI 10.1016/S0165-5728(96)00183-X; KRUSE CA, 1994, J NEURO-ONCOL, V22, P191, DOI 10.1007/BF01052919; KURKI T, 1995, MAGN RESON IMAGING, V13, P501, DOI 10.1016/0730-725X(95)00006-3; LEE KH, 1995, HEARING RES, V87, P9, DOI 10.1016/0378-5955(95)00072-C; LOWENSTEIN PR, 1995, BRAIN RES, V676, P80, DOI 10.1016/0006-8993(95)00091-4; Maron A, 1996, GENE THER, V3, P315; Morelli AE, 1999, J GEN VIROL, V80, P571, DOI 10.1099/0022-1317-80-3-571; PEREZCRUET MJ, 1994, J NEUROSCI RES, V39, P506, DOI 10.1002/jnr.490390417; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; RAM Z, 1994, J NEUROSURG, V81, P256, DOI 10.3171/jns.1994.81.2.0256; SALOMON B, 1995, MOL CELL BIOL, V15, P5322; SHERING AF, 1994, J COMP NEUROL, V347, P433, DOI 10.1002/cne.903470309; Shering AF, 1997, J GEN VIROL, V78, P445, DOI 10.1099/0022-1317-78-2-445; Smith JG, 1997, HUM GENE THER, V8, P943, DOI 10.1089/hum.1997.8.8-943; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; WOLFF SD, 1994, RADIOLOGY, V192, P593, DOI 10.1148/radiology.192.3.8058919	45	273	282	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1256	1263		10.1038/15207	http://dx.doi.org/10.1038/15207			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545991				2022-12-27	WOS:000086550600035
J	Simm, M				Simm, M			New rules for lazy professors	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					974	974		10.1038/12401	http://dx.doi.org/10.1038/12401			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470060	Bronze			2022-12-27	WOS:000082337200016
J	Dexter, M				Dexter, M			The Wellcome Trust: Leadership and partnership in biomedical research	NATURE MEDICINE			English	Editorial Material									Wellcome Trust, London NW1 2BE, England	University of London; University College London	Dexter, M (corresponding author), Wellcome Trust, 183 Euston Rd, London NW1 2BE, England.							[Anonymous], 1997, HIGH ED LEARN SOC RE; Bett M., 1999, INDEPENDENT REV HIGH; Cass S, 1999, NAT MED, V5, P253, DOI 10.1038/6452; Dawson G., 1998, MAPPING LANDSCAPE NA; Dickson D, 1998, NAT MED, V4, P871, DOI 10.1038/nm0898-871; Dickson D, 1998, NAT MED, V4, P542, DOI 10.1038/nm0598-542a; Ogilvie BM, 1997, NAT MED, V3, P1185, DOI 10.1038/nm1197-1185; Rouse R, 1999, NAT MED, V5, P471, DOI 10.1038/8338	8	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					861	864		10.1038/11294	http://dx.doi.org/10.1038/11294			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426301				2022-12-27	WOS:000081684000019
J	Husain, SR; Kreitman, RJ; Pastan, I; Puri, RK				Husain, SR; Kreitman, RJ; Pastan, I; Puri, RK			Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft- model	NATURE MEDICINE			English	Article							CIRCULARLY PERMUTED INTERLEUKIN-4; HUMAN CHORIONIC-GONADOTROPIN; HUMAN-IMMUNODEFICIENCY-VIRUS; ENDOTHELIAL GROWTH-FACTOR; PSEUDOMONAS EXOTOXIN; CELL-LINE; CARCINOMA-CELLS; EXPRESSION; TOXIN; INFECTION	The elusive and enigmatic origin of AIDS-associated Kaposi's sarcoma (AIDS-KS) makes it a complex tumor and therefore difficult to treat. Here we demonstrate that AIDS-KS cells express surface interleukin-4 (IL-4) receptors, and that IL-4 toxin (IL-4(38-37)-PE38KDEL) is specifically cytotoxic to these cells. Intratumoral, intraperitoneal and intravenous administration of IL-4 toxin in nude mice with established subcutaneous AIDS-KS tumors caused considerable antitumor activity in a dose-dependent manner, with highest dose producing durable complete responses. Metabolic changes, including cachexia and lymphopenia, induced by KS tumors were prevented by IL-4 toxin treatment. This report establishes IL-4(38-37)-PE38KDEL as an experimental therapeutic agent for the treatment of AIDS-KS.	US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Lab Mol Tumor Biol, Bethesda, MD 20892 USA; NCI, Div Basic Sci, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Puri, RK (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Lab Mol Tumor Biol, Bethesda, MD 20892 USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; Arora N, 1999, CANCER RES, V59, P183; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Cai J, 1997, INVEST NEW DRUG, V15, P279, DOI 10.1023/A:1005958123893; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Gill PS, 1996, NEW ENGL J MED, V335, P1261, DOI 10.1056/NEJM199610243351702; Gill PS, 1997, NEW ENGL J MED, V336, P670; GILL PS, 1997, NEW ENGL J MED, V226, P1115; HERMANS P, 1994, BRIT J HAEMATOL, V87, P413, DOI 10.1111/j.1365-2141.1994.tb04934.x; Hermans P, 1998, J Hum Virol, V1, P82; Husain SR, 1997, MOL MED, V3, P327, DOI 10.1007/BF03401811; Husain SR, 1998, CANCER RES, V58, P3649; Husain SR, 1997, CLIN CANCER RES, V3, P151; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; KREITMAN RJ, 1994, P NATL ACAD SCI USA, V91, P6889, DOI 10.1073/pnas.91.15.6889; KREITMAN RJ, 1995, CANCER RES, V55, P3357; Krown SE, 1998, J INTERF CYTOK RES, V18, P209, DOI 10.1089/jir.1998.18.209; LOUIE S, 1995, J ACQ IMMUN DEF SYND, V8, P455, DOI 10.1097/00042560-199504120-00004; LUNARDIISKANDAR Y, 1995, NATURE, V375, P64, DOI 10.1038/375064a0; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MASOOD R, 1994, AIDS RES HUM RETROV, V10, P969, DOI 10.1089/aid.1994.10.969; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murata T, 1996, J IMMUNOL, V156, P2972; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; OBIRI NI, 1994, CLIN EXP IMMUNOL, V95, P148; OBIRI NI, 1993, J CLIN INVEST, V91, P83; PAL LH, 1996, NAT MED, V2, P350; PAUL P, 1991, MICROW OPT TECHN LET, V4, P77, DOI 10.1002/mop.4650040207; Puri R. K., 1995, CYTOKINES INTERLEUKI, P143; Puri RK, 1996, CELL IMMUNOL, V171, P80, DOI 10.1006/cimm.1996.0176; PURI RK, 1993, CANCER INVEST, V11, P473, DOI 10.3109/07357909309018879; Puri RK, 1996, CANCER RES, V56, P5631; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; RUSZCZAK Z, 1987, AM J DERMATOPATH, V9, P388, DOI 10.1097/00000372-198710000-00004; Samaniego F, 1999, J NATL CANCER I, V91, P135, DOI 10.1093/jnci/91.2.135; Samaniego F, 1997, J IMMUNOL, V158, P1887; Samaniego F, 1996, IMMUNOLOGY HIV INFEC, P437; SCULLY PA, 1988, AM J PATHOL, V130, P244; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; TEMPLETON AC, 1988, KAPOSIS SARCOMA PATH, P23; Tulpule A, 1997, ANN ONCOL, V8, P79, DOI 10.1023/A:1008205424763; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; ZHANG YM, 1994, AM J PATHOL, V144, P51	48	52	57	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					817	822		10.1038/10541	http://dx.doi.org/10.1038/10541			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395328				2022-12-27	WOS:000081926600038
J	Bickerstaff, MCM; Botto, M; Hutchinson, WL; Herbert, J; Tennent, GA; Bybee, A; Mitchell, DA; Cook, HT; Butler, PJG; Walport, MJ; Pepys, MB				Bickerstaff, MCM; Botto, M; Hutchinson, WL; Herbert, J; Tennent, GA; Bybee, A; Mitchell, DA; Cook, HT; Butler, PJG; Walport, MJ; Pepys, MB			Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity	NATURE MEDICINE			English	Article							C-REACTIVE PROTEIN; SYSTEMIC LUPUS-ERYTHEMATOSUS; SMALL NUCLEAR RIBONUCLEOPROTEIN; ACUTE-PHASE PROTEINS; MICE; BINDS; PENTRAXINS; ANTIBODIES; CLEARANCE; INVITRO	Serum amyloid P component (SAP), a highly conserved plasma protein named for its universal presence in amyloid deposits', is the single normal circulating protein that shows specific calcium-dependent binding to DNA and chromatin in physiological conditions(2,3). The avid binding of SAP displaces Hi-type histones and thereby solubilizes native long chromatin, which is otherwise profoundly insoluble at the physiological ionic strength of extracellular fluids(4). Furthermore, SAP binds in vivo both to apoptotic cells(5), the surface blebs of which bear chromatin fragments(6), and to nuclear debris released by necrosis(7). SAP may therefore participate in handling of chromatin exposed by cell death(2-4,7). Here we show that mice with targeted deletion of the SAP genes spontaneously develop antinuclear autoimmunity and severe glomerulonephritis, a phenotype resembling human systemic lupus erythematosus, a serious autoimmune disease. The SAP(-/-) mice also have enhanced anti-DNA responses to immunization with extrinsic chromatin, and we demonstrate that degradation of long chromatin is retarded in the presence of SAP both in vitro and in vivo. These findings indicate that SAP has an important physiological role, inhibiting the formation of pathogenic autoantibodies against chromatin and DNA, probably by binding to chromatin and regulating its degradation.	Imperial Coll Sch Med, Hammersmith Hosp, Immunol Med Unit, London W12 0NN, England; Imperial Coll Sch Med, Hammersmith Hosp, Rheumatol Sect, London W12 0NN, England; Imperial Coll Sch Med, Hammersmith Hosp, Dept Histopathol, London W12 0NN, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Imperial College London; Imperial College London; Imperial College London; MRC Laboratory Molecular Biology	Pepys, MB (corresponding author), Imperial Coll Sch Med, Hammersmith Hosp, Immunol Med Unit, London W12 0NN, England.		Mitchell, Daniel A/A-6580-2009	Mitchell, Daniel A/0000-0003-0936-6212; Walport, Mark/0000-0001-7220-5273				Botto M, 1997, NAT MED, V3, P855, DOI 10.1038/nm0897-855; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; BREATHNACH SM, 1989, J EXP MED, V170, P1433, DOI 10.1084/jem.170.4.1433; BURLINGAME RW, 1990, J IMMUNOL METHODS, V134, P187, DOI 10.1016/0022-1759(90)90380-E; Burlingame RW, 1996, J IMMUNOL, V156, P4783; BUTLER PJG, 1990, J EXP MED, V172, P13, DOI 10.1084/jem.172.1.13; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; DUCLOS TW, 1989, J IMMUNOL, V143, P2553; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; Gauthier VJ, 1996, J IMMUNOL, V156, P1151; HINTNER H, 1988, J INVEST DERMATOL, V91, P22, DOI 10.1111/1523-1747.ep12463283; HUGHES CRV, 1998, J R COLL PHYSICIANS, V32, P260; HUTCHINSON WL, 1994, J CLIN INVEST, V94, P1390, DOI 10.1172/JCI117474; ISENBERG DA, 1987, ANN RHEUM DIS, V46, P448, DOI 10.1136/ard.46.6.448; MATHER SJ, 1987, J NUCL MED, V28, P1034; MOLDEN DP, 1984, AM J CLIN PATHOL, V82, P57, DOI 10.1093/ajcp/82.1.57; NAKAYAMA S, 1984, J IMMUNOL, V132, P1336; PEPYS MB, 1977, IMMUNOLOGY, V33, P491; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1994, CLIN EXP IMMUNOL, V97, P152; PEPYS MB, 1982, CLIN RHEUM DIS, V8, P91; PEPYS MB, 1979, NATURE, V278, P259, DOI 10.1038/278259a0; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; Pepys MB, 1997, AMYLOID, V4, P274, DOI 10.3109/13506129709003838; REICHLIN M, 1994, J CLIN INVEST, V93, P443, DOI 10.1172/JCI116980; RORDORF C, 1982, J EXP MED, V156, P1268, DOI 10.1084/jem.156.4.1268; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9	28	399	427	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					694	697		10.1038/9544	http://dx.doi.org/10.1038/9544			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371509				2022-12-27	WOS:000080823300039
J	Plebanski, M; Lee, EAM; Hannan, CM; Flanagan, KL; Gilbert, SC; Gravenor, MB; Hill, AVS				Plebanski, M; Lee, EAM; Hannan, CM; Flanagan, KL; Gilbert, SC; Gravenor, MB; Hill, AVS			Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR ANTAGONISTS; CLASS-I; MALARIA; PROTEIN; COMPLEX; PROLIFERATION; RECOGNITION; PROTECTION; VACCINE	Variation in epitopes of infectious pathogens inhibits various effector functions of T lymphocytes through antagonism of the T-cell receptor. However, a more powerful strategy for immune evasion would be to prevent the induction of T-cell responses. We report here mutual 'interference' with the priming of human T-cell responses by a pair of naturally occurring variants of a malaria cytotoxic T-cell epitope. Interference with priming also occurs in vivo for a murine malaria T-cell epitope. Reshaping of the T-cell repertoire by such immune interference during naive T-cell induction may provide a general mechanism for observed patterns of immunodominance and persistence by many polymorphic pathogens.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Plebanski, M (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England.		Gilbert, Sarah C./H-2857-2019; HILL, Adrian V>S>/C-1306-2008; Plebanski, Magdalena/AAU-3144-2021	Gilbert, Sarah C./0000-0002-6823-9750; , Magdalena/0000-0001-6889-3667; Flanagan, Katie/0000-0002-1575-1953	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; Apostolopoulos V, 1996, VACCINE, V14, P930, DOI 10.1016/0264-410X(95)00258-3; BENJAMIN KV, 1996, J EXP MED, V183, P1311; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; Daniel C, 1998, J IMMUNOL, V160, P3244; DAVENPORT MP, 1995, IMMUNOL TODAY, V16, P432, DOI 10.1016/0167-5699(95)80020-4; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280; Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173; GUPTA S, 1995, P ROY SOC B-BIOL SCI, V261, P271, DOI 10.1098/rspb.1995.0147; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HOLLSBERG P, 1995, P NATL ACAD SCI USA, V92, P4036, DOI 10.1073/pnas.92.9.4036; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KANEKO T, 1997, EUR J IMMUNOL, V27, P1787; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; KIENERMAN P, 1995, EUR J IMMUNOL, V25, P1927; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KUMAR V, 1995, P NATL ACAD SCI USA, V92, P9510, DOI 10.1073/pnas.92.21.9510; LANCASTER JS, 1996, NATURE, V363, P156; MOSS PAH, 1993, EUR J IMMUNOL, V23, P1153, DOI 10.1002/eji.1830230526; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; PAGE DM, 1994, P NATL ACAD SCI USA, V91, P4057, DOI 10.1073/pnas.91.9.4057; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PLEBANSKI M, 1995, EUR J IMMUNOL, V25, P1783, DOI 10.1002/eji.1830250645; Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12&lt;4345::AID-IMMU4345&gt;3.0.CO;2-P; Plebanski M, 1997, J IMMUNOL, V158, P2849; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; RUPPERT J, 1995, CHEM IMMUNOL, V60, P61; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; Smith KJ, 1996, IMMUNITY, V4, P203, DOI 10.1016/S1074-7613(00)80429-X; WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0	43	84	87	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					565	571		10.1038/8444	http://dx.doi.org/10.1038/8444			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229235				2022-12-27	WOS:000081497400039
J	Goedert, M; Spillantini, MG; Crowther, RA; Chen, SG; Parchi, P; Tabaton, M; Lanska, DJ; Markesbery, WR; Wilhelmsen, KC; Dickson, DW; Petersen, RB; Gambetti, P				Goedert, M; Spillantini, MG; Crowther, RA; Chen, SG; Parchi, P; Tabaton, M; Lanska, DJ; Markesbery, WR; Wilhelmsen, KC; Dickson, DW; Petersen, RB; Gambetti, P			Tau gene mutation in familial progressive subcortical gliosis	NATURE MEDICINE			English	Article							MULTIPLE SYSTEM TAUOPATHY; PAIRED HELICAL FILAMENTS; FRONTOTEMPORAL DEMENTIA; PROTEIN-TAU; PRESENILE-DEMENTIA; CHROMOSOME-17; ISOFORMS; PARKINSONISM; DISEASE; FTDP-17	Familial forms of frontotemporal dementias are associated with mutations in the tau gene. A kindred affected by progressive subcortical gliosis (PSG), a rare form of presenile dementia, has genetic linkage to chromosome 17q21-22 (refs. 1-3). This kindred (PSG-1) is included in the 'frontotemporal dementias and Parkinsonism linked to chromosome 17' group along with kindreds affected by apparently different forms of atypical dementias(4). Some of these kindreds have mutations in the tau gene(5-10). We report here that PSC-1 has a tau mutation at position +16 of the intron after exon 10. The mutation destabilizes a predicted stem-loop structure and leads to an over-representation of the soluble four-repeat tau isoforms, which assemble into wide, twisted, ribbon-like filaments and ultimately result in abundant neuronal and glial tau pathology. The mutations associated with PSC and other atypical dementias can be subdivided into three groups according to their tau gene locations and effects on tau. The existence of tau mutations with distinct pathogenetic mechanisms may explain the phenotypic heterogeneity of atypical dementias that previously led to their classification into separate disease entities.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Cambridge, Dept Neurol, Cambridge CB2 2PY, England; Case Western Reserve Univ, Div Neuropathol, Cleveland, OH 44106 USA; Univ Genoa, Inst Neurol, I-16132 Genoa, Italy; Vet Affairs Med Ctr, Great Lakes Hlth Care Syst, Tomah, WI 54660 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53792 USA; Univ Kentucky, Dept Neurol & Pathol, Lexington, KY 40536 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Gallo Ctr, San Francisco, CA 94110 USA	MRC Laboratory Molecular Biology; University of Cambridge; Case Western Reserve University; University of Genoa; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Wisconsin System; University of Wisconsin Madison; University of Kentucky; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Goedert, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Chen, Shu G./AAK-7301-2021; Chen, Shu G./O-4750-2014; Chen, Shu/Z-2943-2019; Parchi, Piero/L-9833-2015; Petersen, Robert/B-5075-2011	Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001; Parchi, Piero/0000-0002-9444-9524; Petersen, Robert/0000-0002-3154-0072; Dickson, Dennis W/0000-0001-7189-7917				ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1990, BIOCHIM BIOPHYS ACTA, V1096, P1, DOI 10.1016/0925-4439(90)90004-9; DICKSON DW, 1998, NEUROSCI INTELL UNIT, V3, P165; Dumanchin C, 1998, HUM MOL GENET, V7, P1825, DOI 10.1093/hmg/7.11.1825; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; Gambetti P, 1997, NEUROLOGY, V49, P309, DOI 10.1212/WNL.49.1.309-c; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Goedert M, 1998, NEURON, V21, P955, DOI 10.1016/S0896-6273(00)80615-7; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; LANSKA DJ, 1994, NEUROLOGY, V44, P1633, DOI 10.1212/WNL.44.9.1633; NEUMANN MA, 1967, BRAIN, V90, P405, DOI 10.1093/brain/90.2.405; PETERSEN RB, 1995, NEUROLOGY, V45, P1062, DOI 10.1212/WNL.45.6.1062; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737	25	165	171	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					454	457		10.1038/7454	http://dx.doi.org/10.1038/7454			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202939				2022-12-27	WOS:000079574300039
J	Desbarats, J; Newell, MK				Desbarats, J; Newell, MK			Fas engagement accelerates liver regeneration after partial hepatectomy	NATURE MEDICINE			English	Article							EXPRESSION; APOPTOSIS; RECEPTOR; LIGAND; ACTIVATION; SIGNALS; CELLS; GENE	Fas (CD95) is a receptor involved in induction of apoptotic cell death of Fas-bearing cells, including hepatocytes(1,2) and T cells(3). Injection of Fas-specific antibodies into mice leads to fulminant hepatic failure and death(1). Fas also transduces growth-promoting signals in proliferating T cells(4,5), fibroblasts(6) and some tumor cells'. Here we show that partial hepatectomy, which triggers the immediate onset of liver regeneration(8), protected mice against the lethal effects of Fas-specific antibodies and prevented hepatocyte apoptosis in response to Fas engagement in vivo. Furthermore, Fas engagement accelerated liver regeneration after partial hepatectomy. Liver regeneration kinetics were delayed in mutant mice with decreased cell surface Fas expression (lpr mice(9)), in contrast, regeneration was not delayed in lpr-cg mutant mice, which have a Fas mutation that prevents Fas-induced death(10) but not Fas-dependent proliferative stimulation. Our results indicate that Fas engagement on cells in regenerating or healing tissues may promote cell growth.	Univ Vermont, Dept Med, Burlington, VT 05401 USA; Univ Colorado, Dept Biol, Colorado Springs, CO 80918 USA	University of Vermont; University of Colorado System; University of Colorado at Colorado Springs	Newell, MK (corresponding author), Univ Vermont, Dept Med, Burlington, VT 05401 USA.	mnewell@mail.uccs.edu		Desbarats, Julie/0000-0002-2495-7152	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062562] Funding Source: NIH RePORTER; NIGMS NIH HHS [1RO1GM62562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALBRECHT JH, 1994, FEBS LETT, V347, P157, DOI 10.1016/0014-5793(94)00527-3; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; Desbarats J, 1998, NAT MED, V4, P1377, DOI 10.1038/3965; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; Freiberg RA, 1997, J INVEST DERMATOL, V108, P215, DOI 10.1111/1523-1747.ep12334273; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hikawa N, 1997, J NEUROL SCI, V149, P13, DOI 10.1016/S0022-510X(96)05216-1; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kimura M, 1994, Int Rev Immunol, V11, P193, DOI 10.3109/08830189409061727; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1993, J IMMUNOTHER, V14, P234, DOI 10.1097/00002371-199310000-00011; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; SATO Y, 1993, IMMUNOLOGY, V78, P86; SNELLER MC, 1992, J CLIN INVEST, V90, P334, DOI 10.1172/JCI115867; Tzung SP, 1997, AM J PATHOL, V150, P1985; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410	25	184	192	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					920	923		10.1038/78688	http://dx.doi.org/10.1038/78688			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932231				2022-12-27	WOS:000165473800037
J	Fornas, O; Garcia, J; Petriz, J				Fornas, O; Garcia, J; Petriz, J			Flow cytometry counting of CD34(+) cells in whole blood	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; VIABILITY		Canc Res Inst, Dept Cryobiol & Cell Therapy, Barcelona 08907, Spain		Petriz, J (corresponding author), Hosp Clin Barcelona, Lab Cryobiol, Villarroel 170, E-08036 Barcelona, Spain.		Fornas, Oscar/F-1456-2015; Petriz, Jordi/AAS-4943-2020; Petriz, Jordi/AAB-7293-2019	Fornas, Oscar/0000-0003-2017-9100; Petriz, Jordi/0000-0003-1085-0511; 				Barnett D, 1999, BRIT J HAEMATOL, V106, P1059; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; Broxterman HJ, 1997, BRIT J CANCER, V76, P1029, DOI 10.1038/bjc.1997.503; CANNAVO N, 1998, LEUCOCYTE TYPING, V6, P978; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; Fritsch G, 1997, TRANSFUSION, V37, P775, DOI 10.1046/j.1537-2995.1997.37897424398.x; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; GRATAMA JW, 1997, CYTOMETRY, V15, P166; Hubl W, 1998, CYTOMETRY, V34, P121; Keeney M, 1998, CYTOMETRY, V34, P61, DOI 10.1002/(SICI)1097-0320(19980415)34:2<61::AID-CYTO1>3.0.CO;2-F; Krause DS, 1996, BLOOD, V87, P1; Macey MG, 1997, J IMMUNOL METHODS, V204, P175, DOI 10.1016/S0022-1759(97)00045-8; MCCARTHY DA, 1993, J IMMUNOL METHODS, V163, P155, DOI 10.1016/0022-1759(93)90117-P; METCALF D, 1971, HAEMOPOIETIC CELLS, P550; QUESENBERRY P, 1979, NEW ENGL J MED, V301, P755, DOI 10.1056/NEJM197910043011404; SIENA S, 1989, BLOOD, V74, P1905; SPANGRUDE GJ, 1994, ANNU REV MED, V45, P93; STELZER GT, 1993, ANN NY ACAD SCI, V677, P265, DOI 10.1111/j.1749-6632.1993.tb38783.x; SUTHERLAND DR, 1994, EXP HEMATOL, V22, P1003; Yang HY, 1998, CELL TRANSPLANT, V7, P443, DOI 10.1016/S0963-6897(98)00032-3	20	41	49	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					833	+		10.1038/77571	http://dx.doi.org/10.1038/77571			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888936				2022-12-27	WOS:000088040100044
J	Tang-Christensen, M; Larsen, PJ; Thulesen, J; Romer, J; Vrang, N				Tang-Christensen, M; Larsen, PJ; Thulesen, J; Romer, J; Vrang, N			The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake	NATURE MEDICINE			English	Article							NEUROPEPTIDE-Y; MESSENGER-RNA; HYPOTHALAMIC NUCLEUS; GENE-EXPRESSION; ARCUATE NUCLEUS; BRAIN-STEM; RAT; RECEPTOR; NEURONS; AGONIST	The dorsomedial hypothalamic nucleus harbors leptin sensitive neurons and is intrinsically connected to hypothalamic nuclei involved in feeding behavior. However, It also receives ascending input from the visceroceptive neurons of the brainstem. We have identified a unique glucagon-like-peptide-2 containing neuronal pathway connecting the nucleus of the solitary tract with the dorsomedial hypothalamic nucleus. A glucagon-like-peptide-2 fiber plexus targets neurons expressing its receptor within the dorsomedial hypothalamic nucleus. Pharmacological and behavioral studies confirmed that glucagon-like-peptide-2 signaling is a specific transmitter inhibiting rodent feeding behavior and with potential long-term effects on body weight homeostasis. The glucagon-like-peptide-1 receptor antagonist, Exendin (9-39) is also a functional antagonist of centrally applied glucagon-like-peptide-2.	Univ Copenhagen, Panum Inst, Dept Med Anat, Sect B, DK-1168 Copenhagen, Denmark; Novo Nordisk AS, Discovery, Pharmacol 4, DK-2880 Bagsvaerd, Denmark	University of Copenhagen; Novo Nordisk	Tang-Christensen, M (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Anat, Sect B, DK-1168 Copenhagen, Denmark.	M.Tang@mal.ku.dk		Thulesen, Jesper/0000-0002-5355-8062				Bernardis LL, 1998, P SOC EXP BIOL MED, V218, P284; Brubaker PL, 1997, ENDOCRINOLOGY, V138, P4837, DOI 10.1210/en.138.11.4837; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Gunn I, 1996, BIOCHEM SOC T, V24, P581, DOI 10.1042/bst0240581; Holst JJ, 1997, ANNU REV PHYSIOL, V59, P257, DOI 10.1146/annurev.physiol.59.1.257; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Kesterson RA, 1997, MOL ENDOCRINOL, V11, P630, DOI 10.1210/me.11.5.630; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; Larsen PJ, 1997, NEUROSCIENCE, V77, P257, DOI 10.1016/S0306-4522(96)00434-4; Larsen PJ, 1997, ENDOCRINOLOGY, V138, P4445, DOI 10.1210/en.138.10.4445; Li C, 1998, REGUL PEPTIDES, V75-6, P93, DOI 10.1016/S0167-0115(98)00057-3; Li C, 1998, ENDOCRINOLOGY, V139, P1645, DOI 10.1210/en.139.4.1645; McMahon LR, 1998, AM J PHYSIOL-REG I, V274, pR23, DOI 10.1152/ajpregu.1998.274.1.R23; Merchenthaler I, 1999, J COMP NEUROL, V403, P261, DOI 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5; Munroe DG, 1999, P NATL ACAD SCI USA, V96, P1569, DOI 10.1073/pnas.96.4.1569; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLETIER G, 1990, ANN NY ACAD SCI, V611, P232; Rinaman L, 1999, AM J PHYSIOL-REG I, V277, pR1537, DOI 10.1152/ajpregu.1999.277.5.R1537; Schepp W, 1996, DIGESTION, V57, P398, DOI 10.1159/000201367; SCHEPP W, 1994, EUR J PHARM-MOLEC PH, V269, P183, DOI 10.1016/0922-4106(94)90085-X; SCHWARTZ MW, 1993, ANN NY ACAD SCI, V692, P60; Seeley RJ, 2000, J NEUROSCI, V20, P1616; Serre V, 1998, ENDOCRINOLOGY, V139, P4448, DOI 10.1210/en.139.11.4448; SMITH MS, 1993, ENDOCRINOLOGY, V133, P1258, DOI 10.1210/en.133.3.1258; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; Tang-Christensen M, 1998, DIABETES, V47, P530, DOI 10.2337/diabetes.47.4.530; TangChristensen M, 1996, AM J PHYSIOL-REG I, V271, pR848, DOI 10.1152/ajpregu.1996.271.4.R848; TERHORST GJ, 1987, BRAIN RES BULL, V18, P191, DOI 10.1016/0361-9230(87)90190-0; Thiele TE, 1997, AM J PHYSIOL-REG I, V272, pR726, DOI 10.1152/ajpregu.1997.272.2.R726; Thim L, 1998, FEBS LETT, V428, P263, DOI 10.1016/S0014-5793(98)00543-2; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; VALVERDE I, 1993, ENDOCRINOLOGY, V132, P75, DOI 10.1210/en.132.1.75; vanDijk G, 1996, AM J PHYSIOL-REG I, V271, pR1096, DOI 10.1152/ajpregu.1996.271.4.R1096; Vrang N, 1999, J Neurosci, V19, pRC5; Wilding JPH, 1997, J ENDOCRINOL, V152, P365, DOI 10.1677/joe.0.1520365; Woldbye DPD, 1996, BRAIN RES, V720, P111, DOI 10.1016/0006-8993(96)00158-8; Yusta B, 1999, J BIOL CHEM, V274, P30459, DOI 10.1074/jbc.274.43.30459	40	212	222	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2000	6	7					802	+		10.1038/77535	http://dx.doi.org/10.1038/77535			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888930				2022-12-27	WOS:000088040100038
J	Trojan, A; Schultze, JL; Witzens, M; Vonderheide, RH; Ladetto, M; Donovan, JW; Gribben, JG				Trojan, A; Schultze, JL; Witzens, M; Vonderheide, RH; Ladetto, M; Donovan, JW; Gribben, JG			Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies	NATURE MEDICINE			English	Article							CLASS-I MOLECULES; MULTIPLE-MYELOMA; ENDOGENOUS IMMUNOGLOBULIN; PROTECTIVE IMMUNITY; IDIOTYPIC PROTEIN; BINDING PEPTIDES; DENDRITIC CELLS; LEUKEMIA CELLS; TUMOR-ANTIGEN; LYMPHOMA	Although the idiotypic structures of immunoglobulin from malignant B cells were the first tumor-specific determinants recognized, and clinical vaccination trials have demonstrated induction of tumor-specific immunity, the function of immunoglobulin-specific CD8(+) cytotoxic T lymphocytes in tumor rejection remains elusive. Here, we combined bioinformatics and a T cell-expansion system to identify human immunoglobulin-derived peptides capable of inducing cytotoxic T-lymphocyte responses. Immunogenic peptides were derived from framework regions of the variable regions of the immunoglobulin that were shared among patients. Human-leukocyte-antigen-matched and autologous cytotoxic T lymphocytes specific for these peptides killed primary malignant B cells, demonstrating that malignant B cells are capable of processing and presenting such peptides. Targeting shared peptides to induce T-cell responses might further improve current vaccination strategies in B-cell malignancies.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Trojan, A (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Schultze, Joachim L./ABA-8176-2020; Schultze, Joachim L/D-7794-2011; ladetto, marco/AAA-5546-2022; Witzens-Harig, Mathias/N-1790-2017	Schultze, Joachim L./0000-0003-2812-9853; Schultze, Joachim L/0000-0003-2812-9853; ladetto, marco/0000-0002-8283-2681; Witzens-Harig, Mathias/0000-0002-2799-4661	NCI NIH HHS [P01 CA 66996, CA78378, CA81534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA081534, P01CA078378, P01CA066996, P20CA081534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; Bennett SRM, 1998, J EXP MED, V188, P1977, DOI 10.1084/jem.188.11.1977; Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; BOGEN B, 1986, EUR J IMMUNOL, V16, P1373, DOI 10.1002/eji.1830161110; Brossart P, 1999, BLOOD, V93, P4309, DOI 10.1182/blood.V93.12.4309.412k19_4309_4317; CAMPBELL MJ, 1987, J IMMUNOL, V139, P2825; CAO WX, 1994, J EXP MED, V179, P195, DOI 10.1084/jem.179.1.195; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; Fagerberg J, 1999, INT J CANCER, V80, P671, DOI 10.1002/(SICI)1097-0215(19990301)80:5<671::AID-IJC7>3.0.CO;2-E; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GEORGE AJT, 1987, J IMMUNOL, V138, P628; Gulukota K, 1997, J MOL BIOL, V267, P1258, DOI 10.1006/jmbi.1997.0937; HAWKINS RE, 1994, BLOOD, V83, P3279; Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129; JANEWAY CA, 1975, P NATL ACAD SCI USA, V72, P2357, DOI 10.1073/pnas.72.6.2357; Kessler BM, 1997, J EXP MED, V185, P629, DOI 10.1084/jem.185.4.629; King CA, 1998, NAT MED, V4, P1281, DOI 10.1038/3266; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; LAURITZSEN GF, 1994, P NATL ACAD SCI USA, V91, P5700, DOI 10.1073/pnas.91.12.5700; LAURITZSEN GF, 1993, SCAND J IMMUNOL, V37, P77, DOI 10.1111/j.1365-3083.1993.tb01668.x; Manici S, 1999, J EXP MED, V189, P871, DOI 10.1084/jem.189.5.871; Molldrem J, 1996, BLOOD, V88, P2450, DOI 10.1182/blood.V88.7.2450.bloodjournal8872450; Munthe LA, 1999, EUR J IMMUNOL, V29, P4043, DOI 10.1002/(SICI)1521-4141(199912)29:12<4043::AID-IMMU4043>3.0.CO;2-E; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; NIJMAN HW, 1993, EUR J IMMUNOL, V23, P1215, DOI 10.1002/eji.1830230603; Osterroth F, 2000, BLOOD, V95, P1342, DOI 10.1182/blood.V95.4.1342.004k19_1342_1349; Pardoll DM, 1999, P NATL ACAD SCI USA, V96, P5340, DOI 10.1073/pnas.96.10.5340; PARKER KC, 1995, IMMUNOL RES, V14, P34, DOI 10.1007/BF02918496; PARKER KC, 1994, J IMMUNOL, V152, P163; Provan D, 1996, BLOOD, V88, P2228, DOI 10.1182/blood.V88.6.2228.bloodjournal8862228; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; Schirmbeck R, 1998, EUR J IMMUNOL, V28, P4149, DOI 10.1002/(SICI)1521-4141(199812)28:12<4149::AID-IMMU4149>3.0.CO;2-D; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172/JCI119822; SETTE A, 1994, J IMMUNOL, V153, P5586; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; vanderBurg SH, 1996, J IMMUNOL, V156, P3308; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Wang RF, 1996, J EXP MED, V184, P2207, DOI 10.1084/jem.184.6.2207; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; WEISS S, 1989, P NATL ACAD SCI USA, V86, P282, DOI 10.1073/pnas.86.1.282; Wen YJ, 1998, BRIT J HAEMATOL, V100, P464, DOI 10.1046/j.1365-2141.1998.00592.x; Wen YJ, 1997, EUR J IMMUNOL, V27, P1043, DOI 10.1002/eji.1830270435; Wen YJ, 1998, CLIN CANCER RES, V4, P957	45	149	166	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					667	672		10.1038/76243	http://dx.doi.org/10.1038/76243			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835683				2022-12-27	WOS:000087438300037
J	Ramiya, VK; Maraist, M; Arfors, KE; Schatz, DA; Peck, AB; Cornelius, JG				Ramiya, VK; Maraist, M; Arfors, KE; Schatz, DA; Peck, AB; Cornelius, JG			Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells	NATURE MEDICINE			English	Article							HEPATOCYTE GROWTH-FACTOR; BETA-CELLS; NOD MOUSE; ENDOCRINE PANCREAS; PRECURSOR CELLS; SELF-RENEWAL; AR42J CELLS; DIFFERENTIATION; CULTURE; PROLIFERATION	Ductal structures of the adult pancreas contain stem cells that differentiate into islets of Langerhans. Here, we grew pancreatic ductal epithelial cells isolated from prediabetic adult non-obese diabetic mice in long-term cultures, where they were induced to produce functioning islets containing alpha, beta and delta cells. These in vitro-generated islets showed temporal changes in mRNA transcripts for islet cell-associated differentiation markers, responded in vitro to glucose challenge, and reversed insulin-dependent diabetes after being implanted into diabetic nonobese diabetic mice. The ability to control growth and differentiation of islet stem cells provides an abundant islet source for beta-cell reconstitution in type I diabetes.	Ixion Biotechnol, Alachua, FL 32615 USA; Q Med Scandinavia, San Diego, CA USA; Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Peck, AB (corresponding author), Ixion Biotechnol, 13709 Progr Blvd,Box 13, Alachua, FL 32615 USA.	peck.pathology@mail.health.ufl.edu						ANDERSON JT, 1993, AUTOIMMUNITY, V15, P113, DOI 10.3109/08916939309043886; BAUM J, 1962, DIABETES, V11, P371; BEATTIE GM, 1994, J CLIN ENDOCR METAB, V78, P1232, DOI 10.1210/jc.78.5.1232; BONNER G, 1993, PROTEIN ENG, V6, P41; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; Bouwens L, 1998, DIABETOLOGIA, V41, P629, DOI 10.1007/s001250050960; BRELJE TC, 1989, DIABETES, V38, P808, DOI 10.2337/diabetes.38.6.808; Cornelius JG, 1997, HORM METAB RES, V29, P271, DOI 10.1055/s-2007-979036; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; DUBOIS MP, 1975, P NATL ACAD SCI USA, V72, P1340, DOI 10.1073/pnas.72.4.1340; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; GU DL, 1993, DEVELOPMENT, V118, P33; HELLERSTROM C, 1984, DIABETOLOGIA, V26, P393; LACY PE, 1957, DIABETES, V6, P354, DOI 10.2337/diab.6.4.354; LARSSON LI, 1975, CELL TISSUE RES, V156, P167; LEARY T, 1992, J INVEST DERMATOL, V99, P422, DOI 10.1111/1523-1747.ep12616134; Lefebvre VH, 1998, DIABETES, V47, P134, DOI 10.2337/diabetes.47.1.134; LEITER EH, 1987, AM J PATHOL, V128, P380; Mashima H, 1996, ENDOCRINOLOGY, V137, P3969, DOI 10.1210/en.137.9.3969; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; MENGER MD, 1994, J CLIN INVEST, V93, P2280, DOI 10.1172/JCI117228; OCONNOR NE, 1981, LANCET, V1, P75; OHGAWARA H, 1993, TOHOKU J EXP MED, V169, P159, DOI 10.1620/tjem.169.159; OTONKOSKI T, 1993, J CLIN INVEST, V92, P1459, DOI 10.1172/JCI116723; OTONKOSKI T, 1994, DIABETES, V43, P947, DOI 10.2337/diabetes.43.7.947; PELLETIER G, 1975, J HISTOCHEM CYTOCHEM, V23, P699, DOI 10.1177/23.9.1100709; PICTET R, 1972, HDB PHYSL ENDOCRINOL, V7, P25; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rafaeloff R, 1997, J CLIN INVEST, V99, P2100, DOI 10.1172/JCI119383; RAMRAKHA PS, 1989, TRANSPLANTATION, V48, P676; RAO MS, 1989, AM J PATHOL, V134, P1069; Rooman I, 1997, LAB INVEST, V76, P225; ROSENBERG L, 1992, ADV EXP MED BIOL, V321, P95; SCHOFIELD R, 1985, LEUKEMIA RES, V9, P305, DOI 10.1016/0145-2126(85)90093-1; SENER A, 1990, DIABETES RES CLIN EX, V13, P157; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; Vogel G, 1999, SCIENCE, V283, P1432, DOI 10.1126/science.283.5407.1432; WANG TC, 1993, J CLIN INVEST, V92, P1349, DOI 10.1172/JCI116708; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; WEAVER CV, 1985, DIABETOLOGIA, V28, P781; WEIR GC, 1990, J CLIN INVEST, V85, P983, DOI 10.1172/JCI114574; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143	45	551	740	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					278	282						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700229				2022-12-27	WOS:000085580500037
J	Long, EM; Martin, HL; Kreiss, JK; Rainwater, SMJ; Lavreys, L; Jackson, DJ; Rakwar, J; Mandaliya, K; Overbaugh, J				Long, EM; Martin, HL; Kreiss, JK; Rainwater, SMJ; Lavreys, L; Jackson, DJ; Rakwar, J; Mandaliya, K; Overbaugh, J			Gender differences in HIV-1 diversity at time of infection	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GENITAL SECRETIONS; TRANSMISSION; BLOOD; SEROCONVERSION; HETEROGENEITY; POPULATIONS; WOMEN	To develop an HIV-1 vaccine with global efficacy, it is important to identify and characterize the viruses that are transmitted, particularly to individuals living in areas of high incidence. Several studies have shown that virus from the blood of acutely infected adults was homogeneous, even when the virus population in the index case was genetically diverse(1-4). In contrast to those results with mainly male cohorts in America and Europe, in several cases a heterogeneous virus population has been found early in infection in women in Africa(5,6). Thus, we more closely compared the diversity of transmitted HIV-1 in men and women who became infected through heterosexual contact. We found that women from Kenya were often infected by multiple virus variants, whereas men from Kenya were not. Moreover, a heterogeneous virus was present in the women before their seroconversion, and in each woman it was derived from a single index case, indicating that diversity was most likely to be the result of transmission of multiple variants. Our data indicate that there are important differences in the transmitted virus populations in women and men, even when cohorts from the same geographic region who are infected with the same subtypes of HIV-1 are compared.	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; Coast Prov Gen Hosp, Mombasa, Kenya	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Nairobi	Overbaugh, J (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA.			Starke, Michelle/0000-0003-3239-4801	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI038518, R21AI033873, N01AI035173, R01AI038518] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33873, AI38518, N01-AI35173-119] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; DELWART EL, 1995, PCR METH APPL, V4, pS202; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; HAJJAR AM, 1997, J CLIN MICROBIOL, P2349; Kampinga GA, 1997, VIROLOGY, V227, P63, DOI 10.1006/viro.1996.8318; Karlsson AC, 1998, AIDS, V12, P839, DOI 10.1097/00002030-199808000-00005; Martin HL, 1998, J INFECT DIS, V178, P1053, DOI 10.1086/515654; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MERTENS TE, 1996, AIDS, V10, P5221; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; Neilson JR, 1999, J VIROL, V73, P4393, DOI 10.1128/JVI.73.5.4393-4403.1999; Overbaugh J, 1996, AIDS RES HUM RETROV, V12, P107, DOI 10.1089/aid.1996.12.107; POSS M, 1995, J VIROL, V69, P8118, DOI 10.1128/JVI.69.12.8118-8122.1995; Rakwar J, 1999, AIDS, V13, P607, DOI 10.1097/00002030-199904010-00010; SWOFFORD DL, 1999, PAUP STAR PHYLOGENET; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	19	160	162	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					71	75						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613827				2022-12-27	WOS:000084583300038
J	Birmingham, K				Birmingham, K			Varmus bows out	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1219	1219		10.1038/15151	http://dx.doi.org/10.1038/15151			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545962	Bronze			2022-12-27	WOS:000086550600006
J	Novak, K				Novak, K			NIH backs large transplant tolerance project	NATURE MEDICINE			English	News Item								In a step towards output-targeted university funding, the Italian Ministry of Research has elected a special advisory board to monitor all national research projects. Historically, the use of public funds by universities has never been subjected to rigorous examination-a factor that has contributed to improper use of those funds. The 42-member advisory board, with three individuals dedicated to each research discipline, met for the first time in mid-October to outline appropriate assessment criteria. In the field of medicine and biology, guidelines will focus on the relationship between results and the declared aims of a project, whether or not materials and methods used are state-of-the-art, the effectiveness of inter-university collaborations and publication output. Enrico Solcia, Pavia University, and Mario Sangiorgi, Tor Vergata University, Rome, are both members of the new medicine advisory boards and claim, "[T]his strongly signals that Italy is ready to adopt an investment-oriented culture as the engine of scientific progress in its academic community." Modena University's Fabio Benfenati, who has been appointed to the biology board, adds, "the Research Ministry's decision to implement sound control over spending represents a significant change in the way national funding priorities in biomedicine are defined." The move is believed to go far beyond the reforms launched in 1997 (Nature 387, 538; 1997). "Since the beginning of the reform, the budget for national research projects has increased three-fold," says Jacopo Meldolesi, director of DIBIT, the research institute of the San Raffaele hospital in Milan, head of the biology medicine funding distribution committee. Furthermore, officials from the Research Ministry told Nature Medicine that a large infrastructure fund will also be made available by the end of the year to reward the universities that have been most efficient in spending public money.						Novak, Kristine/0000-0001-9314-1803				Novak K, 1999, NAT MED, V5, P470, DOI 10.1038/8336	1	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1222	1222		10.1038/15162	http://dx.doi.org/10.1038/15162			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545968				2022-12-27	WOS:000086550600012
J	Rouse, R				Rouse, R			Australia harmonizes bioethics guidelines	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					973	973		10.1038/12398	http://dx.doi.org/10.1038/12398			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10471264	Bronze			2022-12-27	WOS:000082337200015
J	Kirk, AD; Burkly, LC; Batty, DS; Baumgartner, RE; Berning, JD; Buchanan, K; Fechner, JH; Germond, RL; Kampen, RL; Patterson, NB; Swanson, SJ; Tadaki, DK; TenHoor, CN; White, L; Knechtle, SJ; Harlan, DM				Kirk, AD; Burkly, LC; Batty, DS; Baumgartner, RE; Berning, JD; Buchanan, K; Fechner, JH; Germond, RL; Kampen, RL; Patterson, NB; Swanson, SJ; Tadaki, DK; TenHoor, CN; White, L; Knechtle, SJ; Harlan, DM			Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates	NATURE MEDICINE			English	Article							CD40 LIGAND; ENDOTHELIAL-CELLS; T-CELLS; HELP; LYMPHOCYTES; ACTIVATION; TOLERANCE; SURVIVAL; GAMMA	CD154 is the ligand for the receptor CD40. This ligand-receptor pair mediates endothelial and antigen-presenting cell activation, and facilitates the interaction of these cells with T cells and platelets. We demonstrate here that administration of a CD154-specific monoclonal antibody (hu5C8) allows for renal allotransplantation in outbred, MHC-mismatched rhesus monkeys without acute rejection. The effect persisted for more than 10 months after therapy termination, and no additional drug was required to achieve extended graft survival. Indeed, the use of tacrolimus or chronic steroids seemed to antagonize the anti-rejection effect. Monkeys treated with antibody against CD154 remained healthy during and after therapy. The mechanism of action does not require global depletion of T or B cells. Long-term survivors lost their mixed lymphocyte reactivity in a donor-specific manner, but still formed donor-specific antibody and generated T cells that infiltrated the grafted organ without any obvious effect on graft function. Thus, therapy with antibody against CD154 is a promising agent for clinical use in human allotransplantation.	USN, Med Res Ctr, Immune Cell Biol Program, Bethesda, MD 20889 USA; Univ Wisconsin, Sch Med, Div Transplantat, Madison, WI 53792 USA; Walter Reed Army Med Ctr, Organ Transplant Serv, Washington, DC 20307 USA; Biogen Inc, Cambridge Ctr 14, Cambridge, MA 02142 USA	United States Department of Defense; United States Navy; University of Wisconsin System; University of Wisconsin Madison; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Biogen	Kirk, AD (corresponding author), USN, Med Res Ctr, Immune Cell Biol Program, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.		Kirk, Allan D./B-6905-2012; Fechner, John/C-5962-2016	Fechner, John/0000-0002-8220-7237; Kirk, Allan/0000-0003-2004-5962; Knechtle, Stuart/0000-0002-1625-385X				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HARLAN DM, 1998, CRAFT, V1, P63; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; KIRK AD, 1995, HUM IMMUNOL, V43, P113, DOI 10.1016/0198-8859(94)00158-M; Kirk AD, 1997, TRANSPLANTATION, V64, P1716, DOI 10.1097/00007890-199712270-00015; Knapp LA, 1997, TISSUE ANTIGENS, V50, P170, DOI 10.1111/j.1399-0039.1997.tb02856.x; Knechtle SJ, 1997, TRANSPLANTATION, V63, P1, DOI 10.1097/00007890-199701150-00002; Konieczny BT, 1998, J IMMUNOL, V160, P2059; Laman JD, 1996, CRIT REV IMMUNOL, V16, P59, DOI 10.1615/CritRevImmunol.v16.i1.40; Larsen CP, 1997, CURR OPIN IMMUNOL, V9, P641, DOI 10.1016/S0952-7915(97)80043-X; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; Markees TG, 1998, J CLIN INVEST, V101, P2446, DOI 10.1172/JCI2703; PIRSCH JD, 1997, CURR OPIN ORGAN TRAN, V2, P76; PLAZ KP, 1991, TRANSPLANTATION, V51, P27; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	23	663	708	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					686	693		10.1038/9536	http://dx.doi.org/10.1038/9536			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371508				2022-12-27	WOS:000080823300038
J	Pitcher, CJ; Quittner, C; Peterson, DM; Connors, M; Koup, RA; Maino, VC; Picker, LJ				Pitcher, CJ; Quittner, C; Peterson, DM; Connors, M; Koup, RA; Maino, VC; Picker, LJ			HIV-1-specific CD4(+) T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; BONE-MARROW; RESPONSES; LYMPHOCYTES; RECONSTITUTION; ACTIVATION; MICE; TRANSPLANTATION; CYTOMEGALOVIRUS	The role of HIV-1-specific CD4(+) T-cell responses in controlling HIV-1 infection remains unclear. Previous work has suggested that such cells are eliminated in the early stages of infection in most subjects, and thus cannot substantially contribute to host defense against HIV-l. Here, using flow cytometric detection of antigen-induced intracellular cytokines, we show that significant frequencies of gag specific, T-helper-l CD4(+) memory T cells are detectable in most subjects with active/progressive HIV-1 infection (median frequency, 0.12% of memory subset; range, 0-0.66%). Median frequencies of these cells were considerably higher in nonprogressive HIV-1 disease (0.40%), but there was substantial overlap between the two groups (range of nonprogressors, 0.10-1.7%). Continuous HIV-1 suppression with anti-retroviral therapy was associated with a time-dependent reduction in median frequencies of gag-specific CD4(+) memory T cells: 0.08% in subjects treated for 4-24 weeks, and 0.03% in subjects treated for 47-112 weeks. Thus, functional HIV-1-specific CD4(+) T cells are commonly available for support of anti-HIV-l effector responses in active disease, but their decline with anti-retroviral therapy indicates that immunologic participation in long-term HIV-1 control will probably require effective vaccination strategies.	Univ Texas, SW Med Ctr, Dept Pathol, Div Hematopathol & Immunol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Div Gen Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, Dallas, TX 75235 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Becton Dickinson Immunocytometry Syst, San Jose, CA 95131 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Becton Dickinson	Pitcher, CJ (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Div Hematopathol & Immunol, Dallas, TX 75235 USA.				NIAID NIH HHS [AI31545, AI35522] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031545, ZIAAI000855, Z01AI000855, R01AI035522, R01AI031545, R37AI035522] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson J, 1998, AIDS, V12, pF123, DOI 10.1097/00002030-199811000-00004; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CALLAHAN KM, 1990, J IMMUNOL, V144, P3341; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Clerici M, 1996, AIDS, V10, P603, DOI 10.1097/00002030-199606000-00005; Collins RH, 1997, EXP HEMATOL, V25, P147; Cottrez F, 1997, J CLIN INVEST, V99, P257, DOI 10.1172/JCI119154; Ferbas J, 1998, AIDS RES HUM RETROV, V14, pS153; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Harcourt GC, 1998, J EXP MED, V188, P1785, DOI 10.1084/jem.188.10.1785; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Johnson R P, 1998, AIDS, V12 Suppl A, pS113; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Mackall CL, 1997, IMMUNOL REV, V157, P61, DOI 10.1111/j.1600-065X.1997.tb00974.x; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Moss RB, 1998, AIDS RES HUM RETROV, V14, pS167; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Romieu R, 1998, INT IMMUNOL, V10, P1273, DOI 10.1093/intimm/10.9.1273; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rosenberg ES, 1998, AIDS RES HUM RETROV, V14, pS143; SCHWARTZ D, 1994, AIDS RES HUM RETROV, V10, P1703, DOI 10.1089/aid.1994.10.1703; Steinman R M, 1998, AIDS, V12 Suppl A, pS97; Valentine FT, 1998, AIDS RES HUM RETROV, V14, pS161; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Waldrop SL, 1998, J IMMUNOL, V161, P5284; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	34	657	668	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					518	525		10.1038/8400	http://dx.doi.org/10.1038/8400			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229228				2022-12-27	WOS:000081497400032
J	Craft, N; Shostak, Y; Carey, M; Sawyers, CL				Craft, N; Shostak, Y; Carey, M; Sawyers, CL			A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase	NATURE MEDICINE			English	Article							EPIDERMAL GROWTH-FACTOR; ESTROGEN-RECEPTOR; BREAST-CANCER; IN-VIVO; MEDIATED TRANSCRIPTION; UPSTREAM ENHANCER; PROTO-ONCOGENE; CELL-LINES; AMPLIFICATION; ACTIVATION	Prostate cancer progresses from a hormone-sensitive, androgen-dependent stage to a hormone-refractory, androgen-independent tumor. The androgen receptor pathway functions in these androgen-independent tumors despite anti-androgen therapy. In our LAPC-4 prostate cancer model, androgen-independent sublines expressed higher levels of the HER-2/neu receptor tyrosine kinase than their androgen-dependent counterparts. Forced overexpression of HER-2/neu in androgen-dependent prostate cancer cells allowed ligand-independent growth. HER-2/neu activated the androgen receptor pathway in the absence of ligand and synergized with low levels of androgen to 'superactivate' the pathway. By modulating the response to low doses of androgen, a tyrosine kinase receptor can restore androgen receptor function to prostate cancer cells, a finding directly related to the clinical progression of prostate cancer.	Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Hematol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Sawyers, CL (corresponding author), Univ Calif Los Angeles, Dept Med, 108333 Le Conte Ave,11-934 Factor Bldg, Los Angeles, CA 90095 USA.		Sawyers, Charles/G-5327-2016	Carey, Michael/0000-0003-3899-6280	NIGMS NIH HHS [GM08042] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADNANE J, 1989, ONCOGENE, V4, P1389; Arai Y, 1997, PROSTATE, V30, P195, DOI 10.1002/(SICI)1097-0045(19970215)30:3<195::AID-PROS8>3.0.CO;2-L; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; COBLEIGH MA, 1998, P AN M AM SOC CLIN, V17, pA97; CULIG Z, 1994, CANCER RES, V54, P5474; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; KUHN EJ, 1993, J UROLOGY, V150, P1427, DOI 10.1016/S0022-5347(17)35799-3; KYPRIANOU N, 1990, CANCER RES, V50, P3748; LEITZEL K, 1995, J CLIN ONCOL, V13, P1129, DOI 10.1200/JCO.1995.13.5.1129; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MELLON K, 1992, J UROLOGY, V147, P496, DOI 10.1016/S0022-5347(17)37287-7; Nagabhushan M, 1996, CANCER RES, V56, P3042; Pang S, 1997, CANCER RES, V57, P495; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; ROMIJN JC, 1988, PROSTATE, V12, P99, DOI 10.1002/pros.2990120112; Ross JS, 1997, CANCER-AM CANCER SOC, V79, P2162, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA98; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TALPIN ME, 1995, NEW ENGL J MED, V332, P1393; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; ZEILLINGER R, 1989, ONCOGENE, V4, P109	45	794	836	0	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					280	285		10.1038/6495	http://dx.doi.org/10.1038/6495			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086382				2022-12-27	WOS:000078851600031
J	Schierle, GS; Hansson, O; Leist, M; Nicotera, P; Widner, H; Brundin, P				Schierle, GS; Hansson, O; Leist, M; Nicotera, P; Widner, H; Brundin, P			Caspase inhibition reduces apoptosis and increases survival of nigral transplants	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; PARKINSONS-DISEASE; DOPAMINERGIC-NEURONS; IN-VIVO; GRAFTS; GROWTH	Transplantation of embryonic nigral tissue ameliorates functional deficiencies in Parkinson disease(1,2). The main practical constraints of neural grafting are the shortage of human donor tissue and the poor survival of dopaminergic neurons grafted into patients, which is estimated at 5-10% (refs. 3,4). The required amount of human tissue could be considerably reduced if the neuronal survival was augmented. Studies in rats indicate that most implanted embryonic neurons die within 1 week of transplantation(5,6), and that most of this cell death is apoptotic(6). Modified peptides, such as acetyl-tyrosinyl-valyl-alanyl-aspartyl-chloro-methylketone (Ac-YVAD-cmk), that specifically inhibit proteases of the caspase family(7) effectively block apoptosis in a plethora of experimental paradigms, such as growth factor withdrawal(8), excitotoxicity(9), axotomy(10), cerebral ischemia(11) and brain trauma(12). Here we examined the effects of caspase inhibition by Ac-YVAD-cmk on cell death immediately after donor tissue preparation and on long-term graft survival. Treatment of the embryonic nigral cell suspension with AcYVAD-cmk mitigated DNA fragmentation and reduced apoptosis in transplants. It also increased survival of dopaminergic neurons grafted to hemiparkinsonian rats, and thereby substantially improved functional recovery.	Univ Lund, Wallenberg Neurosci Ctr, Sect Neuronal Survival, S-22362 Lund, Sweden; Univ Konstanz, Fac Biol, Chair Mol Toxicol, D-78457 Constance, Germany	Lund University; University of Konstanz	Schierle, GS (corresponding author), Univ Lund, Wallenberg Neurosci Ctr, Sect Neuronal Survival, Solvegatan 17, S-22362 Lund, Sweden.	Gabriele.Schierle@mphy.lu.se	Hansson, Oskar/A-7134-2013; Leist, Marcel/D-2133-2010	Hansson, Oskar/0000-0001-8467-7286; Leist, Marcel/0000-0002-3778-8693				Barker RA, 1996, EXP NEUROL, V141, P79, DOI 10.1006/exnr.1996.0141; deBilbao F, 1996, NEUROREPORT, V7, P3051, DOI 10.1097/00001756-199611250-00051; Duan WM, 1998, EUR J NEUROSCI, V10, P2595, DOI 10.1046/j.1460-9568.1998.t01-1-00279.x; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Karlsson J, 1998, BRAIN RES, V805, P155, DOI 10.1016/S0006-8993(98)00702-1; Kordower JH, 1996, J COMP NEUROL, V370, P203; Kordower JH, 1998, MOVEMENT DISORD, V13, P383, DOI 10.1002/mds.870130303; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Lindvall O, 1997, NEUROREPORT, V8, pR3, DOI 10.1097/00001756-199709290-00036; MAHALIK TJ, 1994, EXP NEUROL, V129, P27, DOI 10.1006/exnr.1994.1144; MAYER E, 1993, NEUROSCIENCE, V56, P389, DOI 10.1016/0306-4522(93)90340-L; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; NAKAO N, 1995, NAT MED, V1, P226, DOI 10.1038/nm0395-226; NAKAO N, 1994, P NATL ACAD SCI USA, V91, P12408, DOI 10.1073/pnas.91.26.12408; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Rosenblad C, 1996, NEUROSCIENCE, V75, P979; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Whiteside G, 1998, BRAIN RES PROTOC, V2, P160, DOI 10.1016/S1385-299X(97)00032-9; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zawada WM, 1998, BRAIN RES, V786, P96, DOI 10.1016/S0006-8993(97)01408-X	24	237	255	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					97	100		10.1038/4785	http://dx.doi.org/10.1038/4785			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883846				2022-12-27	WOS:000077885000036
J	Ferber, S; Halkin, A; Cohen, H; Ber, I; Einav, Y; Goldberg, I; Barshack, I; Seijffers, R; Kopolovic, J; Kaiser, N; Karasik, A				Ferber, S; Halkin, A; Cohen, H; Ber, I; Einav, Y; Goldberg, I; Barshack, I; Seijffers, R; Kopolovic, J; Kaiser, N; Karasik, A			Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia	NATURE MEDICINE			English	Article							HOMEODOMAIN PROTEIN IDX-1; STEM-CELLS; ACTIVATION; GLUCOSE; PROMOTER; AGENESIS; ISLETS; PDX-1	Insulin gene expression is restricted to islet beta cells of the mammalian pancreas through specific control mechanisms mediated in part by specific transcription factors(1,2). The protein encoded by the pancreatic and duodenal homeobox gene 1 (PDX-1) is central in regulating pancreatic development and islet cell function(3). PDX-1 regulates insulin gene expression and is involved in islet cell-specific expression of various genes(4-7). Involvement of PDX-1 in islet-cell differentiation and function has been demonstrated mainly by 'loss-of-function' studies(8-11). We used a 'gain-of-function' approach to test whether PDX-1 could endow a non-islet tissue with pancreatic beta-cell characteristics in vivo. Recombinant-adenovirus-mediated gene transfer of PDX-1 to the livers of BALB/C and C57BL/6 mice activated expression of the endogenous, otherwise silent, genes for mouse insulin 1 and 2 and prohormone convertase 1/3 (PC 1/3). Expression of PDX-1 resulted in a substantial increase in hepatic immunoreactive insulin content and an increase of 300% in plasma immunoreactive insulin levels, compared with that in mice treated with control adenovirus. Hepatic immunoreactive insulin induced by PDX-1 was processed to mature mouse insulin 1 and 2 and was biologically active; it ameliorated hyperglycemia in diabetic mice treated with streptozotocin. These data indicate the capacity of PDX-1 to reprogram extrapancreatic tissue towards a beta-cell phenotype, may provide a valuable approach for generating 'self' surrogate beta cells, suitable for replacing impaired islet-cell function in diabetics.	Chaim Sheba Med Ctr, Endocrine Inst, IL-64239 Tel Aviv, Israel; Chaim Sheba Med Ctr, Inst Pathol, IL-64239 Tel Aviv, Israel; Sourasky Med Ctr, Dept Cardiol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Ramat Aviv, Israel; Tel Aviv Univ, Dept Life Sci, IL-69978 Ramat Aviv, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Endocrinol & Metab, IL-91120 Jerusalem, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Hebrew University of Jerusalem; Hadassah University Medical Center	Ferber, S (corresponding author), Chaim Sheba Med Ctr, Endocrine Inst, IL-64239 Tel Aviv, Israel.		Wilson, Matthew H/K-3193-2013	Ferber, Sarah/0000-0003-2764-2786				Alison M, 1998, CURR OPIN CELL BIOL, V10, P710, DOI 10.1016/S0955-0674(98)80111-7; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Gross DJ, 1996, ENDOCRINOLOGY, V137, P5610, DOI 10.1210/en.137.12.5610; Heller RS, 1998, GASTROENTEROLOGY, V115, P381, DOI 10.1016/S0016-5085(98)70204-5; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; Offield MF, 1996, DEVELOPMENT, V122, P983; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Seijffers R, 1999, ENDOCRINOLOGY, V140, P3311, DOI 10.1210/en.140.7.3311; Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, TRENDS ENDOCRIN MET, V8, P145, DOI 10.1016/S1043-2760(97)00008-8; Thorgeirsson SS, 1996, FASEB J, V10, P1249, DOI 10.1096/fasebj.10.11.8836038; vanHolde KE, 1997, J BIOL CHEM, V272, P26073, DOI 10.1074/jbc.272.42.26073; VOLLENWEIDER F, 1992, J BIOL CHEM, V267, P14629; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434	25	586	654	1	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					568	572		10.1038/75050	http://dx.doi.org/10.1038/75050			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802714				2022-12-27	WOS:000086796200042
J	Teitz, T; Wei, T; Valentine, MB; Vanin, EF; Grenet, J; Valentine, VA; Behm, FG; Look, AT; Lahti, JM; Kidd, VJ				Teitz, T; Wei, T; Valentine, MB; Vanin, EF; Grenet, J; Valentine, VA; Behm, FG; Look, AT; Lahti, JM; Kidd, VJ			Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN	NATURE MEDICINE			English	Article							DRUG-INDUCED APOPTOSIS; CELL-DEATH; ISLAND METHYLATION; SIGNALING COMPLEX; FAS; RECEPTOR; GENE; EXPRESSION; ACTIVATION; FAS/APO-1	Caspase 8 is a cysteine protease regulated in both a death-receptor-dependent and -independent manner during apoptosis. Here, we report that the gene for caspase 8 is frequently inactivated in neuroblastoma, a childhood tumor of the peripheral nervous system. The gene is silenced through DNA methylation as well as through gene deletion. Complete inactivation of CASP8 occurred almost exclusively in neuroblastomas with amplification of the oncogene MYCN. Caspase 8-null neuroblastoma cells were resistant to death receptor- and doxorubicin-mediated apoptosis, deficits that were corrected by programmed expression of the enzyme. Thus, caspase 8 acts as a tumor suppressor in neuroblastomas with amplification of MYCN.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA; St Jude Childrens Res Hosp, Dept Expt Hematol, Memphis, TN 38101 USA; St Jude Childrens Res Hosp, Dept Expt Oncol, Memphis, TN 38101 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38101 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38101 USA.	vincent.kidd@stjude.org			NATIONAL CANCER INSTITUTE [R01CA067938, R56CA067938, P30CA021765, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71907, CA 67938, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; Baylin SB, 1998, ADV CANCER RES, V72, P141; BELTINGER CP, 1995, CANCER RES, V55, P2053; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHENG NC, 1995, ONCOGENE, V10, P291; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Corn PG, 1999, CANCER RES, V59, P3352; Easton J, 1998, CANCER RES, V58, P2624; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 1997, CANCER RES, V57, P3823; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Gururajan R, 1998, GENOME RES, V8, P929, DOI 10.1101/gr.8.9.929; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KOHNO T, 1994, ONCOGENE, V9, P103; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; ZORNIG M, 1995, ONCOGENE, V10, P2397	43	642	658	4	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2000	6	5					529	535		10.1038/75007	http://dx.doi.org/10.1038/75007			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802708				2022-12-27	WOS:000086796200036
J	Wong, FS; Karttunen, J; Dumont, C; Wen, L; Visintin, I; Pilip, IM; Shastri, N; Pamer, EG; Janeway, CA				Wong, FS; Karttunen, J; Dumont, C; Wen, L; Visintin, I; Pilip, IM; Shastri, N; Pamer, EG; Janeway, CA			Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library	NATURE MEDICINE			English	Article							CD8(+) T-CELLS; NOD MICE; EXPRESSION CLONING; INSULIN; MOUSE; ANTIGEN; GENE; RARE; CD4+; PROTECTION	Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed at an early age by an immune process that involves both CD4 and CD8 T lymphocytes. The identification of autoantigens in diabetes is very important for the design of antigen-specific immunotherapy. By screening a pancreatic islet cDNA library, we have identified the autoantigen recognized by highly pathogenic CD8 T cells in the non-obese diabetic mouse, one of the best animal models for human diabetes. This is the first identification, to our knowledge, of a CD8 T-cell epitope in an autoimmune disease. The peptide recognized by the cells is in the same region of the insulin B chain as the epitope recognized by previously isolated pathogenic CD4 T cells. This has very important implications for the potential use of insulin in preventative therapy.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Infect Dis Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA	Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University; University of California System; University of California Berkeley	Wong, FS (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, 310 Cedar St, New Haven, CT 06520 USA.			Wen, Li/0000-0002-8805-2934; Wong, F. Susan/0000-0002-2812-8845	NIDDK NIH HHS [DK-53015] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053015] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAEKKESKOV S, 1990, NATURE, V347, P782, DOI 10.1038/347782a0; Bennett ST, 1997, NAT GENET, V17, P350, DOI 10.1038/ng1197-350; BERGEROT I, 1994, J AUTOIMMUN, V7, P655, DOI 10.1006/jaut.1994.1050; BERGMAN B, 1994, DIABETES, V43, P197, DOI 10.2337/diabetes.43.2.197; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Carel JC, 1996, HORM RES, V45, P44, DOI 10.1159/000184829; Daniel D, 1996, P NATL ACAD SCI USA, V93, P956, DOI 10.1073/pnas.93.2.956; DiLorenzo TP, 1998, P NATL ACAD SCI USA, V95, P12538, DOI 10.1073/pnas.95.21.12538; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; French MB, 1997, DIABETES, V46, P924; Harrison LC, 1996, J EXP MED, V184, P2167, DOI 10.1084/jem.184.6.2167; Hutchings P, 1998, J AUTOIMMUN, V11, P127, DOI 10.1006/jaut.1997.0184; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; Kay TWH, 1996, J IMMUNOL, V157, P3688; KELLER RJ, 1993, LANCET, V341, P927, DOI 10.1016/0140-6736(93)91215-8; Malarkannan S, 1996, P NATL ACAD SCI USA, V93, P13991, DOI 10.1073/pnas.93.24.13991; Malarkannan S, 1996, J IMMUNOL, V157, P4464; NAGATA M, 1994, J IMMUNOL, V152, P2042; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; SANDERSON S, 1995, J EXP MED, V182, P1751, DOI 10.1084/jem.182.6.1751; SANTAMARIA P, 1995, J IMMUNOL, V154, P2494; Serreze DV, 1997, J IMMUNOL, V158, P3978; SERREZE DV, 1994, DIABETES, V43, P505, DOI 10.2337/diabetes.43.3.505; SHIMIZU J, 1993, J IMMUNOL, V151, P1723; Smith KM, 1997, INT IMMUNOL, V9, P1355, DOI 10.1093/intimm/9.9.1355; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; Wang B, 1996, EUR J IMMUNOL, V26, P1762, DOI 10.1002/eji.1830260815; WENTWORTH BM, 1986, J MOL EVOL, V23, P305, DOI 10.1007/BF02100639; WICKER LS, 1994, DIABETES, V43, P500, DOI 10.2337/diabetes.43.3.500; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67; Zekzer D, 1998, J CLIN INVEST, V101, P68, DOI 10.1172/JCI119878; Zekzer D, 1997, DIABETES, V46, P1124, DOI 10.2337/diabetes.46.7.1124; 1995, TRANSPLANT P, V27, P3377	35	338	356	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1026	1031		10.1038/12465	http://dx.doi.org/10.1038/12465			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470079				2022-12-27	WOS:000082337200036
J	Flugel, A; Willem, M; Berkowicz, T; Wekerle, H				Flugel, A; Willem, M; Berkowicz, T; Wekerle, H			Gene transfer into CD4(+) T lymphocytes: Green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; MYELIN BASIC-PROTEIN; TOLERANCE INDUCTION; ENCEPHALOMYELITIS; EXPRESSION; LINES; ANTIGEN; VACCINATION; ACTIVATION; APOPTOSIS		Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society; Max Planck Society	Wekerle, H (corresponding author), Max Planck Inst Neurobiol, Dept Neuroimmunol, Am Klopferspitz 18A, D-82152 Martinsried, Germany.	hWekerle@neuro.mpg.de						Agarwal M, 1998, J VIROL, V72, P3720, DOI 10.1128/JVI.72.5.3720-3728.1998; BARBARESE E, 1992, J NEUROIMMUNOL, V39, P151, DOI 10.1016/0165-5728(92)90184-M; Bauer J, 1995, CURR OPIN IMMUNOL, V7, P839, DOI 10.1016/0952-7915(95)80057-3; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; BUNNELL BA, 1995, P NATL ACAD SCI USA, V92, P7739, DOI 10.1073/pnas.92.17.7739; Chiocchetti A, 1997, BBA-GENE STRUCT EXPR, V1352, P193, DOI 10.1016/S0167-4781(97)00010-9; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Ebert O, 1997, GENE THER, V4, P296, DOI 10.1038/sj.gt.3300394; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; KASID A, 1990, P NATL ACAD SCI USA, V87, P473, DOI 10.1073/pnas.87.1.473; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KORNER H, 1995, P NATL ACAD SCI USA, V92, P11066, DOI 10.1073/pnas.92.24.11066; KRAMER R, 1995, NAT MED, V1, P1162, DOI 10.1038/nm1195-1162; LUDOWYK PA, 1992, J NEUROIMMUNOL, V37, P237, DOI 10.1016/0165-5728(92)90008-9; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER JB, 1989, J ATMOS OCEAN TECH, V6, P980, DOI 10.1175/1520-0426(1989)006<0980:VOTMP>2.0.CO;2; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; Qin LH, 1997, HUM GENE THER, V8, P2019, DOI 10.1089/hum.1997.8.17-2019; QIN YF, 1992, EUR J IMMUNOL, V22, P1193, DOI 10.1002/eji.1830220513; Quinn ER, 1998, HUM GENE THER, V9, P1457, DOI 10.1089/hum.1998.9.10-1457; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; Rudoll T, 1996, GENE THER, V3, P695; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; Waisman A, 1996, NAT MED, V2, P899, DOI 10.1038/nm0896-899; WEINBERG AD, 1994, J IMMUNOL, V152, P4712; WEKERLE H, 1994, ANN NEUROL, V36, pS47, DOI 10.1002/ana.410360714; WOFFENDIN C, 1994, P NATL ACAD SCI USA, V91, P11581, DOI 10.1073/pnas.91.24.11581; ZEINE R, 1992, J NEUROIMMUNOL, V40, P57, DOI 10.1016/0165-5728(92)90213-5	31	113	116	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					843	847		10.1038/10567	http://dx.doi.org/10.1038/10567			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395334				2022-12-27	WOS:000081926600044
J	Charrad, RS; Li, Y; Delpech, B; Balitrand, N; Clay, D; Jasmin, C; Chomienne, C; Smadja-Joffe, F				Charrad, RS; Li, Y; Delpech, B; Balitrand, N; Clay, D; Jasmin, C; Chomienne, C; Smadja-Joffe, F			Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia	NATURE MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; MURINE MACROPHAGES; CELL-ADHESION; EXPRESSION; HYALURONATE; RECEPTOR; LYMPHOCYTES; PRECURSORS; ACTIVATION	Blockage in myeloid differentiation characterizes acute myeloid leukemia (AML); the stage of the blockage defines distinct AML subtypes (AML1/2 to AML5). Differentiation therapy in AML has recently raised interest because the survival of AML3 patients has been greatly improved using the differentiating agent retinoic acid. However, this molecule is ineffective in other AML subtypes. The CD44 surface antigen, on leukemic blasts from most AML patients, is involved in myeloid differentiation. Here, we report that ligation of CD44 with specific anti-CD44 monoclonal antibodies or with hyaluronan, its natural ligand, can reverse myeloid differentiation blockage in AML1/2 to AML5 subtypes. The differentiation of AML blasts was evidenced by the ability to produce oxidative bursts, the expression of lineage antigens and cytological modifications, all specific to normal differentiated myeloid cells. These results indicate new possibilities for the development of CD44-targeted differentiation therapy in the AML1/2 to AML5 subtypes.	Hop Paul Brousse, INSERM, U268, Lab Differenciat Hematopoiet Normale & Leucem, F-94807 Villejuif, France; Ctr Henri Becquerel, Oncol Mol Lab, F-76000 Rouen, France; Univ Paris 07, Hop St Louis, Biol Cellulaire Hematol Lab, Inst Hematol,EP CNRS 107, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Henri Becquerel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Smadja-Joffe, F (corresponding author), Hop Paul Brousse, INSERM, U268, Lab Differenciat Hematopoiet Normale & Leucem, 14 Ave PV Couturier, F-94807 Villejuif, France.			CHOMIENNE, Christine/0000-0001-5513-5752				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; AYROLDI E, 1995, BLOOD, V86, P2672; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BERTRAND P, 1985, J NEUROCHEM, V45, P434, DOI 10.1111/j.1471-4159.1985.tb04006.x; Bishop JF, 1996, BLOOD, V87, P1710, DOI 10.1182/blood.V87.5.1710.bloodjournal8751710; CHOMIENNE C, 1990, BLOOD, V76, P1710; CONOVER EJ, 1980, PRACTICAL NONPARAMET, V5, P213; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DELFINO DV, 1994, J IMMUNOL, V152, P5171; DELPECH B, 1985, ANAL BIOCHEM, V149, P555, DOI 10.1016/0003-2697(85)90613-X; DENNING SM, 1990, J IMMUNOL, V144, P7; GALANDRINI R, 1994, J IMMUNOL, V153, P21; Ghaffari S, 1996, LEUKEMIA, V10, P1773; GHAFFARI S, 1995, BLOOD, V86, P2976; GOYERT SM, 1997, LEUKOCYTES TYPING, V6, P963; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; GUNJI Y, 1992, BLOOD, V80, P429; HUET S, 1989, J IMMUNOL, V143, P798; KANNAGI R, 1997, LEUKOCYTES TYPING, V6, P348; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; KOOPMAN G, 1990, J IMMUNOL, V145, P3589; Legras S, 1998, BLOOD, V91, P3401, DOI 10.1182/blood.V91.9.3401.3401_3401_3413; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MENDELSOHN N, 1980, CANCER RES, V40, P1469; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MORIMOTO K, 1994, BLOOD, V83, P657; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; ROWLEY JD, 1977, LANCET, V1, P549; SAMBROOK J, 1989, MOL CLONING LAB MANU, P700; Slack JL, 1999, CANC TREAT, V99, P75; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TERSTAPPEN LWMM, 1991, LEUKEMIA, V5, P315; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; ZHONG Z, 1995, J CELL BIOL, V130, P485	39	135	145	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					669	676		10.1038/9518	http://dx.doi.org/10.1038/9518			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371506				2022-12-27	WOS:000080823300036
J	Karvonen, MK; Pesonen, U; Koulu, M; Niskanen, L; Laakso, M; Rissanen, A; Dekker, JM; 'T Hart, LM; Valve, R; Uusitupa, MIJ				Karvonen, MK; Pesonen, U; Koulu, M; Niskanen, L; Laakso, M; Rissanen, A; Dekker, JM; 'T Hart, LM; Valve, R; Uusitupa, MIJ			Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels	NATURE MEDICINE			English	Article							ENERGY-METABOLISM; ABNORMALITIES; POPULATION; PREVALENCE; BEHAVIOR	High serum levels of Petal and LDL cholesterol are important risk factors in the development of atherosclerotic coronary artery disease. Cholesterol metabolism is affected by nutritional, environmental and genetic factors. Neuropeptide Y (NPY), which is widely expressed in both the central and peripheral nervous systems' : has an important role in the hypothalamic regulation of energy balance by stimulating food intake(3-5) and favoring energy storage through increased lipoprotein lipase activity in white adipose tissue(6,7). As a parr of ongoing study of the genetic basis of obesity, we screened the NPY gene for sequence variants. We report here the identification of a common Leu(7)-to-Pro(7) polymorphism in the signal peptide of NPY. Presence of this Pro(7) in NPY was associated with higher serum levels of total and LDL cholesterol in obese subjects participating in two independent Finnish and Dutch studies. Furthermore, normal-weight Finns with Pro(7) also had higher serum levels of Petal and LDL cholesterol than did subjects with Leu(7)/Leu(7), as analyzed in three subsequent determinations at 5-year Intervals during a 10-year follow-up period. The NPY polymorphism was not associated with higher cholesterol levels in normal-weight Dutch. Our study provides evidence that NPY is linked to cholesterol metabolism and that the polymorphism producing Pro(7) in NPY is one of the strongest genetic factors identified thus far affecting serum cholesterol, particularly in obese subjects.	Univ Turku, Dept Pharmacol & Clin Pharmacol, FIN-20520 Turku, Finland; Univ Kuopio, Dept Med, FIN-70211 Kuopio, Finland; Univ Helsinki, Eating Disorder Unit, FIN-00250 Helsinki, Finland; Free Univ Amsterdam, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cellbiol, NL-2333 AL Leiden, Netherlands; Univ Kuopio, Dept Clin Nutr, FIN-70211 Kuopio, Finland	University of Turku; University of Eastern Finland; University of Helsinki; Vrije Universiteit Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Eastern Finland	Koulu, M (corresponding author), Univ Turku, Dept Pharmacol & Clin Pharmacol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	mkoulu@utu.fi	't Hart, Leen/ABG-3185-2021; Uusitupa, Matti Ilmari Julius/AAX-4929-2020	't Hart, Leen/0000-0003-4401-2938; Pesonen, Ullamari/0000-0002-9962-212X				BILLINGTON CJ, 1991, AM J PHYSIOL, V260, pR321, DOI 10.1152/ajpregu.1991.260.2.R321; BILLINGTON CJ, 1994, AM J PHYSIOL, V266, pR1765, DOI 10.1152/ajpregu.1994.266.6.R1765; CHAN L, 1992, J BIOL CHEM, V267, P25621; CLARK JT, 1985, ENDOCRINOLOGY, V117, P2435, DOI 10.1210/endo-117-6-2435; EHNHOLM C, 1986, J LIPID RES, V27, P227; GRAY TS, 1986, LIFE SCI, V38, P389, DOI 10.1016/0024-3205(86)90061-5; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; LUNDBERG JM, 1990, FUNDAM CLIN PHARM, V4, P373, DOI 10.1111/j.1472-8206.1990.tb00692.x; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P477, DOI 10.1111/j.1748-1716.1982.tb07171.x; MOOY JM, 1995, DIABETES CARE, V18, P1270, DOI 10.2337/diacare.18.9.1270; Nystrom Fredrik, 1996, Blood Pressure, V5, P349, DOI 10.3109/08037059609078073; Sipilainen R, 1997, DIABETES, V46, P77, DOI 10.2337/diabetes.46.1.77; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; UUSITUPA M, 1985, DIABETOLOGIA, V28, P22, DOI 10.1007/BF00276995; Uusitupa MIJ, 1996, AM J CLIN NUTR, V64, P131, DOI 10.1093/ajcn/64.2.131; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063	16	176	183	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1434	1437		10.1038/4027	http://dx.doi.org/10.1038/4027			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846584				2022-12-27	WOS:000077336900042
J	Brandt, ER; Sriprakash, KS; Hobb, RI; Hayman, WA; Zeng, WG; Batzloff, MR; Jackson, DC; Good, MF				Brandt, ER; Sriprakash, KS; Hobb, RI; Hayman, WA; Zeng, WG; Batzloff, MR; Jackson, DC; Good, MF			New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population	NATURE MEDICINE			English	Article							GROUP-A STREPTOCOCCI; B-CELL EPITOPES; M-PROTEIN; SYNTHETIC PEPTIDES; T-CELL; INTRANASAL IMMUNIZATION; RHEUMATIC-FEVER; IDENTIFICATION; ANTIBODIES; POLYMERIZATION	Infection with group A streptococci can result in acute and postinfectious pathology, including rheumatic fever and rheumatic heart disease. These diseases are associated with poverty and are increasing in incidence, particularly in developing countries and amongst indigenous populations, such as Australia's Aboriginal population, who suffer the highest incidence worldwide(1). Immunity to group A streptococci is mediated by antibodies against the M protein, a coiled-coil alpha helical surface protein of the bacterium(2). Vaccine development(3-5) faces two substantial obstacles. Although opsonic antibodies directed against the N terminus of the protein are mostly responsible for serotypic immunity, more than 100 serotypes exist. Furthermore, whereas the pathogenesis of rheumatic fever is not well understood, increasing evidence indicates an autoimmune process(6,7). To develop a suitable vaccine candidate, we first identified a minimum, helical, non-host-cross-reactive peptide from the conserved C-terminal half of the protein and displayed this within a non-M-protein peptide sequence designed to maintain helical folding and antigenicity, J14 (refs. 8,9). As this region of the M protein is identical in only 70% of group A streptococci isolates(10), the optimal candidate might consist of the conserved determinant with common N-terminal sequences found in communities with endemic group A streptococci. We linked seven serotypic peptides with J14 using a new chemistry technique that enables the immunogen to display all the individual peptides pendant from an alkane backbone. This construct demonstrated excellent immunogenicity and protection in mice.	Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia; Univ Queensland, Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld 4029, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Melbourne	Good, MF (corresponding author), Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.			Jackson, David/0000-0001-7255-270X				BEACHEY EH, 1981, NATURE, V292, P457, DOI 10.1038/292457a0; BEACHEY EH, 1986, J IMMUNOL, V136, P2287; BESSEN D, 1988, INFECT IMMUN, V56, P2666, DOI 10.1128/IAI.56.10.2666-2672.1988; Brandt ER, 1996, IMMUNOLOGY, V89, P331, DOI 10.1046/j.1365-2567.1996.d01-754.x; BRANDT ER, 1997, VACCINE, V16, P1805; Carapetis JR, 1996, MED J AUSTRALIA, V164, P146, DOI 10.5694/j.1326-5377.1996.tb122012.x; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V2; Dale JB, 1996, VACCINE, V14, P944, DOI 10.1016/0264-410X(96)00050-3; DEMALMANCHE SA, 1994, MED MICROBIOL IMMUN, V183, P299, DOI 10.1007/BF00196680; GARDINER D, 1995, PCR METH APPL, V4, P288; Hayman WA, 1997, INT IMMUNOL, V9, P1723, DOI 10.1093/intimm/9.11.1723; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5231; Jackson DC, 1997, VACCINE, V15, P1697, DOI 10.1016/S0264-410X(97)00085-6; Ji YD, 1997, INFECT IMMUN, V65, P2080, DOI 10.1128/IAI.65.6.2080-2087.1997; KAPUR V, 1994, MICROB PATHOGENESIS, V16, P443, DOI 10.1006/mpat.1994.1044; KOTB M, 1989, J IMMUNOL, V142, P966; OBrienSimpson NM, 1997, J AM CHEM SOC, V119, P1183, DOI 10.1021/ja962707k; PRUKSAKORN S, 1994, INT IMMUNOL, V6, P1235, DOI 10.1093/intimm/6.8.1235; PRUKSAKORN S, 1994, LANCET, V344, P639, DOI 10.1016/S0140-6736(94)92083-4; PRUKSAKORN S, 1992, J IMMUNOL, V149, P2729; QUINN RW, 1985, PEDIATR INFECT DIS J, V4, P374, DOI 10.1097/00006454-198507000-00008; RELF WA, 1992, J CLIN MICROBIOL, V30, P3190, DOI 10.1128/JCM.30.12.3190-3194.1992; Relf WA, 1996, PEPTIDE RES, V9, P12; ROBINSON JH, 1992, IMMUNOL TODAY, V13, P362, DOI 10.1016/0167-5699(92)90173-5; SALVADORI LG, 1995, J INFECT DIS, V171, P593, DOI 10.1093/infdis/171.3.593	25	127	129	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					455	459		10.1038/74719	http://dx.doi.org/10.1038/74719			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742155				2022-12-27	WOS:000165474100042
J	Liu, P; Aitken, K; Kong, YY; Opavsky, MA; Martino, T; Dawood, F; Wen, WH; Kozieradzki, I; Bachmaier, K; Straus, D; Mak, TW; Penninger, JM				Liu, P; Aitken, K; Kong, YY; Opavsky, MA; Martino, T; Dawood, F; Wen, WH; Kozieradzki, I; Bachmaier, K; Straus, D; Mak, TW; Penninger, JM			The tyrosine kinase p56(lck) is essential in coxsackievirus B3-mediated heart disease	NATURE MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; DECAY-ACCELERATING FACTOR; CELL ANTIGEN RECEPTOR; MICE LACKING P56(LCK); DILATED CARDIOMYOPATHY; SIGNAL TRANSDUCTION; DIFFERENT STRAINS; T-CELLS; MYOCARDITIS; VIRUS	Infections are thought to be important in the pathogenesis of many heart diseases. Coxsackievirus B3 (CVB3) has been linked to chronic dilated cardiomyopathy, a common cause of progressive heart disease, heart failure and sudden death. We show here that the sarcoma (Src) family kinase Lck (p56(kk)) is required for efficient CVB3 replication in T-cell lines and for viral replication and persistence in vivo. Whereas infection of wild-type mice with human pathogenic CVB3 caused acute and very severe myocarditis, meningitis, hepatitis, pancreatitis and dilated cardiomyopathy, mice lacking the p56(lck) gene were completely protected from CVB3-induced acute pathogenicity and chronic heart disease. These data identify a previously unknown function of Src family kinases and indicate that p56(lck) is the essential host factor that controls the replication and pathogenicity of CVB3.	Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Univ Hlth Network, Heart & Stroke Lewar Ctr Excellence Cardiovasc Re, Toronto, ON M5G 2C4, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Chicago; University of Chicago	Penninger, JM (corresponding author), Ontario Canc Inst, Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Aitken, KJ/AAC-5383-2019; Bachmaier, Kurt/B-6331-2014; Penninger, Josef M/I-6860-2013	Bachmaier, Kurt/0000-0002-0299-2707; Penninger, Josef M/0000-0002-8194-3777; Aitken, Karen/0000-0003-2995-0205				Anderson DR, 1996, J VIROL, V70, P4632, DOI 10.1128/JVI.70.7.4632-4645.1996; Archard LC, 1998, HUM PATHOL, V29, P578, DOI 10.1016/S0046-8177(98)80006-3; Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Friman G, 1995, EUR HEART J, V16, P36, DOI 10.1093/eurheartj/16.suppl_O.36; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; Gauntt CJ, 1995, EUR HEART J, V16, P56, DOI 10.1093/eurheartj/16.suppl_O.56; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Huber SA, 1997, LAB INVEST, V76, P691; HUBER SA, 1984, AM J PATHOL, V116, P21; Klingel K, 1996, J VIROL, V70, P8888, DOI 10.1128/JVI.70.12.8888-8895.1996; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MARTINO TA, 1993, J CLIN MICROBIOL, V31, P2634, DOI 10.1128/JCM.31.10.2634-2640.1993; MARTINO TA, 1994, CIRC RES, V74, P182, DOI 10.1161/01.RES.74.2.182; MATSUMORI A, 1982, CIRCULATION, V65, P1230, DOI 10.1161/01.CIR.65.6.1230; MOLINA TJ, 1993, J IMMUNOL, V151, P699; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROSE NR, 1988, IMMUNOL TODAY, V9, P117, DOI 10.1016/0167-5699(88)91282-0; Shafren DR, 1998, J VIROL, V72, P9407, DOI 10.1128/JVI.72.11.9407-9412.1998; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Wang XH, 1999, J VIROL, V73, P2559, DOI 10.1128/JVI.73.3.2559-2562.1999; WOLFGRAM LJ, 1986, J IMMUNOL, V136, P1846; WOODRUFF JF, 1980, AM J PATHOL, V101, P425	27	120	134	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					429	434		10.1038/74689	http://dx.doi.org/10.1038/74689			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742150				2022-12-27	WOS:000165474100037
J	Kost, J; Mitragotri, S; Gabbay, RA; Pishko, M; Langer, R				Kost, Joseph; Mitragotri, Samir; Gabbay, Robert A.; Pishko, Michael; Langer, Robert			Transdermal monitoring of glucose and other analytes using ultrasound	NATURE MEDICINE			English	Article									[Kost, Joseph] Ben Gur Univ, Dept Chem Engn, IL-84105 Beer Sheva, Israel; [Kost, Joseph; Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Mitragotri, Samir] Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; [Gabbay, Robert A.] Beth Israel Deaconess Med Ctr, Endocrine Div, Boston, MA 02215 USA; [Pishko, Michael] Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA; [Gabbay, Robert A.] Penn State Geisinger Hlth Syst, Sect Endocrinol & Diabet, Hershey, PA 17033 USA		Kost, J (corresponding author), Ben Gur Univ, Dept Chem Engn, IL-84105 Beer Sheva, Israel.; Kost, J; Langer, R (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	kost@bgumail.bgu.ac.il; rlanger@mit.edu	Kost, Joseph/F-2155-2012	Kost, Joseph/0000-0002-7854-533X	Juvenile Diabetic Foundation [197033]; United States-Israel Binational Science Foundation [93-00244]; Center for Disease Control; American Diabetes Association	Juvenile Diabetic Foundation; United States-Israel Binational Science Foundation(US-Israel Binational Science Foundation); Center for Disease Control; American Diabetes Association(American Diabetes Association)	We thank R. Rubin and A. Moses for advice; the Massachusetts Institute of Technology/Beth Israel Deaconess Medical Center Clinical Research Center teams and A. Patel for technical assistance; and Nicholas Warner and Tom Devlin for illustrations. This work was supported by American Diabetes Association and Juvenile Diabetic Foundation grants 197033, and the United States-Israel Binational Science Foundation grant 93-00244, and Center for Disease Control.	Antich T J, 1982, J Orthop Sports Phys Ther, V4, P99; Arnowitz J., 1998, NASA JDF TECHN WORKS; CLARKE WL, 1987, DIABETES CARE, V10, P622, DOI 10.2337/diacare.10.5.622; CSOREGI E, 1995, ANAL CHEM, V67, P1240; Eppstein J., 1995, US Patent, Patent No. [US5458140, 5458140]; Gutman S., 1998, REV CRITERIA ASSESSM; JOHNSON KW, 1992, BIOSENS BIOELECTRON, V7, P709, DOI 10.1016/0956-5663(92)85053-D; Klonoff DC, 1997, DIABETES CARE, V20, P433, DOI 10.2337/diacare.20.3.433; Kost J, 1993, TOPICAL DRUG BIOAVAI, P91; Kurnik RT, 1998, J ELECTROCHEM SOC, V145, P4119, DOI 10.1149/1.1838924; Liu J, 1998, PHARMACEUT RES, V15, P918, DOI 10.1023/A:1011984817567; Mastrototaro J., 1998, NASA JDF TECHN WORKS; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; Rao G, 1995, PHARM RES-DORDR, V12, P1869, DOI 10.1023/A:1016271301814; Roe JN, 1998, CRIT REV THER DRUG, V15, P199; Ross D, 1997, BRIT MED J, V315, P288, DOI 10.1136/bmj.315.7103.288; TACHIBANA K, 1992, PHARMACEUT RES, V9, P952, DOI 10.1023/A:1015869420159; TAMADA JA, 1995, NAT MED, V1, P1198, DOI 10.1038/nm1195-1198; Wayforth H.B, 1992, EXPT SURG TECHNIQUES, P215	19	176	181	3	29	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					347	350		10.1038/73213	http://dx.doi.org/10.1038/73213			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK7ZM	10700240				2022-12-27	WOS:000755169100001
J	Steinhoff, M; Vergnolle, N; Young, SH; Tognetto, M; Amadesi, S; Ennes, HS; Trevisani, M; Hollenberg, MD; Wallace, JL; Caughey, GH; Mitchell, SE; Williams, LM; Geppetti, P; Mayer, EA; Bunnett, NW				Steinhoff, M; Vergnolle, N; Young, SH; Tognetto, M; Amadesi, S; Ennes, HS; Trevisani, M; Hollenberg, MD; Wallace, JL; Caughey, GH; Mitchell, SE; Williams, LM; Geppetti, P; Mayer, EA; Bunnett, NW			Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism	NATURE MEDICINE			English	Article							GENE-RELATED PEPTIDE; MAST-CELL TRYPTASE; SPINAL DORSAL HORN; SUBSTANCE-P; ENDOTHELIAL-CELLS; THROMBIN RECEPTOR; IN-VITRO; SKIN; VASODILATOR; CGRP	Trypsin and mast cell tryptase cleave proteinase-activated receptor 2 and, by unknown mechanisms, induce widespread inflammation. We found that a large proportion of primary spinal afferent neurons, which express proteinase-activated receptor 2, also contain the proinflammatory neuropeptides calcitonin gene-related peptide and substance P. Trypsin and tryptase directly signal to neurons to stimulate release of these neuropeptides, which mediate inflammatory edema induced by agonists of proteinase-activated receptor 2. This new mechanism of protease-induced neurogenic inflammation may contribute to the proinflammatory effects of mast cells in human disease. Thus, tryptase inhibitors and antagonists of proteinase-activated receptor 2 may be useful anti-inflammatory agents.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, CURE VA UCLA Digest Dis Res Ctr, Los Angeles, CA 90073 USA; Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada; Rowett Res Inst, Aberdeen LS21 9JT, Scotland; Univ Ferrara, Dept Expt & Clin Med, Headache Ctr, Pharmacol Sect, I-44100 Ferrara, Italy	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Calgary; University of Aberdeen; University of Ferrara	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 513 Parnasus Ave, San Francisco, CA 94143 USA.		Steinhoff, Martin/F-6312-2013; Wallace, John/AAL-3763-2021; Geppetti, Pierangelo/AHA-7897-2022; Hollenberg, Morley/AFV-6966-2022; Vergnolle, Nathalie/C-7677-2018; Gw, Safwan/ABG-4675-2020	Vergnolle, Nathalie/0000-0003-1825-6015; Gw, Safwan/0000-0001-6764-1038; Bunnett, Nigel W./0000-0003-3367-0644; Steinhoff, Martin/0000-0002-7090-2187				BALUK P, 1995, AM J PHYSIOL-LUNG C, V268, pL263, DOI 10.1152/ajplung.1995.268.2.L263; BIELLA G, 1991, BRAIN RES, V559, P352, DOI 10.1016/0006-8993(91)90024-P; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 1998, J IMMUNOL, V161, P1939; Corvera CU, 1999, J PHYSIOL-LONDON, V517, P741, DOI 10.1111/j.1469-7793.1999.0741s.x; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Emilsson K, 1997, J VASC RES, V34, P267, DOI 10.1159/000159233; Ennes HS, 1997, NEUROREPORT, V8, P733, DOI 10.1097/00001756-199702100-00031; GARDINER SM, 1991, EUR J PHARMACOL, V199, P375, DOI 10.1016/0014-2999(91)90504-J; GEPPETTI P, 1988, REGUL PEPTIDES, V23, P289, DOI 10.1016/0167-0115(88)90229-7; He SH, 1997, J IMMUNOL, V159, P6216; He SH, 1997, EUR J PHARMACOL, V328, P89, DOI 10.1016/S0014-2999(97)83033-6; Holzer P, 1998, GEN PHARMACOL, V30, P5, DOI 10.1016/S0306-3623(97)00078-5; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; HUGHES SR, 1991, BRIT J PHARMACOL, V104, P738, DOI 10.1111/j.1476-5381.1991.tb12497.x; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; LEGREVES P, 1985, EUR J PHARMACOL, V115, P309, DOI 10.1016/0014-2999(85)90706-X; McCafferty DM, 1997, AM J PHYSIOL-GASTR L, V272, pG272, DOI 10.1152/ajpgi.1997.272.2.G272; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NAUKKARINEN A, 1994, INT J DERMATOL, V33, P361, DOI 10.1111/j.1365-4362.1994.tb01069.x; NEWBOLD P, 1993, BRIT J PHARMACOL, V108, P705, DOI 10.1111/j.1476-5381.1993.tb12865.x; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OKU R, 1987, BRAIN RES, V403, P350, DOI 10.1016/0006-8993(87)90074-6; Reinshagen M, 1996, AM J PHYSIOL-GASTR L, V270, pG79, DOI 10.1152/ajpgi.1996.270.1.G79; Reinshagen M, 1998, J PHARMACOL EXP THER, V286, P657; RENZI D, 1987, TRENDS CLUSTER HEADA, P125; Saifeddine M, 1996, BRIT J PHARMACOL, V118, P521, DOI 10.1111/j.1476-5381.1996.tb15433.x; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; Vergnolle N, 1998, P NATL ACAD SCI USA, V95, P7766, DOI 10.1073/pnas.95.13.7766; Vu TH, 1991, CELL, V64, P1; Wallace JL, 1998, REGUL PEPTIDES, V73, P95, DOI 10.1016/S0167-0115(97)01064-1; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K	45	733	766	0	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					151	158		10.1038/72247	http://dx.doi.org/10.1038/72247			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655102				2022-12-27	WOS:000085016900034
J	Ronemus, M				Ronemus, M			A new match-maker	NATURE MEDICINE			English	Editorial Material																		WEBER, 1999, CYTOGENETICS CELL GE, V86, P142	1	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					19	19		10.1038/71475	http://dx.doi.org/10.1038/71475			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613814				2022-12-27	WOS:000084583300021
J	Hulett, MD; Freeman, C; Hamdorf, BJ; Baker, RT; Harris, MJ; Parish, CR				Hulett, MD; Freeman, C; Hamdorf, BJ; Baker, RT; Harris, MJ; Parish, CR			Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis	NATURE MEDICINE			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; SULFATE-DEGRADING ENZYMES; FLAVOBACTERIUM-HEPARINUM; SUBSTRATE-SPECIFICITY; BASEMENT-MEMBRANES; FIBROBLAST GROWTH; DEGRADATION; CELLS; ENDOGLYCOSIDASE; INHIBITION	The endoglycosidase heparanase is an important in the degradation of the extracellular matrix by invading cells, notably metastatic tumor cells and migrating leukocytes. Here we report the cDNA sequence of the human platelet enzyme, which encodes a unique protein of 543 amino acids, and the identification of highly homologous sequences in activated mouse T cells and in a highly metastatic rat adenocarcinoma. Furthermore, the expression of heparanase mRNA in rat tumor cells correlates with their metastatic potential. Exhaustive studies have shown only one heparanase sequence, consistent with the idea that this enzyme is the dominant endoglucuronidase in mammalian tissues.	Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol & Immunol, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Mol Med, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research	Parish, CR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol & Immunol, Canberra, ACT 2601, Australia.		Hulett, Mark D/C-4160-2012	Hulett, Mark/0000-0003-2072-5968; Parish, Christopher/0000-0001-7740-0430				BARNER M, 1986, J CELL PHYSIOL, V128, P299, DOI 10.1002/jcp.1041280223; BARTLE RG, 1995, PUBLISH RES Q, V11, P3, DOI 10.1007/BF02680421; CAMPBELL JH, 1992, EXP CELL RES, V200, P156, DOI 10.1016/S0014-4827(05)80084-9; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DEVOUGE MW, 1994, INT J CANCER, V56, P286, DOI 10.1002/ijc.2910560224; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Freeman C, 1997, BIOCHEM J, V325, P229, DOI 10.1042/bj3250229; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Godavarti R, 1996, BIOCHEM BIOPH RES CO, V229, P770, DOI 10.1006/bbrc.1996.1879; GODDER K, 1991, J CELL PHYSIOL, V148, P274, DOI 10.1002/jcp.1041480213; Gonzalez-Stawinski GV, 1999, BBA-PROTEIN STRUCT M, V1429, P431, DOI 10.1016/S0167-4838(98)00254-4; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; GRAHAM LD, 1994, BIOCHEM J, V301, P917, DOI 10.1042/bj3010917; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HERSHKOVIZ R, 1995, J AUTOIMMUN, V8, P741, DOI 10.1006/jaut.1995.0055; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LASKOV R, 1991, INT J CANCER, V47, P92, DOI 10.1002/ijc.2910470117; LIDER O, 1989, J CLIN INVEST, V83, P752, DOI 10.1172/JCI113953; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; Messer M, 1997, COMP BIOCHEM PHYS B, V118, P403, DOI 10.1016/S0305-0491(97)00162-4; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; Parish CR, 1998, IMMUNOL CELL BIOL, V76, P104, DOI 10.1046/j.1440-1711.1998.00722.x; PARISH CR, 1992, INT J CANCER, V52, P378, DOI 10.1002/ijc.2910520309; PARISH CR, 1999, UNPUB CANC RES; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rechter M, 1999, BIOCHEM BIOPH RES CO, V255, P657, DOI 10.1006/bbrc.1999.0181; RICOVERI W, 1986, CANCER RES, V46, P3855; Sambrook J., 2002, MOL CLONING LAB MANU; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEWELL RF, 1989, BIOCHEM J, V264, P777, DOI 10.1042/bj2640777; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1992, INVAS METAST, V12, P112; WILLENBORG DO, 1988, J IMMUNOL, V140, P3401; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	44	453	531	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					803	809		10.1038/10525	http://dx.doi.org/10.1038/10525			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395326				2022-12-27	WOS:000081926600036
J	Finzi, D; Blankson, J; Siliciano, JD; Margolick, JB; Chadwick, K; Pierson, T; Smith, K; Lisziewicz, J; Lori, F; Flexner, C; Quinn, TC; Chaisson, RE; Rosenberg, E; Walker, B; Gange, S; Gallant, J; Siliciano, RF				Finzi, D; Blankson, J; Siliciano, JD; Margolick, JB; Chadwick, K; Pierson, T; Smith, K; Lisziewicz, J; Lori, F; Flexner, C; Quinn, TC; Chaisson, RE; Rosenberg, E; Walker, B; Gange, S; Gallant, J; Siliciano, RF			Latent infection of CD4(+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; PERIPHERAL-BLOOD; LYMPH-NODES; IN-VIVO; LYMPHOCYTES; EXPRESSION; RESERVOIR; PLASMA; INDIVIDUALS	Combination therapy for HIV-1 infection can reduce plasma virus to undetectable levels, indicating that prolonged treatment might eradicate the infection. However, HIV-1 can persist in a latent form in resting CD4(+) T cells. We measured the decay rate of this latent reservoir in 34 treated adults whose plasma virus levels were undetectable. The mean half-life of the latent reservoir was very long (43.9 months). If the latent reservoir consists of only 1 x 10(5) cells, eradication could take as long as 60 years. Thus, latent infection of resting CD4(+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective anti-retroviral therapy.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Cornell Univ, Coll Med, Dept Med, New York, NY 10021 USA; Georgetown Univ, Washington, DC 20007 USA; RIGHT, Washington, DC 20007 USA; NIAID, NIH, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Div Infect Dis, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Cornell University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Johns Hopkins University	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.		Quinn, Thomas/A-2494-2010; Gange, Stephen/AGY-5004-2022	Gange, Stephen/0000-0001-7842-512X; Lisziewicz, Julianna/0000-0002-3349-4495	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000361, R01AI043222, ZIAAI000361] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43222] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTLETT JG, 1998, MED MANAGEMENT HIV I; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; CHUN TW, 1999, 6 C RETR OPP INF CHI; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FOLKS T, 1986, J IMMUNOL, V136, P4049; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GARCIABLANCO MA, 1991, SCIENCE, V254, P815, DOI 10.1126/science.1658933; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 1998, J VIROL, V72, P2422; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; Harris M, 1997, J INFECT DIS, V176, P1388, DOI 10.1086/517328; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	40	1636	1680	0	73	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					512	517		10.1038/8394	http://dx.doi.org/10.1038/8394			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229227				2022-12-27	WOS:000081497400031
J	Kimata, JT; Kuller, L; Anderson, DB; Dailey, P; Overbaugh, J				Kimata, JT; Kuller, L; Anderson, DB; Dailey, P; Overbaugh, J			Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression	NATURE MEDICINE			English	Article							PLASMA VIRAL LOAD; HIV-1 INFECTION; ACQUIRED IMMUNODEFICIENCY; BIOLOGICAL PROPERTIES; REPLICATIVE CAPACITY; MACROPHAGE TROPISM; RHESUS-MONKEYS; MNE VARIANT; MACAQUES; TYPE-1	Genetic variants of human and simian immunodeficiency virus (HIV and SIV) that evolve during the course of infection and progression to AIDS are phenotypically and antigenically distinct from their progenitor viruses present at early stages of infection. However, it has been unclear how these late variants, which are typically T-cell tropic, cytopathic and resistant to neutralizing antibodies, influence the development of clinical AIDS. To address this, we infected macaques with cloned SIVs representing prototype variants from early-, intermediate- and late-stage infection having biological characteristics typical of viruses found at similar stages of HIV infection in humans. These studies demonstrate that sequential, phenotypic and antigenic variants represent viruses that have become increasingly fit for replication in the host, and our data support the hypothesis that emerging variants have increased pathogenicity and drive disease progression in SIV and HIV infection.	Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA; Chiron Diagnost, Chiron Ref Testing Lab, Emeryville, CA 94608 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Novartis; University of Washington; University of Washington Seattle	Overbaugh, J (corresponding author), Fred Hutchinson Canc Res Ctr, Program Mol Med, 1100 Fairview AveN,C3-168, Seattle, WA 98109 USA.			Kimata, Jason/0000-0002-0504-0090	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009337, R01AI034251] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [R01 AI34251, F32 AI09337, F32 AI009337, R01 AI034251] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASJO B, 1986, LANCET, V2, P660; BANAPOUR B, 1991, VIROLOGY, V183, P12, DOI 10.1016/0042-6822(91)90113-P; Chackerian B, 1997, J VIROL, V71, P7719, DOI 10.1128/JVI.71.10.7719-7727.1997; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Connor RI, 1998, J VIROL, V72, P7501, DOI 10.1128/JVI.72.9.7501-7509.1998; Dailey P. J., 1995, Journal of Medical Primatology, V24, P209; DESROSIERS RC, 1991, AM J PATHOL, V139, P29; Edmonson P, 1998, J VIROL, V72, P405, DOI 10.1128/JVI.72.1.405-414.1998; FENYO EM, 1989, AIDS, V3, pS5, DOI 10.1097/00002030-198901001-00002; FENYO EM, 1988, J VIROL, V62, P4414; FIORE JR, 1994, VIROLOGY, V204, P297, DOI 10.1006/viro.1994.1534; FULTZ PN, 1989, AIDS RES HUM RETROV, V5, P397, DOI 10.1089/aid.1989.5.397; Glushakova S, 1998, NAT MED, V4, P346, DOI 10.1038/nm0398-346; Harris M, 1997, J INFECT DIS, V176, P1388, DOI 10.1086/517328; Hirsch VM, 1996, J VIROL, V70, P3741, DOI 10.1128/JVI.70.6.3741-3752.1996; Joag SV, 1996, J VIROL, V70, P3189, DOI 10.1128/JVI.70.5.3189-3197.1996; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; Kimata JT, 1997, J VIROL, V71, P7629, DOI 10.1128/JVI.71.10.7629-7639.1997; Kimata JT, 1998, J VIROL, V72, P245, DOI 10.1128/JVI.72.1.245-256.1998; KIMATA JT, IN PRESS J VIROL; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MORTON WR, 1989, J MED PRIMATOL, V18, P237; NIELSEN C, 1993, AIDS, V7, P1035, DOI 10.1097/00002030-199308000-00002; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OVERBAUGH J, 1992, J VIROL, V66, P5937, DOI 10.1128/JVI.66.10.5937-5948.1992; OVERBAUGH J, 1991, J VIROL, V65, P7025, DOI 10.1128/JVI.65.12.7025-7031.1991; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; Rudensey LM, 1998, J VIROL, V72, P209, DOI 10.1128/JVI.72.1.209-217.1998; RUDENSEY LM, 1995, VIROLOGY, V207, P528, DOI 10.1006/viro.1995.1113; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; Watson A, 1997, J VIROL, V71, P284, DOI 10.1128/JVI.71.1.284-290.1997; ZACK JA, 1994, AIDS S1, V8, pS43	45	154	155	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					535	541		10.1038/8414	http://dx.doi.org/10.1038/8414			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229230				2022-12-27	WOS:000081497400034
J	Burkart, V; Wang, ZQ; Radons, J; Heller, B; Herceg, Z; Stingl, L; Wagner, EF; Kolb, H				Burkart, V; Wang, ZQ; Radons, J; Heller, B; Herceg, Z; Stingl, L; Wagner, EF; Kolb, H			Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin	NATURE MEDICINE			English	Article							NITRIC-OXIDE GENERATION; SYNGENEIC ISLET CELLS; DNA-DAMAGE; NOD MICE; TOXICITY; NICOTINAMIDE; APOPTOSIS; ACTIVATION; SYNTHETASE; ALLOXAN	Human type 1 diabetes results from the selective destruction of insulin-producing pancreatic beta cells during islet inflammation. Cytokines and reactive radicals released during this process con tribute to beta-cell death. Here we show that mice with a disrupted gene coding for poly (ADP-ribose) polymerase (PARP(-/-) mice) are completely resistant to the development of diabetes induced by the beta-cell toxin streptozocin. The mice remained normoglycemic and maintained normal levels of total pancreatic insulin content and normal islet ultrastructure. Cultivated PARP(-/-) islet cells resisted streptozocin-induced lysis and maintained intracellular NAD(+) levels. Our results identify NAD(+) depletion caused by PARP activation as the dominant metabolic event in islet-cell destruction, and provide information for the development of strategies to prevent the progression or manifestation of the disease in individuals at risk of developing type 1 diabetes.	Univ Dusseldorf, Diabet Res Inst, D-40225 Dusseldorf, Germany; Int Agcy Res Canc, F-69008 Lyon, France; Res Inst Mol Pathol, A-1030 Vienna, Austria	Heinrich Heine University Dusseldorf; World Health Organization; International Agency for Research on Cancer (IARC); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Burkart, V (corresponding author), Univ Dusseldorf, Diabet Res Inst, Hennekamp 65, D-40225 Dusseldorf, Germany.			Wagner, Erwin F/0000-0001-7872-0196				APPELS B, 1989, J IMMUNOL, V142, P3803; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BURKART V, 1992, INT J IMMUNOPHARMACO, V14, P1037, DOI 10.1016/0192-0561(92)90148-E; Cardinal JW, 1998, ENDOCRINOLOGY, V139, P2885, DOI 10.1210/en.139.6.2885; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; DELANEY CA, 1993, FEBS LETT, V333, P291, DOI 10.1016/0014-5793(93)80673-I; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Eguchi Y, 1997, CANCER RES, V57, P1835; EIZIRIK DL, 1988, ENDOCRINOLOGY, V123, P1001, DOI 10.1210/endo-123-2-1001; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FEHSEL K, 1993, DIABETES, V42, P496, DOI 10.2337/diabetes.42.3.496; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; KOLB H, 1987, DIABETES METAB REV, V3, P751, DOI 10.1002/dmr.5610030308; KOLB H, 1990, Journal of Autoimmunity, V3, P117; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P179, DOI 10.1515/bchm3.1995.376.3.179; KRONCKE KD, 1991, BIOCHEM BIOPH RES CO, V175, P752, DOI 10.1016/0006-291X(91)91630-U; LAZARUS SS, 1973, DIABETES, V22, P499, DOI 10.2337/diab.22.7.499; LEDOUX SP, 1988, DIABETES, V37, P1015, DOI 10.2337/diabetes.37.8.1015; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; McDaniel ML, 1996, P SOC EXP BIOL MED, V211, P24; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; RASSCHAERT J, 1992, ENDOCRINOLOGY, V130, P3522, DOI 10.1210/en.130.6.3522; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; SCHNEDL WJ, 1994, DIABETES, V43, P1326, DOI 10.2337/diabetes.43.11.1326; SESTILI P, 1990, J CANCER RES CLIN, V116, P615, DOI 10.1007/BF01637083; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simone E, 1996, HORM METAB RES, V28, P332, DOI 10.1055/s-2007-979808; Steiner L, 1997, DIABETOLOGIA, V40, P150, DOI 10.1007/s001250050656; SUAREZPINZON WL, 1994, ENDOCRINOLOGY, V134, P1006, DOI 10.1210/en.134.3.1006; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; TURK J, 1993, BIOCHEM BIOPH RES CO, V197, P1458, DOI 10.1006/bbrc.1993.2641; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YAMADA K, 1982, DIABETES, V31, P749, DOI 10.2337/diabetes.31.9.749; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	38	305	337	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					314	319		10.1038/6535	http://dx.doi.org/10.1038/6535			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086388				2022-12-27	WOS:000078851600037
J	Schnitzler, N; Haase, G; Podbielski, A; Lutticken, R; Schweizer, KG				Schnitzler, N; Haase, G; Podbielski, A; Lutticken, R; Schweizer, KG			A co-stimulatory signal through ICAM-beta(2) integrin-binding potentiates neutrophil phagocytosis	NATURE MEDICINE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; MAC-1 CD11B/CD18; ACTIVATION; STREPTOCOCCI; RECOGNITION; ANTIBODIES; LIGAND; SITE	The beta(2) integrin LFA-1 (lymphocyte function associated antigen; CD11a/CD18) is the common ligand for the intercellular adhesion molecules(1-4) (ICAMs). Integrins support cell function by providing co-stimulatory second signals that are a precondition for full cell activation first described for ICAM-1-binding to LFA-1 in lymphocytes(3,4). Integrins can also serve to activate functions associated with distinct subunits of other integrins(5). In addition to LFA-1, neutrophils express the beta(2) integrin Mac-1 (CD11b/CD18; CR3) that apparently contains multiple sites that bind invading microbes directly or through surface-fixed C3 (ref. 6), resulting in activation of the phagocyte function(7-11). Expression of the LFA-1 counter-receptor ICAM-1 on endothelial cells occurs only at the site of inflammation(12,13). Therefore, in neutrophils, ICAM-1 ligand binding could, as with lymphocytes, also play a part as a costimulatory signal to induce full phagocytotic function. We show that in neutrophils, the LFA-1 ligand interaction is the stimulatory signal to express full phagocytotic activation. This is best demonstrated by the rapid association of Streptococcus pyogenes with neutrophils, followed by ingestion, strong oxidative-burst induction and enhanced killing of these bacteria, which are well-known for their resistance to human neutrophil defense. These findings may contribute to the development of therapeutic strategies targeting the modulation of ICAM-1-leukocyte interaction.	Univ Hosp, Rhein Westfal TH Aachen, Natl Ref Ctr Streptococci, D-52057 Aachen, Germany; Univ Hosp Ulm, Dept Med Microbiol, D-89081 Ulm, Germany; Univ Hosp, Rhein Westfal TH Aachen, Inst Med Immunol, D-52057 Aachen, Germany; Univ Hosp, Rhein Westfal TH Aachen, Inst Med Microbiol, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Ulm University; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Haase, G (corresponding author), Univ Hosp, Rhein Westfal TH Aachen, Inst Med Microbiol, D-52057 Aachen, Germany.	haase@alpha.imib.rwth-aachen.de	Haase, Gerhard/C-6492-2009; Lütticken, Rudolf/B-2620-2009	Haase, Gerhard/0000-0001-7771-3189; Lütticken, Rudolf/0000-0002-7061-4759				BALTIMORE RS, 1977, J IMMUNOL, V118, P673; Berton G, 1996, INT J CLIN LAB RES, V26, P160, DOI 10.1007/BF02592978; Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; Kuhnemund O, 1998, APMIS, V106, P288; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MAYER CL, 1990, INFECT IMMUN, V58, P3765, DOI 10.1128/IAI.58.11.3765-3769.1990; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; Podbielski A, 1996, MOL MICROBIOL, V19, P429, DOI 10.1046/j.1365-2958.1996.377910.x; ROSS GD, 1985, J IMMUNOL, V134, P3307; ROZDZINSKI E, 1995, J CLIN INVEST, V95, P1078, DOI 10.1172/JCI117754; SALVADORI LG, 1995, J INFECT DIS, V171, P593, DOI 10.1093/infdis/171.3.593; SCHLOSSMANN SF, 1995, LEUCOCYTE TYPING, V5, P1548; SCHMIDT KH, 1993, FEMS IMMUNOL MED MIC, V7, P231, DOI 10.1016/0928-8244(93)90017-X; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TUOMANEN EI, 1992, P 6 NOV NORD FDN S L, P297; VAN SG, 1990, J IMMUNOL, V144, P4579; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; VERHOEF J, 1977, J IMMUNOL METHODS, V14, P303, DOI 10.1016/0022-1759(77)90141-7	25	56	59	1	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					231	235		10.1038/5597	http://dx.doi.org/10.1038/5597			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930874				2022-12-27	WOS:000078274400035
J	Moalem, G; Leibowitz-Amit, R; Yoles, E; Mor, F; Cohen, IR; Schwartz, M				Moalem, G; Leibowitz-Amit, R; Yoles, E; Mor, F; Cohen, IR; Schwartz, M			Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy	NATURE MEDICINE			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS PATIENTS; RAT OPTIC-NERVE; LYMPHOCYTE-T; GROWTH-FACTOR; BRAIN INJURY; IMMUNE PRIVILEGE; WHITE MATTER; SPINAL-CORD	Autoimmunity to antigens of the central nervous system is usually considered detrimental. T cells specific to a central nervous system self antigen, such as myelin basic protein, can indeed induce experimental autoimmune encephalomyelitis, but such T cells may nevertheless appear in the blood of healthy individuals. We show here that autoimmune T cells specific to myelin basic protein can protect injured central nervous system neurons from secondary degeneration. After a partial crush injury of the optic nerve, rats injected with activated anti-myelin basic protein T cells retained approximately 300% more retinal ganglion cells with functionally intact axons than did rats injected with activated T cells specific for other antigens. Electrophysiological analysis confirmed this finding and suggested that the neuroprotection could result from a transient reduction in energy requirements owing to a transient reduction in nerve activity. These findings indicate that T-cell autoimmunity in the central nervous system, under certain circumstances, can exert a beneficial effect by protecting injured neurons from the spread of damage.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	bnschwar@weizmann.weizmann.c.il	Moalem-Taylor, Gila/C-3116-2008; Cohen, Irun R/B-3542-2009; Mor, Felix/K-1093-2012	Moalem-Taylor, Gila/0000-0003-3828-9527; 				Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BURNS J, 1983, CELL IMMUNOL, V81, P435, DOI 10.1016/0008-8749(83)90250-2; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1991, ANNU REV IMMUNOL, V9, P567, DOI 10.1146/annurev.iy.09.040191.003031; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GILLIS S, 1978, J IMMUNOL, V120, P2027; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; HIRSHFELD H, 1970, FEBS LETT, V7, P317, DOI 10.1016/0014-5793(70)80193-4; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; Koller H, 1997, PROG NEUROBIOL, V52, P1, DOI 10.1016/S0301-0082(96)00065-2; Lambiase A, 1997, J ALLERGY CLIN IMMUN, V100, P408, DOI 10.1016/S0091-6749(97)70256-2; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; LIU DX, 1994, J NEUROCHEM, V62, P37; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MARTIN R, 1990, J IMMUNOL, V145, P540; Martin R, 1997, J NEURAL TRANSM-SUPP, P53; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MEESON AP, 1994, EXP NEUROL, V129, P299, DOI 10.1006/exnr.1994.1172; MIZRACHI Y, 1983, PARAPLEGIA, V21, P287, DOI 10.1038/sc.1983.48; MOR F, 1993, J CLIN INVEST, V92, P2199, DOI 10.1172/JCI116822; MOR F, 1992, J CLIN INVEST, V90, P2447, DOI 10.1172/JCI116136; MOR F, 1995, J IMMUNOL, V155, P3693; NAPARSTEK Y, 1983, EUR J IMMUNOL, V13, P418, DOI 10.1002/eji.1830130513; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; PALLADINI G, 1987, EXP NEUROL, V95, P639, DOI 10.1016/0014-4886(87)90305-0; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; RANSOM BR, 1990, STROKE, V21, P52; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; SAVIO T, 1989, J NEUROSCI, V9, P1126; SCHLUESENER HJ, 1985, J IMMUNOL, V135, P3128; SPIEGLER OL, 1996, FASEB J, V10, P1296; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; YAROM Y, 1983, NATURE, V303, P246, DOI 10.1038/303246a0; YOLES E, 1992, INVEST OPHTH VIS SCI, V33, P3586; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49; Yoles E, 1997, J NEUROTRAUM, V14, P665, DOI 10.1089/neu.1997.14.665; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZIVIN JA, 1991, SCI AM, V265, P56, DOI 10.1038/scientificamerican0791-56	53	707	729	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	1999	5	1					49	55		10.1038/4734	http://dx.doi.org/10.1038/4734			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883839				2022-12-27	WOS:000077885000029
J	Vocero-Akbani, AM; Vander Heyden, N; Lissy, NA; Ratner, L; Dowdy, SF				Vocero-Akbani, AM; Vander Heyden, N; Lissy, NA; Ratner, L; Dowdy, SF			Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 VARIANTS; IDENTIFICATION; INHIBITORS; INFECTIVITY; RESISTANCE; APOPTOSIS; DEATH	At present, treatment of HIV infection uses small inhibitory molecules that target HIV protease; however, the emergence of resistant HIV strains is increasingly problematic. To circumvent this, we report here a new 'Trojan horse' strategy to kill HIV-infected cells by exploiting HIV protease. We engineered a transducing, modified, apoptosis-promoting caspase-3 protein, TAT-Casp3, that substitutes HIV proteolytic cleavage sites for endogenous ones and efficiently transduces about 100% of cells, but remains inactive in uninfected cells. In HIV-infected cells, TAT-Casp3 becomes processed into an active form by HIV protease, resulting in apoptosis of the infected cell. This strategy could also be applied to other pathogens encoding specific proteases, such as hepatitis C virus, cytomegalovirus and malaria.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Dowdy, SF (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.	dowdy@pathology.wustl.edu		Ratner, Lee/0000-0003-2744-7294				Barrie KA, 1996, VIROLOGY, V219, P407, DOI 10.1006/viro.1996.0266; COATES PJ, 1994, J HISTOTECHNOL, V17, P261, DOI 10.1179/his.1994.17.3.261; Coffin J, 1997, RETROVIRUSES; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Gatlin J, 1998, VIROLOGY, V244, P87, DOI 10.1006/viro.1998.9083; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LILLEHOJ EP, 1988, J VIROL, V62, P3053, DOI 10.1128/JVI.62.8.3053-3058.1988; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; LOU X, 1998, CELL, V94, P481; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICE CM, 1996, FIELDS VIROLOGY, P931; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704; VOCEROAKBANI A, IN PRESS METHODS ENZ; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	32	207	249	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					29	33		10.1038/4710	http://dx.doi.org/10.1038/4710			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883836				2022-12-27	WOS:000077885000026
J	Tazebay, UH; Wapnir, IL; Levy, O; Dohan, O; Zuckier, LS; Zhao, QH; Deng, HF; Amenta, PS; Fineberg, S; Pestell, RG; Carrasco, N				Tazebay, UH; Wapnir, IL; Levy, O; Dohan, O; Zuckier, LS; Zhao, QH; Deng, HF; Amenta, PS; Fineberg, S; Pestell, RG; Carrasco, N			The mammary gland iodide transporter is expressed during lactation and in breast cancer	NATURE MEDICINE			English	Article							THYROID NA+/I-SYMPORTER; TRANSGENIC MICE; PROLACTIN; GRANULOSA; OXYTOCIN; CLONING; AMPLIFICATION; INHIBITION; CARCINOMA; PREGNANCY	The sodium/iodide symporter mediates active iodide transport in both healthy and cancerous thyroid tissue. By exploiting this activity, radioiodide has been used for decades with considerable success in the detection and treatment of thyroid cancer. Here we show that a specialized form of the sodium/iodide symporter in the mammary gland mediates active iodide transport in healthy lactating (but not in nonlactating) mammary gland and in mammary tumors. In addition to characterizing the hormonal regulation of the mammary gland sodium/iodide symporter, we demonstrate by scintigraphy that mammary adenocarcinomas in transgenic mice bearing Ras or Neu oncogenes actively accumulate iodide by this symporter in vivo. Moreover, more than 80% of the human breast cancer samples we analyzed by immunohistochemistry expressed the symporter, compared with none of the normal (nonlactating) samples from reductive mammoplasties. These results indicate that the mammary gland sodium/iodide symporter may be an essential breast cancer marker and that radioiodide should be studied as a possible option in the diagnosis and treatment of breast cancer.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Nucl Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med & Dev & Mol Biol, Bronx, NY 10461 USA; Montefiore Med Ctr, Dept Pathol, Bronx, NY 10467 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol, New Brunswick, NJ 08903 USA; Wyeth Lederle Vaccines, Pearl River, NY 10965 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Pfizer	Carrasco, N (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	carrasco@aecom.yu.edu	Zuckier, Lionel Sydney/I-7114-2019; Carrasco, Nancy/AAH-1053-2019; Dohan, Orsolya/B-3750-2012	Zuckier, Lionel Sydney/0000-0002-7212-0437; Carrasco, Nancy/0000-0003-4137-6162; Dohan, Orsolya/0000-0001-6235-5657; TAZEBAY, UYGAR HALIS/0000-0003-1999-8213	NCI NIH HHS [R29CA70897, R01CA75503] Funding Source: Medline; NIDDK NIH HHS [DK-07218] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070897, R01CA075503] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Villanueva LA, 1996, MOL HUM REPROD, V2, P725, DOI 10.1093/molehr/2.10.725; BALTER M, 1995, SCIENCE, V270, P1758, DOI 10.1126/science.270.5243.1758; BRAVERMAN LE, 2000, WERNER INGBARS THYRO, P295; CANCROFT ET, 1973, RADIOLOGY, V106, P441, DOI 10.1148/106.2.441; CARRASCO N, 1986, METHOD ENZYMOL, V125, P453; CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DEGROOT LJ, 1989, ENDOCRINOLOGY, P821; Digiuseppe JA, 1999, IN VIVO, V13, P1; DORRINGTON J, 1981, NATURE, V290, P600, DOI 10.1038/290600a0; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; FITZGERALD PJ, 1949, J CLIN ENDOCRINOL, V9, P1153, DOI 10.1210/jcem-9-11-1153; GITAYGOREN H, 1989, MOL CELL ENDOCRINOL, V61, P69, DOI 10.1016/0303-7207(89)90190-1; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HIGUCHI T, 1985, J ENDOCRINOL, V105, P339, DOI 10.1677/joe.0.1050339; HILL CR, 1986, NATURE, V321, P655, DOI 10.1038/321655a0; Hung MC, 1999, SEMIN ONCOL, V26, P51; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; KRASNOW JS, 1990, MOL ENDOCRINOL, V4, P13, DOI 10.1210/mend-4-1-13; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; MATTHEIJ JAM, 1982, HORM RES, V16, P219, DOI 10.1159/000179505; Mazzaferri EL, 1999, ONCOLOGY-NY, V13, P391; MCCORMACK JT, 1974, J ENDOCRINOL, V62, P101, DOI 10.1677/joe.0.0620101; MOUNTFORD PJ, 1986, NATURE, V322, P600, DOI 10.1038/322600a0; Nishiwaki H, 1986, Pancreas, V1, P324, DOI 10.1097/00006676-198607000-00006; Ohno M, 1999, MOL CELL BIOL, V19, P2051; PATERSON MC, 1991, CANCER RES, V51, P556; POCHIN EE, 1954, J CLIN ENDOCR METAB, V14, P1300; ROSENBLATT JS, 1988, PSYCHONEUROENDOCRINO, V13, P29, DOI 10.1016/0306-4530(88)90005-4; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; SOCOLOW EL, 1967, ENDOCRINOLOGY, V80, P337, DOI 10.1210/endo-80-2-337; Spitzweg C, 1998, J CLIN ENDOCR METAB, V83, P1746, DOI 10.1210/jc.83.5.1746; STUBBE P, 1986, BIBL NUTR DIET, V38, P206; VALENTA L, 1966, J CLIN ENDOCR METAB, V26, P1317, DOI 10.1210/jcem-26-12-1317; WAKERLEY JB, 1978, J ENDOCRINOL, V76, P493, DOI 10.1677/joe.0.0760493; Zingg HH, 1998, ADV EXP MED BIOL, V449, P287	42	383	409	0	18	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					871	878		10.1038/78630	http://dx.doi.org/10.1038/78630			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932223				2022-12-27	WOS:000165473800029
J	Wickware, P				Wickware, P			$1 million study renews HIV/transplant research	NATURE MEDICINE			English	News Item																			0	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					365	365		10.1038/74602	http://dx.doi.org/10.1038/74602			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742128	Bronze			2022-12-27	WOS:000165474100014
J	Carter, R; Mendis, KN; Miller, LH; Molineaux, L; Saul, A				Carter, R; Mendis, KN; Miller, LH; Molineaux, L; Saul, A			Malaria transmission-blocking vaccines - how can their development be supported?	NATURE MEDICINE			English	Editorial Material									Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; WHO, Roll Back Malaria Project, CH-1211 Geneva 27, Switzerland; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia	University of Edinburgh; World Health Organization; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Carter, R (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.		Saul, Allan J/I-6968-2013; Saul, Allan/ABH-2091-2020	Saul, Allan J/0000-0003-0665-4091; Saul, Allan/0000-0003-0665-4091	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000727, Z01AI000241, ZIAAI000241] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Birmingham K, 1999, NAT MED, V5, P1333, DOI 10.1038/70881; Engers HD, 1998, PARASITOL TODAY, V14, P56, DOI 10.1016/S0169-4758(97)01184-8; Holder AA, 1999, P NATL ACAD SCI USA, V96, P1167, DOI 10.1073/pnas.96.4.1167; Kaslow DC, 1997, INT J PARASITOL, V27, P183, DOI 10.1016/S0020-7519(96)00148-8; Roberts DR, 1997, EMERG INFECT DIS, V3, P295, DOI 10.3201/eid0303.970305; Ross R., 1911, PREVENTION MALARIA; SAUL A, 1993, ACTA TROP, V52, P283, DOI 10.1016/0001-706X(93)90013-2; Saul Allan, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P656; SINTON J. A., 1936, Records of the Malaria Survey of India, V6, P91; SINTON J. A., 1935, REC MALARIA SURV INDIA, V5-6, P223; *WHO, TDRRBMNALVAC20001 WH; World Health Organization, 1999, WORLD HLTH REP MAK D; *WWF CAN WWF US, 1998, RES DDT DIL	13	103	104	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					241	244		10.1038/73062	http://dx.doi.org/10.1038/73062			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700212	Green Published, Bronze			2022-12-27	WOS:000085580500019
J	Aamodt, S				Aamodt, S			Gut reaction	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					130	130		10.1038/72209	http://dx.doi.org/10.1038/72209			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655091				2022-12-27	WOS:000085016900020
J	Xing, XM; Wang, SC; Xia, WY; Zou, YY; Shao, RP; Kwong, KY; Yu, ZM; Zhang, S; Miller, S; Huang, L; Hung, MC				Xing, XM; Wang, SC; Xia, WY; Zou, YY; Shao, RP; Kwong, KY; Yu, ZM; Zhang, S; Miller, S; Huang, L; Hung, MC			The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis	NATURE MEDICINE			English	Article							HUMAN-BREAST-CANCER; E1A GENE-PRODUCTS; CELL LUNG-CANCER; OVARIAN-CANCER; C-ERBB-2 GENE; NEU ONCOGENE; 3T3 CELLS; EXPRESSION; TRANSCRIPTION; METASTASIS	Because HER-2/neu overexpression is important in cancer development, we looked for a method of suppressing the cell transformation mediated by HER-2/neu overexpression. We have identified that the DNA-binding protein PEA3, which is encoded by a previously isolated gene of the ets family, specifically targeted a DNA sequence on the HER-2/neu promoter and downregulated the promoter activity. Expression of PEA3 resulted in preferential inhibition of cell growth and tumor development of HER-2/neu-overexpressing cancer cells. This is a new approach to targeting HER-2/neu overexpression and also provides a rationale to the design for repressors of diseases caused by overexpression of pathogenic genes.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol, Houston, TX 77030 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021; Wang, Shao-Chun/P-9904-2019	Hung, Mien-Chie/0000-0003-4317-4740; Wang, Shao-Chun/0000-0002-5477-1682				Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Baselga J, 1998, CANCER RES, V58, P2825; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; BERCHUCK A, 1990, CANCER RES, V50, P4087; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; DEMILIA J, 1989, ONCOGENE, V4, P1233; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG Y, 1994, J BIOL CHEM, V269, P16566; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; HUNG MC, 1999, TARGETING HER 2 NEUO; PARK JB, 1989, CANCER RES, V49, P6605; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; Tan M, 1997, CANCER RES, V57, P1199; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WEINER DB, 1990, CANCER RES, V50, P421; WHITE MRA, 1992, ONCOGENE, V7, P677; Xia WY, 1997, CLIN CANCER RES, V3, P3; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Xing XM, 1996, CANCER GENE THER, V3, P168; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1992, ONCOGENE, V7, P2263; Yu DH, 1998, CANCER METAST REV, V17, P195, DOI 10.1023/A:1006054421970; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; Yu DH, 1998, ONCOGENE, V16, P2087, DOI 10.1038/sj.onc.1201729; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; ZHANG CT, 1989, CHINESE PHYS LETT, V6, P4, DOI 10.1088/0256-307X/6/1/002; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZHANG YJ, 1995, ONCOGENE, V10, P1947	47	149	152	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					189	195		10.1038/72294	http://dx.doi.org/10.1038/72294			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655108				2022-12-27	WOS:000085016900040
J	Birmingham, K				Birmingham, K			NCI strikes unique agreement with Ireland	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1221	1222		10.1038/15158	http://dx.doi.org/10.1038/15158			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545966				2022-12-27	WOS:000086550600010
J	Cushman, DW; Ondetti, MA				Cushman, DW; Ondetti, MA			Design of angiotensin converting enzyme inhibitors	NATURE MEDICINE			English	Editorial Material							BOTHROPS-JARARACA; RABBIT LUNG; PEPTIDES; VENOM				Cushman, DW (corresponding author), 20 Lake Shore Dr, W Windsor, NJ 08550 USA.							Burnett J C Jr, 1999, J Hypertens Suppl, V17, pS37; BYERS LD, 1973, BIOCHEMISTRY-US, V12, P2070, DOI 10.1021/bi00735a008; CASE DB, 1976, AM J MED, V61, P790, DOI 10.1016/0002-9343(76)90160-1; CHEUNG HS, 1973, BIOCHIM BIOPHYS ACTA, V293, P451, DOI 10.1016/0005-2744(73)90352-5; CUSHMAN DW, 1977, BIOCHEMISTRY-US, V16, P5484, DOI 10.1021/bi00644a014; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; CUSHMAN DW, 1982, ADV PHARMACOL THER, V3, P249; FERREIRA SH, 1970, BIOCHEMISTRY-US, V9, P2583, DOI 10.1021/bi00815a005; Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347; MONZINGO AF, 1982, BIOCHEMISTRY-US, V21, P3390, DOI 10.1021/bi00257a022; NG KKF, 1967, NATURE, V216, P762, DOI 10.1038/216762a0; ONDETTI MA, 1994, ANNU REV PHARMACOL, V34, P1; ONDETTI MA, 1971, BIOCHEMISTRY-US, V10, P4033, DOI 10.1021/bi00798a004; ONDETTI MA, 1984, CRC CR REV BIOCH MOL, V16, P381, DOI 10.3109/10409238409108720; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; PEART WS, 1975, NEW ENGL J MED, V292, P302, DOI 10.1056/NEJM197502062920609; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; STEITZ TA, 1967, J BIOL CHEM, V242, P4662; Summers J. B., 1998, ANNU REP MED CHEM, V33, P131; Weber MA, 1997, J HYPERTENS, V15, pS31, DOI 10.1097/00004872-199715066-00007	20	165	175	0	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1110	1112		10.1038/13423	http://dx.doi.org/10.1038/13423			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502801				2022-12-27	WOS:000082933200022
J	Naveilhan, P; Hassani, H; Canals, JM; Ekstrand, AJ; Larefalk, A; Chhajlani, V; Arenas, E; Gedda, K; Svensson, L; Thoren, P; Ernfors, P				Naveilhan, P; Hassani, H; Canals, JM; Ekstrand, AJ; Larefalk, A; Chhajlani, V; Arenas, E; Gedda, K; Svensson, L; Thoren, P; Ernfors, P			Normal feeding behavior, body weight and leptin response require the neuropeptide YY2 receptor	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; Y RECEPTOR; OBESE GENE; HEART-RATE; MICE; EXPRESSION; CLONING; SUBTYPES	Neuropeptide Y (NPY), a 36-amino-acid peptide widely expressed in the brain(1) is involved in many physiological responses(2), including hypothalamic control of food intake and cardiovascular homeostasis. NPY mediates its effects through binding to the Y1, Y2 and Y5 C-protein-coupled receptors(3-6). Little is known of the role of the Y2 receptor in mediating the different NPY effects. We inactivated the Y2 receptor subtype in mice and found that these mice developed increased body weight, food intake and fat deposition. The null mutant mice showed an attenuated response to leptin administration but a normal response to NPY-induced food intake and intact regulation of re-feeding and body weight after starvation. An absence of the Y2 receptor subtype also affected the basal control of heart rate, but did not influence blood pressure. These findings indicate an inhibitory role for the Y2 receptor subtype in the central regulation of body weight and control of food intake.	Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Lab, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Astra Hassle AB, Dept Biochem & Cell Biol, S-90736 Umea, Sweden	Karolinska Institutet; Karolinska Institutet	Ernfors, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Lab, S-17177 Stockholm, Sweden.		Canals, Josep M/M-3846-2014; Naveilhan, Philippe/K-2377-2015; Arenas, Ernest/AAO-5231-2020	Canals, Josep M/0000-0001-6829-7670; Naveilhan, Philippe/0000-0003-4093-4513; Arenas, Ernest/0000-0003-0197-6577; Ernfors, Patrik/0000-0002-1140-3986				ALLEN JM, 1983, REGUL PEPTIDES, V6, P247, DOI 10.1016/0167-0115(83)90143-X; Broberger C, 1997, NEUROENDOCRINOLOGY, V66, P393, DOI 10.1159/000127265; Chen XL, 1997, AM J PHYSIOL-HEART C, V273, pH1737, DOI 10.1152/ajpheart.1997.273.4.H1737; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; DEQUIDT ME, 1986, NEUROSCIENCE, V18, P545, DOI 10.1016/0306-4522(86)90057-6; DUMONT Y, 1993, J NEUROSCI, V13, P73; EDVINSSON L, 1984, BRIT J PHARMACOL, V83, P519, DOI 10.1111/j.1476-5381.1984.tb16516.x; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GIRARDIER L, 1995, J PHYSIOL-LONDON, V488, P779, DOI 10.1113/jphysiol.1995.sp021009; Johansson C, 1998, AM J PHYSIOL-REG I, V275, pR640, DOI 10.1152/ajpregu.1998.275.2.R640; Johansson C, 1997, ACTA PHYSIOL SCAND, V160, P133, DOI 10.1046/j.1365-201X.1997.00134.x; Kushi A, 1998, P NATL ACAD SCI USA, V95, P15659, DOI 10.1073/pnas.95.26.15659; Marsh DJ, 1998, NAT MED, V4, P718, DOI 10.1038/nm0698-718; McDermott BJ, 1997, EUR J PHARMACOL, V336, P257, DOI 10.1016/S0014-2999(97)01258-2; Naveilhan P, 1998, NEUROSCIENCE, V87, P289, DOI 10.1016/S0306-4522(98)00141-9; Nilsson Torun, 1996, Blood Pressure, V5, P164, DOI 10.3109/08037059609062125; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; Schreyer SA, 1998, ATHEROSCLEROSIS, V136, P17, DOI 10.1016/S0021-9150(97)00165-2; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; WETTSTEIN JG, 1995, PHARMACOL THERAPEUT, V65, P397, DOI 10.1016/0163-7258(95)98598-K; Zhang X, 1997, P NATL ACAD SCI USA, V94, P729, DOI 10.1073/pnas.94.2.729; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	28	219	238	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1188	1193		10.1038/13514	http://dx.doi.org/10.1038/13514			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502824				2022-12-27	WOS:000082933200047
J	Maitra, A; Wistuba, II; Virmani, AK; Sakaguchi, M; Park, IW; Stucky, A; Milchgrub, S; Gibbons, D; Minna, JD; Gazdar, AF				Maitra, A; Wistuba, II; Virmani, AK; Sakaguchi, M; Park, IW; Stucky, A; Milchgrub, S; Gibbons, D; Minna, JD; Gazdar, AF			Enrichment of epithelial cells for molecular studies	NATURE MEDICINE			English	Article							LASER-CAPTURE MICRODISSECTION; BREAST-CANCER; PANCREATIC ADENOCARCINOMA; CARCINOMA; TUMOR; TISSUE; LINES; ALLELOTYPE; XENOGRAFTS; PCR		Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	gazdar@simmons.swmed.edu			NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAR JK, 1994, TUMORI, V80, P290, DOI 10.1177/030089169408000410; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Eaton MC, 1997, BIOTECHNIQUES, V22, P100, DOI 10.2144/97221st01; FOSTER HM, 1990, J SURG ONCOL, V45, P4; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Gazdar AF, 1996, J CELL BIOCHEM, P1; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Going JJ, 1996, J PATHOL, V179, P121; HAHN SA, 1995, CANCER RES, V55, P4670; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; MCQUEEN HA, 1991, BRIT J CANCER, V63, P94, DOI 10.1038/bjc.1991.19; Racila E, 1998, P NATL ACAD SCI USA, V95, P4589, DOI 10.1073/pnas.95.8.4589; Reyes G, 1996, CANCER RES, V56, P5713; Sakaguchi M, 1999, BRIT J CANCER, V79, P416, DOI 10.1038/sj.bjc.6690065; SEYMOUR AB, 1994, CANCER RES, V54, P2761; SHIBATA D, 1992, AM J PATHOL, V141, P539; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; STEVENSON H, 1990, ANN INTERN MED, V113, P764, DOI 10.7326/0003-4819-113-10-764; Thiagalingam S, 1996, CANCER RES, V56, P2936; Wistuba II, 1998, CLIN CANCER RES, V4, P2931; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	23	54	57	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					459	463		10.1038/7458	http://dx.doi.org/10.1038/7458			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202940				2022-12-27	WOS:000079574300040
J	Reina-San-Martin, B; Degrave, W; Rougeot, C; Cosson, A; Chamond, N; Cordeiro-Da-Silva, A; Arala-Chaves, M; Coutinho, A; Minoprio, P				Reina-San-Martin, B; Degrave, W; Rougeot, C; Cosson, A; Chamond, N; Cordeiro-Da-Silva, A; Arala-Chaves, M; Coutinho, A; Minoprio, P			A B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase	NATURE MEDICINE			English	Article							CRUZI; ACTIVATION; MECHANISM; DIFFERENTIATION; PURIFICATION; PROTEIN	Lymphocyte polyclonal activation is a generalized mechanism of immune evasion among pathogens. In a mouse model of Trypanosoma cruzi infection (American trypanosomiasis), reduced levels of polyclonal lymphocyte responses correlate with resistance to infection and cardiopathy. We report here the characterization of a parasite protein with B-cell mitogenic properties in culture supernatants of infective forms, the cloning of the corresponding gene and the analysis of the biological properties of its product. We characterized the protein as a co-factor-independent proline racemase, and show that its expression as a cytoplasmic and/or membrane-associated protein is life-stage specific. Inhibition studies indicate that availability of the racemase active site is necessary for mitogenic activity. This is the first report to our knowledge of a eukaryotic amino acid racemase gene. Our findings have potential consequences for the development of new immune therapies and drug design against pathogens.	Inst Pasteur, Dept Immunol, CNRS, URA 1960, F-75724 Paris 15, France; Fiocruz MS, Inst Oswaldo Cruz, DBBM, BR-21045900 Rio De Janeiro, Brazil; Inst Pasteur, Dept Immunol, Unite Biochim & Genet Dev, CNRS,URA 1960, F-75724 Paris 15, France; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4099 Oporto, Portugal; CNRS, Inst Gulbenkian Ciencia, P-2782 Oeiras, Portugal; Inst Pasteur, Dept Immunol, Unite Immunochim Analyt, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Fundacao Oswaldo Cruz; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidade do Porto; Instituto Gulbenkian de Ciencia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Minoprio, P (corresponding author), Inst Pasteur, Dept Immunol, CNRS, URA 1960, 25 Rue Dr Roux, F-75724 Paris 15, France.	pmm@pasteur.fr	Cordeiro-da-Silva, Anabela/J-7807-2013; Chamond, Nathalie/C-5907-2018; Reina-San-Martin, Bernardo/I-9484-2016; Degrave, Wim/B-4162-2009	Cordeiro-da-Silva, Anabela/0000-0003-2392-6087; Reina-San-Martin, Bernardo/0000-0003-2083-6166; Minoprio, Paola/0000-0002-1659-833X; Chamond, Nathalie/0000-0002-0518-2929				ARALACHAVES M, 1992, MEM I OSWALDO CRUZ, V87, P35, DOI 10.1590/S0074-02761992000900005; BARRETT FM, 1974, COMP BIOCHEM PHYSIOL, V48, P241; CARDINALE GJ, 1968, BIOCHEMISTRY-US, V7, P3970, DOI 10.1021/bi00851a026; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8; COUTINHO A, 1973, NATURE-NEW BIOL, V245, P12, DOI 10.1038/newbio245012a0; COUTINHO A, 1974, J EXP MED, V139, P74, DOI 10.1084/jem.139.1.74; DA Silva AC, 1998, IMMUNOLOGY, V94, P189, DOI 10.1046/j.1365-2567.1998.00498.x; DEISOLA ELD, 1981, J PARASITOL, V67, P53, DOI 10.2307/3280778; DOSSANTOS RR, 1992, J EXP MED, V175, P29, DOI 10.1084/jem.175.1.29; DRAGON EA, 1987, MOL CELL BIOL, V7, P1271, DOI 10.1128/MCB.7.3.1271; EISEN H, 1990, ORIGIN AUTOIMMUNE PA; Fisher G H, 1998, EXS, V85, P109; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; JANEWAY CA, 1970, FOLIA BIOL, V16, P156; Lamzin VS, 1995, CURR OPIN STRUC BIOL, V5, P830, DOI 10.1016/0959-440X(95)80018-2; Lima ECS, 1996, INFECT IMMUN, V64, P215, DOI 10.1128/IAI.64.1.215-221.1996; LIMA MRD, 1986, J IMMUNOL, V137, P353; MINOPRIO P, 1987, J IMMUNOL, V139, P545; MINOPRIO P, 1991, INT IMMUNOL, V3, P427, DOI 10.1093/intimm/3.5.427; MINOPRIO P, 1989, IMMUNOL REV, V112, P183, DOI 10.1111/j.1600-065X.1989.tb00558.x; MORO A, 1995, EMBO J, V14, P2483, DOI 10.1002/j.1460-2075.1995.tb07245.x; MOZES E, 1974, IMMUNOLOGY, V27, P641; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; Reina-San-Martin B, 2000, PARASITOL TODAY, V16, P62, DOI 10.1016/S0169-4758(99)01591-4; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; Sela M, 1997, FASEB J, V11, P449; Shakibaei M, 1996, J EXP MED, V184, P1699, DOI 10.1084/jem.184.5.1699; SYLVESTER D, 1976, COMP BIOCHEM PHYS B, V55, P443, DOI 10.1016/0305-0491(76)90318-7; Tarleton RL, 1997, P NATL ACAD SCI USA, V94, P3932, DOI 10.1073/pnas.94.8.3932; TAVARES D, 1995, INT IMMUNOL, V7, P785, DOI 10.1093/intimm/7.5.785; Thompson RJ, 1998, INFECT IMMUN, V66, P3552, DOI 10.1128/IAI.66.8.3552-3561.1998; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721	33	125	132	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					890	897		10.1038/78651	http://dx.doi.org/10.1038/78651			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932226				2022-12-27	WOS:000165473800032
J	Rose, NR				Rose, NR			Viral damage or 'molecular mimicry' - placing the blame in myocarditis	NATURE MEDICINE			English	Editorial Material							AUTOIMMUNITY; MYOSIN; MICE; INFECTION; LEADS; VIRUS		Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Rose, NR (corresponding author), Johns Hopkins Med Inst, Dept Pathol, MMI Room E5014, Baltimore, MD 21205 USA.							Albert LJ, 1999, NEW ENGL J MED, V341, P2068, DOI 10.1056/NEJM199912303412707; Caforio ALP, 1996, INT J CARDIOL, V54, P157, DOI 10.1016/0167-5273(96)02593-4; Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371; HILL SL, IN PRESS MOL PATHOLO; Horwitz MS, 2000, NAT MED, V6, P693, DOI 10.1038/76277; Huber SA, 1997, CLIN IMMUNOL IMMUNOP, V83, P93, DOI 10.1006/clin.1997.4342; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; NEU N, 1987, CLIN EXP IMMUNOL, V69, P566; NEU N, 1987, J IMMUNOL, V139, P3630; Pauschinger M, 1999, CIRCULATION, V99, P889, DOI 10.1161/01.CIR.99.7.889; Rose NR, 2000, CELL MOL LIFE SCI, V57, P542, DOI 10.1007/PL00000716	11	66	74	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					631	632		10.1038/76199	http://dx.doi.org/10.1038/76199			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835674				2022-12-27	WOS:000087438300024
J	Atreya, R; Mudter, J; Finotto, S; Mullberg, J; Jostock, T; Wirtz, S; Schutz, M; Bartsch, B; Holtmann, M; Becker, C; Strand, D; Czaja, J; Schlaak, JF; Lehr, HA; Autschbach, F; Schurmann, G; Nishimoto, N; Yoshizaki, K; Ito, H; Kishimoto, T; Galle, PR; Rose-John, S; Neurath, MF				Atreya, R; Mudter, J; Finotto, S; Mullberg, J; Jostock, T; Wirtz, S; Schutz, M; Bartsch, B; Holtmann, M; Becker, C; Strand, D; Czaja, J; Schlaak, JF; Lehr, HA; Autschbach, F; Schurmann, G; Nishimoto, N; Yoshizaki, K; Ito, H; Kishimoto, T; Galle, PR; Rose-John, S; Neurath, MF			Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; BOWEL-DISEASE; IL-6 RECEPTOR; MICE; STAT3; ACTIVATION; TERM	The pro-inflammatory cytokine interleukin (IL)-6 (refs. 1-5) can bind to cells lacking the IL-6 receptor (IL-6R) when it forms a complex with the soluble IL-6R (sIL-6R) (trans signaling)(5-7). Here, we have assessed the contribution of this system to the increased resistance of mucosal T cells against apoptosis in Crohn disease (CD), a chronic inflammatory disease of the gastrointestinal tract(8-12). A neutralizing antibody against IL-6R suppressed established experimental colitis in various animal models of CD mediated by type 1 T-helper cells, by inducing apoptosis of lamina propria T cells. Similarly, specific neutralization of sIL-6R in vivo by a newly designed gp130-Fc fusion protein caused suppression of colitis activity and induction of apoptosis, indicating that sIL-6R prevents mucosal T-cell apoptosis. In patients with Co, mucosal T cells showed strong evidence for IL-6 trans signaling, with activation of signal transducer and activator of transcription 3, bcl-2 and bcl-xl. Blockade of IL-6 trans signaling caused T-cell apoptosis, indicating that the IL-6-sIL-6R system mediates the resistance of T cells to apoptosis in CD. These data indicate that a pathway of T-cell activation driven by IL-6-sIL-6R contributes to the perpetuation of chronic intestinal inflammation. Specific targeting of this pathway may be a promising new approach for the treatment of CD.	Johannes Gutenberg Univ Mainz, Med Clin 1, Immunol Lab, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Med Clin 1, Sect Pathophysiol, D-55131 Mainz, Germany; Osaka Univ, Suita, Osaka 5650871, Japan; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55131 Mainz, Germany; Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany; Univ Munster, Dept Surg, D-48129 Munster, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Osaka University; Johannes Gutenberg University of Mainz; Ruprecht Karls University Heidelberg; University of Munster	Neurath, MF (corresponding author), Johannes Gutenberg Univ Mainz, Med Clin 1, Immunol Lab, D-55131 Mainz, Germany.	neurath@1-med.klinik.uni-mainz.de	Becker, Christoph/A-6694-2008; Kishimoto, Tadamitsu/C-8470-2009; Galle, Peter R/T-5292-2018; Finotto, Susetta/H-2753-2019; Becker, Christoph/L-2996-2016; Eckhardt, Erik/G-1567-2010; Galle, Peter/ABE-2872-2021; Rose-John, Stefan/A-7998-2010	Becker, Christoph/0000-0002-1388-1041; Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992; Rose-John, Stefan/0000-0002-7519-3279; Wirtz, Stefan/0000-0001-6936-7431; Schlaak, Joerg/0000-0002-9499-1014				Boirivant M, 1999, GASTROENTEROLOGY, V116, P557, DOI 10.1016/S0016-5085(99)70177-0; Bouhnik Y, 1996, LANCET, V347, P215, DOI 10.1016/S0140-6736(96)90402-X; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GROSS V, 1992, GASTROENTEROLOGY, V102, P514, DOI 10.1016/0016-5085(92)90098-J; Ina K, 1999, J IMMUNOL, V163, P1081; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MITSUYAMA K, 1995, GUT, V36, P45, DOI 10.1136/gut.36.1.45; MULLBERG J, 1995, J IMMUNOL, V155, P5198; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sartor RB, 1998, GASTROENTEROLOGY, V114, P398, DOI 10.1016/S0016-5085(98)70492-5; STROBER W, 1995, CLIN IMMUNOLOGY, P1401; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Teague TK, 1997, J IMMUNOL, V158, P5791; Wirtz S, 1999, J IMMUNOL, V162, P1884	26	1037	1086	3	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2000	6	5					583	588		10.1038/75068	http://dx.doi.org/10.1038/75068			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802717				2022-12-27	WOS:000086796200045
J	Poznansky, MC; Olszak, IT; Foxall, R; Evans, RH; Luster, AD; Scadden, DT				Poznansky, MC; Olszak, IT; Foxall, R; Evans, RH; Luster, AD; Scadden, DT			Active movement of T cells away from a chemokine	NATURE MEDICINE			English	Article							PROTEIN-COUPLED-RECEPTOR; AXON GUIDANCE; SIGNALING PATHWAYS; ATTRACTION; REPULSION; CHEMOTAXIS; CLONING; RANTES; GROWTH; SDF-1	Movement towards or away from a given stimulus guides the directional migration of prokaryotes, simple eukaryotes and neurons. As bi-directional cues may influence entry and exit of immune effector cells from tissue sites, we evaluated the migratory responses of T-cell subsets to varying concentrations of the chemokine stromal cell derived factor-1 (SDF-1). There was selective repulsion of subpopulations of T cells at high concentrations of recombinant SDF-1 or naturally occurring bone marrow-derived SDF-1, which could be inhibited by pertussis toxin and antibody against the chemokine receptor CXCR4. Distinct sensitivity profiles to genistein, herbimycin and 8-Br-cAMP biochemically distinguished movement of cells towards or away from an SDF-1 gradient. In vivo, antigen-induced T-cell recruitment into the peritoneal cavity was reversed by high but not low concentrations of SDF-1. The phenomenon of movement away from a chemokine represents a previously unknown mechanism regulating the localization of mature T cells. It adds to the functional repertoire of chemokines that may participate in immune physiology and may be applied therapeutically to alter the immune response.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr AIDS Res, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Scadden, DT (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr AIDS Res, Boston, MA 02129 USA.		Poznansky, Mark C/M-4996-2015; Luster, Andrew/ABE-6504-2020	Poznansky, Mark C/0000-0003-1344-7103; Luster, Andrew/0000-0001-9679-7912; Foxall, Russell/0000-0001-9821-0708				BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAILEY GB, 1985, J PROTOZOOL, V32, P341; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; COLOMARINO SA, 1995, CELL, V81, P621; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DODD J, 1995, CELL, V81, P471, DOI 10.1016/0092-8674(95)90066-7; DUNN GA, 1990, BIOL CHEMOTACTIC RES, P1; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; KEATING MT, 1977, J BACTERIOL, V130, P144, DOI 10.1128/JB.130.1.144-147.1977; Kim CH, 1998, BLOOD, V91, P4434, DOI 10.1182/blood.V91.12.4434.412k45_4434_4443; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Seeger MA, 1999, CELL, V97, P821, DOI 10.1016/S0092-8674(00)80793-X; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Taylor BL, 1998, FEBS LETT, V425, P377, DOI 10.1016/S0014-5793(98)00253-1; TSO WW, 1974, J BACTERIOL, V118, P560, DOI 10.1128/JB.118.2.560-576.1974; TURNER L, 1995, J IMMUNOL, V155, P2437; TURNER SJ, 1977, BIOCHEM SOC T, V2, P2165; WARD AJI, 1985, LANGMUIR, V1, P24, DOI 10.1021/la00061a003; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; WILKINSON PC, 1990, BIOL CHEMOTACTIC RES, P323; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477	33	243	272	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					543	548		10.1038/75022	http://dx.doi.org/10.1038/75022			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802710				2022-12-27	WOS:000086796200038
J	Restifo, NP				Restifo, NP			Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape	NATURE MEDICINE			English	Editorial Material							LIGAND EXPRESSION; CD95 LIGAND; ALLOGRAFT-REJECTION; GRAFT-REJECTION; MELANOMA-CELLS; T-LYMPHOCYTES; INHIBITION; APOPTOSIS; MYOBLASTS; ISLETS	Based on early studies, it was hypothesized that expression of Fas ligand (FasL) by tumor cells enabled them to counterattack the immune system, and that transplant rejection could be prevented by expressing FasL on transplanted organs. More recent studies have indicated that the notion of FasL as a mediator of immune privilege needed to be reconsidered, and taught a valuable lesson about making broad conclusions based on small amounts of data.	NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Restifo, NP (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.		Restifo, Nicholas Phillip/Z-1614-2019; Restifo, Nicholas Phillip/M-6549-2019; Restifo, Nicholas P/A-5713-2008	Restifo, Nicholas P./0000-0003-4229-4580	Intramural NIH HHS [Z99 CA999999, Z01 BC010763-01] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BELLGRAU D, 1998, NATURE, V394, P133; Chappell DB, 1998, CANCER IMMUNOL IMMUN, V47, P65, DOI 10.1007/s002620050505; Chappell DB, 1999, CANCER RES, V59, P59; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; Ekmekcioglu S, 1999, MELANOMA RES, V9, P261, DOI 10.1097/00008390-199906000-00008; FIEDLER P, 1998, SCIENCE, V279, pA2015; Gastman BR, 1999, CANCER RES, V59, P5356; GRIFFING JH, 1895, PSYCHOL REV MONOGRAP, V1, P1; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Henkart P A, 1997, Semin Immunol, V9, P135, DOI 10.1006/smim.1997.0063; Hohlbaum AM, 2000, J EXP MED, V191, P1209, DOI 10.1084/jem.191.7.1209; Kang SM, 1998, TRANSPLANT P, V30, P538, DOI 10.1016/S0041-1345(97)01396-1; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kang SM, 1997, SCIENCE, V278, P1322, DOI 10.1126/science.278.5341.1322; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; O'Connell J, 1999, NAT MED, V5, P267, DOI 10.1038/6477; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Seino K, 1998, J IMMUNOL, V161, P4484; Seino K, 1997, TRANSPL P, V29, P1092, DOI 10.1016/S0041-1345(96)00421-6; Seino K, 1996, INT IMMUNOL, V8, P1347, DOI 10.1093/intimm/8.9.1347; SELNO K, 1999, TRANSPLANT P, V31, P1942; Smith D, 1998, J IMMUNOL, V160, P4159; Vaux DL, 1998, NATURE, V394, P133, DOI 10.1038/28067; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0; Zaks TZ, 1999, J IMMUNOL, V162, P3273	31	207	229	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					493	495		10.1038/74955	http://dx.doi.org/10.1038/74955			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802692	Green Accepted			2022-12-27	WOS:000086796200018
J	Kung, C; Pingel, JT; Heikinheimo, M; Klemola, T; Varkila, K; Yoo, LI; Vuopala, K; Poyhonen, M; Uhari, M; Rogers, M; Speck, SH; Chatila, T; Thomas, ML				Kung, C; Pingel, JT; Heikinheimo, M; Klemola, T; Varkila, K; Yoo, LI; Vuopala, K; Poyhonen, M; Uhari, M; Rogers, M; Speck, SH; Chatila, T; Thomas, ML			Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease	NATURE MEDICINE			English	Article							CD4(+)CD8(+) THYMOCYTES; CELL MATURATION; LYMPHOCYTE; PROTEIN; MICE; DEFICIENCY; SELECTION; ZAP-70	The hematopoietic-specific transmembrane protein tyrosine phosphatase CD45 functions to regulate Src kinases required for T- and B-cell antigen receptor signal transduction(1,2). So far, there have been no reports to our knowledge of a human deficiency in a tyrosine-specific phosphatase. Here, we identified a male patient with a deficiency in CD45 due to a large deletion at one allele and a point mutation at the other. The point mutation resulted in the alteration of intervening sequence 13 donor splice site. The patient presented at 2 months of age with severe combined immunodeficiency disease. The population of peripheral blood T lymphocytes was greatly diminished and unresponsive to mitogen stimulation. Despite normal B-lymphocyte numbers, serum immunoglobulin levels decreased with age. Thus, CD45 deficiency in humans results in T- and B-lymphocyte dysfunction.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Microbiol & Mol Pathol, St Louis, MO 63110 USA; Univ Helsinki, Childrens Hosp, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, SF-00300 Helsinki, Finland; Oulu Univ Hosp, Dept Pathol, Oulu, Finland; Oulu Univ Hosp, Dept Clin Genet, Oulu, Finland; Univ Oulu, Dept Pediat, Oulu 90220, Finland; Lapland Cent Hosp, Dept Pathol, Rovaniemi 96101, Finland; Family Federat Finland, Dept Med Genet, Helsinki, Finland	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); University of Helsinki; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Oulu; Family Federation of Finland	Chatila, T (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.	chatila@kids.wustl.edu	Speck, Samuel/L-5893-2019; Poyhonen, Minna/K-4866-2018	Poyhonen, Minna/0000-0003-2037-2744; Chatila, Talal/0000-0001-7439-2762				Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; Jirapongsananuruk O, 1999, CLIN EXP IMMUNOL, V118, P1; Kirberg J, 1996, INT IMMUNOL, V8, P1743, DOI 10.1093/intimm/8.11.1743; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Okumura M, 1998, DNA CELL BIOL, V17, P779, DOI 10.1089/dna.1998.17.779; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sato T, 1996, INT IMMUNOL, V8, P1529, DOI 10.1093/intimm/8.10.1529; Seavitt JR, 1999, MOL CELL BIOL, V19, P4200; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	15	217	229	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					343	345						3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700239				2022-12-27	WOS:000085580500047
J	Zhang, M; Volpert, O; Shi, YH; Bouck, N				Zhang, M; Volpert, O; Shi, YH; Bouck, N			Maspin is an angiogenesis inhibitor	NATURE MEDICINE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; TUMOR-SUPPRESSOR; CANCER CELLS; GENE MASPIN; MAMMARY; EXPRESSION; GROWTH; PURIFICATION; INVASION; MOTILITY	Maspin, a unique member of the serpin family, is a secreted protein encoded by a class II tumor suppressor gene whose downregulation is associated with the development of breast and prostate cancers(1,2). Overexpression of maspin in breast tumor cells limits their growth and metastases in vivo. In this report we demonstrate that maspin is an effective inhibitor of angiogenesis. In vitro, it acted directly on cultured endothelial cells to stop their migration towards basic fibroblast growth factor and vascular endothelial growth factor and to limit mitogenesis and tube formation. In vivo, it blocked neovascularization in the rat cornea pocket model. Maspin derivatives mutated in the serpin reactive site lost their ability to inhibit the migration of fibroblasts, keratinocytes, and breast cancer cells but were still able to block angiogenesis in vitro and in vivo. When maspin was delivered locally to human prostate tumor cells in a xenograft mouse model, it blocked tumor growth and dramatically reduced the density of tumor-associated microvessels. These data suggest that the tumor suppressor activity of maspin may depend in large part on its ability to inhibit angiogenesis and raise the possibility that maspin and similar serpins may be excellent leads for the development of drugs that modulate angiogenesis.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA	Baylor College of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University	Zhang, M (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	mzhang@bcm.tmc.edu		Volpert, Olga/0000-0003-1381-5543	NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64239, CA 52750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Gately S, 1996, CANCER RES, V56, P4887; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Obermair A, 1997, J NATL CANCER I, V89, P1212, DOI 10.1093/jnci/89.16.1212; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; SILBERSTEIN GB, 1987, J DAIRY SCI, V70, P1981, DOI 10.3168/jds.S0022-0302(87)80240-0; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; STRINGER HAR, 1995, J BIOL CHEM, V270, P11205, DOI 10.1074/jbc.270.19.11205; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	20	375	394	2	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					196	199		10.1038/72303	http://dx.doi.org/10.1038/72303			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655109				2022-12-27	WOS:000085016900041
J	Dong, HD; Zhu, GF; Tamada, K; Chen, LP				Dong, HD; Zhu, GF; Tamada, K; Chen, LP			B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion	NATURE MEDICINE			English	Article							CTLA-4; CD28; COSTIMULATION; ACTIVATION; LIGAND; CD80; LYMPHOCYTES; RECEPTORS; IMMUNITY; RESIDUES	The B7 family members B7-1 and B7-2 interact with CD28 and constitute an essential T-cell co-stimulatory pathway in the initiation of antigen-specific humoral and cell-mediated immune response. Here, we describe a third member of the B7 family, called B7-H1 that does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). Ligation of B7-H1 co-stimulated T-cell responses to polyclonal stimuli and allogeneic antigens, and preferentially stimulated the production of interleukin-10. Interleukin-2, although produced in small amounts, was required for the effect of B7-H1 co-stimulation. Our studies thus define a previously unknown co-stimulatory molecule that may be involved in the negative regulation of cell-mediated immune responses.	Mayo Clin, Dept Immunol, Mayo Grad Sch, Rochester, MN 55905 USA; Mayo Clin, Dept Immunol, Mayo Med Sch, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Dong, HD (corresponding author), Mayo Clin, Dept Immunol, Mayo Grad Sch, 200 1st St SW, Rochester, MN 55905 USA.			Dong, Haidong/0000-0002-5782-2983; Chen, Lieping/0000-0002-6825-3069	NCI NIH HHS [CA09127, CA79915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079915] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BAJORATH J, 1994, PROTEIN SCI, V3, P2148, DOI 10.1002/pro.5560031128; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P369; CHEN LP, 1993, IMMUNOL TODAY, V14, P483, DOI 10.1016/0167-5699(93)90262-J; CHEN YM, 1993, MOL CRYST LIQ CRYS B, V4, P71; FARGEAS CA, 1995, J EXP MED, V182, P667, DOI 10.1084/jem.182.3.667; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; Georgescu L, 1997, J CLIN INVEST, V100, P2622, DOI 10.1172/JCI119806; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; INABA K, 1994, J EXP MED, V180, P1849, DOI 10.1084/jem.180.5.1849; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Li YW, 1996, J EXP MED, V183, P639, DOI 10.1084/jem.183.2.639; LI YW, 1994, J IMMUNOL, V153, P421; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Nakajima A, 1997, INT IMMUNOL, V9, P637, DOI 10.1093/intimm/9.5.637; PEACH RJ, 1995, J BIOL CHEM, V270, P21181, DOI 10.1074/jbc.270.36.21181; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541	23	1730	2064	12	160	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1365	1369						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581077				2022-12-27	WOS:000084049700034
J	Neirynck, S; Deroo, T; Saelens, X; Vanlandschoot, P; Jou, WM; Fiers, W				Neirynck, S; Deroo, T; Saelens, X; Vanlandschoot, P; Jou, WM; Fiers, W			A universal influenza A vaccine based on the extracellular domain of the M2 protein	NATURE MEDICINE			English	Article							HEPATITIS-B VIRUS; INTEGRAL MEMBRANE-PROTEIN; CORE PARTICLES; A VIRUSES; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; VIRAL PROTEIN; GENE; AMANTADINE; NEURAMINIDASE	The antigenic variation of influenza virus represents a major health problem. However, the extracellular domain of the minor, virus-coded M2 protein is nearly invariant in all influenza A strains. We genetically fused this M2 domain to the hepatitis B virus core (HBc) protein to create fusion gene coding for M2HBc; this gene was efficiently expressed in Escherichia coli. Intraperitoneal or intranasal administration of purified M2HBc particles to mice provided 90-100% protection against a lethal virus challenge. The protection was mediated by antibodies, as it was transferable by serum. The enhanced immunogenicity of the M2 extracellular domain exposed on HBc particles allows broad-spectrum, long-lasting protection against influenza A infections.	State Univ Ghent, Dept Biol Mol, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, B-9000 Ghent, Belgium	Ghent University	Fiers, W (corresponding author), State Univ Ghent, Dept Biol Mol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		Saelens, Xavier/N-5728-2015	, Xavier/0000-0002-3861-6965				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; APPLEYARD G, 1977, J GEN VIROL, V36, P249, DOI 10.1099/0022-1317-36-2-249; BAEZ M, 1980, J INFECT DIS, V141, P362, DOI 10.1093/infdis/141.3.362; BELSHE RB, 1988, J VIROL, V62, P1508, DOI 10.1128/JVI.62.5.1508-1512.1988; BLACK RA, 1993, J GEN VIROL, V74, P143, DOI 10.1099/0022-1317-74-1-143; BORISOVA GP, 1989, FEBS LETT, V259, P121, DOI 10.1016/0014-5793(89)81509-1; Chen Z, 1998, VACCINE, V16, P1544, DOI 10.1016/S0264-410X(98)00043-7; CLARKE BE, 1987, NATURE, V330, P381, DOI 10.1038/330381a0; COHEN BJ, 1982, NATURE, V296, P677, DOI 10.1038/296677a0; Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1; DAVIES WL, 1964, SCIENCE, V144, P862, DOI 10.1126/science.144.3620.862; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Deroo T, 1996, VACCINE, V14, P561, DOI 10.1016/0264-410X(95)00157-V; FANG RX, 1981, CELL, V25, P315, DOI 10.1016/0092-8674(81)90049-0; HAY AJ, 1979, J GEN VIROL, V42, P189, DOI 10.1099/0022-1317-42-1-189; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; ITO T, 1991, J VIROL, V65, P5491, DOI 10.1128/JVI.65.10.5491-5498.1991; Johansson BE, 1998, VACCINE, V16, P1009, DOI 10.1016/S0264-410X(97)00279-X; JOHANSSON BE, 1989, J VIROL, V63, P1239, DOI 10.1128/JVI.63.3.1239-1246.1989; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAMB RA, 1981, P NATL ACAD SCI-BIOL, V78, P4170, DOI 10.1073/pnas.78.7.4170; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LUBECK MD, 1978, J VIROL, V28, P710, DOI 10.1128/JVI.28.3.710-716.1978; MIN JW, 1980, CELL, V19, P683; NASSAL M, 1988, GENE, V66, P279, DOI 10.1016/0378-1119(88)90364-2; Nicholson KG, 1998, TXB INFLUENZA, P219; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; REMAUT E, 1983, NUCLEIC ACIDS RES, V11, P4677, DOI 10.1093/nar/11.14.4677; SCHODEL F, 1992, J VIROL, V66, P106; SLEPUSHKIN VA, 1995, VACCINE, V13, P1399, DOI 10.1016/0264-410X(95)92777-Y; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TREANOR JJ, 1990, J VIROL, V64, P1375, DOI 10.1128/JVI.64.3.1375-1377.1990; Tsuji M, 1998, J VIROL, V72, P6907, DOI 10.1128/JVI.72.8.6907-6910.1998; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Ulmer JB, 1998, J VIROL, V72, P5648, DOI 10.1128/JVI.72.7.5648-5653.1998; Ulrich R, 1998, ADV VIRUS RES, V50, P141, DOI 10.1016/S0065-3527(08)60808-8; *US DEP HHS, 1982, CONC PROC LAB BAS IN, pB7; VERHOEYEN M, 1980, NATURE, V286, P771, DOI 10.1038/286771a0; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; ZEBEDEE SL, 1989, NUCLEIC ACIDS RES, V17, P2870, DOI 10.1093/nar/17.7.2870; ZHOU XZ, 1995, P NATL ACAD SCI USA, V92, P3009, DOI 10.1073/pnas.92.7.3009	44	599	738	1	69	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1157	1163		10.1038/13484	http://dx.doi.org/10.1038/13484			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502819				2022-12-27	WOS:000082933200042
J	Nakashima, M; Sonoda, K; Watanabe, T				Nakashima, M; Sonoda, K; Watanabe, T			Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1	NATURE MEDICINE			English	Article							HUMAN UTERINE; EXPRESSION; MELANOMA; CANCER; LYMPHOCYTES; MECHANISMS; ESCAPE	Tumor-associated antigens that can be recognized by the immune system include the MAGE-family, p53, MUC-1, HER2/neu and p21ras (refs. 1-6). Despite their expression of these distinct antigens, tumor elimination by the immune system is often inefficient. Postulated mechanisms include insufficient expression of co-stimulatory or adhesion molecules by tumor cells, or defective processing and presentation of antigens on their cell surfaces(7-10) Tumor cells may also evade immune attack by expressing CD95 (APO-1/Fas) ligand or other molecules that induce apoptosis in activated T cells(11-13). Here we describe RCAS1 (receptor-binding cancer antigen expressed on SiSo cells), a membrane molecule expressed on human cancer cells. RCAS1 acts as a ligand for a putative receptor present on various human cell lines and normal peripheral lymphocytes such as T, B and NK cells. The receptor expression was enhanced by activation of the lymphocytes. RCAS1 inhibited the in vitro growth of receptor-expressing cells and induced apoptotic cell death. Given these results, tumor cells may evade immune surveillance by expression of RCAS1, which would suppress clonal expansion and induce apoptosis in RCAS1 receptor-positive immune cells.	Kyushu Univ, Med Inst Bioregulat, Dept Mol Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Obstet & Gynecol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Watanabe, T (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; BECKER JC, 1993, INT IMMUNOL, V5, P1501, DOI 10.1093/intimm/5.12.1501; CLAUDE DG, 1996, NAT MED, V2, P1367; Edward Michael, 1995, Current Opinion in Oncology, V7, P185, DOI 10.1097/00001622-199503000-00015; FERRONE S, 1995, IMMUNOL TODAY, V16, P487, DOI 10.1016/0167-5699(95)80033-6; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; GOSSEN M, 1995, SCIENCE, V268, P17636; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KAKU T, IN PRESS CLIN CANC R; MELIEF CJM, 1991, RES IMMUNOL, V142, P425, DOI 10.1016/0923-2494(91)90042-H; Munker R, 1997, HEMATOL CELL THER, V39, P75, DOI 10.1007/s00282-997-0075-7; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Peiper M, 1997, EUR J IMMUNOL, V27, P1115, DOI 10.1002/eji.1830270511; Runger T M, 1994, Curr Opin Oncol, V6, P188; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; SONODA K, 1995, INT J ONCOL, V6, P1099; Sonoda K, 1996, CANCER, V77, P1501, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1501::AID-CNCR12>3.0.CO;2-3; Sonoda K, 1998, CLIN CANCER RES, V4, P1517; SUSANNE S, 1996, NAT MED, V2, P1361; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; WHITESIDE TL, 1995, CURR OPIN IMMUNOL, V7, P704, DOI 10.1016/0952-7915(95)80080-8; [No title captured]	25	218	240	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					938	942		10.1038/11383	http://dx.doi.org/10.1038/11383			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426319				2022-12-27	WOS:000081684000039
J	Wang, JL; Liu, R; Liu, LS; Chowdhury, R; Barzilai, N; Tan, JZ; Rossetti, L				Wang, JL; Liu, R; Liu, LS; Chowdhury, R; Barzilai, N; Tan, JZ; Rossetti, L			The effect of leptin on Lep expression is tissue-specific and nutritionally regulated	NATURE MEDICINE			English	Article							OBESE GENE-EXPRESSION; BODY-WEIGHT; FOOD-INTAKE; OB/OB MICE; RECEPTOR; IDENTIFICATION; HUMANS; INSULIN; MOUSE; HYPOTHALAMUS	Leptin, the product of the Obese (Lep) gene, orchestrates behavioral and metabolic responses to nutrient intake. Here, we demonstrate tissue-specific autoregulation of Lep. Moderate increases in circulating leptin considerably decreased Lep expression in adipose tissue and induced lep expression in skeletal muscle, a tissue that normally does not express this gene. Changes in nutrient availability resulted in rapid alterations in Lep autoregulation. These findings demonstrate negative feedback regulation of Lep in fat, and indicate that leptin secretion can function as a vehicle of 'cross-talk' between adipose tissue and skeletal muscle, leading to tissue-specific modulation of the 'leptin signal'.	Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res & Training, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045024, R01DK048321, R37DK048321, R01DK045024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 45024, DK 48321] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Boston BA, 1997, SCIENCE, V278, P1641, DOI 10.1126/science.278.5343.1641; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, DIABETES, V45, P992, DOI 10.2337/diabetes.45.7.992; CONSIDINE RV, 1996, NEW ENGL J MED, V334, P324; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Jacob RJ, 1997, DIABETES, V46, P150, DOI 10.2337/diabetes.46.1.150; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; Kim YB, 1998, DIABETES, V47, pA317; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Ravussin E, 1997, NAT MED, V3, P238, DOI 10.1038/nm0297-238; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Seeley RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/s-2007-979874; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; ZHANG Y, 1994, NATURE, V372, P42; Zhang YY, 1997, BIOCHEM BIOPH RES CO, V240, P492, DOI 10.1006/bbrc.1997.7622	40	64	66	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					895	899		10.1038/11335	http://dx.doi.org/10.1038/11335			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426312				2022-12-27	WOS:000081684000032
J	Lewis, J; Oyler, GA; Ueno, K; Fannjiang, YR; Chau, BN; Vornov, J; Korsmeyer, SJ; Zou, SF; Hardwick, JM				Lewis, J; Oyler, GA; Ueno, K; Fannjiang, YR; Chau, BN; Vornov, J; Korsmeyer, SJ; Zou, SF; Hardwick, JM			Inhibition of virus-induced neuronal apoptosis by Bax	NATURE MEDICINE			English	Article							DRUG-INDUCED APOPTOSIS; CELL-DEATH; BCL-2; CONVERSION; MODULATION; BCL-X(L); PROTEIN; MICE	The Bax protein is widely known as a pro-apoptotic Bcl-2 family member that when overexpressed can trigger apoptosis in multiple cell types and is important for the developmental cell death of neurons(1,2). However, Bax was found here to be a potent inhibitor of neuronal cell death in mice infected with Sindbis virus. Newborn mice, which are highly susceptible to a fatal infection with neurotropic Sindbis virus, were significantly protected from neuronal apoptosis and fatal disease when infected with a recombinant Sindbis virus encoding Bax. Deletion of the N terminus of Bax, which mimics cleaved Bax, converted Bax into a pro-apoptotic factor in vivo. As mice mature during the first week after birth, they acquire resistance to a fatal Sindbis virus infection(3,4). However, Bax-deficient mice remained very sensitive to fatal disease compared with their control littermates, indicating that endogenous Bax functions as a survival factor and contributes to age-dependent resistance to Sindbis virus-induced mortality. The protective effects of Bax were reproduced in cultured hippocampal neurons but not in cultured dorsal root ganglia neurons. These findings indicate that cell-specific factors determine the anti-apoptotic versus pro-apoptotic function of Bax.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Kagoshima 8908520, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol & Med, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Kagoshima University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Hardwick, JM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, E5132,SPH,615 N Wolfe St, Baltimore, MD 21205 USA.		Vornov, James/F-6794-2013	Vornov, James/0000-0003-1965-5456	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034175] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34175] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Hardwick JM, 1999, CELL DEATH AND DISEASES OF THE NERVOUS SYSTEM, P295; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KIRSCH DG, IN PRESS J BIOL CHEM; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lewis J, 1996, J VIROL, V70, P1828, DOI 10.1128/JVI.70.3.1828-1835.1996; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Middleton G, 1996, DEVELOPMENT, V122, P695; Oh JH, 1997, NEUROREPORT, V8, P1851, DOI 10.1097/00001756-199705260-00012; Thomas A, 1996, ONCOGENE, V12, P1055; UBOL S, 1994, P NATL ACAD SCI USA, V91, P5202, DOI 10.1073/pnas.91.11.5202; VORNOV JJ, 1995, EXP NEUROL, V133, P7, DOI 10.1006/exnr.1995.1002; White FA, 1998, J NEUROSCI, V18, P1428; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930	25	89	93	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					832	835		10.1038/10556	http://dx.doi.org/10.1038/10556			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395331				2022-12-27	WOS:000081926600041
J	Frank, DA; Mahajan, S; Ritz, J				Frank, DA; Mahajan, S; Ritz, J			Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling	NATURE MEDICINE			English	Article							TARGETED DISRUPTION; GENE; PROTEINS; CELLS; ACTIVATION; PHOSPHATE; LEUKEMIA; PATHWAY; GAMMA; ALPHA	Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies(1) that can induce severe and prolonged immunosuppression(2,3). Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction(4,5), thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections(6,7). Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Frank, DA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Ritz, Jerome/C-7929-2009	Ritz, Jerome/0000-0001-5526-4669	NCI NIH HHS [CA41619, CA66996] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041619, P01CA066996] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CHESON BD, 1992, SEMIN ONCOL, V19, P695; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FENCHEL K, 1995, LEUKEMIA LYMPHOMA, V18, P485, DOI 10.3109/10428199509059649; Frank DA, 1996, LEUKEMIA, V10, P1724; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; Gimeno R, 1996, J IMMUNOL, V156, P1378; Gollob JA, 1998, BLOOD, V91, P1341, DOI 10.1182/blood.V91.4.1341; HOCHSTER H, 1990, SEMIN ONCOL, V17, P63; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KEATING MJ, 1990, SEMIN ONCOL, V17, P49; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KORNBLUTH J, 1982, J IMMUNOL, V129, P2831; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PLUNKETT W, 1993, SEMIN ONCOL, V20, P2; Robertson MJ, 1996, EXP HEMATOL, V24, P406; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836	19	193	205	2	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					444	447		10.1038/7445	http://dx.doi.org/10.1038/7445			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202937				2022-12-27	WOS:000079574300037
J	Kadkol, SS; Brody, JR; Pevsner, J; Bai, JN; Pasternack, GR				Kadkol, SS; Brody, JR; Pevsner, J; Bai, JN; Pasternack, GR			Modulation of oncogenic potential by alternative gene use in human prostate cancer	NATURE MEDICINE			English	Article							PROTEIN; IDENTIFICATION; CARCINOMA; PHAPI; CELLS; PP32	Only a small percentage of primary prostate cancers have genetic changes. In contrast, nearly 90% of clinically significant human prostate cancers seems to express high levels of the nuclear phosphoprotein pp32 by in situ hybridization. Because pp32 inhibits oncogene-mediated transformation, we investigated its paradoxical expression in cancer by comparing the sequence and function of pp32 species from paired benign prostate tissue and adjacent prostatic carcinoma from three patients. Here we demonstrate that pp32 is expressed in benign prostatic tissue, but pp32r1 and pp32r2, closely-related genes located on different chromosomes, are expressed in prostate cancer. Although pp32 is a tumor suppressor, pp32r1 and pp32r2 are tumorigenic. Alternative use of the pp32, pp32r1 and pp32r2 genes may modulate the oncogenic potential of human prostate cancer.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Baltimore, MD 21205 USA; Kennedy Krieger Inst, Dept Neurol, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute	Pasternack, GR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, 720 Rutland Ave, Baltimore, MD 21205 USA.	gpastern@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA054404] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 54404] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; FINK TM, 1995, GENOMICS, V29, P309, DOI 10.1006/geno.1995.1257; FLEMING WH, 1986, CANCER RES, V46, P1535; Gusev Y, 1996, CELL PROLIFERAT, V29, P643, DOI 10.1111/j.1365-2184.1996.tb00978.x; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; MALEK SN, 1990, J BIOL CHEM, V265, P13400; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Mencinger M, 1998, BBA-GENE STRUCT EXPR, V1395, P176, DOI 10.1016/S0167-4781(97)00165-6; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Ulitzur N, 1997, J BIOL CHEM, V272, P30577, DOI 10.1074/jbc.272.48.30577; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; WALENSKY LD, 1993, CANCER RES, V53, P4720	17	46	52	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					275	279		10.1038/6488	http://dx.doi.org/10.1038/6488			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086381				2022-12-27	WOS:000078851600030
J	Bordignon, C				Bordignon, C			The challenge of private biomedical research funding in Italy	NATURE MEDICINE			English	Editorial Material									Ist Sci San Raffaele, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Bordignon, C (corresponding author), Ist Sci San Raffaele, Via Ogettina 58, Milan, Italy.							Abbott A, 1998, NATURE, V395, P827, DOI 10.1038/27492; Abbott A, 1998, NATURE, V392, P531, DOI 10.1038/33224; Ballmaier M, 1998, NAT MED, V4, P751, DOI 10.1038/nm0798-751a; Ballmaier M, 1998, NAT MED, V4, P1218, DOI 10.1038/3193; Kafatos FC, 1998, SCIENCE, V280, P1327; May RM, 1998, SCIENCE, V281, P49, DOI 10.1126/science.281.5373.49	6	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					135	137		10.1038/5491	http://dx.doi.org/10.1038/5491			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930852				2022-12-27	WOS:000078274400013
J	Ueki, T; Kaneda, Y; Tsutsui, H; Nakanishi, K; Sawa, Y; Morishita, R; Matsumoto, K; Nakamura, T; Takahashi, H; Okamoto, E; Fujimoto, J				Ueki, T; Kaneda, Y; Tsutsui, H; Nakanishi, K; Sawa, Y; Morishita, R; Matsumoto, K; Nakamura, T; Takahashi, H; Okamoto, E; Fujimoto, J			Hepatocyte growth factor gene therapy of liver cirrhosis in rats	NATURE MEDICINE			English	Article							SCATTER FACTOR; CELL-DEATH; MOLECULAR-CLONING; FACTOR-BETA; EXPRESSION; FIBROSIS; PROTEIN; IDENTIFICATION; PURIFICATION; MECHANISM	Liver cirrhosis is the irreversible end result of fibrous scarring and hepatocellular regeneration, characterized by diffuse disorganization of the normal hepatic structure of regenerative nodules and fibrotic tissue(1). It is associated with prominent morbidity and mortality, and is induced by many factors, including chronic hepatitis virus infections, alcohol drinking and drug abuse. Hepatocyte growth factor (HGF), originally identified and cloned as a potent mitogen for hepatocytes(2-5), shows mitogenic, motogenic and morphogenic activities for a wide variety of cells(6-9). Moreover, HGF plays an essential part in the development and regeneration of the liver(6.7.10), and shows anti-apoptotic activity in hepatocytes(11). In a rat model of lethal liver cirrhosis produced by dimethylnitrosamine administrations, repeated transfections of the human HGF gene into skeletal muscles induced a high plasma level of human as well as enodogenous rat HGF, and tyrosine phosphorylation of the c-Met/HGF receptor. Transduction with the HGF gene also suppressed the increase of transforming growth factor-beta 1 (TGF-beta 1), which plays an essential part in the progression of liver cirrhosis, inhibited fibrogenesis and hepatocyte apoptosis, and produced the complete resolution of fibrosis in the cirrhotic liver, thereby improving the survival rate of rats with this severe illness. Thus, HGF gene therapy may be potentially useful for the treatment of patients with liver cirrhosis, which is otherwise fatal and untreatable by conventional therapy.	Hyogo Coll Med, Dept Surg 1, Nishinomiya, Hyogo 6638501, Japan; Osaka Univ, Sch Med, Inst Cellular & Mol Biol, Suita, Osaka 5650871, Japan; Hyogo Coll Med, Dept Immunol & Med Zool, Nishinomiya, Hyogo, Japan; Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Geriatr Med, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Suita, Osaka 565, Japan; Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Hyogo College of Medicine; Osaka University; Hyogo College of Medicine; Osaka University; Osaka University; Osaka University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Fujimoto, J (corresponding author), Hyogo Coll Med, Dept Surg 1, 1-1 Mukogawacho, Nishinomiya, Hyogo 6638501, Japan.		; MATSUMOTO, Kunio/D-8441-2015	Tsutsui, Hiroko/0000-0001-7928-4875; MATSUMOTO, Kunio/0000-0002-6532-4482				Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BLOMHOFF R, 1991, FASEB J, V5, P271, DOI 10.1096/fasebj.5.3.2001786; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CONN HO, 1993, DIS LIVER, V2, P875; COOMBS DW, 1994, ACTA ANAESTH SCAND, V38, P388, DOI 10.1111/j.1399-6576.1994.tb03913.x; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; Hayashi S, 1996, BIOCHEM BIOPH RES CO, V220, P539, DOI 10.1006/bbrc.1996.0440; Hirano T, 1998, GENE THER, V5, P459, DOI 10.1038/sj.gt.3300617; JEZEQUEL AM, 1989, J HEPATOL, V8, P42, DOI 10.1016/0168-8278(89)90160-8; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PRITCHARD DJ, 1989, J PATHOL, V158, P253, DOI 10.1002/path.1711580314; RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TANAKA Y, 1991, J PATHOL, V164, P273, DOI 10.1002/path.1711640314; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	30	515	562	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					226	230		10.1038/5593	http://dx.doi.org/10.1038/5593			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930873				2022-12-27	WOS:000078274400034
J	Calandra, T; Echtenacher, B; Le Roy, D; Pugin, J; Metz, CN; Hultner, L; Heumann, D; Mannel, D; Bucala, R; Glauser, MP				Calandra, T; Echtenacher, B; Le Roy, D; Pugin, J; Metz, CN; Hultner, L; Heumann, D; Mannel, D; Bucala, R; Glauser, MP			Protection from septic shock by neutralization of macrophage migration inhibitory factor	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; CYTOKINE PRODUCTION; REGULATORY ROLE; MICE; EFFICACY; MIF; LIPOPOLYSACCHARIDE; MONOCYTOGENES; PATHOGENESIS; ENDOTOXEMIA	Identification of new therapeutic targets for the management of septic shock remains imperative as all investigational therapies, including anti-tumor necrosis factor (TNF) and anti-interleukin (IL)-1 agents, have uniformly failed to lower the mortality of critically ill patients with severe sepsis. We report here that macrophage migration inhibitory factor (MIF) is a critical mediator of septic shock. High concentrations of MIF were detected in the peritoneal exudate fluid and in the systemic circulation of mice with bacterial peritonitis. Experiments performed in TNF alpha knockout mice allowed a direct evaluation of the part played by MIF in sepsis in the absence of this pivotal cytokine of inflammation. Anti-MIF antibody protected TNF alpha knockout from lethal peritonitis induced by cecal ligation and puncture (CLP), providing evidence of an intrinsic contribution of MIF to the pathogenesis of sepsis. Anti-MIF antibody also protected normal mice from lethal peritonitis induced by both CLP and Escherichia coli, even when treatment was started up to 8 hours after CLP. Conversely co-injection of recombinant MIF and E. coli markedly increased the lethality of peritonitis. Finally, high concentrations of MIF were detected in the plasma of patients with severe sepsis or septic shock. These studies define a critical part for MIF in the pathogenesis of septic shock and identify a new target for therapeutic intervention.	CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland; Univ Regensburg, Dept Pathol, D-93042 Regensburg, Germany; Univ Hosp Geneva, Dept Med, Div Med Intens Care, CH-1211 Geneva 14, Switzerland; Picower Inst Med Res, Manhasset, NY 11030 USA; GSF Forschungszentrum Umwelt & Gesundheit GMBH, Inst Expt Hamatol, D-81337 Munich, Germany	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Regensburg; University of Geneva; Northwell Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Calandra, T (corresponding author), CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland.	Thierry.Calandra@chuv.hospvd..ch	Calandra, Thierry/D-9017-2015	Calandra, Thierry/0000-0003-3051-1285; Christine, Metz/0000-0002-1013-1691				Abraham E, 1999, INTENS CARE MED, V25, P556, DOI 10.1007/s001340050903; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bacher M, 1997, AM J PATHOL, V150, P235; BAGBY GJ, 1991, J INFECT DIS, V163, P83, DOI 10.1093/infdis/163.1.83; BAUMGARTNER JD, 1990, J EXP MED, V171, P889, DOI 10.1084/jem.171.3.889; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Cohen J, 1999, J INFECT DIS, V180, P116, DOI 10.1086/314839; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; Heumann D, 1996, J INFLAMM, V47, P173; KOHLER J, 1993, J IMMUNOL, V151, P916; Lan HY, 1997, J EXP MED, V185, P1455, DOI 10.1084/jem.185.8.1455; Lan HY, 1998, TRANSPLANTATION, V66, P1465, DOI 10.1097/00007890-199812150-00009; Leech M, 1998, ARTHRITIS RHEUM-US, V41, P910, DOI 10.1002/1529-0131(199805)41:5<910::AID-ART19>3.0.CO;2-E; MARSHALL JC, 1998, SEPSIS, V2, P187; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; Mikulowska A, 1997, J IMMUNOL, V158, P5514; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; NATHAN CF, 1973, J EXP MED, V137, P275, DOI 10.1084/jem.137.2.275; NATHAN CF, 1971, J EXP MED, V133, P1356, DOI 10.1084/jem.133.6.1356; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PORAT R, 1991, SCIENCE, V254, P430, DOI 10.1126/science.1833820; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; ZANETTI G, 1992, J IMMUNOL, V148, P1890	36	618	713	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					164	170		10.1038/72262	http://dx.doi.org/10.1038/72262			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655104				2022-12-27	WOS:000085016900036
J	Pastey, MK; Gower, TL; Spearman, PW; Crowe, JE; Graham, BS				Pastey, MK; Gower, TL; Spearman, PW; Crowe, JE; Graham, BS			A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3	NATURE MEDICINE			English	Article							CELL-FUSION; POTENT INHIBITORS; GLYCOPROTEINS; INFECTION; PROTEIN; RSV; REPLICATION; ATTACHMENT; REGIONS; DOMAIN	The fusion glycoproteins of human respiratory syncytial virus (RSV) and human parainfluenza virus type-3 (PIV-3) mediate virus entry and syncytium formation. Interaction between the fusion protein of RSV and RhoA, a small GTPase, facilitates virus-induced syncytium formation. We show here a RhoA-derived peptide inhibits RSV and syncytium formation induced by RSV and PIV-3, both in vitro by inhibition of cell-to-cell fusion and in vivo by reduction of peak titer by 2 log(10) in RSV-infected mice. These findings indicate that the interaction between these two paramyxovirus fusion proteins and RhoA is an important target for new antiviral strategies.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Graham, BS (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 221 Kirkland Hall, Nashville, TN 37232 USA.		Graham, Barney S./AAC-5898-2019; Crowe, James/B-5549-2009	Graham, Barney S./0000-0001-8112-0853; Crowe, James/0000-0002-0049-1079	NCI NIH HHS [P30 CA068485, CA68485] Funding Source: Medline; NIAID NIH HHS [R01-AI-33933, R01 AI033933] Funding Source: Medline; NIDDK NIH HHS [DK20593, P30 DK020593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033933, Z01AI005030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROETI B, 1988, BIOCHEMISTRY-US, V27, P5654, DOI 10.1021/bi00415a039; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; COLLINS PL, 1991, J GEN VIROL, V72, P3095, DOI 10.1099/0022-1317-72-12-3095; Collins PL, 1996, FIELDS VIROLOGY, P1313; DAYA M, 1988, VIROLOGY, V163, P276, DOI 10.1016/0042-6822(88)90267-X; Dutch RE, 1998, J VIROL, V72, P7745, DOI 10.1128/JVI.72.10.7745-7753.1998; Feldman SA, 1999, J VIROL, V73, P6610, DOI 10.1128/JVI.73.8.6610-6617.1999; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; HEMINWAY BR, 1994, VIROLOGY, V200, P801, DOI 10.1006/viro.1994.1245; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Karron RA, 1997, P NATL ACAD SCI USA, V94, P13961, DOI 10.1073/pnas.94.25.13961; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Krusat T, 1997, ARCH VIROL, V142, P1247, DOI 10.1007/s007050050156; Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186; LEVINE S, 1987, J GEN VIROL, V68, P2521, DOI 10.1099/0022-1317-68-9-2521; MURPHY BR, 1989, VACCINE, V7, P533, DOI 10.1016/0264-410X(89)90278-8; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Pastey MK, 1999, J VIROL, V73, P7262, DOI 10.1128/JVI.73.9.7262-7270.1999; Pastey MK, 1997, J GEN VIROL, V78, P1885, DOI 10.1099/0022-1317-78-8-1885; RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x; RUSSELL R, 1994, VIROLOGY, V199, P160, DOI 10.1006/viro.1994.1108; SCHEID A, 1972, VIROLOGY, V50, P640, DOI 10.1016/0042-6822(72)90418-7; SYLWESTER A, 1993, J CELL SCI, V106, P941; WELLIVER R, 1982, J PEDIATR-US, V101, P180, DOI 10.1016/S0022-3476(82)80113-3; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Yang CL, 1997, J VIROL, V71, P8490, DOI 10.1128/JVI.71.11.8490-8496.1997; Yao QZ, 1996, VIROLOGY, V223, P103, DOI 10.1006/viro.1996.0459	27	64	70	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					35	40		10.1038/71503	http://dx.doi.org/10.1038/71503			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613821	Green Published			2022-12-27	WOS:000084583300032
J	Brown, KL; Stewart, K; Ritchie, DL; Mabbott, NA; Williams, A; Fraser, H; Morrison, WI; Bruce, ME				Brown, KL; Stewart, K; Ritchie, DL; Mabbott, NA; Williams, A; Fraser, H; Morrison, WI; Bruce, ME			Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells	NATURE MEDICINE			English	Article							B-CELL; MOUSE SCRAPIE; CRUCIAL ROLE; MICE; PRP; PATHOGENESIS; PATHOLOGY; RESPONSES; SPLEENS; IMMUNE	The immune system is central in the pathogenesis of scrapie and other transmissible spongiform encephalopathies (TSEs) or 'prion' diseases(1). After infecting by peripheral (intraperitoneal or oral) routes, most TSE agents replicate in spleen and lymph nodes before neuroinvasion(2). Characterization of the cells supporting replication in these tissues is essential to understanding early pathogenesis and may indicate potential targets for therapy, for example, in 'new variant' Creutzfeldt-Jakob disease. The host 'prion' protein (PrP) is required for TSE agent replication(3,4) and accumulates in modified forms in infected tissues. Abnormal PrP is detected readily on follicular dendritic cells (FDCs) in lymphoid tissues of patients with 'new variant' Creutzfeldt-Jakob disease(5), sheep with natural scrapie(6) and mice experimentally infected with scrapie(7). The normal protein is present on FDCs in uninfected mice(7) and, at lower levels, on lymphocytes(8). Studies using severe combined immunodeficiency (SCID) mice, with and without bone marrow (BM) grafts, have indicated involvement of FDCs and/or lymphocytes in scrapie pathogenesis(9). To clarify the separate roles of FDCs and lymphocytes, we produced chimeric mice with a mismatch in PrP status between FDCs and other cells of the immune system, by grafting bone marrow from PrP-deficient knockout mice(4) into PrP-expressing mice and vice versa. Using these chimeric models, we obtained strong evidence that FDCs themselves produce PrP and that replication of a mouse-passaged scrapie strain in spleen depends on PrP-expressing FDCs rather than on lymphocytes or other bone marrow-derived cells.	Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh EH9 3JF, Midlothian, Scotland; Univ Glasgow, Sch Vet, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland; Inst Anim Hlth, Newbury RG20 7NN, Berks, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Edinburgh; University of Glasgow; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Bruce, ME (corresponding author), Inst Anim Hlth, Neuropathogenesis Unit, Ogston Bldg,W Mains Rd, Edinburgh EH9 3JF, Midlothian, Scotland.		Mabbott, Neil/AAF-8777-2020	Mabbott, Neil/0000-0001-7395-1796				Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; FRASER H, 1987, VET MICROBIOL, V13, P211, DOI 10.1016/0378-1135(87)90084-8; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; KAPASI ZF, 1993, J IMMUNOL, V150, P2648; KIMBERLIN RH, 1979, J COMP PATHOL, V89, P551, DOI 10.1016/0021-9975(79)90046-X; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; KOSCO MH, 1992, J IMMUNOL, V148, P2331; LeHir M, 1996, J EXP MED, V183, P2367, DOI 10.1084/jem.183.5.2367; Mabbott NA, 1998, IMMUNOL TODAY, V19, P201, DOI 10.1016/S0167-5699(98)01253-5; Mabbott NA, 1997, IMMUNOLOGY, V92, P161, DOI 10.1046/j.1365-2567.1997.00331.x; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MCBRIDE PA, 1992, J PATHOL, V168, P413, DOI 10.1002/path.1711680412; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Raeber AJ, 1999, EMBO J, V18, P2702, DOI 10.1093/emboj/18.10.2702; RITCHIE DL, 1999, J CELL PATHOL, V4, P3; Tkachuk M, 1998, J EXP MED, V187, P469, DOI 10.1084/jem.187.4.469; vanKeulen LJM, 1996, J CLIN MICROBIOL, V34, P1228, DOI 10.1128/JCM.34.5.1228-1231.1996	22	301	307	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1308	1312		10.1038/15264	http://dx.doi.org/10.1038/15264			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545999				2022-12-27	WOS:000086550600043
J	Heaney, AP; Horwitz, GA; Wang, ZY; Singson, R; Melmed, S				Heaney, AP; Horwitz, GA; Wang, ZY; Singson, R; Melmed, S			Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis	NATURE MEDICINE			English	Article							CELLS	Pituitary tumors are commonly encountered, and result from clonal expansion of a single mutated cell(1). Hypothalamic hormones, local growth factors and circulating sex steroid hormones promote pituitary tumor growth and expansion into large invasive tumors(2). Estrogen acting directly through its receptor and by stimulation of fibroblast growth factor regulates prolactin synthesis and secretion(3-4). Fibroblast growth factor-2 (bFGF) modulates angiogenesis, tumor formation and progression in many tissues, including the anterior pituitary(5-8). A pituitary tumor-derived transforming gene (PTTG) has been isolated, which is tumorigenic in vivo, regulates bFGF secretion, and inhibits chromatid separation(9-11). The human PTTG family consists of at least three homologous genes, of which PTTG1 is located on chromosome 5q33(12) and is expressed at low levels in most normal human tissues but is highly expressed in malignant human cell lines and in pituitary tumors(13). We report here that pituitary pttg is regulated in vivo and in vitro by estrogen. Maximal induction of rat pituitary pttg mRNA in vivo occurred early in pituitary transformation (normal cell to hypertrophic/hyperplastic cell), coincident with bFGF and vascular endothelial growth factor induction and pituitary angiogenesis. We also demonstrate that pttg expression is induced by bFGF, and show concordant pttg and bFGF expression in experimental and human pituitary adenomas. As bFGF and estrogen both induce pttg, and pttg expression coincides with the early lactotrophic hyperplastic response, angiogenesis and prolactinoma development, we propose a previously unknown paracrine growth factor-mediated mechanism for pituitary tumor pathogenesis and potentially other estrogen-regulated tumors.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Pathol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med, Los Angeles, CA 90048 USA.				NATIONAL CANCER INSTITUTE [R01CA075979] Funding Source: NIH RePORTER; NCI NIH HHS [CA75979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIRD A, 1985, P NATL ACAD SCI USA, V82, P5545, DOI 10.1073/pnas.82.16.5545; Gothard LQ, 1996, MOL ENDOCRINOL, V10, P185, DOI 10.1210/me.10.2.185; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KOVACS K, 1978, HORM METAB RES, V10, P409, DOI 10.1055/s-0028-1093402; LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Prezant TR, 1999, J CLIN ENDOCR METAB, V84, P1149, DOI 10.1210/jc.84.3.1149; SCHECHTER J, 1988, J CLIN ENDOCR METAB, V67, P713, DOI 10.1210/jcem-67-4-713; Scully KM, 1997, MOL ENDOCRINOL, V11, P674, DOI 10.1210/me.11.6.674; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Serri O, 1996, J CLIN ENDOCR METAB, V81, P3177, DOI 10.1210/jc.81.9.3177; Shimon I, 1997, J CLIN ENDOCR METAB, V82, P1675, DOI 10.1210/jc.82.6.1675; SHUPNIK MA, 1991, J BIOL CHEM, V266, P17084; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; STEFANEANU L, 1994, J CLIN ENDOCR METAB, V78, P83, DOI 10.1210/jc.78.1.83; WEINER RI, 1995, PROLACTIN BASIC CLIN, P641; WIKLUND J, 1981, ENDOCRINOLOGY, V109, P1700, DOI 10.1210/endo-109-5-1700; Wilson CB, 1997, J CLIN ENDOCR METAB, V82, P2381, DOI 10.1210/jc.82.8.2381; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; ZIMMERING MB, 1993, J CLIN ENDOCR METAB, V76, P1182; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	22	280	301	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1317	1321		10.1038/15275	http://dx.doi.org/10.1038/15275			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10546001				2022-12-27	WOS:000086550600045
J	Swingler, S; Mann, A; Jacque, JM; Brichacek, B; Sasseville, VG; Williams, K; Lackner, AA; Janoff, EN; Wang, R; Fisher, D; Stevenson, M				Swingler, S; Mann, A; Jacque, JM; Brichacek, B; Sasseville, VG; Williams, K; Lackner, AA; Janoff, EN; Wang, R; Fisher, D; Stevenson, M			HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCYTE-DERIVED MACROPHAGES; INFLAMMATORY PROTEIN-1-BETA; CHEMOKINE RECEPTOR; NONDIVIDING CELLS; VIRAL REPLICATION; BETA-CHEMOKINES; DENDRITIC CELLS; VPR PROTEIN; T-CELLS	Infection of macrophage lineage cells is a feature of primate lentivirus replication, and several properties of primate lentiviruses seem to have evolved to promote the infection of macrophages. Here we demonstrate that the accessory gene product Nef induces the production of two CC-chemokines, macrophage inflammatory proteins 1 alpha and 1 beta, by HIV-1-infected macrophages. Adenovirus-mediated expression of Nef in primary macrophages was sufficient for chemokine induction. Supernatants from Nef-expressing macrophages induced both the chemotaxis and activation of resting T lymphocytes, permitting productive HIV-1 infection. These results indicate a role for Nef in lymphocyte recruitment and activation at sites of virus replication.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Vet Adm Med Ctr, Minneapolis, MN 55417 USA; Univ Massachusetts, Med Ctr, Dept Cardiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Massachusetts System; University of Massachusetts Worcester	Stevenson, M (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.		Jacque, Jean-Marc/B-6875-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039445, K99AI139445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030769, R01NS035732] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR011589] Funding Source: Medline; NHLBI NIH HHS [R01 HL057880] Funding Source: Medline; NIAID NIH HHS [R01 AI032890, R01 AI037475, R37 AI037475, R01 AI049152, AI39445] Funding Source: Medline; NIMH NIH HHS [R01 MH064411] Funding Source: Medline; NINDS NIH HHS [NS30769, R01 NS030769, NS35732] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Canque B, 1996, BLOOD, V87, P2011; CHOE H, 1996, CELL, V85, P1; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Dairaghi DJ, 1998, BLOOD, V91, P2905, DOI 10.1182/blood.V91.8.2905.2905_2905_2913; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Esser R, 1996, BLOOD, V88, P3474, DOI 10.1182/blood.V88.9.3474.bloodjournal8893474; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GRUBER MF, 1995, J IMMUNOL, V154, P5528; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; HITT M, 1995, METH MOL G, V7, P13; Jansson M, 1996, P NATL ACAD SCI USA, V93, P15382, DOI 10.1073/pnas.93.26.15382; KALTER DC, 1991, J IMMUNOL, V146, P298; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Sasseville VG, 1996, AM J PATHOL, V149, P1459; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; Stevenson M, 1996, NAT STRUCT BIOL, V3, P303, DOI 10.1038/nsb0496-303; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; Ullum H, 1998, J INFECT DIS, V177, P331, DOI 10.1086/514192; Van Kooten Cees, 1997, Frontiers in Bioscience (online), V2, pD1; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; ZACK JA, 1995, ADV EXP MED BIOL, V374, P27; ZHOU LJ, 1995, BLOOD, V86, P3295, DOI 10.1182/blood.V86.9.3295.bloodjournal8693295; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zou WP, 1997, J VIROL, V71, P1227, DOI 10.1128/JVI.71.2.1227-1236.1997	52	303	307	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					997	1003		10.1038/12433	http://dx.doi.org/10.1038/12433			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470075	Green Accepted			2022-12-27	WOS:000082337200032
J	Matsue, H; Matsue, K; Walters, M; Okumura, K; Yagita, H; Takashima, A				Matsue, H; Matsue, K; Walters, M; Okumura, K; Yagita, H; Takashima, A			Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells	NATURE MEDICINE			English	Article							DELAYED-TYPE HYPERSENSITIVITY; LIGAND-INDUCED APOPTOSIS; STIMULATING FACTOR-I; FAS-LIGAND; PRESENTING CELLS; T-CELLS; CONTACT HYPERSENSITIVITY; AUTOIMMUNE-DISEASES; MURINE EPIDERMIS; DEATH RECEPTORS	Dendritic cells (DCs) are special subsets of antigen-presenting cells characterized by their highly potent capacity to activate immunologically naive T cells. Here we report that DCs that are transfected with CD95 ligand (CD95L) cDNA, called 'killer' DCs, deliver death signals, instead of activation signals, to T cells after antigen-specific interaction. Injection of antigen-pulsed killer DCs into mice before sensitization induced antigen-specific immunosuppression. When administered after sensitization, killer DCs suppressed immune responses almost completely after subsequent challenge. Thus, killer DCs represent an entirely new immunomodulatory protocol, which may become directly applicable in preventing and even treating T cell-mediated inflammatory diseases.	Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA; Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 113, Japan; CREST Japan Sci & Technol Corp, Chiyoda Ku, Tokyo 101, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Juntendo University; Japan Science & Technology Agency (JST)	Matsue, H (corresponding author), Univ Texas, SW Med Ctr, Dept Dermatol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035068, R01AR043777] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI43262] Funding Source: Medline; NIAMS NIH HHS [R01-AR43777, R01-AR35068] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett SRM, 1998, J EXP MED, V188, P1977, DOI 10.1084/jem.188.11.1977; Bhardwaj N, 1997, J EXP MED, V186, P795, DOI 10.1084/jem.186.6.795; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; CLARESALZLER MJ, 1992, J CLIN INVEST, V90, P741, DOI 10.1172/JCI115946; CRUZ PD, 1989, J INVEST DERMATOL, V92, P160, DOI 10.1111/1523-1747.ep12276682; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Gould DS, 1999, IMMUNOL TODAY, V20, P77, DOI 10.1016/S0167-5699(98)01394-2; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Johnson LL, 1997, J EXP MED, V186, P1799, DOI 10.1084/jem.186.11.1799; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kayagaki N, 1997, P NATL ACAD SCI USA, V94, P3914, DOI 10.1073/pnas.94.8.3914; Khoury SJ, 1996, J IMMUNOL, V157, P3700; KITAJIMA T, 1995, J IMMUNOL, V155, P5190; Kitajima T, 1996, J IMMUNOL, V157, P2340; Kronin V, 1996, J IMMUNOL, V157, P3819; Liblau R, 1997, IMMUNOL TODAY, V18, P599, DOI 10.1016/S0167-5699(97)01171-7; Lu LN, 1997, J IMMUNOL, V158, P5676; Magee CC, 1997, CURR OPIN IMMUNOL, V9, P669, DOI 10.1016/S0952-7915(97)80047-7; Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; Matsue H, 1999, J IMMUNOL, V162, P5287; MATSUE H, 1993, J IMMUNOL, V151, P6012; MORIKAWA Y, 1993, CELL IMMUNOL, V152, P200, DOI 10.1006/cimm.1993.1279; MORIKAWA Y, 1992, IMMUNOLOGY, V77, P81; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NOONAN FP, 1981, IMMUNOLOGY, V43, P527; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; POSSELT AM, 1992, SCIENCE, V256, P1321, DOI 10.1126/science.1598576; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shurin MR, 1996, CANCER IMMUNOL IMMUN, V43, P158, DOI 10.1007/s002620050317; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; TAKASHIMA A, 1995, J IMMUNOL, V154, P5128; Timares L, 1998, P NATL ACAD SCI USA, V95, P13147, DOI 10.1073/pnas.95.22.13147; TOEWS GB, 1980, J IMMUNOL, V124, P445; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; XU S, 1995, EUR J IMMUNOL, V25, P1018, DOI 10.1002/eji.1830250424; XU S, 1995, J IMMUNOL, V154, P2697; Zhang H, 1999, J IMMUNOL, V162, P1423; Zhang HG, 1998, NAT BIOTECHNOL, V16, P1045, DOI 10.1038/3488	47	138	141	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					930	937		10.1038/11375	http://dx.doi.org/10.1038/11375			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426318				2022-12-27	WOS:000081684000038
J	Lee, PP; Yee, C; Savage, PA; Fong, L; Brockstedt, D; Weber, JS; Johnson, D; Swetter, S; Thompson, J; Greenberg, PD; Roederer, M; Davis, MM				Lee, PP; Yee, C; Savage, PA; Fong, L; Brockstedt, D; Weber, JS; Johnson, D; Swetter, S; Thompson, J; Greenberg, PD; Roederer, M; Davis, MM			Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients	NATURE MEDICINE			English	Article							MARROW-DERIVED CELLS; INFILTRATING LYMPHOCYTES; EXPRESSION; CARCINOMA; CD8(+); GROWTH; SIGNAL; MICE; IMMUNOTHERAPY; STIMULATION	We identified circulating CD8(+) T-cell populations specific for the tumor-associated antigens (TAAs) MART-1 (27-35) or tyrosinase (368-376) in six of eleven patients with metastatic melanoma using peptide/HLA-A*0201 tetramers. These TAA-specific populations were of two phenotypically distinct types: one, typical for memory/effector T cells; the other, a previously undescribed phenotype expressing both naive and effector cell markers. This latter type represented more than 2% of the total CD8(+) T cells in one patient, permitting detailed phenotypic and functional analysis. Although these cells have many of the hallmarks of effector T cells, they were functionally unresponsive, unable to directly lyse melanoma target cells or produce cytokines in response to mitogens. In contrast, CD8(+) T cells from the same patient were able to lyse EBV-pulsed target cells and showed robust allogeneic responses. Thus, the clonally expanded TAA-specific population seems to have been selectively rendered anergic in vivo. Peptide stimulation of the TAA-specific T-cell populations in other patients failed to induce substantial upregulation of CD69 expression, indicating that these cells may also have functional defects, leading to blunted activation responses. These data demonstrate that systemic TAA-specific T-cell responses can develop de novo in cancer patients, but that antigen-specific unresponsiveness may explain why such cells are unable to control tumor growth.	Stanford Univ, Howard Hughes Med Inst, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Ctr Blood, Stanford, CA 94305 USA; Stanford Univ, Dept Surg, Div Surg Oncol, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Dept Dermatol, Stanford, CA 94305 USA; Palo Alto Vet Adm Hosp, Palo Alto, CA USA; Univ Washington, Dept Med, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ So Calif, Norris Canc Ctr, Los Angeles, CA 90033 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Southern California	Davis, MM (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Microbiol & Immunol, Stanford, CA 94305 USA.		Ferris, Laura/I-7689-2012; Roederer, Mario/G-1887-2011	Lee, Peter P./0000-0002-2660-4377; Davis, Mark/0000-0001-6868-657X	NCI NIH HHS [CA-42509, CA-81543, K08 CA72976] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042509, K08CA072976, R21CA081543] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Barth RJ, 1996, CANCER, V78, P1168, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1168::AID-CNCR2>3.0.CO;2-6; Beagley KW, 1998, CRIT REV IMMUNOL, V18, P237, DOI 10.1615/CritRevImmunol.v18.i3.40; Bell EB, 1998, IMMUNOL TODAY, V19, P60, DOI 10.1016/S0167-5699(97)01211-5; BOON T, 1994, IMPORTANT ADV ONCOL, V130, P53; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Chai JG, 1998, J IMMUNOL, V160, P3655; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Cormier JN, 1998, INT J CANCER, V75, P517, DOI 10.1002/(SICI)1097-0215(19980209)75:4<517::AID-IJC5>3.3.CO;2-M; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; FINKE JH, 1993, CANCER RES, V53, P5613; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; HE XS, IN PRESS P NATL ACAD; HUANG AYC, 1994, CIBA F SYMP, V187, P229; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KAMINSKI MJ, 1993, CANCER RES, V53, P4014; Kawakami Y, 1997, IMMUNOL RES, V16, P313, DOI 10.1007/BF02786397; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Ku CC, 1997, IMMUNOL REV, V160, P139, DOI 10.1111/j.1600-065X.1997.tb01034.x; Lahat N, 1998, THYROID, V8, P361, DOI 10.1089/thy.1998.8.361; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Maeurer MJ, 1996, J CLIN INVEST, V98, P1633, DOI 10.1172/JCI118958; Maeurer MJ, 1996, MELANOMA RES, V6, P11, DOI 10.1097/00008390-199602000-00003; Maio M, 1996, IMMUNOL TODAY, V17, P405, DOI 10.1016/0167-5699(96)30014-5; Marrogi AJ, 1997, INT J CANCER, V74, P492, DOI 10.1002/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z; McMichael AJ, 1998, J EXP MED, V187, P1367, DOI 10.1084/jem.187.9.1367; Merogi AJ, 1997, HUM PATHOL, V28, P321, DOI 10.1016/S0046-8177(97)90131-3; MIZOGUCHI H, 1992, SCIENCE, V258, P1795, DOI 10.1126/science.1465616; NAKAGOMI H, 1993, CANCER RES, V53, P5610; NATALI PG, 1989, P NATL ACAD SCI USA, V86, P6719, DOI 10.1073/pnas.86.17.6719; OCHOA AC, 1995, IMP ADV ONCOL, V55, P43; Ogg GS, 1998, J EXP MED, V188, P1203, DOI 10.1084/jem.188.6.1203; RIDDELL SR, 1991, REV INFECT DIS, V13, pS966; ROCHA B, 1994, J EXP MED, V180, P681, DOI 10.1084/jem.180.2.681; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; Rosenberg SA, 1996, J IMMUNOTHER, V19, P81, DOI 10.1097/00002371-199601000-00009; Shiohara T, 1997, J INVEST DERMATOL, V109, P271, DOI 10.1111/1523-1747.ep12335465; Sperling AI, 1996, J IMMUNOL, V157, P3909; SUNDSTEDT A, 1995, J IMMUNOL, V154, P6306; TOPALIAN SL, 1989, J IMMUNOL, V142, P3714; Trimble LA, 1998, BLOOD, V91, P585, DOI 10.1182/blood.V91.2.585.585_585_594; Yannelli JR, 1996, INT J CANCER, V65, P413, DOI 10.1002/(SICI)1097-0215(19960208)65:4<413::AID-IJC3>3.0.CO;2-#; Yee C, 1996, J IMMUNOL, V157, P4079; Yee C, 1997, CURR OPIN IMMUNOL, V9, P702, DOI 10.1016/S0952-7915(97)80052-0; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	46	912	986	2	59	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					677	685		10.1038/9525	http://dx.doi.org/10.1038/9525			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371507				2022-12-27	WOS:000080823300037
J	Kaplan, HJ; Leibole, MA; Tezel, T; Ferguson, TA				Kaplan, HJ; Leibole, MA; Tezel, T; Ferguson, TA			Fas ligand (CD95 ligand) controls angiogenesis beneath the retina	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; BASEMENT-MEMBRANE; FACTOR EXPRESSION; IMMUNE PRIVILEGE; APOPTOSIS; DEATH; CELLS; INVOLVEMENT	A principal cause of blindness is subretinal neovascularization associated with age-related macular degeneration. Excised neovascular membranes from patients with age-related macular degeneration demonstrated a pattern of Fas(+) new vessels in the center of the vascular complex, surrounded by FasL(+) retinal pigment epithelial cells. In a murine model, Fas (CD95)-deficient (lpr) and Fast-defective (gld) mice had a significantly increased incidence of neovascularization compared with normal mice. Furthermore, in gld mice there is massive subretinal neovascularization with uncontrolled growth of vessels. We found that cultured choroidal endothelial cells were induced to undergo apoptosis by retinal pigment epithelial cells through a Fas-FasL interaction. In addition, antibody against Fas prevented vascular tube formation of choroidal endothelial cells derived from the eye in a three-dimensional in vitro assay. Thus, Fast expressed on retinal pigment epithelial cells may control the growth and development of new subretinal vessels that can damage vision.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Ferguson, TA (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.	ferguson@am.seer.wustl.edu			NEI NIH HHS [EY06765, EY08972] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008972] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; Chan CC, 1997, ARCH OPHTHALMOL-CHIC, V115, P1559, DOI 10.1001/archopht.1997.01100160729010; DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974; DeLisser HM, 1997, AM J PATHOL, V151, P671; Ferguson TA, 1997, IMMUNOL REV, V156, P167, DOI 10.1111/j.1600-065X.1997.tb00967.x; FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gratas C, 1997, BRAIN PATHOL, V7, P863, DOI 10.1111/j.1750-3639.1997.tb00889.x; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hammes HP, 1996, NAT MED, V2, P820; Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590; KINSELLA JL, 1992, EXP CELL RES, V199, P56, DOI 10.1016/0014-4827(92)90461-G; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; Luna J, 1996, LAB INVEST, V75, P563; Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741; MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SATA M, 1998, NAT MED, V4, P1; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Sekine C, 1996, BIOCHEM BIOPH RES CO, V228, P14, DOI 10.1006/bbrc.1996.1610; Stuart PM, 1997, J CLIN INVEST, V99, P396, DOI 10.1172/JCI119173; SUDA T, 1995, J IMMUNOL, V154, P3806; Suhara T, 1998, J IMMUNOL, V160, P4042; Thilenius ARB, 1997, EUR J IMMUNOL, V27, P1108, DOI 10.1002/eji.1830270510; WATANABE D, 1995, EMBO J, V14, P12, DOI 10.1002/j.1460-2075.1995.tb06970.x; Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641	43	138	156	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					292	297		10.1038/6509	http://dx.doi.org/10.1038/6509			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086384				2022-12-27	WOS:000078851600033
J	Nishimura, M; Yu, G; Levesque, G; Zhang, DM; Ruel, L; Chen, F; Milman, P; Holmes, E; Liang, Y; Kawarai, T; Jo, E; Supala, A; Rogaeva, E; Xu, DM; Janus, C; Levesque, L; Bi, Q; Duthie, M; Rozmahel, R; Mattila, K; Lannfelt, L; Westaway, D; Mount, HTJ; Woodgett, J; Fraser, PE; St George-Hyslop, P				Nishimura, M; Yu, G; Levesque, G; Zhang, DM; Ruel, L; Chen, F; Milman, P; Holmes, E; Liang, Y; Kawarai, T; Jo, E; Supala, A; Rogaeva, E; Xu, DM; Janus, C; Levesque, L; Bi, Q; Duthie, M; Rozmahel, R; Mattila, K; Lannfelt, L; Westaway, D; Mount, HTJ; Woodgett, J; Fraser, PE; St George-Hyslop, P			Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex	NATURE MEDICINE			English	Article							SYNTHASE KINASE-3 ACTIVITY; MISSENSE MUTATIONS; TRANSFECTED CELLS; IN-VIVO; LITHIUM; GENE; CHROMOSOME-1; APOPTOSIS; MECHANISM; XENOPUS	The presenilin proteins are components of high-molecular-weight protein complexes in the endoplasmic reticulum and Golgi apparatus that also contain beta-catenin. We report here that presenilin mutations associated with familial Alzheimer disease (but not the non-pathogenic Glu318Gly polymorphism) alter the intracellular trafficking of beta-catenin after activation of the Wnt/beta-catenin signal transduction pathway. As with their effect on beta APP processing, the effect of PS1 mutations on trafficking of beta-catenin arises from a dominant 'gain of aberrant function' activity. These results indicate that mistrafficking of selected presenilin ligands is a candidate mechanism for the genesis of Alzheimer disease associated with presenilin mutations, and that dysfunction in the presenilin-beta-catenin protein complexes is central to this process.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Pathol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 3H2, Canada; Toronto Hosp, Dept Med, Div Neurol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys & Expt Therapeut, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Karolinska Inst, Huddinge Hosp, Novum, KFC,Dept Clin Neurosci & Family Med, S-14186 Huddinge, Sweden	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Karolinska Institutet	St George-Hyslop, P (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	p.hyslop@utoronto.ca	Mount, Howard/B-4097-2013; Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Jo, Euijung/0000-0003-1131-2723	Canadian Institutes of Health Research [37920] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; ANANTH UEA, 1998, NEUROLOGY, V50, P111; Aplin AE, 1997, NEUROREPORT, V8, P639, DOI 10.1097/00001756-199702100-00012; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bird TD, 1996, ANN NEUROL, V40, P932, DOI 10.1002/ana.410400619; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Han YQ, 1997, J BIOL CHEM, V272, P9825; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Imahori K, 1997, J BIOCHEM, V121, P179; Irving NG, 1997, NEUROSCI LETT, V222, P71, DOI 10.1016/S0304-3940(97)13343-2; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; Mattila KM, 1998, ANN NEUROL, V44, P965, DOI 10.1002/ana.410440617; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tan YZ, 1998, BBA-MOL BASIS DIS, V1407, P69, DOI 10.1016/S0925-4439(98)00031-3; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	42	198	207	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	1999	5	2					164	169		10.1038/5526	http://dx.doi.org/10.1038/5526			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930863				2022-12-27	WOS:000078274400024
J	Loder, N				Loder, N			Wellcome extension to UK science museum	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					846	846		10.1038/78582	http://dx.doi.org/10.1038/78582			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932205				2022-12-27	WOS:000165473800010
J	Bodinier, M; Peyrat, MA; Tournay, C; Davodeau, F; Romagne, F; Bonneville, M; Lang, F				Bodinier, M; Peyrat, MA; Tournay, C; Davodeau, F; Romagne, F; Bonneville, M; Lang, F			Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding	NATURE MEDICINE			English	Article							ALPHA-3 DOMAIN; LYMPHOCYTES; AVIDITY; HLA-A2		INSERM, U463, Nantes, France; Immunotech SA, Beckman Coulter Co, Marshfield, WI USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Beckman Coulter Inc.	Lang, F (corresponding author), INSERM, U463, 9 Quai 9 Quai Moncousu, Nantes, France.		Davodeau, Francois/M-1888-2015; LANG, François/K-7403-2015; François, Davodeau/GLU-4061-2022	LANG, François/0000-0002-0762-4647; François, Davodeau/0000-0001-8181-0192				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bousso P, 1998, IMMUNITY, V9, P169, DOI 10.1016/S1074-7613(00)80599-3; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Couedel C, 1999, J IMMUNOL, V162, P6351; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Gervois N, 1996, J EXP MED, V183, P2403, DOI 10.1084/jem.183.5.2403; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Luxembourg AT, 1998, NAT BIOTECHNOL, V16, P281, DOI 10.1038/nbt0398-281; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; Scotet E, 1996, J EXP MED, V184, P1791, DOI 10.1084/jem.184.5.1791	14	131	142	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					707	710		10.1038/76292	http://dx.doi.org/10.1038/76292			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835691				2022-12-27	WOS:000087438300045
J	Conway, DJ; Cavanagh, DR; Tanabe, K; Roper, C; Mikes, ZS; Sakihama, N; Bojang, KA; Oduola, AMJ; Kremsner, PG; Arnot, DE; Greenwood, BM; McBride, JS				Conway, DJ; Cavanagh, DR; Tanabe, K; Roper, C; Mikes, ZS; Sakihama, N; Bojang, KA; Oduola, AMJ; Kremsner, PG; Arnot, DE; Greenwood, BM; McBride, JS			A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses	NATURE MEDICINE			English	Article							MEROZOITE SURFACE PROTEIN-1; PLASMODIUM-FALCIPARUM MEROZOITES; CARBOXY-TERMINAL FRAGMENT; NATURAL-SELECTION; SERUM ANTIBODIES; SOUTHERN VIETNAM; ANTIGEN GENE; PARASITE; RECOMBINATION; RESPONSES	New strategies are required to identify the most important targets of protective immunity in complex eukaryotic pathogens. Natural selection maintains allelic variation in some antigens of the malaria parasite Plasmodium falciparum(1-3). Analysis of allele frequency distributions could identify the loci under most intense selection(4-7). The merozoite surface protein 1 (Msp1) is the most-abundant surface component on the erythrocyte-invading stage of P. falciparum(8-10). Immunization with whole Msp1 has protected monkeys completely against homologous(11) and partially against non-homologous(12) parasite strains. The single-copy msp1 gene, of about 5 kilobases, has highly divergent alleles(13) with stable frequencies in endemic populations(14,15). To identify the region of msp1 under strongest selection to maintain alleles within populations, we studied multiple intragenic sequence loci in populations in different regions of Africa and Southeast Asia. On both continents, the locus with the lowest inter-population variance in allele frequencies was block 2 indicating selection in this part of the gene. To test the hypothesis of immune selection, we undertook a large prospective longitudinal cohort study. This demonstrated that serum IgG antibodies against each of the two most frequent allelic types of block 2 of the protein were strongly associated with protection from P. falciparum malaria.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Osaka Inst Technol, Biol Lab, Osaka 5358535, Japan; Osaka Inst Technol, Biol Lab, Osaka 5358535, Japan; MRC Labs, Banjul, Gambia; Univ Ibadan, Coll Med, Postgrad Inst Med Res & Training, Ibadan, Nigeria; Univ Tubingen, Inst Trop Med, Dept Parasitol, Tubingen, Germany	University of London; London School of Hygiene & Tropical Medicine; University of Edinburgh; Osaka Institute of Technology; Osaka Institute of Technology; MRC Laboratory Molecular Biology; University of Ibadan; Eberhard Karls University of Tubingen	Conway, DJ (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.	david.conway@lshtm.ac.uk	Roper, Cally/K-2989-2013; Arnot, David/S-1984-2019; Cavanagh, David R/A-1828-2008	Roper, Cally/0000-0002-6545-309X; Arnot, David/0000-0002-3027-1130; Conway, David/0000-0002-8711-3037; Bojang, Kalifa/0000-0001-7506-0938				AlYaman F, 1996, AM J TROP MED HYG, V54, P443, DOI 10.4269/ajtmh.1996.54.443; Anderson TJC, 1999, PARASITOLOGY, V119, P113, DOI 10.1017/S0031182099004552; Beaumont MA, 1996, P ROY SOC B-BIOL SCI, V263, P1619, DOI 10.1098/rspb.1996.0237; BERRY A, 1993, GENETICS, V134, P869; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9; Cavanagh DR, 1997, MOL BIOCHEM PARASIT, V85, P197, DOI 10.1016/S0166-6851(96)02826-5; Cavanagh DR, 1998, J IMMUNOL, V161, P347; CONWAY DJ, 1991, PARASITOLOGY, V103, P1, DOI 10.1017/S0031182000059217; CONWAY DJ, 1992, INFECT IMMUN, V60, P1122, DOI 10.1128/IAI.60.3.1122-1127.1992; Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6; Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; Dodoo D, 1999, INFECT IMMUN, V67, P2131, DOI 10.1128/IAI.67.5.2131-2137.1999; EGAN AF, 1995, INFECT IMMUN, V63, P456, DOI 10.1128/IAI.63.2.456-466.1995; Egan AF, 1996, J INFECT DIS, V173, P765, DOI 10.1093/infdis/173.3.765; Escalante AA, 1998, GENETICS, V149, P189; Ferreira MU, 1998, J EUKARYOT MICROBIOL, V45, P131, DOI 10.1111/j.1550-7408.1998.tb05080.x; Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689; Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437; HALL R, 1984, NATURE, V311, P379, DOI 10.1038/311379a0; Hastings IM, 1996, PARASITOLOGY, V112, P155, DOI 10.1017/S0031182000084717; HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0; HUGHES MK, 1995, MOL BIOCHEM PARASIT, V71, P99, DOI 10.1016/0166-6851(95)00037-2; Kaneko O, 1997, EXP PARASITOL, V86, P45, DOI 10.1006/expr.1997.4147; Locher CP, 1996, EXP PARASITOL, V84, P74, DOI 10.1006/expr.1996.0091; MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7; McDonald John H., 1994, P88; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x; Sakihama N, 1999, GENE, V230, P47, DOI 10.1016/S0378-1119(99)00069-4; SIDDIQUI WA, 1987, P NATL ACAD SCI USA, V84, P3014, DOI 10.1073/pnas.84.9.3014; Su XZ, 1996, GENOMICS, V33, P430, DOI 10.1006/geno.1996.0218; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; TAYLOR MFJ, 1995, SCIENCE, V270, P1497, DOI 10.1126/science.270.5241.1497; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x	37	218	220	0	18	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2000	6	6					689	692		10.1038/76272	http://dx.doi.org/10.1038/76272			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835687	Green Published			2022-12-27	WOS:000087438300041
J	Jo, M; Kim, TH; Seol, DW; Esplen, JE; Dorko, K; Billiar, TR; Strom, SC				Jo, M; Kim, TH; Seol, DW; Esplen, JE; Dorko, K; Billiar, TR; Strom, SC			Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand	NATURE MEDICINE			English	Article							POLY(ADP-RIBOSE) POLYMERASE; FAMILY; TRAIL; CLEAVAGE; RECEPTOR; MEMBER; INDUCTION; TNF	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been reported to induce apoptosis in various tumor cells but not in nontransformed, normal cells(1-3). Preclinical studies in mice and nonhuman primates have shown that administration of TRAIL can induce apoptosis in human tumors, but that no cytotoxicity to normal organs or tissues is found(3,4). The susceptibility of tumor cells to TRAIL and an apparent lack of activity in normal cells has lead to a proposal to use TRAIL in cancer therapy. Here, we assessed the sensitivity of hepatocytes from rat, mouse, rhesus monkey and human livers to TRAIL-induced apoptosis. TRAIL induced apoptosis in normal human hepatocytes in culture but not in hepatocytes isolated from the other species. Human hepatocytes showed characteristic features of apoptosis, including cytoplasmic shrinkage, the activation of caspases and DNA fragmentation. Apoptosis and cell death in human hepatocytes was massive and rapid, occurring in more than 60% of the cells exposed to TRAIL within 10 hours. These results indicate that there are species differences in sensitivity to TRAIL, and that substantial liver toxicity might result if TRAIL were used in human cancer therapy.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Strom, SC (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 200 Lothrop St,BST S-450, Pittsburgh, PA 15261 USA.		Strom, Stephen C/A-6501-2008		NIDDK NIH HHS [N01-DK-92310] Funding Source: Medline; NIGMS NIH HHS [R01-GM-50441] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK092310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050441] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bohlinger I, 1996, AM J PATHOL, V149, P1381; D'Amours D, 1998, RADIAT RES, V150, P3, DOI 10.2307/3579638; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Nussler AK, 1999, IN VITRO CELL DEV-AN, V35, P190, DOI 10.1007/s11626-999-0026-4; OGASAWARA J, 1993, NATURE, V365, P568, DOI 10.1038/365568a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Strom SC, 1996, METHOD ENZYMOL, V272, P388, DOI 10.1016/S0076-6879(96)72044-X; STROM SC, 1998, ILOTS LANGERHANS HEP, P195; Tanaka M, 1997, J IMMUNOL, V158, P2303; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	24	742	817	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					564	567		10.1038/75045	http://dx.doi.org/10.1038/75045			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802713				2022-12-27	WOS:000086796200041
J	Takaki, A; Wiese, M; Maertens, G; Depla, E; Seifert, U; Liebetrau, A; Miller, JL; Manns, MP; Rehermann, B				Takaki, A; Wiese, M; Maertens, G; Depla, E; Seifert, U; Liebetrau, A; Miller, JL; Manns, MP; Rehermann, B			Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C	NATURE MEDICINE			English	Article							T-LYMPHOCYTE RESPONSE; VIRUS-INFECTION; NONSTRUCTURAL PROTEIN-3; CELLS; CLEARANCE; MICE	As acute hepatitis C virus (HCV) infection is clinically inapparent in most cases, the immunologic correlates of recovery are not well defined. The cellular immune response is thought to contribute to the elimination of HCV-infected cells(1) and a strong HCV-specific T-helper-cell (Th) response is associated with recovery from acute hepatitis C (ref. 2). However, diagnosis of resolved hepatitis C is based at present on the detection of HCV-specific antibodies and the absence of detectable HCV RNA, and detailed comparison of the humoral and cellular immune response has been hampered by the fact that patient cohorts as well as HCV strains are usually heterogeneous and that clinical data from acute-phase and long-term follow-up after infection generally are not available. We studied a cohort of women accidentally exposed to the same HCV strain of known sequence(3) and found that circulating HCV-specific antibodies were undetectable in many patients 18-20 years after recovery, whereas HCV-specific helper and cytotoxic T-cell responses with an interferon (IFN)-gamma-producing (Tc1) phenotype persisted. The data indicate these HCV-specific CD4(+) and CD8(+) T cells are biomarkers for a prior HCV exposure and recovery. Because of undetectable antibodies against HCV, the incidence of self-limited HCV infections and recovery may be underestimated in the general population.	Med Hsch Hannover, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany; Stadt Klinikum St Georg, Klin Innere Med 2, D-04129 Leipzig, Germany; Hepatitits Program, B-9052 Ghent, Belgium; NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Liver Dis Sect, NIH, Bethesda, MD 20892 USA	Hannover Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rehermann, B (corresponding author), Med Hsch Hannover, Dept Gastroenterol & Hepatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.			Rehermann, Barbara/0000-0001-6832-9951	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054509, Z01DK054508, ZIADK054509, ZIADK054508] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CERNY A, 1995, J CLIN INVEST, V95, P521, DOI 10.1172/JCI117694; Chang KM, 1999, J IMMUNOL, V162, P1156; Diepolder HM, 1997, J VIROL, V71, P6011, DOI 10.1128/JVI.71.8.6011-6019.1997; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; HENLE W, 1970, SCIENCE, V169, P188, DOI 10.1126/science.169.3941.188; Koziel MJ, 1997, J INFECT DIS, V176, P859, DOI 10.1086/516546; MAERTENS G, 1994, VIRAL HEPATITIS LIVE, P314; MAERTENS G, 1999, METHODS MOL BIOL HEP, P11; *MIN GES DDR, 1995, BER STAATL HYG INSP; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Rehermann B, 1996, NAT MED, V2, P1104, DOI 10.1038/nm1096-1104; Rehermann B, 2000, CURR TOP MICROBIOL, V242, P299; Rehermann B, 1996, J HEPATOL, V24, P15, DOI 10.1016/S0168-8278(96)80180-2; Rehermann B, 1996, J VIROL, V70, P7092, DOI 10.1128/JVI.70.10.7092-7102.1996; Scognamiglio P, 1999, J IMMUNOL, V162, P6681; Selin LK, 1997, J IMMUNOL, V158, P5366; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; WIESE M, 1996, KASSENARZT, V5, P36; WIESE M, 1991, NON A NON B HEPATITI, P146	19	612	628	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					578	582		10.1038/75063	http://dx.doi.org/10.1038/75063			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802716				2022-12-27	WOS:000086796200044
J	Carmeliet, P				Carmeliet, P			Mechanisms of angiogenesis and arteriogenesis	NATURE MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; MICE LACKING; IN-VIVO; TIE2 RECEPTOR; CELLS; TUMOR; VEGF; REQUIREMENT; REGULATOR	Endothelial and smooth muscle cells interact wit each other to form new blood vessels. In this review, the cellular and molecular mechanisms underlying the formation of endothelium-lined channels (angiogenesis) and their maturation via recruitment of smooth muscle cells (arteriogenesis) during physiological and pathological conditions are summarized, alongside with possible therapeutic applications.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821				ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1999, NATURE, V401, P657, DOI 10.1038/44304; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Creazzo TL, 1998, ANNU REV PHYSIOL, V60, P267, DOI 10.1146/annurev.physiol.60.1.267; Dettman RW, 1998, DEV BIOL, V193, P169, DOI 10.1006/dbio.1997.8801; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gohongi T, 1999, NAT MED, V5, P1203, DOI 10.1038/13524; Gourdie RG, 1998, P NATL ACAD SCI USA, V95, P6815, DOI 10.1073/pnas.95.12.6815; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; ISNER J, 2000, NAT MED, V6, P405; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lindahl P, 1998, CURR OPIN LIPIDOL, V9, P407, DOI 10.1097/00041433-199810000-00004; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Patan S, 1998, MICROVASC RES, V56, P1, DOI 10.1006/mvre.1998.2081; Peeters MPFMV, 1997, CARDIOVASC RES, V36, P101, DOI 10.1016/S0008-6363(97)00146-6; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Reddi V, 1998, J AM SOC NEPHROL, V9, P63; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RISAU W, 1998, KIDNEY INT S, V67, P53; Schaper W, 1996, CIRC RES, V79, P911, DOI 10.1161/01.RES.79.5.911; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Taipale J, 1999, CURR TOP MICROBIOL, V237, P85; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1998, AM J PATHOL, V153, P1099, DOI 10.1016/S0002-9440(10)65654-4; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Yanagisawa H, 1998, J CLIN INVEST, V102, P22, DOI 10.1172/JCI2698; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	71	3157	3378	4	405	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2000	6	4					389	395		10.1038/74651	http://dx.doi.org/10.1038/74651			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742145				2022-12-27	WOS:000165474100032
J	Noble, M				Noble, M			Can neural stem cells be used as therapeutic vehicles in the treatment of brain tumors?	NATURE MEDICINE			English	Editorial Material							APOPTOSIS; RADIOTHERAPY; SEQUELAE	The most exciting recently developed therapeutic approaches for glioma and other types of nervous system tumors involve combinations of immune-therapy and neural stem cells. But we must bear in mind that the human brain differs greatly from the mouse brain, and that approaches that are effective in animal models may not always be safe for humans.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Noble, M (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	mark.noble@hci.utah.edu						Benedetti S, 2000, NAT MED, V6, P447, DOI 10.1038/74710; Cetingul N, 1999, PEDIATR HEMAT ONCOL, V16, P213, DOI 10.1080/088800199277263; Grill J, 1999, INT J RADIAT ONCOL, V45, P137, DOI 10.1016/S0360-3016(99)00177-7; Gritti A, 1996, J NEUROSCI, V16, P1091; Kalyani A, 1997, DEV BIOL, V186, P202, DOI 10.1006/dbio.1997.8592; Keime-Guibert F, 1998, J NEUROL, V245, P695, DOI 10.1007/s004150050271; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; Peissner W, 1999, MOL BRAIN RES, V71, P61, DOI 10.1016/S0169-328X(99)00170-9; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; Schlegel U, 1999, J NEURO-ONCOL, V43, P277, DOI 10.1023/A:1006214804736; SHAPIRO JR, 1985, CANCER METAST REV, V4, P107, DOI 10.1007/BF00050691; Shinohara C, 1997, CANCER RES, V57, P2694; Vigliani MC, 1999, J NEURO-ONCOL, V41, P137, DOI 10.1023/A:1006183730847; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0	15	19	22	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2000	6	4					369	370		10.1038/74610	http://dx.doi.org/10.1038/74610			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742131				2022-12-27	WOS:000165474100017
J	Ohashi, K; Marion, PL; Nakai, H; Meuse, L; Cullen, JM; Bordier, BB; Schwall, R; Greenberg, HB; Glenn, JS; Kay, MA				Ohashi, K; Marion, PL; Nakai, H; Meuse, L; Cullen, JM; Bordier, BB; Schwall, R; Greenberg, HB; Glenn, JS; Kay, MA			Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses	NATURE MEDICINE			English	Article							LIVER-REGENERATION; TRANSGENIC MICE; TRANSPLANTATION; EXPRESSION; GENOME; MOUSE; REPLICATION; DEFICIENT; SEQUENCE; DNA	Persistence of hepatocytes transplanted into the same or related species has been established(1-8). The long-term engraftment of human hepatocytes into rodents would be useful for the study of human viral hepatitis, where it might allow the species, technical and size limitations of the current animal models to be overcome. Although transgenic mice expressing the hepatitis B virus (HBV) genome produce infectious virus in their serum, the viral life cycle is not complete, in that the early stages of viral binding and entry into hepatocytes and production of an episomal transcriptional DNA template do not occur(9,10). As for hepatitis delta virus (HDV), another cause of liver disease(11,12), no effective therapy exists to eradicate infection, and it remains resistant even to recent regimens that have considerably changed the treatment of HBV (ref. 13). Here, we demonstrate long-term engraftment of primary human hepatocytes transplanted in a matrix under the kidney capsule of mice with administration of an agonistic antibody against c-Met. These mice were susceptible to HBV infection and completion of the viral life cycle. In addition, we demonstrate super-infection of the HBV-infected mice with HDV. Our results describe a new xenotransplant model that allows study of multiple aspects of human hepatitis viral infections, and may enhance studies of human liver diseases.	Stanford Univ, Sch Med, Program Human Gene Therapy, Dept Pediat & Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; N Carolina State Univ, Coll Vet Med, Raleigh, NC 27606 USA; Stanford Univ, Sch Med, Div Gastroenterol, Stanford, CA 94305 USA; Vet Adm Med Ctr, Stanford, CA 94305 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	Stanford University; Stanford University; University of North Carolina; North Carolina State University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Roche Holding; Genentech	Kay, MA (corresponding author), Stanford Univ, Sch Med, Program Human Gene Therapy, Dept Pediat & Genet, Stanford, CA 94305 USA.		Cullen, John M/I-2051-2019	greenberg, harry/0000-0002-2128-9080; Kay, Mark/0000-0002-2799-2615	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI041320] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41320] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; Casey JL, 1996, CLIN LAB MED, V16, P451, DOI 10.1016/S0272-2712(18)30279-8; Erhardt A, 1996, J CLIN MICROBIOL, V34, P1885, DOI 10.1128/JCM.34.8.1885-1891.1996; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; GLENN JS, 1999, VIRAL HEPAT REV, V5, P13; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; GUPTA S, 1995, P NATL ACAD SCI USA, V92, P5860, DOI 10.1073/pnas.92.13.5860; Ilan E, 1999, HEPATOLOGY, V29, P553, DOI 10.1002/hep.510290228; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; Lau DTY, 1999, HEPATOLOGY, V30, P546, DOI 10.1002/hep.510300217; Lieber A, 1996, J VIROL, V70, P8782, DOI 10.1128/JVI.70.12.8782-8791.1996; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; NETTER HJ, 1993, J VIROL, V67, P3357, DOI 10.1128/JVI.67.6.3357-3362.1993; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Peeters MJTFDV, 1997, HEPATOLOGY, V25, P884, DOI 10.1002/hep.510250416; Petersen J, 1998, P NATL ACAD SCI USA, V95, P310, DOI 10.1073/pnas.95.1.310; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; RAY MB, 1979, HEPATITIS B VIRUS AN, P69; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; VERME G, 1986, HEPATOLOGY, V6, P1303, DOI 10.1002/hep.1840060613; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0	25	134	157	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					327	331						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700236				2022-12-27	WOS:000085580500044
J	Lo, WF; Woods, AS; DeCloux, A; Cotter, RJ; Metcalf, ES; Soloski, MJ				Lo, WF; Woods, AS; DeCloux, A; Cotter, RJ; Metcalf, ES; Soloski, MJ			Molecular mimicry mediated by MHC class Ib molecules after infection with Gram-negative pathogens	NATURE MEDICINE			English	Article							HEAT-SHOCK PROTEINS; REACTIVE ARTHRITIS; T-CELLS; SALMONELLA INFECTIONS; AUTOIMMUNE-DISEASE; IDENTIFICATION; RECOGNITION; EXPRESSION; ANTIGEN; BINDING	The development of many autoimmune diseases has been etiologically linked to exposure to infectious agents(1). For example, a subset of patients with a history of Salmonella infection develop reactive arthritis(2-6). The persistence of bacterial antigen in arthritic tissue and the isolation of Salmonella or Yersinia reactive CD8(+) T cells from the joints of patients with reactive arthritis support the etiological link between Gram-negative bacterial infection and autoimmune disease(7,8). Models proposed to account for the link between infection and autoimmunity include inflammation-induced presentation of cryptic self-epitopes, antigen persistence and molecular mimicry(1). Several studies support molecular mimicry as a mechanism for the involvement of class II epitopes in infectious disease-induced self-reactivity(9-12). Here, we have identified an immunodominant epitope derived from the S. typhimurium GroEL molecule. This epitope is presented by the mouse H2-T23-encoded class Ib molecule Qa-l and was recognized by CD8(+) cytotoxic T lymphocytes induced after natural infection. S. typhimurium-stimulated cytotoxic T lymphocytes recognizing the GroEL epitope cross-reacted with a peptide derived from mouse heat shock protein 60 and recognized stressed macrophages. Our results indicate involvement of MHC class ib molecules in infection-induced autoimmune recognition and indicate a mechanism for the etiological link between Gram-negative bacterial infection and autoimmunity.	Johns Hopkins Univ, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Grad Program Immunol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA; Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Uniformed Services University of the Health Sciences - USA	Soloski, MJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21218 USA.				NIAID NIH HHS [R01AI32951, R01AI42287, R01AI20922] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042287, R01AI020922, R01AI032951] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; COICO R, 1994, CURRENT PROTOCOLS IM; DECLOUX A, 1997, J IMMUNOL, V158, P2193; GRANFORS K, 1990, LANCET, V335, P685, DOI 10.1016/0140-6736(90)90804-E; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; HERMANN E, 1993, APMIS, V101, P177, DOI 10.1111/j.1699-0463.1993.tb00099.x; HERMANN E, 1992, CELL IMMUNOL, V143, P253, DOI 10.1016/0008-8749(92)90023-I; IMANI F, 1991, P NATL ACAD SCI USA, V88, P10475, DOI 10.1073/pnas.88.23.10475; KOGA T, 1989, SCIENCE, V245, P1112, DOI 10.1126/science.2788923; KONDOWE GB, 1989, IRISH J MED SCI, V158, P274, DOI 10.1007/BF02942069; Kurepa Z, 1997, J IMMUNOL, V158, P3244; Lee N, 1998, J IMMUNOL, V160, P4951; LIFE PF, 1991, IMMUNOL REV, V121, P113, DOI 10.1111/j.1600-065X.1991.tb00825.x; MAKIIKOLA O, 1990, LANCET, V336, P1387, DOI 10.1016/0140-6736(90)92949-I; Rose NR, 1998, SEMIN IMMUNOL, V10, P5, DOI 10.1006/smim.1997.0100; Russmann H, 1998, SCIENCE, V281, P565, DOI 10.1126/science.281.5376.565; SIEPER J, 1995, ARTHRITIS RHEUM, V38, P1547, DOI 10.1002/art.1780381105; TAGGART AJ, 1989, BRIT MED J, V298, P674, DOI 10.1136/bmj.298.6674.674-a; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YU D, 1991, Current Opinion in Rheumatology, V3, P581, DOI 10.1097/00002281-199108000-00004; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344; Zugel U, 1997, INFECT IMMUN, V65, P3947	25	129	133	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					215	218		10.1038/72329	http://dx.doi.org/10.1038/72329			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655113				2022-12-27	WOS:000085016900045
J	Ramratnam, B; Mittler, JE; Zhang, LQ; Boden, D; Hurley, A; Fang, F; Macken, CA; Perelson, AS; Markowitz, M; Ho, DD				Ramratnam, B; Mittler, JE; Zhang, LQ; Boden, D; Hurley, A; Fang, F; Macken, CA; Perelson, AS; Markowitz, M; Ho, DD			The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy	NATURE MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; RAPID TURNOVER; LIFE-SPAN; IN-VIVO; INFECTION; LYMPHOCYTES	Replication-competent HIV-1 can be isolated from infected patients despite prolonged plasma virus suppression by anti-retroviral treatment(1-3). Recent studies have identified resting, memory CDC T lymphocytes as a long-lived latent reservoir of HIV-1 (refs. 4,5). Cross-sectional analyses indicate that the reservoir is rather small, between 10(3) and 10(7) cells per patient(5,6). In individuals whose plasma viremia levels are well suppressed by anti-retroviral therapy, peripheral blood mononuclear cells containing replication-competent HIV-1 were found to decay with a mean half-life of approximately 6 months(7), close to the decay characteristics of memory lymphocytes in humans and monkeys(8-10). In contrast, little decay was found in a less-selective patient population(11). We undertook this study to address this apparent discrepancy. Using a quantitative micro-culture assay, we demonstrate here that the latent reservoir decays with a mean half-life of 6.3 months in patients who consistently maintain plasma HIV-1 RNA levels of fewer than 50 copies/ml. Slower decay rates occur in individuals who experience intermittent episodes of plasma viremia. Our findings indicate that the persistence of the latent reservoir of HIV-1 despite prolonged treatment is due not only to its slow intrinsic decay characteristics but also to the inability of current drug regimens to completely block HIV-1 replication.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA	Rockefeller University; United States Department of Energy (DOE); Los Alamos National Laboratory	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.		Abrams, William R/A-5782-2008; Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040387, U01AI041534] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06555] Funding Source: Medline; NIAID NIH HHS [AI41534, AI40387] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altice FL, 1998, ANN INTERN MED, V129, P503, DOI 10.7326/0003-4819-129-6-199809150-00015; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gunthard HF, 1999, VIROLOGY, V259, P154, DOI 10.1006/viro.1999.9774; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Ho DD, 1998, SCIENCE, V280, P1866, DOI 10.1126/science.280.5371.1866; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Macken C, 1999, J IMMUNOL METHODS, V222, P13, DOI 10.1016/S0022-1759(98)00133-1; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	25	392	402	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					82	85		10.1038/71577	http://dx.doi.org/10.1038/71577			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613829				2022-12-27	WOS:000084583300040
J	Aszterbaum, M; Epstein, J; Oro, A; Douglas, V; LeBoit, PE; Scott, MP; Epstein, EH				Aszterbaum, M; Epstein, J; Oro, A; Douglas, V; LeBoit, PE; Scott, MP; Epstein, EH			Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice	NATURE MEDICINE			English	Article							BASAL-CELL CARCINOMA; HUMAN HOMOLOG; IN-VIVO; SONIC HEDGEHOG; NEVUS SYNDROME; SKIN-CANCER; EXPRESSION; MUTATIONS; GENE; TRICHOEPITHELIOMAS	Basal cell carcinomas, the commonest human skin cancers, consistently have abnormalities of the hedgehog signaling pathway and often have PTCH gene mutations. We report here that Ptch(+/-) mice develop primordial follicular neoplasms resembling human trichoblastomas, and that exposure to ultraviolet radiation or ionizing radiation results in an increase in the number and size of these tumors and a shift in their histologic features so that they more closely resemble human basal cell carcinoma. The mouse basal cell carcinomas and trichoblastoma-like tumors resemble human basal cell carcinomas in their loss of normal hemidesmosomal components, presence of p53 mutations, frequent loss of the normal remaining Ptch allele, and activation of hedgehog target gene transcription. The Ptch mutant mice provide the first mouse model, to our knowledge, of ultraviolet and ionizing radiation-induced basal cell carcinoma-like tumors, and also demonstrate that Ptch inactivation and hedgehog target gene activation are essential for basal cell carcinoma tumorigenesis.	Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94110 USA; Stanford Univ, Dept Dermatol, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Dermatol & Pathol, San Francisco, CA 94115 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Stanford University; University of California System; University of California San Francisco; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Epstein, EH (corresponding author), Univ Calif San Francisco, Dept Dermatol, Bldg 100,Room 269,1001 Potrero Ave, San Francisco, CA 94110 USA.			Oro, Anthony/0000-0002-6261-138X	NCI NIH HHS [CA81888] Funding Source: Medline; NIAMS NIH HHS [AR39959, AR4311] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA081888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039959] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Bahadoran P, 1997, BRIT J DERMATOL, V136, P35, DOI 10.1111/j.1365-2133.1997.tb08743.x; BOGOVSKI P, 1994, TUMOURS MOUSE PATHOL, V2, P11; BONIFAS JM, 1994, HUM MOL GENET, V3, P447, DOI 10.1093/hmg/3.3.447; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; DELLAPORTA G, 1960, J NATL CANCER I, V25, P573; Epstein J.H., 1985, MODELS DERMATOLOGY, V2, P303; EPSTEIN JH, 1965, J NATL CANCER I, V34, P741; FAIRLEY JA, 1995, BRIT J DERMATOL, V133, P385, DOI 10.1111/j.1365-2133.1995.tb02665.x; Gailani MR, 1996, J NATL CANCER I, V88, P349, DOI 10.1093/jnci/88.6.349; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GARRIGUE JL, 1994, CONTACT DERMATITIS, V30, P231, DOI 10.1111/j.1600-0536.1994.tb00650.x; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Grando SA, 1996, ARCH DERMATOL, V132, P1185, DOI 10.1001/archderm.132.10.1185; Green J, 1998, BRIT J DERMATOL, V139, P911; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HASHIMOTO K, 1972, J INVEST DERMATOL, V59, P380, DOI 10.1111/1523-1747.ep12627507; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kallassy M, 1997, CANCER RES, V57, P4731; Karagas MR, 1996, J NATL CANCER I, V88, P1848, DOI 10.1093/jnci/88.24.1848; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRESS S, 1992, CANCER RES, V52, P6400; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; MARKEY AC, 1992, BRIT J DERMATOL, V126, P154, DOI 10.1111/j.1365-2133.1992.tb07813.x; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MILLER SJ, 1993, J INVEST DERMATOL, V100, pS288, DOI 10.1111/1523-1747.ep12470169; NISHIGORI C, 1996, J INVEST DERMATOL S, V1, P143; OMalley S, 1997, J NEUROSURG, V86, P286, DOI 10.3171/jns.1997.86.2.0286; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; Raffel C, 1997, CANCER RES, V57, P842; SMOLLER BR, 1994, BRIT J DERMATOL, V131, P28, DOI 10.1111/j.1365-2133.1994.tb08453.x; VANDERRIET P, 1994, CANCER RES, V54, P25; Vorechovsky I, 1997, CANCER RES, V57, P4677; WALSH N, 1990, MODERN PATHOL, V3, P599; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	39	319	328	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1285	1291		10.1038/15242	http://dx.doi.org/10.1038/15242			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545995				2022-12-27	WOS:000086550600039
J	Bell, JI				Bell, JI			Clinical research is dead; long live clinical research	NATURE MEDICINE			English	Editorial Material							DIFFERENTIATION; CANCER		Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DS, England	University of Oxford	Bell, JI (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DS, England.							Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Geisow MJ, 1998, NAT BIOTECHNOL, V16, P206, DOI 10.1038/nbt0298-206; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Pappworth M. H., 1967, HUMAN GUINEA PIG EXP; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	10	19	19	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					477	478		10.1038/8353	http://dx.doi.org/10.1038/8353			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229217				2022-12-27	WOS:000081497400020
J	Braun, JS; Novak, R; Herzog, KH; Bodner, SM; Cleveland, JL; Tuomanen, EI				Braun, JS; Novak, R; Herzog, KH; Bodner, SM; Cleveland, JL; Tuomanen, EI			Neuroprotection by a caspase inhibitor in acute bacterial meningitis	NATURE MEDICINE			English	Article							PROGRAMMED CELL-DEATH; TISSUE-DAMAGE; APOPTOSIS; PROTEASE; PATHOPHYSIOLOGY; PATHOGENESIS; INFLAMMATION; GENERATION; ISCHEMIA	Half of the survivors of bacterial meningitis experience motor deficits, seizures, hearing loss or cognitive impairment, despite adequate bacterial killing by antibiotics. We demonstrate that the broad-spectrum caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone (z-VAD-fmk) prevented hippocampal neuronal cell death and white blood cell influx into the cerebrospinal fluid compartment in experimental pneumococcal meningitis. Hippocampal neuronal death was due to apoptosis derived from the inflammatory response in the cerebrospinal fluid. Apoptosis was induced in vitro in human neurons by inflamed cerebrospinal fluid and was blocked by z-VAD-fmk. As apoptosis drives neuronal loss in pneumococcal meningitis, caspase inhibitors might provide a new therapeutic option directed specifically at reducing brain damage.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol & Lab Med, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Tuomanen, EI (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	elaine.tuomanen@stjude.org	Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA076379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027913] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76379, P30 CA21765] Funding Source: Medline; NIAID NIH HHS [AI 27913] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; BRAUN JS, 1998, ADV PEDIAT INFECT DI, V14, P49; CHEN YJ, 1994, MICROB PATHOGENESIS, V17, P203, DOI 10.1006/mpat.1994.1066; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dodel RC, 1998, NEUROSCIENCE, V86, P701, DOI 10.1016/S0306-4522(98)00154-7; Eichhold TH, 1997, J PHARMACEUT BIOMED, V16, P459, DOI 10.1016/S0731-7085(97)00102-7; Evers P, 1998, METHODS, V15, P133, DOI 10.1006/meth.1998.0616; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; LACKS S, 1960, BIOCHIM BIOPHYS ACTA, V39, P508, DOI 10.1016/0006-3002(60)90205-5; Leib SL, 1996, J INFECT DIS, V173, P166, DOI 10.1093/infdis/173.1.166; Leib SL, 1996, J CLIN INVEST, V98, P2632, DOI 10.1172/JCI119084; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Pitrak DL, 1996, J CLIN INVEST, V98, P2714, DOI 10.1172/JCI119096; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; RONNETT GV, 1994, NEUROSCIENCE, V63, P1081, DOI 10.1016/0306-4522(94)90574-6; Roos Karen L., 1997, P335; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; TAUBER MG, 1992, J INFECT DIS, V166, P1045, DOI 10.1093/infdis/166.5.1045; TAUBER MG, 1994, METHOD ENZYMOL, V235, P93; TAUBER MG, 1997, DEFENSE BRAIN, P125; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557; Zysk G, 1996, J NEUROPATH EXP NEUR, V55, P722, DOI 10.1097/00005072-199606000-00006	31	217	228	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					298	302		10.1038/6514	http://dx.doi.org/10.1038/6514			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086385				2022-12-27	WOS:000078851600034
J	Schneider, H; Coutelle, C				Schneider, H; Coutelle, C			In utero gene therapy - The case for	NATURE MEDICINE			English	Editorial Material									Imperial Coll Sch Med, Div Biomed Sci, Cyst Fibrosis Gene Therapy Res Grp, London, England	Imperial College London	Schneider, H (corresponding author), Imperial Coll Sch Med, Div Biomed Sci, Cyst Fibrosis Gene Therapy Res Grp, London, England.							Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Clothier C., 1992, REPORT COMMITTEE ETH; COUTELLE C, 1995, NAT MED, V1, P864, DOI 10.1038/nm0995-864; Fox JL, 1998, NAT BIOTECHNOL, V16, P1002, DOI 10.1038/3445; Porada CD, 1998, HUM GENE THER, V9, P1571, DOI 10.1089/hum.1998.9.11-1571; Tebbutt SJ, 1998, MUTAT RES-GENOMICS, V382, P93, DOI 10.1016/S1383-5726(97)00012-5; Wadman M, 1999, NATURE, V397, P94, DOI 10.1038/16316	7	32	32	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					256	257		10.1038/6458	http://dx.doi.org/10.1038/6458			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086371				2022-12-27	WOS:000078851600020
J	Fang, GW; Weiser, B; Visosky, A; Moran, T; Burger, H				Fang, GW; Weiser, B; Visosky, A; Moran, T; Burger, H			PCR-mediated recombination: A general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA	NATURE MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; THERMOSTABLE DNA-POLYMERASE; OVERLAP EXTENSION; FIDELITY; AMPLIFICATION		New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; Albany Med Coll, Albany, NY 12208 USA	State University of New York (SUNY) System; Wadsworth Center; Albany Medical College	Burger, H (corresponding author), New York State Dept Hlth, Wadsworth Ctr, POB 22002,120 New Scotland Ave, Albany, NY 12201 USA.				NIAID NIH HHS [R01AI33334, U01AI35004] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033334, U01AI035004] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Eckert K A, 1991, PCR Methods Appl, V1, P17; Fang GW, 1996, J ACQ IMMUN DEF SYND, V12, P352, DOI 10.1097/00042560-199608010-00004; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; GU HM, 1991, BIOCHEM BIOPH RES CO, V177, P202, DOI 10.1016/0006-291X(91)91968-I; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORTON RM, 1995, MOL BIOTECHNOL, V3, P93, DOI 10.1007/BF02789105; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KLUG J, 1991, NUCLEIC ACIDS RES, V19, P2793, DOI 10.1093/nar/19.10.2793; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MATTILA P, 1991, NUCLEIC ACIDS RES, V19, P4967, DOI 10.1093/nar/19.18.4967; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; MYERS G, 1996, HUMAN RETROVIRUSES A; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALMINEN MO, 1995, VIROLOGY, V213, P80, DOI 10.1006/viro.1995.1548; SANDHU GS, 1992, BIOTECHNIQUES, V12, P14; YOLOV AA, 1990, NUCLEIC ACIDS RES, V18, P3483	20	45	53	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					239	242		10.1038/5607	http://dx.doi.org/10.1038/5607			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930876				2022-12-27	WOS:000078274400037
J	Wickware, P				Wickware, P			... and AHA announces support for the technique	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					845	845		10.1038/78576	http://dx.doi.org/10.1038/78576			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932203				2022-12-27	WOS:000165473800008
J	Holzman, PS				Holzman, PS			Seymour S. Kety 1915-2000 - Obituary	NATURE MEDICINE			English	Biographical-Item									Harvard Univ, Cambridge, MA 02138 USA; McLean Hosp, Cambridge, MA 02138 USA	Harvard University; Harvard University; McLean Hospital	Holzman, PS (corresponding author), Harvard Univ, 33 Kirkland St, Cambridge, MA 02138 USA.								0	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					727	+		10.1038/77435	http://dx.doi.org/10.1038/77435			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888908	Bronze			2022-12-27	WOS:000088040100018
J	Kisilevsky, R				Kisilevsky, R			Amyloids: Tombstones or triggers?	NATURE MEDICINE			English	Editorial Material							FIBRIL		Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Kingston Gen Hosp, Syl & Molly Apps Res Ctr, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Kisilevsky, R (corresponding author), Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada.							Haggqvist B, 1999, P NATL ACAD SCI USA, V96, P8669, DOI 10.1073/pnas.96.15.8669; Janciauskiene S, 1998, BIOCHEM BIOPH RES CO, V251, P888, DOI 10.1006/bbrc.1998.9574; KISILEVSKY R, 1983, LAB INVEST, V48, P53; Kisilevsky R, 1997, CRIT REV BIOCHEM MOL, V32, P361, DOI 10.3109/10409239709082674; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; SNOW AD, 1987, LAB INVEST, V56, P665; Westermark P, 1997, AMYLOID, V4, P216, DOI 10.3109/13506129709014387; Yan SD, 2000, NAT MED, V6, P643, DOI 10.1038/76216	8	16	16	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					633	634		10.1038/76203	http://dx.doi.org/10.1038/76203			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835676				2022-12-27	WOS:000087438300026
J	Li, YS; Li, XC; Zheng, XX; Wells, AD; Turka, LA; Strom, TB				Li, YS; Li, XC; Zheng, XX; Wells, AD; Turka, LA; Strom, TB			Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance	NATURE MEDICINE			English	Article							CYCLOSPORINE-A; CD28 COSTIMULATION; CARDIAC ALLOGRAFTS; REJECTION; SURVIVAL; EXPRESSION; RAPAMYCIN; RESPONSES; RECEPTOR; PATHWAYS	The alloimmune response against fully MHC-mismatched allografts, compared with immune responses to nominal antigens, entails an unusually large clonal size of alloreactive T cells(1). Thus, induction of peripheral allograft tolerance established in the absence of immune system ablation and reconstitution is a challenging task in transplantation. Here, we determined whether a reduction in the mass of alloreactive T cells due to apoptosis is an essential initial step for induction of stable allograft tolerance with non-lymphoablative therapy. Blocking both CD28-B7 and CD40-CD40 ligand interactions (co-stimulation blockade) inhibited proliferation of alloreactive T cells in vivo while allowing cell cycle-dependent T-cell apoptosis of proliferating T cells, with permanent engraftment of cardiac allografts but not skin allografts. Treatment with rapamycin plus co-stimulation blockade resulted in massive apoptosis of alloreactive T cells and produced stable skin allograft tolerance, a very stringent test of allograft tolerance. In contrast, treatment with cyclosporine A and co-stimulation blockade abolished T-cell proliferation and apoptosis, as well as the induction of stable allograft tolerance. Our data indicate that induction of T-cell apoptosis and peripheral allograft tolerance is prevented by blocking both signal 1 and signal 2 of T-cell activation.	Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr,Div Immunol, Boston, MA 02215 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Pennsylvania	Strom, TB (corresponding author), Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr,Div Immunol, Boston, MA 02215 USA.		Strom, Terry B./E-9268-2010	Strom, Terry B./0000-0002-7570-0736; Li, Xian Chang/0000-0002-5981-2762	NIAID NIH HHS [P01 AI041521, R01AI42298, P0 AI/GF 41521] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI041521, R01AI042298] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Adachi M, 1996, BLOOD, V88, P4118, DOI 10.1182/blood.V88.11.4118.bloodjournal88114118; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Cobbold S, 1998, CURR OPIN IMMUNOL, V10, P518, DOI 10.1016/S0952-7915(98)80217-3; Dai ZH, 1998, J IMMUNOL, V161, P1659; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Li XC, 1998, J IMMUNOL, V161, P2241; Li XC, 1998, TRANSPLANTATION, V65, pS169; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Song HK, 1999, J IMMUNOL, V162, P2467; Sykes M, 1996, CURR OPIN IMMUNOL, V8, P694, DOI 10.1016/S0952-7915(96)80088-4; Tivol EA, 1997, J IMMUNOL, V158, P5091; Warrens A N, 1994, Transpl Immunol, V2, P103, DOI 10.1016/0966-3274(94)90036-1; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437	22	586	606	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1298	1302		10.1038/15256	http://dx.doi.org/10.1038/15256			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545997				2022-12-27	WOS:000086550600041
J	Lacroix-Desmazes, S; Moreau, A; Sooryanarayana; Bonnemain, C; Stieltjes, N; Pashov, A; Sultan, Y; Hoebeke, J; Kazatchkine, MD; Kaveri, SV				Lacroix-Desmazes, S; Moreau, A; Sooryanarayana; Bonnemain, C; Stieltjes, N; Pashov, A; Sultan, Y; Hoebeke, J; Kazatchkine, MD; Kaveri, SV			Catalytic activity of antibodies against factor VIII in patients with hemophilia A	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-C; FACTOR-IXA; FACTOR XA; VONWILLEBRAND-FACTOR; COFACTOR ACTIVITY; LIGHT CHAIN; THROMBIN; INACTIVATION; INHIBITION; CLEAVAGE	Hemophilia A is an X chromosome-linked recessive disorder resulting in defective or deficient factor VIII (FVIII) molecules, which, in its severe form, is a life-threatening and crippling hemorrhagic disease. Infusion of homologous FVIII to patients with severe hemophilia A results, in 25% of patients, in the emergence of alloantibodies against FVIII (inhibitors)(ref. 1) that inhibit FVIII procoagulant activity by steric hindrance of the interaction of FVIII either with stabilizing molecules(2), with molecules essential for its activity(3,4) Or With activating molecules(5). Here, we report on the proteolysis of FVIII by alloantibodies of two patients with severe hemophilia A, demonstrating a previously unknown mechanism by which FVIII inhibitors may prevent the pro-coagulant function of FVIII. The kinetic parameters of FVIII hydrolysis indicate a functional role for the catalytic immune response in the inactivation of FVIII in vivo. The characterization of alloantibodies against FVIII as site-specific proteases may provide new approaches to the treatment of FVIII inhibitors.	INSERM U430, F-75014 Paris, France; Univ Paris 06, Hop Broussais, F-75014 Paris, France; Hop Cochin, Ctr Hemophiles, F-75674 Paris, France; IBMC, CNRS, UPR 9021, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Lacroix-Desmazes, S (corresponding author), INSERM U430, F-75014 Paris, France.		Pashov, Anastas/AAE-7997-2019	Pashov, Anastas/0000-0002-6033-3566; Lacroix-Desmazes, Sebastien/0000-0001-5625-8447				ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BRONSHTEIN IB, 1992, FEBS LETT, V314, P259, DOI 10.1016/0014-5793(92)81484-4; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; EHRENFORTH S, 1992, LANCET, V339, P594, DOI 10.1016/0140-6736(92)90874-3; GALLACHER G, 1991, BIOCHEM J, V279, P871, DOI 10.1042/bj2790871; GILLES JGG, 1993, BLOOD, V82, P2452; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; Kaveri S, 1996, J CLIN INVEST, V97, P865, DOI 10.1172/JCI118488; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LEYTE A, 1990, J BIOL CHEM, V226, P740; LI L, 1995, J IMMUNOL, V154, P3328; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; NEUENSCHWANDER PF, 1992, ARCH BIOCHEM BIOPHYS, V296, P426, DOI 10.1016/0003-9861(92)90593-L; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; Paul S, 1997, J IMMUNOL, V159, P1530; PAUL S, 1990, J BIOL CHEM, V265, P11910; REGAN LM, 1994, J BIOL CHEM, V269, P9445; RICKARD KA, 1995, HAEMOPHILIA, V1, P8, DOI 10.1111/j.1365-2516.1995.tb00104.x; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; Zhong DG, 1998, BLOOD, V92, P136, DOI 10.1182/blood.V92.1.136.413k35_136_142	25	170	184	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1044	1047		10.1038/12483	http://dx.doi.org/10.1038/12483			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470082				2022-12-27	WOS:000082337200039
J	Brini, M; Pinton, P; King, MP; Davidson, M; Schon, EA; Rizzuto, R				Brini, M; Pinton, P; King, MP; Davidson, M; Schon, EA; Rizzuto, R			A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency	NATURE MEDICINE			English	Article							RAGGED-RED FIBERS; MTDNA MUTATION; CELLS; ATP; HOMEOSTASIS; METABOLISM; TRNA(LYS); RESPONSES; AEQUORIN; EPILEPSY	In recent years, genetic defects of the mitochondrial genome (mtDNA) were shown to be associated with a heterogeneous group of disorders, known as mitochondrial diseases(1,2), but the cellular events deriving from the molecular lesions and the mechanistic basis of the specificity of the syndromes are still incompletely understood. Mitochondrial calcium (Ca2+) homeostasis depends on close contacts with the endoplasmic reticulum(3) and is essential in modulating organelle function(4-6). Given the strong dependence of mitochondrial Ca2+ uptake on the membrane potential and the intracellular distribution of the organelle, both of which may be altered in mitochondrial diseases, we investigated the occurrence of defects in mitochondrial Ca2+ handling in living cells with either the tRNA(Lys) mutation of MERRF (myoclonic epilepsy with ragged-red fibers)(7-9) or the ATPase mutation of NARP (neurogenic muscle weakness, ataxia and retinitis pigmentosa)(10-13). There was a derangement of mitochondrial Ca2+ homeostasis in MERRF, but not in NARP cells, whereas cytosolic Ca2+ responses were normal in both cell types. Treatment of MERRF cells with drugs affecting organellar Ca2+ transport mostly restored both the agonist-dependent mitochondrial Ca2+ uptake and the ensuing stimulation of ATP production. These results emphasize the differences in the cellular pathogenesis of the various mtDNA defects and indicate specific pharmacological approaches to the treatment of some mitochondrial diseases.	Univ Padua, Dept Biomed Sci, I-35100 Padua, Italy; Univ Padua, Dept Biochem, I-35100 Padua, Italy; Univ Padua, CNR, Ctr Study Biomembranes, I-35100 Padua, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet, New York, NY 10032 USA	University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Ferrara; Columbia University; Columbia University	Rizzuto, R (corresponding author), Univ Padua, Dept Biomed Sci, I-35100 Padua, Italy.		Brini, Marisa/K-5189-2016; Rizzuto, Rosario/B-6312-2008; Pinton, Paolo/J-8025-2012	Pinton, Paolo/0000-0001-7108-6508; Rizzuto, Rosario/0000-0001-7044-5097; Brini, Marisa/0000-0001-5141-0243	NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766, NS28828] Funding Source: Medline; Telethon [850] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011766, R01NS028828, P50NS011766] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allue I, 1996, BIOCHEM J, V319, P463, DOI 10.1042/bj3190463; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; COX DA, 1993, J BIOL CHEM, V268, P938; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SILVESTRI G, 1992, AM J HUM GENET, V51, P1213; TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390; VazquezMemije ME, 1996, J INHERIT METAB DIS, V19, P43, DOI 10.1007/BF01799347; WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096	22	138	140	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					951	954		10.1038/11396	http://dx.doi.org/10.1038/11396			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426322				2022-12-27	WOS:000081684000042
J	Mutis, T; Gillespie, G; Schrama, E; Falkenburg, JHF; Moss, P; Goulmy, E				Mutis, T; Gillespie, G; Schrama, E; Falkenburg, JHF; Moss, P; Goulmy, E			Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease	NATURE MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; BYSTANDER ACTIVATION; CELL PRECURSORS; H-Y; ABSENCE; IDENTIFICATION; RECIPIENTS; VIVO; HA-1	Graft-versus-host disease (GvHD) is a chief complication of allogeneic bone marrow transplantation(1). In HLA-identical bone marrow transplantation, GvHD may be induced by disparities in minor histocompatibility antigens (mHags) between the donor and the recipient, with the antigen being present in the recipient and not in the donort(2). Cytotoxic T lymphocytes (CTLs) specific for mHags of the recipients can be isolated from the blood of recipients with severe GvHD (ref. 3). A retrospective study demonstrated an association between mismatch for mHags HA-1, -2, -4 and -5 and the occurrence of GvHD in adult recipients of bone marrow from HLA genotypically identical donors(4). Tetrameric HLA-peptide complexes have been used to visualize and quantitate antigen-specific CTLs in HIV-infected individuals and during Epstein-Barr virus and lymphocytic choriomeningitis virus infections(5-8). Here we show the direct ex vivo visualization of mHag-specific CTLs during GvHD using tetrameric HLA-class and 1-mHag HA-1 and HY peptide complexes. In the peripheral blood of 17 HA-1 or HY mismatched marrow recipients, HA-1-and MY-specific CTLs were detected as early as 14 days after bone marrow transplantation. The tetrameric complexes demonstrated a significant increase in HA-1- and MY-specific CTLs during acute and chronic GvHD, which decreased after successful GvHD treatment. HLA class 1-mHag peptide tetramers may serve as clinical tools for the diagnosis and monitoring of GvHD patients.	Leiden Univ, Ctr Med, Dept Immunohaematol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Ctr Med, Blood Bank, NL-2300 RC Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Hematol, NL-2300 RC Leiden, Netherlands; Univ Hosp, Dept Hematol, Birmingham, W Midlands, England; John Radcliffe Hosp, Mol Immunol Grp, Oxford OX3 9DU, England	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; University of Birmingham; University of Oxford	Mutis, T (corresponding author), Leiden Univ, Ctr Med, Dept Immunohaematol, Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.							Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; DEBUEGER M, 1993, BONE MARROW TRANSPL, V11, P363; den Haan JMM, 1998, SCIENCE, V279, P1054, DOI 10.1126/science.279.5353.1054; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Ehl S, 1997, J EXP MED, V185, P1241, DOI 10.1084/jem.185.7.1241; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; Goulmy E, 1996, CURR OPIN IMMUNOL, V8, P75, DOI 10.1016/S0952-7915(96)80108-7; Gratwohl A, 1998, BLOOD, V92, p320A; HAMILTON BL, 1984, TRANSPLANTATION, V38, P357, DOI 10.1097/00007890-198410000-00009; HOROWITZ MM, 1990, BLOOD, V75, P555; Liem LM, 1996, BONE MARROW TRANSPL, V18, P73; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NIEDERWIESER D, 1993, BLOOD, V81, P2200; SCHWARER AP, 1993, LANCET, V341, P203, DOI 10.1016/0140-6736(93)90067-Q; THEOBALD M, 1993, BLOOD, V82, P298, DOI 10.1182/blood.V82.1.298.bloodjournal821298; TSOI MS, 1980, J IMMUNOL, V125, P2258; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; Wilke M, 1998, TISSUE ANTIGENS, V52, P312, DOI 10.1111/j.1399-0039.1998.tb03053.x; Zarozinski CC, 1997, J EXP MED, V185, P1629, DOI 10.1084/jem.185.9.1629	24	215	226	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					839	842		10.1038/10563	http://dx.doi.org/10.1038/10563			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395333				2022-12-27	WOS:000081926600043
J	Robinson, HL; Montefiori, DC; Johnson, RP; Manson, KH; Kalish, ML; Lifson, JD; Rizvi, TA; Lu, S; Hu, SL; Mazzara, GP; Panicali, DL; Herndon, JG; Glickman, R; Candido, MA; Lydy, SL; Wyand, MS; McClure, HM				Robinson, HL; Montefiori, DC; Johnson, RP; Manson, KH; Kalish, ML; Lifson, JD; Rizvi, TA; Lu, S; Hu, SL; Mazzara, GP; Panicali, DL; Herndon, JG; Glickman, R; Candido, MA; Lydy, SL; Wyand, MS; McClure, HM			Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations	NATURE MEDICINE			English	Article							T-LYMPHOCYTE RESPONSES; VACCINIA VIRUS; PROTECTIVE EFFICACY; ATTENUATED SIV; FOWLPOX VIRUS; HIV VACCINE; TYPE-1 ENV; INFECTION; CELLS; GENE	Eight different protocols were compared for their ability to raise protection against immunodeficiency virus challenges in rhesus macaques. The most promising containment of challenge infections was achieved by intradermal DNA priming followed by recombinant fowl pox virus booster immunizations. This containment did not require neutralizing antibody and was active for a series of challenges ending with a highly virulent virus with a primary isolate envelope heterologous to the immunizing strain.	Yerkes Reg Primate Res Ctr, Atlanta, GA 30329 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Harvard Univ, Sch Med, AIDS Res Ctr, Southborough, MA 01772 USA; GTC Mason Labs, Worcester, MA 01608 USA; Ctr Dis Control, Atlanta, GA 30333 USA; NCI, Frederick Canc Res Ctr, Frederick, MD 21702 USA; Univ Texas, MD Anderson Canc Ctr, Bastrop, TX 78802 USA; Univ Massachusetts, Med Ctr, Div Infect Dis, Worcester, MA 01655 USA; Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA; Therion Biol, Cambridge, MA 02142 USA	Duke University; Harvard University; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center; University of Massachusetts System; University of Massachusetts Worcester; University of Washington; University of Washington Seattle	Robinson, HL (corresponding author), Yerkes Reg Primate Res Ctr, Atlanta, GA 30329 USA.		Hu, Shiu-Lok/A-3196-2008	Hu, Shiu-Lok/0000-0003-4336-7964; Rizvi, Tahir A/0000-0002-2572-1678	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI043045, R01AI034241] Funding Source: NIH RePORTER; NIAID NIH HHS [P01-AI-43045, R01-AI-34241, R01-AI-40334] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; Boyer JD, 1997, NAT MED, V3, P526, DOI 10.1038/nm0597-526; Burton DR, 1998, NAT MED, V4, P495, DOI 10.1038/nm0598supp-495; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Dittmer U, 1999, NAT MED, V5, P189, DOI 10.1038/5550; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; EARL PL, 1994, J VIROL, V68, P3015, DOI 10.1128/JVI.68.5.3015-3026.1994; Feltquate DM, 1997, J IMMUNOL, V158, P2278; Finzi D, 1998, CELL, V93, P665, DOI 10.1016/S0092-8674(00)81427-0; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Graham BS, 1998, J INFECT DIS, V177, P310, DOI 10.1086/514209; GRITZ L, 1990, J VIROL, V64, P5948, DOI 10.1128/JVI.64.12.5948-5957.1990; HU SL, 1995, TRANSMEMBRANE PROTEI, P167; JENKINS S, 1991, AIDS RES HUM RETROV, V7, P991, DOI 10.1089/aid.1991.7.991; Johnson RP, 1997, J VIROL, V71, P7711, DOI 10.1128/JVI.71.10.7711-7718.1997; Johnson RP, 1999, NAT MED, V5, P154, DOI 10.1038/5515; Kent SJ, 1998, J VIROL, V72, P10180, DOI 10.1128/JVI.72.12.10180-10188.1998; KLANIECKI J, 1991, AIDS RES HUM RETROV, V7, P791, DOI 10.1089/aid.1991.7.791; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; LI JT, 1995, J VIROL, V69, P7061, DOI 10.1128/JVI.69.11.7061-7067.1995; Lu S, 1996, J VIROL, V70, P3978, DOI 10.1128/JVI.70.6.3978-3991.1996; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; Montefiori David C., 1999, AIDS Research and Human Retroviruses, V15, P689, DOI 10.1089/088922299310773; MONTEFIORI DC, 1988, J CLIN MICROBIOL, V26, P231, DOI 10.1128/JCM.26.2.231-235.1988; Moore J P, 1995, AIDS, V9 Suppl A, pS117; Moss B, 1990, Semin Immunol, V2, P317; OGARRA A, 1994, CURR OPIN IMMUNOL, V6, P458, DOI 10.1016/0952-7915(94)90128-7; PERTMER TM, 1995, VACCINE, V13, P1427, DOI 10.1016/0264-410X(95)00069-D; Polacino P, 1999, J VIROL, V73, P618, DOI 10.1128/JVI.73.1.618-630.1999; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; Richmond JFL, 1998, J VIROL, V72, P9092, DOI 10.1128/JVI.72.11.9092-9100.1998; Robinson H L, 1997, Semin Immunol, V9, P271, DOI 10.1006/smim.1997.0083; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Ruprecht RM, 1996, SCIENCE, V271, P1790; Schacker TW, 1998, ANN INTERN MED, V128, P613, DOI 10.7326/0003-4819-128-8-199804150-00001; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Schochetman Gerald, 1996, P25; Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Stott J, 1998, AIDS, V12 Suppl A, pS95; Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183; Tartaglia J, 1998, AIDS RES HUM RETROV, V14, pS291; *WHO, 1998, AIDS EP UPD JOINT UN; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996; Yang OO, 1997, P NATL ACAD SCI USA, V94, P11478, DOI 10.1073/pnas.94.21.11478	49	341	354	0	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					526	534		10.1038/8406	http://dx.doi.org/10.1038/8406			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229229				2022-12-27	WOS:000081497400033
J	Fernandez, NC; Lozier, A; Flament, C; Ricciardi-Castagnoli, P; Bellet, D; Suter, M; Perricaudet, M; Tursz, T; Maraskovsky, E; Zitvogel, L				Fernandez, NC; Lozier, A; Flament, C; Ricciardi-Castagnoli, P; Bellet, D; Suter, M; Perricaudet, M; Tursz, T; Maraskovsky, E; Zitvogel, L			Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo	NATURE MEDICINE			English	Article							NATURAL-KILLER-CELLS; FLT3 LIGAND; T-CELLS; MURINE TUMORS; IN-VIVO; INTERLEUKIN-12; MICE; ACTIVATION; THERAPY; COSTIMULATION	Cytotoxic T lymphocytes and natural killer cells are essential effecters of anti-tumor immune responses in vivo. Dendritic cells (DC) 'prime' tumor antigen-specific cytotoxic T lymphocytes; thus, we investigated whether DC might also trigger the innate, NK cell-mediated anti-tumor immunity. In mice with MHC class I-negative tumors, adoptively transferred- or Flt3 ligand-expanded DC promoted NK cell-dependent anti-tumor effects. In vitro studies demonstrated a cell-to-cell contact between DC and resting NK cells that resulted in a substantial increase in both NK cell cytolytic activity and IFN-gamma production. Thus, DC are involved in the interaction between innate and adaptive immune responses.	Inst Gustave Roussy, Dept Biol Clin, Unite Immunol, Villejuif, France; Inst Gustave Roussy, CNRS, UMR1582, Villejuif, France; Univ Milan, Dept Biotechnol & Biosci, Milan, Italy; Univ Zurich, Inst Virol, Zurich, Switzerland; Immunex Res & Dev Corp, Dept Immunobiol, Seattle, WA 98101 USA; Repatriat Med Ctr, Heidelberg, Vic, Australia; Ludwig Oncol Unit, Austin, Australia	UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University of Milan; University of Milano-Bicocca; University of Zurich	Zitvogel, L (corresponding author), Inst Gustave Roussy, Dept Biol Clin, Unite Immunol, Villejuif, France.	zitvogel@igr.fr	Castagnoli, Paola/E-8288-2010	ZITVOGEL, laurence/0000-0003-1596-0998				ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BANDYOPADHYAY S, 1986, J EXP MED, V164, P180, DOI 10.1084/jem.164.1.180; Carbone E, 1997, J EXP MED, V185, P2053, DOI 10.1084/jem.185.12.2053; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; Chambers BJ, 1996, IMMUNITY, V5, P311, DOI 10.1016/S1074-7613(00)80257-5; CHANG ZL, 1990, CELL IMMUNOL, V125, P183, DOI 10.1016/0008-8749(90)90073-Z; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; Chen KY, 1997, CANCER RES, V57, P3511; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; GISMONDI A, 1991, J IMMUNOL, V146, P384; GRABBE S, 1991, J IMMUNOL, V146, P3656; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Johnson LL, 1997, J EXP MED, V186, P1799, DOI 10.1084/jem.186.11.1799; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Lang S, 1998, EUR J IMMUNOL, V28, P780, DOI 10.1002/(SICI)1521-4141(199803)28:03<780::AID-IMMU780>3.3.CO;2-#; Lanier LL, 1998, CELL, V92, P705, DOI 10.1016/S0092-8674(00)81398-7; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Lynch DH, 1997, NAT MED, V3, P625, DOI 10.1038/nm0697-625; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; MOALLI PA, 1987, AM J PATHOL, V128, P426; MONTEL AH, 1995, CELL IMMUNOL, V160, P104, DOI 10.1016/0008-8749(95)80015-B; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; SalazarMather TP, 1996, J IMMUNOL, V157, P3054; Shaw SG, 1998, J IMMUNOL, V161, P2817; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; TALMADGE JE, 1980, NATURE, V284, P622, DOI 10.1038/284622a0; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	40	853	892	4	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					405	411		10.1038/7403	http://dx.doi.org/10.1038/7403			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202929				2022-12-27	WOS:000079574300029
J	Makgoba, MW				Makgoba, MW			The South African Medical Research Council: Africanizing health research	NATURE MEDICINE			English	Editorial Material									S African MRC, ZA-7505 Tygerberg, South Africa	South African Medical Research Council	Makgoba, MW (corresponding author), S African MRC, POB 19070, ZA-7505 Tygerberg, South Africa.								0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					367	370		10.1038/7351	http://dx.doi.org/10.1038/7351			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202916				2022-12-27	WOS:000079574300015
J	Georgakopoulos, D; Christe, ME; Giewat, M; Seidman, CM; Seidman, JG; Kass, DA				Georgakopoulos, D; Christe, ME; Giewat, M; Seidman, CM; Seidman, JG; Kass, DA			The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation	NATURE MEDICINE			English	Article							RECEPTOR	Familial hypertrophic cardiomyopathy (FHC) is a genetic disorder resulting from mutations in genes encoding sarcomeric proteins(1,2). This typically induces hyperdynamic ejection(3), impaired relaxation, delayed early filling(4), myocyte disarray and fibrosis, and increased chamber end-systolic stiffness(5,6). To better understand the disease pathogenesis, early (primary) abnormalities must be distinguished from evolving responses to the genetic defect. We did in vivo analysis using a mouse model of FHC with an Arg403Gln alpha-cardiac myosin heavy chain missense mutation(7) and used newly developed methods for assessing in situ pressure-volume relations(8). Hearts of young mutant mice (6 weeks old), which show no chamber morphologic or gross histologic abnormalities, had altered contraction kinetics, with considerably delayed pressure relaxation and chamber filling, yet accelerated systolic pressure rise. Older mutant mice (20 weeks old), which develop fiber disarray and fibrosis, had diastolic and systolic kinetic changes similar to if not slightly less than those of younger mice. However, the hearts of older mutant mice also showed hyperdynamic contraction, with increased end-systolic chamber stiffness, outflow tract pressure gradients and a lower cardiac index due to reduced chamber filling; all 'hallmarks' of human disease. These data provide new insights into the temporal evolution of FHC. Such data may help direct new therapeutic strategies to diminish disease progression.	Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21287 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Div Cardiol, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute	Kass, DA (corresponding author), Johns Hopkins Med Inst, Dept Med, Div Cardiol, 600 N Wolfe St, Baltimore, MD 21287 USA.	dkass@eureka.wbme.jhu.edu						BONOW RO, 1983, CIRCULATION, V68, P1062, DOI 10.1161/01.CIR.68.5.1062; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Georgakopoulos D, 1998, AM J PHYSIOL-HEART C, V274, pH1416, DOI 10.1152/ajpheart.1998.274.4.H1416; Gotshall KR, 1997, P NATL ACAD SCI USA, V94, P4710, DOI 10.1073/pnas.94.9.4710; Grupp IL, 1998, AM J PHYSIOL-HEART C, V275, pH1338, DOI 10.1152/ajpheart.1998.275.4.H1338; KAPUKU GK, 1993, AM HEART J, V125, P1710, DOI 10.1016/0002-8703(93)90763-Y; LORENZ JN, 1997, AM J PHYSIOL-HEART C, V273, pH2826; Maughan DW, 1998, CIRCULATION, V98, P625; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Oberst L, 1998, J CLIN INVEST, V102, P1498, DOI 10.1172/JCI4088; Pak PH, 1998, CIRCULATION, V98, P242, DOI 10.1161/01.CIR.98.3.242; Pak PH, 1996, CIRCULATION, V94, P52, DOI 10.1161/01.CIR.94.1.52; Palatini P, 1998, AM J HYPERTENS, V11, P147, DOI 10.1016/S0895-7061(97)00412-3; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Seidman CE, 1995, MOL CARDIOVASCULAR M, P193; Shen YT, 1996, J PHARMACOL EXP THER, V278, P1435; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; SUGA H, 1974, CIRC RES, V35, P117, DOI 10.1161/01.RES.35.1.117; Sutton MS, 1998, NEW ENGL J MED, V338, P1303, DOI 10.1056/NEJM199804303381810; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WELCH WJ, 1995, AM J PHYSIOL-RENAL, V268, pF175, DOI 10.1152/ajprenal.1995.268.1.F175; Wen C, 1996, J CARDIOVASC PHARM, V27, P482, DOI 10.1097/00005344-199604000-00005; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680	25	110	112	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					327	330		10.1038/6549	http://dx.doi.org/10.1038/6549			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086390				2022-12-27	WOS:000078851600039
J	Perl, AK; Dahl, U; Wilgenbus, P; Cremer, H; Semb, H; Christofori, G				Perl, AK; Dahl, U; Wilgenbus, P; Cremer, H; Semb, H; Christofori, G			Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic beta tumor cells	NATURE MEDICINE			English	Article							N-CAM; DIFFERENTIAL EXPRESSION; NEURITE OUTGROWTH; POLYSIALIC ACID; NERVOUS-SYSTEM; GROWTH-FACTOR; NCAM; ISLETS; TUMORIGENESIS; AGGREGATION	As in the development of many human cancers, in a transgenic mouse model of beta-cell carcinogenesis (Rip1Tag2), expression of neural cell adhesion molecule (NCAM) changes from the 120-kDa isoform in normal tissue to the 140/180-kDa isoforms in tumors. NCAM-deficient Rip1Tag2 mice, generated by crossing Rip1Tag2 mice with NCAM knockout mice, develop metastases, a tumor stage that is not seen in normal Rip1Tag2 mice. In contrast, overexpression of NCAM 120 in NCAM-deficient Rip1Tag2 mice prevents tumor metastasis. The results indicate that the loss of NCAM-mediated cell adhesion is one rate-limiting step in the actual metastatic dissemination of beta tumor cells.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Umea Univ, Dept Microbiol, S-90187 Umea, Sweden; Univ Marseille, CNRS,INSERM, IBDM LGPD, Marseille, France	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Umea University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Christofori, G (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Perl, Anne-Karina T/M-7174-2013	Perl, Anne-Karina T/0000-0002-8445-4565; Semb, Henrik/0000-0002-6747-787X; Cremer, Harold/0000-0002-8673-5176				Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; CIRULLI V, 1994, J CELL SCI, V107, P1429; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CROSSIN KL, 1985, P NATL ACAD SCI USA, V82, P6942, DOI 10.1073/pnas.82.20.6942; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; Dahl U, 1996, DEVELOPMENT, V122, P2895; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Esni F, 1999, J CELL BIOL, V144, P325, DOI 10.1083/jcb.144.2.325; Fogar P, 1997, ANTICANCER RES, V17, P1227; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Goridis C, 1992, Semin Cell Biol, V3, P189; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hogan B, 1994, MANIPULATING MOUSE E; HUTTON JC, 1993, MOL ENDOCRINOL, V7, P1151, DOI 10.1210/me.7.9.1151; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; Kaiser U, 1996, LEUKEMIA LYMPHOMA, V20, P389, DOI 10.3109/10428199609052420; LACKIE PM, 1994, DIFFERENTIATION, V57, P119, DOI 10.1046/j.1432-0436.1994.5720119.x; LANGLEY OK, 1989, J HISTOCHEM CYTOCHEM, V37, P781, DOI 10.1177/37.6.2723399; LIPINSKI M, 1987, INT J CANCER, V40, P81, DOI 10.1002/ijc.2910400115; MOLLER CJ, 1992, MOL ENDOCRINOL, V6, P1332, DOI 10.1210/me.6.8.1332; MOOLENAAR CEC, 1992, INT J CANCER, V51, P238, DOI 10.1002/ijc.2910510212; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROUILLER DG, 1990, EXP CELL RES, V191, P305, DOI 10.1016/0014-4827(90)90019-7; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2	38	114	115	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					286	291		10.1038/6502	http://dx.doi.org/10.1038/6502			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086383				2022-12-27	WOS:000078851600032
J	Vandecasteele, G; Eschenhagen, T; Scholz, H; Stein, B; Verde, I; Fischmeister, R				Vandecasteele, G; Eschenhagen, T; Scholz, H; Stein, B; Verde, I; Fischmeister, R			Muscarinic and beta-adrenergic regulation of heart rate, force of contraction and calcium current is preserved in mice lacking endothelial nitric oxide synthase	NATURE MEDICINE			English	Article							CARDIAC MYOCYTES; MYOCARDIUM; HYPERTENSION; GENE	Nitric oxide (NO) is an ubiquitous signaling molecule produced from L-arginine by NO synthase (NOS). In the Vasculature, NO mediates parasympathetic endothelium-dependent vasodilation. NO may also mediate the parasympathetic control of myocardial function(1). This is supported by the observations that NOS3, the endothelial constitutive NOS, is expressed in normal cardiac myocytes from rodents(2) and human(3), and NOS and/or guanylyl cyclase inhibitors antagonize the effect of muscarinic agonists on heart rate(4,5), atrio-ventricular conduction(6), contractility(2,4,7) and L-type calcium current(1,2,5,6). Here we examine the autonomic regulation of the heart in genetically engineered mice deficient in NOS3 (NOS3-KO)(ref. 8). We show that the chronotropic and inotropic responses to both beta-adrenergic and muscarinic agonists were unaltered in isolated cardiac tissue preparations from NOS3-KO mice, although these mice have a defective parasympathetic regulation of Vascular tone(8,9). Similarly, beta-adrenergic stimulation and muscarinic inhibition of the calcium current did not differ in cardiac myocytes from NOS3-KO mice and those from wild-type mice. RT-PCR did not demonstrate upregulation of other NOS isoforms. Similarly, G(i)/G(o) proteins and muscarinic receptor density were unaltered. These data refute the idea that NOS3 is obligatory for the normal autonomic control of cardiac muscle function(10).	Univ Paris Sud, Lab Cardiol Cellulaire & Mol, Fac Pharm, INSERM,U446, F-92296 Chatenay Malabry, France; Univ Hamburg, Krankenhaus Eppendorf, Inst Pharmakol, D-20246 Hamburg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Hamburg	Fischmeister, R (corresponding author), Univ Paris Sud, Lab Cardiol Cellulaire & Mol, Fac Pharm, INSERM,U446, F-92296 Chatenay Malabry, France.	Fisch@vjf.inserm.fr	Verde, Ignacio/M-3991-2013; Fischmeister, Rodolphe/L-6061-2018; Vandecasteele, Gregoire/M-2922-2018	Verde, Ignacio/0000-0003-3492-5725; Fischmeister, Rodolphe/0000-0003-2086-9865; Vandecasteele, Gregoire/0000-0002-4046-4171				BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Eschenhagen T, 1996, CIRCULATION, V93, P763, DOI 10.1161/01.CIR.93.4.763; Gallo MP, 1998, J PHYSIOL-LONDON, V506, P639, DOI 10.1111/j.1469-7793.1998.639bv.x; HAN X, 1994, J PHYSIOL-LONDON, V476, P309, DOI 10.1113/jphysiol.1994.sp020132; Han X, 1996, CIRC RES, V78, P998, DOI 10.1161/01.RES.78.6.998; Han XQ, 1998, P NATL ACAD SCI USA, V95, P6510, DOI 10.1073/pnas.95.11.6510; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; Hare JM, 1998, J CLIN INVEST, V101, P1424, DOI 10.1172/JCI1012; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; HUI J, 1995, CARDIOVASC RES, V30, P372, DOI 10.1016/0008-6363(95)00055-0; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KILTER H, 1995, N-S ARCH PHARMACOL, V352, P308, DOI 10.1007/BF00168562; Kleinert H, 1998, HYPERTENSION, V31, P582, DOI 10.1161/01.HYP.31.2.582; Mery PF, 1997, LIFE SCI, V60, P1113, DOI 10.1016/S0024-3205(97)00055-6; Mery PF, 1996, AM J PHYSIOL-HEART C, V270, pH1178, DOI 10.1152/ajpheart.1996.270.4.H1178; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; Vandecasteele G, 1998, J PHYSIOL-LONDON, V506, P653, DOI 10.1111/j.1469-7793.1998.653bv.x; Wei CM, 1996, MAYO CLIN PROC, V71, P346, DOI 10.4065/71.4.346; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250	20	144	147	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	1999	5	3					331	334		10.1038/6553	http://dx.doi.org/10.1038/6553			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086391	Green Submitted			2022-12-27	WOS:000078851600040
J	Hollon, T				Hollon, T			Transplant organ allocation squabble continues	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					611	611		10.1038/76156	http://dx.doi.org/10.1038/76156			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835656	Bronze			2022-12-27	WOS:000087438300010
J	Arad, G; Levy, R; Hillman, D; Kaempfer, R				Arad, G; Levy, R; Hillman, D; Kaempfer, R			Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation	NATURE MEDICINE			English	Article							STAPHYLOCOCCAL-ENTEROTOXIN-B; TUMOR-NECROSIS-FACTOR; RECEPTOR-BETA-CHAIN; COMPLEX CLASS-II; INTERLEUKIN-2 GENE-EXPRESSION; AUREUS TOXIN SUPERANTIGENS; CRYSTAL-STRUCTURE; BINDING-SITES; HLA-DR; MICE	Superantigens trigger an excessive cellular immune response, leading to toxic shock. We have designed a peptide antagonist that inhibits superantigen-induced expression of human genes for interleukin-2, gamma interferon and tumor necrosis factor-b, which are cytokines that mediate shock. The peptide shows homology to a b-strand-hinge-a-helix domain that is structurally conserved in superantigens, yet is remote from known binding sites for the major histocompatibility class II molecule and T-cell receptor. Superantigens depend on this domain for T-cell activation. The peptide protected mice against lethal challenge with staphylococcal and streptococcal superantigens. Moreover, it rescued mice undergoing toxic shock. Surviving mice rapidly developed protective antibodies against superantigen that rendered them resistant to further lethal challenges, even with different superantigens. Thus, the lethal effect of superantigens can be blocked with a peptide antagonist that inhibits their action at the beginning of the toxicity cascade, before activation of T cells takes place.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Virol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kaempfer, R (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Virol, IL-91120 Jerusalem, Israel.	kaempfer@cc.huji.ac.il		Kaempfer, Raymond/0000-0002-5865-4619				ABRAHMSEN L, 1995, EMBO J, V14, P2978, DOI 10.1002/j.1460-2075.1995.tb07300.x; ARAD G, 1995, CELL IMMUNOL, V160, P240, DOI 10.1016/0008-8749(95)80034-G; Basma H, 1999, INFECT IMMUN, V67, P1871; BEAN AGD, 1993, INFECT IMMUN, V61, P4937, DOI 10.1128/IAI.61.11.4937-4939.1993; BETLEY MJ, 1988, J BACTERIOL, V170, P34, DOI 10.1128/jb.170.1.34-41.1988; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; BUELOW R, 1992, J IMMUNOL, V148, P1; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; Earhart CA, 1998, BIOCHEMISTRY-US, V37, P7194, DOI 10.1021/bi9721896; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GEREZ L, 1991, CLIN IMMUNOL IMMUNOP, V58, P251, DOI 10.1016/0090-1229(91)90140-6; GEREZ L, 1995, J BIOL CHEM, V270, P19569, DOI 10.1074/jbc.270.33.19569; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; HACKETT SP, 1993, J INFECT DIS, V168, P232, DOI 10.1093/infdis/168.1.232; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HOFFMANN ML, 1994, INFECT IMMUN, V62, P3396, DOI 10.1128/IAI.62.8.3396-3407.1994; HUDSON KR, 1995, J EXP MED, V182, P711, DOI 10.1084/jem.182.3.711; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Jarrous N, 1996, MOL CELL BIOL, V16, P2814; JETT M, 1994, INFECT IMMUN, V62, P3408, DOI 10.1128/IAI.62.8.3408-3415.1994; Kaempfer R, 1996, J CLIN ONCOL, V14, P1778, DOI 10.1200/JCO.1996.14.6.1778; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; KOMISAR JL, 1994, INFECT IMMUN, V62, P4775, DOI 10.1128/IAI.62.11.4775-4780.1994; Leder L, 1998, J EXP MED, V187, P823, DOI 10.1084/jem.187.6.823; Lowell GH, 1996, INFECT IMMUN, V64, P1706, DOI 10.1128/IAI.64.5.1706-1713.1996; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; MURAILLE E, 1995, EUR J IMMUNOL, V25, P2111, DOI 10.1002/eji.1830250747; MURAILLE E, 1995, CELL IMMUNOL, V162, P315, DOI 10.1006/cimm.1995.1084; MURRAY DL, 1995, ASM NEWS, V61, P229; Papageorgiou AC, 1998, J MOL BIOL, V277, P61, DOI 10.1006/jmbi.1997.1577; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; Saha B, 1996, J IMMUNOL, V157, P3869; SCHAD EM, 1995, EMBO J, V14, P3292, DOI 10.1002/j.1460-2075.1995.tb07336.x; SCHLIEVERT PM, 1993, J INFECT DIS, V167, P997, DOI 10.1093/infdis/167.5.997; SCHOLL P, 1989, P NATL ACAD SCI USA, V86, P4210, DOI 10.1073/pnas.86.11.4210; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; UCHIYAMA T, 1989, CLIN EXP IMMUNOL, V75, P239; Wang Z.-M., 1993, PSYCHOL DEV SOC, V5, P151, DOI [10. 1177/097133369300500204, DOI 10.1177/097133369300500204]	46	124	144	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2000	6	4					414	421		10.1038/74672	http://dx.doi.org/10.1038/74672			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742148				2022-12-27	WOS:000165474100035
J	Clynes, RA; Towers, TL; Presta, LG; Ravetch, JV				Clynes, RA; Towers, TL; Presta, LG; Ravetch, JV			Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; CELL-LINES; ANTITUMOR-ACTIVITY; GROWTH-INHIBITION; RESPONSES; LYMPHOMA; THERAPY; MICE	Inhibitory receptors have been proposed to modulate the in vivo cytotoxic response against tumor targets for both spontaneous and antibody-dependent pathways'. Using a variety of syngenic and xenograft models, we demonstrate here that the inhibitory Fc gamma RIIB molecule is a potent regulator of antibody-dependent cell-mediated cytotoxicity in vivo, modulating the activity of Fc gamma RIII on effector cells. Although many mechanisms have been proposed to account for the anti-tumor activities of therapeutic antibodies, including extended half-life, blockade of signaling pathways, activation of apoptosis and effector-cell-mediated cytotoxicity, we show here that engagement of Fc gamma receptors on effector cells is a dominant component of the in vivo activity of antibodies against tumors. Mouse monoclonal antibodies, as well as the humanized, clinically effective therapeutic agents trastuzumab (Herceptin(R)) and rituximab (Rituxan(R)), engaged both activation (Fc gamma RIII) and inhibitory (Fc gamma RIIB) antibody receptors on myeloid cells, thus modulating their cytotoxic potential. Mice deficient in Fc gamma RIIB showed much more antibody-dependent cell-mediated cytotoxicity; in contrast, mice deficient in activating Fc receptors as well as antibodies engineered to disrupt Fc binding to those receptors were unable to arrest tumor growth in vivo. These results demonstrate that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner Fc gamma RIIB.	Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10021 USA; Genentech Inc, Dept Immunol, S San Francisco, CA 94080 USA	Rockefeller University; Roche Holding; Genentech	Ravetch, JV (corresponding author), Rockefeller Univ, Lab Mol Genet & Immunol, 1230 York Ave, New York, NY 10021 USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				Baselga J, 1998, CANCER RES, V58, P2825; Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; FAN Z, 1993, CANCER RES, V53, P4322; Funakoshi S, 1996, J IMMUNOTHER, V19, P93, DOI 10.1097/00002371-199603000-00002; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Kopreski MS, 1996, ANTICANCER RES, V16, P433; Leget Gail A., 1998, Current Opinion in Oncology, V10, P548, DOI 10.1097/00001622-199811000-00012; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; MASUI H, 1986, CANCER RES, V46, P5592; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; Taji H, 1998, JPN J CANCER RES, V89, P748, DOI 10.1111/j.1349-7006.1998.tb03280.x; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tutt AL, 1998, J IMMUNOL, V161, P3176; WALDMANN TA, 1994, ANN ONCOL S13, V5, P1	19	2134	2399	3	137	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					443	446		10.1038/74704	http://dx.doi.org/10.1038/74704			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742152				2022-12-27	WOS:000165474100039
J	Collins, KB; Patterson, BK; Naus, GJ; Landers, DV; Gupta, P				Collins, KB; Patterson, BK; Naus, GJ; Landers, DV; Gupta, P			Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FLOW CYTOMETRIC ANALYSIS; EPITHELIAL-CELL LINE; INTRAVAGINAL INOCULATION; RHESUS MACAQUES; INFECTION; SEMEN; MEN; EXPRESSION; CARCINOMA		Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA; Northwestern Univ, Sch Med, Childrens Mem Hosp, Dept Pediat,Div Special Infect Dis, Chicago, IL 60614 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gupta, P (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.		Abrams, William R/A-5782-2008		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032256] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD-32256] Funding Source: Medline; PHS HHS [2P01A139061] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atula S, 1997, EXP CELL RES, V235, P180, DOI 10.1006/excr.1997.3676; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; DELVENNE P, 1995, AM J PATHOL, V146, P589; GOSSELIN EJ, 1995, ADV EXP MED BIOL, V371, P1003; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; Howell AL, 1997, J VIROL, V71, P3498, DOI 10.1128/JVI.71.5.3498-3506.1997; LEVY J, 1998, HIV PATHOGENESIS, P29; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; Meyers Craig, 1996, Methods in Cell Science, V18, P201, DOI 10.1007/BF00132885; MILLER CJ, 1994, J VIROL, V68, P6391, DOI 10.1128/JVI.68.10.6391-6400.1994; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; Patterson BK, 1999, LANCET, V353, P211, DOI 10.1016/S0140-6736(05)77222-6; Patterson BK, 1998, CYTOMETRY, V31, P265, DOI 10.1002/(SICI)1097-0320(19980401)31:4&lt;265::AID-CYTO6&gt;3.0.CO;2-I; Patterson BK, 1998, AM J PATHOL, V153, P481, DOI 10.1016/S0002-9440(10)65591-5; PUDNEY J, 1991, AM J PATHOL, V139, P149; SCHUTTE B, 1995, CYTOMETRY, V21, P177, DOI 10.1002/cyto.990210210; Scurry J, 1998, HISTOPATHOLOGY, V32, P399; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TAN X, 1993, J VIROL, V67, P6447, DOI 10.1128/JVI.67.11.6447-6452.1993; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; WATSON AJ, 1990, AIDS RES HUM RETROV, V6, P503, DOI 10.1089/aid.1990.6.503	22	158	167	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					475	479		10.1038/74743	http://dx.doi.org/10.1038/74743			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742159				2022-12-27	WOS:000165474100046
J	Wells, AD; Li, XC; Li, YS; Walsh, MC; Zheng, XX; Wu, ZH; Nunez, G; Tang, AM; Sayegh, M; Hancock, WW; Strom, TB; Turka, LA				Wells, AD; Li, XC; Li, YS; Walsh, MC; Zheng, XX; Wu, ZH; Nunez, G; Tang, AM; Sayegh, M; Hancock, WW; Strom, TB; Turka, LA			Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance	NATURE MEDICINE			English	Article							CLONAL EXPANSION; SELF-TOLERANCE; CD40 LIGAND; SURVIVAL; LYMPHOCYTES; MICE; EXPRESSION; ALLOGRAFTS; BCL-X(L); DELETION	The mechanisms of allograft tolerance have been classified as deletion, anergy, ignorance and suppression/regulation. Deletion has been implicated in central tolerance(1), whereas peripheral tolerance has generally been ascribed to clonal anergy and/or active immunoregulatory states(2). Here, we used two distinct systems to assess the requirement for T-cell deletion in peripheral tolerance induction. in mice transgenic for Bcl-x(L), T cells were resistant to passive cell death through cytokine withdrawal, whereas T cells from interleukin-2-deficient mice did not undergo activation-induced cell death. Using either agents that block co-stimulatory pathways or the immunosuppressive drug rapamycin, which we have shown here blocks the proliferative component of interleukin-2 signaling but does not inhibit priming for activation-induced cell death, we found that mice with defective passive or active T-cell apoptotic pathways were resistant to induction of transplantation tolerance. Thus, deletion of activated T cells through activation-induced cell death or growth factor withdrawal seems necessary to achieve peripheral tolerance across major histocompatibility complex barriers.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02142 USA; LeukoSite Inc, Cambridge, MA 02142 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA	University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Michigan System; University of Michigan; Harvard University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Turka, LA (corresponding author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA.		Strom, Terry B./E-9268-2010; Nuñez, Gabriel/A-7160-2014	Strom, Terry B./0000-0002-7570-0736; Li, Xian Chang/0000-0002-5981-2762	NIAID NIH HHS [AI34665, AI37798, AI37691] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037798, R01AI037691] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Dai ZH, 1998, J IMMUNOL, V161, P1659; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Gudmundsdottir H, 1999, J IMMUNOL, V162, P5212; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KNEITZ B, 1995, EUR J IMMUNOL, V25, P2572, DOI 10.1002/eji.1830250925; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Li XC, 1998, J IMMUNOL, V161, P2241; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; Sykes M, 1990, Semin Immunol, V2, P401; Tanchot C, 1998, IMMUNITY, V8, P581, DOI 10.1016/S1074-7613(00)80563-4; Tran HM, 1997, J IMMUNOL, V159, P2232; Van Parijs L, 1998, SCIENCE, V280, P243; Waldmann H, 1998, ANNU REV IMMUNOL, V16, P619, DOI 10.1146/annurev.immunol.16.1.619; Wekerle T, 1998, J EXP MED, V187, P2037, DOI 10.1084/jem.187.12.2037; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873	24	483	503	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1303	1307		10.1038/15260	http://dx.doi.org/10.1038/15260			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545998				2022-12-27	WOS:000086550600042
J	Groner, W; Winkelman, JW; Harris, AG; Ince, C; Bouma, GJ; Messmer, K; Nadeau, RG				Groner, W; Winkelman, JW; Harris, AG; Ince, C; Bouma, GJ; Messmer, K; Nadeau, RG			Orthogonal polarization spectral imaging: A new method for study of the microcirculation	NATURE MEDICINE			English	Article							CAPILLARY DENSITY; IN-VIVO; SKIN; LIGHT; MICROSCOPY; SYSTEM		Cytometr Inc, Philadelphia, PA 19106 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-81377 Munich, Germany; Univ Amsterdam, Acad Med Ctr, Dept Anesthesiol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, NL-1105 AZ Amsterdam, Netherlands	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Munich; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Nadeau, RG (corresponding author), Cytometr Inc, 615 Chestnut St, Philadelphia, PA 19106 USA.			Bouma, Gerrit/0000-0002-2772-7475				BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bussau LJ, 1998, J ANAT, V192, P187, DOI 10.1046/j.1469-7580.1998.19220187.x; DAVIS E, 1966, CLIN CAPILLARY MICRO; Fagrell B, 1997, J INTERN MED, V241, P349, DOI 10.1046/j.1365-2796.1997.125148000.x; Fagrell B., 1990, CLIN CAPILLAROSCOPY; FENTON BM, 1979, MICROVASC RES, V18, P153, DOI 10.1016/0026-2862(79)90025-6; Forst T, 1998, CLIN SCI, V94, P255, DOI 10.1042/cs0940255; Harris AG, 1996, AM J PHYSIOL-HEART C, V271, pH2388, DOI 10.1152/ajpheart.1996.271.6.H2388; Harris AG, 1997, INT J MICROCIRC, V17, P322, DOI 10.1159/000179247; Klyscz T, 1997, BIOMED TECH, V42, P168, DOI 10.1515/bmte.1997.42.6.168; Kortum G., 1969, SPECTROSCOPY-US, P5; LIPOWSKY HH, 1982, MICROVASC RES, V24, P42, DOI 10.1016/0026-2862(82)90041-3; MACKINTOSH FC, 1989, PHYS REV B, V40, P9342, DOI 10.1103/PhysRevB.40.9342; Nolte D, 1995, INT J MICROCIRC, V15, P244, DOI 10.1159/000179025; Nolte D, 1995, INT J MICROCIRC, V15, P9, DOI 10.1159/000179088; PEELE JD, 1977, CLIN CHEM, V123, P2238; PITTMAN RN, 1975, J APPL PHYSIOL, V38, P321, DOI 10.1152/jappl.1975.38.2.321; PITTMAN RN, 1975, J APPL PHYSIOL, V38, P315, DOI 10.1152/jappl.1975.38.2.315; RAJADHYAKSHA M, 1995, J INVEST DERMATOL, V104, P946, DOI 10.1111/1523-1747.ep12606215; SCHMITT JM, 1992, APPL OPTICS, V31, P6535, DOI 10.1364/AO.31.006535; STAR WM, 1988, PHYS MED BIOL, V33, P437, DOI 10.1088/0031-9155/33/4/004; WINKELMAN, 1991, Patent No. 4998553; WOLF S, 1994, HYPERTENSION, V23, P464, DOI 10.1161/01.HYP.23.4.464	23	577	668	5	52	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1209	1213		10.1038/13529	http://dx.doi.org/10.1038/13529			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502828				2022-12-27	WOS:000082933200051
J	Kety, SS				Kety, SS			Mental illness and the sciences of brain and behavior	NATURE MEDICINE			English	Editorial Material							SCHIZOPHRENIA; ADOPTEES; VIRUSES; GENE		McLean Hosp, Belmont, MA 02478 USA	Harvard University; McLean Hospital	Kety, SS (corresponding author), McLean Hosp, 115 Mill St, Belmont, MA 02478 USA.							ERLENMEYERKIMLING N, 1992, J PSYCHIAT RES, V26, P221, DOI 10.1016/0022-3956(92)90028-M; Folstein Marshal F., J PSYCHIATR RES, V12, P189, DOI [10.1016/0022-3956(75)90026-6, DOI 10.1016/0022-3956(75)90026-6, DOI 10.1016/0022-3956(68)90026-5]; HESTON LL, 1966, BRIT J PSYCHIAT, V112, P819, DOI 10.1192/bjp.112.489.819; HIGGINS J, 1976, J PSYCHIAT RES, V13, P1, DOI 10.1016/0022-3956(76)90004-2; HOLZMAN PS, 1988, ARCH GEN PSYCHIAT, V45, P641; HOLZMAN PS, 1992, J PSYCHIATR RES, V26, P427, DOI 10.1016/0022-3956(92)90044-O; Kety S S, 1975, Proc Annu Meet Am Psychopathol Assoc, P147; KETY SS, 1950, AM J MED, V8, P205, DOI 10.1016/0002-9343(50)90363-9; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KETY SS, 1959, SCIENCE, V129, P1528, DOI 10.1126/science.129.3362.1528; KETY SS, 1992, J PSYCHIAT RES, V26, P247, DOI 10.1016/0022-3956(92)90031-I; KETY SS, 1994, ARCH GEN PSYCHIAT, V51, P442; KETY SS, 1951, PHARMACOL REV, V3, P1; Kety SS, 1944, AM HEART J, V27, P601, DOI 10.1016/S0002-8703(44)90553-3; KNIGHT JG, 1982, LANCET, V2, P1073; LAING P, 1989, P NATL ACAD SCI USA, V86, P1998, DOI 10.1073/pnas.86.6.1998; Landau WM, 1955, T AM NEUROL ASSOC, V80, P125; McNeil TF, 1978, NATURE SCHIZOPHRENIA, P401; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013; MIRSKY AF, 1992, J PSYCHIAT RES, V26, P383, DOI 10.1016/0022-3956(92)90042-M; MURRAY RM, 1992, J PSYCHIAT RES, V26, P225, DOI 10.1016/0022-3956(92)90029-N; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; ROSENTHAL D, 1968, TRANSMISSION SCHIZOP, P155; Sokoloff L., 1961, REGIONAL CHEM PHYSL, P107	24	5	5	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1113	1116		10.1038/13427	http://dx.doi.org/10.1038/13427			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502802				2022-12-27	WOS:000082933200023
J	Kadkol, SS; Brody, JR; Pevsner, J; Bai, J; Pasternack, GR				Kadkol, SS; Brody, JR; Pevsner, J; Bai, J; Pasternack, GR			Modulation of oncogenic potential by alternative gene use in human prostate cancer (vol 5, pg 275, 1999)	NATURE MEDICINE			English	Correction																		Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488	1	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1087	1087		10.1038/12530	http://dx.doi.org/10.1038/12530			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10471270	Bronze			2022-12-27	WOS:000082337200048
J	Chen, K; Baram, TZ; Soltesz, I				Chen, K; Baram, TZ; Soltesz, I			Febrile seizures in the developing brain result in persistent modification of neuronal excitability in limbic circuits	NATURE MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; LONG-TERM POTENTIATION; INHIBITORY SYNAPTIC TRANSMISSION; RECEPTOR SUBUNIT EXPRESSION; RAT HIPPOCAMPAL SLICES; PROTEIN-KINASE-A; GABA(A) RECEPTORS; INCREASED NUMBER; MINIATURE IPSCS; DENTATE GYRUS	Febrile (fever-induced) seizures affect 3-5% of infants and young children. Despite the high incidence of febrile seizures, their contribution to the development of epilepsy later in life has remained controversial. Combining a new rat model of complex febrile seizures and patch clamp techniques, we determined that hyperthermia-induced seizures in the immature rat cause a selective presynaptic increase in inhibitory synaptic transmission in the hippocampus that lasts into adulthood. The long-lasting nature of these potent alterations in synaptic communication after febrile seizures does not support the prevalent view of the 'benign' nature of early-life febrile convulsions.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Soltesz, I (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	isoltesz@uci.edu	Baram, Tallie Z/J-6447-2014		NINDS NIH HHS [NS38580, R37 NS035439, NS35439, R01 NS035439, R01 NS038580] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038580, R01NS035439, R37NS035439] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABOUKHALIL B, 1993, EPILEPSIA, V34, P878, DOI 10.1111/j.1528-1157.1993.tb02105.x; ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; Auger C, 1997, NEURON, V19, P139, DOI 10.1016/S0896-6273(00)80354-2; Baram TZ, 1997, DEV BRAIN RES, V98, P265, DOI 10.1016/S0165-3806(96)00190-3; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; Berg AT, 1997, J CLIN NEUROPHYSIOL, V14, P102, DOI 10.1097/00004691-199703000-00003; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bonci A, 1997, J NEUROSCI, V17, P796; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brunson KL, 1998, DEV BRAIN RES, V111, P119, DOI 10.1016/S0165-3806(98)00130-8; Brussaard AB, 1997, NEURON, V19, P1103, DOI 10.1016/S0896-6273(00)80401-8; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; CAMFIELD P, 1997, EPILEPSY COMPREHENSI, P1305; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; CENDES F, 1993, NEUROLOGY, V43, P1083, DOI 10.1212/WNL.43.6.1083; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; DOZE VA, 1995, J NEUROPHYSIOL, V74, P43, DOI 10.1152/jn.1995.74.1.43; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; HJERESEN DL, 1988, DEV PSYCHOBIOL, V21, P261, DOI 10.1002/dev.420210307; Hollrigel GS, 1997, J NEUROSCI, V17, P5119; Holmes GL, 1998, NEURON, V21, P1231, DOI 10.1016/S0896-6273(00)80642-X; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; JENSEN FE, 1992, EPILEPSIA, V33, P971, DOI 10.1111/j.1528-1157.1992.tb01746.x; Jensen FE, 1998, J NEUROPHYSIOL, V79, P73, DOI 10.1152/jn.1998.79.1.73; KOMATSU Y, 1994, J NEUROSCI, V14, P6488; Kondo S, 1997, J PHYSIOL-LONDON, V498, P165, DOI 10.1113/jphysiol.1997.sp021849; KORN H, 1992, P NATL ACAD SCI USA, V89, P440, DOI 10.1073/pnas.89.1.440; Liu XB, 1997, NEUROREPORT, V8, P1475, DOI 10.1097/00001756-199704140-00030; MACCAFERRI G, 1995, NEURON, V15, P137, DOI 10.1016/0896-6273(95)90071-3; McBain CJ, 1997, CAN J PHYSIOL PHARM, V75, P488, DOI 10.1139/cjpp-75-5-488; MOSHE SL, 1983, DEV BRAIN RES, V7, P81, DOI 10.1016/0165-3806(83)90083-4; Nusser Z, 1997, NEURON, V19, P697, DOI 10.1016/S0896-6273(00)80382-7; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; Owens J, 1997, ANN NEUROL, V41, P187, DOI 10.1002/ana.410410210; SCHWARTZKROIN PA, 1984, ELECTROPHYSIOLOGY EP, P389; Shinnar S, 1998, ANN NEUROL, V43, P411, DOI 10.1002/ana.410430402; SHINNAR S, 1990, CURRENT THERAPY NEUR; Sik A, 1998, P NATL ACAD SCI USA, V95, P3245, DOI 10.1073/pnas.95.6.3245; Smith KL, 1998, J NEUROPHYSIOL, V79, P106, DOI 10.1152/jn.1998.79.1.106; Taubenfeld SM, 1999, NAT NEUROSCI, V2, P309, DOI 10.1038/7217; Toth Z, 1998, J NEUROSCI, V18, P4285; VanLandingham KE, 1998, ANN NEUROL, V43, P413, DOI 10.1002/ana.410430403; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wasterlain CG, 1997, EPILEPSIA, V38, P728, DOI 10.1111/j.1528-1157.1997.tb01244.x; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; Xie Z, 1995, CAN J PHYSIOL PHARM, V73, P1706, DOI 10.1139/y95-734	50	227	229	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1999	5	8					888	894		10.1038/11330	http://dx.doi.org/10.1038/11330			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426311	Green Published, Green Accepted			2022-12-27	WOS:000081684000031
J	Young, D; Lawlor, PA; Leone, P; Dragunow, M; During, MJ				Young, D; Lawlor, PA; Leone, P; Dragunow, M; During, MJ			Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective	NATURE MEDICINE			English	Article							NMDA RECEPTOR ACTIVATION; FIBROBLAST GROWTH-FACTOR; GENERATED GRANULE CELLS; RAT DENTATE GYRUS; NEUROTROPHIC FACTOR; ADULT-RAT; HIPPOCAMPAL-NEURONS; PROGENITOR CELLS; NEUROGENESIS; BRAIN	The mammalian brain has a high degree of plasticity, with dentate granule cell neurogenesis(1) and glial(2,3) proliferation stimulated by an enriched environment combining both complex inanimate and social stimulation. Moreover, rodents exposed to an enriched environment both before and after a cerebral insult show improved cognitive performance(1,4). One of the most robust associations of environmental enrichment is improved learning and memory in the Morris water maze, a spatial task that mainly involves the hippocampus(5). Furthermore, clinical evidence showing an association between higher educational attainment and reduced risk of Alzheimer(6) and Parkinson-related dementia(7) indicates that a stimulating environment has positive effects on cerebral health that may provide some resilience to cerebral insults. Here we show that in addition to its effects on neurogenesis, an enriched environment reduces spontaneous apoptotic cell death in the rat hippocampus by 45%. Moreover, these environmental conditions protect against kainate-induced seizures and excitotoxic injury. The enriched environment induces expression of glial-derived neurotrophic factor and brain-derived neurotrophic factor and increases phosphorylation of the transcription factor cyclic-AMP response element binding protein, indicating that the; influence of the environment on spontaneous apoptosis and cerebral resistance to insults may be mediated through transcription factor activation and induction of growth factor expression.	Univ Auckland, Sch Med, Dept Mol Med, Auckland 1, New Zealand; Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurosurg, Philadelphia, PA 19107 USA	University of Auckland; Jefferson University	During, MJ (corresponding author), Univ Auckland, Sch Med, Dept Mol Med, Auckland 1, New Zealand.	Matthew.During@mail.tju.edu	During, Matthew/AAC-1388-2020	Young, Deborah/0000-0003-1085-2824				Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; CAMERON HA, 1995, J NEUROSCI, V15, P4687; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; CHENG B, 1995, J NEUROCHEM, V65, P2525; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CRESPO D, 1986, EXP BRAIN RES, V62, P541; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; Dragunow M, 1996, BEHAV GENET, V26, P293, DOI 10.1007/BF02359385; DRAGUNOW M, 1995, MOL BRAIN RES, V32, P279, DOI 10.1016/0169-328X(95)00088-A; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FIALA BA, 1978, EXP NEUROL, V59, P372, DOI 10.1016/0014-4886(78)90229-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glatt SL, 1996, NEUROEPIDEMIOLOGY, V15, P20, DOI 10.1159/000109885; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; HUGHES P, 1993, NEUROSCIENCE, V57, P319, DOI 10.1016/0306-4522(93)90065-N; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LIU Z, 1993, BRAIN RES, V626, P335, DOI 10.1016/0006-8993(93)90598-H; LOTHMAN EW, 1993, EPILEPSIA, V34, pS59, DOI 10.1111/j.1528-1157.1993.tb05907.x; MARTIN D, 1995, BRAIN RES, V683, P172, DOI 10.1016/0006-8993(95)00369-2; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/S0006-8993(96)00273-9; OLSSON T, 1995, NEUROSCI LETT, V189, P113, DOI 10.1016/0304-3940(95)11467-B; Parent JM, 1997, J NEUROSCI, V17, P3727; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; Sah DWY, 1997, J NEUROBIOL, V32, P95, DOI 10.1002/(SICI)1097-4695(199701)32:1<95::AID-NEU9>3.0.CO;2-9; SEKI T, 1993, J NEUROSCI, V13, P2351, DOI 10.1523/JNEUROSCI.13-06-02351.1993; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Voyvodic JT, 1996, NEURON, V16, P693, DOI 10.1016/S0896-6273(00)80089-6; WALSH RN, 1969, J COMP NEUROL, V137, P361, DOI 10.1002/cne.901370309; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306	45	605	624	0	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	1999	5	4					448	453		10.1038/7449	http://dx.doi.org/10.1038/7449			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202938				2022-12-27	WOS:000079574300038
J	Hellerstein, M; Hanley, MB; Cesar, D; Siler, S; Papageorgopoulos, C; Wieder, E; Schmidt, D; Hoh, R; Neese, R; Macallan, D; Deeks, S; McCune, JM				Hellerstein, M; Hanley, MB; Cesar, D; Siler, S; Papageorgopoulos, C; Wieder, E; Schmidt, D; Hoh, R; Neese, R; Macallan, D; Deeks, S; McCune, JM			Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans	NATURE MEDICINE			English	Article							HIV-1 INFECTION; RAPID TURNOVER; CELL TURNOVER; IN-VIVO; DISEASE; RATES	The dynamic basis for T-cell depletion in late-stage HIV-1 disease remains controversial. Using a new, non-radioactive, endogenous labeling technique(1), we report direct measurements of circulating T-cell kinetics in normal and in HIV-l-infected humans. In healthy, HIV-l-seronegative subjects, CD4(+) and CD8(+) T cells had half-lives of 87 days and 77 days, respectively, with absolute production rates of 10 CD4(+) T cells/mu l per day and 6 CD8(+) T cells/mu l per day. In untreated HIV-l-infected subjects (with a mean CD4 level of 342 cells/mu l), the half-life of each subpopulation was less than 1/3 as long as those of healthy, HIV-l-seronegative subjects but was not compensated by an increased absolute production rate of CD4(+) T cells. After viral replication was suppressed by highly active antiretroviral therapy for 12 weeks, the production rates of circulating CD4(+) and CD8(+) T cells were considerably elevated; the kinetic basis of increased CD4 levels was greater production, not a longer half-life, of circulating cells. These direct measurements indicate that CD4(+) T-cell lymphopenia is due to both a shortened survival time and a failure to increase the production of circulating CD4(+) T cells. Our results focus attention on T-cell production systems in the pathogenesis of HIV-1 disease and the response to antiretroviral therapy.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94110 USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; The J David Gladstone Institutes	Hellerstein, M (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA.			Macallan, Derek/0000-0002-3014-7148				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bell E B, 1997, Semin Immunol, V9, P347, DOI 10.1006/smim.1997.0092; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Fleury S, 1998, NAT MED, V4, P794, DOI 10.1038/nm0798-794; Hellerstein MK, 1997, IMMUNITY, V7, P583, DOI 10.1016/S1074-7613(00)80379-9; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; Mackall C L, 1997, Semin Immunol, V9, P339, DOI 10.1006/smim.1997.0091; McCune J M, 1997, Semin Immunol, V9, P397, DOI 10.1006/smim.1997.0098; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Palmer LD, 1997, J EXP MED, V185, P1381, DOI 10.1084/jem.185.7.1381; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; ROSENBERG A, 1981, BIOMATHEMATICS CELL, V8, P143; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; WAINHOBSON S, 1995, NATURE, V373, P102, DOI 10.1038/373102a0; WATERLOW JC, 1978, PROTEIN TURNOVER MAM, P216; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weng NP, 1997, IMMUNOL REV, V160, P43, DOI 10.1111/j.1600-065X.1997.tb01026.x; Wolthers KC, 1998, IMMUNOL TODAY, V19, P44, DOI 10.1016/S0167-5699(97)01188-2; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; YOUNG AJ, 1995, INT IMMUNOL, V7, P1607, DOI 10.1093/intimm/7.10.1607; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	27	440	466	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					83	89		10.1038/4772	http://dx.doi.org/10.1038/4772			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883844				2022-12-27	WOS:000077885000034
J	Dick, JE				Dick, JE			Gene therapy turns the corner	NATURE MEDICINE			English	Editorial Material							CELLS; TRANSDUCTION; MICE		Univ Toronto, Hosp Sick Children, Res Inst, Program Canc Blood, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Res Inst, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Dick, JE (corresponding author), Univ Toronto, Hosp Sick Children, Res Inst, Program Canc Blood, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Dick, John/0000-0002-9527-8317				Abonour R, 2000, NAT MED, V6, P652, DOI 10.1038/76225; [Anonymous], 1996, B MED ETHICS; Brennan MF, 1997, ANN SURG ONCOL, V4, P1, DOI 10.1007/BF02316804; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; GUENECHEA G, IN PRESS MOL THER; Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876; Hennemann B, 2000, HUM GENE THER, V11, P43, DOI 10.1089/10430340050016148; KLEM HP, 1998, BLOOD, V92, P1878; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682	11	20	20	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					624	626		10.1038/76188	http://dx.doi.org/10.1038/76188			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835670				2022-12-27	WOS:000087438300020
J	Novak, K				Novak, K			Oral examination	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					141	141		10.1038/72232	http://dx.doi.org/10.1038/72232			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655099	Bronze			2022-12-27	WOS:000085016900028
J	Smith, LEH; Shen, W; Perruzzi, C; Soker, S; Kinose, F; Xu, XH; Robinson, G; Driver, S; Bischoff, J; Zhang, B; Schaeffer, JM; Senger, DR				Smith, LEH; Shen, W; Perruzzi, C; Soker, S; Kinose, F; Xu, XH; Robinson, G; Driver, S; Bischoff, J; Zhang, B; Schaeffer, JM; Senger, DR			Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor	NATURE MEDICINE			English	Article							PROLIFERATIVE DIABETIC-RETINOPATHY; ACTIVATED PROTEIN-KINASE; FACTOR-I; CELL-PROLIFERATION; FACTOR EXPRESSION; FOLLOW-UP; IGF-I; MELLITUS; HORMONE; MOUSE	Although insulin-like growth factor 1 (IGF-1) has been associated with retinopathy, proof of a direct relationship has been lacking. Here we show that an IGF-1 receptor antagonist suppresses retinal neovascularization in vivo, and infer that interactions between IGF-1 and the IGF-1 receptor are necessary for induction of maximal neovascularization by vascular endothelial growth factor (VEGF). IGF-1 receptor regulation of VEGF action is mediated at least in part through control of VEGF activation of p44/42 mitogen- activated protein kinase, establishing a hierarchical relationship between IGF-1 and VECF receptors. These findings establish an essential role for IGF-1 in angiogenesis and demonstrate a new target for control of retinopathy. They also explain why diabetic retinopathy initially increases with the onset of insulin treatment. IGF-1 levels, low in untreated diabetes, rise with insulin therapy, permitting VEGF-induced retinopathy.	Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Merck Res Labs, Rahway, NJ 07065 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Merck & Company	Smith, LEH (corresponding author), Harvard Univ, Sch Med, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.	smith_lo@a1.tch.harvard.edu	BISCHOFF, JOYCE/K-3354-2019	BISCHOFF, JOYCE/0000-0002-6367-1974	NATIONAL EYE INSTITUTE [R01EY008670] Funding Source: NIH RePORTER; NEI NIH HHS [EY08670] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ALELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AMIEL SA, 1984, DIABETES, V33, P1175, DOI 10.2337/diabetes.33.12.1175; Bischoff J, 1997, MICROCIRCULATION-LON, V4, P279, DOI 10.3109/10739689709146791; Borgstrom P, 1998, PROSTATE, V35, P1; Boulton M, 1998, BRIT J OPHTHALMOL, V82, P561, DOI 10.1136/bjo.82.5.561; CAPETANDES A, 1990, INVEST OPHTH VIS SCI, V31, P1738; Chantelau E, 1997, BMJ-BRIT MED J, V315, P1105; Chantelau E, 1997, BRIT J OPHTHALMOL, V81, P169; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; DAMATO R, 1993, MICROVASC RES, V46, P135, DOI 10.1006/mvre.1993.1042; Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647; DILLS DG, 1990, DIABETES, V39, P191, DOI 10.2337/diabetes.39.2.191; DILLS DG, 1991, DIABETES, V40, P1725, DOI 10.2337/diabetes.40.12.1725; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416; GRANT MB, 1993, REGUL PEPTIDES, V48, P267, DOI 10.1016/0167-0115(93)90356-D; Graves JD, 1995, ANN NY ACAD SCI, V766, P320, DOI 10.1111/j.1749-6632.1995.tb26684.x; Hammes HP, 1998, DIABETES, V47, P401, DOI 10.2337/diabetes.47.3.401; HANSSEN KF, 1985, ACTA ENDOCRINOL-COP, V110, P57; HAYRY P, 1995, FASEB J, V9, P1336; HOLLY JMP, 1988, J ENDOCRINOL, V118, P353, DOI 10.1677/joe.0.1180353; HYER SL, 1989, METABOLISM, V38, P586, DOI 10.1016/0026-0495(89)90222-9; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; MERIMEE TJ, 1970, J CLIN INVEST, V49, P1096, DOI 10.1172/JCI106325; MERIMEE TJ, 1983, NEW ENGL J MED, V309, P527, DOI 10.1056/NEJM198309013090904; MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877; MOSKALETS E, 1994, J DIABETES COMPLICAT, V8, P45, DOI 10.1016/1056-8727(94)90010-8; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Pedram A, 1997, J BIOL CHEM, V272, P17097, DOI 10.1074/jbc.272.27.17097; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; Pfeiffer A, 1997, DIABETES, V46, pS26, DOI 10.2337/diab.46.2.S26; Pierce EA, 1997, ARCH OPHTHALMOL-CHIC, V115, P427; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHAMOON H, 1995, ARCH OPHTHALMOL-CHIC, V113, P36; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHARP PS, 1987, DIABETOLOGIA, V30, P199, DOI 10.1007/BF00270416; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706; SONKSEN PH, 1993, HORM RES, V40, P68, DOI 10.1159/000183770; Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; WRIGHT AD, 1969, BRIT MED J, V2, P346, DOI 10.1136/bmj.2.5653.346; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZIMMERGALLER IE, 1995, INT OPHTHALMOL CLIN, V35, P37, DOI 10.1097/00004397-199503540-00005	54	430	462	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1999	5	12					1390	1395		10.1038/70963	http://dx.doi.org/10.1038/70963			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581081				2022-12-27	WOS:000084049700038
J	Gohongi, T; Fukumura, D; Boucher, Y; Yun, CO; Soff, GA; Compton, C; Todoroki, T; Jain, RK				Gohongi, T; Fukumura, D; Boucher, Y; Yun, CO; Soff, GA; Compton, C; Todoroki, T; Jain, RK			Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor beta 1	NATURE MEDICINE			English	Article							ENDOTHELIAL-CELLS; GROWTH-FACTOR-BETA-1; CANCER; CARCINOMA; MICROENVIRONMENT; PROLIFERATION; METASTASIS; EXPRESSION; MICE	Angiogenesis inhibitors produced by a primary tumor can create a systemic anti-angiogenic environment and maintain metastatic tumor cells in a state of dormancy(1,2). We show here that the gallbladder microenvironment modulates the production of transforming growth factor (TGF)-beta 1, a multifunctional cytokine that functions as an endogenous anti-angiogenic and antitumor factor in a cranial window preparation. We found that a wide variety of human gallbladder tumors express TGF-beta 1 irrespective of histologic type. We implanted a gel impregnated with basic fibroblast growth factor(3) or Mz-ChA-2 tumor in the cranial windows of mice without tumors or mice with subcutaneous or gallbladder tumors to study angiogenesis and tumor growth at a secondary site. Angiogenesis, leukocyte-endothelial interaction in vessels and tumor growth in the cranial window were substantially inhibited in mice with gallbladder tumors. The concentration of TGF-beta 1 in the plasma of mice with gallbladder tumors was 300% higher than that in the plasma of mice without tumors or with subcutaneous tumors. In contrast, there was no difference in the plasma levels of other anti- and pro-angiogenic factors. Treatment with neutralizing antibody against TGF-beta 1 reversed both angiogenesis suppression and inhibition of leukocyte rolling induced by gallbladder tumors. TGF-beta 1 also inhibited Mz-ChA-2 tumor cell proliferation. Our results indicate that the production of anti-angiogenesis/proliferation factors is regulated by tumor-host interactions.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA; Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA; Univ Tsukuba, Inst Clin Med, Dept Surg, Tsukuba, Ibaraki 305, Japan	Harvard University; Harvard Medical School; Massachusetts General Hospital; Northwestern University; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Tsukuba	Jain, RK (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA.		Jain, Rakesh K/I-1384-2017; Yun, Chae-Ok/P-3698-2015	Jain, Rakesh K/0000-0001-7571-3548; Yun, Chae-Ok/0000-0002-9466-4531	NATIONAL CANCER INSTITUTE [R35CA056591] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA56591] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Dellian M, 1996, AM J PATHOL, V149, P59; Engle SJ, 1999, CANCER RES, V59, P3379; Fajardo LF, 1996, LAB INVEST, V74, P600; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; GAJDUSEK CM, 1993, J CELL PHYSIOL, V157, P133, DOI 10.1002/jcp.1041570118; GAMBLE JR, 1993, J IMMUNOL, V150, P4494; ITO N, 1995, CANCER LETT, V89, P45, DOI 10.1016/0304-3835(94)03651-X; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; Nakanishi Y, 1997, INT J GYNECOL PATHOL, V16, P256, DOI 10.1097/00004347-199707000-00011; NORGAARD P, 1995, CANCER TREAT REV, V21, P367, DOI 10.1016/0305-7372(95)90038-1; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Picon A, 1998, CANCER EPIDEM BIOMAR, V7, P497; ROBERTS BV, 1999, MICROVASC RES, V57, P118; Sckell A, 1998, CANCER RES, V58, P5866; THEODORESCU D, 1991, J CELL PHYSIOL, V148, P380, DOI 10.1002/jcp.1041480308; TODOROKI T, 1991, WORLD J SURG, V15, P357, DOI 10.1007/BF01658729; UEKI N, 1992, BIOCHIM BIOPHYS ACTA, V1137, P189; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WALKER RA, 1992, EUR J CANCER, V28A, P641, DOI 10.1016/S0959-8049(05)80116-9; Wikstrom P, 1998, PROSTATE, V37, P19, DOI 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	25	113	115	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1203	1208		10.1038/13524	http://dx.doi.org/10.1038/13524			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502827	Green Submitted			2022-12-27	WOS:000082933200050
J	Ballmaier, M				Ballmaier, M			Cancer center combines public and private groups	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					973	973		10.1038/12400	http://dx.doi.org/10.1038/12400			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10471265	Bronze			2022-12-27	WOS:000082337200014
J	Lanza, RP; Cibelli, JB; West, MD				Lanza, RP; Cibelli, JB; West, MD			Human therapeutic cloning	NATURE MEDICINE			English	Editorial Material							CELLS; FETAL	Somatic cell nuclear 'reprogramming' in livestock species is now routine in many laboratories. Here, Robert Lanza, jose Cibelli and Michael West discuss how these techniques may soon be used to clone genetically matched cells and tissues for transplantation into patients suffering from a wide range of disorders that results from tissues loss or dysfunction.	Adv Cell Technol, Worcester, MA 01605 USA		Lanza, RP (corresponding author), Adv Cell Technol, 1 Innovat Dr, Worcester, MA 01605 USA.			Cibelli, Jose/0000-0002-2176-3854; West, Michael/0000-0002-4842-5468				Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Cibelli JB, 1998, NAT BIOTECHNOL, V16, P642, DOI 10.1038/nbt0798-642; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Dominko T, 1999, BIOL REPROD, V60, P1496, DOI 10.1095/biolreprod60.6.1496; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lanza R. P., 1997, PRINCIPLES TISSUE EN; Mooney DJ, 1999, SCI AM, V280, P60, DOI 10.1038/scientificamerican0499-60; ROBL J, 1998, Patent No. 9807841; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vogel G, 1999, SCIENCE, V283, P1432, DOI 10.1126/science.283.5407.1432; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	15	102	127	0	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					975	977		10.1038/12404	http://dx.doi.org/10.1038/12404			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470061				2022-12-27	WOS:000082337200019
J	Baghdiguian, S; Martin, M; Richard, I; Pons, F; Astier, C; Bourg, N; Hay, RT; Chemaly, R; Halaby, G; Loiselet, J; Anderson, LVB; de Munain, AL; Fardeau, M; Mangeat, P; Beckmann, JS; Lefranc, G				Baghdiguian, S; Martin, M; Richard, I; Pons, F; Astier, C; Bourg, N; Hay, RT; Chemaly, R; Halaby, G; Loiselet, J; Anderson, LVB; de Munain, AL; Fardeau, M; Mangeat, P; Beckmann, JS; Lefranc, G			Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the I kappa B alpha/NF-kappa B pathway in limb-girdle muscular dystrophy type 2A	NATURE MEDICINE			English	Article							MUSCLE-SPECIFIC CALPAIN; NUCLEAR-LOCALIZATION; DNA-FRAGMENTATION; EXPRESSION; PROTEIN; ACTIVATION; BCL-2; DOMAIN; VITRO; GENE		Univ Montpellier 2, CNRS, UMR 5539, Lab Dynam Mol Interact Membranaires, F-34095 Montpellier 5, France; Univ Montpellier 2, Lab Motilite Cellulaire, EPHE, F-34095 Montpellier, France; CNRS, URA 1992, F-91002 Evry, France; Fac Pharm Montpellier, INSERM, U300, F-34060 Montpellier 1, France; Univ St Andrews, Sch Biol & Med Sci, St Andrews KY16 9AL, Fife, Scotland; St Josephs Univ, Hotel Dieu, Beyrouth, Lebanon; St Josephs Univ, Fac Med, Beyrouth, Lebanon; Univ Newcastle Upon Tyne, Sch Med, Dept Neurobiol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Hosp Ntra SRA, Dept Neurol, San Sebastian 20080, Spain; INSERM, CNRS, U153, UA614, F-75005 Paris, France; CNRS, UPR 1142, Inst Human Genet, Immunogenet Mol Lab, F-34095 Montpellier 5, France; Univ Montpellier 2, F-34095 Montpellier 5, France; Genethon, F-91002 Evry, France; URA CNRS 1992, F-91002 Evry, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of St Andrews; Saint Joseph University Beirut; Saint Joseph University Beirut; Newcastle University - UK; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)	Lefranc, G (corresponding author), Univ Montpellier 2, CNRS, UMR 5539, Lab Dynam Mol Interact Membranaires, Case 107,Pl Eugene Bataillon, F-34095 Montpellier 5, France.		DE MUNAIN, ADOLFO LOPEZ/AAB-1824-2020; Beckmann, Jacques S/A-9772-2008; Hay, Ronald T/F-9338-2011; Richard, isabelle/J-8298-2013	Beckmann, Jacques S/0000-0002-9741-1900; Hay, Ronald T/0000-0001-7113-9024; MARTIN, Marianne/0000-0001-8932-3129; Baghdiguian, Stephen/0000-0002-2992-9708; /0000-0002-9509-4032				Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, pC579, DOI 10.1152/ajpcell.1997.273.2.C579; Anderson LVB, 1998, AM J PATHOL, V153, P1169, DOI 10.1016/S0002-9440(10)65661-1; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Beckmann J, 1998, NEUROMUSCULAR DISORD, P123; BUSHBY KMD, 1995, NEUROMUSCULAR DISORD, V5, P337, DOI 10.1016/0960-8966(95)00005-8; EDOM F, 1994, DEV BIOL, V164, P219, DOI 10.1006/dbio.1994.1193; Fardeau M, 1996, BRAIN, V119, P295, DOI 10.1093/brain/119.1.295; Fougerousse F, 1998, GENOMICS, V48, P145, DOI 10.1006/geno.1997.5160; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KLIETSCH R, 1993, CIRC RES, V72, P349, DOI 10.1161/01.RES.72.2.349; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Marini J F, 1991, Neuromuscul Disord, V1, P397, DOI 10.1016/0960-8966(91)90003-B; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; PONS F, 1993, NEUROMUSCULAR DISORD, V3, P507, DOI 10.1016/0960-8966(93)90106-T; Richard I, 1997, AM J HUM GENET, V60, P1128; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sandri M, 1998, LAB INVEST, V78, P1005; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; Spencer MJ, 1997, J CLIN INVEST, V99, P2745, DOI 10.1172/JCI119464; Stehlik C, 1998, BIOCHEM BIOPH RES CO, V243, P827, DOI 10.1006/bbrc.1998.8185; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tews DS, 1997, NEUROPATH APPL NEURO, V23, P331, DOI 10.1046/j.1365-2990.1997.5998059.x; Tews DS, 1996, NEUROMUSCULAR DISORD, V6, P265, DOI 10.1016/0960-8966(96)00018-1; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZHILIANG C, 1997, P NATL ACAD SCI USA, V94, P10057	39	234	245	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					503	511		10.1038/8385	http://dx.doi.org/10.1038/8385			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229226				2022-12-27	WOS:000081497400030
J	Wang, CY; Cusack, JC; Liu, R; Baldwin, AS				Wang, CY; Cusack, JC; Liu, R; Baldwin, AS			Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappa B	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; TNF-ALPHA; IONIZING-RADIATION; CELL-DEATH; ANTICANCER DRUGS; NECROSIS-FACTOR; CANCER-THERAPY; GENE-TRANSFER; LUNG-CANCER; ACTIVATION	Programmed cell death (apoptosis) seems to be the principal mechanism whereby anti-oncogenic therapies such as chemotherapy and radiation effect their responses. Resistance to apoptosis, therefore, is probably a principal mechanism whereby tumors are able to overcome these cancer therapies. The transcription factor NF-kappa B is activated by chemotherapy and by irradiation in some cancer cell lines. Furthermore, inhibition of NF-kappa B in vitro leads to enhanced apoptosis in response to a variety of different stimuli. We show here that inhibition of NF-kappa B through the adenoviral delivery of a modified form of I kappa B alpha, the inhibitor of NF-kappa B, sensitizes chemoresistant tumors to the apoptotic potential of TNF alpha and of the chemotherapeutic compound CPT-11, resulting in tumor regression. These results demonstrate that the activation of NF-kappa B in response to chemotherapy is a principal mechanism of inducible tumor chemoresistance, and establish the inhibition of NF-kappa B as a new approach to adjuvant therapy in cancer treatment.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Dent, Dept Endodont, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cusack, JC (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biol, Campus Box 7295, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA073756, R01CA075080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [CA75080, CA73756] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chmura SJ, 1997, CANCER RES, V57, P4340; Conner EM, 1997, J PHARMACOL EXP THER, V282, P1615; Cusack JC, 1996, CANCER GENE THER, V3, P245; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Eggermont AMM, 1996, J INFLAMM, V47, P104; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CANCER RES, V58, P4453; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Held KD, 1997, APOPTOSIS, V2, P265, DOI 10.1023/A:1026485003280; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; KAWATO Y, 1991, CANCER RES, V51, P4187; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lowe SW, 1997, NAT MED, V3, P606, DOI 10.1038/nm0697-606; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; Mauceri HJ, 1996, CANCER RES, V56, P4311; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MERLINO G, 1994, SEMIN CANCER BIOL, V5, P13; Oshita F, 1997, J CLIN ONCOL, V15, P304, DOI 10.1200/JCO.1997.15.1.304; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Slater AFG, 1995, BIOCHEM J, V312, P833, DOI 10.1042/bj3120833; Spriggs D. R., 1992, TUMOR NECROSIS FACTO, P383; TAKIMOTO CH, 1996, CANC CHEMOTHERAPY BI, P463; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weichselbaum Ralph R., 1997, Lancet (North American Edition), V349, P10	43	893	931	1	43	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					412	417		10.1038/7410	http://dx.doi.org/10.1038/7410			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202930	Green Submitted			2022-12-27	WOS:000079574300030
J	Billings, PR				Billings, PR			In utero gene therapy - The case against	NATURE MEDICINE			English	Editorial Material									Council Responsible Genet, Cambridge, MA 02140 USA		Billings, PR (corresponding author), Council Responsible Genet, 5 Upland Rd, Cambridge, MA 02140 USA.								0	27	27	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	1999	5	3					255	256		10.1038/6457	http://dx.doi.org/10.1038/6457			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	171FH	10086370				2022-12-27	WOS:000078851600019
J	Qing, K; Mah, C; Hansen, J; Zhou, SZ; Dwarki, V; Srivastava, A				Qing, K; Mah, C; Hansen, J; Zhou, SZ; Dwarki, V; Srivastava, A			Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; SURFACE HEPARAN-SULFATE; TRANSGENE EXPRESSION; HUMAN-CELLS; TRANSDUCTION; BINDING; INTEGRATION; SITE; AAV; DIFFERENTIATION	Adeno-associated virus 2 (AAV)-based vectors have gained attention as a potentially useful alternative to the more commonly used retroviral and adenoviral vectors for human gene therapy. Although AAV uses the ubiquitously expressed cell surface heparan sulfate proteoglycan (HSPG) as a receptor, the transduction efficiency of AAV vectors varies greatly in different cells and tissues in vitro and in vivo. We demonstrate here that cell surface expression of HSPG alone is insufficient for AAV infection, and that AAV also requires human fibroblast growth factor receptor 1 (FGFR1) as a co-receptor for successful viral entry into the host cell. We document that cells that do not express either HSPG or FGFR1 fail to bind AAV and, consequently, are resistant to infection by AAV. These non-permissive cells are successfully transduced by AAV vectors after stable transfections with cDNAs encoding the murine HSPG and the human FGFR1. Furthermore, AAV infection of permissive cells, known to express both FGFR1 and the epidermal growth factor receptor, is abrogated by treatment of cells with basic fibroblast growth factor, but not with epidermal growth factor. The identification of FGFR1 as a co-receptor for AAV should provide new insights not only into its role in the life cycle of AAV, but also in the optimal use of AAV vectors in human gene therapy.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Chiron Corp, Dept Virol, Emeryville, CA 94608 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Novartis	Srivastava, A (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058881, R01HL048342, P01HL053586] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-53586, HL-48342, HL-58881] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bartlett JS, 1998, NAT MED, V4, P635, DOI 10.1038/nm0598-635; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Berns KI, 1996, CURR TOP MICROBIOL, V218, P1; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Jackson T, 1996, J VIROL, V70, P5282, DOI 10.1128/JVI.70.8.5282-5287.1996; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kearns WG, 1996, GENE THER, V3, P748; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y; Kube DM, 1997, NUCLEIC ACIDS RES, V25, P3375, DOI 10.1093/nar/25.16.3375; Laquerre S, 1998, J VIROL, V72, P6119, DOI 10.1128/JVI.72.7.6119-6130.1998; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; Ledoux Dominique, 1992, Progress in Growth Factor Research, V4, P107, DOI 10.1016/0955-2235(92)90026-E; Mah C, 1998, J VIROL, V72, P9835, DOI 10.1128/JVI.72.12.9835-9843.1998; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; Ponnazhagan S, 1997, GENE, V190, P203, DOI 10.1016/S0378-1119(96)00576-8; Ponnazhagan S, 1997, J VIROL, V71, P8262, DOI 10.1128/JVI.71.11.8262-8267.1997; Ponnazhagan S, 1996, J GEN VIROL, V77, P1111, DOI 10.1099/0022-1317-77-6-1111; Ponnazhagan S, 1997, HUM GENE THER, V8, P275, DOI 10.1089/hum.1997.8.3-275; Qing KY, 1997, P NATL ACAD SCI USA, V94, P10879, DOI 10.1073/pnas.94.20.10879; Qing KY, 1998, J VIROL, V72, P1593, DOI 10.1128/JVI.72.2.1593-1599.1998; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHEIH H, 1992, J CELL BIOL, V116, P1273; SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983; Strawn LM, 1996, CANCER RES, V56, P3540; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Wang XS, 1998, J VIROL, V72, P5472, DOI 10.1128/JVI.72.7.5472-5480.1998	40	521	569	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					71	77		10.1038/4758	http://dx.doi.org/10.1038/4758			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883842				2022-12-27	WOS:000077885000032
J	Yang, ZY; Duckers, HJ; Sullivan, NJ; Sanchez, A; Nabel, EG; Nabel, GJ				Yang, ZY; Duckers, HJ; Sullivan, NJ; Sanchez, A; Nabel, EG; Nabel, GJ			Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury	NATURE MEDICINE			English	Article							TRANSIENT TRANSFECTION; INFECTION	Here we defined the main viral determinant of Ebola virus pathogenicity; synthesis of the virion glycoprotein (CP) of Ebola virus Zaire induced cytotoxic effects in human endothelial cells in vitro and in vivo. This effect mapped to a serine-threonine-rich, mucin-like domain of this type I transmembrane glycoprotein, one of seven gene products of the virus. Gene transfer of GP into explanted human or porcine blood vessels caused massive endothelial cell loss within 48 hours that led to a substantial increase in vascular permeability. Deletion of the mucin-like region of GP abolished these effects without affecting protein expression or function. CP derived from the Reston strain of virus, which causes disease in nonhuman primates but not in man, did not disrupt the vasculature of human blood vessels. In contrast, the Zaire CP induced endothelial cell disruption and cytotoxicity in both nonhuman primate and human blood vessels, and the mucin domain was required for this effect. These findings indicate that CP, through its mucin domain, is the viral determinant of Ebola pathogenicity and likely contributes to hemorrhage during infection.	NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA; NHLBI, Vasc Biol Branch, NIH, Bethesda, MD 20892 USA; Ctr Dis Control & Prevent, Special Pathogens Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA	Nabel, GJ (corresponding author), NIH, Vaccine Res Ctr, 40 Convent Dr, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422; BASKERVILLE A, 1978, J PATHOL, V125, P131, DOI 10.1002/path.1711250303; BASKERVILLE A, 1985, J PATHOL, V147, P199, DOI 10.1002/path.1711470308; BOWEN ETW, 1977, LANCET, V1, P571; CDC, 1995, MMWR-MORBID MORTAL W, V44, P381; FELDMANN H, 1994, VIROLOGY, V199, P469, DOI 10.1006/viro.1994.1147; Feldmann H, 1996, J VIROL, V70, P2208, DOI 10.1128/JVI.70.4.2208-2214.1996; Mbiene JP, 1997, J COMP NEUROL, V377, P324, DOI 10.1002/(SICI)1096-9861(19970120)377:3<324::AID-CNE2>3.0.CO;2-4; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Peters C.J., 1996, FIELDS VIROLOGY, P1161; Sanchez A, 1998, J VIROL, V72, P6442, DOI 10.1128/JVI.72.8.6442-6447.1998; Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034	18	311	343	1	66	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					886	889		10.1038/78654	http://dx.doi.org/10.1038/78654			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932225				2022-12-27	WOS:000165473800031
J	Oritani, K; Medina, KL; Tomiyama, Y; Ishikawa, J; Okajima, Y; Ogawa, M; Yokota, T; Aoyama, K; Takahashi, I; Kincade, PW; Matsuzawa, Y				Oritani, K; Medina, KL; Tomiyama, Y; Ishikawa, J; Okajima, Y; Ogawa, M; Yokota, T; Aoyama, K; Takahashi, I; Kincade, PW; Matsuzawa, Y			Limitin: An interferon-like cytokine that preferentially influences B-lymphocyte precursors	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; PROTEIN-TYROSINE KINASE; BONE-MARROW; IFN-ALPHA; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; PROGENITOR CELLS; GROWTH-FACTORS; STROMAL CELLS; IN-VITRO	We have identified an interferon-like cytokine, limitin, on the basis of its ability to arrest the growth of or kill lympho-hematopoietic cells. Limitin strongly inhibited B lymphopoiesis in vitro and in vivo but had little influence on either myelopoiesis or erythropoiesis. Because limitin uses the interferon alpha/beta receptors and induces interferon regulatory factor-1, it may represent a previously unknown type I interferon prototype. However, preferential B-lineage growth inhibition and activation of Janus kinase 2 in a myelomonocytic leukemia line have not been described for previously known interferons.	Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	Osaka University; Oklahoma Medical Research Foundation	Oritani, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, 2-2 Yamada-oka, Suita, Osaka 5650871, Japan.			Tomiyama, Yoshiaki/0000-0001-7645-0989	NIAID NIH HHS [AI-20069, AI-33085] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033085, R37AI020069, R01AI020069] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; Borghesi LA, 1997, J IMMUNOL, V159, P4171; BROXMEYER HE, 1992, AM J PEDIAT HEMATOL, V14, P22; Burrows PD, 1997, CURR OPIN IMMUNOL, V9, P239, DOI 10.1016/S0952-7915(97)80142-2; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; Dexter T M, 1976, Methods Cell Biol, V14, P387, DOI 10.1016/S0091-679X(08)60498-7; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; DORSHKIND K, 1988, J IMMUNOL, V141, P531; GIMBLE JM, 1993, EXP HEMATOL, V21, P224; GIMBLE JM, 1989, MOL CELL BIOL, V9, P4587, DOI 10.1128/MCB.9.11.4587; Graham GJ, 1997, INT J EXP PATHOL, V78, P197, DOI 10.1046/j.1365-2613.1997.270361.x; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; Haque SJ, 1998, SEMIN ONCOL, V25, P14; HAUPTMANN R, 1985, NUCLEIC ACIDS RES, V13, P4739, DOI 10.1093/nar/13.13.4739; HIGASHI Y, 1983, J BIOL CHEM, V258, P9522; HIRAYAMA F, 1994, P NATL ACAD SCI USA, V91, P469, DOI 10.1073/pnas.91.2.469; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ITRI LM, 1992, CANCER, V70, P940; Kelly KA, 1998, ENDOCRINOLOGY, V139, P2092, DOI 10.1210/en.139.4.2092; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kincade PW, 1998, CELL ADHES COMMUN, V6, P211, DOI 10.3109/15419069809004476; KINCADE PW, 1991, ADV EXP MED BIOL, V292, P227; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; LEAMAN DW, 1992, J INTERFERON RES, V12, P1, DOI 10.1089/jir.1992.12.1; LEE G, 1987, J EXP MED, V166, P1290, DOI 10.1084/jem.166.5.1290; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MAZUR EM, 1986, J INTERFERON RES, V6, P199, DOI 10.1089/jir.1986.6.199; MEDINA KL, 1994, P NATL ACAD SCI USA, V91, P5382, DOI 10.1073/pnas.91.12.5382; MEDINA KL, 1993, J EXP MED, V178, P1507, DOI 10.1084/jem.178.5.1507; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771; Oritani K, 1998, LEUKEMIA LYMPHOMA, V32, P1; PIETRANGELI CE, 1988, EUR J IMMUNOL, V18, P863, DOI 10.1002/eji.1830180606; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; SHAW GD, 1983, NUCLEIC ACIDS RES, V11, P555, DOI 10.1093/nar/11.3.555; Shimozato T, 1997, J IMMUNOL, V158, P5178; SMITHSON G, 1995, J IMMUNOL, V155, P3409; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; TOMIYAMA Y, 1992, BLOOD, V79, P2303; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Verfaillie CM, 1996, J LAB CLIN MED, V127, P148; WANG JY, 1995, IMMUNITY, V3, P475, DOI 10.1016/1074-7613(95)90176-0; Weiss K, 1998, SEMIN ONCOL, V25, P9; Whetton AD, 1998, CURR OPIN CELL BIOL, V10, P721, DOI 10.1016/S0955-0674(98)80113-0; WHITLOCK CA, 1984, J IMMUNOL METHODS, V6, P7353; Yokota T, 1998, BLOOD, V91, P3263, DOI 10.1182/blood.V91.9.3263.3263_3263_3272; Zavyalov VP, 1997, APMIS, V105, P161, DOI 10.1111/j.1699-0463.1997.tb00556.x	57	100	105	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					659	666		10.1038/76233	http://dx.doi.org/10.1038/76233			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835682				2022-12-27	WOS:000087438300036
J	Asea, A; Kraeft, SK; Kurt-Jones, EA; Stevenson, MA; Chen, LB; Finberg, RW; Koo, GC; Calderwood, SK				Asea, A; Kraeft, SK; Kurt-Jones, EA; Stevenson, MA; Chen, LB; Finberg, RW; Koo, GC; Calderwood, SK			HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine	NATURE MEDICINE			English	Article							HEAT-SHOCK-PROTEIN; NF-KAPPA-B; HUMAN MONOCYTES; BACTERIAL LIPOPOLYSACCHARIDE; ANTIINFLAMMATORY DRUGS; INTRACELLULAR CALCIUM; LYMPHOCYTES-T; CUTTING EDGE; INDUCE HSP70; NK CELLS	Here, we demonstrate a previously unknown function for the 70-kDa heat-shock protein (HSP70) as a cytokine. HSP70 bound with high affinity to the plasma membrane, elicited a rapid intracellular calcium flux, activated nuclear factor (NF)-kappaB and upregulated the expression of pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta and IL-6 in human monocytes. Furthermore, two different signal transduction pathways were activated by exogenous HSP70: one dependent on CD14 and intracellular calcium, which resulted in increased IL-1 beta, IL-6 and TNF-alpha; and the other independent of CD14 but dependent on intracellular calcium, which resulted in an increase in TNF-alpha but not IL-1 beta or IL-6. These findings indicate that CD14 is a co-receptor for HSP70-mediated signaling in human monocytes and are indicative of an previously unrecognized function for HSP70 as an extracellular protein with regulatory effects on human monocytes, having a dual role as chaperone and cytokine.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Merck Res Labs, Dept Immunol Res, Rahway, NJ 07065 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Merck & Company	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Asea, Alexzander/X-6432-2019; Finberg, Robert W/E-3323-2010; Asea, Alexzander/I-4112-2013	Asea, Alexzander/0000-0003-3592-3481	NATIONAL CANCER INSTITUTE [P01CA031303, R01CA047407, R01CA050642] Funding Source: NIH RePORTER; NCI NIH HHS [CA31303, CA47407, CA50642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 1996, CLIN EXP IMMUNOL, V105, P376, DOI 10.1046/j.1365-2249.1996.d01-755.x; ASEA A, 1995, THESIS U GOTEBORG GO; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; CALDERWOOD SK, 1995, P 86 ANN M AM ASS CA, V682; Capra, 1997, IMMUNOBIOLOGY IMMUNE; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DUFF GW, 1982, J IMMUNOL METHODS, V52, P333, DOI 10.1016/0022-1759(82)90005-9; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Hansson M, 1996, J IMMUNOL, V156, P42; HAREGEWOIN A, 1991, J INFECT DIS, V163, P156, DOI 10.1093/infdis/163.1.156; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HOLOSHITZ J, 1984, J CLIN INVEST, V73, P211, DOI 10.1172/JCI111193; HOLOSHITZ J, 1989, NATURE, V339, P226, DOI 10.1038/339226a0; Hoshino K, 1999, J IMMUNOL, V162, P3749; Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437; Kaufmann S., 1994, BIOL HEAT SHOCK PROT, P495; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Koo GC, 1996, CELL IMMUNOL, V174, P107, DOI 10.1006/cimm.1996.0300; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MCLEISH KR, 1989, INFLAMMATION, V13, P681, DOI 10.1007/BF00914312; MINOTA S, 1988, J EXP MED, V168, P1475, DOI 10.1084/jem.168.4.1475; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; ROLLINS BJ, 1991, BLOOD, V78, P1112; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; Solomon KR, 1998, J CLIN INVEST, V102, P2019, DOI 10.1172/JCI4317; Soncin F, 1996, BIOCHEM BIOPH RES CO, V229, P479, DOI 10.1006/bbrc.1996.1829; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; SRIVASTAVA PK, 1994, CURR OPIN IMMUNOL, V6, P728, DOI 10.1016/0952-7915(94)90076-0; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; Stevenson MA, 1999, J IMMUNOL, V163, P5608; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Tapping RI, 1999, J IMMUNOL, V162, P5483; Todryk S, 1999, J IMMUNOL, V163, P1398; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; van Eden W, 1998, IMMUNOL REV, V164, P169; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	44	1273	1363	6	63	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					435	442		10.1038/74697	http://dx.doi.org/10.1038/74697			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742151				2022-12-27	WOS:000165474100038
J	Mills, J				Mills, J			Varicella-Zoster vaccine: The bad news may be good	NATURE MEDICINE			English	Editorial Material							UNITED-STATES; CHILDREN; VIRUS	Clinically-evident reactivation of the Oka vaccine strain appears common and may have public health benefits for vaccine-induced immunity (pages 451-454).	Macfarlane Burnet Ctr Med Res, Fairfield, Vic 3078, Australia		Mills, J (corresponding author), Macfarlane Burnet Ctr Med Res, Yarra Bend Rd, Fairfield, Vic 3078, Australia.							[Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P365; Arvin A M, 1997, Curr Clin Top Infect Dis, V17, P110; Cohen JI, 1999, ANN INTERN MED, V130, P922, DOI 10.7326/0003-4819-130-11-199906010-00017; HALLORAN ME, 1994, AM J EPIDEMIOL, V140, P81, DOI 10.1093/oxfordjournals.aje.a117238; Hussell T, 1999, CURR OPIN MICROBIOL, V2, P410, DOI 10.1016/S1369-5274(99)80072-1; Krause PR, 2000, NAT MED, V6, P451, DOI 10.1038/74715; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; TAKAHASHI M, 1986, PEDIATRICS, V78, P736; Varicella-related deaths among adults-United States 1997, 1997, MMWR MORB MORTAL WKL, V46, P409; 2000, PEDIATRICS, V105, P136	10	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					381	382		10.1038/74636	http://dx.doi.org/10.1038/74636			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742140				2022-12-27	WOS:000165474100023
J	Blouin, MJ; Beauchemin, H; Wright, A; De Paepe, M; Sorette, M; Bleau, AM; Nakamoto, B; Ou, CN; Stamatoyannopoulos, G; Trudel, M				Blouin, MJ; Beauchemin, H; Wright, A; De Paepe, M; Sorette, M; Bleau, AM; Nakamoto, B; Ou, CN; Stamatoyannopoulos, G; Trudel, M			Genetic correction of sickle cell disease: Insights using transgenic mouse models	NATURE MEDICINE			English	Article							STAGE-SPECIFIC EXPRESSION; FETAL-GLOBIN GENE; GAMMA-GLOBIN; HEMOGLOBIN CONCENTRATION; LIGHT-SCATTERING; RISK-FACTORS; SAD MICE; ANEMIA; INDUCTION; VOLUME	Sickle cell disease is a hereditary disorder characterized by erythrocyte deformity due to hemoglobin polymerization. We assessed in vivo the potential curative threshold of fetal hemoglobin in the SAD transgenic mouse model of sickle cell disease using mating with mice expressing the human fetal A gamma-globin gene. With increasing levels of HbF, A gamma SAD mice showed considerable improvement in all hematologic parameters, morphopathologic features and life span/survival. We established the direct therapeutic effect of fetal hemoglobin on sickle cell disease end demonstrated correction by increasing fetal hemoglobin to about 9-16% in this mouse model. This in vivo study emphasizes the potential of the SAD mouse models for quantitative analysis of gene therapy approaches.	Univ Montreal, Fac Med, Inst Rech Clin Montreal, Montreal, PQ H3C 3J7, Canada; Bayer Corp, Tarrytown, NY USA; Brown Univ, Sch Med, Dept Pathol, Providence, RI 02912 USA; Univ Washington, Dept Med, Seattle, WA USA; Texas Childrens Hosp, Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Bayer AG; Brown University; University of Washington; University of Washington Seattle; Baylor College of Medicine	Trudel, M (corresponding author), Univ Montreal, Fac Med, Inst Rech Clin Montreal, Montreal, PQ H3C 3J7, Canada.	trudelm@IRCM.qc.ca						ALTER BP, 1980, BRIT J HAEMATOL, V44, P527, DOI 10.1111/j.1365-2141.1980.tb08706.x; BERTLES JF, 1968, J CLIN INVEST, V47, P1731, DOI 10.1172/JCI105863; Blouin MJ, 1999, BLOOD, V94, P1451, DOI 10.1182/blood.V94.4.1451.416k02_1451_1459; BRUGNARA C, 1994, AM J CLIN PATHOL, V102, P623, DOI 10.1093/ajcp/102.5.623; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P690; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; CORASH LM, 1974, J LAB CLIN MED, V84, P147; CROIZAT H, 1990, BLOOD, V75, P1006; Croizat H, 1999, AM J HEMATOL, V60, P105, DOI 10.1002/(SICI)1096-8652(199902)60:2<105::AID-AJH4>3.0.CO;2-Z; CROIZAT H, 1988, EXP HEMATOL, V16, P946; DEFRANCESCHI L, 1994, J CLIN INVEST, V93, P1670, DOI 10.1172/JCI117149; DEPAEPE ME, 1994, KIDNEY INT, V46, P1337, DOI 10.1038/ki.1994.403; DOVER GJ, 1994, BLOOD, V84, P339; ENVER T, 1989, P NATL ACAD SCI USA, V86, P7033, DOI 10.1073/pnas.86.18.7033; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; KIM YR, 1983, CYTOMETRY, V3, P419, DOI 10.1002/cyto.990030606; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; MOHANDAS N, 1989, BLOOD, V74, P442; MOHANDAS N, 1986, BLOOD, V68, P506; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; OU CN, 1993, CLIN CHEM, V39, P820; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Popp RA, 1997, BLOOD, V89, P4204, DOI 10.1182/blood.V89.11.4204; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; SCHROEDER WA, 1985, HEMOGLOBIN, V9, P461, DOI 10.3109/03630268508997024; SERJEANT GR, 1970, BRIT J HAEMATOL, V19, P635, DOI 10.1111/j.1365-2141.1970.tb01647.x; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; STAMATOYANNOPOULOS G, 1994, BLOOD, V84, P3198, DOI 10.1182/blood.V84.9.3198.bloodjournal8493198; STAMATOYANNOPOULOS G, 1983, BLOOD, V61, P530; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; TRUDEL M, 1987, MOL CELL BIOL, V7, P4024, DOI 10.1128/MCB.7.11.4024; TRUDEL M, 1994, BLOOD, V84, P3189; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; TYCKO DH, 1985, APPL OPTICS, V24, P1355, DOI 10.1364/AO.24.001355	39	44	45	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					177	182		10.1038/72279	http://dx.doi.org/10.1038/72279			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655106				2022-12-27	WOS:000085016900038
J	Burton, DR; Parren, PWHI				Burton, DR; Parren, PWHI			Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; GP120 ENVELOPE GLYCOPROTEIN; NEUTRALIZATION SEROTYPES; EPITOPE; BINDING; COMPLEX; HIV-1		Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	burton@scripps.edu; parren@scripps.edu		Parren, Paul/0000-0002-4365-3859				Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Barber B H, 1997, Semin Immunol, V9, P293, DOI 10.1006/smim.1997.0085; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Casadevall A, 1998, TRENDS MICROBIOL, V6, P102, DOI 10.1016/S0966-842X(98)01208-6; Chargelegue D, 1998, J VIROL, V72, P2040, DOI 10.1128/JVI.72.3.2040-2046.1998; Connolly BM, 1999, J INFECT DIS, V179, pS203, DOI 10.1086/514305; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Edelson BT, 1999, J IMMUNOL, V163, P4087; Fouts TR, 1997, J VIROL, V71, P2779, DOI 10.1128/JVI.71.4.2779-2785.1997; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; Griffin D., 1996, FIELDS VIROLOGY, V3rd ed., P1267; Hilleman MR, 1998, NAT MED, V4, P507, DOI 10.1038/nm0598supp-507; Kostrikis LG, 1996, J VIROL, V70, P445, DOI 10.1128/JVI.70.1.445-458.1996; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Maruyama T, 1999, J VIROL, V73, P6024, DOI 10.1128/JVI.73.7.6024-6030.1999; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Moog C, 1997, J VIROL, V71, P3734, DOI 10.1128/JVI.71.5.3734-3741.1997; Moore JP, 1996, J VIROL, V70, P427, DOI 10.1128/JVI.70.1.427-444.1996; Mulligan MJ, 1999, AIDS, V13, pS105; MURPHY N, 1996, LINGUA FRANCA, V6, P6; Nyambi PN, 1997, J VIROL, V71, P2320, DOI 10.1128/JVI.71.3.2320-2330.1997; Parren PWHI, 1998, J VIROL, V72, P3512, DOI 10.1128/JVI.72.5.3512-3519.1998; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; Puntoriero G, 1998, EMBO J, V17, P3521, DOI 10.1093/emboj/17.13.3521; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Sanchez A, 1998, J VIROL, V72, P6442, DOI 10.1128/JVI.72.8.6442-6447.1998; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; STEWARD MW, 1995, J VIROL, V69, P7668, DOI 10.1128/JVI.69.12.7668-7673.1995; WANG H, IN PRESS P NATL ACAD; WOLINSKY JS, 1996, FIELDS VIROLOGY, P899; WRIN T, 1994, J ACQ IMMUN DEF SYND, V7, P211; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	35	58	61	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					123	125		10.1038/72200	http://dx.doi.org/10.1038/72200			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655088				2022-12-27	WOS:000085016900018
J	Li, YS; Strom, TB				Li, YS; Strom, TB			Failure of combined costimulatory blockade in animal transplant model - Reply	NATURE MEDICINE			English	Letter									Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Immunol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Li, YS (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Immunol, Res N,Rm 380,POB 15707, Boston, MA 02215 USA.		Strom, Terry B./E-9268-2010	Strom, Terry B./0000-0002-7570-0736				Honey K, 1999, J IMMUNOL, V163, P4805; Newell KA, 1999, J IMMUNOL, V163, P2358; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260	3	8	8	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					115	115		10.1038/72168	http://dx.doi.org/10.1038/72168			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655075				2022-12-27	WOS:000085016900005
J	Jimenez, B; Volpert, OV; Crawford, SE; Febbraio, M; Silverstein, RL; Bouck, N				Jimenez, B; Volpert, OV; Crawford, SE; Febbraio, M; Silverstein, RL; Bouck, N			Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1	NATURE MEDICINE			English	Article							PROTEIN-TYROSINE KINASES; FOCAL ADHESION KINASE; ENDOTHELIAL-CELLS; TUMOR-GROWTH; INDUCE APOPTOSIS; IN-VIVO; ANGIOGENESIS; ACTIVATION; ANGIOSTATIN; REQUIRES	Thrombospondin-1 (TSP-1) is a naturally occurring inhibitor of angiogenesis that limits vessel density in normal tissues and curtails tumor growth. Here, we show that the inhibition of angiogenesis in vitro and in vivo and the induction of apoptosis by thrombospondin-1 all required the sequential activation of CD36, p59(fyn), caspase-3 like proteases and p38 mitogen-activated protein kinases. We also detected increased endothelial cell apoptosis in situ at the margins of tumors in mice treated with thrombospondin-1. These results indicate that thrombospondin-1, and possibly other broad-spectrum natural inhibitors of angiogenesis, act in vivo by inducing receptor-mediated apoptosis in activated microvascular endothelial cells.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Cornell Univ, Coll Med, Dept Med, Div Hematol Oncol, New York, NY 10021 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Cornell University	Bouck, N (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.		Cuenca, Benilde Jimenez/K-9959-2014	Volpert, Olga/0000-0003-1381-5543; Jimenez Cuenca, Benilde/0000-0002-1806-6636	NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER; NCI NIH HHS [CA52750, CA64239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Castle VP, 1997, LAB INVEST, V77, P51; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Cosulich S, 1996, CURR BIOL, V6, P1586, DOI 10.1016/S0960-9822(02)70779-3; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DAWSON DW, 1998, ANTIANGIOGENIC AGENT, P185; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; DIPIETRO LA, 1997, REGULATION ANGIOGENE, P295; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Guo NH, 1997, CANCER RES, V57, P1735; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lucas R, 1998, BLOOD, V92, P4730; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Salazar R, 1999, EXP CELL RES, V249, P22, DOI 10.1006/excr.1999.4460; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951	48	786	826	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2000	6	1					41	48		10.1038/71517	http://dx.doi.org/10.1038/71517			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613822				2022-12-27	WOS:000084583300033
J	Qiu, BS; Vallance, BA; Blennerhassett, PA; Collins, SM				Qiu, BS; Vallance, BA; Blennerhassett, PA; Collins, SM			The role of CD4(+) lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis	NATURE MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; SULFONIC-ACID; RAT MODEL; T-CELLS; EVENTS; COLON	Idiopathic inflammatory bowel disease is a chronic relapsing condition. The role of stress in causing relapses of inflammatory bowel disease remains controversial. We now show that colitis induced in mice by dinitrobenzenesulfonic acid (DNBS) resolves by 6 weeks, but can subsequently be reactivated by stress plus a sub-threshold dose of DNBS, but not by DNBS alone. Stress reduced colonic mucin and increased colon permeability. Susceptibility to reactivation by stress required CD4(+) lymphocytes and could be adoptively transferred. We conclude that stress reactivates experimental colitis by facilitating entry of luminal contents that activate previously sensitized CD4 cells in the colon.	McMaster Univ, Fac Hlth Sci, Dept Med, Div Gastroenterol,Intestinal Dis Res Unit, Hamilton, ON L8N 3Z5, Canada; Hamilton Hlth Sci Corp, Digest Dis Program, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Collins, SM (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Med, Div Gastroenterol,Intestinal Dis Res Unit, Room 4W8, Hamilton, ON L8N 3Z5, Canada.			Vallance, Bruce/0000-0003-1345-6747				BOUGHTONSMITH NK, 1988, AGENTS ACTIONS, V25, P115, DOI 10.1007/BF01969102; Brandwein SL, 1997, J IMMUNOL, V159, P44; Castagliuolo I, 1996, AM J PHYSIOL-GASTR L, V271, pG884, DOI 10.1152/ajpgi.1996.271.5.G884; CLARK DA, 1993, AM J REPROD IMMUNOL, V29, P141, DOI 10.1111/j.1600-0897.1993.tb00579.x; Collins SM, 1996, GASTROENTEROLOGY, V111, P1509, DOI 10.1016/S0016-5085(96)70012-4; Drossman DA, 1995, INFLAMM BOWEL DIS, P492; Duffy L C, 1991, Epidemiology, V2, P141, DOI 10.1097/00001648-199103000-00009; DUFFY LC, 1991, BEHAV MED, V17, P101, DOI 10.1080/08964289.1991.9937553; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; ENGEL GL, 1969, GASTROENTEROLOGY, V57, P362; Fava G A, 1976, Psychother Psychosom, V27, P93; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GARRETT VD, 1991, J BEHAV MED, V14, P87, DOI 10.1007/BF00844770; GONG H, 1990, AM J PHYSIOL, V259, pG681; GREENE BR, 1994, BEHAV RES THER, V32, P217, DOI 10.1016/0005-7967(94)90114-7; Gue M, 1997, AM J PHYSIOL-GASTR L, V272, pG84, DOI 10.1152/ajpgi.1997.272.1.G84; Kemler MA, 1999, GASTROENTEROLOGY, V117, P215, DOI 10.1016/S0016-5085(99)70570-6; LOPEZ Y, 1991, GASTROENTEROLOGY, V101, P1249, DOI 10.1016/0016-5085(91)90074-U; Million M, 1999, AM J PHYSIOL-GASTR L, V276, pG1027, DOI 10.1152/ajpgi.1999.276.4.G1027; MILNE B, 1986, J ADV NURS, V11, P561, DOI 10.1111/j.1365-2648.1986.tb01288.x; MONNIKES H, 1992, AM J PHYSIOL, V262, pG137, DOI 10.1152/ajpgi.1992.262.1.G137; Neurath MF, 1996, J EXP MED, V183, P2605, DOI 10.1084/jem.183.6.2605; NORTH CS, 1991, ANN INTERN MED, V114, P381, DOI 10.7326/0003-4819-114-5-381; NORTH CS, 1990, AM J PSYCHIAT, V147, P974; Palmen MJHJ, 1998, CLIN EXP IMMUNOL, V112, P216; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; POTHOULAKIS C, 1993, GASTROENTEROLOGY, V105, P701, DOI 10.1016/0016-5085(93)90886-H; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; Reuter BK, 1996, J CLIN INVEST, V98, P2076, DOI 10.1172/JCI119013; Rubio C A, 1992, In Vivo, V6, P81; SALEM SN, 1967, LANCET, V1, P473; Saunders PR, 1997, AM J PHYSIOL-GASTR L, V273, pG486, DOI 10.1152/ajpgi.1997.273.2.G486; SCHWARZ TL, 1990, NEURON, V2, P119; Sternberg EM, 1995, ANN NY ACAD SCI, V771, P364, DOI 10.1111/j.1749-6632.1995.tb44695.x; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; STERNBERG EM, 1992, ANN INTERN MED, V117, P854, DOI 10.7326/0003-4819-117-10-854; STOUT C, 1969, GASTROENTEROLOGY, V57, P256; STURIALE S, IN PRESS P NATL ACAD; Vallance BA, 1998, GASTROENTEROLOGY, V115, P978, DOI 10.1016/S0016-5085(98)70270-7; WALLACE JL, 1990, AM J PHYSIOL, V258, pG527, DOI 10.1152/ajpgi.1990.258.4.G527; WALLACE JL, 1995, J PHARMACOL TOXICOL, V33, P237, DOI 10.1016/1056-8719(95)00001-X; WILKINSON CW, 1981, ENDOCRINOLOGY, V109, P162, DOI 10.1210/endo-109-1-162; ZHOU DH, 1993, ENDOCRINOLOGY, V133, P2523, DOI 10.1210/en.133.6.2523	43	196	199	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1178	1182		10.1038/13503	http://dx.doi.org/10.1038/13503			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502822				2022-12-27	WOS:000082933200045
J	Sebolt-Leopold, JS; Dudley, DT; Herrera, R; Van Becelaere, K; Wiland, A; Gowan, RC; Tecle, H; Barrett, SD; Bridges, A; Przybranowski, S; Leopold, WR; Saltiel, AR				Sebolt-Leopold, JS; Dudley, DT; Herrera, R; Van Becelaere, K; Wiland, A; Gowan, RC; Tecle, H; Barrett, SD; Bridges, A; Przybranowski, S; Leopold, WR; Saltiel, AR			Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; IN-VITRO; RAS; TRANSFORMATION; SCATTERING; PHOSPHORYLATION; DIFFERENTIATION	The mitogen-activated protein kinase pathway is thought to be essential in cellular growth and differentiation. Here we report the discovery of a highly potent and selective inhibitor of the upstream kinase MEK that is orally active. Tumor growth was inhibited as much as 80% in mice with colon carcinomas of both mouse and human origin after treatment with this inhibitor. Efficacy was achieved with a wide range of doses with no signs of toxicity, and correlated with a reduction in the levels of activated mitogen-activated protein kinase in excised tumors. These data indicate that MEK inhibitors represent a promising, noncytotoxic approach to the clinical management of colon cancer.	Parke Davis Pharmaceut Res, Div Warner Lambert, Dept Cell Biol, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Div Warner Lambert, Dept Chem, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Div Warner Lambert, Dept Canc Res, Ann Arbor, MI 48105 USA	Pfizer; Pfizer; Pfizer	Sebolt-Leopold, JS (corresponding author), Parke Davis Pharmaceut Res, Div Warner Lambert, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CORBETT TH, 1975, CANCER RES, V35, P2434; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUDLEY DT, SIGNAL TRANSDUCTION; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Herrera R, 1998, J CELL SCI, V111, P1039; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; Licato LL, 1998, DIGEST DIS SCI, V43, P1454, DOI 10.1023/A:1018894227169; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Petit AMV, 1997, AM J PATHOL, V151, P1523; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; SEGER R, 1992, J BIOL CHEM, V267, P14373; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Streit M, 1996, J MOL MED-JMM, V74, P253, DOI 10.1007/s001090050027; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	37	833	885	0	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					810	816		10.1038/10533	http://dx.doi.org/10.1038/10533			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395327				2022-12-27	WOS:000081926600037
J	French, RR; Chan, HTC; Tutt, AL; Glennie, MJ				French, RR; Chan, HTC; Tutt, AL; Glennie, MJ			CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help	NATURE MEDICINE			English	Article							HUMAN B-CELLS; DENDRITIC CELLS; IN-VIVO; MEDIATED-IMMUNITY; LEISHMANIA-MAJOR; APOPTOTIC CELLS; TUMOR-ANTIGENS; LIGAND; LYMPHOCYTES; ACTIVATION	CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat mice with syngeneic lymphoma, a rapid cytotoxic T-cell response independent of T-helper cells occurs, with tenfold expansion of CD8(+) T cells over a period of 5 days. This response eradicates the lymphoma and provides protection against tumor rechallenge without further antibody treatment. Thus, it seems that by treating mice with monoclonal antibody against CD40, we are immunizing against syngeneic tumors. The phenomenon proved reproducible with two antibodies against CD40 (3/23 and FGK-45) in three CD40(+) lymphomas (A20, A31 and BCL1) and gave partial protection in one of two CD40(-) lymphomas (EL4 and Ten1). Although the nature of the target antigens on these lymphomas is unknown, CD8(+) T cells recovered from responding mice showed powerful cytotoxic activity against the target B-cell lymphoma in vitro.	Gen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Glennie, MJ (corresponding author), Gen Hosp, Tenovus Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England.	M.J.Glennie@soton.ac.uk		chan, claude/0000-0003-0530-9480				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; Cardoso AA, 1997, BLOOD, V90, P549, DOI 10.1182/blood.V90.2.549.549_549_561; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; Dilloo D, 1997, BLOOD, V90, P1927, DOI 10.1182/blood.V90.5.1927; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Ferlin WG, 1998, EUR J IMMUNOL, V28, P525, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;525::AID-IMMU525&gt;3.0.CO;2-M; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GEORGE AJT, 1991, HYBRIDOMA, V10, P219, DOI 10.1089/hyb.1991.10.219; GEORGE AJT, 1987, J IMMUNOL, V138, P628; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; Honeychurch J, 1997, CANCER IMMUNOL IMMUN, V45, P171, DOI 10.1007/s002620050425; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; Kamanaka M, 1996, IMMUNITY, V4, P275, DOI 10.1016/S1074-7613(00)80435-5; Kato K, 1998, J CLIN INVEST, V101, P1133, DOI 10.1172/JCI1472; Khanna R, 1997, J IMMUNOL, V159, P5782; Kurts C, 1998, J EXP MED, V188, P409, DOI 10.1084/jem.188.2.409; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; Pistoia V, 1997, IMMUNOL TODAY, V18, P343, DOI 10.1016/S0167-5699(97)01080-3; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Roskrow M, 1997, BLOOD, V90, P2601; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172/JCI119822; Schultze JL, 1997, BLOOD, V89, P3806, DOI 10.1182/blood.V89.10.3806.3806_3806_3816; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; Stout RD, 1996, J IMMUNOL, V156, P8; Tutt AL, 1998, J IMMUNOL, V161, P3176; TUTT AL, 1995, J IMMUNOL, V155, P2960; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; Wiley JA, 1997, J IMMUNOL, V158, P2932	41	344	383	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	1999	5	5					548	553		10.1038/8426	http://dx.doi.org/10.1038/8426			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229232				2022-12-27	WOS:000081497400036
J	Parman, T; Wiley, MJ; Wells, PG				Parman, T; Wiley, MJ; Wells, PG			Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity	NATURE MEDICINE			English	Article							SYNTHASE-CATALYZED BIOACTIVATION; EMBRYONIC-TISSUES; CELL-LINE; IN-VIVO; PHENYTOIN; EXPRESSION	The sedative drug thalidomide ([+]-alpha-phthalimidoglutarimide), once abandoned for causing birth defects in humans', has found new therapeutic license in leprosy and other diseases, with renewed teratological consequences(2). Although the mechanism of teratogenesis(3) and determinants of risk remain unclear, related teratogenic xenobiotics are bioactivated by embryonic prostaglandin H synthase (PHS) to a free-radical intermediates that produce reactive oxygen species (ROS), which cause oxidative damage to DNA and other cellular macromolecules(4,5) Similarly, thalidomide is bioactivated by horseradish peroxidase, and oxidizes DNA(6) and glutathione(7), indicating free radical-mediated oxidative stress. Furthermore, thalidomide teratogenicity in rabbits is reduced by the PHS inhibitor acetylsalicylic acid, indicating PHS-catalyzed bioactivation(8). Here, we show in rabbits that thalidomide initiates embryonic DNA oxidation and teratogenicity, both of which are abolished by pre-treatment with the free radical spin trapping agent alpha-phenyl-N-t-butylnitrone (PBN). In contrast, in mice, a species resistant to thalidomide teratogenicity, thalidomide does not enhance DNA oxidation, even at a dose 300% higher than that used in rabbits, providing insight into an embryonic determinant of species-dependent susceptibility. In addition to their therapeutic implications, these results constitute direct evidence that the teratogenicity of thalidomide may involve free radical-mediated oxidative damage to embryonic cellular macromolecules.	Univ Toronto, Fac Pharm, Toronto, ON M5S, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S, Canada; Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S, Canada	University of Toronto; University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S, Canada.							ARLEN R R, 1990, FASEB Journal, V4, pA608; Arlen RR, 1996, J PHARMACOL EXP THER, V277, P1649; Ashby J, 1997, MUTAT RES-FUND MOL M, V396, P45, DOI 10.1016/S0027-5107(97)00174-7; BRAUN AG, 1986, TOXICOL APPL PHARM, V82, P175, DOI 10.1016/0041-008X(86)90449-7; Castilla EE, 1996, TERATOLOGY, V54, P273, DOI 10.1002/(SICI)1096-9926(199612)54:6<273::AID-TERA1>3.0.CO;2-#; CHENG KC, 1992, J BIOL CHEM, V267, P166; GORDON GB, 1981, P NATL ACAD SCI-BIOL, V78, P2545, DOI 10.1073/pnas.78.4.2545; HATFILL SJ, 1991, LEUKEMIA RES, V15, P129, DOI 10.1016/0145-2126(91)90093-9; Huang PHT, 1997, TERATOGEN CARCIN MUT, V17, P1, DOI 10.1002/(SICI)1520-6866(1997)17:1<1::AID-TCM2>3.0.CO;2-L; JONSSON NA, 1972, ACTA PHARM SUEC, V9, P521; Kim PM, 1996, MOL PHARMACOL, V49, P172; KITADA M, 1994, DRUG METAB REV, V26, P305, DOI 10.3109/03602539409029800; LENZ W, 1988, TERATOLOGY, V38, P203, DOI 10.1002/tera.1420380303; LIU L, 1995, FREE RADICAL BIO MED, V19, P639, DOI 10.1016/0891-5849(95)00082-9; Neubert D, 1997, TERATOGEN CARCIN MUT, V17, pR1, DOI 10.1002/(SICI)1520-6866(1997)17:1<I::AID-TCM1>3.0.CO;2-L; Parman T, 1998, J BIOL CHEM, V273, P25079, DOI 10.1074/jbc.273.39.25079; POTTENGER LH, 1990, CARCINOGENESIS, V11, P321, DOI 10.1093/carcin/11.2.321; SCHUMACHER H, 1965, BRIT J PHARM CHEMOTH, V25, P338, DOI 10.1111/j.1476-5381.1965.tb02054.x; STEPHENS TD, 1988, TERATOLOGY, V38, P229, DOI 10.1002/tera.1420380307; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574; WELLS PG, 1997, HDB EXPT PHARM 1, V124, pCH17; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; Winn LM, 1999, FREE RADICAL BIO MED, V26, P266, DOI 10.1016/S0891-5849(98)00193-2; WUEST HM, 1968, EXPERIENTIA, V24, P993, DOI 10.1007/BF02138700; YANG HYL, 1994, MOL PHARMACOL, V46, P922	25	367	383	1	38	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					582	585		10.1038/8466	http://dx.doi.org/10.1038/8466			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229238				2022-12-27	WOS:000081497400042
J	Guo, Q; Fu, WM; Sopher, BL; Miller, MW; Ware, CB; Martin, GM; Mattson, MP				Guo, Q; Fu, WM; Sopher, BL; Miller, MW; Ware, CB; Martin, GM; Mattson, MP			Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice	NATURE MEDICINE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; CORTICAL-NEURONS; BETA-PEPTIDE; GLUTAMATE; CALCIUM; NEUROTOXICITY; HOMEOSTASIS; APOPTOSIS; MUTATION	Excitotoxicity, a form of neuronal injury in which excessive activation of glutamate receptors results in cellular calcium overload(1,2) has been implicated in the pathogenesis of Alzheimer disease(3,4) (AD), although direct evidence is lacking. Mutations in the presenilin-1 (PS1) gene on chromosome 14 are causally linked to many cases of early-onset inherited AD (refs. 5,6). We generated PS1 mutant mice (PS1M146VKI) that express the PS1 M146V targeted allele at normal physiological levels. Although PS1M146VKI mice have no overt mutant phenotype, they are hypersensitive to seizure-induced synaptic degeneration and necrotic neuronal death in the hippocampus. Cultured hippocampal neurons from PS1M146VKI mice have increased vulnerability to death induced by glutamate, which is correlated with perturbed calcium homeostasis, increased oxidative stress and mitochondrial dysfunction. Agents that suppress calcium influx or release and antioxidants protect neurons against the excitotoxic action of the PS1 mutation. These findings establish a direct link between a genetic defect that causes AD and excitotoxic neuronal degeneration, and indicate new avenues for therapeutic intervention in AD patients.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA	University of Kentucky; University of Kentucky; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Mattson, MP (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.	mmattson@aging.coa.uky.edu	Mattson, Mark P/F-6038-2012					Ancolio K, 1997, J NEUROCHEM, V69, P2494, DOI 10.1046/j.1471-4159.1997.69062494.x; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; Guo Q, 1997, J NEUROSCI, V17, P4212; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Keller JN, 1998, J NEUROSCI, V18, P4439; Kim TW, 1997, CURR OPIN NEUROBIOL, V7, P683, DOI 10.1016/S0959-4388(97)80089-X; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OLNEY JW, 1978, NATURE, V271, P557, DOI 10.1038/271557a0; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; White RJ, 1996, J NEUROSCI, V16, P5688; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0	30	391	411	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	1999	5	1					101	106		10.1038/4789	http://dx.doi.org/10.1038/4789			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	154JD	9883847				2022-12-27	WOS:000077885000037
J	Chen, M; Ona, VO; Li, MW; Ferrante, RJ; Fink, KB; Zhu, S; Bian, J; Guo, L; Farrell, LA; Hersch, SM; Hobbs, W; Vonsattel, JP; Cha, JHJ; Friedlander, RM				Chen, M; Ona, VO; Li, MW; Ferrante, RJ; Fink, KB; Zhu, S; Bian, J; Guo, L; Farrell, LA; Hersch, SM; Hobbs, W; Vonsattel, JP; Cha, JHJ; Friedlander, RM			Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease	NATURE MEDICINE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; NEURONAL INTRANUCLEAR INCLUSIONS; POLYGLUTAMINE TRACT; MICE DEFICIENT; BRAIN; DYSFUNCTION; APOPTOSIS; PROTEASE; GENE; TETRACYCLINES	Huntington disease is an autosomal dominant neurodegenerative disease with no effective treatment. Minocycline is a tetracycline derivative with proven safety. After ischemia, minocycline inhibits caspase-1 and inducible nitric oxide synthetase upregulation, and reduces infarction. As caspase-1 and nitric oxide seem to play a role in Huntington disease, we evaluated the therapeutic efficacy of minocycline in the R6/2 mouse model of Huntington disease. We report that minocycline delays disease progression, inhibits caspase-1 and caspase-3 mRNA upregulation, and decreases inducible nitric oxide synthetase activity. In addition, effective pharmacotherapy in R6/2 mice requires caspase-1 and caspase-3 inhibition. This is the first demonstration of caspase-1 and caspase-3 transcriptional regulation in a Huntington disease model.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Neurosurg Serv,Neuroapoptosis Lab, Boston, MA 02115 USA; Bedford VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA USA; Boston Univ, Sch Med, Bedford, MA 01730 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Univ Bonn, Sch Med, Dept Pharmacol, D-5300 Bonn, Germany; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neuropathol, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Geriatric Research Education & Clinical Center; Boston University; Boston University; Boston University; Boston University; University of Bonn; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Emory University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Friedlander, RM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Neurosurg Serv,Neuroapoptosis Lab, Boston, MA 02115 USA.		Longo, Kenneth A/A-5631-2010; Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARONSON AL, 1980, J AM VET MED ASSOC, V176, P1061; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Ferrante RJ, 1997, J NEUROSCI, V17, P3052; FORSYTH DA, 1990, INT J COMPUT VISION, V5, P5, DOI 10.1007/BF00056770; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gottlieb A, 1997, LANCET, V349, P374, DOI 10.1016/S0140-6736(97)80006-2; Goulden V, 1996, BRIT J DERMATOL, V134, P693, DOI 10.1111/j.1365-2133.1996.tb06972.x; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Schapira AHV, 1998, BBA-BIOENERGETICS, V1366, P225, DOI 10.1016/S0005-2728(98)00115-7; Tabrizi SJ, 2000, ANN NEUROL, V47, P80; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	31	856	902	2	57	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					797	+		10.1038/77528	http://dx.doi.org/10.1038/77528			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888929				2022-12-27	WOS:000088040100037
J	Schaub, FJ; Han, DKM; Liles, WC; Adams, LD; Coats, SA; Ramachandran, RK; Seifert, RA; Schwartz, SM; Bowen-Pope, DF				Schaub, FJ; Han, DKM; Liles, WC; Adams, LD; Coats, SA; Ramachandran, RK; Seifert, RA; Schwartz, SM; Bowen-Pope, DF			Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells	NATURE MEDICINE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; RECEPTOR-DEFICIENT MICE; TUMOR-NECROSIS-FACTOR; IL-8 SECRETION; CD95 LIGAND; FAS LIGAND; IN-VIVO; APOPTOSIS; MACROPHAGES; INDUCTION	Apoptosis of smooth muscle cells is a common feature of vascular lesions but its pathophysiological significance is not known. We demonstrate that signals initiated by regulated Fas-associated death domain protein overexpression in rat vascular smooth muscle cells in the carotid artery induce expression of monocyte-chemoattractant protein-1 and interleukin-8, and cause massive immigration of macrophages in vivo. These chemokines, and a specific set of other pro-inflammatory genes, are also upregulated in human vascular smooth muscle cells during Fas-induced apoptosis, in part through a process that requires interleukin-1 alpha activation. Induction of a proinflammatory program by apoptotic vascular smooth muscle cells may thus contribute to the pathogenesis of vascular disease.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bowen-Pope, DF (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062995] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03174, HL62995] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; Belvisi MG, 1997, BRIT J PHARMACOL, V120, P910, DOI 10.1038/sj.bjp.0700963; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLOWES MM, 1994, J CLIN INVEST, V93, P644, DOI 10.1172/JCI117016; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Frevert CW, 1998, J IMMUNOL METHODS, V213, P41, DOI 10.1016/S0022-1759(98)00016-7; GENG YJ, 1995, AM J PATHOL, V147, P251; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; HAN DKM, 1995, AM J PATHOL, V147, P267; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Kiener PA, 1997, J EXP MED, V185, P1511, DOI 10.1084/jem.185.8.1511; KOCH AE, 1993, AM J PATHOL, V142, P1423; Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307; Kollum M, 1997, ARTERIOSCL THROM VAS, V17, P2383, DOI 10.1161/01.ATV.17.11.2383; Lie YS, 1998, CURR OPIN BIOTECH, V9, P43, DOI 10.1016/S0958-1669(98)80082-7; Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Perlman H, 1997, CIRCULATION, V95, P981; Reckless J, 1999, CIRCULATION, V99, P2310, DOI 10.1161/01.CIR.99.17.2310; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Saas P, 1999, J IMMUNOL, V162, P2326; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SAYERS TJ, 1988, J IMMUNOL, V141, P1670; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Sekine C, 1996, BIOCHEM BIOPH RES CO, V228, P14, DOI 10.1006/bbrc.1996.1610; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; VERHEYEN AK, 1988, ARTERIOSCLEROSIS, V8, P759, DOI 10.1161/01.ATV.8.6.759; WANG JM, 1991, ARTERIOSCLER THROMB, V11, P1166, DOI 10.1161/01.ATV.11.5.1166; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Wu JC, 1999, METHODS, V17, P320, DOI 10.1006/meth.1999.0746; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; ZAGORSKI J, 1993, BIOCHEM BIOPH RES CO, V190, P104, DOI 10.1006/bbrc.1993.1017; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	42	176	181	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					790	796		10.1038/77521	http://dx.doi.org/10.1038/77521			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888928				2022-12-27	WOS:000088040100036
J	Yan, SD; Zhu, HJ; Zhu, AP; Golabek, A; Du, H; Roher, A; Yu, J; Soto, C; Schmidt, AM; Stern, D; Kindy, M				Yan, SD; Zhu, HJ; Zhu, AP; Golabek, A; Du, H; Roher, A; Yu, J; Soto, C; Schmidt, AM; Stern, D; Kindy, M			Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis	NATURE MEDICINE			English	Article							GLYCATION END-PRODUCTS; ACTIVATED MICROGLIAL CELLS; COLONY-STIMULATING FACTOR; E-DEFICIENT MICE; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; DIABETIC VASCULOPATHY; SOLUBLE RECEPTOR; P-COMPONENT; IN-VIVO	Accumulation of fibrils composed of amyloid A in tissues resulting in displacement of normal structures and cellular dysfunction is the characteristic feature of systemic amyloidoses. Here we show that RAGE, a multiligand immunoglobulin superfamily cell surface molecule, is a receptor for the amyloidogenic form of serum amyloid A. Interactions between RAGE and amyloid A induced cellular perturbation. In a mouse model, amyloid A accumulation, evidence of cell stress and expression of RAGE were closely linked. Antagonizing RAGE suppressed cell stress and amyloid deposition in mouse spleens. These data indicate that RAGE is a potential target for inhibiting accumulation of amyloid A and for limiting cellular dysfunction induced by amyloid A.	Univ Kentucky, Sanders Brown Ctr Aging, Stroke Program, Dept Biochem, Lexington, KY 40506 USA; Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA; Sun Hlth Res inst, Haldeman Lab Alzheimers Dis Res, Sun City, AZ 85372 USA; Vet Adm Med Ctr, Lexington, KY 40506 USA; Serono Pharmaceut Res Inst, Geneva, Switzerland; Univ Chile, Santiago, Chile; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	University of Kentucky; Columbia University; Columbia University; Institute for Basic Research in Developmental Disabilities; Banner Research; Banner Health; Banner Sun Health Research Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; Universidad de Chile; Columbia University	Kindy, M (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Stroke Program, Dept Biochem, Lexington, KY 40506 USA.				NIA NIH HHS [AG14103, AG12891, AG00690] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014103, K01AG000690] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando Y, 1997, BIOCHEM BIOPH RES CO, V232, P497, DOI 10.1006/bbrc.1996.5997; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Botto M, 1997, NAT MED, V3, P855, DOI 10.1038/nm0897-855; BRETT J, 1993, AM J PATHOL, V143, P1699; COLLINS T, 1993, LAB INVEST, V68, P499; DEBEER MC, 1993, J BIOL CHEM, V268, P20606; Dickson DW, 1999, AM J PATHOL, V154, P1627, DOI 10.1016/S0002-9440(10)65416-8; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; Fixe P, 1998, CYTOKINE, V10, P32, DOI 10.1006/cyto.1997.0249; Gillmore JD, 1997, BRIT J HAEMATOL, V99, P245, DOI 10.1046/j.1365-2141.1997.303194.x; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HAWKINS PN, 1991, CLIN EXP IMMUNOL, V84, P308; HOFMANNM, 1999, CELL, V97, P889; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hoshii Y, 1997, AM J PATHOL, V151, P911; Hume DA, 1997, MOL REPROD DEV, V46, P46; HUSEBEKK A, 1985, SCAND J IMMUNOL, V21, P283, DOI 10.1111/j.1365-3083.1985.tb01431.x; KIMBALL MR, 1979, BIOCHEM BIOPH RES CO, V88, P950, DOI 10.1016/0006-291X(79)91500-6; KINDY MS, 1995, LAB INVEST, V73, P469; Kindy MS, 1998, AM J PATHOL, V152, P1387; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KLOTZ I, 1984, J BIOL CHEM, V258, P11442; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; PRELLI F, 1987, BIOCHEMISTRY-US, V26, P8251, DOI 10.1021/bi00399a035; RITTHALER U, 1995, AM J PATHOL, V146, P688; RUDDERMAN N, 1992, FASEB J, V6, P2905; Rysava R, 1999, BIOCHEM MOL BIOL INT, V47, P845; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; SHIROO M, 1998, SCAND J IMMUNOL, V332, P721; SIPE JD, 1993, AM J PATHOL, V143, P1480; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Suffredini AF, 1999, J CLIN IMMUNOL, V19, P203, DOI 10.1023/A:1020563913045; TAGUCHI A, IN PRESS NATURE; Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Yan SD, 1999, AM J PATHOL, V155, P1403, DOI 10.1016/S0002-9440(10)65452-1; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	43	251	284	2	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					643	651		10.1038/76216	http://dx.doi.org/10.1038/76216			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835680				2022-12-27	WOS:000087438300034
J	Benedetti, S; Pirola, B; Pollo, B; Magrassi, L; Bruzzone, MG; Rigamonti, D; Galli, R; Selleri, S; Di Meco, F; De Fraja, C; Vescovi, A; Cattaneo, E; Finocchiaro, G				Benedetti, S; Pirola, B; Pollo, B; Magrassi, L; Bruzzone, MG; Rigamonti, D; Galli, R; Selleri, S; Di Meco, F; De Fraja, C; Vescovi, A; Cattaneo, E; Finocchiaro, G			Gene therapy of experimental brain tumors using neural progenitor cells	NATURE MEDICINE			English	Article							MULTIPOTENTIAL STEM-CELLS; TRANSPLANTATION; INTEGRATION; LINES; DIFFERENTIATION; EXPRESSION; SURVIVAL	Glioblastomas, the most frequent and malignant of primary brain tumors, have a very poor prognosis'. Gene therapy of glioblastomas is limited by the short survival of viral vectors and by their difficulty in reaching glioblastoma cells infiltrating the brain parenchyma. Neural stem/progenitor cells can be engineered to produce therapeutic molecules and have the potential to overcome these limitations because they may travel along the white matter, like neoplastic cells, and engraft stably into the brain(2,3). Retrovirus-mediated transfer of the gene for interleukin-4 is an effective treatment for rat brain glioblastomas(4). Here, we transferred the gene for interleukin-4 into C57BL6J mouse primary neural progenitor cells and injected those cells into established syngeneic brain glioblastomas. This led to the survival of most tumor-bearing mice. We obtained similar results by implanting immortalized neural progenitor cells derived from Sprague-Dawley rats into C6 glioblastomas. We also documented by magnetic resonance imaging the progressive disappearance of large tumors, and detected 5-bromodeoxyuridine-labeled progenitor cells several weeks after the injection. These findings support a new approach for gene therapy of brain tumors, based on the grafting of neural stem cells producing therapeutic molecules.	Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy; Univ Pavia, IRCCS S Matteo, Neurosurg Dept Surg, I-27100 Pavia, Italy; Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy	IRCCS Istituto Neurologico Besta; IRCCS Fondazione San Matteo; University of Pavia; University of Milan	Finocchiaro, G (corresponding author), Ist Nazl Neurol Carlo Besta, Via Celoria 11, I-20133 Milan, Italy.	finocchiaro@istituto-besta.it	Bruzzone, Maria/AAM-4478-2021; Vescovi, Angelo Luigi/A-4919-2015; Finocchiaro, Gaetano/AAG-6791-2020; DiMeco, Francesco/Z-5431-2019; Pollo, Bianca/K-5347-2018; Galli, Rossella/AAI-8028-2020; Magrassi, Lorenzo/AAJ-3105-2020; DiMeco, Francesco/Q-3785-2016	Bruzzone, Maria/0000-0002-2786-1471; Vescovi, Angelo Luigi/0000-0002-1742-4112; Pollo, Bianca/0000-0002-5523-4256; Galli, Rossella/0000-0001-9023-7033; DiMeco, Francesco/0000-0001-6213-5793; Benedetti, Sara/0000-0003-2826-3040; Magrassi, Lorenzo/0000-0002-8308-2720; CATTANEO, ELENA/0000-0002-0755-4917; Finocchiaro, Gaetano/0000-0003-3583-4040				AUSMAN JI, 1970, CANCER RES, V30, P2394; BARTH RF, 1998, RAT BRAIN TUMOR MODE, P313; Benedetti S, 1999, CANCER RES, V59, P645; Cattaneo E, 1996, J BIOL CHEM, V271, P23374, DOI 10.1074/jbc.271.38.23374; CATTANEO E, 1994, DEV BRAIN RES, V83, P197, DOI 10.1016/0165-3806(94)00137-5; Cattaneo E, 1998, J NEUROSCI RES, V53, P223, DOI 10.1002/(SICI)1097-4547(19980715)53:2<223::AID-JNR11>3.0.CO;2-7; Dewey RA, 1999, NAT MED, V5, P1256, DOI 10.1038/15207; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Gritti A, 1996, J NEUROSCI, V16, P1091; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; Lundberg C, 1997, EXP NEUROL, V145, P342, DOI 10.1006/exnr.1997.6503; Magrassi L, 1998, DEVELOPMENT, V125, P2847; Pincus DW, 1998, NEUROSURGERY, V42, P858, DOI 10.1097/00006123-199804000-00103; Saleh M, 1999, J NATL CANCER I, V91, P438, DOI 10.1093/jnci/91.5.438; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Torchiana E, 1998, NEUROREPORT, V9, P3823, DOI 10.1097/00001756-199812010-00011; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998	21	358	397	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2000	6	4					447	450		10.1038/74710	http://dx.doi.org/10.1038/74710			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742153				2022-12-27	WOS:000165474100040
J	Beeson, JG; Rogerson, SJ; Cooke, BM; Reeder, JC; Chai, WG; Lawson, AM; Molyneux, ME; Brown, GV				Beeson, JG; Rogerson, SJ; Cooke, BM; Reeder, JC; Chai, WG; Lawson, AM; Molyneux, ME; Brown, GV			Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria	NATURE MEDICINE			English	Article							CHONDROITIN SULFATE-A; ADHERENCE; PREGNANCY; RECEPTOR; CELLS; FLOW; CD36	Infection with Plasmodium falciparum during pregnancy leads to the accumulation of parasite-infected erythrocytes in the placenta(1), and is associated with excess perinatal mortality, premature delivery and intrauterine growth retardation in the infant, as well as increased maternal mortality and morbidity(2,3). P. falciparum can adhere to specific receptors on host cells, an important virulence factor enabling parasites to accumulate in various organs(4). We report here that most P. falciparum isolates from infected placentae can bind to hyaluronic acid, a newly discovered receptor for parasite adhesion that is present on the placental lining. In laboratory isolates selected for specific high-level adhesion, binding to hyaluronic acid could be inhibited by dodecamer or larger oligosaccharide fragments or polysaccharides, treatment of immobilized receptor with hyaluronidase, or treatment of infected erythrocytes with trypsin. In vitro flow-based assays demonstrated that high levels of adhesion occurred at low wall shear stress, conditions thought to prevail in the placenta. Our findings indicate that adhesion to hyaluronic acid is involved in mediating placental parasite accumulation, thus changing the present understanding of the mechanisms of placental infection, with implications for the development of therapeutic and preventative interventions.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Malawi, Coll Med, Wellcome Trust Res Labs, Blantyre, Malawi; Univ Malawi, Coll Med, Malaria Project, Blantyre, Malawi; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Northwick Pk Hosp, Imperial Coll, Sch Med, Glycosci Lab, Harrow HA1 3UJ, Middx, England	Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Malawi; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool; Monash University; Imperial College London	Beeson, JG (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.			Reeder, John/0000-0003-1395-1289; Rogerson, Stephen/0000-0003-4287-1982	Wellcome Trust [063215] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899; Beeson JG, 1998, INFECT IMMUN, V66, P3397, DOI 10.1128/IAI.66.7.3397-3402.1998; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; Chai WG, 1998, EUR J BIOCHEM, V251, P114, DOI 10.1046/j.1432-1327.1998.2510114.x; Chien S., 1972, HEMODILUTION THEORET, P1; COOKE BM, 1995, PARASITOL TODAY, V11, P282, DOI 10.1016/0169-4758(95)80040-9; Cooke BM, 1998, MOL MICROBIOL, V30, P83, DOI 10.1046/j.1365-2958.1998.01040.x; COWMAN MK, 1981, BIOCHEMISTRY-US, V20, P1379, DOI 10.1021/bi00508a053; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; KIRBY DRS, 1964, NATURE, V204, P548, DOI 10.1038/204548a0; KUTNER S, 1985, J CELL PHYSIOL, V125, P521, DOI 10.1002/jcp.1041250323; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lea RG, 1997, CURR OPIN INFECT DIS, V10, P171, DOI 10.1097/00001432-199706000-00003; MARTIN BJ, 1974, ANAT REC, V178, P769, DOI 10.1002/ar.1091780408; McCormick CJ, 1997, J CLIN INVEST, V100, P2521, DOI 10.1172/JCI119794; MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517, DOI 10.4269/ajtmh.1984.33.517; Newbold CI, 1997, ANN TROP MED PARASIT, V91, P551, DOI 10.1080/00034989760923; Ramsey EM, 1980, ANATOMY PHYSL RADIOL; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; SUNDERLAND CA, 1985, J REPROD IMMUNOL, V8, P197, DOI 10.1016/0165-0378(85)90041-5; WALTER PR, 1982, AM J PATHOL, V109, P330	24	245	250	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					86	90		10.1038/71582	http://dx.doi.org/10.1038/71582			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613830	Green Accepted			2022-12-27	WOS:000084583300041
J	Chan, SY; Li, KW; Piccotti, JR; Louie, MC; Judge, TA; Turka, LA; Eichwald, EJ; Bishop, DK				Chan, SY; Li, KW; Piccotti, JR; Louie, MC; Judge, TA; Turka, LA; Eichwald, EJ; Bishop, DK			Tissue-specific consequences of the anti-adenoviral immune response: implications for cardiac transplants	NATURE MEDICINE			English	Article							MEDIATED GENE-TRANSFER; VIRAL-ANTIGENS; IN-VIVO; RECOMBINANT ADENOVIRUS; TRANSGENE EXPRESSION; INFECTED HEPATOCYTES; LIVER ALLOGRAFTS; MOUSE-LIVER; THERAPY; VECTORS	The immune response to adenoviral vectors can induce inflammation and loss of transgene expression in transfected tissues. This would limit the use of adenovirus-mediated gene transfer in disease states in which long-term gene expression is required. While studying the effect of the anti-adenoviral immune response in transplantation, we found that transgene expression persisted in cardiac isografts transfected with an adenovirus encoding beta-galactosidase. Transfected grafts remained free of inflammation, despite the presence of an immune response to the vector. Thus, adenovirus-mediated gene transfer may have therapeutic value in cardiac transplantation and heart diseases. Furthermore, immunological limitations of adenoviral vectors for gene therapy are not universal for all tissue types.	Univ Michigan, Sch Med, Dept Surg, Sect Gen Surg, Ann Arbor, MI 48109 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA	University of Michigan System; University of Michigan; University of Pennsylvania; Utah System of Higher Education; University of Utah	Bishop, DK (corresponding author), Univ Michigan, Sch Med, Dept Surg, Sect Gen Surg, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031946] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI HL 31946] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSTYN JM, 1994, J IMMUNOL, V152, P2401; BISHOP DK, 1992, TRANSPLANTATION, V53, P849, DOI 10.1097/00007890-199204000-00027; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; CRYSTAL RG, 1995, NAT MED, V1, P15, DOI 10.1038/nm0195-15; Dematteo RP, 1996, GENE THER, V3, P4; DeMatteo RP, 1997, TRANSPLANTATION, V63, P315, DOI 10.1097/00007890-199701270-00024; Drazan KE, 1996, TRANSPLANTATION, V62, P1080, DOI 10.1097/00007890-199610270-00010; DRAZAN KE, 1995, J SURG RES, V59, P299, DOI 10.1006/jsre.1995.1168; Gao X, 1995, GENE THER, V2, P710; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; Gunzburg WH, 1996, J MOL MED, V74, P171; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lee K, 1996, INT J HEALTH PLAN M, V11, P1, DOI 10.1002/(SICI)1099-1751(199601)11:1<1::AID-HPM420>3.0.CO;2-V; LOGAN J, 1984, P NATL ACAD SCI-BIOL, V81, P3655, DOI 10.1073/pnas.81.12.3655; MCCOY RD, 1995, GENE THER, V2, P437; Merrick AF, 1996, TRANSPLANTATION, V62, P1085, DOI 10.1097/00007890-199610270-00011; Olthoff KM, 1998, NAT MED, V4, P194, DOI 10.1038/nm0298-194; Qin LH, 1997, HUM GENE THER, V8, P1365, DOI 10.1089/hum.1997.8.11-1365; SHAKED A, 1994, TRANSPLANTATION, V57, P1508; Shiraishi M, 1996, SURG TODAY, V26, P624, DOI 10.1007/BF00311668; Trapnell Bruce C., 1994, Current Opinion in Biotechnology, V5, P617, DOI 10.1016/0958-1669(94)90084-1; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; VILQUIN JT, 1995, HUM GENE THER, V6, P1391, DOI 10.1089/hum.1995.6.11-1391; Wang J, 1996, TRANSPLANTATION, V61, P1726, DOI 10.1097/00007890-199606270-00011; Wilson JM, 1996, NEW ENGL J MED, V334, P1185, DOI 10.1056/NEJM199605023341809; Yang Y, 1996, GENE THER, V3, P137; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, J IMMUNOL, V155, P2564; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Ye XH, 1996, J BIOL CHEM, V271, P3639	31	45	47	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1143	1149		10.1038/13467	http://dx.doi.org/10.1038/13467			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502817				2022-12-27	WOS:000082933200040
J	Tassignon, J; Ismaili, J; Le Moine, A; Van Laethem, F; Leo, O; Vandevelde, M; Goldman, M				Tassignon, J; Ismaili, J; Le Moine, A; Van Laethem, F; Leo, O; Vandevelde, M; Goldman, M			Azodicarbonamide inhibits T-cell responses in vitro and in vivo	NATURE MEDICINE			English	Article							NUCLEOCAPSID PROTEIN; LYMPHOCYTES; REPLICATION	Azodicarbonamide was recently identified as a new anti-HIV agent that targets the zinc finger domains of the HIV-1 NCp7 nucleocapsid protein(1-3). Here, we demonstrate that azodicarbonamide inhibits in a dose-dependent manner the responses of purified human CD4(+) T lymphocytes stimulated either by monoclonal antibodies against CD3 and CD28 or by allogeneic dendritic cells. These suppressive effects involve a direct action on the calcium mobilization machinery, as azodicarbonamide strongly inhibited the calcium influx induced either by antibodies against CD3 and CD28 or the chemokine RANTES, as well as by thapsigargin, an activator of depletion-activated calcium channels. In vivo, administration of azodicarbonamide into mice blunted their response to polyclonal T-cell activation induced by the injection of monoclonal antibody against CD3 and resulted in delayed rejection of skin allografts. In addition to its anti-HIV properties, azodicarbonamide is a new immunosuppressive agent that might have therapeutic applications in T cell-mediated inflammatory disorders.	Free Univ Brussels, Expt Immunol Lab, B-1070 Brussels, Belgium; Free Univ Brussels, Dept Biol Mol, B-1640 Rhode St Genese, Belgium; Hubriphar SA, Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Goldman, M (corresponding author), Free Univ Brussels, Expt Immunol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.							ALEGRE ML, 1991, J IMMUNOL, V146, P1184; BACON KB, 1995, METHOD ENZYMOL, V288, P362; BAUS E, 1994, J IMMUNOL METHODS, V173, P41, DOI 10.1016/0022-1759(94)90281-X; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Huang MJ, 1998, J MED CHEM, V41, P1371, DOI 10.1021/jm9708543; ICHIMURA H, 1995, VIROLOGY, V211, P554, DOI 10.1006/viro.1995.1437; Jaworowski A, 1999, IMMUNOL CELL BIOL, V77, P90, DOI 10.1046/j.1440-1711.1999.00798.x; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Rice WG, 1997, NAT MED, V3, P341, DOI 10.1038/nm0397-341; ROSENBERG AS, 1992, ANNU REV IMMUNOL, V10, P333, DOI 10.1146/annurev.immunol.10.1.333; THALI M, 1995, MOL MED TODAY, V1, P287, DOI 10.1016/S1357-4310(95)91208-8; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; Vandevelde M, 1996, AIDS RES HUM RETROV, V12, P567, DOI 10.1089/aid.1996.12.567	13	25	27	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					947	950		10.1038/11392	http://dx.doi.org/10.1038/11392			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426321				2022-12-27	WOS:000081684000041
J	Chui, DH; Tanahashi, H; Ozawa, K; Ikeda, S; Checler, F; Ueda, O; Suzuki, H; Araki, W; Inoue, H; Shirotani, K; Takahashi, K; Gallyas, F; Tabira, T				Chui, DH; Tanahashi, H; Ozawa, K; Ikeda, S; Checler, F; Ueda, O; Suzuki, H; Araki, W; Inoue, H; Shirotani, K; Takahashi, K; Gallyas, F; Tabira, T			Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation	NATURE MEDICINE			English	Article							BETA-PROTEIN; MUTANT PRESENILIN-1; PRECURSOR PROTEIN; SENILE PLAQUES; IN-VIVO; DISEASE; APOPTOSIS; DEPOSITION; NEURONS; CELLS	Familial Alzheimer disease mutations of presenilin 1 (PS-1) enhance the generation of A beta 1-42, indicating that PS-1 is involved in amyloidogenesis. However, PS-l transgenic mice have failed to show amyloid plaques in their brains. Because PS-l mutations facilitate apoptotic neuronal death in vitro, we did careful quantitative studies in PS-1 transgenic mice and found that neurodegeneration was significantly accelerated in mice older than 13 months (aged mice) with familial Alzheimer disease mutant PS-1, without amyloid plaque formation. However, there were significantly more neurons containing intracellularly deposited A beta 42 in aged mutant transgenic mice. Our data indicate that the pathogenic role of the PS-1 mutation is upstream of the amyloid cascade.	NCNP, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan; Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Shizuoka 4128531, Japan; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Pecs, Sch Med, Dept Neurosurg, Pecs, Hungary	National Center for Neurology & Psychiatry - Japan; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Pecs	Tabira, T (corresponding author), NCNP, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.		Checler, Frederic/C-1241-2009; Gallyas, Ferenc/C-5450-2009; Araki, Wataru/G-7913-2014	Checler, Frederic/0000-0003-2098-1750; Araki, Wataru/0000-0001-8467-6937; Inoue, Haruhisa/0000-0003-4736-9537				Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; CHUI DH, 1994, AM J PATHOL, V145, P771; Chui DH, 1998, J NEUROSCI RES, V53, P99; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GALLYAS F, 1993, J NEUROSCI METH, V50, P159, DOI 10.1016/0165-0270(93)90004-B; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P504, DOI 10.1007/BF00310027; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Guo Q, 1997, J NEUROSCI, V17, P4212; Haass C, 1998, J NEURAL TRANSM-SUPP, P159; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Kamimura K, 1998, J NEUROL SCI, V160, P76, DOI 10.1016/S0022-510X(98)00219-6; KOIKE F, 1988, J NEUROL SCI, V85, P9, DOI 10.1016/0022-510X(88)90031-7; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Liu XZ, 1997, J NEUROSCI, V17, P5395; MIZOGUCHI K, 1992, NEUROSCI LETT, V138, P157, DOI 10.1016/0304-3940(92)90495-S; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	29	316	332	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	1999	5	5					560	564		10.1038/8438	http://dx.doi.org/10.1038/8438			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	217KA	10229234				2022-12-27	WOS:000081497400038
J	Baize, S; Leroy, EM; Georges-Courbot, MC; Capron, M; Lansoud-Soukate, J; Debre, P; Fisher-Hoch, SP; McCormick, JB; McCormick, JB; Georges, AJ				Baize, S; Leroy, EM; Georges-Courbot, MC; Capron, M; Lansoud-Soukate, J; Debre, P; Fisher-Hoch, SP; McCormick, JB; McCormick, JB; Georges, AJ			Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients	NATURE MEDICINE			English	Article							FAS LIGAND; RHESUS-MONKEYS; T-CELLS; RELEASE	Ebola virus is very pathogenic in humans. It induces an acute hemorrhagic fever that leads to death in about 70% of patients'. We compared the immune responses of patients who died from Ebola virus disease with those who survived during two large outbreaks in 1996 in Gabon. In survivors, early and increasing levels of IgG, directed mainly against the nucleoprotein and the 40-kDa viral protein, were followed by clearance of circulating viral antigen and activation of cytotoxic T cells, which was indicated by the upregulation of Fast, perforin, CD28 and gamma interferon mRNA in peripheral blood mononuclear cells. In contrast, fatal infection was characterized by impaired humoral responses, with absent specific IgG and barely detectable IgM. Early activation of T cells, indicated by mRNA patterns in peripheral blood mononuclear cells and considerable release of gamma interferon in plasma, was followed in the days preceding death by the disappearance of T cell-related mRNA (including CD3 and CD8). DNA fragmentation in blood leukocytes and release of 41/7 nuclear matrix protein in plasma indicated that massive intravascular apoptosis proceeded relentlessly during the last 5 days of life. Thus, events very early in Ebola virus infection determine the control of viral replication and recovery or catastrophic illness and death.	Ctr Int Rech Med Franceville, Franceville, Gabon; Inst Pasteur, Ctr Immunol & Biol Parasitaire, INSERM, U167, F-59019 Lille, France; Hop La Pitie Salpetriere, Lab Cent Immunol Cellulaire & Tissulaire, CNRS, U625, Paris, France; Fdn Marcel Merieux, F-69002 Lyon, France; Pasteur Merieux Connaught, F-69260 Marcy Etoile, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Baize, S (corresponding author), Ctr Int Rech Med Franceville, BP 769, Franceville, Gabon.	sbaize@cirmf.sci.ga; eleroy@cirmf.sci.ga	LEROY, Eric M/I-4347-2016	LEROY, Eric M/0000-0003-0022-0890; McCormick, Joseph/0000-0002-5844-8102; Baize, Sylvain/0000-0002-3234-7477				BASKERVILLE A, 1978, J PATHOL, V125, P131, DOI 10.1002/path.1711250303; BASKERVILLE A, 1985, J PATHOL, V147, P199, DOI 10.1002/path.1711470308; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; FELDMANN H, 1991, VIROLOGY, V182, P353, DOI 10.1016/0042-6822(91)90680-A; Feldmann H, 1996, J VIROL, V70, P2208, DOI 10.1128/JVI.70.4.2208-2214.1996; FISHERHOCH SP, 1985, J INFECT DIS, V152, P887, DOI 10.1093/infdis/152.5.887; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; GeorgesCourbot MC, 1997, EMERG INFECT DIS, V3, P59, DOI 10.3201/eid0301.970107; Jaax NK, 1996, ARCH PATHOL LAB MED, V120, P140; Jeon SH, 1998, INT IMMUNOL, V10, P1519, DOI 10.1093/intimm/10.10.1519; JOHNSON E, 1995, INT J EXP PATHOL, V76, P227; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kiener PA, 1997, J IMMUNOL, V159, P1594; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KSIAZEK TG, 1992, J CLIN MICROBIOL, V30, P947, DOI 10.1128/JCM.30.4.947-950.1992; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MILLER T, 1993, BIOTECHNIQUES, V15, P1042; Peters CJ, 1999, CURR TOP MICROBIOL, V235, P85; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; *WHO, 1985, WORKSH VIR HAEM FEV; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034; ZAKI SR, 1996, INT C EB VIR RES	24	426	443	0	52	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	1999	5	4					423	426		10.1038/7422	http://dx.doi.org/10.1038/7422			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	183VG	10202932				2022-12-27	WOS:000079574300032
J	Baba, TW; Liska, V; Khimani, AH; Ray, NB; Dailey, PJ; Penninck, D; Bronson, R; Greene, MF; McClure, HM; Martin, LN; Ruprecht, RM				Baba, TW; Liska, V; Khimani, AH; Ray, NB; Dailey, PJ; Penninck, D; Bronson, R; Greene, MF; McClure, HM; Martin, LN; Ruprecht, RM			Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques	NATURE MEDICINE			English	Article							CELL-FREE SIV; RHESUS-MONKEYS; NEF GENE; MUCOSAL INFECTION; IN-VIVO; VACCINE; LYMPHOCYTES; PROTECTION; CHALLENGE; CD4	A substantial risk in using live attenuated, multiply deleted viruses as vaccines against AIDS is their potential to induce AIDS. A mutant of the simian immunodeficiency virus (SIV) with large deletions in nef and vpr and in the negative regulatory element induced AIDS in six of eight infant macaques vaccinated orally or intravenously. Early signs of immune dysfunction were seen in the remaining two offspring. Prolonged follow-up of sixteen vaccinated adult macaques also showed resurgence of chronic viremia in four animals: two of these developed early signs of disease and one died of AIDS. We conclude that this multiply deleted SIV is pathogenic and that human AIDS vaccines built on similar prototypes may cause AIDS.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pediat, Div Newborn Med, Boston, MA 02111 USA; Chiron Corp, Emeryville, CA 94608 USA; Tufts Univ, Sch Vet Med, Dept Radiol, N Grafton, MA 01536 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA; Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA; Emory Univ, Yerkes Reg Primate Res Ctr, Atlanta, GA 30322 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Tufts University; Novartis; Tufts University; Tufts University; Harvard University; Massachusetts General Hospital; Emory University; Emory University	Ruprecht, RM (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NIAID NIH HHS [R01-AI32330, R01-AI35533, UO1-AI24345] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024345, R01AI032330, R01AI024345, R01AI035533] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; AMEDEE AM, 1995, J VIROL, V69, P7982, DOI 10.1128/JVI.69.12.7982-7990.1995; BABA TW, 1995, SCIENCE, V270, P1220; BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; Baba TW, 1996, SCIENCE, V272, P1486, DOI 10.1126/science.272.5267.1486; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BASKIN GB, 1991, VET PATHOL, V28, P506, DOI 10.1177/030098589102800607; Binley JM, 1997, J VIROL, V71, P2799, DOI 10.1128/JVI.71.4.2799-2809.1997; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; CLEMENTS JE, 1995, J VIROL, V69, P2737, DOI 10.1128/JVI.69.5.2737-2744.1995; Connor RI, 1998, J VIROL, V72, P7501, DOI 10.1128/JVI.72.9.7501-7509.1998; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DAVISONFAIRBURN B, 1990, J MED PRIMATOL, V19, P381; DESROSIERS RC, 1994, AIDS RES HUM RETROV, V10, P331, DOI 10.1089/aid.1994.10.331; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAZELY F, 1993, J ACQ IMMUN DEF SYND, V6, P107; FOX CH, 1993, CURRENT PROTOCOLS IM; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KINDT TJ, 1992, ADV IMMUNOL, V52, P425, DOI 10.1016/S0065-2776(08)60880-9; KIRCHHOFF F, 1994, J VIROL, V68, P2031, DOI 10.1128/JVI.68.3.2031-2037.1994; LETVIN NL, 1990, J ACQ IMMUN DEF SYND, V3, P1023; LETVIN NL, 1993, NEW ENGL J MED, V329, P1400, DOI 10.1056/NEJM199311043291908; Liska V, 1997, AIDS RES HUM RETROV, V13, P1147, DOI 10.1089/aid.1997.13.1147; Liska V, 1997, AIDS RES HUM RETROV, V13, P433, DOI 10.1089/aid.1997.13.433; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Norley S, 1996, VIROLOGY, V219, P195, DOI 10.1006/viro.1996.0237; OCHS HD, 1991, J MED PRIMATOL, V20, P193; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; ROSENBERG YJ, 1994, AIDS RES HUM RETROV, V10, P863, DOI 10.1089/aid.1994.10.863; Ruprecht R M, 1996, AIDS, V10 Suppl A, pS33, DOI 10.1097/00002030-199601001-00005; SABIN AB, 1985, J INFECT DIS, V151, P420, DOI 10.1093/infdis/151.3.420; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Tsai CC, 1997, AIDS RES HUM RETROV, V13, P707, DOI 10.1089/aid.1997.13.707; WHATMORE AM, 1995, J VIROL, V69, P5117, DOI 10.1128/JVI.69.8.5117-5123.1995; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996; ZHANG JY, 1988, J INFECT DIS, V158, P1277, DOI 10.1093/infdis/158.6.1277	42	321	331	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	1999	5	2					194	203		10.1038/5557	http://dx.doi.org/10.1038/5557			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	161DX	9930868				2022-12-27	WOS:000078274400029
J	Nagahara, H; Vocero-Akbani, AM; Snyder, EL; Ho, A; Latham, DG; Lissy, NA; Becker-Hapak, M; Ezhevsky, SA; Dowdy, SF				Nagahara, H; Vocero-Akbani, AM; Snyder, EL; Ho, A; Latham, DG; Lissy, NA; Becker-Hapak, M; Ezhevsky, SA; Dowdy, SF			Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27(Kip1) induces cell migration	NATURE MEDICINE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; PHOSPHORYLATION; INHIBITION; DELIVERY; DOMAINS; PRB		Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Dowdy, SF (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.							Anderson WF, 1998, NATURE, V392, P25; BARSAGI D, 1995, METHOD ENZYMOL, V255, P436; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010	19	851	978	0	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1998	4	12					1449	1452		10.1038/4042	http://dx.doi.org/10.1038/4042			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	144VW	9846587				2022-12-27	WOS:000077336900045
J	Birmingham, K				Birmingham, K			UK approves human stem cell research	NATURE MEDICINE			English	News Item																		DONALDSON L, 1999, NAT MED, V5, P855	1	0	0	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					950	950		10.1038/79622	http://dx.doi.org/10.1038/79622			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973298				2022-12-27	WOS:000089190500014
J	Chien, KR				Chien, KR			Re-evaluating sarcoplasmic reticulum function in heart failure	NATURE MEDICINE			English	Letter							DILATED CARDIOMYOPATHY; MICE		Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Chien, KR (corresponding author), Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA.			Molkentin, Jeffery/0000-0002-3558-6529				Chien KR, 2000, J CLIN INVEST, V105, P1339, DOI 10.1172/JCI10079; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; CHIEN KR, 2000, IN PRESS NATURE; HO KKL, 1993, J AM COLL CARDIOL  S, V22, P6; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Kiriazis H, 2000, ANNU REV PHYSIOL, V62, P321, DOI 10.1146/annurev.physiol.62.1.321; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Sussman MA, 1999, AM J PATHOL, V155, P2101, DOI 10.1016/S0002-9440(10)65528-9; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167	12	28	28	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					942	943		10.1038/79595	http://dx.doi.org/10.1038/79595			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973287				2022-12-27	WOS:000089190500002
J	Birmingham, K				Birmingham, K			NIH funds gender biology research	NATURE MEDICINE			English	News Item																			0	0	0	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2000	6	9					950	950		10.1038/79622	http://dx.doi.org/10.1038/79622			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	351ZR	10973298				2022-12-27	WOS:000089190500013
